{"numRecords":"2228","DataElementQueryResults":[{"publicId":"1235","version":"4","preferredName":"Patient Eligibility Indicator","preferredDefinition":"the indicator that asks the investigator to stipulate whether the patient is eligible for inclusion on this protocol.","longName":"PT_ELIG_IND-3","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"B45F073A-2314-00F0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-16","endDate":null,"createdBy":"PWEST","dateCreated":"2003-01-16","modifiedBy":"ZHWENDY","dateModified":"2024-02-05","changeNote":"12/11/14 jc added Exceptional Responder CSI.  Replaced VD Eligibility Ind-3 (2018259v1) with VD Yes No Unknown Indicator (3506034v1) - dbw; 05/11/16 Moved to NRDS context as part of NRDS Standardization WG","administrativeNotes":"11.02.2023_Added Alt Short Name per request ticket CADSR0003036_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3855573","version":"1","preferredName":"Disease Response Other Status","preferredDefinition":"Text term to describe the disease status based on criteria not listed elsewhere.","longName":"RESP_OTHR_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-3597-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SOKKERL","dateModified":"2018-08-04","changeNote":"9/11/17 tt unretired for Theradex 10026 and transferred context. 8/24/17 jk retired per Round 5 finalization task comments.  8/14/13 mc Created per request by CRF Harmonization Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4288020","version":"1","preferredName":"Retinal Vein Thrombosis Yes No Indicator","preferredDefinition":"The yes/no indicator related to determining the formation of a blood clot in the vein that drains the retina of the eye.","longName":"RETNL_VN_THROM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F86B23AB-9DA0-2EB9-E040-BB89AD432F65","latestVersionIndicator":"Yes","beginDate":"2014-05-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-05-02","modifiedBy":"MAESKEB","dateModified":"2014-05-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4288103","version":"1","preferredName":"Ophthalmologic Abnormality Present Yes No Indicator","preferredDefinition":"The yes/no indicator that describes the absense or the presence of whether or not any abnormal condition with the structure and function of the eye is present.","longName":"OPHTH_ABNORM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F86B9B43-B8E5-032D-E040-BB89AD430E5E","latestVersionIndicator":"Yes","beginDate":"2014-05-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-05-02","modifiedBy":"TSESU","dateModified":"2023-01-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4290994","version":"1","preferredName":"Central Serous Chorioretinopathy Indicator","preferredDefinition":"The indicator that describes the absence or presence of whether or not a self-resolving eye condition characterized by fluid accumulation under the macula in the retina is present.","longName":"CSC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F8A8D990-7AA1-6509-E040-BB89AD434A31","latestVersionIndicator":"Yes","beginDate":"2014-05-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-05-05","modifiedBy":"MAESKEB","dateModified":"2014-05-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363553","version":"1","preferredName":"Primary Site of Disease Disorders Anatomic Site Text Code","preferredDefinition":"The 8 character name of the primary anatomic site of disease.","longName":"PRIM_SITE_DIS_ANAT_TXT_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC88F450-0E33-248C-E040-BB89AD431A3B","latestVersionIndicator":"Yes","beginDate":"2014-06-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-06-23","modifiedBy":"MAESKEB","dateModified":"2014-06-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363639","version":"1","preferredName":"Histological Or Cytopathological Diagnosis Refractory Advanced Cancer No Therapy Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has histological or cytopathological diagnosis of an advanced cancer that is refractory to standard therapy or for which no standard therapy exists.","longName":"PT_EC_1001","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC959792-2973-61C2-E040-BB89AD4370C2","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"GDEEN","dateModified":"2022-09-14","changeNote":"6/24/14 created for Theradex eligibiliy CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363937","version":"1","preferredName":"Histological Or Cytopathological Diagnosis Unresectable Colorectal Cancer With KRAS Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has histological  cytopathological diagnosis of advanced/metastatic unresectable colorectal cancer with known KRAS.","longName":"PT_EC_1002","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC997A54-D16D-137A-E040-BB89AD4330E3","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"HARTLEYG","dateModified":"2015-05-28","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363939","version":"1","preferredName":"Patient No BRAF V600 Mutation Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no indicator that describes if patient does not have known BRAF mutations.","longName":"PT_EC_1003","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC997A54-D194-137A-E040-BB89AD4330E3","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-14","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363940","version":"1","preferredName":"Patient Intolerance Oxaliplatin And IrinotecanTreatment Regimen Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient  received and progressed or is intolerant of an oxaliplatin-containing regimen and an irinotecan-containing regimen.","longName":"PT_EC_1004","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC99C622-2398-D35E-E040-BB89AD432856","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-14","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363941","version":"1","preferredName":"Patient Tumor Amenable Core Needle Biopsy Without Unacceptable Risk Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has at least one tumor lesion amenable to core needle biopsy without unacceptable risk of a major procedural complication.","longName":"PT_EC_1005","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC99C622-23BF-D35E-E040-BB89AD432856","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-14","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363942","version":"1","preferredName":"Brain Metastases Less Than 1 Month From Therapy Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has brain metastases, is patient < 1 month from definitive therapy, receiving steroid therapy or taper, or anti-convulsant medications (started for brain metastases).","longName":"PT_EC_1007","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC99C622-23F4-D35E-E040-BB89AD432856","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"VUJANOVA","dateModified":"2020-02-20","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363943","version":"1","preferredName":"Patient History AZD6244 Or Cyclosporine Allergic Reaction Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or cyclosporine A.","longName":"PT_EC_1008","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC99C622-241B-D35E-E040-BB89AD432856","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"MAESKEB","dateModified":"2014-10-15","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363947","version":"1","preferredName":"Cardiac Condition NYHA Congestive Heart Failure Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has Class II-IV New York Heart Association (NYHA) congestive heart failure.","longName":"PT_EC_1010","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC99C622-2465-D35E-E040-BB89AD432856","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363949","version":"1","preferredName":"Cardiac Condition Uncontrolled Hypertension Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has uncontrolled hypertension.","longName":"PT_EC_1011","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC99C622-24B4-D35E-E040-BB89AD432856","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeNote":"11-21-18 TT changed reg status to Application.  6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":"7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363953","version":"1","preferredName":"Cardiac Condition QTcF Prolongation Greater Than 480 msec Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has QTc (Frederica) prolongation > 480 msec.","longName":"PT_EC_1013","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC99C622-24E7-D35E-E040-BB89AD432856","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2023-07-28","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363954","version":"1","preferredName":"Cardiac Condition Antiarrhythmic Therapy Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.","longName":"PT_EC_1012","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9A280D-109B-F11E-E040-BB89AD437627","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2021-09-10","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4363955","version":"1","preferredName":"Cardiac Condition CTCAE Grade 2 Valvular Heart Disease Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has  valvular heart disease CTCAE (Version 4.0) Grade 2.","longName":"PT_EC_1014","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9A280D-10C2-F11E-E040-BB89AD437627","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2017-04-17","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4364011","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Received Radiation Therapy Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient received radiotherapy prior to first study drug administration.","longName":"PT_EC_1006","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9A280D-11D0-F11E-E040-BB89AD437627","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2020-07-31","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4364111","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Active Coronary Disease Less Than 12 Month Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 12 months prior to first study drug administration.","longName":"PT_EC_1009","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9B2610-95EA-3899-E040-BB89AD4338F9","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2021-08-30","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4364112","version":"1","preferredName":"Cardiac Condition Left Ventricular Ejection Fraction (LVEF) Less Than 50 Percent Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has left ventricular ejection fraction (LVEF) less than 50%.","longName":"PT_EC_1015","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9A280D-1225-F11E-E040-BB89AD437627","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2022-11-17","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4364113","version":"1","preferredName":"Patient Ophthalmological Condition Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient has any known ophthalmological conditions.","longName":"PT_EC_1016","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9B2610-961A-3899-E040-BB89AD4338F9","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2023-05-30","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4364114","version":"1","preferredName":"Patient Unable to comply with treatment Yes No Not Applicable Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient was unable to comply with study and/or follow-up procedures.","longName":"PT_EC_1017","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9B2610-9660-3899-E040-BB89AD4338F9","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4364115","version":"1","preferredName":"Patient Prisoners Or Compulsory  Participation Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if patient is a prisoner or is involuntarily incarcerated or has been compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.","longName":"PT_EC_1018","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FC9B2610-9687-3899-E040-BB89AD4338F9","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-06-24","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"6/24/14 created for Theradex eligibility CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379755","version":"1","preferredName":"Eastern Cooperative Oncology Group Performance Status Assessment Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator relating to the ECOG performance status of a patient.","longName":"ECOG_PERF_AS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6AB1-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-05-05","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379766","version":"1","preferredName":"Patient Age Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator that asks about the patient/participant's age.","longName":"PT_AGE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6AD1-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-05-24","changeNote":"2020-8-3 AQT added for P10398. AK  Theradex_ghd_07-02-14 2021-4-27 ak Removed duplicate QT.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379767","version":"1","preferredName":"Laboratory Procedure Absolute Neutrophil Count Eligibility Determination Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether a medical procedure has been performed that involves testing a sample of blood for the absolute neutrophil count, the real number of white blood cells (WBC) that are neutrophils and is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count, as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"LAB_ANC_ELG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3B1E00-3268-A136-E040-BB89AD4324EB","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-27","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379783","version":"1","preferredName":"Laboratory Procedure Platelet Count Eligibility Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether a medical procedure has been performed that involves testing a sample of blood for the platelet count, the real number of irregularly shaped disk like cytoplasmic fragment of a megakaryocyte that is shed in the marrow sinus and subsequently found in the peripheral blood where it functions in clotting, as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"LAB_PLT_ELG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6AF1-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-27","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379789","version":"1","preferredName":"Hematology Hemoglobin Assessment Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether there was a hematology assessment for hemoglobin, the red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","longName":"HMT_HGB_AS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6B11-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-13","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379838","version":"1","preferredName":"Laboratory Procedure Creatinine Result Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to a creatinine laboratory procedure.","longName":"LAB_CREAT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6B31-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2024-01-03","changeNote":"2020-7-27 AQT added for protocol 10389. AK Theradex_ghd_07-02-14 AQT added. AK 2020-7-24","administrativeNotes":"08/07/23 Added AQT per ticket request #CADSR0002703_mmt\r\n2023.6.26 AQT added per ticket request CADSR0002556. ak 2023.4.5 AQT added per ticket request CADSR0002271. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379839","version":"1","preferredName":"Laboratory Procedure Within Clinical Study Protocol Upper Limit of Normal Total Bilirubin Measurement Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to the top value of the range for total bilirubin falling within parameters set forth by the guidelines for a clinical trial.","longName":"LAB_TBM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3B5F10-7826-5EEF-E040-BB89AD4330C9","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2024-01-31","changeNote":"Theradex_ghd_07-02-14 2021-3-29 ak Added AQT.","administrativeNotes":"8/2/2022: fixed the x symbol in AQTs_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379840","version":"1","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"LAB_AST_ALT_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6B68-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-10-23","changeNote":"Theradex_ghd_07-02-14 Removed duplicate AQT per LK. AK","administrativeNotes":"2022.8.10 Corrected special character in AQT. Ticket CADSR0001350. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379841","version":"1","preferredName":"Laboratory Procedure Albumin Result  Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to result of the medical procedure that involves testing a sample of blood for albumin, the main protein in blood plasma.","longName":"LAB_ALUM_RS_COD_IND2","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6BAD-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"KUMMEROA","dateModified":"2023-11-08","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":"2023.11.8 AQT added per ticket request CADSR0003059. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379842","version":"1","preferredName":"Blood Coagulation Assessment  Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to assessment of clot formation in blood.","longName":"LAB_BLD_COAG_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3B5F10-787D-5EEF-E040-BB89AD4330C9","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeNote":"Theradex_ghd_07-02-14 03-09-2018 Changed Theradex 25 and 26 to lower case x DW","administrativeNotes":"2023.6.23 Special character corrected per ticket request CADSR0002546. ak 7/26/2022: fixed the symbol x in AQTs per ticket #.CADSR0001349.wz 7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379843","version":"1","preferredName":"Contraception Agreement Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator relating to the patient's agreement to use effective contraception during protocol treatment.","longName":"CTCPT_AGR_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3B5F10-789F-5EEF-E040-BB89AD4330C9","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-18","changeNote":"2020-7-27 AQT added for protocol 10389. AK Theradex_ghd_07-02-14","administrativeNotes":"6/23/23 Added AQT for Theradex ticket number CADSR0002547 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379851","version":"1","preferredName":"Contraception Agree Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator that asks whether patients receiving therapy or interventions have agreed to prevent pregnancy until the end of therapy or interventions.","longName":"CONTCPT_AGR_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6C89-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-01","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379852","version":"1","preferredName":"Contraception Agreement Female Code Indicator","preferredDefinition":"The coded yes/no/not applicable coded indicator relating to the patient's agreement to use effective contraception during protocol treatment.","longName":"CTCPT_AG_FM_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6CAE-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeNote":"2020-7-27 AQT added for protocol 10389. AK Theradex_ghd_07-02-14","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379853","version":"1","preferredName":"Patient Negative Pregnancy Test  Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator for eligibility relating to a negative pregnancy test for a patient.","longName":"PT_NG_PRGTST_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6CCF-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"2020-7-27 AQT added for Theradex protocol 10389. AK Theradex_ghd_07-02-14","administrativeNotes":"2023.8.8 AQT added per ticket request CADSR0002710. ak 2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379856","version":"1","preferredName":"Person Prior Therapy Adverse Event Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response related to whether a person has fully recovered from adverse events as a result of prior agent administration.","longName":"PRTX_AE_CTE_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6CF0-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379957","version":"1","preferredName":"Thrombosis Adverse Event Observed Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator relateing to whether a thrombotic event was observed.","longName":"THRMB_AE_OBS_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6D11-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2022-11-17","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379958","version":"1","preferredName":"Person Uncontrolled Concurrent Disease or Disorder Exclusion Criteria Code Indicator","preferredDefinition":"The coded yes/no/unknown indicator whether a person has an uncontrolled, concurrent disease, any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person, that would restrict entrance or bar from participation in a clinical trial.","longName":"UNCTL_DZ_CRT_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6D32-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-09-20","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak 2023.7.21 AQT added per ticket request CADSR0002642. ak 7/21/23 removed special character from AQTs_mmt\r\n2023.6.27 AQT added per ticket request CADSR0002556. ak 7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379960","version":"1.1","preferredName":"Person Surgical Procedure Injury Eligibility Determination Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether a patient has had a major surgical procedure, open biopsy, or traumatic injury in order to determine if a person is suitable for enrollment in a study.","longName":"PR_SX_INJ_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B42F37A-053C-730C-E053-F662850A808E","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"SOKKERL","dateModified":"2021-12-21","changeNote":"3/21/17 tt, versioned due to change in def.  07-02-14_Theradex_ghd.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379961","version":"1","preferredName":"Patient Swallowing Assessment Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator that asks whether the patient has the ability to swallow oral medication.","longName":"PT_SWAL_AS_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3C0926-74CD-B943-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-01-30","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379962","version":"1","preferredName":"Patient Prior Disease or Disorder Systemic Antibiotic Antiviral Therapy Eligibility Determination Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether a person has had a prior disease or disorder requiring the administration of systemic antibiotics, a drug used to treat infections caused by bacteria and other microorganisms, or antiviral therapy, treatment of viral infections with agents that prevent viral replication in infected cells without impairing the host cell function, as factor used to determine enrollment in a clinical trial.","longName":"PRDZ_XBIO_XV_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6D74-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2019-04-08","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379964","version":"1","preferredName":"Person Hyponatremia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator regarding whether a person has a lower than normal levels of sodium in the circulating blood as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"HYPON_ELIG_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3C0926-7510-B943-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2022-11-10","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379965","version":"1","preferredName":"Person Serum Potassium Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator regarding whether a person has a lower serum potassium level, a metallic element that is important in body functions such as regulation of blood pressure and of water content in cells, transmission of nerve impulses, digestion, muscle contraction, and heartbeat, as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"SER_K_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6DC1-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379966","version":"1","preferredName":"Person Serum Calcium Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator regarding whether a person's serum calcium level, a metallic element of the alkaline hearth group that is an essential constituent of bones and teeth, was within defined limits as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"SER_CA_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3C0926-754B-B943-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379970","version":"1","preferredName":"Person Malignant Neoplasm Measurable Disease Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/not/not applicable indicator regarding whether a person has a malignant neoplastic tumor that can be accurately measured in size as information that can be used to judge response to treatment as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"MLNEO_MEA_DZ_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6DE2-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-01-26","changeNote":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4382991","version":"1","preferredName":"Patient Consent Ability Code Indicator","preferredDefinition":"a yes/no/not applicable question related to a person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary being able to give permission.","longName":"PT_CONS_ABIL_IND_3","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDC74663-AAEC-780B-E040-BB89AD4340DA","latestVersionIndicator":"Yes","beginDate":"2014-07-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-09","modifiedBy":"SOKKERL","dateModified":"2023-06-09","changeNote":"2020-8-4 AQT added for P10398. AK Curated new from existing 3014444","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4382992","version":"1","preferredName":"Patient Chemotherapy Nitrosourea Compound Mitomycin C Radiation Therapy Exclusion Criteria Code Indicator","preferredDefinition":"the yes/no/not applicable indicator related to the administration of chemotherapy and radiation therapy as medical characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"PT_CHEMO_NITRO_MITO_C_RD_IND_3","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDC74663-AB13-780B-E040-BB89AD4340DA","latestVersionIndicator":"Yes","beginDate":"2014-07-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-09","modifiedBy":"KUMMEROA","dateModified":"2023-09-15","changeNote":"2021-4-27 ak Removed duplicate QT. Curated new from existing 3536201.","administrativeNotes":"2023.9.15 AQT added per ticket request CADSR0002856. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4382993","version":"1","preferredName":"Cancer Treatment Concurrent Administered Code Indicator","preferredDefinition":"Concurrent use of other anti-cancer therapy including chemotherapy agents, target agents, or biological agents.","longName":"CATX_CONC_ADM_IND3","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDC74663-AB3A-780B-E040-BB89AD4340DA","latestVersionIndicator":"Yes","beginDate":"2014-07-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-09","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"Curated new from existing 2186021.","administrativeNotes":"7/20/2022: fixed the box symbol in AQTs.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4382994","version":"1","preferredName":"Patient Pregnancy Code Indicator","preferredDefinition":"an assessment response or indicator that can have a value of yes, no, or not applicable regarding a patient's pregnancy.","longName":"PT_PREG_IND3","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDC74663-AB61-780B-E040-BB89AD4340DA","latestVersionIndicator":"Yes","beginDate":"2014-07-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-09","modifiedBy":"TYRRELLM","dateModified":"2023-11-09","changeNote":"Created new from existing 2958020.","administrativeNotes":"11.09.2023 Added AQT per request ticket CADSR0003062_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4386401","version":"1","preferredName":"Treatment Cohort Study Code","preferredDefinition":"The code that represents the information pertaining to studies in which subsets of a defined population are identified.","longName":"TX_COHORT_ST_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FE558C16-1C7C-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"MAESKEB","dateModified":"2014-07-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449891","version":"1","preferredName":"Patient Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based on any abnormal condition of the body or mind that causes discomfort, dysfunction or distress to the person affected or those in contact with the person as an element of the personal medical history.","longName":"PT_DZ_DO_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008A98E5-D152-BB3E-E050-BB89AD43079C","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2023.8.9 AQT added per ticket request CADSR0002718. ak 2023.6.27 AQT added per ticket request CADSR0002556. ak 2/16/23 added AQT for URMC ticket number CADSR0002058 cjl; 7/20/2022: fixed the box symbol in AQTs.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449892","version":"1","preferredName":"Person Specified Malignant Neoplasm Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to person's cancer diagnosis for eligibility on a clinical trial.","longName":"MAL_NEO_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008A98E5-D178-BB3E-E050-BB89AD43079C","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2021-09-28","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449893","version":"1","preferredName":"Person Prior Treatment Regimen Complete Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to a person having completed a prior therapy regimen as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"PR_TX_CMP_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008AB063-786D-1A43-E050-BB89AD4350F8","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449894","version":"1","preferredName":"Patient Life Expectancy Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has a life expectancy that meets the requirements for participation on a clinical trial.","longName":"LF_EXP_ELI_DT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008AB063-7893-1A43-E050-BB89AD4350F8","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449895","version":"1","preferredName":"Person Gastrointestinal Absorption Inhibition Exclusion Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a person has a gastrointestinal absorption inhibition, involves interference with, or restraint of, activities of uptake from the intestinal lumen of fluids, solutes, proteins, fats, and other nutrients into the intestinal epithelial cells, blood, lymph, or interstitial fluids, as the medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"GI_ABS_INH_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008AB063-78B9-1A43-E050-BB89AD4350F8","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2022-11-08","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449896","version":"1","preferredName":"Person Oral Route of Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a person has the ability to take medication orally, the introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"OR_RT_AD_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008AB063-78DF-1A43-E050-BB89AD4350F8","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2022-12-20","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"12/20/22 added alt OID, CCTG and AQT for ticket number CADSR0001818 cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449897","version":"1","preferredName":"Person Therapy-Related Toxicity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a person has bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"TX_RL_TX_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008ADD9E-043A-2860-E050-BB89AD4341AB","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-26","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2023.9.26 AQT added per ticket request CADSR0002860. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449911","version":"1","preferredName":"Patient Protein Urinalysis Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to patient's urine protein as a criteria in determining eligibility in medical care programs and services.","longName":"PRO_UR_EL_DT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008BF974-4330-54F9-E050-BB89AD43385B","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"KUMMEROA","dateModified":"2022-07-27","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449912","version":"1","preferredName":"Person Ejection Fraction Lower Limit of Normal Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a person has an ejection fraction, a measure of how much blood the left ventricle of the heart pumps out with each contraction, that is lower than the defined limit of normal as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"EF_LLN_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008BF974-4364-54F9-E050-BB89AD43385B","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"TYRRELLM","dateModified":"2023-07-21","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"7/21/23 removed special text from AQT_mmt\r\n7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449913","version":"1","preferredName":"Patient Contraception Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to patient's criteria to determine eligibility based on the use of prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"CONT_EL_DT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008BF974-438A-54F9-E050-BB89AD43385B","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2023.8.8 AQT added per ticket request CADSR0002710. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449931","version":"1","preferredName":"Patient Neoplasm Personal Medical History Code Indicator","preferredDefinition":"The yes/no/not applicable response related to a person who receives medical attention, care, or treatment with history of an abnormal tissue growth resulted from uncontrolled cell proliferation.","longName":"PT_NEO_PMEDHX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008BF974-43B0-54F9-E050-BB89AD43385B","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449932","version":"1","preferredName":"Patient Interstitial Disease Lung Personal Medical History Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient/participant has interstitial lung disease.","longName":"INT_DZ_LUN_MHX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008BF974-43E2-54F9-E050-BB89AD43385B","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"TYRRELLM","dateModified":"2023-10-23","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"10.23.2023 Added AQT per ticket request CADSR0002989 _mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449933","version":"1","preferredName":"Current Therapeutic Procedure Biphosphonate Administered Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether current biphosphonate therapy is being administered.","longName":"TX_PROC_BIP_AD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BD65-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2022-01-18","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449934","version":"1","preferredName":"External Medullary Bone Disease or Disorder Present Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has external medullary bone disease.","longName":"EMED_BN_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BD97-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2017-08-24","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449951","version":"1","preferredName":"Prior Investigational Therapeutic Procedure Administered Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether prior investigational therapies were administered.","longName":"PR_INV_TX_PRO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BDC9-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2022-12-20","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449952","version":"1","preferredName":"Patient Central Nervous System Disease or Disorder Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to eligibility criteria for a person who receives medical treatment having disease related to the brain and spinal cord.","longName":"CNS_DX_EL_DT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BDFB-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"KUMMEROA","dateModified":"2024-02-16","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2024.2.16 AQT added per ticket request CADSR0003416. ak 2023.8.2 AQT added per ticket request CADSR0002682. ak 2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449953","version":"1","preferredName":"Person Clinical Study Agent Hypersensitivity Exclusion Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to a person's hypersensitivity or allergy to study agent that prevents a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"SDY_AG_HYP_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BE21-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"2020-7-27 Added AQT for protocol 10389. AK 9591_Theradex_08.13.14_ghd","administrativeNotes":"11/09/22 added AQT for study ticket CADSR0001669 cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449954","version":"1","preferredName":"Concomitant Medication Use Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient is taking any medication that is not part of protocol treatment (including medication prescribed for other medical conditions).","longName":"CON_MD_USE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BE53-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2021-06-07","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449955","version":"1","preferredName":"Non-protocol Therapy Administered Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has received further (non-protocol) treatment for this cancer.","longName":"NPTX_ADM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BE79-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2021-03-15","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449956","version":"1","preferredName":"Therapy Complementary and Alternative Medicine Administered Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether nontraditional therapeutic agents/procedures were administered for treatment to alter a disease process (e.g., herbal preparation, vitamin, massage, magnets).","longName":"TX_ALT_MD_ADM_CD_IN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BEAB-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"12/5/16 tt, added CSIs.9591_Theradex_08.13.14_ghd 3/18/2020 fixed Ref Docs with special characters DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449957","version":"1","preferredName":"Patient Cardiac Medical Device Implantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial. regarding a person who has any physical object that is useful for prevention, diagnosis, monitoring, or treatment of disease or other conditions in the heart.","longName":"CMDEV_IM_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BED1-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2017-08-17","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449971","version":"1","preferredName":"Female Breast Feeding Or Pregnancy Status Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a female is currently pregnant or breast feeding/nursing an infant.","longName":"2419418v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BEF7-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"TSESU","dateModified":"2023-05-30","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449972","version":"1","preferredName":"Patient Other Medical Contraindicated Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether there were additional or unlisted medical contraindications of patient .","longName":"PT_OMD_CIND_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BF1D-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2023.8.9 AQT added per ticket request CADSR0002722. ak 7/21/23 removed special character from AQT_mmt\r\n8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4450074","version":"1","preferredName":"Patient Active Hemolysis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient is/is not experiencing disruption of the integrity of the erythrocyte membrane causing release of hemoglobin (hemolysis) that meets the criteria for eligibility in a clinical trial.","longName":"ACT_HEM_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008D8EC4-8603-55CB-E050-BB89AD434A06","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"HARTLEYG","dateModified":"2014-08-18","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4450075","version":"1","preferredName":"Patient RAF And/Or MEK Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to whether a patient previously received treatment with RAF and/or MEK inhibitors that meet the criteria required for participation in a clinical trial.","longName":"RAF_MEK_ADM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008DE48D-2865-B799-E050-BB89AD437097","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"HARTLEYG","dateModified":"2014-08-18","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456211","version":"1","preferredName":"Patient Cardiovascular Disorder LVEF Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with LVEF that meets the criteria for participation in a clinical trial.","longName":"CV_LVEF_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FAE0-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"SOKKERL","dateModified":"2023-01-27","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456212","version":"1","preferredName":"Patient Cardiovascular Disorder Corrected QT Interval Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with corrected QT Interval that meets the criteria for participation in a clinical trial.","longName":"CV_CQT_RF_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FB06-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"TYRRELLM","dateModified":"2023-07-20","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"7/20/23 removed special character from AQT_mmt\r\n8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456213","version":"1","preferredName":"Patient Cardiovascular Disorder Uncontrolled Arrhythmia Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with uncontrolled arrhythmia that meets the criteria for participation in a clinical trial.","longName":"CV_ARR_RF_CTE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FB30-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"SOKKERL","dateModified":"2021-01-20","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456214","version":"1","preferredName":"Patient Cardiovascular Disorder  Acute Coronary Syndrome Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with acute coronary syndromes, coronary angioplasty, or stenting that meets the criteria for participation in a clinical trial.","longName":"CV_ACS_RF_CTEC_CD_ING","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FB56-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"ZHWENDY","dateModified":"2022-08-05","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456215","version":"1","preferredName":"Patient Cardiovascular Disorder Congestive Heart Failure Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with congestive heart failure that meets the criteria for participation in a clinical trial.","longName":"CV_CHF_RF_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FB7C-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"SOKKERL","dateModified":"2020-01-10","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456216","version":"1","preferredName":"Patient Cardiovascular Disorder Refractory Hypertension Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with treatment-refractory hypertension that meets the criteria for participation in a clinical trial.","longName":"CV_RHY_RF_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FBA2-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"HARTLEYG","dateModified":"2014-09-03","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456217","version":"1","preferredName":"Patient Cardiovascular Disorder Cardiac Metastasis Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with cardiac metastases that meets the criteria for participation in a clinical trial.","longName":"CV_MET_RF_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FBC8-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"SOKKERL","dateModified":"2019-02-19","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456218","version":"1","preferredName":"Hepatitis B Hepatitis C Infection Personal Medical History Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient has evidence of active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).","longName":"HEP_B_C_PMDHX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FBEE-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"KUMMEROA","dateModified":"2023-06-23","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2023.6.23 Special character corrected per ticket request CADSR0002546. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4456219","version":"1","preferredName":"Patient Antiviral Agent Administer Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether anti-viral agents are being administered to a patient that meets the criteria for participation in a clinical trial.","longName":"XVIR_AD_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00A006E7-FC14-5442-E050-BB89AD4309E3","latestVersionIndicator":"Yes","beginDate":"2014-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-14","modifiedBy":"SOKKERL","dateModified":"2021-12-21","changeNote":"9591_Theradex_08.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4459198","version":"1","preferredName":"Theradex Treatment Cohort Study Type","preferredDefinition":"The response that represents the information pertaining to studies in which subsets of a defined population are identified.","longName":"TDX_TX_CO_SDY_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0116AD40-5131-D42D-E050-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-20","modifiedBy":"HARTLEYG","dateModified":"2014-08-20","changeNote":"9591_Theradex_08-20-14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4463701","version":"1","preferredName":"Patient Chemotherapy Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to patient determination of eligibility in reference to use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"CHEMO_ED_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"018EB20D-77E4-F12A-E050-BB89AD437B1B","latestVersionIndicator":"Yes","beginDate":"2014-08-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-26","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeNote":"9591_Theradex_ghd_08-26-14","administrativeNotes":"2022.12.21 AQT added per ticket request CADSR0001812. ak 2022.11.4 AQT added for ticket request CADSR0001656. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474271","version":"1","preferredName":"Patient Correlative Study Tissue Specimen Consent Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding the patient's consent for the use of tissue samples in a correlative study.","longName":"COR_SDY_TIS_SPEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-040A-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2020-05-11","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474272","version":"1","preferredName":"Laboratory Procedure BRAF Gene Mutation Abnormality Present Outcome Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has been screened for BRAF and has a V600 mutation.","longName":"BRAF_MUT_PRE_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-043C-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"HARTLEYG","dateModified":"2014-09-08","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474273","version":"1","preferredName":"Patient Renal And Hepatic Function Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient meets the criteria for renal and hepatic function for participation in a clinical trial.","longName":"REN_HEP_FUN_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-0462-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"HARTLEYG","dateModified":"2014-09-08","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474274","version":"1","preferredName":"Person Specimen Use Consent Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has given consent for use of tissue and/or blood samples as required per protocol.","longName":"SPE_USE_CON_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-0495-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474275","version":"1","preferredName":"Patient Clinical Benefits Result Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has received clinical benefit from therapy.","longName":"CLI_BEN_RES_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-04BB-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2020-02-28","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474276","version":"1","preferredName":"Anticoagulant Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether a patient receives anticoagulant medication.","longName":"XCOA_AGT_ADM_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-04ED-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"ZHWENDY","dateModified":"2022-08-05","changeNote":"12/5/16 tt, added CSI. 9343_Theradex_ghd_09.03.14","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474277","version":"1","preferredName":"Bile Duct Obstruction Finding Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a blockage in the tubes that carry bile from the liver to the gallbladder and small intestine.","longName":"BILE_DUC_OBS_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-051F-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"MAESKEB","dateModified":"2014-10-16","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474278","version":"1","preferredName":"Patient Strong CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient received strong inhibitors and/or inductors of cytochrome P450.","longName":"STR_P450_IND_INH_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-0545-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2024-01-08","changeNote":"9343_Theradex_ghd_09.03.14 - Changed Theradex Text 32 from \"Application Standard Question Text\" to \"Alternate Question Text\"","administrativeNotes":"7/21/23 removed special characters from AQTs_mmt\r\n2023.6.22 AQT added per ticket request CADSR0002541. ak 8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474279","version":"1","preferredName":"Adverse Event Pre-Existing Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient has an unresolved toxicity from previous anti-cancer therapy.","longName":"AE_PRE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-056B-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"TSESU","dateModified":"2023-05-24","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474280","version":"1","preferredName":"Person Human Immunodeficiency Virus Highly Active Antiretroviral Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient is HIV positive and receiving combination antiretroviral therapy that meets the requirements for participation in a clinical trial.","longName":"HIV_POS_XRET_TX_COD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-059D-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2021-03-25","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474281","version":"1","preferredName":"Person Cardiac Valve Problem Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a difficulty, disorder or condition needing resolution in any of the four valves of the heart.","longName":"CAR_VAL_PRO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-05D0-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2017-01-20","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474284","version":"1","preferredName":"Patient Intermediate CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient meets the criteria for enrollment on a clinical trial with regards to administration of intermediate inducers and/or inhibitors of CYP3A or CYP2C8.","longName":"INT_CYP3A_CYP2C8_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-068B-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2020-12-03","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474391","version":"1","preferredName":"Person Radiation Therapy Discontinued Prior Registration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a person has discontinued any treatment of a disease by means of exposure of the target or the whole body to radiation prior to registration as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"RX_TX_DIS_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0232C837-C782-0996-E050-BB89AD434422","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2019-10-09","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4474392","version":"1","preferredName":"Person Therapeutic Procedure Discontinued Prior Registration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a person has discontinued any action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process prior to registration as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"TX_PRO_DIS_REG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0232C837-C7B4-0996-E050-BB89AD434422","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"TAYLORT","dateModified":"2021-07-07","changeNote":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4475081","version":"1","preferredName":"Treatment Cohort Study 9343 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9343 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9343_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0240CB81-4BF2-D6E7-E050-BB89AD4330DF","latestVersionIndicator":"Yes","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-04","modifiedBy":"HARTLEYG","dateModified":"2014-09-08","changeNote":"9343_Theradex_ghd_09.04.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484031","version":"1","preferredName":"Laboratory Procedure Leukocyte Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a medical procedure has been performed that involves testing a sample of blood for a leukocyte, a blood cell that does not contain hemoglobin and are made by bone marrow and help the body fight infection and other diseases as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"LAB_WBC_ELG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02E8CECD-DA08-0ECC-E050-BB89AD43275A","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484051","version":"1","preferredName":"Hepatocellular Carcinoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether an individual has met the requirements of Hepatocellular Carcinoma diagnosis necessary to allow a subject to participate in a clinical study as indicated by the protocol.","longName":"HCC_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02E8CECD-DA58-0ECC-E050-BB89AD43275A","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2021-03-15","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484052","version":"1","preferredName":"Patient Prior Chronic Hepatic Disease or Disorder Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to the eligibility of a patient for enrollment onto a clinical trial based on their diagnosis of prior chronic hepatic disease.","longName":"PR_CHR_HEP_ED_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02E90140-5E28-9813-E050-BB89AD43121A","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2018-11-29","changeNote":"9608_Theradex_09.12.14_ghd 03-09-2018 fixed line control character in question text DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484056","version":"1","preferredName":"Person Alpha-fetoprotein Measurement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding the determination of the amount of alpha-fetoprotein present in a sample necessary to participate in a clinical study.","longName":"AFP_MEA_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02E8CECD-DAAA-0ECC-E050-BB89AD43275A","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"MAESKEB","dateModified":"2014-10-15","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484073","version":"1","preferredName":"Prior Therapy Measurable Disease Evaluable Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding the presence of measurable and evaluable disease after administration of prior therapy that meets the criteria for a person to participate in a clinical trial.","longName":"PTX_ME_EV_DZ_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02EA60DB-F8DF-EDC9-E050-BB89AD435237","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2017-06-09","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484075","version":"1","preferredName":"Person Child-Pugh Classification Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has liver disease categorized by the Child Pugh system that meets the criteria for participation in a clinical trial.","longName":"PN_CH_PUGH_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02EA9538-BB99-79D2-E050-BB89AD435442","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2023-01-17","changeNote":"9608_Theradex_09.12.14","administrativeNotes":"2022.11.29 AQT added for ticket request CADSR0001742. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484076","version":"1","preferredName":"Chronic Disease Hepatic Insufficiency Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient meets the criteria for participation in a clinical trial based on chronic hepatic insufficiency.","longName":"CH_DZ_HEP_INS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02EAB788-46A6-88F0-E050-BB89AD4327C0","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"HARTLEYG","dateModified":"2014-09-16","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484077","version":"1","preferredName":"Person QTcB Prolongation Greater Than 500 msec Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a person has a history of QTc prolongation, a time interval between the start of the Q wave and the end of the T wave in the cardiac cycle longer than 500 msec, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"QTc_PRO_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02EAB788-46D9-88F0-E050-BB89AD4327C0","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"TYRRELLM","dateModified":"2023-07-21","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":"7/21/23 removed special character from AQT_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484082","version":"1","preferredName":"Person Prolonged QT Interval by ECG Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a prolonged QT interval that meets the criteria for participation in a clinical trial.","longName":"PR_QT_ECG_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02EAB788-4744-88F0-E050-BB89AD4327C0","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2023-07-14","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484083","version":"1","preferredName":"Person Agent QTcB Prolongation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient is receiving or has received agents which are known to prolog QTc measurements that meet the criteria for participation in a clinical trial.","longName":"PE_AGT_QTC_PRO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02EAB788-476A-88F0-E050-BB89AD4327C0","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2023-08-16","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484084","version":"1","preferredName":"Patient Nonsteroidal Antiinflammatory Drug Regular Use Personal Medical History Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding the use of non-steroidal anti-inflammatory agents as it pertains to the patient's personal medical history.","longName":"NSAID_PS_MED_HX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"02EAB788-4790-88F0-E050-BB89AD4327C0","latestVersionIndicator":"Yes","beginDate":"2014-09-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-12","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"9608_Theradex_09.12.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484714","version":"1","preferredName":"Patient Strong Cytochrome P450 3A4 Inhibition Medication Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has received a strong Cytochrome P450 3A4 inhibitor that would determine their eligibility to participate in a clinical trial.","longName":"ST_CYP3A_INH_MD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03239D41-5D56-9682-E050-BB89AD4319F9","latestVersionIndicator":"Yes","beginDate":"2014-09-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-15","modifiedBy":"SOKKERL","dateModified":"2023-09-19","changeNote":"9608_Theradex_09.15.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484715","version":"1","preferredName":"Patient Strong Cytochrome P450 3A4 Induction Medication Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has received a strong Cytochrome P450 C3A inducer that would determine their eligibility for a clinical trial.","longName":"ST_CYP3A_IND_MD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03239D41-5D7C-9682-E050-BB89AD4319F9","latestVersionIndicator":"Yes","beginDate":"2014-09-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-15","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"Add Denise Sentinel Classification to check edits. fixed special characters in ref docs 03-24-2020 DW","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484720","version":"1","preferredName":"Patient Refuse Contraception Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding a patient's refusal to use contraception and its affect on the patient being eligible to participate in a clinical trial.","longName":"PT_REF_CON_ED_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03239D41-5DEB-9682-E050-BB89AD4319F9","latestVersionIndicator":"Yes","beginDate":"2014-09-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-15","modifiedBy":"SOKKERL","dateModified":"2023-06-09","changeNote":"9608_Theradex_09.15.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484721","version":"1","preferredName":"Human Immunodeficiency Virus Positive Patient Refuse Cessation Highly Active Antiretroviral Therapy Assessment Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding a patient's refusal to suspend highly active antiretroviral therapy (HAART) and it's determination on the eligibility of the patient to participate in a clinical trial.","longName":"HIV_REF_CE_XVIR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03239D41-5E11-9682-E050-BB89AD4319F9","latestVersionIndicator":"Yes","beginDate":"2014-09-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-15","modifiedBy":"TAYLORT","dateModified":"2017-10-12","changeNote":"9608_Theradex_09.15.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484731","version":"1","preferredName":"Person Serious Adverse Event Hemorrhage Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding how the presence of hemorrhaging affects the patient's ability to participate in a clinical trial.","longName":"SAE_HEM_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03239D41-5E37-9682-E050-BB89AD4319F9","latestVersionIndicator":"Yes","beginDate":"2014-09-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-15","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeNote":"9608_Theradex_09.15.14_ghd","administrativeNotes":"2023.4.12 AQT added per ticket request CADSR0002300. ak 2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4484732","version":"1","preferredName":"Susceptibility Disease or Disorder Occurrence Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding how a patient's susceptibility to disease affects the ability of the patient to participate in a clinical trial.","longName":"SUS_DZ_OCC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03239D41-5E62-9682-E050-BB89AD4319F9","latestVersionIndicator":"Yes","beginDate":"2014-09-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-15","modifiedBy":"SOKKERL","dateModified":"2017-07-25","changeNote":"9608_Theradex_09.15.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4485878","version":"1","preferredName":"Treatment Study 9608 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol 9608 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9608_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0336808E-4418-4D16-E050-BB89AD436ADF","latestVersionIndicator":"Yes","beginDate":"2014-09-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-16","modifiedBy":"HARTLEYG","dateModified":"2014-09-17","changeNote":"9608_Theradex_ghd_09.16.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4493431","version":"1","preferredName":"Patient Ineligibility Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has been deemed ineligible for treatment based on a specific set of criteria.","longName":"PT_INEL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0402169A-4745-C032-E050-BB89AD43287D","latestVersionIndicator":"Yes","beginDate":"2014-09-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-26","modifiedBy":"SOKKERL","dateModified":"2021-12-08","changeNote":"9653_Theradex_09.26.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4493432","version":"1","preferredName":"Bladder Cancer Treatment Administered Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has received therapeutic treatment for bladder cancer.","longName":"BLA_CAN_TRT_AD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0402169A-476B-C032-E050-BB89AD43287D","latestVersionIndicator":"Yes","beginDate":"2014-09-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-26","modifiedBy":"HARTLEYG","dateModified":"2014-09-29","changeNote":"9653_Theradex_09.26.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4493451","version":"1","preferredName":"Patient Congenital Abnormality Long QT Interval Exclusion Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient was born with an abnormality of long time interval between the start of the Q wave and the end of the T wave in the cardiac cycle that would preclude participation in a clinical trial.","longName":"CON_ABN_QT_INT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0402169A-4791-C032-E050-BB89AD43287D","latestVersionIndicator":"Yes","beginDate":"2014-09-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-26","modifiedBy":"SOKKERL","dateModified":"2020-05-26","changeNote":"9653_Theradex_09.26.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538099","version":"1","preferredName":"Patient Warfarin Treatment Code Indicator","preferredDefinition":"The yes/no/not applicable coded response that indicates if the patient is receiving warfarin treatment.","longName":"PT_WARFN_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058BDB0C-86C6-DD6B-E050-BB89AD437FA9","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeNote":null,"administrativeNotes":"2023.8.9 AQT added per ticket request CADSR0002718. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538115","version":"1","preferredName":"Anticonvulsant Medication Received Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that asks whether the patient is receiving enzyme-inducing anticonvulsant medication.","longName":"ACON_MEDS_RECD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058CE577-3D56-B141-E050-BB89AD437447","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-16","modifiedBy":"SOKKERL","dateModified":"2023-05-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538131","version":"1","preferredName":"Carcinoid Tumor Histologic Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that asks if that patient has a neuroendocrine tumor.","longName":"CARC_TUM_HIST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058D7687-E0C7-B9E6-E050-BB89AD4332B8","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-16","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538156","version":"1","preferredName":"Thiazolidinedione Antidiabetic Agent Received Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that asks if the patient is taking a thiazolidinedione agent.","longName":"THIAZLD_AGT_RCVD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058DAA38-EE17-1545-E050-BB89AD437524","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-16","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538171","version":"1","preferredName":"Chronic Lymphocytic Leukemia Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that asks if the information relating to clinical trial eligibility criteria (elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial) and therapy (an action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process) for chronic lymphocytic leukemia (a slowly progressing disease in which too many white blood cells (called lymphocytes) are found in the body).","longName":"CLL_ELIG_CRIT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058DEE71-0D77-6375-E050-BB89AD437525","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-16","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538213","version":"1","preferredName":"Gamma Knife And/Or Radiation Surgery Administered Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that represents is radiation therapy in which high-energy rays are aimed at a tumor from many angles in a single treatment session.","longName":"GAMMA_KNF_RAD_TX_ADMIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058E2646-D26B-62A7-E050-BB89AD433060","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-16","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538215","version":"1","preferredName":"Cytochrome P450 Concomitant Medication Drug Interaction Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that represents the alteration of the disposition and/or effect of a concomitant medication due to the presence of Cytochrome P450 enzymes.","longName":"CYP450_CONCMT_MED_INTERAC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058E2646-D3C0-62A7-E050-BB89AD433060","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-16","modifiedBy":"SOKKERL","dateModified":"2021-03-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550859","version":"1","preferredName":"Concomitant Medication Romidepsin Administered Code Indicator","preferredDefinition":"The yes/no/not applicable indicator related to the concomintant medication romidepsin being administered.","longName":"CNMD_ROMDPSN_ADMIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06047D53-A427-FF3E-E050-BB89AD430B5B","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-22","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550886","version":"1","preferredName":"Patient Cardiovascular Disorder Corrected QT Interval Risk Factor Assessment Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has a cardiovascular risk associated with corrected QT Interval that meets the criteria by the cardiologist.","longName":"CV_CQT_RF_ASSESS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-64C6-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-22","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550954","version":"1","preferredName":"Patient Concomitant Medication Effect Corrected QT Interval Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient is receiving or has received agents which are known to affect their QTc measurements.","longName":"PT_CNMD_EF_QTC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-6552-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-22","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550972","version":"1","preferredName":"Consent Form Patient Responsible Person Signed Code Indicator","preferredDefinition":"A yes/no/not applicable response to a question related to signature on a document explaining all relevant study information to assist the study volunteer in understanding the expectations and requirements of participation in a clinical trial by patient and person conducting the form discussion.","longName":"CF_PT_RESP_PRSN_SG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-6578-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-22","modifiedBy":"MAESKEB","dateModified":"2014-10-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550993","version":"1","preferredName":"Current Systemic Chemotherapy Or Radiation Therapy Cancer Treatment For Prior Or Synchronous Administered Code Indicator","preferredDefinition":"The yes/no/not applicable response to a question related to concurrent use of other anti-cancer therapy including chemotherapy agents, target agents, or biological agents.","longName":"CA_TX_CON_ADMIN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-6609-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-22","modifiedBy":"SOKKERL","dateModified":"2022-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572454","version":"1","preferredName":"Mutation Variation Codon Position Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether mutations in the genetic material of an organism are present in codons in specific locations.","longName":"MUT_VAR_COD_PS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07103C5B-8377-455B-E050-BB89AD431543","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-04","modifiedBy":"TAYLORT","dateModified":"2015-09-11","changeNote":"9/11/15 releaed.tt_9525_Theradex_11.04.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572455","version":"1","preferredName":"Biopsy Specimen Pair Pretreatment Post-Treatment Availability Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a paired set of pre-treatment and post-treatment biopsy specimens are available for diagnostic examination.","longName":"BX_PRE_POS_AV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07103C5B-83BA-455B-E050-BB89AD431543","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-04","modifiedBy":"TAYLORT","dateModified":"2015-09-11","changeNote":"9/11/15 released.tt_9525_Theradex_11.04.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572456","version":"1","preferredName":"Intervention or Procedure Discontinued Indicator","preferredDefinition":"A response for questions addressing the discontinuation of interventions and/or procedures.","longName":"INT_PROC_DISCON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07103C5B-8434-455B-E050-BB89AD431543","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-04","modifiedBy":"TSESU","dateModified":"2023-03-27","changeNote":"9/10/15 released.tt_9/8/15 edit to draft new CDE unused on 9525. tt_9525_Theradex_11.04.14_ghd","administrativeNotes":"3/7/23 added 1 alt OID and 1 AQT for CCTG ticket request CADSR0002117 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4604211","version":"1","preferredName":"Patient Peripheral Sensory Neuropathy Indicator","preferredDefinition":"The response regarding whether a patient is experiencing peripheral sensory neuropathy, a nerve disorder that affects the patient's sensory nerves.","longName":"PT_PER_SEN_NEU_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0854ADB6-A88E-A1FB-E050-BB89AD430707","latestVersionIndicator":"Yes","beginDate":"2014-11-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-20","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":"9653_Theradex_11.20.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4604212","version":"1","preferredName":"Patient Peripheral Motor Neuropathy Indicator","preferredDefinition":"The response regarding whether the patient is experiencing peripheral motor neuropathy, a nerve disorder that affects the patient's motor nerves.","longName":"PT_PER_MOT_NEU_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0854ADB6-A8AE-A1FB-E050-BB89AD430707","latestVersionIndicator":"Yes","beginDate":"2014-11-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-20","modifiedBy":"HARTLEYG","dateModified":"2014-11-21","changeNote":"9653_Theradex_11.20.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614355","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Peripheral Motor Neuropathy Severity Grade","preferredDefinition":"The severity for peripheral motor neuropathy according to CTC adverse event v.4 criteria.","longName":"CTCAE_P_MOT_NEU_SV_GD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08C960E0-CBCD-FF38-E050-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-26","modifiedBy":"HARTLEYG","dateModified":"2014-11-26","changeNote":"9653_Theradex_11.26.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614356","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Hearing Loss Severity Grade","preferredDefinition":"The severity for hearing loss according to CTC adverse event v.4 criteria.","longName":"CTCAE_HEAR_LOSS_SV_GD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08C960E0-CBED-FF38-E050-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-26","modifiedBy":"PROSVIROVAB","dateModified":"2019-01-10","changeNote":"9653_Theradex_11.26.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617794","version":"1","preferredName":"Patient Histological Procedure Or Cytological Procedure Confirmation Metastatic Solid Neoplasm Diagnosis Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has histologic or cytologic confirmation of metastatic disease from a solid tumor.","longName":"CNF_MT_SOL_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0944E511-7D16-3F82-E050-BB89AD431F76","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2023-02-06","changeNote":"9676_Theradex_12.01.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617811","version":"1","preferredName":"Patient Histological Procedure Or Cytological Procedure Confirmation Metastatic Melanoma Renal Cell Carcinoma Ovarian Carcinoma Colorectal Carcinoma Diagnosis Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has a histologic or cytologic confirmation of metastases for one of the following diagnoses: melanoma, renal cell carcinoma, ovarian cancer or colorectal cancer.","longName":"HI_CY_CON_MET_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0944E511-7D48-3F82-E050-BB89AD431F76","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2017-12-19","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617812","version":"1","preferredName":"Therapeutic Procedure Prior VEGFR Tyrosine Kinase Inhibitor Administered Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has received prior treatment with VEGFR-TKI.","longName":"PRI_VEGFR_ TKI_AD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0944E511-7D7A-3F82-E050-BB89AD431F76","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"ZHWENDY","dateModified":"2022-08-05","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617831","version":"1","preferredName":"Person Prior Platinum Compound Chemotherapy Primary Neoplasm Resistance Process Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient is resistant to platinum therapy due to prior treatment with platinum-based chemotherapy.","longName":"PLAT_CHEM_RES_CTE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-729F-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2023-01-26","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617835","version":"1","preferredName":"Patient Oxaliplatin Treatment Regimen Failed Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient did not respond to an oxaliplatin containing regimen.","longName":"OX_TX_RG_FAIL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-72FE-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"HARTLEYG","dateModified":"2014-12-04","changeNote":"9676_Theradex_12.01.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617836","version":"1","preferredName":"Prior Therapy Metastatic Neoplasm Administered Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has received prior therapy for a metastatic neoplasm.","longName":"PR_TX_MET_NEO_AD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-7330-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2020-12-04","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617837","version":"1","preferredName":"Measured Less Than or Equal 1.5 Times Upper Limit of Normal International Normalized Ratio Or Prothrombin Time Within Anticoagulant Agent Therapeutic Range Occurrence Code Indicator","preferredDefinition":"The coded indicator response regarding whether the result of the International Normalized Ratio (INR) or Prothrombin Time (PT) is less than or equal to 1.5 times the institution upper limit of normal (ULN), unless the use of anticoagulant therapy requires a therapeutic range that must be observed.","longName":"INR_PT_1.5ULN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-7362-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2020-11-16","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617851","version":"1","preferredName":"Malignant Neoplasm Specimen Availability Code Indicator","preferredDefinition":"The coded indicator response regarding whether specimen is available from either archival sources or from newly obtained tissue.","longName":"MLGNEO_SPE_AV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-7388-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"DWARZEL","dateModified":"2022-05-24","changeNote":"10/13/16 tt, added classifications. 9676_Theradex_12.02.14_ghd","administrativeNotes":"5/11/22 cjl added AQT and SN for COG","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617852","version":"1","preferredName":"Patient Measurable Disease Response Evaluation Criteria in Solid Tumors Eligibility Determination  Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has measurable disease as defined by RECIST v1.1.","longName":"MEA_DS_RECIST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-73BA-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":"7/21/23 removed special character from AQT _mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617871","version":"1","preferredName":"Stable Metastatic Malignant Neoplasm to the Brain Without Steroid Therapy Within Integer::7 Day Prior Study Protocol Clinical Treatment Administration Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient's brain metastases are stable without use of steroids for 7 days prior to the start of protocol therapy.","longName":"ST_BRA_MET_WO_STE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-73E0-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"HARTLEYG","dateModified":"2014-12-04","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617891","version":"1","preferredName":"Therapeutic Corticosteroid Or Immunodeficiency Diagnosis 7 Day Prior Treatment Regimen First Dose Occurrence Code Indicator","preferredDefinition":"The coded indicator response regarding whether the patient has a diagnosis of immunodeficiency or is receiving steroid therapy within the 7 days prior to start of protocol therapy.","longName":"STE_IMM_DX_7D_TRT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0946C404-07B6-7A31-E050-BB89AD430E2A","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2021-11-22","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617971","version":"1","preferredName":"Measured Less Than or Equal 1.5 Times Upper Limit of Normal Activated Partial Thromboplastin Time (aPTT) Within Anticoagulant Agent Therapeutic Range Occurrence Code Indicator","preferredDefinition":"The coded indicator response regarding whether the result of the Activated Partial Thromboplastin Time (aPTT) is less than or equal to 1.5 times the institution upper limit of normal (ULN), unless the use of anticoagulant therapy requires a therapeutic range that must be observed.","longName":"PPT_1.5ULN_COA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09488622-D3F5-7C38-E050-BB89AD43041E","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"GDEEN","dateModified":"2022-09-09","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617972","version":"1","preferredName":"Patient Suspected High Risk Hemorrhage Lesion Present Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has lesions that are suspected to be at high risk for bleeding.","longName":"SUS_HRK_HEM_LS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09488622-D421-7C38-E050-BB89AD43041E","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"BRETTS","dateModified":"2015-12-16","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617973","version":"1","preferredName":"Skin Ulcer Lesion Present Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has ulcerated skin lesions.","longName":"SKN_ULC_CS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09488622-D447-7C38-E050-BB89AD43041E","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"HARTLEYG","dateModified":"2014-12-04","changeNote":"9676_Theradex_12.02.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4617974","version":"1","preferredName":"Patient Monoclonal Antibody Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the eligibility criteria for enrollment in a clinical trial based on prior treatment with monoclonal antibodies.","longName":"MON_AB_PMH_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09488622-D46D-7C38-E050-BB89AD43041E","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2023-05-09","changeNote":"12/5/16 tt, added CSI. 9676_Theradex_12.02.14_ghd","administrativeNotes":"5/13/22 CJL AQT added for Theradex for protocol 10405","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4619897","version":"1","preferredName":"Patient History Pembrolizumab Or Ziv-Aflibercept Allergic Reaction Code Indicator","preferredDefinition":"The coded indicator response that indicates if the patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or Ziv-Aflibercept.","longName":"PEM_ZIV_ALL_RX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-669C-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"HARTLEYG","dateModified":"2014-12-05","changeNote":"9676_Theradex_12.04.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4619898","version":"1","preferredName":"Severe Autoimmune History Or Active Disease Diagnosis With Past 3 Month Therapeutic Procedure Clinical Trial Eligibility Code Indicator","preferredDefinition":"The coded indicator response that signifies whether a patient has an active autoimmune disease needing treatment in the past 3 months or a history of severe autoimmune disease, or a syndrome that requires autoimmunosuppressive agents.","longName":"SV_AUT_DIS_3MO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-66BC-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"SOKKERL","dateModified":"2021-03-16","changeNote":"9676_Theradex_12.04.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4619914","version":"1","preferredName":"Person Psychiatric Disorder Or Substance Abuse Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the psychiatric and substance abuse criteria for participation in a clinical trial.","longName":"PSY_SUB_ABU_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-670A-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"ZHWENDY","dateModified":"2022-08-05","changeNote":"9676_Theradex_12.04.14_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4619915","version":"1","preferredName":"Patient Antibody Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the antibody therapy criteria in order to participate in a clinical trial.","longName":"XBOD_TX_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-6730-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"SOKKERL","dateModified":"2023-07-18","changeNote":"12/5/16 tt, added CSI. 9676_Theradex_12.04.14_ghd","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4619916","version":"1","preferredName":"Attenuated Live Virus Vaccine Immunization Integer::30 Day Prior First Therapy Code Indicator","preferredDefinition":"The coded indicator response that signifies whether a patient has been vaccinated with a live vaccine within 30 days of receiving the first dose of clinical trial treatment.","longName":"VACC_30D_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-6756-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":"9676_Theradex_12.04.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4619917","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Active Coronary Disease Less Than 6 Month Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has active coronary disease within 6 months before the start of protocol therapy.","longName":"COR_DZ_LT6MO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-677C-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeNote":"9676_Theradex_12.04.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4619918","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Active Gastrointestinal Disorder Less Than 3 Month Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has an active gastrointestinal disorder within 3 months before the start of protocol therapy.","longName":"GAST_DIS_LT3MO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"096DEA00-67A2-66A9-E050-BB89AD437F99","latestVersionIndicator":"Yes","beginDate":"2014-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-04","modifiedBy":"HARTLEYG","dateModified":"2014-12-05","changeNote":"9676_Theradex_12.04.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648591","version":"1","preferredName":"Concomitant Medication Antiplatelet Agent Receive Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient is/has received medication that affects platelet function.","longName":"CNMD_XPLA_RCV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FC74-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2023-05-16","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648592","version":"1","preferredName":"Patient Glucose-6-Phosphate 1-Dehydrogenase Deficiency Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has a history of glucose-6-phosphate dehydrogenase deficiency.","longName":"G6PD_DEF_PMHX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FC9A-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2020-08-06","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648593","version":"1","preferredName":"Patient Moderate Cardiac Valve Fibrosis Present Code Indicator","preferredDefinition":"The coded response regarding whether a patient has moderate cardiac valve thickening.","longName":"M_CAR_VLV_FIB_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FCC0-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"HARTLEYG","dateModified":"2015-05-07","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648611","version":"1","preferredName":"Patient Visible Retinal Pathology Risk Factor Present Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has visible retinal pathology observed via an ophthalmic exam that is considered a risk factor for retinal vein occlusion. and/or central serous retinopathy.","longName":"VS_RET_PTH_RF_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0CB15-8316-9C8E-E050-BB89AD433DAA","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2017-08-17","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648612","version":"1","preferredName":"Patient Retinal Vein Occlusion Or Central Serous Chorioretinopathy Susceptibility Present Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has predisposing factors that results in susceptibility to retinal vein occlusion and/or central serous retinopathy.","longName":"RVO_CSR_SUS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FD09-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeNote":"9466_Theradex_01.2.15_ghd","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648613","version":"1","preferredName":"Patient RAS Family Gene Mutation Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has a history of RAS-mutation positive tumor.","longName":"RAS_GEN_MU_PMX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FD46-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2020-12-01","changeNote":"9466_Theradex_01.2.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648632","version":"1","preferredName":"Patient Protocol Agent Allergic Reaction Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has a history of allergic reactions to the study agent or to compounds of similar chemical or biologic composition.","longName":"PXA_ALG_RX_PMH_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FD85-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648633","version":"1","preferredName":"Person Prior Biological Therapy Exclusion Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has received biological therapy prior to administration of protocol agent.","longName":"PR_BIO_TX_XCRI_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FDAB-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SPRINGERL","dateModified":"2020-08-20","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648634","version":"1","preferredName":"Patient Systemic Cancer Therapeutic Procedure Integer::3 Week Prior Protocol Agent Receive Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has received systemic anti-cancer therapy within 3 weeks before the administration of protocol agent.","longName":"STX_PR_3W_AGT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FDD1-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2023-08-28","changeNote":"9466_Theradex_01.2.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648635","version":"1","preferredName":"Patient Therapeutic Procedure Integer:14 Day Prior Protocol Agent Receive Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has had prior therapy within 14 days before the first dose of protocol agent.","longName":"TX_14D_PR_PXAG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FDF7-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2021-07-14","changeNote":"9466_Theradex_01.2.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648651","version":"1","preferredName":"Patient Enzyme Induction Anticonvulsant Agent Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient's personal medical history includes administration of enzyme-inducing anticonvulsant agents.","longName":"ENZ_IN_XCNV_MX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FE5E-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"HARTLEYG","dateModified":"2015-05-07","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648652","version":"1","preferredName":"Patient Corticosteroid Use Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient's personal medical history includes administration of corticosteroids.","longName":"COR_USE_PMX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FE84-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2020-12-01","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648671","version":"1","preferredName":"Laboratory Finding Pre-study Corrected QT Interval Less Than Integer::480 Millisecond Outcome Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient's corrected baseline QT Interval is < 480 msec.","longName":"CQTC_LT_480MS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FEAD-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"HARTLEYG","dateModified":"2015-06-02","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648672","version":"1","preferredName":"Patient Navitoclax BRAF Gene Inhibition Mitogen-Activated Protein Kinase Kinase Inhibitor Negation Prior Medication Usage Receive Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has not previously received navitoclax, BRAF inhibitors and/or MEK inhibitors.","longName":"NAV_BRAF_MEK_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FED3-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"KUMMEROA","dateModified":"2023-06-12","changeNote":"9466_Theradex_01.2.15_ghd","administrativeNotes":"2023.6.12 AQT added per ticket request CADSR0002508. ak 2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648673","version":"1","preferredName":"Patient Navitoclax Negation Prior Medication Usage Receive Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has not previously received navitoclax.","longName":"NAV_NEG_REC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FEF9-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2017-07-21","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648674","version":"1","preferredName":"Melanoma BRAF Gene Mutation Abnormality Histologic Diagnosis Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has been histologically diagnosed with BRAF-mutant melanoma.","longName":"MEL_BRAF_HDX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FF23-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2020-12-01","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648675","version":"1","preferredName":"Malignant Neoplasm BRAF Gene Mutation Abnormality Histologic Diagnosis Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has been histologically diagnosed with a BRAF-mutant malignant neoplasm.","longName":"MNEO_BRAF_HDX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB0696E-FF49-E657-E050-BB89AD432FC7","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2017-08-17","changeNote":"9466_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4648711","version":"1","preferredName":"Patient Infection Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether the patient's personal medical history includes known infectious diseases.","longName":"INF_PMHX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB28205-0424-BBBA-E050-BB89AD436C15","latestVersionIndicator":"Yes","beginDate":"2015-01-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-02","modifiedBy":"SOKKERL","dateModified":"2023-05-19","changeNote":"9846_Theradex_01.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4659035","version":"1","preferredName":"National Cancer Institute Tissue Procurement Protocol Consent Signature Confirmation Code Indicator","preferredDefinition":"The coded indicator response regarding whether an individual has confirmed a patient's signature for consent to participate in the NCI Tissue Procurement Protocol (P9846).","longName":"NCI_TIS_PRO_CON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C1B788D-4FC7-1791-E050-BB89AD4315B8","latestVersionIndicator":"Yes","beginDate":"2015-01-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-07","modifiedBy":"HARTLEYG","dateModified":"2015-01-08","changeNote":"9846_Theradex_01.07.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4659039","version":"1","preferredName":"Disease Progression Or Off Treatment Occurrence Date","preferredDefinition":"The date response regarding the patient's date of disease progression or the date on which the patient is no longer receiving protocol therapy.","longName":"PD_OFF_TX_OCC_DATE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C1B788D-500B-1791-E050-BB89AD4315B8","latestVersionIndicator":"Yes","beginDate":"2015-01-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-07","modifiedBy":"HARTLEYG","dateModified":"2015-01-08","changeNote":"9846_Theradex_01.07.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4659043","version":"1","preferredName":"Longitudinal Specimen Collection Plan Code Indicator","preferredDefinition":"The coded indicator response regarding whether longitudinal specimen collection is planned.","longName":"LNG_SPE_COL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C1B788D-504F-1791-E050-BB89AD4315B8","latestVersionIndicator":"Yes","beginDate":"2015-01-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-07","modifiedBy":"HARTLEYG","dateModified":"2015-01-08","changeNote":"9846_Theradex_01.07.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4669013","version":"1","preferredName":"Smoking History Smoking Cessation Duration Category Number","preferredDefinition":"The value representing the number of smoking cessation duration categories.","longName":"SM_HX_CES_DUR_CAT_NU","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CBB63F3-D5E6-3243-E050-BB89AD433995","latestVersionIndicator":"Yes","beginDate":"2015-01-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-01-15","modifiedBy":"HARTLEYG","dateModified":"2015-01-16","changeNote":"Theradex_01.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722444","version":"1","preferredName":"Patient Percutaneous Needle Biopsy Amenable Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the eligibility criteria for percutaneous needle biopsy amenable tumor.","longName":"PE_NBX_NE_CTEC_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F7B5E2D-5415-DE4D-E050-BB89AD433C84","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"TAYLORT","dateModified":"2020-12-10","changeNote":"9149_Theradex_02.19.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722445","version":"1","preferredName":"Person Karnofsky Performance Status Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the eligibility criteria for Karnofsky performance status score.","longName":"KAR_PE_ST_CTEC_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F7BCB13-1643-EF18-E050-BB89AD4330EA","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SOKKERL","dateModified":"2022-07-01","changeNote":"9149_Theradex_02.19.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722446","version":"1","preferredName":"Person Breast Feeding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response indicating whether a person meets the eligibility criteria with regards to breast feeding.","longName":"BRFD_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F7BCB13-1669-EF18-E050-BB89AD4330EA","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SOKKERL","dateModified":"2023-12-01","changeNote":"9149_Theradex_02.19.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722447","version":"1","preferredName":"Patient Digestive System Disorder Agent Intolerance Or Absorption Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response indicating whether a patient meets the eligibility criteria regarding digestive system disorders effects on agent intolerance or absorption.","longName":"GI_DIS_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F7BCB13-168F-EF18-E050-BB89AD4330EA","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"9149_Theradex_02.19.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722448","version":"1","preferredName":"Patient Gastrointestinal Tract Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding gastrointestinal tract diseases or disorders.","longName":"GI_DZ_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F7BCB13-16B5-EF18-E050-BB89AD4330EA","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SOKKERL","dateModified":"2024-02-13","changeNote":"9149_Theradex_02.19.15_ghd","administrativeNotes":"7/21/23 removed special character from AQT_mmt\r\n8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722826","version":"1","preferredName":"Patient Target Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient meets the eligibility criteria regarding the occurrence of target mutations in specimen samples.","longName":"TG_MUT_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8AE8-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722827","version":"1","preferredName":"Patient Eligibility Determination Toxicity Recovery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding recovery from toxicity to eligibility levels.","longName":"ELIG_TOX_REC_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8B1B-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2022-04-18","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722830","version":"1","preferredName":"Radiofrequency Ablation Timing Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding timing of radiofrequency ablation.","longName":"RAD_ABL_TIM_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8D0418-396F-9FCA-E050-BB89AD43212D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2020-06-02","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722831","version":"1","preferredName":"Patient BRAF Gene Inhibition Therapeutic Procedure Disease Progression Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding disease progression on BRAF inhibitor therapy.","longName":"BRAF_IN_TX_PRO_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8B68-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2017-01-17","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722832","version":"1","preferredName":"Patient EGFR Tyrosine Kinase Inhibitor Therapy Disease Progression Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding the occurrence of disease progression while receiving EGFR tyrosine kinase inhibitor therapy.","longName":"EGFR_TKI_PD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8B8E-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2019-12-26","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722834","version":"1","preferredName":"Patient Antibiotic Therapy Pneumonitis Recovery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility requirements regarding resolution of infectious pneumonitis symptom resolution and completion of antibiotic therapy.","longName":"XBI_PNE_REC_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8BB4-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"HARTLEYG","dateModified":"2015-02-25","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722835","version":"1","preferredName":"Patient Fasting Serum Total Cholesterol Measurement And Triglyceride Measurement Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility requirements regarding fasting serum cholesterol levels and fasting triglyceride levels.","longName":"FA_SE_CHO_TRI_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8BDA-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"HARTLEYG","dateModified":"2015-02-25","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722836","version":"1","preferredName":"Patient Principal Investigator Negation Review Pharmacokinetic Effect Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding a principle investigator review of the administration of medications that my affect the study drug pharmacokinetics.","longName":"PI_NRE_PK_EFF_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8D4ABD-8DFE-F5FC-E050-BB89AD43066E","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"AQT added for protocol 10389. AK 9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722837","version":"1","preferredName":"Patient Strong And Moderate Cytochrome P450 Induction Or Inhibition Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding administration of strong and moderate cytochrome P450 system inducers or inhibitors.","longName":"ST_MO_CYT_IND_INH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8D4ABD-8E24-F5FC-E050-BB89AD43066E","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722959","version":"1","preferredName":"Patient Prior Carboplatin WEE1 Inhibitor MK-1775 Combination Chemotherapy Received Code Indicator","preferredDefinition":"The coded response indicating whether a patient has received prior combination therapy with carboplatin and MK-1775.","longName":"PR_CAR_MK1775_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8FFE3B-3760-E261-E050-BB89AD430EB0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722960","version":"1","preferredName":"Combination Chemotherapy Most Recent Carboplatin WEE1 Inhibitor MK-1775 Administered Agent Start Date","preferredDefinition":"The date response indicating the start date of the most recent combination chemotherapy administered using carboplatin and MK-1775.","longName":"MR_CA_MK1775_ST_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8FFE3B-3780-E261-E050-BB89AD430EB0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722961","version":"1","preferredName":"Combination Chemotherapy Most Recent Carboplatin WEE1 Inhibitor MK-1775 Administration Day Duration","preferredDefinition":"The response indicating the number of days duration of the most recent administration of combination chemotherapy using carboplatin and MK-1775.","longName":"MR_CAR_MK1775_DY_DUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8FFE3B-37A0-E261-E050-BB89AD430EB0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722963","version":"1","preferredName":"Patient Prior Poly (ADP-Ribose) Polymerase Inhibitor Received Code Indicator","preferredDefinition":"The coded response indicating whether a patient has previously received a PARP inhibitor for the treatment of cancer.","longName":"PR_PARP_INH_REC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8FFE3B-37E0-E261-E050-BB89AD430EB0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"TYRRELLM","dateModified":"2023-12-07","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":"12.07.2023 Added AQT per request ticket CADSR0003164_mmt\r\n2023.11.22 AQT added per ticket request CADSR0003113. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4722964","version":"1","preferredName":"Chemotherapy Most Recent Poly (ADP-Ribose) Polymerase Inhibitor Administered Agent Name","preferredDefinition":"The response indicating the agent name of the most recently administered PARP inhibitor.","longName":"MR_PARP_INH_AGT_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8FFE3B-3800-E261-E050-BB89AD430EB0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2019-01-16","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723210","version":"1","preferredName":"Chemotherapy Most Recent Poly (ADP-Ribose) Polymerase Inhibitor Administered Agent Start Date","preferredDefinition":"The response indicating the first date of PARP inhibitor drug administration for the most recent therapy regimen.","longName":"MR_PARP_INH_ST_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5A4E2-2C48-EAEF-E050-BB89AD432EE0","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723215","version":"1","preferredName":"Chemotherapy Most Recent Poly (ADP-Ribose) Polymerase Inhibitor Administered Agent Day Duration","preferredDefinition":"The response indicating the number of days from the date of the first dose to the date of the last dose of PARP inhibitor during the most recent therapy regimen administration.","longName":"MR_PARP_IN_AD_DY_DUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5FDC1-F194-BED9-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723230","version":"1","preferredName":"Patient Prior Everolimus Or mTOR Inhibitor Received Code Indicator","preferredDefinition":"The coded response indicating whether a patient has received previous therapy containing everolimus or an mTOR inhibitor.","longName":"EVE_MTOR_RCV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC55BB8-0E5F-71C2-E050-BB89AD433E6E","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723231","version":"1","preferredName":"Chemotherapy Most Recent Everolimus Or mTOR Inhibitor Administered Agent Name","preferredDefinition":"The response indicating the agent name of the most recently administered everolimus or other mTOR inhibitor.","longName":"4722946v1.0:2018334v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5FDC1-F1BD-BED9-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723232","version":"1","preferredName":"Chemotherapy Most Recent Everolimus Or mTOR Inhibitor Administered Agent Start Date","preferredDefinition":"The response indicating the first date of everolimus or other mTOR inhibitor drug administration for the most recent therapy regimen.","longName":"MR_EVE_MTOR_IN_ST_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5FDC1-F1F4-BED9-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723234","version":"1","preferredName":"Chemotherapy Most Recent Everolimus Or mTOR Inhibitor Administered Agent Administration Day Duration","preferredDefinition":"The response indicating the number of days from the date of the first dose to the date of the last dose of everolimus or other mTOR inhibitor during the most recent therapy regimen administration.","longName":"MR_EVE_MTOR_ADM_DUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC55BB8-0E88-71C2-E050-BB89AD433E6E","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723243","version":"1","preferredName":"Patient Prior Mitogen-Activated Protein Kinase Kinase Inhibitor Received Code Indicator","preferredDefinition":"The coded response indicating whether a patient has previously received a MEK inhibitor for the treatment of cancer.","longName":"PR_MEK_INH_AD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5FDC1-F29F-BED9-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"SOKKERL","dateModified":"2023-01-26","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723246","version":"1","preferredName":"Chemotherapy Most Recent Mitogen-Activated Protein Kinase Kinase Inhibitor Administered Agent Start Date","preferredDefinition":"The response indicating the first date of MEK inhibitor drug administration for the most recent therapy regimen.","longName":"MR_MEK_INH_ADM_AG_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5FDC1-F2F2-BED9-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723251","version":"1","preferredName":"Chemotherapy Most Recent Mitogen-Activated Protein Kinase Kinase Inhibitor Administered Agent Day Duration","preferredDefinition":"The response indicating the number of days from the date of the first dose to the date of the last dose of MEK inhibitor during the most recent therapy regimen administration.","longName":"MR_MEK_INH_AG_DY_DUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5FDC1-F31B-BED9-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723255","version":"1","preferredName":"Patient Prior Veliparib Received Code Indicator","preferredDefinition":"The coded response indicating whether a patient has previously received ABT-888 (veliparib) for the treatment of cancer.","longName":"PR_VEL_REC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC63D96-5108-4D86-E050-BB89AD436C7F","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723257","version":"1","preferredName":"Chemotherapy Most Recent Veliparib Administered Agent Start Date","preferredDefinition":"The response indicating the first date of veliparib (ABT-888) administration for the most recent therapy regimen.","longName":"MR_VEL_ADM_AGT_ST_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC5FDC1-F38A-BED9-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723258","version":"1","preferredName":"Chemotherapy Most Recent Veliparib Administered Agent Administration Day Duration","preferredDefinition":"The response indicating the number of days from the date of the first dose to the date of the last dose of veliparib (ABT-888) during the most recent therapy regimen administration.","longName":"MR_VEL_ADM_DY_DUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FC63D96-5128-4D86-E050-BB89AD436C7F","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723674","version":"1","preferredName":"Patient Protocol Agent Prior Therapy Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient has received any prior therapy with any of the investigational agents used in the protocol.","longName":"PAGT_PTX_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FCC71F1-D9B1-C925-E050-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"STARGELM","dateModified":"2020-09-16","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723675","version":"1","preferredName":"Patient BRCA Gene Mutation And Ovarian Carcinoma Or Breast Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient has met the eligibility criteria regarding a BRCA mutation and breast or ovarian cancer.","longName":"BRCA_MU_OV_BR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FCC71F1-D9D8-C925-E050-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"TYRRELLM","dateModified":"2023-12-07","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":"12.07.2023 Added AQT per request ticket CADSR0003164_mmt\r\n2023.11.22 AQT added per ticket request CADSR0003113. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723676","version":"1","preferredName":"Patient PARP1 Gene PARP2 Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient meets the eligibility criteria with regards to PARP 1 and PARP 2 mutations.","longName":"PARP_1_2_MU_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FCC71F1-D9FE-C925-E050-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723677","version":"1","preferredName":"Patient Function Loss TP53 Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient meets the eligibility criteria with regards to p53 mutations.","longName":"FUN_LOS_TP53_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FCC71F1-DA24-C925-E050-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"ZHWENDY","dateModified":"2022-08-05","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723678","version":"1","preferredName":"Patient Function Loss FBXW7 Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient meets the eligibility criteria with regards to FBXW7 mutations.","longName":"FUN_LOS_TFBXW7_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FCC71F1-DA4A-C925-E050-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723679","version":"1","preferredName":"Patient Function Loss ERCC1 Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient meets the eligibility criteria with regards to ERCC1 mutations.","longName":"FUN_LOS_ERCC1_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FCC71F1-DA70-C925-E050-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723680","version":"1","preferredName":"Patient Lesser Control Diabetes Mellitus Eligibility Determination Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to having poorly controlled diabetes.","longName":"LE_CO_DIA_MEL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FCC71F1-DA96-C925-E050-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2015-02-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-23","modifiedBy":"SOKKERL","dateModified":"2023-04-20","changeNote":"9149_Theradex_02.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723792","version":"1","preferredName":"Patient Pancreatic Carcinoma And RAS Family Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient meets the eligibility criteria regarding pancreatic cancer and RAS mutations for participation in a clinical trial.","longName":"PAN_CA_RAS_MU_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDAC505-39F1-75B0-E050-BB89AD430E57","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723795","version":"1","preferredName":"Participant Personal Medical History Epilepsy Seizure Code Indicator","preferredDefinition":"The coded response indicating that a patient meets the eligibility criteria with regards to a medical history of seizures.","longName":"PMHX_EPI_SEI_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDAC505-3A3C-75B0-E050-BB89AD430E57","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SOKKERL","dateModified":"2020-07-16","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723796","version":"1","preferredName":"Patient Stable Metastatic Malignant Neoplasm in the Brain And Steroid Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding having stabilized metastatic brain disease and treatment with steroid therapy.","longName":"S_NEO_BRA_STE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDAC505-3AEE-75B0-E050-BB89AD430E57","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"KUMMEROA","dateModified":"2022-04-01","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723803","version":"1","preferredName":"Patient Anticonvulsant Agent And Negation Seizure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to anticonvulsant medication administration and the occurrence of seizures.","longName":"XCON_AG_N_SEI_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDAC505-3B7F-75B0-E050-BB89AD430E57","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"TAYLORT","dateModified":"2017-03-08","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723806","version":"1","preferredName":"Patient Stable Metastatic Malignant Neoplasm in the Brain Post Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding stable metastatic brain disease following treatment for the brain metastases.","longName":"SME_DZ_BR_POS_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDB5117-FEAB-1E4B-E050-BB89AD430AD9","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SOKKERL","dateModified":"2021-03-11","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723813","version":"1","preferredName":"Patient Prior Temozolomide Poly (ADP-Ribose) Polymerase Inhibitor Combination Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding prior combination therapy with temozolomide and a PARP inhibitor.","longName":"COTX_TEM_PARP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDB5117-FF2B-1E4B-E050-BB89AD430AD9","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SOKKERL","dateModified":"2018-12-05","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723819","version":"1","preferredName":"Patient Prior Everolimus Or mTOR Inhibitor Or Known Temsirolimus Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to prior therapy with everolimus or other mTOR inhibitors or has known hypersensitivity to rapamycin analogs.","longName":"EVE_MTO_RAP_HY_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDB06BA-2FA0-46B7-E050-BB89AD430896","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"HARTLEYG","dateModified":"2015-03-09","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723829","version":"1","preferredName":"Patient Prior Mitogen-Activated Protein Kinase Kinase Inhibitor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding prior treatment with a MEK inhibitor.","longName":"PR_MEK_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDAC505-3BD2-75B0-E050-BB89AD430E57","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-06-12","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":"2023.6.12 AQT added per ticket request CADSR0002508. ak 2022.12.20 AQT added for ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723834","version":"1","preferredName":"Patient Prior Immunosuppressive Therapy Administered Code Indicator","preferredDefinition":"The coded response indicating whether a patient has received prior treatment with immunosuppressive agents.","longName":"PR_IMM_TX_AD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDAC505-3C09-75B0-E050-BB89AD430E57","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723838","version":"1","preferredName":"Patient Prior Attenuated Live Virus Vaccine Administered Code Indicator","preferredDefinition":"The coded response indicating whether a patient has received live virus vaccines.","longName":"LIV_VIR_VAC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDAC505-3C56-75B0-E050-BB89AD430E57","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SOKKERL","dateModified":"2023-06-12","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723846","version":"1","preferredName":"NCI CTEP Simplified Disease Classification Terminology MedDRA Version 10 Code","preferredDefinition":"The coded response indicating the MedDRA code Version 10 used in the NCI Simplified Disease Classification (SDC) Terminology for diagnoses.","longName":"CTEP_SDC_MED_V10_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDBD6FE-B42C-A4AB-E050-BB89AD43240A","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SOKKERL","dateModified":"2023-02-22","changeNote":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4743100","version":"1","preferredName":"Treatment Cohort Study 9149 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol 9149 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9149_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2DDB-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"HARTLEYG","dateModified":"2015-03-11","changeNote":"9149_Theradex_03.10.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4743611","version":"1","preferredName":"Combination Chemotherapy Most Recent Carboplatin WEE1 Inhibitor MK-1775 Administered Time Duration Unit of Measure Code","preferredDefinition":"The response indicating the units of measure used when administering combination chemotherapy using carboplatin and MK-1775.","longName":"MR_CAR_MK1775_UOM_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1105A90E-7175-ED37-E050-BB89AD43028A","latestVersionIndicator":"Yes","beginDate":"2015-03-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-11","modifiedBy":"HARTLEYG","dateModified":"2015-03-11","changeNote":"9149_Theradex_03.11.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4743612","version":"1","preferredName":"Chemotherapy Most Recent Poly (ADP-Ribose) Polymerase Inhibitor Administered Time Duration Unit of Measure Code","preferredDefinition":"The response indicating the units of measure used when administering chemotherapy using Poly (ADP-Ribose) Polymerase inhibitor.","longName":"MR_PARP_DUR_UOM_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1105A90E-719A-ED37-E050-BB89AD43028A","latestVersionIndicator":"Yes","beginDate":"2015-03-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-11","modifiedBy":"HARTLEYG","dateModified":"2015-03-11","changeNote":"9149_Theradex_03.11.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4743613","version":"1","preferredName":"Chemotherapy Most Recent Everolimus Or mTOR Inhibitor Administered Time Duration Unit of Measure Code","preferredDefinition":"The response indicating the units of measure used when administering chemotherapy using everolimus or other mTOR inhibitor.","longName":"EVE_MTOR_INH_UOM_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1105A90E-71BA-ED37-E050-BB89AD43028A","latestVersionIndicator":"Yes","beginDate":"2015-03-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-11","modifiedBy":"HARTLEYG","dateModified":"2015-03-11","changeNote":"9149_Theradex_03.11.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4743614","version":"1","preferredName":"Chemotherapy Most Recent Mitogen-Activated Protein Kinase Kinase Inhibitor Administered Time Duration Unit of Measure Code","preferredDefinition":"The response indicating the units of measure used when administering chemotherapy using mitogen-activated protein kinase kinase inhibitor.","longName":"MR_MEK_INH_UOM_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1105A90E-71DA-ED37-E050-BB89AD43028A","latestVersionIndicator":"Yes","beginDate":"2015-03-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-11","modifiedBy":"TAYLORT","dateModified":"2015-08-27","changeNote":"9149_Theradex_03.11.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4743615","version":"1","preferredName":"Chemotherapy Most Recent Veliparib Administered Time Duration Unit of Measure Code","preferredDefinition":"The response indicating the units of measure used when administering chemotherapy using veliparib (ABT-888).","longName":"MR_VEL_DUR_UCOM_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1105A90E-71FA-ED37-E050-BB89AD43028A","latestVersionIndicator":"Yes","beginDate":"2015-03-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-11","modifiedBy":"HARTLEYG","dateModified":"2015-03-11","changeNote":"9149_Theradex_03.11.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4747331","version":"1","preferredName":"Patient Prior Registration Identifier Number","preferredDefinition":"The response regarding a patient's identification number assigned when previously registered to a clinical trial.","longName":"PT_PRIOR_REG_ID_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"119364CC-A982-61AE-E050-BB89AD436B73","latestVersionIndicator":"Yes","beginDate":"2015-03-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-18","modifiedBy":"MAESKEB","dateModified":"2016-03-14","changeNote":"9149_Theradex_03.18.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4747332","version":"1","preferredName":"Patient Prior Registration Code Indicator","preferredDefinition":"The coded response indicating whether a patient had been previously registered to a clinical trial.","longName":"PT_PRIOR_REG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"119364CC-A9AA-61AE-E050-BB89AD436B73","latestVersionIndicator":"Yes","beginDate":"2015-03-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-18","modifiedBy":"SOKKERL","dateModified":"2019-01-15","changeNote":"9149_Theradex_03.18.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750611","version":"1","preferredName":"Patient Additional Therapeutic Procedure Prior Enrollment Negation Evaluation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has not been evaluated for the potential need for additional treatment before enrollment onto a clinical trial.","longName":"NO_EVAL_ADD_TR_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11F97955-E9EA-7C12-E050-BB89AD436DE4","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"KUMMEROA","dateModified":"2023-06-27","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750626","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has meets the eligibility criteria for immunosuppressive therapy.","longName":"IMMUNO_TX_CTEC_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11F97955-EA10-7C12-E050-BB89AD436DE4","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"SOKKERL","dateModified":"2023-08-28","changeNote":"12/5/16 tt, added CSI. 9672_Theradex_03.23.15_ghd","administrativeNotes":"2022.11.18 AQT added for NRG ticket request CADSR0001716 cjl; 2022.11.15 AQT added for ticket request CADSR0001687. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750627","version":"1","preferredName":"Patient Expected Recurrence Disease or Disorder Without Initiator Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the criteria for diseases/disorders that are expected to recur without an initiator in order to enroll in a clinical trial.","longName":"REC_DZ_WO_INIT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11F97955-EA36-7C12-E050-BB89AD436DE4","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"SOKKERL","dateModified":"2021-02-24","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750651","version":"1","preferredName":"Autoimmune Or Immunodeficiency Disease or Disorder Personal Medical History Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has a personal medical history of autoimmune disease or immunodeficiency disease/disorder.","longName":"AUT_IMMUN_DZ_PMH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11F97955-EA5C-7C12-E050-BB89AD436DE4","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"9672_Theradex_03.23.15_ghd 03-20-2018 Fixed Theradex CRF Text 12, 13, 14, 4, 9 to replace upside question mark with apostrophe DW","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak 8/5/2022: fixed the box symbol in AQT_wz 2022.8.10 Corrected special character Ticket CADSR0001350. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750667","version":"1","preferredName":"Patient Human Immunodeficiency Virus Or Acquired Immunodeficiency Syndrome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the criteria for human immunodeficiency virus or acquired immunodeficiency syndrome to allow for enrollment onto a clinical trial.","longName":"PT_HIV_AIDS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11F97955-EAAB-7C12-E050-BB89AD436DE4","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-31","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750668","version":"1","preferredName":"Patient Monoclonal Antibody Infusion Hypersensitivity Personal Medical History Code Indicator","preferredDefinition":"The coded response indicating whether or not a patient has a personal medical history of hypersensitivity to any monoclonal antibody.","longName":"M_AXBD_HYPER_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11FA4939-27C5-EFB3-E050-BB89AD4350C3","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"SOKKERL","dateModified":"2021-07-30","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750696","version":"1","preferredName":"Patient Residual Inflammatory Bowel Disease Or Intestinal Toxicity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for enrollment onto a clinical trial regarding residual inflammatory bowel disease or residual intestinal toxicity.","longName":"RES_IBF_INT_TOX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11FA4939-2804-EFB3-E050-BB89AD4350C3","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"HARTLEYG","dateModified":"2015-03-24","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750699","version":"1","preferredName":"Patient Prior Palliative Limited Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria for enrollment onto a clinical trial with regards to prior palliative limited radiation therapy.","longName":"PAL_LIM_RX_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11FA6CE1-4E19-6CCA-E050-BB89AD4348D6","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"SOKKERL","dateModified":"2021-05-18","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750740","version":"1","preferredName":"Patient Prior First-Line Chemotherapy Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria for enrolling onto a clinical trial with regards to first-line chemotherapy administration.","longName":"FIR_LINE_CHEM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11FA4939-282A-EFB3-E050-BB89AD4350C3","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4750777","version":"1","preferredName":"Patient Histological Or Cytopathological Confirmation Advanced Leiomyosarcoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for enrollment onto a clinical trial with regards to histological or cytological confirmation of leiomyosarcoma of the uterus.","longName":"HIST_CYT_ULMS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11FA6CE1-4EFC-6CCA-E050-BB89AD4348D6","latestVersionIndicator":"Yes","beginDate":"2015-03-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-23","modifiedBy":"SOKKERL","dateModified":"2023-07-26","changeNote":"9672_Theradex_03.23.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4769531","version":"1","preferredName":"Patient Complete Remission Or Complete Response with Incomplete Bone Marrow Recovery Acute Myeloid Leukemia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding the remission status Acute Myeloid Leukemia for enrollment onto a clinical trial.","longName":"CR_CRI_AML_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12B06A28-4BF4-123E-E050-BB89AD43630F","latestVersionIndicator":"Yes","beginDate":"2015-04-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-01","modifiedBy":"TAYLORT","dateModified":"2017-10-10","changeNote":"9706_Theradex_04.01.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4769537","version":"1","preferredName":"Patient Bone Marrow Confirmed Remission Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria for enrollment on a clinical trial with regards to confirmed remission after bone marrow biopsy.","longName":"BM_REM_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12B06A28-4C1A-123E-E050-BB89AD43630F","latestVersionIndicator":"Yes","beginDate":"2015-04-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-01","modifiedBy":"HARTLEYG","dateModified":"2015-04-03","changeNote":"9706_Theradex_04.01.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4769538","version":"1","preferredName":"Patient Negation Hematopoietic Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to enroll on a clinical trial with regards to not being a candidate for stem cell transplant.","longName":"ST_CEL_TRAN_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12B06A28-4C43-123E-E050-BB89AD43630F","latestVersionIndicator":"Yes","beginDate":"2015-04-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-01","modifiedBy":"SOKKERL","dateModified":"2018-09-10","changeNote":"9706_Theradex_04.01.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4772103","version":"1","preferredName":"Treatment Cohort Study Date","preferredDefinition":"The response indicating the date that a patient participating in a Theradex clinical trial will be assigned to a cohort.","longName":"TRT_COH_SDY_DATE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12D80060-A298-A855-E050-BB89AD435CE3","latestVersionIndicator":"Yes","beginDate":"2015-04-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-03","modifiedBy":"HARTLEYG","dateModified":"2015-04-03","changeNote":"Theradex_04.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4786479","version":"1","preferredName":"Patient CD4 Antigen And Antiviral Agent Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for enrollment in a clinical trial with regards to CD4 antigen count and antiviral agent administration.","longName":"CD4_XVIR_AGT_ADM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133E88EC-0FF5-8F43-E050-BB89AD4364A0","latestVersionIndicator":"Yes","beginDate":"2015-04-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-08","modifiedBy":"SOKKERL","dateModified":"2020-12-31","changeNote":"9008_Theradex_04.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787911","version":"1","preferredName":"Patient Histological Or Cytopathological Confirmation Previously Treated Anal Canal Metastatic Squamous Cell Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether or not a patient meets the criteria for enrollment onto a clinical trial with regards to the histological or cytological confirmation of previously treated squamous cell carcinoma of the anal canal.","longName":"CONF_SQU_CL_CARC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"135323BA-E9C5-718E-E050-BB89AD431898","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"HARTLEYG","dateModified":"2015-04-10","changeNote":"9673_Theradex_04.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787932","version":"1","preferredName":"Patient Radiation Therapy Treatment Completed as Prescribed Prior to Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient met the eligibility criteria with regards to completion of radiation therapy prior to study drug administration.","longName":"RX_COM_PRIOR_PX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"135323BA-E9F4-718E-E050-BB89AD431898","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"SOKKERL","dateModified":"2022-04-18","changeNote":"9673_Theradex_04.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787933","version":"1","preferredName":"Patient Sufficient Prior Radiation Or Surgery Stable Disease 3 Month Prior to Registration Neurologically Asymptomatic Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for enrollment on a clinical trial with regards to having received sufficient radiation or surgical treatment and having stable disease for 3 months prior to registration and being neurologically asymptomatic.","longName":"PR_TX_SD_ASY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"135323BA-EA1C-718E-E050-BB89AD431898","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"HARTLEYG","dateModified":"2015-04-10","changeNote":"9673_Theradex_04.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787934","version":"1","preferredName":"Patient MRI Report Without Progressive Disease Evidence After Prior Therapy And Prior to Nivolumab Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria for enrollment onto a clinical trial with regards to whether there is no evidence of progressive disease on MRI after treatment is completed but prior to first dose of nivolumab.","longName":"MRI_WO_PD_PR_NIV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"135323BA-EA43-718E-E050-BB89AD431898","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"HARTLEYG","dateModified":"2015-04-10","changeNote":"9673_Theradex_04.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787939","version":"1","preferredName":"Patient Human Immunodeficiency Virus Testing Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for enrollment on a clinical trial with regards to consenting for HIV testing.","longName":"HIV_TEST_CONS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"13540CE7-2890-B4D5-E050-BB89AD434FCF","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"TAYLORT","dateModified":"2018-02-21","changeNote":"2/21/18 removed redundant term from question text/9673.  9673_Theradex_04.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787940","version":"1","preferredName":"Patient Infectious Disorder Specialist Physician Patient Care Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for enrollment into a clinical trial with regards to receipt of care from an infectious disease specialist.","longName":"INF_DS_SPEC_CARE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"13540CE7-28B7-B4D5-E050-BB89AD434FCF","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"HARTLEYG","dateModified":"2015-04-10","changeNote":"9673_Theradex_04.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787941","version":"1","preferredName":"Patient Hepatitis Disease Screening Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria for enrollment into a clinical trial with regarding consent for hepatitis screening.","longName":"HEP_SCRE_CON_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"13540CE7-28DE-B4D5-E050-BB89AD434FCF","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"SOKKERL","dateModified":"2018-04-25","changeNote":"9673_Theradex_04.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4787942","version":"1","preferredName":"Patient Autoimmune Disease Active Or Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility critieria for enrollment into a clinical trial regarding active autoimmune disease or a history of autoimmune disease.","longName":"AUTO_DZ_PMHX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"13540CE7-2905-B4D5-E050-BB89AD434FCF","latestVersionIndicator":"Yes","beginDate":"2015-04-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-09","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"9673_Theradex_04.09.15_ghd","administrativeNotes":"7/20/23 removed special character from AQT_mmt\r\n2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4791549","version":"1","preferredName":"Treatment Cohort Study 9008 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9008 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9008_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"13B28949-6420-9492-E050-BB89AD431C69","latestVersionIndicator":"Yes","beginDate":"2015-04-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-14","modifiedBy":"HARTLEYG","dateModified":"2015-04-14","changeNote":"9008_Theradex_04.14.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798571","version":"1","preferredName":"Patient Histologically Confirmed Metastatic Genitourinary Solid Tumor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to having a histologically confirmed diagnosis of metastatic, genitourinary solid tumor.","longName":"HIS_CONF_MET_GEN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"145ABE7C-84E2-1C28-E050-BB89AD4368D3","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-22","modifiedBy":"HARTLEYG","dateModified":"2015-04-28","changeNote":"9681_Theradex_04.22.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798572","version":"1","preferredName":"Patient Metastatic Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to metastatic disease.","longName":"MET_DZ_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"145ABE7C-853F-1C28-E050-BB89AD4368D3","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-22","modifiedBy":"SOKKERL","dateModified":"2023-05-10","changeNote":"9681_Theradex_04.22.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798591","version":"1","preferredName":"Patient Histologically Confirmed Metastatic Progressive Urothelial Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to a histologically confirmed diagnosis of metastatic progressive urothelial carcinoma.","longName":"CONF_MET_URO_CAR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"145ABE7C-85C9-1C28-E050-BB89AD4368D3","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-22","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeNote":"9681_Theradex_04.22.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798592","version":"1","preferredName":"Patient RECIST Metastatic Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient meets the criteria with regards to a diagnosis of progressive metastatic disease as defined by RECIST criteria.","longName":"RECIST_MET_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"145ABE7C-862D-1C28-E050-BB89AD4368D3","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-22","modifiedBy":"SOKKERL","dateModified":"2017-06-09","changeNote":"9681_Theradex_04.22.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798593","version":"1","preferredName":"Patient Standard Therapeutic Procedure Failure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility critieria with regards to failed standard therapy.","longName":"STD_TX_FAIL_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"145ABE7C-8654-1C28-E050-BB89AD4368D3","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-22","modifiedBy":"SOKKERL","dateModified":"2021-03-11","changeNote":"9681_Theradex_04.22.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798594","version":"1","preferredName":"Laboratory Procedure Lipase Outcome Code Indicator","preferredDefinition":"The coded response indicating whether the outcome from a laboratory procedure to measure lipase met the pre-determined criteria.","longName":"LAB_PROC_LIPASE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"145ABE7C-867B-1C28-E050-BB89AD4368D3","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-22","modifiedBy":"SOKKERL","dateModified":"2020-07-31","changeNote":"9681_Theradex_04.22.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798595","version":"1","preferredName":"Laboratory Procedure Phosphorus Calcium Magnesium Potassium Assessment Code Indicator","preferredDefinition":"The coded response indicating whether the outcome of a laboratory procedure to measure phosphorus, calcium and magnesium met the pre-defined criteria.","longName":"LAB_P_CA_MG_ASM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"145ABE7C-86A2-1C28-E050-BB89AD4368D3","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-22","modifiedBy":"SOKKERL","dateModified":"2023-05-30","changeNote":"9681_Theradex_04.22.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798914","version":"1","preferredName":"Patient Cytotoxic Chemotherapy Biological Agent Nitrosourea Compound Mitomycin Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility requirements for participation in a clinical trial regarding prior treatment with cytotoxic chemotherapy, biologic agents or nitrosoureas/mitomycin C.","longName":"CYT_CHX_BIO_NIT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6902-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"BROWNTY","dateModified":"2022-03-07","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798915","version":"1","preferredName":"Patient c-MET Inhibitor Or VEGFR Tyrosine Kinase Inhibitor Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria to participate in a clinical trial with regards to prior treatment MET or VEGFR inhibitors.","longName":"PR_TX_MET_VEGFR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6929-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"KENNISHM","dateModified":"2022-03-01","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798916","version":"1","preferredName":"Patient Thoracic Cavity Or Abdomen Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to prior radiation therapy to the thoracic cavity or abdomen.","longName":"THO_ABD_RX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6951-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2021-09-21","changeNote":"2020-7-27 AQT added for protocol 10389.  AK 9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798917","version":"1","preferredName":"Patient Bone Or Metastatic Malignant Neoplasm in the Brain Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to prior radiation therapy to bone or brain metastases.","longName":"BONE_BRA_MET_RX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6978-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"HARTLEYG","dateModified":"2015-04-28","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798918","version":"1","preferredName":"Patient Other Anatomic Site Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to prior radiation therapy administered to other sites.","longName":"OTH_SIT_RX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-699F-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2019-06-03","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798919","version":"1","preferredName":"Patient Isotope Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to administration or prior isotope therapy.","longName":"ISO_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-69C6-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2022-07-18","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798921","version":"1","preferredName":"Patient Small Molecule Kinase Enzyme Inhibitor Or Endocrine Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding administration of prior treatment with a small molecule kinase inhibitor or hormonal therapy.","longName":"KIN_ENZ_INH_ENDO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6A0B-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2022-07-18","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798922","version":"1","preferredName":"Patient Gastrointestinal Hemorrhage Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding gastrointestinal bleeding prior to study treatment.","longName":"GI_HEM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6A32-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2017-07-19","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798923","version":"1","preferredName":"Patient Hemoptysis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding the presence of hemoptysis prior to administration of study treatment.","longName":"HEMOP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6A59-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798924","version":"1","preferredName":"Patient Pulmonary Hemorrhage Sign Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding the presence of other signs indicative of pulmonary hemorrhage prior to study treatment.","longName":"PUL_HEM_SIG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6A80-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"HARTLEYG","dateModified":"2015-04-28","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798926","version":"1","preferredName":"Neoplasm Major Blood Vessel Involvement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding tumor involvement with major blood vessels.","longName":"NEO_MAJ_BV_INV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6AC3-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2019-06-24","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798931","version":"1","preferredName":"Patient Gastrointestinal Tract Or Respiratory System Tumor Cell Invasion Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding evidence of tumor invading the gastrointestinal tract or respiratory tract prior to study treatment.","longName":"GI_RESP_TUM_INVA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6B26-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2020-09-14","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798933","version":"1","preferredName":"Patient Gastrointestinal Disease or Disorder Integer::14 Day Prior Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding gastrointestinal disease or disorders present 14 days prior to study treatment.","longName":"GI_DZ_DS_14DY_PX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146CB4EC-E120-6E94-E050-BB89AD4322BC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2020-09-15","changeNote":"9681_Theradex_04.23.15 3-18-2020 Fixed special characters in Ref Docs DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798934","version":"1","preferredName":"Patient Gastrointestinal Disease or Disorder Integer::6 Month Prior Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding gastrointestinal disease or disorder present 6 months prior to study treatment.","longName":"GI_DZ_DS_6MO_PX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146CB4EC-E147-6E94-E050-BB89AD4322BC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2017-11-29","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798935","version":"1","preferredName":"Patient High Risk Fistula Formation Disease or Disorder Integer::3 Month Prior Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding other disorders associated with a high risk of fistula formation present 3 months prior to study therapy.","longName":"HR_FIS_DZ_DS_3MO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146CB4EC-E16E-6E94-E050-BB89AD4322BC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2017-11-29","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798939","version":"1","preferredName":"Patient Active Infectious Disorder Systemic Therapy Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding the presence of an active infection requiring systemic treatment prior to study therapy.","longName":"ACT_INF_DS_SYSTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146CB4EC-E1BF-6E94-E050-BB89AD4322BC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798944","version":"1","preferredName":"Patient Serious Negation Healed Injury Ulceration Fracture Prior Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding the presence of a serious non-healing wound/ulcer/bone fracture prior to study treatment.","longName":"SER_NEG_HEAL_WOU_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146CB4EC-E238-6E94-E050-BB89AD4322BC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2022-11-16","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798951","version":"1","preferredName":"Patient Personal Medical History Organ Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding a personal medical history of organ transplant.","longName":"PMHX_ORG_TRANS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146CB4EC-E27D-6E94-E050-BB89AD4322BC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798952","version":"1","preferredName":"Patient Concurrent Negation Corrected Thyroid Gland Disease or Disorder Prior Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding the presence of concurrent uncompensated thyroid gland disease or disorder prior to study treatment.","longName":"CONCUR_THY_DZ_DS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146D4F3D-14B4-B7A6-E050-BB89AD437D02","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2019-04-25","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798953","version":"1","preferredName":"Patient Major Surgical Procedure And Wound Complication Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding the occurrence of major surgery with or without wound healing prior to study treatment.","longName":"MAJ_SUR_WOU_COM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146D4F3D-14DB-B7A6-E050-BB89AD437D02","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2018-03-05","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798954","version":"1","preferredName":"Patient Minor Surgical Procedure And Wound Complication Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding the occurrence of minor surgery with or without wound healing prior to study treatment.","longName":"MIN_SUR_WOU_COM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146D4F3D-1502-B7A6-E050-BB89AD437D02","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"SOKKERL","dateModified":"2017-12-28","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798955","version":"1","preferredName":"Injury Completely Healed Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding complete wound healing prior to study treatment.","longName":"INJ_HEAL_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146D4F3D-1529-B7A6-E050-BB89AD437D02","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"HARTLEYG","dateModified":"2015-04-28","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798956","version":"1","preferredName":"Patient Personal Medical History Severe Monoclonal Antibody Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding a personal medical history of severe hypersensitivity to monoclonal antibodies.","longName":"PMHX_SEV_XBD_HYP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"146D4F3D-1550-B7A6-E050-BB89AD437D02","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-23","modifiedBy":"HARTLEYG","dateModified":"2015-04-28","changeNote":"9681_Theradex_04.23.15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4800951","version":"1","preferredName":"Test Result Reference Object Range Flag Code Indicator","preferredDefinition":"The coded response indicating a laboratory value that lies outside of the boundaries of a reference range.","longName":"TEST_RES_REF_RNG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"14BC44E7-7FB6-E77A-E050-BB89AD433FE4","latestVersionIndicator":"Yes","beginDate":"2015-04-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-04-27","modifiedBy":"SOKKERL","dateModified":"2020-07-16","changeNote":"Theradex_04.27.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4811991","version":"1","preferredName":"Patient Carboplatin Paclitaxel Expected Response Or BRCA1/BRCA2 Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial with regards to an expectation of response to carboplatin/paclitaxel combination therapy OR a BRCA1/2 mutation.","longName":"CAR_PAC_BRCA_MUT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15708BAB-0B3F-6EB0-E050-BB89AD43090A","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"HARTLEYG","dateModified":"2015-05-07","changeNote":"9782_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4811992","version":"1","preferredName":"Prior Therapy Carboplatin Administered Code Indicator","preferredDefinition":"The coded response indicating whether the patient has met the eligibility criteria regarding having received prior carboplatin therapy.","longName":"PR_TX_CARB_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15708BAB-0B66-6EB0-E050-BB89AD43090A","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"MAESKEB","dateModified":"2016-04-28","changeNote":"9782_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4811993","version":"1","preferredName":"Peripheral Neuropathy Mild Adverse Event Present Code Indicator","preferredDefinition":"The coded response indicating whether a disorder affecting the peripheral nervous system and manifests with pain, tingling, numbness, and muscle weakness experienced as a transient event, requiring no special treatment or intervention is present.","longName":"PER_NEU_MILD_AE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1570B87C-8E73-5634-E050-BB89AD43559C","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"SOKKERL","dateModified":"2018-03-16","changeNote":"9782_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4812034","version":"1","preferredName":"Patient Histologically Confirmed Gastrointestinal Malignant Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether or not a patient has been diagnosed with histologically confirmed, gastrointestinal malignancy that meets the eligibility criteria for participation in a clinical trial.","longName":"HIS_CON_GI_MAL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15731758-0281-7551-E050-BB89AD4367EC","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"HARTLEYG","dateModified":"2015-05-07","changeNote":"9824_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4812035","version":"1","preferredName":"Lesion Evaluable Disease Status Code Indicator","preferredDefinition":"The coded response indicating whether a patient has disease that cannot be measured directly by the size of the tumor but can be evaluated by other clinical trial specific methods that meets the eligibility criteria for participation in a clinical trial.","longName":"LES_EVAL_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15731758-02A8-7551-E050-BB89AD4367EC","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"SOKKERL","dateModified":"2023-07-11","changeNote":"9824_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4812036","version":"1","preferredName":"Patient Allogeneic Bone Marrow Transplantation Or Organ Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient has or has not had an allogeneic bone marrow transplant or an organ transplant that meets the eligibility criteria for participation in a clinical trial.","longName":"ALL_BMT_ORG_TRAN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15731758-02CF-7551-E050-BB89AD4367EC","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"KUMMEROA","dateModified":"2023-11-03","changeNote":"9824_Theradex_05.06.15_ghd","administrativeNotes":"2023.11.3 AQT added per ticket request CADSR0003032. ak 2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4812037","version":"1","preferredName":"Person Sleep Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial regarding sleep disorders.","longName":"SLEEP_DIS_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15731758-02F6-7551-E050-BB89AD4367EC","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"HARTLEYG","dateModified":"2015-05-07","changeNote":"9824_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4812051","version":"1","preferredName":"Patient Proton Pump Inhibitor Or Pancreatic Enzyme Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial regarding proton pump inhibitors or pancreatic enzymes.","longName":"PPI_PANCR_ENZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15731758-031D-7551-E050-BB89AD4367EC","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"SOKKERL","dateModified":"2023-03-27","changeNote":"9824_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4812052","version":"1","preferredName":"Person Oral Route of Administration Or Fasting Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial regarding the ability to take medication via the mouth or into the gastrointestinal tract by the way of the mouth or to withhold food or drink for a specified period of time.","longName":"ORAL_ADM_FAST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15731758-0344-7551-E050-BB89AD4367EC","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"HARTLEYG","dateModified":"2015-05-07","changeNote":"9824_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4812053","version":"1","preferredName":"Peripheral Neuropathy Moderate Adverse Event Present Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial regarding moderate peripheral neuropathy.","longName":"PER_NEU_MOD_AE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15731758-036B-7551-E050-BB89AD4367EC","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-06","modifiedBy":"SOKKERL","dateModified":"2022-08-23","changeNote":"9824_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4821391","version":"1","preferredName":"Patient Histological Or Cytopathological Confirmation Nasopharyngeal Nonkeratinizing Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial regarding histological and cytopathological confirmation of nasopharyngeal nonkeratinizing carcinoma diagnosis.","longName":"HIS_CYT_NAS_CAR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"158504CD-3627-791F-E050-BB89AD431C92","latestVersionIndicator":"Yes","beginDate":"2015-05-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-07","modifiedBy":"HARTLEYG","dateModified":"2015-05-13","changeNote":"9742_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4821392","version":"1","preferredName":"Patient Hepatitis B Virus HBsAg Surface Protein Antigen Positive Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial regarding a positive finding of the Hepatitis B Virus HBsAg surface protein antigen.","longName":"HEPB_SUR_ANT_POS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"158504CD-364E-791F-E050-BB89AD431C92","latestVersionIndicator":"Yes","beginDate":"2015-05-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-07","modifiedBy":"SOKKERL","dateModified":"2022-03-15","changeNote":"9742_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4821393","version":"1","preferredName":"Patient Hepatitis C Antibody Positive Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria for participation in a clinical trial regarding a positive finding for Hepatitis C antibody.","longName":"HEPC_ANTI_POS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"158504CD-3675-791F-E050-BB89AD431C92","latestVersionIndicator":"Yes","beginDate":"2015-05-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-07","modifiedBy":"SOKKERL","dateModified":"2022-03-15","changeNote":"9742_Theradex_05.06.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4830074","version":"1","preferredName":"Treatment Cohort Study 9706 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9706 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9706_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"168633DC-6289-AA0A-E050-BB89AD433556","latestVersionIndicator":"Yes","beginDate":"2015-05-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-20","modifiedBy":"HARTLEYG","dateModified":"2015-05-20","changeNote":"9706_Theradex_05.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4839328","version":"1","preferredName":"Estimated Glomerular Filtration Rate Result Requirement Code Indicator","preferredDefinition":"The coded response indicating whether the required results of an eGFR lab test were met.","longName":"EGFR_RES_REQU_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17142362-12D9-B797-E050-BB89AD4301A2","latestVersionIndicator":"Yes","beginDate":"2015-05-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-27","modifiedBy":"SOKKERL","dateModified":"2023-12-27","changeNote":"Theradex_05.27.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4839931","version":"1","preferredName":"Prior Chemotherapy Intravesical Treatment Code Indicator","preferredDefinition":"The coded response indicating whether a patient has previously received intravesical therapy per the indicated criteria.","longName":"PR_INTRAVES_TRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17177F19-1BAE-F8A3-E050-BB89AD431CEE","latestVersionIndicator":"Yes","beginDate":"2015-05-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-27","modifiedBy":"HARTLEYG","dateModified":"2015-05-28","changeNote":"9653_Theradex_05.27.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4839971","version":"1","preferredName":"Patient Upper Urothelial Carcinoma Diagnosis Code Indicator","preferredDefinition":"The coded response indicating whether a patient has been diagnosed with urothelial carcinoma originating from the upper portion of the transitional epithelium of the urinary tract..","longName":"UP_UROTHEL_CAR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17177F19-1C35-F8A3-E050-BB89AD431CEE","latestVersionIndicator":"Yes","beginDate":"2015-05-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-27","modifiedBy":"HARTLEYG","dateModified":"2015-05-28","changeNote":"9653_Theradex_05.27.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4839972","version":"1","preferredName":"Patient Non-Urothelial Carcinoma Histology Present Code Indicator","preferredDefinition":"The coded response indicating whether the patient has a diagnosis of bladder cancer that is non-urothelial in nature such as such as pure squamous carcinoma, adenocarcinoma and small cell carcinoma.","longName":"NON_UROTHEL_HIST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17177F19-1C8F-F8A3-E050-BB89AD431CEE","latestVersionIndicator":"Yes","beginDate":"2015-05-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-27","modifiedBy":"HARTLEYG","dateModified":"2016-02-22","changeNote":"9653_Theradex_05.27.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845371","version":"1","preferredName":"Patient Histologically Or Cytology Confirmation Previous Untreated Squamous Cell Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient's diagnosis of untreated squamous cell carcinoma has been histologically or cytologically confirmed and meets the criteria for enrollment on a clinical trial.","longName":"UTRT_SQCELL_CARC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0752C-9BD0-C7D3-E050-BB89AD434683","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"HARTLEYG","dateModified":"2015-06-04","changeNote":"9874_Theradex_06.03.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845372","version":"1","preferredName":"Squamous Cell Carcinoma AJCC Stage Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates that a patient's squamous cell carcinoma has been staged using the AJCC and meets the criteria for enrollment into a clinical trial.","longName":"SQCEL_AJCC_STG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0752C-9BF7-C7D3-E050-BB89AD434683","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":"2023.4.5 AQT added per ticket request CADSR0002271. ak 8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845373","version":"1","preferredName":"Disease or Disorder Potential Cure Radiation Therapy And Cisplatin Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient's disease is potentially curable with a combination of radiation therapy and cisplatin based chemotherapy that meets the criteria for enrollment into a clinical trial.","longName":"DZ_CURE_RXCHEM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0752C-9C1E-C7D3-E050-BB89AD434683","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"HARTLEYG","dateModified":"2015-06-04","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845374","version":"1","preferredName":"Laboratory Finding Pre-study Corrected QT Interval Less Than Integer::470 Millisecond Outcome Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient's pre-study corrected QT Interval is < 480 msec and meets the criteria for enrollment into a clinical trial.","longName":"QTC_LT_470MS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0A81E-4687-035A-E050-BB89AD433E51","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"TAYLORT","dateModified":"2015-09-29","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845375","version":"1","preferredName":"Patient Future Follow-up Code Indicator","preferredDefinition":"The coded response indicating whether a patient is available for long term disease follow-up after completion of treatment.","longName":"FUTURE_FLWUP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0A81E-46AE-035A-E050-BB89AD433E51","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"TAYLORT","dateModified":"2015-09-30","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845377","version":"1","preferredName":"Patient Nasopharynx Paranasal Sinus Skin Or Unknown Primary Anatomic Site Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient has a primary site of disease is either nasopharyngeal, paranasal sinus, skin or unknown site that meets the eligibility criteria for enrollment in a clinical trial.","longName":"N_SIN_SK_UNK_SIT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0A81E-46D5-035A-E050-BB89AD433E51","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2021-12-20","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845379","version":"1","preferredName":"Distant Metastasis Present Code Indicator","preferredDefinition":"The coded response that indicates whether a patient has distant metastases (M1).","longName":"DIST_METAST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0BE55-6AA5-E39C-E050-BB89AD436158","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2021-12-21","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845384","version":"1","preferredName":"Prior Head and Neck Radiation Therapy Occurrence Code Indicator","preferredDefinition":"The coded response that indicates whether a patient has previously received head and neck radiation therapy.","longName":"PRIOR_HD_NECK_RX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0A81E-474C-035A-E050-BB89AD433E51","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"HARTLEYG","dateModified":"2015-06-04","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845388","version":"1","preferredName":"Patient Sensorineural Hearing Loss Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient has experienced sensorineural hearing loss that meets the eligibility criteria for enrollment into a clinical trial.","longName":"SENS_HEAR_LOSS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0A81E-4776-035A-E050-BB89AD433E51","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"HARTLEYG","dateModified":"2015-06-04","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845395","version":"1","preferredName":"Patient Visual Loss Syndrome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates that a patient experienced(s) visual loss syndromes that meet the eligibility criteria for enrollment into a clinical trial.","longName":"VIS_LOSS_SYN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0A81E-479D-035A-E050-BB89AD433E51","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"TAYLORT","dateModified":"2018-01-12","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4845407","version":"1","preferredName":"Patient Known Human Immunodeficiency Virus And Inadequate CD4 Expressing Cell Count Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has known HIV and has inadequate CD4 cell count that meets the eligibility criteria for enrollment into a clinical trial.","longName":"HIV_INAD_CD4_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A0A81E-4866-035A-E050-BB89AD433E51","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"TAYLORT","dateModified":"2016-11-15","changeNote":"9874_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851481","version":"1","preferredName":"Patient Histologically Or Cytology Confirmation Acute Myeloid Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has a histological or cytological confirmation of an AML or CML diagnosis that meets the eligibility criteria in order to enroll in a clinical trial.","longName":"HIS_CYT_AML_CML_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A787B8-4934-2DB0-E050-BB89AD435338","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"MAESKEB","dateModified":"2015-12-29","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851491","version":"1","preferredName":"Patient Acute Myeloid Leukemia Recurrent Disease Or Refractory First-Line Therapy Refractory Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded response that indicates that a patient has a diagnosis of AML that is recurrent or refractory to first-line therapy that meets the eligibility criteria to enroll into a clinical trial.","longName":"AML_RCR_RFR_1LIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A8BF64-5820-F9FB-E050-BB89AD437669","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2019-11-05","changeNote":"9853_Theradex_06.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851492","version":"1","preferredName":"Patient Untreated Unfavorable Molecular Abnormality Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded response indicating that a treatment naive patient does not express molecular abnormalities that meet the eligibility criteria for enrolling in a clinical trial.","longName":"UTRT_NO_MOL_ABN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A8BF64-5847-F9FB-E050-BB89AD437669","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"MAESKEB","dateModified":"2015-12-30","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851496","version":"1","preferredName":"Patient Failed Hypomethylation Agent Or Intolerance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has failed or is intolerant to hypomethylating agents that meet the eligibility criteria for enrolling into a clinical trial.","longName":"FAIL_HYPOMETHYL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EB48-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"ZHWENDY","dateModified":"2022-08-05","changeNote":"9853_Theradex_06.02.15_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851497","version":"1","preferredName":"Patient BCR/ABL1 Fusion Protein Inhibition Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has received therapy with Bcr-Abl-TKI containing regimen that meets the eligibility criteria for enrollment into a clinical trial.","longName":"BCR_ABL_TKI_TRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EB6F-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"MAESKEB","dateModified":"2015-12-29","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851498","version":"1","preferredName":"Patient Leukostasis Or Disseminated Coagulation Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient appears to have leukostasis or has evidence of disseminated coagulation disorder that meets the eligibility criteria for enrollment into a clinical trial.","longName":"LEUKO_DIS_COAG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EB96-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2021-11-19","changeNote":"9853_Theradex_06.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851499","version":"1","preferredName":"Acute Promyelocytic Leukemia Diagnosis Code Indicator","preferredDefinition":"The coded response that indicates a patient has a diagnosis of acute promyelocytic leukemia that meets the eligibility criteria for participation in a clinical trial.","longName":"APL_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EBBD-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"9853_Theradex_06.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851511","version":"1","preferredName":"Patient Stem Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has received a stem cell transplant that meets the eligibility criteria for participation in a clinical trial.","longName":"STEM_CELL_TRANSP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EBE4-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2020-07-31","changeNote":"9853_Theradex_06.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851512","version":"1","preferredName":"Patient Blast Cell Count Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient's blast cell count meets the eligibility criteria to participate in a clinical trial.","longName":"BLAST_CEL_CT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EC0B-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2021-11-18","changeNote":"9853_Theradex_06.02.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851513","version":"1","preferredName":"Patient Curable Allogenic Hematopoietic Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient is a candidate for a curative allogenic stem cell transplant that meets the eligibility criteria to participate in a clinical study.","longName":"CUR_ALLO_CEL_TPT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EC32-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2017-02-06","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851514","version":"1","preferredName":"Laboratory Finding Pre-study Corrected QT Interval Greater Than or Equal To Integer::450 Millisecond Outcome Code Indicator","preferredDefinition":"The coded response that indicates the pre-study corrected QTc interval is greater than or equal to 450 ms.","longName":"QTC_GTE_450MS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EC59-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851515","version":"1","preferredName":"Patient Physician Read Corrected QT Interval Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a physician has manually read and corrected a patient's QT interval using a protocol specified formula that meets the eligibility criteria for a patient's participation in a clinical trial.","longName":"MD_READ_QTC_INVL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-EC80-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2019-02-05","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851516","version":"1","preferredName":"Patient AV Block Second Degree Mobitz Type II Or AV Block Third Degree by ECG Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates that the patient has a AV block second degree type 2 or 3rd degree AV block that meets the eligibility criteria for participating in a clinical trial.","longName":"PT_AV_BLOCK_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-ECA7-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2018-03-05","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851517","version":"1","preferredName":"Patient Ventricular Heart Rate Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient's ventricular heart rate meets the eligibility criteria for participation in a clinical trial.","longName":"VENTR_HRT_RT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-ECCE-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2017-01-20","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851521","version":"1","preferredName":"Patient Cardiovascular Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has a cardiovascular disorder that meets the eligibility criteria for participation in a clinical trial.","longName":"CARDIOVASC_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-ED22-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2023-01-24","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851531","version":"1","preferredName":"Patient Clinical Study Protocol Specified Cardiovascular Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient has (is or will) received a protocol specified cardiovascular agent that meets the eligibility criteria for participation in a clinical trial.","longName":"PROT_SPEC_CV_AGT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17AA17F4-FFF0-CB7C-E050-BB89AD43536F","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2022-07-20","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851532","version":"1","preferredName":"Patient UDP-Glucuronosyltransferase 1-1 Genetic Polymorphism Clinical Trial Eligibility Criteria Yes No Not Applicable Code Indicator","preferredDefinition":"The coded response that indicates the patient has a UGT1A polymorphism that meets the eligibility criteria for participation in a clinical trial.","longName":"UGT1A_POLYMORPH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17AA17F5-0018-CB7C-E050-BB89AD43536F","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2022-07-20","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851533","version":"1","preferredName":"Patient Belinostat Or WEE1 Inhibitor MK-1775 Prior Therapy Code Indicator","preferredDefinition":"The coded response that indicates a patient has received prior therapy with belinostat or MK-1775.","longName":"BELI_MK1775_PRTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17AA17F5-003F-CB7C-E050-BB89AD43536F","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SOKKERL","dateModified":"2018-01-03","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4851551","version":"1","preferredName":"Patient Heart Disease or Disorder Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating the patient has a heart disease or disorder that meets the eligibility criteria for participation in a clinical trial.","longName":"HRT_DZ_PMH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17AA4D0F-C510-C3FD-E050-BB89AD430FE8","latestVersionIndicator":"Yes","beginDate":"2015-06-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-04","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"9853_Theradex_06.03.15_ghd","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak 8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4860791","version":"1","preferredName":"Patient Prior Radical Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has received prior radical radiation therapy that meets the eligibility criteria in order to participate in a clinical trial.","longName":"PR_RADICAL_RXN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18199818-F656-18F2-E050-BB89AD4304B5","latestVersionIndicator":"Yes","beginDate":"2015-06-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-09","modifiedBy":"WANGC","dateModified":"2020-09-26","changeNote":"Theradex_06.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4860792","version":"1","preferredName":"Patient Abdominal Carcinomatosis Abscess Or Gastrointestinal Obstruction And Additional Therapeutic Procedure Negation Evaluation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has(had) abdominal carcinomatosis, abscess or GI obstruction and has not been evaluated for additional treatment that meets the eligibility criteria for participation in a clinical trial.","longName":"GI_DZ_NOTRT_EVAL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18199818-F677-18F2-E050-BB89AD4304B5","latestVersionIndicator":"Yes","beginDate":"2015-06-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-09","modifiedBy":"SOKKERL","dateModified":"2022-03-25","changeNote":"Theradex_06.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4860814","version":"1","preferredName":"Patient Known Intestinal Perforation Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has known risk factors for bowel perforation which meet the eligibility criteria for participation in a clinical trial.","longName":"BWL_PERF_RISKFAC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"181A0826-D125-DA26-E050-BB89AD4323F3","latestVersionIndicator":"Yes","beginDate":"2015-06-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-09","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"Theradex_06.09.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4868994","version":"1","preferredName":"Patient Percutaneous Needle Biopsy Or Excisional Biopsy Amenable Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient meets the eligibility criteria for percutaneous needle biopsy or excisional biopsy amenable tumor.","longName":"PCUT_NDL_EXC_BX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18973F0A-DB49-B6A8-E050-BB89AD43561C","latestVersionIndicator":"Yes","beginDate":"2015-06-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-15","modifiedBy":"SOKKERL","dateModified":"2020-12-01","changeNote":"9149_Theradex_06.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4869006","version":"1","preferredName":"Patient Anticonvulsant Agent And Negation Seizure Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to receiving protocol agent, anticonvulsant medication administration and the occurrence of seizures.","longName":"XCON_AGT_SEIZ_PXAX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18973F0A-DBD3-B6A8-E050-BB89AD43561C","latestVersionIndicator":"Yes","beginDate":"2015-06-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-15","modifiedBy":"SOKKERL","dateModified":"2017-08-08","changeNote":"9149_Theradex_06.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4869011","version":"1","preferredName":"Patient Gonadotropin-releasing Hormone Analog Agonist Or Antagonist Prostate Carcinoma Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has prostate cancer and is receiving LHRH agonists or antagonists therapy that meets the eligibility criteria for participation in a clinical trial.","longName":"LHRH_AGO_XAG_PRST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18973F0A-DBFE-B6A8-E050-BB89AD43561C","latestVersionIndicator":"Yes","beginDate":"2015-06-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-15","modifiedBy":"HARTLEYG","dateModified":"2015-06-16","changeNote":"9149_Theradex_06.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4875491","version":"1","preferredName":"Patient Histologically Or Cytology Confirmation Uveal Melanoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has a histological and cytological confirmation of uveal melanoma that meets the eligibility criteria for participation in a clinical trial.","longName":"HISCYT_UVEAL_MEL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18C07F21-7898-2E26-E050-BB89AD434BED","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-17","modifiedBy":"HARTLEYG","dateModified":"2015-06-19","changeNote":"9855_Theradex_06.17.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4875492","version":"1","preferredName":"Patient Chemotherapy No Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient is chemotherapy naive that meets the eligibility criteria for participation in a clinical trial.","longName":"CHEMO_NOPRIOR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18C07F21-78BF-2E26-E050-BB89AD434BED","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-17","modifiedBy":"HARTLEYG","dateModified":"2018-06-19","changeNote":"9855_Theradex_06.17.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4875493","version":"1","preferredName":"Lesion Prior Therapy Administered Growth Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a previously treated lesion has increased in size that meets the eligibility criteria for a patient to participate in a clinical trial.","longName":"LES_PRTX_GROW_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18C07F21-78E6-2E26-E050-BB89AD434BED","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-17","modifiedBy":"HARTLEYG","dateModified":"2015-06-19","changeNote":"9855_Theradex_06.17.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4875494","version":"1","preferredName":"Patient Drug Interaction Advising Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has received counseling on the risk of study drug interactions that meets the eligibility criteria for participation in a clinical trial.","longName":"DRUG_XACT_COUNEL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18C07F21-790D-2E26-E050-BB89AD434BED","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-17","modifiedBy":"HARTLEYG","dateModified":"2015-06-19","changeNote":"9855_Theradex_06.17.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4875495","version":"1","preferredName":"Patient Washout Period Negation Complete Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a the washout period after drug administration has not been met that meets the eligibility criteria for participation in a clinical trial.","longName":"WASH_OUT_NOTCOMP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18C0BDBA-558B-25F3-E050-BB89AD432795","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-17","modifiedBy":"TSESU","dateModified":"2023-05-30","changeNote":"9855_Theradex_06.17.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4882715","version":"1","preferredName":"Patient Glembatumumab Vedotin Or Monomethyl Auristatin E Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient has received prior therapy with CDX-011 (glembatumumab vetodin) or MMAE agents that meet the eligibility criteria for participation in a clinical trial.","longName":"CDX011_MMAE_PR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"18E227E4-0DD0-F3A9-E050-BB89AD436452","latestVersionIndicator":"Yes","beginDate":"2015-06-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-19","modifiedBy":"DAVISJ","dateModified":"2015-12-10","changeNote":"9855_Theradex_06.19.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4889631","version":"1","preferredName":"Patient Chronic Graft Versus Host Disease Post Hematopoietic Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based upon an incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor.","longName":"PT_C_GVHD_P_HSCT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"19BF863A-34C7-D5FD-E050-BB89AD436632","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-06-30","modifiedBy":"BMAESKE","dateModified":"2022-09-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4889654","version":"1","preferredName":"Patient Failed Corticosteroid Response Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based on whether the hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation) failed to respond.","longName":"PT_FAIL_CORTICO_RESP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"19BF863A-352C-D5FD-E050-BB89AD436632","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-06-30","modifiedBy":"MAESKEB","dateModified":"2015-07-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4889731","version":"1","preferredName":"Patient Personal Medical History Liver Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based on the person's medical history of liver disease.","longName":"PT_HX_LIVER_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"19BF863A-3697-D5FD-E050-BB89AD436632","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-06-30","modifiedBy":"TAYLORT","dateModified":"2019-04-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4889751","version":"1","preferredName":"Malignant Neoplasm Recurrent Disease Post Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based on a replapse after transplantation.","longName":"MALIGN_RECUR_P_TRANSP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"19C0DF64-ED94-AFBE-E050-BB89AD43785F","latestVersionIndicator":"Yes","beginDate":"2015-06-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-06-30","modifiedBy":"MAESKEB","dateModified":"2015-07-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4890157","version":"1","preferredName":"Patient Uncontrolled Electrolytes Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/unknown indicator whether a person has an uncontrolled substances that break up into ions (electrically charged particles) when they are dissolved in body fluids or water that would restrict entrance or bar from participation in a clinical trial.","longName":"PT_UNCRLD_ELECTROLY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"19D177A1-81BE-0A2C-E050-BB89AD434D64","latestVersionIndicator":"Yes","beginDate":"2015-07-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-07-01","modifiedBy":"MAESKEB","dateModified":"2015-07-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4890174","version":"1","preferredName":"Patient Receive Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to administration of therapy.","longName":"PT_RCVD_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"19D177A1-8211-0A2C-E050-BB89AD434D64","latestVersionIndicator":"Yes","beginDate":"2015-07-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-07-01","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"7/12/18 tt changed reg status from 'qualified' to 'application'/BR. 12/6/16 tt - added CSI. 9/10/15 added CSI.tt","administrativeNotes":"1/19/2023: added AQT per CADSR0001933.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4890777","version":"1","preferredName":"Advanced Head and Neck Squamous Cell Carcinoma AJCC UICC TNM Staging Code","preferredDefinition":"A system for clinicopathologic evaluation of tumors based on the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion), and lymph node involvement (N) and metastasis (M) each followed by a number starting at 0 for no evident metastasis; numbers used depend on the organ involved and influence the prognosis and choice of treatment.","longName":"AD_H_N_SCC_TNM_STG_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"19FA8891-C5E4-8CA2-E050-BB89AD432A24","latestVersionIndicator":"Yes","beginDate":"2015-07-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-07-03","modifiedBy":"HARTLEYG","dateModified":"2015-07-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897291","version":"1","preferredName":"Patient Histologically Or Cytological Procedure Confirmation Best Practice Negation Availability Advanced Solid Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient's advanced solid tumor diagnosis that has no standard therapy available has been confirmed through histological or cytological procedures that meets the criteria for participating in a clinical trial.","longName":"SOL_TUM_NOSTD TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8C454D-5440-3F48-E050-BB89AD433471","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"SOKKERL","dateModified":"2021-12-20","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897331","version":"1","preferredName":"Patient Histologic Or Cytopathology Confirmation No Prior Chemotherapy Unresectable Pleural Or Malignant Mesothelioma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient 's malignant pleural or peritoneal mesothelioma progressed during treatment or recurred after treatment with a pemetrexed/cisplatin regimen that meets the criteria for participation in a clinical trial.","longName":"MAL_PLEU_PER_MESO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8C7232-741A-F626-E050-BB89AD433F7D","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"SOKKERL","dateModified":"2017-11-07","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897348","version":"1","preferredName":"Patient Less Than or Equal To 2 Prior Cytotoxic Chemotherapy Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has received less than or equal to 2 cytotoxic chemotherapy regimens that meet the criteria for participation in a clinical trial.","longName":"LTE_2PR_CYT_CHEM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8C7232-744E-F626-E050-BB89AD433F7D","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"SOKKERL","dateModified":"2020-12-03","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897400","version":"1","preferredName":"Patient Histologically Confirmed Chemotherapy Naive Advanced Unresectable Pemetrexed-Cisplatin Regimen Recommended Solid Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient's diagnosis of advanced unresectable solid tumor for which pemetrexed/cisplatin regimen is indicated has been histologically and cytologically confirmed that meets the criteria for participation in a clinical trial.","longName":"CX_NAIV_SOL_TUM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8CBF79-6B3B-19DC-E050-BB89AD435153","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"HARTLEYG","dateModified":"2018-12-28","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897401","version":"1","preferredName":"Patient No Prior Therapy Pemetrexed Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has not previously received treatment with pemetrexed that meets the criteria for participation in a clinical trial.","longName":"NO_PRIOR_PEMET_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8CBF79-6B6E-19DC-E050-BB89AD435153","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"HARTLEYG","dateModified":"2015-07-14","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897451","version":"1","preferredName":"Patient Pemetrexed-Cisplatin Regimen Treated Pleural Or Peritoneal Malignant Mesothelioma Disease Progression Or Recurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that the patient's pemetrexed/cisplatin regimen treated malignant melanoma has recurred or progressed during or after treatment that meets the criteria for participation in a clinical trial.","longName":"TRT_MLG_MESO_PROG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8E88A2-2028-632C-E050-BB89AD437252","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"SBR","dateModified":"2016-11-07","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897452","version":"1","preferredName":"Patient Signature Consent Code Indicator","preferredDefinition":"The coded response indicating the patient's understanding and written consent to participate in research activities.","longName":"PT_SIG_CONSENT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8EC905-AA62-0E94-E050-BB89AD431417","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"COLLIED","dateModified":"2021-06-24","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897453","version":"1","preferredName":"Therapeutic Procedure Targeted Therapy Administered Code Indicator","preferredDefinition":"The coded response indicating that the patient meets the criteria for participation in a clinical trial with regards to receiving targeted therapy.","longName":"TX_PROC_TARG_ADM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8EC905-AA89-0E94-E050-BB89AD431417","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"SOKKERL","dateModified":"2021-09-28","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897454","version":"1","preferredName":"Patient Hemolysis Associated Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that the patient meets the eligibility criteria for participation in a clinical trial with regards to having known disorders associated with hemolysis.","longName":"HEMOL_ASSOC_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8EC905-AAB0-0E94-E050-BB89AD431417","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"HARTLEYG","dateModified":"2015-07-14","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897455","version":"1","preferredName":"Patient Anticoagulation Therapy Administered Thromboembolism Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial with regards to anticoagulation therapy for a thromboembolic disease.","longName":"XCOAG_ADM_THROMB_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8EC905-AAD7-0E94-E050-BB89AD431417","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"TAYLORT","dateModified":"2017-11-15","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897472","version":"1","preferredName":"Patient Malignant Pleural Effusion Or Malignant Ascites Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that the patient meets the eligibility criteria for participation in a clinical trial regarding the presence of malignant pleural effusion or ascites.","longName":"MLG_PLEF_OR_ASCIT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8F51FA-AB12-08BB-E050-BB89AD434ADF","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"SOKKERL","dateModified":"2019-12-19","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4897473","version":"1","preferredName":"Patient Prior Cumulative Dose Cisplatin Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient meets the criteria for participation in a clinical trial regarding their prior cumulative cisplatin dose.","longName":"CUM_DOSE_CISPLATIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A8F51FA-AB3A-08BB-E050-BB89AD434ADF","latestVersionIndicator":"Yes","beginDate":"2015-07-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-10","modifiedBy":"SOKKERL","dateModified":"2020-08-25","changeNote":"9837_Theradex_07.08.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902224","version":"1","preferredName":"Patient Myelodysplastic Syndrome Or Acute Myeloid Leukemia Characteristic Specimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient's specimen has characteristics suggestive of MDS or AML that meets the eligibility criteria for participation in a clinical trial.","longName":"MDS_AML_CHAR_SPEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-A9EB-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2023-01-09","changeNote":null,"administrativeNotes":"2022.12.21 AQT added per ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902225","version":"1","preferredName":"Patient Coagulation Disorder Or Bleeding Diathesis Evidence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has evidence of a coagulation disorder or bleeding diathesis that meets the eligibility criteria for participation in a clinical trial.","longName":"COAG_BLEED_DIATH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-AA10-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"TYRRELLM","dateModified":"2023-12-20","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":"12.10.2023 AQT added per request ticket CADSR0003202_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902226","version":"1","preferredName":"Patient Vascular Or Peripheral Vascular Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has peripheral vascular disease or vascular disease that meets the eligibility criteria for participation in a clinical trial.","longName":"VASC_PER_VASC_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-AA37-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2019-04-09","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902227","version":"1","preferredName":"Patient Cerebrovascular Accident Or Transient Ischemic Attack Personal Medical History Code Indicator","preferredDefinition":"The coded response that indicates cerebrovascular accidents (strokes) or transient ischemic attacks are part of a patient's personal medical history.","longName":"STROKE_TIA_PMH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-AA5E-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"ZHWENDY","dateModified":"2023-01-25","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902228","version":"1","preferredName":"Patient Long QT Syndrome Family Medical History Code Indicator","preferredDefinition":"The coded response that indicates a patient has a family medical history of long QT syndrome.","longName":"LONG_QT_SYN_FMH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-AA85-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"TAYLORT","dateModified":"2017-06-27","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902234","version":"1","preferredName":"Laboratory Finding Pre-study Corrected QT Interval Greater Than 470 Millisecond Outcome Code Indicator","preferredDefinition":"The coded response that indicates the pre-study corrected QTc interval is greater than 470 msec.","longName":"4902233v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-AAE0-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2023-06-13","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902235","version":"1","preferredName":"Patient Left Ventricular Ejection Fraction Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient meets the eligibility criteria for participation in a clinical trial regarding a left ventricular ejection fraction measurement.","longName":"LVEF_OUTCOME_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-AB07-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2022-11-01","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902236","version":"1","preferredName":"Patient Concomitant Or Prior Invasive Malignant Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient meets the eligibility criteria for participation in a clinical trial regarding concomitant or prior invasive malignancies.","longName":"CONC_PR_INVAS_MAL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF28D1D-AB2E-8831-E050-BB89AD431645","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2022-05-23","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902237","version":"1","preferredName":"Patient IV Fluid Or Total Parenteral Nutrition Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating the patient meets the eligibility criteria for participation in a clinical trial based on IV hydration or total parencheral nutrition dependency.","longName":"IV_FLUID_TPN_REQ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF4203F-0716-E680-E050-BB89AD436F72","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2023-01-26","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902238","version":"1","preferredName":"Person Bowel Obstruction Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a person meets the eligibility criteria for participation in a clinical trial regarding bowel obstruction.","longName":"BOWEL_OBST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF4203F-073D-E680-E050-BB89AD436F72","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2021-07-12","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902251","version":"1","preferredName":"Patient Abdominal Fistula Digestive System Perforation Or Abdominal Abscess Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating the patient meets the eligibility criteria for participation in a clinical trial regarding history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscesses.","longName":"FIST_PERF_ABSCES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BABB-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2020-12-21","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902252","version":"1","preferredName":"Patient Hypertension Emergency Or Hypertensive Encephalopathy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial with regards to a history of hypertensive crisis or hypertensive encephalopathy.","longName":"HYPERTEN_ENCEPH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BAE2-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2018-03-05","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902253","version":"1","preferredName":"Patient Vascular Endothelial Growth Factor Receptor Biochemical Pathway Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding the administration of prior therapy affecting the VEGF pathway.","longName":"VEGF_PATH_PRIORTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BB09-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2018-04-23","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902254","version":"1","preferredName":"Patient Prior Enrollment Endocrine Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding the receipt of endocrine therapy prior to study enrollment.","longName":"PR_ENR_ENDO_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BB30-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"TSESU","dateModified":"2023-06-23","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902255","version":"1","preferredName":"Patient Oral Medication Administration And Gastrointestinal Disease or Disorder Protocol Agent Biological Absorption Inhibition Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding tolerance to oral medication and the absence of gastrointestinal illnesses that prohibit study drug absorption.","longName":"ORAL_MED_GI_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BB57-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902256","version":"1","preferredName":"Patient Controlled Thyroid Gland Function Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for adequately controlled thyroid function in order to participate in a clinical study.","longName":"CONT_THYROID_FUN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BB7E-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2019-05-16","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902257","version":"1","preferredName":"Patient Resectable Neoplasm And Pretreatment Biopsy Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient has resectable disease and has consented to a biopsy that meets the eligibility criteria for participation in a clinical trial.","longName":"RESECT_NEO_CONS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BBA5-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902258","version":"1","preferredName":"Laboratory Procedure International Normalized Ratio Partial Thromboplastin Time Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding the results of INR and aPTT measurement.","longName":"LAB_INR_PTT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BBCC-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2023-02-07","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":"7/26/2022: fixed the symbol x in AQT per ticket #CADSR0001349.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902259","version":"1","preferredName":"Patient Disease Progression 6 Month Platinum-Based Chemotherapy And Less Than One Prior Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding disease progression post platinum-based chemotherapy.","longName":"PROG_PLAT_CHEMO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BBF3-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2017-10-03","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902260","version":"1","preferredName":"Patient Progression-free Survival Post Platinum-Based And Greater Than One Negation Platinum-Based Chemotherapy Negation Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding progression free survival post platinum based chemotherapy and has not received more than one prior non-platinum line of therapy.","longName":"PROG_FREE_PST_PLAT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BC1A-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"HARTLEYG","dateModified":"2015-07-20","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902261","version":"1","preferredName":"Patient Prior Antiangiogenesis Therapy Progression-free Survival Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding receiving prior anti-angiogenic therapy without disease progression.","longName":"PR_XANGIO_PRO_FRE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BC41-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"HARTLEYG","dateModified":"2015-07-20","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902262","version":"1","preferredName":"Genetic Counseling Report BRCA1 Or BRCA2 Gene Mutation Or Gene Rearrangement Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding the confirmation of BRCA1 or BRCA2 mutation or BRCA rearrangements by genetic consultation reports.","longName":"BRCA_GN_MUT_REARR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BC68-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"HARTLEYG","dateModified":"2016-07-05","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902263","version":"1","preferredName":"Patient Ovarian Peritoneal Fallopian Tube Malignant Neoplasm Or High Grade Serous Adenocarcinoma Or Endometrial Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding confirmation of ovarian cancer, peritoneal cancer, fallopian tube cancer, high grade serous or high grade endometrioid cancer.","longName":"OVA_PER_FAL_HGSER_END_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF488FF-BC8F-EF42-E050-BB89AD435DE4","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"SOKKERL","dateModified":"2023-01-26","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4902276","version":"1","preferredName":"Human Papillomavirus Positive Finding Patient High Risk Characteristic Neoplasm Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating an HPV positive patient meets the eligibility criteria for participation in a clinical trial regarding the presence of one high risk feature.","longName":"HPVPOS_HRISK_CHAR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AF5873B-C08F-4470-E050-BB89AD432CE6","latestVersionIndicator":"Yes","beginDate":"2015-07-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-07-15","modifiedBy":"HARTLEYG","dateModified":"2015-07-16","changeNote":"Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4925318","version":"2","preferredName":"Patient Specimen Collection Personal Medical History Entered Off Study Code Indicator","preferredDefinition":"The coded indicator response regarding whether all patient samples have been collected, medical history has been entered and patient is now off study.","longName":"SP_CO_MHX_OFF_STDY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"Toronto Extremity Salvage Score (TESS); 1996","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2653AD7D-EB3F-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-07","modifiedBy":"MAESKEB","dateModified":"2015-12-08","changeNote":"Versioned CDE to update PVs. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4940372","version":"2","preferredName":"Platinum Compound Therapeutic Procedure Resistance Sensitivity Status","preferredDefinition":"A response to address the platinum-based treatment resistant/sensitivity status from initial treatment to a specified time.","longName":"PLAT_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46F0EFFF-97F2-4AA8-E053-F662850A4C89","latestVersionIndicator":"Yes","beginDate":"2015-08-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-01-25","modifiedBy":"MAESKEB","dateModified":"2017-01-25","changeNote":"1/25/17 Versioned VD and CDE_8/10/15 approved and released/tt_8/7/15 curated by tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4944280","version":"1","preferredName":"Mutation Abnormality Negative Positive Status","preferredDefinition":"A negative/positive response for questions related to the status of gene mutations.","longName":"MUT_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D0A673A-D185-6D7F-E050-BB89AD437D69","latestVersionIndicator":"Yes","beginDate":"2015-08-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-11","modifiedBy":"TAYLORT","dateModified":"2015-08-11","changeNote":"8/11/15 curated by tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4975891","version":"1","preferredName":"Non-Protocol Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response for questions addressing non-protocol treatment(s) in order to determine eligibility for clinical trial participation.","longName":"NPTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DC1931B-D33F-A7A8-E050-BB89AD4369D2","latestVersionIndicator":"Yes","beginDate":"2015-08-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-20","modifiedBy":"SOKKERL","dateModified":"2022-07-13","changeNote":"8/20/15 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4976711","version":"1","preferredName":"Breast Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response for questions addressing abnormal conditions of the breast in order to determine eligibility for clinical trial participation.","longName":"BR_DZ_DO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DD764D3-63D0-7492-E050-BB89AD434496","latestVersionIndicator":"Yes","beginDate":"2015-08-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-21","modifiedBy":"SOKKERL","dateModified":"2023-03-30","changeNote":"8/26/15 approved and released. tt_8/25/15 edit to classification/tt_8/21/15 Protocol 9844 tt.","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4980851","version":"1","preferredName":"Oxygen Saturation Measurement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response for questions related to oxygen levels to determine eligibility for clinical trial participation.","longName":"OX_SAT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E126609-ECFF-F9A4-E050-BB89AD437CFB","latestVersionIndicator":"Yes","beginDate":"2015-08-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-24","modifiedBy":"SOKKERL","dateModified":"2023-06-02","changeNote":"8/26/15 approved and releaed. tt_8/25/15 edit to classification/tt_8/24/15 edit to draft new DE_tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4982118","version":"1","preferredName":"Clinical Study Follow-up Consent Code Indicator","preferredDefinition":"A response for questions addressing the patient's consent to participate in the follow-up activities of the clinical trial.","longName":"FLWUP_CONS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E13FD74-CE1A-22DE-E050-BB89AD4352E6","latestVersionIndicator":"Yes","beginDate":"2015-08-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-24","modifiedBy":"SOKKERL","dateModified":"2017-04-14","changeNote":"8/26/15 approved/released.tt_8/25/15 edit to def/classification tt_8/24/15 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4982174","version":"1","preferredName":"HER2 ICH ISH Eligibility Determination Code Indicator","preferredDefinition":"A response for questions addressing eligibility based on the results of HER2 testing by immunohistochemistry (IHC) and in situ hybridization (ISH).","longName":"HER2_ICH_ISH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E15BD81-D44D-C5B7-E050-BB89AD430B0D","latestVersionIndicator":"Yes","beginDate":"2015-08-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-24","modifiedBy":"SOKKERL","dateModified":"2020-04-08","changeNote":"8/26/15 approved/released.tt_8/24/15 edits to draft new DE/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4982771","version":"1","preferredName":"Patient Lesion Core Biopsy Eligibility Determination Code Indicator","preferredDefinition":"A response for questions addressing the core biopsy procedure(s) of abnormal tissue to determine eligibility.","longName":"LES_BX_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E2306CC-CD8B-42DB-E050-BB89AD431D90","latestVersionIndicator":"Yes","beginDate":"2015-08-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-25","modifiedBy":"TAYLORT","dateModified":"2015-08-26","changeNote":"8/26/15 approved and released. tt_8/25/15 edit to classification/ tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4983231","version":"1","preferredName":"Prior Intervention or Procedure Protocol Chair Discussion Eligibility Determination Code Indicator","preferredDefinition":"A response for questions addressing eligibility based on discussion(s) with the protocol chair in regards to prior treatments and/or procedures.","longName":"INTRV_PRCDR_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E2629DD-4E3B-838D-E050-BB89AD430258","latestVersionIndicator":"Yes","beginDate":"2015-08-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-25","modifiedBy":"SOKKERL","dateModified":"2017-10-10","changeNote":"8/26/15 approved/released. tt_8/25/15 edit to classification tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4983461","version":"1","preferredName":"Concurrent Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A repsonse for questions addressing the use of concurrent agents in order to determine eligiblity for clinical trial participation.","longName":"CNCRNT_AGNT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E2629DD-5256-838D-E050-BB89AD430258","latestVersionIndicator":"Yes","beginDate":"2015-08-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-25","modifiedBy":"SOKKERL","dateModified":"2019-09-27","changeNote":"8/26/15 approved/released. tt_8/25/15 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4986871","version":"1","preferredName":"Chemotherapy Most Recent MEK Inhibitor Administered Agent Name","preferredDefinition":"A response for the agent name of the most recently administered MEK inhibitor.","longName":"MR_MEK_AGT_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E4C3ADD-24A1-A4E9-E050-BB89AD434700","latestVersionIndicator":"Yes","beginDate":"2015-08-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-27","modifiedBy":"TAYLORT","dateModified":"2015-08-27","changeNote":"8/27/15 approved and released_ tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4987358","version":"1","preferredName":"Treatment Assignment Code Category","preferredDefinition":"A response to denote the treatment assignment code.","longName":"TAC_CTGRY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E52F9B2-AE63-135D-E050-BB89AD430BA0","latestVersionIndicator":"Yes","beginDate":"2015-08-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-27","modifiedBy":"HARTLEYG","dateModified":"2015-08-28","changeNote":"8/27/15 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4997291","version":"1","preferredName":"Eye Disease or Disorder Personal Medical History Code Indicator","preferredDefinition":"A response for questions related to the patient's medical history of abnormal eye conditions.","longName":"EYE_DZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EC6608B-048A-3A87-E050-BB89AD434653","latestVersionIndicator":"Yes","beginDate":"2015-09-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-02","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeNote":"9/8/15 approved/released. tt_9/2/15 tt.","administrativeNotes":"2022.12.21 AQT added per ticket request. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5002971","version":"1","preferredName":"Laboratory Procedure Bone Marrow Blast Cell Percentage Code Indicator","preferredDefinition":"A response for questions addressing the percentage of blasts in bone marrow.","longName":"BM_BL_PTG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F52119D-34CB-6EDB-E050-BB89AD436340","latestVersionIndicator":"Yes","beginDate":"2015-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-09","modifiedBy":"BROWNTY","dateModified":"2022-04-14","changeNote":"9/10/15 released. tt_9/9/15 curated for 9775. tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5016774","version":"1","preferredName":"Patient Prior First-Line Chemotherapy Administration Documented Disease Progression Or Intolerance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria for enrolling onto a clinical trial with regards to disease progression or intolerance to first-line chemotherapy administration.","longName":"FSTLN_CHEM_PROG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1FF44F9E-633A-0DB3-E050-BB89AD4340F4","latestVersionIndicator":"Yes","beginDate":"2015-09-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-17","modifiedBy":"SOKKERL","dateModified":"2022-11-16","changeNote":"Theradex_09.17.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5022984","version":"1","preferredName":"Cancer Timing Classification Category","preferredDefinition":"The response that indicates the category of chronological order of the cancer diagnosis compared to the primary cancer diagnosis.","longName":"CANCER_TIME_CLASS_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"205BE62B-2B9B-F9B2-E050-BB89AD4371F8","latestVersionIndicator":"Yes","beginDate":"2015-09-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-22","modifiedBy":"HARTLEYG","dateModified":"2015-09-22","changeNote":"Theradex_09.22.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5024278","version":"1","preferredName":"Breast Carcinoma Estrogen Receptor And Progesterone Receptor Protein Overexpression Negative Finding Outcome Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding a negative finding of estrogen receptor and progesterone receptor protein overexpression.","longName":"ESR_PGR_OVERX_NEG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2087B0D5-E0EE-BC64-E050-BB89AD4377E3","latestVersionIndicator":"Yes","beginDate":"2015-09-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-24","modifiedBy":"TAYLORT","dateModified":"2016-12-15","changeNote":"12/15/16 - Corrected typo in question text. 9876_Theradex_09.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5024279","version":"1","preferredName":"Breast Carcinoma HER2/Neu Status Protein Overexpression Negative Finding Outcome Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding a negative finding of HER2/NEU protein overexpression.","longName":"HER2_NEU_OVERX_NG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2087B0D5-E115-BC64-E050-BB89AD4377E3","latestVersionIndicator":"Yes","beginDate":"2015-09-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-24","modifiedBy":"SOKKERL","dateModified":"2023-08-16","changeNote":"9876_Theradex_09.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5024280","version":"1","preferredName":"Patient Prior Chemotherapy Taxane Compound LTE Grade 1 Neuropathy No Disease Progression Prior Enrollment Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding prior taxane therapy administration when neuropathy is less than or equal to grade 1 and there has been no history of disease progression while on taxane therapy prior to study enrollment.","longName":"PR_TAX_NEU_NO_PG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2087B0D5-E13C-BC64-E050-BB89AD4377E3","latestVersionIndicator":"Yes","beginDate":"2015-09-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-24","modifiedBy":"SOKKERL","dateModified":"2016-12-19","changeNote":"9876_Theradex_09.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5024281","version":"1","preferredName":"Patient Biphosphonate Or Denosumab Therapeutic Procedure Prior Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding administration of bisphosphonate or denosumab prior to study drug administration.","longName":"BIPH_DEN_TX_PR_AGT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2087B0D5-E163-BC64-E050-BB89AD4377E3","latestVersionIndicator":"Yes","beginDate":"2015-09-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-24","modifiedBy":"SOKKERL","dateModified":"2020-12-29","changeNote":"9876_Theradex_09.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5024282","version":"1","preferredName":"Patient Prior Therapy Heat Shock Protein Inhibitor Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding prior therapy with heat shock protein inhibitors.","longName":"PR_HSP90_INH_ADM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2087B0D5-E18A-BC64-E050-BB89AD4377E3","latestVersionIndicator":"Yes","beginDate":"2015-09-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-24","modifiedBy":"SOKKERL","dateModified":"2017-08-17","changeNote":"9876_Theradex_09.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5024283","version":"1","preferredName":"Patient Personal Medical History Paclitaxel Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding a history of hypersensitivity to paclitaxel.","longName":"PMHX_PACL_HYPER_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2087B0D5-E1B1-BC64-E050-BB89AD4377E3","latestVersionIndicator":"Yes","beginDate":"2015-09-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-09-24","modifiedBy":"SOKKERL","dateModified":"2023-01-04","changeNote":"9876_Theradex_09.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026334","version":"1","preferredName":"Non-Small Cell Lung Carcinoma EGFR Activating Mutation Code Indicator","preferredDefinition":"A coded response for questions addressing EGFR activating mutations with regards to NSCLC.","longName":"NSCLC_EGFR_ACTVT_MUTN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20D4CC75-C67F-DB2D-E050-BB89AD433D84","latestVersionIndicator":"Yes","beginDate":"2015-09-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-28","modifiedBy":"FINCHAMB","dateModified":"2023-01-13","changeNote":"9/30/15 released/tt_9/28/15- 9910_tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026424","version":"1","preferredName":"Patient Specimen Availability Or Biopsy Consent Code Indicator","preferredDefinition":"A coded response for questions addressing archived specimens or the willingness of the patient to consent to a biopsy procedure.","longName":"SPE_AV_BX_CONS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20D52C8D-C0C1-51C7-E050-BB89AD43701D","latestVersionIndicator":"Yes","beginDate":"2015-09-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-28","modifiedBy":"SOKKERL","dateModified":"2021-07-27","changeNote":"9/30/15 approved & released/tt_9/28/15 - 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026557","version":"1","preferredName":"Agent Intervention Disease or Disorder Status Code Indicator","preferredDefinition":"A coded response for questions related to the use of agents that produce an effect, or that are intended to alter the course of a disease in a patient, and the status of the patient's disease.","longName":"AGNT_INT_DZ_STS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E2CCF0-EE29-0D47-E050-BB89AD434682","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2024-01-25","changeNote":"12/5/16 tt, added CSI. 9/30/15 approved & released/tt_9/29/15 curated for 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026591","version":"1","preferredName":"Laboratory Procedure Fasting Plasma Glucose Measurement Eligibility Determination Code Indicator","preferredDefinition":"A coded response for questions related to the value of the amount of glucose present in a sample of blood while abstaining from food in order to determine eligibility.","longName":"FA_PGM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E2CCF0-EF2A-0D47-E050-BB89AD434682","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2023-10-04","changeNote":"9/30/15 approved & released/tt_9/29/15 - 9910/tt.","administrativeNotes":"2023.4.5 AQT added per ticket request CADSR0002271. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026592","version":"1","preferredName":"Laboratory Procedure Fasting Triglyceride Measurement Outcome Code Indicator","preferredDefinition":"A coded response for questions related to the quantitative measurement of the amount of triglyceride present in a sample taken following a period of abstaining from food.","longName":"FA_TRI_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E2CCF0-EF51-0D47-E050-BB89AD434682","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"TAYLORT","dateModified":"2016-09-09","changeNote":"9/30/15 approved & released/tt_9/29/15 - 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026631","version":"1","preferredName":"Prior Agent Intervention And Therapy-Related Toxicity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether a patient meets the eligibility criteria addressing prior agents that produce an effect, or alter the course of a disease in a patient and their associated  toxicities.","longName":"AGNT_TOX_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E49FDE-086C-DE2F-E050-BB89AD434A31","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"TYRRELLM","dateModified":"2023-07-21","changeNote":"9/30/15 approved&release/tt_9/29/15 - 9910/tt.","administrativeNotes":"7/21/23 removed special characters from AQT_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026691","version":"1","preferredName":"Prior Agent Intervention And Therapy-Related Toxicity Inclusion Criteria Code Indicator","preferredDefinition":"A coded response as to whether a patient meets the inclusion criteria addressing prior agents that produce an effect, or alter the course of a disease in a patient and their associated  toxicities.","longName":"AGNT_TOX_INC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E4F3C3-41FE-B758-E050-BB89AD43375A","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2020-09-17","changeNote":"9/30/15 approved & released/tt_9/29/15 - 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026735","version":"1","preferredName":"Patient Surgical Procedure And Wound Healing Status Code Indicator","preferredDefinition":"A coded response for questions addressing the patient's surgery and the restoration of diseased or damaged tissues naturally by healing processes at a particular time.","longName":"SUR_WOU_STS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E4F3C3-4292-B758-E050-BB89AD43375A","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2020-11-09","changeNote":"9/30/15 approved and released/tt_9/29/15 - 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026754","version":"1","preferredName":"Radiation Therapy And Therapy-Related Toxicity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether a patient meets the eligibility criteria addressing radiation treatments and their associated  toxicities.","longName":"RT_TOX_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E683EC-2DBB-1998-E050-BB89AD4336C0","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2020-12-21","changeNote":"9/30/15 approved and released/tt_9/29/15 - 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026771","version":"1","preferredName":"Patient Uncontrolled Concurrent Disease or Disorder Exclusion Criteria Code Indicator","preferredDefinition":"A coded response for questions as to whether a person has an uncontrolled, concurrent disease, any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person, that would restrict entrance or bar from participation in a clinical trial.","longName":"UNCTL_DZ_CRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E7449E-21AC-D691-E050-BB89AD43401F","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"9/30/15 approved & released/tt_9/29/15 - 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026811","version":"1","preferredName":"Patient Or Family Medical History Heart Disease or Disorder Code Indicator","preferredDefinition":"A coded response for questions addressing heart disease or disorders of the patient or blood relatives.","longName":"PT_FAMHX_HRT_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E7F252-EFD4-6F19-E050-BB89AD4333EC","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"TAYLORT","dateModified":"2015-09-30","changeNote":"9/30/15 approved & released/tt_9/29/15 - 9910/tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5026851","version":"1","preferredName":"Patient Discontinue Strong Cytochrome P450 Inhibition Induction Agent Code Indicator","preferredDefinition":"A coded response for questions related to the patient's discontinuation of of strong cytochrome P450 system inhibitors and/or inducers.","longName":"DSCT_ST_CYT_INH_IND_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E90547-1322-BD6E-E050-BB89AD4337C0","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SOKKERL","dateModified":"2023-04-21","changeNote":"9/30/15 approved & released/tt_9/29/15 - 9910/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5028291","version":"1","preferredName":"Specimen Collection Method Type","preferredDefinition":"The response that indicates the type of procedure or method used in obtaining a biopsecimen or tissue sample.","longName":"SPEC_COLL_METH_TYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2189EF50-FF70-CB37-E050-BB89AD437EA1","latestVersionIndicator":"Yes","beginDate":"2015-10-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-10-07","modifiedBy":"HARTLEYG","dateModified":"2015-10-07","changeNote":"Theradex_10.07.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036319","version":"1","preferredName":"Patient Standard Therapeutic Procedure Disease Progression Or Negation Standard Therapeutic Procedure Extend Survival Clinical Trial Eligibility Criteria Yes No Not Applicable Code Indicator","preferredDefinition":"The response that indicates that a patient meets the eligibility criteria regarding experiencing disease progression while on a standard therapy or no standard therapy extends patient survival for that patient's particular diagnosis.","longName":"STD_TX_PD_NO_EXT_SURV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"228C30EA-7BAD-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-10-20","modifiedBy":"SOKKERL","dateModified":"2017-03-01","changeNote":"Theradex_10.20.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036334","version":"1","preferredName":"Patient Histologic Confirmation NSCLC EGFR Activating Mutation Prior Therapy Progressive Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to the histologic verification of non-small cell lung carcinoma, mutations of the epidermal growth factor receptor gene, prior administration of therapeutic agents and cancer that is increasing in scope or severity as outlined in the protocol.","longName":"NSCLC_EFGR_TKI_PD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"228C30EA-7C47-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-20","modifiedBy":"SOKKERL","dateModified":"2017-10-27","changeNote":"10/23/15: Approved and released-tt._10/20/15 Protocol 9878, additional edits/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036354","version":"1","preferredName":"Patient Histologic Confirmation NSCLC EGFR Exon 20 Insertion Current Treatment Progressive Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to the histologic verification of non-small cell lung carcinoma, the presence of EGFR Exon 20 insertion mutation, current administration of therapeutic agents and cancer that is increasing in scope or severity as outlined in the protocol.","longName":"NSCLC_EFGR_EX20_ONTX_PD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"228C30EA-7D19-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-20","modifiedBy":"TAYLORT","dateModified":"2015-10-23","changeNote":"10/23/15: Approved and released-tt._10/20/2015 Protocol 9878 and additonal edits/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036371","version":"1","preferredName":"Recurrent  Disease Therapeutic Procedure Administered Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator that asks if the patients disease is resistant to therapy.","longName":"RECUR_DX_THERP_ADMIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"228C30EA-7D4E-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-10-20","modifiedBy":"SOKKERL","dateModified":"2023-09-20","changeNote":"Created for Protocol 9930.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036394","version":"1","preferredName":"Patient Measurable Disease Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded yes/not/not applicable indicator regarding whether a person has a tumor that can be accurately measured in size.","longName":"PT_MEASR_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"228DDD24-659A-32EA-E050-BB89AD43248D","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-10-20","modifiedBy":"FINCHAMB","dateModified":"2023-11-16","changeNote":"Created for Protocol 9930.","administrativeNotes":"10/22/2023_Added AQT per request CADSR0002989_mmt\r\n8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036401","version":"1","preferredName":"Laboratory Procedure Absolute CD4 Expressing Cell Count Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether a medical procedure has been performed that involves testing a sample of blood for the determination of the amount of the CD4 expressing cells in the sample.","longName":"LAB_PROC_ABSL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"228C30EA-7E0C-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-10-20","modifiedBy":"SOKKERL","dateModified":"2021-06-09","changeNote":"Created for Protocol 9930.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036411","version":"1","preferredName":"Person Opportunistic Infection Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response to whetther an infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.","longName":"PRSN_OPPORT_INFEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"228E2A3C-B076-36A2-E050-BB89AD43231A","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-10-20","modifiedBy":"CLOHNES","dateModified":"2023-06-08","changeNote":"Created for Protocol 9930.","administrativeNotes":"2023.4.4 AQT added per ticket request CADSR0002268. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036420","version":"1","preferredName":"Person HIV Infection Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response that asks if the patient has any state accompanied by evidence of HIV in the body.","longName":"PRSN_HIV_INFEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"228E2A3C-B0E3-36A2-E050-BB89AD43231A","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-10-20","modifiedBy":"TYRRELLM","dateModified":"2023-12-27","changeNote":"12/5/16 tt, added CSIs.Created for Protocol 9930.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036431","version":"1","preferredName":"Person Tuberculosis Personal Medical History Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response that asks if the patient has a background of a chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis (TB).","longName":"PRSN_TB_HX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"228C30EA-7EA1-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-10-20","modifiedBy":"SOKKERL","dateModified":"2022-07-18","changeNote":"Created for Protocol 9930.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036435","version":"1","preferredName":"Person Allogeneic Hematopoietic Stem Cell Transplantation Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response that asks if the patient has undergone a clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.","longName":"PRSN_ALLOG_STEM_CELL_TRANS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"228E9099-2E59-04F1-E050-BB89AD43752B","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-10-20","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeNote":"Created for Protocol 9930.","administrativeNotes":"2023.4.4 AQT added per ticket request CADSR0002268. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036436","version":"1","preferredName":"Patient Histologic Confirmation NSCLC EGFR Activating Mutation Agent Intervention Disease Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to the histologic verification of non-small cell lung carcinoma, mutations of the epidermal growth factor receptor gene, substances that produce a therapeutic effect, or intended to alter the course of the disease and the assessment of disease as outlined in the protocol.","longName":"NSCLC_EFGR_PD_SD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"228E9099-2E80-04F1-E050-BB89AD43752B","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-20","modifiedBy":"TAYLORT","dateModified":"2015-10-23","changeNote":"10/23/15: Approved and released-tt._10/20/15 Protocol 9878/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036462","version":"1","preferredName":"Patient Histologic Confirmation NSCLC EGFR Exon 20 Insertion Agent Intervention Progressive Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions addressing the histologic verification of non-small cell lung carcinoma, the presence of EGFR Exon 20 insertion mutation, substances that produce a therapeutic effect, or intended to alter the course of the disease and cancer that is increasing in scope or severity as outlined in the protocol.  ","longName":"NSCLC_EFGR_EX20_TX_PD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"228C30EA-7FAE-39E8-E050-BB89AD437985","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-20","modifiedBy":"TAYLORT","dateModified":"2015-10-23","changeNote":"10/23/15: Approved and released-tt._10/20/15 Protocol 9878; edit to long name/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036513","version":"1","preferredName":"Performing Laboratory CLIA Certification Code Indicator","preferredDefinition":"A response for questions related to CLIA certification of the lab testing/providing analyses of samples collected in clinical care or research.","longName":"LAB_CLIA_CERT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"22908208-16B3-915C-E050-BB89AD437004","latestVersionIndicator":"Yes","beginDate":"2015-10-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-20","modifiedBy":"SOKKERL","dateModified":"2023-03-30","changeNote":"10/23/15: Approved and released-tt._10/21/15 edits to draft new DE/tt_10/20/15 protocol 9878; edit to long name/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036631","version":"1","preferredName":"Intervention or Procedure Occurrence Prior To Subject's Signature on Informed Consent Form Code Indicator","preferredDefinition":"A response for questions related to activities that produce an effect, or intended to alter the course of a disease in a patient encompassing the medical acts that can have preventive, therapeutic, or palliative effects that occured before the inscription provided by a human subject on the informed consent document.","longName":"INT_PROC_PRIOR_SIG_CONS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"229DF856-5AA4-8433-E050-BB89AD436878","latestVersionIndicator":"Yes","beginDate":"2015-10-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-21","modifiedBy":"TAYLORT","dateModified":"2015-10-23","changeNote":"10/23/15: Approved and released-tt._10/21/15 protocol 9878/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5036920","version":"1","preferredName":"Person Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation regarding the resolution of adverse events from prior therapy.","longName":"AE_REC_PR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"229DF856-5B02-8433-E050-BB89AD436878","latestVersionIndicator":"Yes","beginDate":"2015-10-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-21","modifiedBy":"SOKKERL","dateModified":"2023-11-20","changeNote":"10/23/15: Approved and released-tt._10/21/15 protocol 9878/tt.","administrativeNotes":"12/21/22 added AQT and alt OID, CCTG for ticket number CADSR0001818 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5043374","version":"1","preferredName":"Vision Assessment Normal Abnormal Not Done Indicator Category","preferredDefinition":"The results of normal, abnormal, or not done for the determination of the visual capabilities of a person by completion of an ophthalmologic evaluation.","longName":"VSN_ASSESS_IND_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"24217E2F-1716-718B-E050-BB89AD4318A8","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-11-09","modifiedBy":"MAESKEB","dateModified":"2015-11-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5062175","version":"1","preferredName":"Patient Pathologic Diagnosis Uterus Cervix Uteri Vulva Malignant Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding disease or pathology of the hollow, thick-walled, muscular organ located within the pelvic cavity of a woman, the lower part of the uterus occupying the region between the isthmus of the uterus and the vagina, and the external, visible part of the female genitalia surrounding the urethral and vaginal opening.","longName":"PT_PATHDX_UT_CER_VUL_MN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"25C8A295-984C-98AF-E050-BB89AD437F6B","latestVersionIndicator":"Yes","beginDate":"2015-11-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-11-30","modifiedBy":"TAYLORT","dateModified":"2020-09-22","changeNote":"Curated for Protocol 9892. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5062181","version":"1","preferredName":"Patient Image Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding any record of an imaging event requirement.","longName":"PT_IMAG_REQ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"25C8A295-9873-98AF-E050-BB89AD437F6B","latestVersionIndicator":"Yes","beginDate":"2015-11-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-11-30","modifiedBy":"WANGC","dateModified":"2020-09-26","changeNote":"Curated for Protocol 9892. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5062197","version":"1","preferredName":"Patient Not Pregnant Or Breast Feeding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a female patient meets the eligibility criteria that she is not currently pregnant or nursing an infant from her breast.","longName":"PT_N_PREG_BRSTFEED_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"25C93633-9933-B35E-E050-BB89AD434365","latestVersionIndicator":"Yes","beginDate":"2015-11-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-11-30","modifiedBy":"RODGERSC","dateModified":"2018-09-21","changeNote":"Curated for Protocol 9892. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5062374","version":"1","preferredName":"Patient Prior Pelvic Radiation Therapy Or Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding prior pelvic radiation therapy or chemotherapy.","longName":"PT_PR_PELVIC_RAD_TX_CHEMO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"25C93633-998B-B35E-E050-BB89AD434365","latestVersionIndicator":"Yes","beginDate":"2015-11-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-11-30","modifiedBy":"CLOHNES","dateModified":"2023-11-16","changeNote":"Curated for Protocol 9892. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5066954","version":"1","preferredName":"Patient Hypermetabolic Paraaortic Region Disease or Disorder Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding the increased basal metabolic rate in regions near to the aorta.","longName":"PT_HYPRMET_PARAORTC_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"25F0974A-51E1-C047-E050-BB89AD4332B5","latestVersionIndicator":"Yes","beginDate":"2015-12-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-02","modifiedBy":"SOKKERL","dateModified":"2019-03-06","changeNote":"Curated for Protocol #9892. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5071255","version":"1","preferredName":"Patient AIDS Related Non Hodgkin Lymphoma Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has a syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV) related non-Hodgkin lymphoma.","longName":"PT_AIDS_RLD_NON_HDGKN_LYPM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2606C3A9-A6F3-ECF3-E050-BB89AD431F0B","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-03","modifiedBy":"MAESKEB","dateModified":"2015-12-10","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5071274","version":"1","preferredName":"Patient Convention Hodgkin Lymphoma Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has classical lymphoma, previously known as Hodgkin's disease.","longName":"PT_CONV_HDGKN_LYMP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2606C3A9-A748-ECF3-E050-BB89AD431F0B","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-03","modifiedBy":"KUMMEROA","dateModified":"2022-04-06","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5071295","version":"1","preferredName":"Patient Kaposi Sarcoma Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has a malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells.","longName":"PT_KAPOSI_SARCMA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2606C3A9-A79C-ECF3-E050-BB89AD431F0B","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-03","modifiedBy":"SOKKERL","dateModified":"2021-03-15","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5071312","version":"1","preferredName":"Patient Combination Antiretroviral Therapy Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient in on an effective collection retroviral treatment medications that target the virus directly, limiting the ability of infected cells to produce new virus particles.","longName":"PT_C_ART_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2606C3A9-A7F1-ECF3-E050-BB89AD431F0B","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-03","modifiedBy":"SOKKERL","dateModified":"2020-09-14","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5071320","version":"1","preferredName":"Patient Abnormal Laboratory Value Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has abnormal laboratory values.","longName":"PT_ABN_LAB_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2606C3A9-A886-ECF3-E050-BB89AD431F0B","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-03","modifiedBy":"SOKKERL","dateModified":"2022-08-10","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5071336","version":"1","preferredName":"Laboratory Procedure Creatine Kinase Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether a medical procedure has been performed that involves testing a sample of blood to test creatine kinase.","longName":"LAB_PROC_CK_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"26076773-A1D1-0E10-E050-BB89AD436499","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-03","modifiedBy":"ZHWENDY","dateModified":"2023-01-18","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5071791","version":"1","preferredName":"Patient Prior Chemotherapy With Neutropenia Resolution Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether the patient has received previous use of synthetic or naturally-occurring chemicals for the treatment of diseases with a decrease in the number of neutrophils in the peripheral blood.","longName":"PT_P_CHEMO_W_NEUTROPN_RSLN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2607B62B-6B7E-28CD-E050-BB89AD43690F","latestVersionIndicator":"Yes","beginDate":"2015-12-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-03","modifiedBy":"MAESKEB","dateModified":"2015-12-10","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5073087","version":"1","preferredName":"Patient Uncontrolled Human Papillomavirus Infectious Disorder Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient has an uncontrolled strain of papillomavirus that can infect the skin and mucous membranes of humans.","longName":"PT_UNCTRLD_HPV_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"26168C17-0CA9-584F-E050-BB89AD4377CD","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-04","modifiedBy":"SOKKERL","dateModified":"2022-03-22","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5073115","version":"1","preferredName":"Patient Immune Related Toxicity Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response that asks if the patient have immune related toxicity.","longName":"PT_IMMUN_REL_TOX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2617DC93-8B11-9DF5-E050-BB89AD434BBD","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-12-04","modifiedBy":"MAESKEB","dateModified":"2015-12-10","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5084313","version":"1","preferredName":"Patient Visible Retinal Pathology Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient meets the eligibility criteria for participation in a clinical trial regarding visible retinal pathology.","longName":"VIS_RET_PATH_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"26DF52B6-3A05-10EC-E050-BB89AD432DED","latestVersionIndicator":"Yes","beginDate":"2015-12-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-12-14","modifiedBy":"HARTLEYG","dateModified":"2015-12-14","changeNote":"9149_Theradex_12.14.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5090565","version":"2.2","preferredName":"Treatment Cohort Study CITN12 Code","preferredDefinition":"The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study CITN-12.","longName":"TX_COH_SDY_CITN12_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C4561060-CE0E-7F40-E053-4EBD850A50D0","latestVersionIndicator":"Yes","beginDate":"2018-05-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-09","modifiedBy":"SOKKERL","dateModified":"2022-06-13","changeNote":"5/29/18LS Versioned PV /VD for New PV definition:CDE versioned for new VD version .Curated for the CITN-12 protocol. bsm. 4/27/20 VD for updating PV definition. Ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5096157","version":"1","preferredName":"Person No Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has not previously received treatment(s) that meets the criteria for participation in a clinical trial.","longName":"NO_PR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"28896A3F-7747-664C-E050-BB89AD4360F0","latestVersionIndicator":"Yes","beginDate":"2016-01-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-04","modifiedBy":"SOKKERL","dateModified":"2024-01-02","changeNote":"1/5/16 tt, released CDE.  1/4/16 tt, curated for Theradex.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5096158","version":"1","preferredName":"Prior Therapy Irinotecan Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to a person having completed a prior therapy regimen of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminataas as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"PRIOR_TX_IRINTCN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"28896A3F-776E-664C-E050-BB89AD4360F0","latestVersionIndicator":"Yes","beginDate":"2016-01-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-04","modifiedBy":"SOKKERL","dateModified":"2022-04-22","changeNote":"Curated for Protocol 9938. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5096162","version":"1","preferredName":"Person No Disease Progression Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to no disease progression in order to determine if the patient meets the eligibility criteria for enrollment onto a clinical trial.","longName":"NO_DZ_PROG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"28896A3F-77BC-664C-E050-BB89AD4360F0","latestVersionIndicator":"Yes","beginDate":"2016-01-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-04","modifiedBy":"SOKKERL","dateModified":"2022-03-25","changeNote":"1/5/16 tt, released CDE.  1/4/16 tt, curated for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5096200","version":"1","preferredName":"Person No Hypersensitivity Or Contraindicated Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions which are necessary to allow a subject to participate in a clinical study with regards to no hypersensitivities or contraindications to the treatment as outlined in the study protocol.","longName":"NO_TX_HYPER_CIND_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"288AEFCA-FDBE-1E26-E050-BB89AD4319EB","latestVersionIndicator":"Yes","beginDate":"2016-01-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-04","modifiedBy":"SOKKERL","dateModified":"2018-04-10","changeNote":"1/5/16 tt, released CDE.  1/4/16 tt, curated for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5096858","version":"1","preferredName":"Treatment Cohort Study 9878 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9878 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9878_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"28AC5722-18FA-46F8-E050-BB89AD433B2B","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-06","modifiedBy":"MAESKEB","dateModified":"2016-01-06","changeNote":"Curated for Protocol 9787. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5098566","version":"1","preferredName":"Patient Prior Temozolomide Or Known Dacarbazine Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria with regards to prior therapy with temozolomide or has known hypersensitivity to dacarbazine.","longName":"PT_P_TMOZLMD_OR_DACRBZN_HY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"29125CA3-B655-76A7-E050-BB89AD43284F","latestVersionIndicator":"Yes","beginDate":"2016-01-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-11","modifiedBy":"SOKKERL","dateModified":"2022-07-01","changeNote":"Curated for Protocol 9149. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5098971","version":"1","preferredName":"Primary Diagnosis Disease or Disorder Group Type","preferredDefinition":"A textual response for the type of disease or disorder group occurring first in signs and symptoms by scientific determination.","longName":"PRMY_DX_DZDSR_GRP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2925C740-7CF2-2208-E050-BB89AD436290","latestVersionIndicator":"Yes","beginDate":"2016-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-01-12","modifiedBy":"CHANGP","dateModified":"2016-11-01","changeNote":"1/21/16 approved and released.  1/12/16 tt, curated for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105854","version":"2","preferredName":"Laboratory Procedure Absolute Neutrophil Count Code Indicator","preferredDefinition":"The coded indicator related to criteria to determine eligibility of patients formedical procedure that involves testing a sample of blood for the absolute neutrophil count, the real number of white blood cells (WBC) that are neutrophils and is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count, as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"LAB_ANC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B3AF4F3-3CF1-4726-E053-F662850ABCF7","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-03","modifiedBy":"SOKKERL","dateModified":"2022-06-07","changeNote":"Curated for CITN-12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105871","version":"1","preferredName":"Laboratory Procedure Platelet Count Eligibility Determination Yes No Exception Code Indicator","preferredDefinition":"The coded yes/no/exception indicator whether a medical procedure has been performed that involves testing a sample of blood for the platelet count, the real number of irregularly shaped disk like cytoplasmic fragment of a megakaryocyte that is shed in the marrow sinus and subsequently found in the peripheral blood where it functions in clotting, as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"LAB_PLT_ELG_Y_N_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"29CBBF66-9AFE-E0CF-E050-BB89AD43442E","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-20","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeNote":"Curated for CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105872","version":"1","preferredName":"Hematology Hemoglobin Assessment Yes No Exception Code Indicator","preferredDefinition":"The coded yes/no/exception indicator whether there was a hematology assessment for hemoglobin, the red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","longName":"HMT_HGB_AS_Y_N_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"29CBBF66-9B25-E0CF-E050-BB89AD43442E","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-20","modifiedBy":"TAYLORT","dateModified":"2021-07-08","changeNote":"4/16/19 tmt changed Registration Status from Qualified to Application.  Curated for CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105879","version":"2","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Code Indicator","preferredDefinition":"The coded indicator related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"LAB_AST_ALT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B3E9395-6C07-4718-E053-F662850AE613","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-03","modifiedBy":"SOKKERL","dateModified":"2024-02-13","changeNote":"Curated for CITN-12. bsm Version to 2.0 , different VD attached 1/3/20 ls","administrativeNotes":"7/28/2022: fixed the symbol x in AQTs.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105880","version":"1","preferredName":"Laboratory Procedure Creatine Kinase Clinical Trial Eligibility Criteria Yes No Exception Code Indicator","preferredDefinition":"The coded yes/no/exception indicator whether a medical procedure has been performed that involves testing a sample of blood to test creatine kinase.","longName":"LAB_PROC_CK_Y_N_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"29CBBF66-9BA3-E0CF-E050-BB89AD43442E","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-20","modifiedBy":"GALITG","dateModified":"2022-04-18","changeNote":"Curated for Protocol CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105881","version":"1","preferredName":"Laboratory Procedure Creatinine Result Yes No Exception Code Indicator","preferredDefinition":"The coded yes/no/exception indicator related to a creatinine laboratory procedure.","longName":"LAB_CREAT_Y_N_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"29CB5FC4-8A65-F5B1-E050-BB89AD43632D","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-20","modifiedBy":"SOKKERL","dateModified":"2019-05-22","changeNote":"Curated for CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105882","version":"1","preferredName":"Patient Controlled Thyroid Gland Function Clinical Trial Eligibility Criteria Yes No Exception Code Indicator","preferredDefinition":"The yes/no/exception coded response indicating a patient meets the eligibility criteria for adequately controlled thyroid function in order to participate in a clinical study.","longName":"CONT_THYROID_FUN_Y_N_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"29CBBF66-9BCA-E0CF-E050-BB89AD43442E","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-20","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeNote":"Curated for CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5105885","version":"1","preferredName":"Laboratory Procedure Within Clinical Study Protocol Upper Limit of Normal Total Bilirubin Measurement Yes No Exception Code Indicator","preferredDefinition":"The coded yes/no/exception indicator related to the top value of the range for total bilirubin falling within parameters set forth by the guidelines for a clinical trial.","longName":"LAB_TBM_Y_N_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"29CBBF66-9BF2-E0CF-E050-BB89AD43442E","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-20","modifiedBy":"SOKKERL","dateModified":"2019-06-13","changeNote":"Curated for CITN-12. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5114450","version":"1","preferredName":"Patient Receive Prior EGFR Tyrosine Kinase Inhibitor Therapy Prior Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response to a question that asks is the patient received prior EGFR tyrosine kinase inhibitors before study enrollment.","longName":"PT_PR_EGFR_TKI_PR_ENRL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2A5813BD-279D-CB70-E050-BB89AD430676","latestVersionIndicator":"Yes","beginDate":"2016-01-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-27","modifiedBy":"MAESKEB","dateModified":"2016-02-04","changeNote":"Curated for Protocol 9898. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5119260","version":"1","preferredName":"Participant Sight Change Indicator","preferredDefinition":"The yes/no response to a question that asks if the person's faculty of vision, the perception of objects by the eye has altered or modified.","longName":"PT_SIGHT_CHNG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B483721-AE99-431F-E050-BB89AD435180","latestVersionIndicator":"Yes","beginDate":"2016-02-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-08","modifiedBy":"MAESKEB","dateModified":"2016-02-12","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5120775","version":"1","preferredName":"Participant Medical Record Identifier Text","preferredDefinition":"The text used to identify medical record identification.","longName":"PT_MED_REC_ID_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6C6094-E837-355F-E050-BB89AD435657","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"MAESKEB","dateModified":"2016-02-12","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5120791","version":"1","preferredName":"Computer Program Created Record Generation Time","preferredDefinition":"Time on which an entry or record generated by a computer program is created.","longName":"COMP_RECD_GEN_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6C892C-EACB-338D-E050-BB89AD4310FF","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"MAESKEB","dateModified":"2016-02-12","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5120795","version":"1","preferredName":"Ileostomy Procedure Performed Outcome","preferredDefinition":"The result of the surgical creation of an external opening into the ileum for fecal diversion or drainage being carried out.","longName":"ILEOST _PROC_PERF_OUTCM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6C892C-EB5D-338D-E050-BB89AD4310FF","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"MAESKEB","dateModified":"2016-02-25","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5120812","version":"1","preferredName":"Bowel Movement Observed Frequency Assessment Count","preferredDefinition":"The numeric value counting the occurrences of stool passed from the rectum as a measure to evaluate the function of the digestive tract.","longName":"BOWEL_MVMT_OBS_FREQ_ASS_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6C7AF0-C46A-E3B2-E050-BB89AD430FD3","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"ZHANGWE","dateModified":"2021-04-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5121291","version":"1","preferredName":"Therapeutic Procedure Response Text","preferredDefinition":"The text that provides a description of the action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"THERAP_PROC_RESP_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6D6C25-B9E2-93CD-E050-BB89AD430AED","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"MAESKEB","dateModified":"2016-02-12","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5121316","version":"1","preferredName":"Protocol Agent Hold Present Indicator","preferredDefinition":"The yes/no response to a question that asks if the medical product, practice, or application that is tested in a clinical trial is on hold.","longName":"PROT_AGT_HOLD_PRES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6DF537-7359-5D06-E050-BB89AD4370F1","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"MAESKEB","dateModified":"2016-02-12","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5121331","version":"1","preferredName":"Clinical Study Team Edit Occurrence Date","preferredDefinition":"The date at which the study corrected or revised a record.","longName":"CLIN_STD_TEAM_EDIT_OCCR_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6E1A2F-4E15-19DD-E050-BB89AD43419E","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"MAESKEB","dateModified":"2016-02-25","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5121332","version":"1","preferredName":"Clinical Study Team Edit Occurrence Time","preferredDefinition":"The time at which the study corrected or revised a record.","longName":"CLIN_STD_TEAM_EDIT_OCCR_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B6E1A2F-4E3C-19DD-E050-BB89AD43419E","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-10","modifiedBy":"MAESKEB","dateModified":"2016-02-25","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5122216","version":"1","preferredName":"BRAT Diet Administered Yes No Indicator","preferredDefinition":"The yes/no response to a question that asks if a bland-food diet consisting of bananas, rice, applesauce, and toast has been given.","longName":"BRAT_DIET_ADMIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2B9518FF-2543-A831-E050-BB89AD435E19","latestVersionIndicator":"Yes","beginDate":"2016-02-12","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-12","modifiedBy":"MAESKEB","dateModified":"2016-02-24","changeNote":"Curated for Protocol 9825. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5133262","version":"1","preferredName":"Person Malignant Neoplasm Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response for questions addressing cancer and treatments for cancer, as outlined in the clinical trial protocol, to determine a person's elgibility to participate in the clinical trial.","longName":"MAL_NEO_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C8B370A-483F-1ADC-E050-BB89AD430EE8","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-02-24","modifiedBy":"SOKKERL","dateModified":"2022-03-11","changeNote":"2/25/16 tt, approved by ZP; released. 2/24/16 tt, curated for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5142751","version":"1","preferredName":"Person Disease or Disorder Clinical Stage Excision Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions, which are necessary to allow a person to participate in a clinical study, addressing the extent of cancer and the surgical removal of part or all of a structure or organ as outlined in the study protocol.","longName":"CLNL_DZ_STG_EXSN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF3096-9792-003C-E050-BB89AD4320A2","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-02-26","modifiedBy":"SOKKERL","dateModified":"2022-08-09","changeNote":"2/26/16 curated for 9950' approved and released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143651","version":"1","preferredName":"Person Prior Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study that address previous treatment(s) of a disease by means of exposure of the target or the whole body to radiation, as outlined in the clinical trial protocol.","longName":"PR_RADTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CEAABEC-1442-42A3-E050-BB89AD436EF6","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-02-29","modifiedBy":"CLOHNES","dateModified":"2023-09-29","changeNote":"2/29/16 tt, curated for 9950; approved and released.","administrativeNotes":"9/26/23 Added alt OID, CCTG and AQT for CCTG ticket number CADSR0002884 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143691","version":"1","preferredName":"Person Histologic Or Cytology Confirmation Malignant Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study addressing the histological or cytological verification of malignant neoplastic disease as outlined in the clinical trial protocol.","longName":"HISCYT_MALNEO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CEB3BA5-F099-D931-E050-BB89AD4325E4","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2023-12-11","changeNote":"2/29/16 tt, curated for 9950 and edit to long name and question text; approved and released.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143717","version":"1","preferredName":"Person Clinical Or Performed Imaging Evidence Metastatic Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study that address the clinical and imaging evidence of metastic disease as outlined in the clinical trial protocol.","longName":"CLN_IMG_EVNC_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CEC508B-054C-F6CC-E050-BB89AD432250","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2019-08-20","changeNote":"2/29/16 tt, curated for 9950; approved and released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143951","version":"1","preferredName":"Patient Histologic Confirmation Metastatic Or Unresectable Malignant Neoplasm Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient's histologically confirmed diagnosis of metastatic or unresectable malignancy meets the criteria for participation in a clinical trial.","longName":"HXCONF_MET_UNRES_MAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF0D295-EB72-83C1-E050-BB89AD431A7F","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2023-05-09","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143952","version":"1","preferredName":"Patient Non-Small Cell Lung Carcinoma Requirements Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient with a diagnosis of advanced non-small cell lung cancer (NSCLC) meets additional criteria for participation in a clinical trial.","longName":"NSCLC_REQ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF0D295-EB99-83C1-E050-BB89AD431A7F","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"DWARZEL","dateModified":"2017-08-29","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143953","version":"1","preferredName":"Patient Triple-Negative Breast Cancer Finding Requirements Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient with the diagnosis of triple-negative breast cancer meets additional requirements for participation in a clinical trial.","longName":"TNBC_REQ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF0D295-EBC0-83C1-E050-BB89AD431A7F","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2023-01-18","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143992","version":"1","preferredName":"Patient Prior Chemotherapy For Metastatic Breast Carcinoid Tumor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has received prior chemotherapy in a metastatic setting that meets the criteria for participation in a clinical trial.","longName":"PR_CHEM_MET_BRST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C902-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2022-03-03","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143993","version":"1","preferredName":"Patient Chemotherapy With Or Without Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has received prior chemotherapy with or without radiation therapy that meets the criteria for participation in a clinical trial.","longName":"CHEM_WWO_RX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C929-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2016-03-01","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143994","version":"1","preferredName":"Patient Prior Platinum Compound Chemotherapy For Limited Stage Or Extensive Stage Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has received prior chemotherapy with a platinum-based regimen for limited or extensive stage disease that meets the criteria for participation in a clinical trial.","longName":"PLAT_LMT_EXT_STG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C950-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2016-03-01","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143995","version":"1","preferredName":"Patient Sufficient Control Hypertension Clinical Trial Eligibility Criteria Yes No Not Applicable Code Indicator","preferredDefinition":"The coded response indicating that a patient has sufficiently controlled hypertension that meets the criteria for participation in a clinical trial.","longName":"5143733v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C977-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2017-12-05","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143999","version":"1","preferredName":"Patient Treated Metastatic Malignant Neoplasm in the Brain Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient with previously treated known brain metastases meets additional criteria for participation in a clinical trial.","longName":"TRT_BRAIN_MET_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C9CD-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2023-03-30","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5144000","version":"1","preferredName":"Patient Abdominal Aortic Aneurysm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient with abdominal aortic aneurysm meets additional criteria for participation in a clinical trial.","longName":"ABD_AOR_ANEUR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C9F4-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2017-08-10","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5144001","version":"1","preferredName":"Patient BRCA Gene Deleterious Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has BRCA germline deleterious mutation that meets the criteria for participation in a clinical trial.","longName":"BRCA_DEL_MUT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-CA1E-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5144004","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Chemotherapy Or Radiation Therapy Received Code Indicator","preferredDefinition":"The coded response indicating that prior to the start of study agent administration, a patient received chemotherapy or radiotherapy that meets the criteria for participation in a clinical trial.","longName":"PR_SAGT_CX_RX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-CA85-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2019-09-27","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5144005","version":"1","preferredName":"Patient Prior Poly (ADP-Ribose) Polymerase Inhibitor And VEGFR Tyrosine Kinase Inhibitor Combination Drug Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient has received prior VEGF inhibitors and PARP inhibitors in combination that meets the criteria for participation in a clinical trial.","longName":"VEGF_PARP_COMB_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-CAAC-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2016-03-01","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5144007","version":"1","preferredName":"Patient Antiarrhythmic Agent Or Arrhythmia Induction Pharmacologic Substance Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response regarding whether a patient has an antiarrhythmic agent or arrhythmic agent requirement that meets the criteria for participation in a clinical trial.","longName":"XARR_ARR_REQ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-CAF2-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"SOKKERL","dateModified":"2017-08-10","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5144008","version":"1","preferredName":"Patient Pulmonary Lesion Cavitation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response regarding whether a patient has cavitation of central pulmonary lesion that meets the criteria for participation in a clinical trial.","longName":"PUL_LES_CAV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-CB19-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2016-03-01","changeNote":"9881_Theradex_02.29.16_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154111","version":"1","preferredName":"Person Discontinue Teatment Or Stable Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study that address the permanent or temporary stop of therapeutic agents, or if the patient is on a stable dose, as outlined in the clinical trial protocol.","longName":"DSCT_TX_STB_DOS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC7CA8E-41F1-0FA0-E050-BB89AD437CCE","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"KRYSTKIA","dateModified":"2018-03-26","changeNote":"3/15/16 tt, approved/released. 3/11/16 tt, curated for 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154214","version":"1","preferredName":"Person Recurrent Disease Or Refractory Malignant Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study that address the return of disease, or no response to cancer treatment, as outlined the clinical trial protocol.","longName":"RECREF_MAL_NPLM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCA48BC-1553-935B-E050-BB89AD430DF4","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"SOKKERL","dateModified":"2023-06-08","changeNote":"3/15/16 tt, released. 3/11/16 tt, curated for 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154218","version":"1","preferredName":"Person Malignant Neoplasm Recurrent Or Refractory Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study that address the return of disease, or no response to cancer treatment, as outlined the clinical trial protocol.","longName":"MAL_NPLM_RECREF_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCA48BC-15AA-935B-E050-BB89AD430DF4","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"SOKKERL","dateModified":"2023-06-08","changeNote":"3/15/16 approved/released. 3/11/16 tt, curated for 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154232","version":"1","preferredName":"Person MCL Recurrent Or Refractory Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study that address the return of MCL, or no response to cancer treatment, as outlined the clinical trial protocol.","longName":"MCL_RECREF_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCA9F95-9AC2-3F50-E050-BB89AD432C38","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"TAYLORT","dateModified":"2016-11-04","changeNote":"3/15/16 approved/released. 3/11/16 tt, curated for 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154254","version":"1","preferredName":"Person Autologous Hematopoietic Stem Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study that address stem cell transfer or transplantation in which the patient is his own donor, as outlined the clinical trial protocol.","longName":"AUGS_STEM_CELL_TRANS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCA9F95-9B19-3F50-E050-BB89AD432C38","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"SOKKERL","dateModified":"2022-07-19","changeNote":"3/15/16 tt, approved/released. 3/11/16 tt, curated for 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154291","version":"1","preferredName":"Person Diet And Medication Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions necessary to allow a patient to participate in a clinical study that address the patient's agreement to diet requirements and the use of drug products intended to treat, prevent, or alleviate symptoms of disease, as outlined the clinical trial protocol.","longName":"DIET_MEDS_AGMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCB6D99-7885-F9BE-E050-BB89AD43788E","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"TYRRELLM","dateModified":"2023-11-16","changeNote":"3/15/16 tt, appoved/released. 3/11/16 tt, curated for 9875.","administrativeNotes":"11.16.2023 Added AQT per request ticket CADSR0003088_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154314","version":"1","preferredName":"Person Medical History Patient Noncompliance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response for questions related to the patient's medical history of failure to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment as outlined the clinical trial protocol, to allow a subject to participate in a clinical study.","longName":"PRSN_MEDHX_NONCMP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCC255B-1F4D-E1C0-E050-BB89AD431F11","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"TAYLORT","dateModified":"2016-03-15","changeNote":"3/15/16 tt, approved/released. 3/11/16 tt, curated for 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154331","version":"1","preferredName":"Person Measurable Disease Prior Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response for questions as to whether a tumor can be accurately measured in size, and the prior treatment of a disease by means of exposure to radiation as outlined the clinical trial protocol, to allow a subject to participate in a clinical study.","longName":"5154321v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCC9D23-00A3-3243-E050-BB89AD43022A","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-11","modifiedBy":"SOKKERL","dateModified":"2017-03-08","changeNote":"3/15/16 tt, approved/released. 3/11/16 tt, curated for 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5154411","version":"1","preferredName":"Patient Prior Registration Companion Protocol Identifier","preferredDefinition":"The identification number assigned to a previously registered clinical trial.","longName":"PT_PR_REG_COMP_PROT_ID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2E046F58-B61C-870D-E050-BB89AD4348CB","latestVersionIndicator":"Yes","beginDate":"2016-03-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-14","modifiedBy":"MAESKEB","dateModified":"2016-03-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5205574","version":"1","preferredName":"Person Imaging Procedure Contraindicated Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether any method of imaging is considered unsuitable or inadvisable as outlined in the study protocol, to allow a patient to participate in the clinical trial.","longName":"IMG_CNTRD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F355989-E8B9-464A-E050-BB89AD43666D","latestVersionIndicator":"Yes","beginDate":"2016-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-29","modifiedBy":"SOKKERL","dateModified":"2021-01-15","changeNote":"4/4/16 tt, approved/released. 3/29/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5206991","version":"1","preferredName":"Person Iron Overload Evidence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the evidence of the accumulation of iron in tissues, as outlined in the study protocol, to allow clinical trial participation.","longName":"IRN_OVLD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F443E01-36C0-D307-E050-BB89AD43589B","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-30","modifiedBy":"SOKKERL","dateModified":"2017-04-21","changeNote":"4/6/16 tt, approved/released. 3/30/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5207031","version":"1","preferredName":"Person Prior Biological And Or Targeted Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions necessary to allow a patient to participate in a clinical study that address treatment(s) of substances which produce a biological reaction in the organism and/or treatment(s) that use drugs or other substances, as outlined in the study protocol.","longName":"BGL_TGT_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F45D766-68B1-235B-E050-BB89AD43611F","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-30","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"4/4/16 tt, approved/released. 3/30/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5207113","version":"1","preferredName":"Person Receive Radiation Therapy Bone Marrow Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions that are necessary to allow a patient to participate in a clinical study regarding the receipt of radiation therapy and bone marrow assessments as outlined in the study protocol.","longName":"RX_BNMW_ASMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F476D4D-7069-2C4A-E050-BB89AD4318EA","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-30","modifiedBy":"TSESU","dateModified":"2023-05-30","changeNote":"4/4/16 tt, approved/released. 3/30/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5207134","version":"1","preferredName":"Person High Risk Seizure Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the high risk of seizures as outlined in the study protocol to allow clinical trial participation.","longName":"HIRSK_SZRDR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F48A39D-443C-292D-E050-BB89AD4344DE","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-30","modifiedBy":"TAYLORT","dateModified":"2016-04-04","changeNote":"4/4/16 tt, approved/released. 3/30/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5207157","version":"1","preferredName":"Laboratory Procedure Magnesium Assessment Code Indicator","preferredDefinition":"The coded response indicating whether the outcome of a laboratory procedure to measure magnesium met the pre-defined criteria.","longName":"LAB_PROC_MAGNSM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2F48A39D-44B4-292D-E050-BB89AD4344DE","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-30","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"Curated for Protocol 9875.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5207158","version":"1","preferredName":"Person Receive Radiation Therapy Or Neurologic Resection Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions that address the receipt of treatment of a disease by means of radiation or neurologic excision as outlined in the study protocol in order to allow a patient to participate in a clinical study.","longName":"5207153v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F48A39D-44DB-292D-E050-BB89AD4344DE","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-30","modifiedBy":"SOKKERL","dateModified":"2018-05-15","changeNote":"4/4/16 tt, approved/released. 3/30/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5207199","version":"1","preferredName":"Person Agent Severe Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to an intensely bad immune response to a substance as outlined in the study protocol, in order to allow a patient to participate in a clinical study.","longName":"SVR_AGT_HSVY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F499E09-41B3-CF28-E050-BB89AD4321FA","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-30","modifiedBy":"TAYLORT","dateModified":"2016-04-04","changeNote":"4/4/16 approved/released. 3/30/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5207218","version":"1","preferredName":"Patient Medical History Allergic Reaction Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the personal medical history of immune response(s) that occur following re-exposure to an innocuous antigen, as outlined in the study protocol, in order to allow a patient to participate in a clinical study.","longName":"MEDHX_ALG_RTN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F499E09-425F-CF28-E050-BB89AD4321FA","latestVersionIndicator":"Yes","beginDate":"2016-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-03-30","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"4/4/16 tt, edit to long name, released. 3/30/16 tt, curated for 9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5209317","version":"1","preferredName":"Treatment Assignment Code","preferredDefinition":"The code that represents the treatment assignment code.","longName":"TAC_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2FA8D132-C6B2-B9C6-E050-BB89AD432CD8","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-04-04","modifiedBy":"MAESKEB","dateModified":"2016-04-04","changeNote":"Curated for Protocol 9881.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5215440","version":"1","preferredName":"Patient Avoidance Strong Inhibitor Or Inducer CYP3SA4 Gene Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable indicator that asks if the patient agrees to avoid the concomitant administration of strong inhibitors or inducers of CYP3A4.","longName":"PT_AVD_STRN_INH_CYP3SA4_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2FEC538A-160F-DBE9-E050-BB89AD436B0C","latestVersionIndicator":"Yes","beginDate":"2016-04-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-04-07","modifiedBy":"TYRRELLM","dateModified":"2023-12-20","changeNote":"Curated for Protocol 9950. bsm","administrativeNotes":"12.20.2023 Added AQT per request ticket CADSR0003202_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5226431","version":"1","preferredName":"Person Concomitant Agent Enhance Glucuronidation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether a patient meets the eligibility criteria addressing concomitant medications that enhance glucuronidation.","longName":"CONMED_ENHC_GRDN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"30790258-5949-C5E5-E050-BB89AD43259D","latestVersionIndicator":"Yes","beginDate":"2016-04-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-04-14","modifiedBy":"TAYLORT","dateModified":"2016-04-18","changeNote":"4/18/16 tt, approved/released. 4/14/14 tt, curated for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5226486","version":"1","preferredName":"Person Lesser Control Human Immunodeficiency Virus Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether a patient meets the eligibility criteria related to poorly controlled HIV.","longName":"LSR_CTRL_HIV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3079897A-2FF9-EC30-E050-BB89AD436ED9","latestVersionIndicator":"Yes","beginDate":"2016-04-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-04-14","modifiedBy":"SOKKERL","dateModified":"2018-05-11","changeNote":"4/18/16 tt, approved/released. 4/14/16 tt, curated for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5226525","version":"1","preferredName":"Person Laboratory Procedure BUN Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether a patient meets the eligibility criteria related to BUN measurements.","longName":"BUN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"307A354D-9A8A-411F-E050-BB89AD430882","latestVersionIndicator":"Yes","beginDate":"2016-04-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-04-14","modifiedBy":"TAYLORT","dateModified":"2016-04-18","changeNote":"4/18/16 tt, approved and released. 4/14/16 tt, curated for 9892.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5229644","version":"1","preferredName":"Patient Pathologic Confirmation Adult T-Cell Leukemia/Lymphoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if the patient has pathologically confirmed peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).","longName":"PT_PATH_CONF_ATLL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"310523BC-98E2-0B75-E050-BB89AD43184C","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-04-21","modifiedBy":"MAESKEB","dateModified":"2016-04-29","changeNote":"Curated for Protocol 9925.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5229650","version":"1","preferredName":"HTLV-1 Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes the Human T-lymphotropic virus-1 (HTLV-1) having been established or verified.","longName":"HTLV_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3104FC5B-DAAD-25B5-E050-BB89AD433A04","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-04-21","modifiedBy":"SOKKERL","dateModified":"2020-03-26","changeNote":"Curated for Protocol 9925.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5229658","version":"1","preferredName":"Patient Pathologic Confirmation Adult T-Cell Leukemia/Lymphoma Chemotherapy Received Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if the patient has received chemotherpay for the pathologically confirmed peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).","longName":"PT_PATH_CONF_ATLL_CHEM_REC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3104FC5B-DBB9-25B5-E050-BB89AD433A04","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-04-21","modifiedBy":"MAESKEB","dateModified":"2016-04-29","changeNote":"Curated for Protocol 9925.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5229662","version":"1","preferredName":"Patient Current Or Prior HTLV-1 Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable indicator that describes if the patient has current or prior Human T-lymphotropic virus-1 (HTLV-1).","longName":"PT_C_OR_PR_HLTV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3104FC5B-DC26-25B5-E050-BB89AD433A04","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-04-21","modifiedBy":"HARTLEYG","dateModified":"2018-07-20","changeNote":"Curated for Protocol 9925.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5230301","version":"1","preferredName":"Person Prior Blinatumomab Or Chimeric Antigen Receptor Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding prior Blinatumomab or Chimeric Antigen Receptor treatments.","longName":"BTMB_CAR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"31139850-485F-ED93-E050-BB89AD436CAE","latestVersionIndicator":"Yes","beginDate":"2016-04-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-04-22","modifiedBy":"BROWNTY","dateModified":"2021-05-04","changeNote":"4/22/16 tt, created for 9924.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5230651","version":"1","preferredName":"Person Prior Lenalidomide Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial with regards to prior treatment of Lenalidomide.","longName":"LDMD_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"311573D0-C491-140F-E050-BB89AD43140B","latestVersionIndicator":"Yes","beginDate":"2016-04-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-04-22","modifiedBy":"TAYLORT","dateModified":"2016-04-22","changeNote":"4/22/16 tt, created for 9924.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5236587","version":"1","preferredName":"Recurrent Disease Malignant Ovarian Neoplasm Carboplatin Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient has met the eligibility criteria regarding having received prior carboplatin therapy since the return of malignant neoplasm involving the ovary.","longName":"R_DX_OVRN_CARBP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3191CB1F-88B0-F58A-E050-BB89AD431379","latestVersionIndicator":"Yes","beginDate":"2016-04-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-04-28","modifiedBy":"MAESKEB","dateModified":"2016-04-28","changeNote":"Curated for Prtocol 9782. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5242122","version":"1","preferredName":"Patient Metastatic Malignant Neoplasm in the Brain Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded yes/no/not applicable indicator response relating to a malignant neoplasm that has spread to the brain from another anatomic site or system.","longName":"PT_MET_MALGNT_CA_BRAIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"31E17E92-782C-2840-E050-BB89AD432A6A","latestVersionIndicator":"Yes","beginDate":"2016-05-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-02","modifiedBy":"TYRRELLM","dateModified":"2023-10-22","changeNote":"Curated for Protocol 9952. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5242126","version":"1","preferredName":"Patient Phenytoin Administration Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding the administration of phenytoin.","longName":"PT_PHEN_ADMIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"31E17E92-788C-2840-E050-BB89AD432A6A","latestVersionIndicator":"Yes","beginDate":"2016-05-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-02","modifiedBy":"TAYLORT","dateModified":"2021-07-07","changeNote":"Curated for Protocol 9952. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5242210","version":"1","preferredName":"Patient Dexamethasone Use Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding the use of dexamethasone.","longName":"PT_DEXA_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"31E17E92-78E1-2840-E050-BB89AD432A6A","latestVersionIndicator":"Yes","beginDate":"2016-05-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-02","modifiedBy":"SOKKERL","dateModified":"2016-12-19","changeNote":"Curated for Protocol 9952. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5243427","version":"1","preferredName":"Histologically Confirmed NSCLC Indicator","preferredDefinition":"The yes/no/not applicable response to a question related to verified diagnosis through use of histology or histological techniques of non-small cell lung carcinoma.","longName":"HIST_CONF_NSCLC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"31F4EB7F-9364-6DA7-E050-BB89AD437A36","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-03","modifiedBy":"SOKKERL","dateModified":"2022-02-28","changeNote":"Curated for Protocol 9952. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255237","version":"1","preferredName":"Patient Cutaneous Melanoma Histologically Confirmation Clinical Trial Eligibility Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has a histologic confirmed cutaneous melanoma.","longName":"PT_CUTMEL_HIST_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"327FF9F4-DDE1-7D69-E050-BB89AD4331B2","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"HARTLEYG","dateModified":"2018-07-20","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255239","version":"1","preferredName":"Assessment Stage IV Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding disease that has spread to distant anatomic sites beyond its original site of growth.","longName":"ASSESS_STG_IV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"327FF9F4-DE29-7D69-E050-BB89AD4331B2","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"SHEARMA","dateModified":"2019-03-29","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255272","version":"1","preferredName":"PDL1/PD1 Pharmacologic Substance Administered Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regardingI PDL1/PD1 therapy.","longName":"PDL1_PD1_PHARM_SUB_ADMIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3280DF81-E038-028E-E050-BB89AD432306","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"MAESKEB","dateModified":"2016-05-12","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255281","version":"1","preferredName":"Patient Consent Biopsy Metastatic Tumor Tissue Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for question addressing the patient's willingness to consent to a biopsy procedure.","longName":"PT_CON_BX_MET_TUM_TISS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"32812732-DFA2-20E6-E050-BB89AD436645","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"MAESKEB","dateModified":"2017-01-20","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255298","version":"1","preferredName":"Patient Melanoma Mucosa Or Ocular Primary Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for question addressing if the patient has a malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes of the mucous membrane or relating to the eye.","longName":"PT_MEL_MUC_OR_OCUL_PRIM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"32812732-DFFB-20E6-E050-BB89AD436645","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"MAESKEB","dateModified":"2016-05-12","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255315","version":"1","preferredName":"Patient Uncontrolled Autoimmune Hemolytic Anemia Or Idiopathic Thrombocytopenic Purpura Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for question addressing the patients uncontrolled autoimmune hemolytic anemia or ITP.","longName":"5255314v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3281791B-01E1-E493-E050-BB89AD4317A6","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"MAESKEB","dateModified":"2016-05-12","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255321","version":"1","preferredName":"Patient Blood Transfusion Dependent Thrombocytopenia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for question addressing the infusion of components of blood or whole blood into the bloodstream dependent on a laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.","longName":"PT_TRNSF_DEP_THROMBPN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"32819441-EDFB-AA82-E050-BB89AD436D9A","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"LISU","dateModified":"2022-03-15","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255352","version":"1","preferredName":"Patient Prior Exposure Ibrutinib Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for question addressing prior exposure to an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.","longName":"PT_PR_EXP_IBRUB_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"32819441-EE77-AA82-E050-BB89AD436D9A","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"MAESKEB","dateModified":"2016-05-12","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255354","version":"1","preferredName":"Hepatic Infection Personal Medical History Code Indicator","preferredDefinition":"The coded response regarding pertaining to the patient's hepatic medical history.","longName":"HEP_INFCTN_PRSNL_MEDHX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3282C903-E9CC-7B50-E050-BB89AD430762","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-10","modifiedBy":"MAESKEB","dateModified":"2016-05-12","changeNote":"Curated for Protocol 9922. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5282236","version":"1","preferredName":"Treatment Cohort Study 9947 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9947 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9947_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"33D70387-3DCE-5D18-E050-BB89AD432CD6","latestVersionIndicator":"Yes","beginDate":"2016-05-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-05-27","modifiedBy":"MAESKEB","dateModified":"2016-05-27","changeNote":"Curated for 9947 protocol. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5291111","version":"1","preferredName":"Primary Tumor Diagnosis Indicator","preferredDefinition":"The coded response that indicates a patient's primary tumor diagnosis.","longName":"PRIM_TUMOR_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"353E4D5F-E4AD-BE52-E050-BB89AD435C44","latestVersionIndicator":"Yes","beginDate":"2016-06-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-06-14","modifiedBy":"TSESU","dateModified":"2022-11-21","changeNote":"Curated for Protocol 9979.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5291125","version":"1","preferredName":"Surgical Excision And Or Radiation Therapy Boost Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded response indicating whether a surgical removal of part or all of a structure or organ and/or treatment of a disease by means of exposure of the target or the whole body to radiation.","longName":"SURG_EXCSN_RT_BOOST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"353EE0ED-AAC3-FCAF-E050-BB89AD43034A","latestVersionIndicator":"Yes","beginDate":"2016-06-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-06-14","modifiedBy":"MAESKEB","dateModified":"2018-01-02","changeNote":"Curated for Protocol 9979.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5326191","version":"1","preferredName":"Person Neoplasm Or Complete Remission Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the eligibility criteria for enrollment onto a clinical trial regarding benign and/or malignant tissue growth, or the disappearance of all signs of cancer in response to treatment.","longName":"NEO_CR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"364A5371-6225-CBFB-E050-BB89AD43035C","latestVersionIndicator":"Yes","beginDate":"2016-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-06-27","modifiedBy":"SOKKERL","dateModified":"2023-09-20","changeNote":"6/28/16 tt, released approved DE. 6/27/16 tt, created for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5326214","version":"1","preferredName":"Person Partial Remission Or Current Therapeutic Procedure With Stable Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the eligibility criteria for enrollment onto a clinical trial regarding the decrease in size and extent of cancer, or current treatment of cancer that is neither decreasing nor increasing in extent or severity.","longName":"PR_TX_SD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"364B7871-03A0-33A4-E050-BB89AD4319AD","latestVersionIndicator":"Yes","beginDate":"2016-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-06-27","modifiedBy":"TAYLORT","dateModified":"2016-06-28","changeNote":"6/28/16 tt, released approved DE. 6/27/16 tt, created for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5328694","version":"1","preferredName":"Patient Negation Infectious Disorder Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether the patient's personal medical history includes known non-infectious diseases.","longName":"PT_NONINF_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"365E7ED3-178E-2BC4-E050-BB89AD4328C9","latestVersionIndicator":"Yes","beginDate":"2016-06-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-06-28","modifiedBy":"KNABLEJ","dateModified":"2017-10-09","changeNote":"Curated for Theradex. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5331562","version":"1","preferredName":"Patient Histologically Confirmation Metastatic Progressive Clear Cell Renal Cell Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has histologic confirmation of progressive metastatic clear cell renal carcinoma.","longName":"HIST_MET_CCRC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"366EA8BB-9942-2A35-E050-BB89AD43104A","latestVersionIndicator":"Yes","beginDate":"2016-06-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-06-29","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"9681","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5331645","version":"1","preferredName":"Patient Response Evaluation Criteria in Solid Tumors Metastatic Neoplasm Renal Cell Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating that a patient meets the criteria with regards to a diagnosis of progressive metastatic renal cell carcinoma as defined by RECIST criteria.","longName":"RECIST_MET_RCC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"366EA8BB-99A2-2A35-E050-BB89AD43104A","latestVersionIndicator":"Yes","beginDate":"2016-06-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-06-29","modifiedBy":"HARTLEYG","dateModified":"2016-06-29","changeNote":"9681","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5335694","version":"1","preferredName":"Patient Blood Pressure Measurement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient meets the criteria for participation in a clinical trial regarding blood pressure measurements.","longName":"PT_BP_MEAS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"36EB3082-D789-16EE-E050-BB89AD43176D","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-07-05","modifiedBy":"SOKKERL","dateModified":"2023-05-15","changeNote":"9825","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5343234","version":"1","preferredName":"Patient Platinum Refractory Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient meets the criteria for participation in a clinical trial with regards to platinum resistant disease.","longName":"PLAT_REFR_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"37766921-1E2E-3429-E050-BB89AD434DB1","latestVersionIndicator":"Yes","beginDate":"2016-07-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-07-12","modifiedBy":"TYRRELLM","dateModified":"2023-12-19","changeNote":"9944","administrativeNotes":"12.19.2023 Added AQT for request ticket CADSR0003202_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5343711","version":"1","preferredName":"Person Pathology Review And Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding the evaluation and verification of pathology.","longName":"PATH_RVW_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"379896CB-D26B-807C-E050-BB89AD4307AA","latestVersionIndicator":"Yes","beginDate":"2016-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-07-14","modifiedBy":"SOKKERL","dateModified":"2023-11-06","changeNote":"7/15/16 tt, released CDE.  7/14/16 tt, created for 9948.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5343734","version":"1","preferredName":"Person Platinum Compound Chemotherapy Sensitivity Recurrent Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding platinum-based therapy sensitivity recurrence.","longName":"PLAT_SENS_RECR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"379A3111-BE9B-43F9-E050-BB89AD436D31","latestVersionIndicator":"Yes","beginDate":"2016-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-07-14","modifiedBy":"VUJANOVA","dateModified":"2019-08-01","changeNote":"7/15/16 tt, released. 7/14/16 tt, created for 9948/ edit to long name/def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5343810","version":"1","preferredName":"Person Prior Exposure Gemcitabine Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding prior exposure to Gemcitabine.","longName":"GMTB_PREXP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"379C33A6-5E1D-99C9-E050-BB89AD436982","latestVersionIndicator":"Yes","beginDate":"2016-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-07-14","modifiedBy":"SOKKERL","dateModified":"2022-11-08","changeNote":"7/15/16 tt, released. 7/14/16 tt, created for 9948.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5351744","version":"1","preferredName":"Treatment Cohort Study 9944 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9944 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9944_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3802BC38-0D0A-2D60-E050-BB89AD430907","latestVersionIndicator":"Yes","beginDate":"2016-07-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-07-19","modifiedBy":"TAYLORT","dateModified":"2016-07-19","changeNote":"7/19/16 tt, curated, approved, and released for 9944.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5351815","version":"1","preferredName":"Person Receive Immunosuppressive Therapy With Drug Interaction Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the eligibility criteria regarding the receipt of anti-rejection therapy with drug interaction.","longName":"IMMTX_DRG_INTRN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"380549D5-5B66-7DD0-E050-BB89AD431119","latestVersionIndicator":"Yes","beginDate":"2016-07-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-07-19","modifiedBy":"KUMMEROA","dateModified":"2021-04-05","changeNote":"8/2/16 tt, releaed.  7/19/16 tt, curated for 9950.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5351826","version":"1","preferredName":"Person Attenuated Live Virus Vaccine Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the eligibility criteria regarding the requirement of live virus vaccines.","longName":"RQR_LIV_VIR_VAC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"380549D5-5BC4-7DD0-E050-BB89AD431119","latestVersionIndicator":"Yes","beginDate":"2016-07-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-07-19","modifiedBy":"BOWSERC","dateModified":"2021-06-29","changeNote":"8/2/16 tt, released.  7/19/16 tt, curated for 9950.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5355859","version":"1","preferredName":"Laboratory Procedure Creatinine Clearance Assessment Method Type","preferredDefinition":"The response that indicates the method used to determine creatinine clearance.","longName":"CRCL_ASMT_MTH_TYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3841C594-F373-FDBB-E050-BB89AD435321","latestVersionIndicator":"Yes","beginDate":"2016-07-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-07-22","modifiedBy":"HARTLEYG","dateModified":"2016-07-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5355860","version":"1","preferredName":"Laboratory Procedure Creatinine Clearance Assessment Calculation Method Type","preferredDefinition":"The response that indicates the method used to calculate creatinine clearance.","longName":"CRCL_CALC_MTH_TYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3841C594-F393-FDBB-E050-BB89AD435321","latestVersionIndicator":"Yes","beginDate":"2016-07-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-07-22","modifiedBy":"HARTLEYG","dateModified":"2016-07-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5356719","version":"1","preferredName":"Laboratory Procedure Glycosylated Hemoglobin Measurement Outcome Code Indicator","preferredDefinition":"A coded response regarding the amount of glycosylated hemoglobin present in a sample of blood.","longName":"HBA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"387B39C2-44C5-22FB-E050-BB89AD43458F","latestVersionIndicator":"Yes","beginDate":"2016-07-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-07-25","modifiedBy":"SOKKERL","dateModified":"2023-03-15","changeNote":"10/19/16 tt, released. 7/25/16 tt, created for 9910, edit to DEC, Long Name and Def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5363714","version":"1","preferredName":"Treatment Cohort Study 9944 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9944 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_9944_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"389E8F7D-A939-32D1-E050-BB89AD4358CF","latestVersionIndicator":"Yes","beginDate":"2016-07-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-07-27","modifiedBy":"MAESKEB","dateModified":"2016-07-28","changeNote":"Curated for Protocol 9944. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5367414","version":"1","preferredName":"Patient Platinum Free Interval Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding a metal that is an important component of some anticancer drugs, such as cisplatin and carboplatin.","longName":"PT_PFI_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"38B8A0A2-DB3D-5CA5-E050-BB89AD430F5F","latestVersionIndicator":"Yes","beginDate":"2016-07-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-07-28","modifiedBy":"MAESKEB","dateModified":"2016-07-28","changeNote":"Curated for Protocol 9948. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5369046","version":"1","preferredName":"Treatment Cohort Study 9681 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9681 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9681_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39042A75-1307-0BEA-E050-BB89AD436114","latestVersionIndicator":"Yes","beginDate":"2016-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-08-01","modifiedBy":"SOKKERL","dateModified":"2017-07-26","changeNote":"8/1/2016 tt, curated for 9681.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455494","version":"1","preferredName":"Person Bradycardia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to abnormally slow heart rates.","longName":"BDYCDA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C062F5A-A74F-AA31-E050-BB89AD432D4A","latestVersionIndicator":"Yes","beginDate":"2016-09-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-08","modifiedBy":"TAYLORT","dateModified":"2016-09-20","changeNote":"9/20/16 tt, approved/released. 9/8/16 tt, curated for 9910.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455571","version":"1","preferredName":"Person Valvular Heart Disorder Personal Medical History Code Indicator","preferredDefinition":"A response for questions that address the patient's background medical health related to heart disorders characterized by a defect in valve structure or function.","longName":"VLVR_MEDHX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C12D13E-3807-0F8E-E050-BB89AD4353A6","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"SBR","dateModified":"2016-09-20","changeNote":"9/20/16 tt, approved/released. 9/9/16 tt, created for 9910.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455593","version":"1","preferredName":"Person Gastrointestinal Tract Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding gastrointestinal tract diseases or disorders.","longName":"GI_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C132B8D-752D-5C59-E050-BB89AD435E33","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"SOKKERL","dateModified":"2022-03-21","changeNote":"9/20/16 tt, approved/released. 9/9/16 tt, created for 9910.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455614","version":"1","preferredName":"Person Pulmonary Hypertension Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to the diagnosis of elevated pulmonary vascular pressure.","longName":"PLM_HYP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C132B8D-7587-5C59-E050-BB89AD435E33","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"SOKKERL","dateModified":"2021-09-20","changeNote":"9/20/16 tt, approved/released. 9/9/16 tt, created for 9910.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455673","version":"1","preferredName":"Person Uncontrolled Asthma Oxygen Saturation Measurement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to uncontrolled chronic respiratory disease due to the narrowing of bronchial passageways or the determination of oxygen-hemoglobin saturation of blood.","longName":"ASM_OXYSAT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C1400D3-AAB8-997F-E050-BB89AD434323","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"SOKKERL","dateModified":"2020-04-16","changeNote":"6/26/17 tt, released/form use.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455931","version":"1","preferredName":"Person Medical History Prior To Pharmacologic Substance Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the patient's medical background prior to treatment with an agent or drug.","longName":"MEDHX_PRR_SUBADMN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C152060-44F5-93FE-E050-BB89AD437A82","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"SOKKERL","dateModified":"2019-12-26","changeNote":"9/20/16 tt, approved/released. 9/9/16 tt, created/edits - 9910.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5456180","version":"1","preferredName":"Person Receive Systemic Corticosteroid Therapy Prior To Protocol Agent Pharmacologic Substance Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the patient's receipt of treatment with corticosteroids prior to the act of the dispensing, applying, or tendering a substance that is tested in a clinical trial.","longName":"CRSTD_TX_PRR_STDYAGT_ADMN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C162112-C94A-827D-E050-BB89AD435030","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"BERGANTW","dateModified":"2020-03-20","changeNote":"9/20/16 tt, approved/released. 9/9/16 tt, created for 991.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5456351","version":"1","preferredName":"Person Food Beverage Consumption Prior To Protocol Agent Pharmacologic Substance Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the patient's consumption of substances or liquids prior to the act of the dispensing, applying, or tendering an agent/drug that is tested in a clinical trial.","longName":"FDBVG_PR_STDYAGT_ADMN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C16DAF7-650A-63DE-E050-BB89AD437935","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"SOKKERL","dateModified":"2022-11-15","changeNote":"9/20/16 tt, approved/released. 9/9/16 tt, created for 9910.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5473447","version":"1","preferredName":"Person Laboratory Procedure Alkaline Phosphatase Measurement Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the measurement of alkaline phosphatase present in a sample with any abnormal medical condition of the patient.","longName":"ALP_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3CF3DD88-0F3C-32C2-E053-F662850A64EC","latestVersionIndicator":"Yes","beginDate":"2016-09-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-20","modifiedBy":"KUMMEROA","dateModified":"2023-06-23","changeNote":"9/26/16 tt, approved/released. 9/20/16 tt, created for 10020.","administrativeNotes":"2023.6.23 Special character corrected per ticket request CADSR0002546. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5477039","version":"1","preferredName":"Person Receive Radiation Therapy Prior Protocol Agent Initiation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to the receipt of radiation therapy prior to the start of an investigational agent as outlined in the study protocol.","longName":"RT_PRR_AGNT_SRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D0686A6-46C8-3D42-E053-F662850A9FE4","latestVersionIndicator":"Yes","beginDate":"2016-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-21","modifiedBy":"SOKKERL","dateModified":"2021-09-28","changeNote":"9/26/16 tt, approved/released.  9/21/16 tt, created for 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5477060","version":"1","preferredName":"Patient Receive Radiation Therapy Prior Protocol Agent Initiation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to the receipt of radiation therapy prior to the start of an investigational agent as outlined in the study protocol.","longName":"RT_PRR_SDYAGN_SRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D069D91-7585-51F6-E053-F662850A41F1","latestVersionIndicator":"Yes","beginDate":"2016-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-21","modifiedBy":"TAYLORT","dateModified":"2016-09-26","changeNote":"9/26/16 tt, approved/released.\r\n9/21/16 tt, created for 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5477147","version":"1","preferredName":"Prior Investigational Therapeutic Procedure Adverse Event Recovery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to prior experimental therapeutic agents and outcomes of adverse events as outlined in the study protocol.","longName":"PRR_INVTX_AE_RCVRY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D082941-9F32-3DCD-E053-F662850A52F5","latestVersionIndicator":"Yes","beginDate":"2016-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-21","modifiedBy":"SOKKERL","dateModified":"2023-01-19","changeNote":"9/26/16 tt, approved/released. 9/21/16 tt, created for 10020.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5478454","version":"1","preferredName":"Patient Biopsy Assessment Intervention or Procedure Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the determination of biopsies to establish a diagnosis and the patient's consent to interventional strategies.","longName":"BX_ASMT_PROC_CNST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1A6AC1-A9E4-5B42-E053-F662850A350A","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2023-01-24","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, created for 10020.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5479293","version":"1","preferredName":"Patient Asymptomatic Untreated Central Nervous System Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to asymptomatic central nervous system disease that has not been treated.","longName":"ASYM_UNTX_CNSDZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1C696E-CB5A-292C-E053-F662850ABE93","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2020-07-27","changeNote":"2020-7-24 AQT added. AK  12/5/16 tt, added CSI. 9/26/16 tt, approved/released. 9/22/16 tt, created for 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5479341","version":"1","preferredName":"Patient Untreated Central Nervous System Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to central nervous system disease that has not been treated.","longName":"UNTX_CNSDZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1D093E-D4D6-0BAA-E053-F662850A8AA7","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2022-03-09","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5479475","version":"1","preferredName":"Person Dermatologic Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to any abnormal condition having to do with the skin or the practice of dermatology.","longName":"DRM_DZDR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1DB56C-BCD3-0751-E053-F662850A3577","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"KUMMEROA","dateModified":"2022-07-28","changeNote":"2020-7-24 AQT added. AK  9/26/16 tt, approved/released. 9/22/16 tt, 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5479511","version":"1","preferredName":"Person Transplantation Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to procedures involving the transference of tissue or organ.","longName":"TRPT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1DB5F2-9CC4-7971-E053-F662850ABCEC","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-27","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, 10020.","administrativeNotes":"2023.3.27 AQT added per ticket request CADSR0002214. ak 2023.3.17 AQT added per ticket request CADSR0002164. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5479618","version":"1","preferredName":"Patient CHO Cells Other Recombinant Human Anti-TGF-beta Monoclonal Antibody Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to an immune response that occurs following exposure to CHO Cells or other recombinant human IgG4 monoclonal antibodies directed against transforming growth factor-beta (TGFb).","longName":"CHO_RHMA_HYSTV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1DB56C-BD51-0751-E053-F662850A3577","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"TAYLORT","dateModified":"2020-12-16","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5479731","version":"1","preferredName":"Personal Medical History Severe Allergic Reaction Or Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to the patient's medical background regarding severe allergic reactions and hypersensitivities following exposure to an innocuous substance.","longName":"HX_ALCRN_HPSY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1F326E-0E4F-21B4-E053-F662850A6586","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2023-02-09","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, 10020. Fix spec character in definition 03-24-2020 DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5480024","version":"1","preferredName":"Person Psoriatic Arthritis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to joint inflammation associated with psoriasis.","longName":"PRTC_ATHS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1FCE19-B0B4-5F05-E053-F662850A3E9C","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"TAYLORT","dateModified":"2016-09-26","changeNote":"9/26/16 tt, approved/released.\r\n9/22/16 tt, 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5480029","version":"1","preferredName":"Person Pulmonary Inflammation Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to lung inflammation and disease.","longName":"LNG_IFMN_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D201387-0A8B-2F01-E053-F662850AA0B7","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5480033","version":"1","preferredName":"Patient Major Surgical Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to major surgical interventions.","longName":"MAJ_SUR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D201387-0AE0-2F01-E053-F662850AA0B7","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, 10020.","administrativeNotes":"12/20/22 added alt OID, CCTG and AQT for ticket number CADSR0001818; 8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5480037","version":"1","preferredName":"Patient Attenuated Live Virus Vaccine Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to the administration of live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strain.","longName":"LIV_VIR_VAC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1FCE19-B140-5F05-E053-F662850A3E9C","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2023-09-26","changeNote":"9/26/16 tt, approved/released. 9/22/16 t, 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5480128","version":"1","preferredName":"Person Adverse Event Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation as outlined in the study protocol for questions related to assessments of the patient's unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure.","longName":"AE_ASMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D1FCE19-B167-5F05-E053-F662850A3E9C","latestVersionIndicator":"Yes","beginDate":"2016-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-22","modifiedBy":"SOKKERL","dateModified":"2022-03-02","changeNote":"9/26/16 tt, approved/released. 9/22/16 tt, 10020. Fix special char in definition  03-24-2020 DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5482049","version":"1","preferredName":"Laboratory Procedure Serum Follicle Stimulating Hormone Measurement Eligibility Determination Code Indicator","preferredDefinition":"The response that indicates whether the laboratory results of a patient meet the criteria for enrollment in a clinical trial regarding the level of serum follicle stimulating hormone.","longName":"SER_FSH_MEAS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3177B2-FF7E-23A6-E053-F662850AFC84","latestVersionIndicator":"Yes","beginDate":"2016-09-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-09-23","modifiedBy":"SOKKERL","dateModified":"2023-01-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5505492","version":"1","preferredName":"Chronic Graft Versus Host Disease Erythema Severity Assessment Score","preferredDefinition":"The response that indicates the severity of red discoloration of the skin caused by infectious agents, inflammation, drug hypersensitivity, or underlying disease using a 4-point Likert scale.","longName":"CGVHD_ERYTH_SEV_SCO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E239D51-835D-0A88-E053-F662850A7ABC","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-05","modifiedBy":"HARTLEYG","dateModified":"2016-10-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5505493","version":"1","preferredName":"Chronic Graft Versus Host Disease Erythema Severity Assessment Type","preferredDefinition":"The response that indicates the type of erythema severity assessment performed.","longName":"CGVHD_ERYT_SEV_TYPE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E239D51-843C-0A88-E053-F662850A7ABC","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-05","modifiedBy":"HARTLEYG","dateModified":"2016-10-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5509403","version":"1","preferredName":"Patient Li-Fraumeni Syndrome Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether a patient meets the eligibility criteria for participation in a clinical trial regarding a diagnosis of Li-Fraumeni syndrome.","longName":"LIFRAU_SYN_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E9E312B-012F-4EB5-E053-F662850A8F15","latestVersionIndicator":"Yes","beginDate":"2016-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-11","modifiedBy":"SOKKERL","dateModified":"2019-08-20","changeNote":"Curated for 9948_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5511060","version":"1","preferredName":"Person Diabetes Mellitus Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to a metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","longName":"DM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB2D1E4-D908-25AF-E053-F662850A4C86","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-12","modifiedBy":"SOKKERL","dateModified":"2022-01-18","changeNote":"2020-8-3 AQT added for P10398. AK 10/19/16 tt, released. 10/12/16 tt, 9767.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5514976","version":"1","preferredName":"Person Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for any questions related to the results of gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA as outlined in the protocol.","longName":"GNMTN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC09928-DD48-2B1A-E053-F662850A1238","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"SOKKERL","dateModified":"2024-02-23","changeNote":"10/19/16 tt, released. 10/13/16 tt, 9767. Fix special char in Ref Doc 03-24-2020 DW","administrativeNotes":"5/4/23:Add AQT LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5515190","version":"1","preferredName":"Person Spermatozoon Donor Consent Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation related to the patient's agreement/consent for any questions related to sperm donation as outlined in the protocol.","longName":"SPRM_DNR_CNST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC1F446-732A-6589-E053-F662850A0523","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"SOKKERL","dateModified":"2023-03-13","changeNote":"AQT added for protocol 10389. AK 10/19/16 tt, released. 10/13/16 tt, 9767.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5515215","version":"1","preferredName":"Patient Disease or Disorder Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for any questions related to the final determination of any abnormal conditions of the body or mind that cause discomfort, dysfunction, or distress to the person as outlined in the protocol.","longName":"PT_DZ_DSOR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC251B1-27EF-440D-E053-F662850ACFC2","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"TYRRELLM","dateModified":"2023-07-20","changeNote":"10/19/16 tt, released. 10/13/16 tt, 9767.","administrativeNotes":"7/20/23 removed special character from AQT_mmt\r\n8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5515274","version":"1","preferredName":"Personal Medical History Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the patient's medical records or background of any abnormal conditions as outlined in the protocol.","longName":"PRSN_MEDHX_DZDZDR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC3A8AD-B100-0FE1-E053-F662850ABEC3","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"10/19/16 tt, released. 10/13/16 tt, 9767.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5515645","version":"1","preferredName":"Person Therapeutic Procedure Initiation Prior To Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for any questions related to the administration of therapeutic agents before dispensing, applying, or tendering a medical product or other agent as outlined in the protocol.","longName":"TX_PRR_AGTADMN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EC69F40-6BE4-6DB6-E053-F662850A0339","latestVersionIndicator":"Yes","beginDate":"2016-10-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-13","modifiedBy":"SOKKERL","dateModified":"2018-08-07","changeNote":"10/19/16 tt, released. 10/13/16 tt, 9767.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5546513","version":"1","preferredName":"Person Progressive Disease Or Recurrent Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the protocol for any questions related to cancer that is increasing in scope or severity, or the return of disease after a period of remission.","longName":"PRGDZ_RCTDZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FDC3D81-FA8F-6556-E053-F662850A2341","latestVersionIndicator":"Yes","beginDate":"2016-10-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-27","modifiedBy":"TAYLORT","dateModified":"2021-07-07","changeNote":"10/27/16 tt, 9767.2020-7-21 AK Added AQT for 10100 update.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5555746","version":"1","preferredName":"Patient Histologic Or Cytopathology Confirmation Standard Therapeutic Procedure Recurrent Cancer Diagnosis Or Triple-Negative Breast Cancer Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient has a histologically or cytologically confirmed recurrent cancer diagnosis or recurrent triple-negative breast cancer diagnosis after receiving standard therapy that meets the criteria for participation in a clinical trial.","longName":"REC_CANC_TNBC_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"The Iowa Study of Environment and Health; National Health and Nutrition Examination Survey, 2005-2006","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FF6938A-11DA-70E2-E053-F662850A4A73","latestVersionIndicator":"Yes","beginDate":"2016-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-28","modifiedBy":"HARTLEYG","dateModified":"2016-11-03","changeNote":"10031_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5555747","version":"1","preferredName":"Patient Platinum Compound Resistance Process Third-Line Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient has received up to 3 prior lines of therapy in a platinum resistant setting that meets the criteria for participation in a clinical trial.","longName":"PLAT_RES_THRD_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FF61525-65EF-5BF3-E053-F662850A80E1","latestVersionIndicator":"Yes","beginDate":"2016-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-28","modifiedBy":"SOKKERL","dateModified":"2020-12-03","changeNote":"10031_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5555748","version":"1","preferredName":"Patient BRCA1 BRCA2 Gene Mutation Non Genetic Carrier And Triple-Negative Breast Carcinoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient diagnosed with triple-negative breast carcinoma does not carry the BRCA1/2 gene mutation that meets the criteria for participation in a clinical trial.","longName":"BRCA1_2_MUT_TNBC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FF61525-6616-5BF3-E053-F662850A80E1","latestVersionIndicator":"Yes","beginDate":"2016-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-28","modifiedBy":"HARTLEYG","dateModified":"2016-11-03","changeNote":"10031_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5555750","version":"1","preferredName":"Patient Clinically Significant Indicator Electrolyte Imbalance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient meets the criteria for participation in a clinical trial regarding whether they have any clinically significant electrolyte imbalances.","longName":"CL_SIG_ELEC_IMB_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FF61525-6640-5BF3-E053-F662850A80E1","latestVersionIndicator":"Yes","beginDate":"2016-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-28","modifiedBy":"SOKKERL","dateModified":"2017-09-08","changeNote":"10031_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5555751","version":"1","preferredName":"Patient Ophthalmologist Performed Ophthalmology Medical Examination Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether the patient meets the criteria for participation in a clinical trial regarding receipt of an ophthalmologist performed ophthalmology exam.","longName":"OPHTH_EXAM_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FF5F508-DCB2-476D-E053-F662850A6BC8","latestVersionIndicator":"Yes","beginDate":"2016-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-28","modifiedBy":"SOKKERL","dateModified":"2021-09-10","changeNote":"10031_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5555752","version":"1","preferredName":"Patient Prolonged QTc Interval Adverse Event Or Torsade de Pointes Adverse Event Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether a patient meets the criteria for participation in a clinical trial regarding a known history of QT/QTc prolongation or Torsdes de Pointes.","longName":"P_QT_TORPOINT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FF61525-6667-5BF3-E053-F662850A80E1","latestVersionIndicator":"Yes","beginDate":"2016-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-05-01","changeNote":"10031_ghd","administrativeNotes":"2023.3.9 AQT added per ticket request CADSR0002149. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5557008","version":"1","preferredName":"Biospecimen Freeze Date","preferredDefinition":"The date when a biological sample transitions from a liquid to solid matter.","longName":"SPMN_FRZ_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4004BA06-804A-31CC-E053-F662850AB2FB","latestVersionIndicator":"Yes","beginDate":"2016-10-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-10-31","modifiedBy":"TAYLORT","dateModified":"2016-11-09","changeNote":"11/9/16 tt, approved/released. 10/31/16 tt, ETCTN Tissue Acquisition protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566295","version":"1","preferredName":"Patient Histological Or Cytopathological Confirmation Embryonal Rhabdomyosarcoma Or Alveolar Rhabdomyosarcoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient's diagnosis of embryonal or alveolar rhabdomyosarcoma has been histologically or cytologically confirmed that meets the criteria for participation in a clinical trial.","longName":"CFM_EMBALV_RBD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4082AA1C-E9C8-50FC-E053-F662850A4E5F","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"SOKKERL","dateModified":"2018-07-03","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566296","version":"1","preferredName":"Patient Prior Local Palliative External Beam Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient that has received local palliative external beam radiation therapy meets the criteria for participation in a clinical trial.","longName":"LCL_PAL_EXBMRX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40828D26-41B7-6628-E053-F662850A1F3D","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"TAYLORT","dateModified":"2019-05-16","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566297","version":"1","preferredName":"Patient Bone Marrow Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response indicating whether a patient that received substantial bone marrow radiation meets the criteria for participation in a clinical trial.","longName":"BMRX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4082AA1C-E9EF-50FC-E053-F662850A4E5F","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"SPRINGERL","dateModified":"2020-08-24","changeNote":"10003","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566298","version":"1","preferredName":"Patient Alkylating Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response indicating whether a patient received alkylating agents that meets the criteria for participation in a clinical trial.","longName":"ALKY_AGT_AD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4082AA1C-EA16-50FC-E053-F662850A4E5F","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"TAYLORT","dateModified":"2018-07-13","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566299","version":"1","preferredName":"Patient Prior Enrollment Biological Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response indicating whether a patient that received biological therapy meets the criteria for participation in a clinical trial.","longName":"PRIO_ENR_BIOTX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4082AA1C-EA40-50FC-E053-F662850A4E5F","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"HARTLEYG","dateModified":"2016-11-09","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566300","version":"1","preferredName":"Patient Prior Clinical Study Blood Glucose Measurement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response indicating whether a patient's pre-study blood glucose level meets the criteria for participation in a clinical trial.","longName":"PRI_SDY_BLD_GLUC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40828D26-41DE-6628-E053-F662850A1F3D","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"MARTINEZW","dateModified":"2017-03-16","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566301","version":"1","preferredName":"Patient Prior Clinical Study Corrected QT Interval And Left Ventricular Ejection Fraction Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response indicating whether a patient's pre-study QTc and LVEF meet the criteria for participation in a clinical trial.","longName":"PRISDY_QTC_LVEF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40828D26-4205-6628-E053-F662850A1F3D","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"SOKKERL","dateModified":"2022-12-16","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566302","version":"1","preferredName":"Patient Or Guardian Consent Comprehension Code Indicator","preferredDefinition":"The response indicating whether a patient or their guardian/legal representative comprehend and are able to sign a written consent document.","longName":"PT_GAURD_CONS_CMP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40828D26-422C-6628-E053-F662850A1F3D","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"SOKKERL","dateModified":"2023-02-14","changeNote":"10003_ghd.  AQT added. AK2020-5-11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566303","version":"1","preferredName":"Patient Correlative Study Participation Recommendation Code Indicator","preferredDefinition":"The response indicating whether a patient has been encouraged to participate in a correlative study.","longName":"PT_CRLSDY_REC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4082AA1C-EA67-50FC-E053-F662850A4E5F","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"HARTLEYG","dateModified":"2016-11-09","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566304","version":"1","preferredName":"Patient Clinically Significant Indicator Cardiovascular Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response indicating whether a patient has a clinically significant cardiovascular disease or disorder meets the criteria for participation in a clinical trial.","longName":"SIG_CARDVSC_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4082AA1C-EA8E-50FC-E053-F662850A4E5F","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5566305","version":"1","preferredName":"Patient Latent Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response indicating whether a patient diagnosed with any underlying cardiopulmonary dysfunction meets the criteria for participation in a clinical trial.","longName":"LAT_DZDRD_CTEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40828D26-4253-6628-E053-F662850A1F3D","latestVersionIndicator":"Yes","beginDate":"2016-11-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-11-04","modifiedBy":"HARTLEYG","dateModified":"2016-11-09","changeNote":"10003_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5573072","version":"1","preferredName":"Biospecimen Collection Type","preferredDefinition":"A response for the kind of sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes.","longName":"BSMN_CLN_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40F3F085-12ED-1537-E053-F662850A5014","latestVersionIndicator":"Yes","beginDate":"2016-11-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-10","modifiedBy":"TAYLORT","dateModified":"2016-11-22","changeNote":"11/22/16 tt, released. 11/10/16 tt, created for specimen tracking and the ETCTN Tissue Acquisition protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5573223","version":"1","preferredName":"Biospecimen Submission Description Type","preferredDefinition":"A desciptor related to the kind of specimen submitted for the judgment or consideration of others.","longName":"BSMN_SBMN_DCPN_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40F7840C-63FA-4494-E053-F662850AB73D","latestVersionIndicator":"Yes","beginDate":"2016-11-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-10","modifiedBy":"TAYLORT","dateModified":"2016-11-22","changeNote":"11/16/22 tt, released. 11/10/12 tt, created for specimen tracking and the ETCTN Tissue Acquisition protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5573292","version":"1","preferredName":"Biospecimen Collection Tube Device Component Type","preferredDefinition":"The kind of tube used to collect the sample(s) taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes.","longName":"TUBE_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40F8A22F-F1B2-17B9-E053-F662850A4CBE","latestVersionIndicator":"Yes","beginDate":"2016-11-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-10","modifiedBy":"KUMMEROA","dateModified":"2022-09-07","changeNote":"11/22/16 tt, released. 11/10/16 tt, created for specimen tracking and the ETCTN Tissue Acquisition protocol.","administrativeNotes":"2022.9.37 AQT added for ticket request CADSR0001486. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577294","version":"1","preferredName":"Systemic Immunostimulant Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study that address the systemic treatment of substances that stimulate the immune system as outlined in the clinical trial protocol.","longName":"IMSTIMTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"416CF88B-FE3D-6DD6-E053-F662850ADE0C","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"SOKKERL","dateModified":"2022-08-10","changeNote":"2020-8-3 AQT added for P10398. AK 12/5/16 tt, added CSI. 11/30/16 tt, approved/released. 11/16/16 tt, 1005.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577308","version":"1","preferredName":"Steroid Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study that address the treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation as outlined in the clinical trial protocol.","longName":"STRDTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"416CF88B-FE92-6DD6-E053-F662850ADE0C","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"SOKKERL","dateModified":"2017-11-07","changeNote":"11/30/16 approved/released. 11/16/16 tt, 10005.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577324","version":"1","preferredName":"Intervention or Procedure Screening Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to the assessments of activities that produce an effect, or intended to alter the course of a disease as outlined in the clinical trial protocol.","longName":"SCRN_INTPRDR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"416DC01C-9C97-3719-E053-F662850A4017","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"2020-8-3 AQT added for P10398. AK 11/30/16 approved/released. 11/16/16 tt, 10005.","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577815","version":"1","preferredName":"Infectious Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to disorders resulting from the presence and activities of microbial, viral, fungal, or parasitic agents as outlined in the study protocol.","longName":"INFDR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"416EFFB6-E4FA-65FA-E053-F662850A1146","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeNote":"11/30/16 approved/released. 11/16/16 tt, 10005.","administrativeNotes":"2023.3.6 AQT added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577840","version":"1","preferredName":"Infectious Disorder Sign or Symptom Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to the evidence of disorders resulting from the presence and activities of microbial, viral, fungal, or parasitic agents as outlined in the study protocol.","longName":"INF_SYPM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"416EFF7C-6E31-23B7-E053-F662850A87DC","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"SOKKERL","dateModified":"2018-06-04","changeNote":"11/30/16 approved/released. 11/16/16tt, 10005.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577858","version":"1","preferredName":"Antibiotic Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to the administration of substances used in the treatment of bacterial and other microbial infections.","longName":"ABX_ADMN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"417013D8-8E71-3396-E053-F662850A3AB7","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"WISEM","dateModified":"2021-02-04","changeNote":"11/30/16 approved/released. 11/16/16 tt, 10005.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577914","version":"1","preferredName":"Person Asymptomatic Central Nervous System Disease Prior Treatment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to asymptomatic central nervous system disease and previous therapies.","longName":"ASYM_TX_CNSDZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"41729FAF-8242-42A0-E053-F662850AF34D","latestVersionIndicator":"Yes","beginDate":"2016-11-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-16","modifiedBy":"SOKKERL","dateModified":"2022-03-09","changeNote":"2020-7-24 AQT added. AK 12/5/16 tt, added CSI and corrected typo in def. 11/30/16 approved/released. 11/16/16 tt, 10005","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5581117","version":"1","preferredName":"Patient Universal Identifier","preferredDefinition":"One or more characters used to identify, name, or characterize a person who receives medical attention, care, or treatment occurring everywhere.","longName":"PT_UVL_ID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"41EC5944-44E4-3F25-E053-F662850A317E","latestVersionIndicator":"Yes","beginDate":"2016-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-22","modifiedBy":"TAYLORT","dateModified":"2016-11-28","changeNote":"11/28/16 tt, edit to Long/Short Names and def, approved and released. 11/22/16 tt, specimen tracking and Tissue Acquisition protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5581120","version":"1","preferredName":"Patient Intrinsic Identifier","preferredDefinition":"One or more characters used to identify, name, or characterize the essential qualities or features of a person who receives medical attention, care, or treatment.","longName":"PT_INTC_ID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"41EC682D-FE76-33C1-E053-F662850A382B","latestVersionIndicator":"Yes","beginDate":"2016-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-22","modifiedBy":"TAYLORT","dateModified":"2016-11-29","changeNote":"11/28/16 tt, edit to Long/Short Names and def, approved and released. 11/22/16 tt, specimen tracking and Tissue Acquisition protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5582209","version":"1","preferredName":"Metastatic Neoplasm Pathology Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the histologic verification of metastatic disease as outlined in the protocol.","longName":"METNPM_PTH_CFM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4277E96E-8CD1-1926-E053-F662850ACBA9","latestVersionIndicator":"Yes","beginDate":"2016-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-29","modifiedBy":"SOKKERL","dateModified":"2020-04-28","changeNote":"1/10/17 tt, approved/released. 11/30/16 tt, edit to long name/def. 11/29/16 tt, 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5582810","version":"1","preferredName":"Metastatic Neoplasm Histologic Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the histologic verification of metastatic disease as outlined in the protocol.","longName":"METNPM_HST_CFM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4284E254-B4B2-65AB-E053-F662850A45B4","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2023-01-10","changeNote":"1/10/17 tt, approved/released. 11/30/16 tt, 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5582959","version":"1","preferredName":"Prior Agent Intervention or Procedure Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to assessments of prior substances and activities that produce an effect, or intended to alter the course of disease as outlined in the protocol.","longName":"PR_AGTIVN_ASMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42887499-E845-21F7-E053-F662850A7970","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2023-07-18","changeNote":"11/30/16 tt, 9984.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5583106","version":"1","preferredName":"Gonadotropin-releasing Hormone Analog Therapeautic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to luteinizing hormone-releasing hormone agonist therapy as outlined in the protocol.","longName":"LHRHTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"428911D6-973E-4981-E053-F662850A01F6","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2022-07-13","changeNote":"1/10/17 tt, approved/released. 11/30/16 tt, 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5583113","version":"1","preferredName":"Progressive Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to cancer that is increasing in scope or severity as outlined in the protocol.","longName":"PRVDZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"428911D6-9781-4981-E053-F662850A01F6","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2022-11-16","changeNote":"1/10/17 tt, approved/released. 11/30/16 tt, 9984.  03/08/2018 fixed apostrophe in Question text DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5583175","version":"1","preferredName":"Biopsy Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to assessments of the removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis as outlined in the protocol.","longName":"BX_ASMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"428A219E-1060-535D-E053-F662850AB38B","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2023-03-14","changeNote":"4-15-19 corrected typo in definition. 12/8/16 tt, approved/released. 11/30/16 tt, 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5583248","version":"1","preferredName":"Patient Prior VEGFR Tyrosine Kinase Inhibitor Or Poly (ADP-Ribose) Polymerase Inhibitor Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the prior administration of VEGF inhibitors or PARP inhibitors as outlined in the protocol.","longName":"PRR_VEGF_PARP_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"428B8B91-7769-5DCB-E053-F662850ADC38","latestVersionIndicator":"Yes","beginDate":"2016-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-11-30","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"1/10/17 tt, approved/released. 11/30/16 t, 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5589061","version":"1","preferredName":"Clinical Study Protocol Biospecimen Acquisition Timepoint Identifier","preferredDefinition":"One or more characters used to identify, name, or characterize the protocol point in time when the sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes is obtained.","longName":"BSMN_AQN_TPT_ID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B3C23D-F66D-0896-E053-F662850AED73","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-12-02","modifiedBy":"TAYLORT","dateModified":"2017-03-08","changeNote":"3/8/17 tt, approved/released.  12/2/16 tt, ETCTN Tissue Acquisition protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5589091","version":"1","preferredName":"Castration-Resistant Prostate Carcinoma Intervention or Procedure Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation related to the assessments of activities that produce an effect, or that is intended to alter the course of CRPR as outlined in the protocol.","longName":"CRPR_INVN_PRDR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B52859-8096-6258-E053-F662850A6D18","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-12-02","modifiedBy":"CLOHNES","dateModified":"2023-11-17","changeNote":"1/10/17 tt, approved/released. 12/2/16 tt, 9984.","administrativeNotes":"11/17/23 Added AQT and alt OID for CCTG ticket number CADSR0003085 cjl; 5/4/23 added AQT LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5604191","version":"1","preferredName":"Treatment Cohort Study 10014 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10014 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10014_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"43A51663-FD1E-2994-E053-F662850A6EFE","latestVersionIndicator":"Yes","beginDate":"2016-12-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-12-14","modifiedBy":"SOKKERL","dateModified":"2017-01-05","changeNote":"12/14/16 tt, 10014. 01/05/17 ls approved and released","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5606959","version":"1","preferredName":"Persistent Progressive Disease Post Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to persistent/progressive disease after treatment of a disease by radiation as outlined in the protocol.","longName":"PST_PGVDZ_POSTRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"43CD1E3A-93D0-4862-E053-F662850AAA4C","latestVersionIndicator":"Yes","beginDate":"2016-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-12-16","modifiedBy":"SOKKERL","dateModified":"2017-03-21","changeNote":"12/27/16 tt, approved/released. 12/16/16 tt, 10010.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5608361","version":"1.1","preferredName":"Treatment Cohort Study 9681 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9681 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_9681_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7250ACDA-E320-0BB6-E053-F662850A1F46","latestVersionIndicator":"Yes","beginDate":"2016-12-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-31","modifiedBy":"SOKKERL","dateModified":"2018-11-08","changeNote":"7/31/18 Version VD to Change PVs: 12/20/2016 TT/LS-9681","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5611338","version":"1","preferredName":"Label Needs Count","preferredDefinition":"A response for the number or amount of labels needed.","longName":"LBL_ND_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44D4C49F-C393-0751-E053-F662850A8049","latestVersionIndicator":"Yes","beginDate":"2016-12-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-12-29","modifiedBy":"HARTLEYG","dateModified":"2016-12-30","changeNote":"12/29/16 tt, specimen tracking.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5611384","version":"1","preferredName":"Specimen Identifier Generation Boolean Integer","preferredDefinition":"The Boolean integer response regarding whether a new specimen identifier should be generated for a specimen used on a clinical trial.","longName":"SPEC_ID_GEN_BOO_INT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44E4FA3F-EF8F-76F7-E053-F662850A38A4","latestVersionIndicator":"Yes","beginDate":"2016-12-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-12-30","modifiedBy":"HARTLEYG","dateModified":"2016-12-30","changeNote":"Curated for Boolean programming","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5611385","version":"1","preferredName":"Specimen Identifier Status Boolean Integer","preferredDefinition":"The Boolean integer response regarding whether the specimen identifier is new or has already been created.","longName":"SPEC_ID_STS_BOO_INT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"44E4D9C4-4651-76F3-E053-F662850AE45B","latestVersionIndicator":"Yes","beginDate":"2016-12-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-12-30","modifiedBy":"HARTLEYG","dateModified":"2016-12-30","changeNote":"Curated for use in Boolean programming","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5612590","version":"1","preferredName":"Person Weight Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the patient's weight as outlined in the protocol.","longName":"WT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45499203-18CE-3B37-E053-F662850AC6C1","latestVersionIndicator":"Yes","beginDate":"2017-01-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-04","modifiedBy":"ZHWENDY","dateModified":"2022-08-04","changeNote":"1/4/17 tt/l; 9930.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5626400","version":"1","preferredName":"Negation Disease or Disorder Specimen Characteristic Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation that address specimens which do not have characteristics suggestive of any abnormal condition, as outlined in the protocol.","longName":"NO_DZ_SPEC_CHAR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45E7E809-B030-241A-E053-F662850A1E0C","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-12","modifiedBy":"SOKKERL","dateModified":"2017-11-22","changeNote":"6/26/17 tt, released.  1/12/17 tt, 9974.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5626760","version":"1","preferredName":"Specimen Availability Person Biopsy Ability Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine clinical trial eligibility that address the availability of specimens and the ability of a person to have a biopsy as outlined in the study protocol.","longName":"SPMN_AVBY_BX_ABLY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EB9F75-EE2B-2BC6-E053-F662850A2AEA","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-12","modifiedBy":"SOKKERL","dateModified":"2022-12-16","changeNote":"1/12/17 LS/TT 9974","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632130","version":"1","preferredName":"Patient Recurrent Disease Refractory Disease Acute Myeloid Leukemia Or Myelodysplastic Syndrome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether a patient has recurrent/refractory acute myeloid leukemia or recurrent/refractory myelodysplastic syndrome that meets the eligibility criteria for participation in a clinical trial.","longName":"REC_REF_AML_MDS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"469226E7-4FC6-2004-E053-F662850A17BE","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-01-20","modifiedBy":"SOKKERL","dateModified":"2018-02-05","changeNote":"10026_Theradex_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632131","version":"1","preferredName":"Patient Clinical Trial Enrollment Consideration Post Principal Investigator Discussion Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether a patient has considered study enrollment after discussion with the principle investigator that meets the eligibility criteria for participation in a clinical trial.","longName":"ENROLL_POST_DISC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46909AEB-B267-6D22-E053-F662850A42A7","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-01-20","modifiedBy":"SOKKERL","dateModified":"2021-01-15","changeNote":"10026_Theradex_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632132","version":"1","preferredName":"Patient Personal Medical History Myelodysplastic Syndrome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether a patient has a history of myelodysplastic syndrome that meets the eligibility criteria for participation in a clinical trial.","longName":"PMHX_MDS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46909AEB-B28E-6D22-E053-F662850A42A7","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-01-20","modifiedBy":"SOKKERL","dateModified":"2019-11-05","changeNote":"10026_Theradex_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632133","version":"1","preferredName":"Patient Donor Cellular Infusion T-Lymphocyte Chimerism Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether the chimerism of donor T-lymphocytes received by a patient through allogeneic stem cell transplant, meets the eligibility criteria for participation in a clinical trial.","longName":"DON_TCEL_CHIM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46909AEB-B2B5-6D22-E053-F662850A42A7","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-01-20","modifiedBy":"HARTLEYG","dateModified":"2017-01-24","changeNote":"10026_Theradex_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632134","version":"1","preferredName":"Patient Central Nervous System Involvement Or Intrathecal Route of Administration Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether a patient has CNS involvement or is receiving intrathecal chemotherapy that meets the eligibility criteria for participation in a clinical trial.","longName":"CNS_ITCL_CHEMO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"469226E7-4FED-2004-E053-F662850A17BE","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-01-20","modifiedBy":"SOKKERL","dateModified":"2020-05-11","changeNote":"10026_Theradex_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632135","version":"1","preferredName":"Patient Personal Medical History Acute Graft Versus Host Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether a patient has prior history of acute GVHD that meets the eligibility criteria for participation in a clinical trial.","longName":"HX_ACT_GVHD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46902264-1D1E-754C-E053-F662850A921A","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-01-20","modifiedBy":"SOKKERL","dateModified":"2019-03-12","changeNote":"10026_Theradex_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632136","version":"1","preferredName":"Patient Donor Lymphocyte Infusion Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether a patient has received a donor lymphocyte infusion that meets the eligibility criteria for participation in a clinical trial.","longName":"DNR_LYMP_INFS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"468FDDA5-DA42-3625-E053-F662850AF5DD","latestVersionIndicator":"Yes","beginDate":"2017-01-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-01-20","modifiedBy":"LEEW","dateModified":"2022-02-07","changeNote":"10026_Theradex_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632608","version":"1","preferredName":"Person Body Surface Area Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation related to body surface area (BSA), as outlined in the protocol.","longName":"BSA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46C957B0-945A-0EB8-E053-F662850A45E8","latestVersionIndicator":"Yes","beginDate":"2017-01-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-23","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/23/17 tt, ls; 10007.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632613","version":"1","preferredName":"Person Neurofibromatosis Type 1 Diagnosis Or Mutation Abnormality Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation related to the diagnosis of NF1 or genetic mutations as outlined in the protocol.","longName":"NF1_DX_MUTN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46C983A7-2F68-23D5-E053-F662850A766F","latestVersionIndicator":"Yes","beginDate":"2017-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-23","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/23/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5632805","version":"1","preferredName":"Gastrointestinal Stromal Tumor Neurofibromatosis Type 1 Mutation Abnormality Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to GIST and NF1 mutation abnormalities as outlined in the protocol.","longName":"GIST_NF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46D8EB46-204C-6E5C-E053-F662850AEF38","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/24/17 ls/tt 10007.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633107","version":"1","preferredName":"Person Neurofibromatosis Type 1 Diagnosis Diagnostic Criteria Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the diagnosis of NF1 and the standards from which a judgment concerning the medical diagnosis of NF1 was established as outlined in the protocol.","longName":"NF_DX_CRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DA17F2-4FD5-51A8-E053-F662850A6479","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633118","version":"1","preferredName":"GIST Histological Or Cytological Procedure Confirmation Mutation Abnormality Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to histological and cytological confirmation of GIST and mutation abnormalities as outlined in the protocol.","longName":"GIST_HIS_CYT_MUT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DAB110-6578-7248-E053-F662850A733A","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633127","version":"1","preferredName":"Metastatic Neoplasm Or Excision Risk Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to metastatic tumor and the estimated probability that one or more adverse event(s) will occur as a result of resection as outlined in the protocol.","longName":"MET_EXC_RISK_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46D97062-2D9C-28BA-E053-F662850A94B4","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"MAESKEB","dateModified":"2017-01-31","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633131","version":"1","preferredName":"Prior Surgical Procedure Measurable Disease Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to prior surgeries and the presence of measurable disease as outlined in the protocol.","longName":"PR_SRG_MDX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46D9FDFC-1565-4A2A-E053-F662850A1735","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633139","version":"1","preferredName":"Prior Therapeutic Procedure Progressive Disease Or Intolerance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to prior treatments, progressive disease, and the inability to absorb or metabolize certain substances in a normal way as outlined in the protocol.","longName":"PRTX_PRDZ_ILC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DABDE8-DC70-4A11-E053-F662850A98A2","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2021-01-05","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633203","version":"1","preferredName":"Biological Therapy Last Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the last administration of biological therapy as outlined in the protocol.","longName":"BIOTX_LST_DS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DC6AFD-7065-5BF8-E053-F662850AE6AC","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633207","version":"1","preferredName":"Growth Factor Therapeutic Procedure Last Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the last administration of substances made by the body that function to regulate cell division and cell survival as outlined in the protocol.","longName":"GFTX_LST_DS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DCA19B-03E0-7C06-E053-F662850A65DA","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2020-07-31","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633233","version":"1","preferredName":"Sun Exposure Avoidance And Sunscreen Use Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patients agreement to sun exposure requirements and the use of chemical or physical agents that protect the skin from sunburn as outlined in the protocol.","longName":"SUN_EXP_AVD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DCED78-DCE7-1E91-E053-F662850A6A10","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633247","version":"1","preferredName":"Food And Beverage Avoidance Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patient's agreement to avoid food and beverages as outlined in the protocol.","longName":"FD_BVG_AVD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DCF862-7E8F-31CF-E053-F662850A8F9A","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2021-01-15","changeNote":"1/24/17 03/09/2018 fixed apostrophe in definition DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633279","version":"1","preferredName":"Other Disease or Disorder Therapeutic Procedure Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to any abnormal condition of the body or mind that requires treatment as outlined in the protocol.","longName":"OTH_DZDIS_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DD61F8-D7BA-3123-E053-F662850AB1A6","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2023-06-15","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633281","version":"1","preferredName":"Person Clinical Trial Participation Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine clinical trial eligibility related to patient assessments in taking part in a research study as outlined in the protocol.","longName":"CLTRL_PTPN_ASMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DC8967-C8BE-5BFC-E053-F662850AB48E","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2018-02-22","changeNote":"1/24/17 tt/ls 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633297","version":"1","preferredName":"Personal Medical History Cardiomyopathy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patients medical background for cardiomyopathy as outlined in the protocol.","longName":"PERHX_CARDIO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DC8967-C8E5-5BFC-E053-F662850AB48E","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2019-02-05","changeNote":"1/24/17 ls/tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633300","version":"1","preferredName":"Person Arrhythmogenic Right Ventricular Cardiomyopathy Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine eligibility for clinical trial participation related to the diagnosis of an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death (ARVC).","longName":"ARVC_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DD61F8-D7E1-3123-E053-F662850AB1A6","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeNote":"1/24/17 tt/ls 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633315","version":"1","preferredName":"Intraocular Pressure Outcome Or Uncontrolled Glaucoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation as outlined in the protocol for questions related to IOP results, or increased pressure in the eyeball due to obstruction of the outflow of aqueous humor that is not controlled.","longName":"IOP_UNCD_GOMA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DE9ACB-76E7-5BFA-E053-F662850A3056","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"TYRRELLM","dateModified":"2023-09-29","changeNote":"1/24/17 tt 10007","administrativeNotes":"9.29.2023 Added AQT per request CADSR0002901_mmt\r\n2022.12.21 AQT added per ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633321","version":"1","preferredName":"Prior Therapeutic Procedure Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation as outlined in the protocol for questions related to the prior administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"PRTX_RCD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DF2B16-0FAA-0BC5-E053-F662850A78CE","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeNote":"2020-8-3 AQT added for P10398. AK 1/25/17 tt 10007","administrativeNotes":"2023.9.18 AQT added per ticket request CADSR0002860. ak 2022.11.14 AQT added for ticket request CADSR0001676. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633334","version":"1","preferredName":"Person Receive Inhibition Or Induction Medication Substance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation as outlined in the protocol for questions related to taking drug products or substances that bring about something, interfere with, or prevent an action or response.","longName":"IBTN_IDTN_RECV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46E05C25-4562-6F82-E053-F662850AF54C","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"FINCHAMB","dateModified":"2023-12-05","changeNote":"1/24/17 tt 10007","administrativeNotes":"2023.6.8 AQT added per ticket request CADSR0002503. ak 2022.12.21 AQT added per ticket request CADSR0001812. ak 8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633338","version":"1","preferredName":"Clinical Trial Safety Monitoring Requirement Patient Compliance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation as outlined in the protocol for questions related to patient compliance of safety monitoring requirements of a research study.","longName":"CTSM_RQMT_CMPL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46E0BEB6-6E5E-6F76-E053-F662850A1137","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2019-11-14","changeNote":"1/24/17 tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633341","version":"1","preferredName":"Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation as outlined in the protocol related to any activity that produces an effect, or that is intended to alter the course of a disease in a patient or population.","longName":"IVNPR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46E161FD-E2EE-6F78-E053-F662850AA799","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"1/24/17 tt  10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5651769","version":"1","preferredName":"Response in Target Lesion Reference Sum Value","preferredDefinition":"The qualitative or quantitative measurement for the reference sum of target lesion response.","longName":"TL_REF_SUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4793AA64-9448-7FCE-E053-F662850AFA7E","latestVersionIndicator":"Yes","beginDate":"2017-02-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-02","modifiedBy":"TAYLORT","dateModified":"2017-02-08","changeNote":"2/8/17 tt, approved/released.  2/2/17 ls/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5651974","version":"1","preferredName":"Response in Target Lesion Reference Sum Percent Difference Value","preferredDefinition":"The qualitative or quantitative measurement of the percentage difference from reference sum for target lesion response.","longName":"PER_DIF_REF_SUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4793CC8B-297E-612F-E053-F662850AB3D1","latestVersionIndicator":"Yes","beginDate":"2017-02-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-02-02","modifiedBy":"TAYLORT","dateModified":"2017-02-08","changeNote":"2/8/17 tt, approved/released.  2/2/2017 ls/tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5654659","version":"1","preferredName":"No Evidence of Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation related to the absence of detectable disease(s) as outlined in the study protocol.","longName":"NO_ EVD_DZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E2075D-C932-609F-E053-F662850AE8BF","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-02-06","modifiedBy":"SOKKERL","dateModified":"2017-02-08","changeNote":"2/6/2017 ls/tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5654660","version":"1","preferredName":"Breast Cancer TNM Finding v7 American Joint Committee on Cancer T Stage Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation that address characteristics of breast cancer, following the rules of the TNM AJCC v7 classification system related to the extent of tumor involvement at the primary site.","longName":"BRCA_TSTG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E1CC92-102B-412F-E053-F662850AB13D","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-06","modifiedBy":"TAYLORT","dateModified":"2017-06-26","changeNote":"6/26/17 tt, released.   2/6/17 tt, 10013.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5654674","version":"1","preferredName":"Confirmation Pathologic Disease or Disorder Diagnosis Prior Therapeutic Procedure Failure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation, as outlined in the protocol, to address pathological confirmation of any disease and prior treatment failures.","longName":"PATH_CONF_DZDIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E1DD91-454E-5FC7-E053-F662850AF991","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-02-06","modifiedBy":"SOKKERL","dateModified":"2017-02-08","changeNote":"2/6/2017 ls/tt 10009","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5654782","version":"1","preferredName":"Person Neoadjuvant Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation that address the administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment for effective.","longName":"NEOTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E22FDA-53F7-0E13-E053-F662850AD9C8","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-06-27","changeNote":"6/26/17 tt, released.   2/6/17 tt,10013.","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5654816","version":"1","preferredName":"Person Negation Serious Uncontrolled Medical Condition Clinical Trial Elgibility Criteria Indicator","preferredDefinition":"A coded response to questions that are necessary for clinical study participation to determine that the patient does not have any serious or medical conditions as outlined in the study protocol.","longName":"NO_SER_UNCON_MED_COND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E1D71B-53B1-5BF3-E053-F662850A2042","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-02-06","modifiedBy":"SOKKERL","dateModified":"2022-11-15","changeNote":"2/6/17 ls/tt 10009","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655100","version":"1","preferredName":"Target Lesion Response Status","preferredDefinition":"The response status for target lesions.","longName":"TL_RSPN_STS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F31BD5-D3BE-7439-E053-F662850A8E40","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-07","modifiedBy":"SOKKERL","dateModified":"2017-06-22","changeNote":"2/7/17 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655101","version":"1","preferredName":"Overall Lesion Response Status","preferredDefinition":"The status of overall lesion response.","longName":"OVL_LSN_RSPSTS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F34A44-BE53-7AFE-E053-F662850A31F8","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-07","modifiedBy":"TAYLORT","dateModified":"2017-02-08","changeNote":"2/8/17 tt, corrected typo.  2/7/17 tt,","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655103","version":"1","preferredName":"Non-Target Lesion Response Status","preferredDefinition":"The response status for non-target lesions.","longName":"NTLSN_RSPN_STS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F2F094-FB57-749B-E053-F662850ABC9E","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-07","modifiedBy":"TAYLORT","dateModified":"2017-02-07","changeNote":"2/7/17 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655121","version":"1","preferredName":"Response in Target Lesion Restaging Sum Value","preferredDefinition":"A sum that represents the qualitative or quantitative measurement to determine the extent of cancer that has reoccurred following treatment or how the cancer responded to treatment.","longName":"TL_RSTG_SUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F4094D-3F02-2809-E053-F662850A6B6E","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-07","modifiedBy":"TAYLORT","dateModified":"2017-02-08","changeNote":"2/8/17 tt, approved/released.  2/7/17 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655146","version":"1","preferredName":"Patient Consent Neoplasm Biopsy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient's willingness to undergo a tumor biopsy that meets the criteria for participation in a clinical trial.","longName":"CONS_TUM_BX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F2AA77-028F-71F0-E053-F662850A18A2","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-07","modifiedBy":"SOKKERL","dateModified":"2023-03-30","changeNote":"10010_02.07.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5656773","version":"1","preferredName":"Breast Primary Invasive Adenocarcinoma Histologically Confirmed Stage Code","preferredDefinition":"The code that represents the extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body, of established or verified by the use of histology or histological techniques of primary invasive breast adenocarcinoma (a malignant epithelial tumor with a glandular organization).","longName":"BRST_P_I_AD_HIS_C_ST_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"481A7738-EE10-089D-E053-F662850A3435","latestVersionIndicator":"Yes","beginDate":"2017-02-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-02-09","modifiedBy":"MAESKEB","dateModified":"2017-02-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5675520","version":"1","preferredName":"Patient Parent Or Guardian Informed Consent Signature Code Indicator","preferredDefinition":"The coded response indicating whether the patient, parent, or guardian signed a written consent document.","longName":"PPG_CONS_SIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"490F6D4B-D58A-1344-E053-F662850AF290","latestVersionIndicator":"Yes","beginDate":"2017-02-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-02-21","modifiedBy":"SOKKERL","dateModified":"2017-02-21","changeNote":"2/21/2017 LS 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5690436","version":"1","preferredName":"Patient Informed Other Therapeutic Procedure Options Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation as to whether the patient is knowledgeable of other alternative choices for treatment.","longName":"INF_OTH_TX_OPN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49AC3EF6-6B0C-5CAA-E053-F662850A56B4","latestVersionIndicator":"Yes","beginDate":"2017-03-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-01","modifiedBy":"TAYLORT","dateModified":"2017-06-26","changeNote":"6/26/17 tt, released.   3/1/17 tt, 10017.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5692314","version":"1","preferredName":"Patient or Guardian Investigational Clinical Trial Comprehension and Informed Consent Signature Obtain Prior To Study Intervention or Procedure Code Indicator","preferredDefinition":"A response as to whether the patient or guardian understands the clinical trial experimental health-related interventions and that written informed consent was obtained prior to any study activities that produce an effect, or intended to alter the course of a disease.","longName":"PT_GRDN_CTR_COMP_ICF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49B4796A-E273-1E84-E053-F662850AA7E2","latestVersionIndicator":"Yes","beginDate":"2017-03-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-01","modifiedBy":"TAYLORT","dateModified":"2017-06-26","changeNote":"6/26/17 tt, released.   3/1/17 tt, 10017.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695405","version":"1","preferredName":"Patient Receive Concomitant Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study that address the receipt of any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.","longName":"RCV_CONTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C350A2-FD02-6AD7-E053-F662850AA53D","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"SOKKERL","dateModified":"2023-03-24","changeNote":"6/26/17 tt, released.   3/2/17 tt, 10017.","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695476","version":"1","preferredName":"Prior Hypomethylation Therapy Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study that address the prior receipt of therapies (hypomethylating agents) that target the activity of DNA methyltransferases.","longName":"PR_HYPTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C35469-2144-2177-E053-F662850A7A37","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"SOKKERL","dateModified":"2023-06-09","changeNote":"6/26/17 tt, released.   3/2/17 tt, 10017.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695482","version":"1","preferredName":"Cognitive Impairment Diagnosis Informed Consent Ability Clinical Trial Patient Compliance Code Indicator","preferredDefinition":"A coded response for questions related to the presence of diminished mental function, the quality of being able to perform informed consent, and the extent to which a patient conforms to studies that test new methods of screening, prevention, diagnosis, or treatment of a disease.","longName":"COGIMP_ICF_PTCOMP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C1F5E8-F71E-5392-E053-F662850A4373","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"SOKKERL","dateModified":"2022-03-24","changeNote":"6/26/17 tt, released.   3/2/17 tt, 10017.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695489","version":"1","preferredName":"Negation Ability Patient Compliance Immunology And Clinical Follow-up Exclusion Criteria Code Indicator","preferredDefinition":"A coded response to questions that address medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study related to the inability of a patient to conform to immunological and clinical follow-up activities.","longName":"NEG_ABTY_COMP_IMGY_FU","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C54F21-3C03-19D2-E053-F662850A2087","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"SOKKERL","dateModified":"2018-08-16","changeNote":"6/26/17 tt, released.  3/2/17 tt, 10017.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695527","version":"1","preferredName":"Clinical Study Protocol Patient Refuse Or Unable Follow Requirement Code Indicator","preferredDefinition":"A coded response as to whether the patient declines or is unable to adhere to study protocol requirements.","longName":"CSP_RFS_UN_FLW_REQ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C1F680-A923-5470-E053-F662850A6741","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"TAYLORT","dateModified":"2017-06-26","changeNote":"6/26/17 tt, released.  3/2/17 tt, 10017.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695543","version":"1","preferredName":"Cohort Study One Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions to determine eligibility for clinical trial participation, as outlined in the study protocol, for patients registered in Cohort Study One.","longName":"CO_SDY_ONE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C5AECF-CB62-05D4-E053-F662850ACD2A","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"TAYLORT","dateModified":"2019-03-18","changeNote":"3/2/17 tt, 10021.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695551","version":"1","preferredName":"Cohort Study Two Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions to determine eligibility for clinical trial participation, as outlined in the study protocol, for patients registered in Cohort Study Two.","longName":"CO_SDY_TWO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C6979C-25BA-5B34-E053-F662850AE975","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"TAYLORT","dateModified":"2019-03-18","changeNote":"3/2/17 tt, 10021.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695553","version":"1","preferredName":"Person Malignant Neoplasm Detection Evaluation Method Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions to determine patient eligibility for clinical trial participation, as outlined in the study protocol, that address evaluation procedures and methods used to identify malignant neoplastic disease.","longName":"MAL_NEO_DET_EVAL_MET","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C93C9F-A470-19D6-E053-F662850AC7EA","latestVersionIndicator":"Yes","beginDate":"2017-03-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-02","modifiedBy":"KUMMEROA","dateModified":"2023-05-03","changeNote":"3/2/17 tt, 10021.","administrativeNotes":"2023.5.3 AQT added per ticket request CADSR0002390. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695564","version":"1","preferredName":"Person Human Immunodeficiency Virus Positive Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient is HIV positive.","longName":"PRSN_HIV_POS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49D42494-6FA8-022E-E053-F662850AA06B","latestVersionIndicator":"Yes","beginDate":"2017-03-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-03-03","modifiedBy":"TSESU","dateModified":"2023-09-28","changeNote":"Curated 3/3 for EC10021-bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695701","version":"1","preferredName":"Person Prior Antibody Therapy Experience Toxicity And Discontinue Prior Immunotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient has received prior antibody therapy which resulted in a toxicity that led to discontinuation of prior immunotherapy.","longName":"PRSN_P_ANTI_TOX_DISCN_P_IMMUNO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49D43EB6-2F07-022A-E053-F662850A0563","latestVersionIndicator":"Yes","beginDate":"2017-03-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-03-03","modifiedBy":"SOKKERL","dateModified":"2018-09-25","changeNote":"Curated 3/3/17 for EC10021-bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695709","version":"1","preferredName":"Person Experience Adverse Event Receive Prior Immunotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient has experienced an adverse event while receiving prior immunotherapy.","longName":"PRSN_AE_P_IMMUNO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49D49B2A-320A-17A5-E053-F662850AABBA","latestVersionIndicator":"Yes","beginDate":"2017-03-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-03-03","modifiedBy":"SOKKERL","dateModified":"2018-09-25","changeNote":"Curated 3/3/17 from EC10021-bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695714","version":"1","preferredName":"Person Prior Antibody Therapy Require Additional Immunosuppressive Therapy For Adverse Event Management Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient has received prior antibody therapy requiring additional immunosuppression for the management of an adverse event.","longName":"PRSN_P_ANTI_REQ_IMMUMO_AE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49D43156-B495-56F4-E053-F662850AD703","latestVersionIndicator":"Yes","beginDate":"2017-03-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-03-03","modifiedBy":"SOKKERL","dateModified":"2019-03-08","changeNote":"Curated 3/3/17 for EC10021-bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5695718","version":"1","preferredName":"Person Eligible Food and Drug Administration Approved Agent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether the patient has is eligible for FDA approved agents.","longName":"PRSN_ELIG_FDA_APPR_AGT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49D4DDD1-989B-6CE6-E053-F662850AC8DE","latestVersionIndicator":"Yes","beginDate":"2017-03-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-03-03","modifiedBy":"SOKKERL","dateModified":"2018-09-25","changeNote":"Curated 3/3/17 for EC10021-bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5697878","version":"1","preferredName":"Personal Medical History Biopsy Confirmation Ovarian Fallopian Tube Malignant Neoplasm Or Primary Peritoneal Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow participation in a clinical trial related to the patient's medical background of biopsy proven ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma.","longName":"MEDHX_BXCON_OV_FT_PPC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A257CF2-9917-491A-E053-F662850A43B6","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-07","modifiedBy":"TAYLORT","dateModified":"2017-03-09","changeNote":"3/9/17 tt, approved/released. 3/7/17 tt, 8329.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5697896","version":"1","preferredName":"Laboratory Procedure Partial Thromboplastin Time Result Code Indicator","preferredDefinition":"A coded response to questions related to the result of the medical procedure that involves testing a sample of blood for partial thromboplastin time, a measurement of the intrinsic pathway of coagulation","longName":"PTT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A258907-845B-609D-E053-F662850AB518","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-07","modifiedBy":"SOKKERL","dateModified":"2019-03-21","changeNote":"3/9/17 tt, approved/released.  3/7/17 TT, 8329.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5698074","version":"1","preferredName":"Disease or Disorder Curative Therapeutic Procedure Or Extend Life Expectancy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial related to treatments of any abnormal condition of the body or mind that tend to restore health or are expected to increase the duration of life.","longName":"CURTX_EXD_LIFE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A26710C-DA60-763A-E053-F662850A8FD9","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-07","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"3/9/17 tt, approved/released.  3/7/17 tt, 8329.","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5698084","version":"1","preferredName":"Prior Immunotherapy Or Biological Therapy Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to the administration of immunotherapy or biotherapy preceding enrollment.","longName":"PR_IMTX_BIOTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A274020-44EC-73EC-E053-F662850A02B3","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-07","modifiedBy":"SOKKERL","dateModified":"2020-03-27","changeNote":"3/9/17 tt, approved/released.  3/7/17 tt, 8329.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5698091","version":"1","preferredName":"Patient Immunocompromised Exclusion Criteria Code Indicator","preferredDefinition":"A coded response for questions to address medical and/or social characteristics that prevent a person from being allowed to participate in a clinical study, as outlined in the study protocol, related to the loss of any arm of immune functions caused by certain diseases or treatments.","longName":"PT_IMMUNO_EXCL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2872EE-0936-3EA3-E053-F662850AB378","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-07","modifiedBy":"TAYLORT","dateModified":"2019-04-16","changeNote":"3/9/17 tt, approved/released.  3/7/17 tt, 8329.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5698095","version":"1","preferredName":"Primary Neoplasm Therapeutic Procedure Investigational New Drug Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that address the receipt of therapeutic agents and new drugs for primary tumor treatment.","longName":"PRNPM_TX_IND_RCV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A290FC4-7264-6A07-E053-F662850A284C","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-07","modifiedBy":"TAYLORT","dateModified":"2017-03-09","changeNote":"3/9/17 tt, released.  3/7/17 tt, 8329.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5698549","version":"1","preferredName":"Biopsy Confirmation Non-Small Cell Lung EGFR Gene Mutation Abnormality Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to biopsy verification of NSCLC associated with EFGR mutations.","longName":"BXCON_NSCLC_MUTAB_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2BF932-5FEE-092A-E053-F662850A1AE2","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-07","modifiedBy":"SOKKERL","dateModified":"2017-03-14","changeNote":"3/7/17 tt, 10042.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5699523","version":"1","preferredName":"EGFR T790M Mutation Biopsy Present Post EFGR TKI Progression Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to biopsy existence of genetic alterations of EGFR T790M after EGFR TKI progression.","longName":"5699521v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3A0F61-09C5-0C6C-E053-F662850A4CC3","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-08","modifiedBy":"SOKKERL","dateModified":"2017-03-14","changeNote":"3/8/17 tt, 10042","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5699576","version":"1","preferredName":"Investigational New Drug Investigational Medical Device Receive Or Trial Participation Prior To Treatment Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to IND/IDE receipt or clinical trial participation prior to treatment occurrence.","longName":"IND_IDE_PR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3C29CA-1161-58F5-E053-F662850A968E","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-08","modifiedBy":"SOKKERL","dateModified":"2020-11-16","changeNote":"3/8/17 tt, 10042.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5699875","version":"1","preferredName":"Patient Serious Negation Healed Injury Ulceration Fracture Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to serious non-healing wound, ulcer, or bone fracture.","longName":"NEG_HEAL_INJ_FX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3D99FF-E18F-1C2E-E053-F662850A4122","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-08","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeNote":"3/29/17 tt, minor edit to def. 3/8/17 tt, 10042.","administrativeNotes":"2022.9.30 AQT added for ticket request CADSR0001561. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5699888","version":"1","preferredName":"Person Surgical Procedure Biopsy Injury Prior Therapeutic Procedure Occurrence Or Surgery Intent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to surgical procedures, biopsies, and injuries prior to treatment occurrence, and the anticipation of operative procedures.","longName":"SGY_BX_INJ_PRTX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3E046C-D4C2-63F0-E053-F662850AF4E7","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-08","modifiedBy":"GALITG","dateModified":"2022-01-26","changeNote":"4/20/17 tt, corrected context.  3//17 tt, 10042","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5699946","version":"1","preferredName":"Cardiovascular Disease or Disorder Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to risk factors of the heart or blood vessels.","longName":"CDVDZ_RSK_FCTR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3ED1D3-FB19-2EF4-E053-F662850A2150","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-08","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"3/8/17 tt, 10042.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5720348","version":"1","preferredName":"First-Line Therapy Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical trial for questions related to prior initial treatments as outlined in the study protocol.","longName":"FIR_LINE_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B2FBDF2-E420-3BFB-E053-F662850A4923","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"CLOHNES","dateModified":"2023-09-19","changeNote":"3/21/17 tt, 10067.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5721867","version":"1","preferredName":"Recurrent Glioblastoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical trial for questions related to the reemergence of glioblastoma after a period of remission as outlined in the study protocol.","longName":"RCR_GBM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3F10AB-245F-4DB6-E053-F662850AADA8","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"SOKKERL","dateModified":"2022-07-01","changeNote":"3/21/17 tt, 10067.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5721872","version":"1","preferredName":"Prior Investigational New Drug Administration Half Life Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical trial for questions related to the amount of time needed for a material to lose half of its physical, chemical, or biological activity for the prior administration of new drugs or biological drugs that are used in a clinical investigation as outlined in the study protocol.","longName":"PR_IND_HFLF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3F5818-B4A0-7BBD-E053-F662850AE51B","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"SOKKERL","dateModified":"2019-06-12","changeNote":"3/21/17 tt, 10067.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5721885","version":"1","preferredName":"Prior Therapeutic Procedure Administration Elapsed Time Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical trial for questions related to the interval between the prior administration of therapeutic agents that produce an effect intended to alter or stop a pathologic process as outlined in the study protocol.","longName":"PRTX_ELTM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3FB402-649C-392D-E053-F662850A0AE5","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"KUMMEROA","dateModified":"2023-08-11","changeNote":"3/21/17 tt, 10067.","administrativeNotes":"2023.8.11 AQT added per ticket request CADSR0002726. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5721910","version":"1","preferredName":"Imaging Procedure Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical trial for questions related to imaging and the act of dispensing, applying, or tendering a medical product or other agents as outlined in the study protocol.","longName":"IMG_AGT_ADM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3FDA84-9B1C-4F04-E053-F662850A763A","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"SOKKERL","dateModified":"2018-09-06","changeNote":"3/21/17 tt, 10067.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5722192","version":"1","preferredName":"Investigational New Drug Or Prior Clinical Study Participation Eligibility Determination Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical study for questions related to new drugs or biological drugs used in a clinical investigations or the act of taking part in research which includes the development of new technologies, study of mechanisms of human diseases, therapies, epidemiologic, behavior, and health services research.","longName":"IND_PR_CLTRL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3FB402-6547-392D-E053-F662850A0AE5","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"TYRRELLM","dateModified":"2023-10-23","changeNote":"3/21/17 tt, 10067.","administrativeNotes":"10.23.23_Added AQT per request ticket CADSR0002989_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5722208","version":"1","preferredName":"Patient Corrected QT Interval Outcome Or Family Medical History Long QT Syndrome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical study for questions related to QTc results of the patient or the patient's family medical history of a ventricular arrhythmia characterized by a long QT interval as outlined in the study protocol.","longName":"CQT_FAMHX_LQT_SDRM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3FF942-4E95-350C-E053-F662850A06D7","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"TYRRELLM","dateModified":"2023-07-20","changeNote":"3/21/17 tt, 10067.","administrativeNotes":"7/20/23 removed special character from AQT_mmt\r\n8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5722243","version":"1","preferredName":"Vascular Disorder Prior To Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical study for questions related to a non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels prior to a medical product, practice, or application that is tested in a clinical trial.","longName":"VASDZ_PR_AGT_ADMN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B42A850-BF74-0823-E053-F662850AF439","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"3/21/17 tt, 10067.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5722285","version":"1","preferredName":"Female Gender Childbearing Potential Non Lactating And Negative Pregnancy Test Confirmation Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a female patient meets the criteria for enrolling onto a clinical study for questions that address child bearing potential and verification that the patient is not breast feeding, and is not pregnant, as outlined in the study protocol.","longName":"FEML_CHBR_NOLAC_NEGPRG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B43E75D-1ABF-2DFD-E053-F662850A4CEE","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-21","modifiedBy":"SOKKERL","dateModified":"2019-03-12","changeNote":"3/21/17 tt, 10067.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727153","version":"1","preferredName":"Clinical Trial Eligibility Criteria Disease or Disorder Diagnosis Histopathologic Examination Confirmation Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address histopathological confirmation for the diagnosis of disease.","longName":"DZDSR_HISTP_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BDE5BBD-E1DC-2F96-E053-F662850A7CF6","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"SOKKERL","dateModified":"2024-02-21","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727160","version":"1","preferredName":"Clinical Trial Eligibility Criteria Intervention or Procedure Diagnosis Method Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address the interventions or procedures performed in order to recognize the presence and nature of disease.","longName":"INTPR_DX_MTHD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BDF06A8-26AA-63D6-E053-F662850A0FB0","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"SOKKERL","dateModified":"2021-12-16","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727176","version":"1","preferredName":"Clinical Trial Eligibility Criteria Imaging Procedure Disease or Disorder Primary Neoplasm Measurement Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address imaging procedures used in screening, diagnosis of disease, surgical procedures, and primary tumor measurements.","longName":"IMG_DZ_PRTMR_MMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BDF65B9-5C1C-1A45-E053-F662850ADBBE","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727187","version":"1","preferredName":"Clinical Trial Eligibility Criteria Malignant Neoplasm Sarcoma by FNCLCC Grade Histological Procedure Confirmation Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address the histologic confirmation of malignant neoplasms by the French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system of soft tissue sarcomas.","longName":"FNCLCC_HIST_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BDF076F-BB9D-2A87-E053-F662850A8D35","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"TAYLORT","dateModified":"2017-04-06","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727199","version":"1","preferredName":"Clinical Trial Eligibility Criteria Primary Neoplasm Intervention Required Management Assessment Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address the determination of primary tumor and required interventions for management.","longName":"PRTMR_INTV_RQR_MGMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BE06283-193C-0933-E053-F662850A7774","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"TAYLORT","dateModified":"2017-04-06","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727218","version":"1","preferredName":"Clinical Trial Eligibility Criteria Laboratory Procedure Absolute Blood Lymphocyte Count Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address the number of lymphocytes found in a given volume of blood.","longName":"LAB_ALC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BE1F36B-5A3D-6B52-E053-F662850AAB07","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"SOKKERL","dateModified":"2022-02-24","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727219","version":"1","preferredName":"Clinical Trial Eligibility Criteria Localized Malignant Neoplasm Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address malignant neoplasms which are confined to a specific anatomic site and have not spread to other sites.","longName":"LOC_MAL_NEOP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BE1F36B-5A65-6B52-E053-F662850AAB07","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-03-29","modifiedBy":"TAYLORT","dateModified":"2017-11-15","changeNote":"11/15/17 tt grammatical correction to question text. 4/6/17  tt, approved/released. 3/29/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727756","version":"1","preferredName":"Clinical Trial Eligibility Criteria Soft Tissue Sarcoma Grade 1 And Neoplasm Size Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address grade 1 non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and tumor size.","longName":"NRSTS_GR_SZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BE581DF-D769-2102-E053-F662850AA11D","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"TAYLORT","dateModified":"2017-11-15","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727811","version":"1","preferredName":"Clinical Trial Eligibility Criteria Primary Neoplasm Gross Total Resection Or Recurrent Neoplasm Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address gross total resection of the primary tumor and tumor recurrence.","longName":"PRNEO_GTRES_RCRT_NEO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BE3E323-1F18-5845-E053-F662850A6E3B","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"TAYLORT","dateModified":"2017-11-15","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727815","version":"1","preferredName":"Clinical Trial Eligibility Criteria Prior Oncolytic Virus Therapy Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that are related to prior targeted therapy that uses viral infection to cause the lysis of tumor cells.","longName":"PRR_OVTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BE37C65-391B-7D14-E053-F662850A4F20","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"SOKKERL","dateModified":"2017-06-08","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5727835","version":"1","preferredName":"Clinical Trial Eligibility Criteria Clinically Significant Indicator Immunodeficiency and Immunosuppression Or Opportunistic Infection Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that are related to clinically significant immunosuppression or immunodeficiency disorders, or infections caused by organisms that are capable of causing disease in immunocompromised patients.","longName":"CLN_SIG_IMMUN_DSDR_OPINF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BE581DF-D791-2102-E053-F662850AA11D","latestVersionIndicator":"Yes","beginDate":"2017-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-29","modifiedBy":"SOKKERL","dateModified":"2019-05-23","changeNote":"4/6/17  tt, approved/released. 3/29/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5728080","version":"1","preferredName":"Clinical Trial Eligibility Criteria Active Herpes Virus Skin Lesion Or Prior Infection Complication Occurrence Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that are related to active herpes virus skin lesions or prior complications of the infection.","longName":"HRPVS_SKN_LSN_PRR_INF_COMP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BF477CE-EE0B-6705-E053-F662850A13EE","latestVersionIndicator":"Yes","beginDate":"2017-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-30","modifiedBy":"TAYLORT","dateModified":"2017-04-06","changeNote":"4/6/17  tt, approved/released. 3/30/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5728085","version":"1","preferredName":"Clinical Trial Eligibility Criteria Viral Infection Therapeutic Procedure Requirement Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that are related to viral infections and treatment requirements.","longName":"VRLINF_TX_REQ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BF351B5-6007-6BD7-E053-F662850ADB60","latestVersionIndicator":"Yes","beginDate":"2017-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-30","modifiedBy":"TAYLORT","dateModified":"2017-04-06","changeNote":"4/6/17  tt, approved/released. 3/30/17 tt, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5728141","version":"1","preferredName":"Clinical Trial Eligibility Criteria Patient Refusal to Participate Exposure Restriction To Member Of High Risk Population Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow clinical study participation that address the patients' refusal to take part in the limitations of exposing something, as outlined in the study protocol, to a population group that has a greater chance of contracting a disease or disorder.","longName":"PT_RFSL_EXPR_RTCN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BF6E6FD-A59E-5565-E053-F662850A5CAD","latestVersionIndicator":"Yes","beginDate":"2017-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-30","modifiedBy":"DWARZEL","dateModified":"2018-03-08","changeNote":"4/6/17  tt, approved/released. 3/30/17 tt. 10056. Fixed apostrope in definition 3/8/2018 DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5729308","version":"1","preferredName":"Clinical Trial Eligibility Criteria Disease Anatomic Site Direct Or Image-Guided Therapy Procedure Location Access Code Indicator","preferredDefinition":"The coded response as to whether the location of the disease site within the body is accessible to direct or ultrasound guided therapeutic injection procedures, as outlined in the protocol, in order to allow a subject to participate in a clinical study.","longName":"DZ_SIT_DIR_IMG_TX_ACC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BF5B0EA-066B-681E-E053-F662850A9D22","latestVersionIndicator":"Yes","beginDate":"2017-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-30","modifiedBy":"TAYLORT","dateModified":"2017-04-06","changeNote":"4/6/17  tt, approved/released. 3/30/17 tt, edits, 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5731470","version":"1","preferredName":"Patient EGFR Gene Exon 20 Insertion Mutation Non-Small Cell Lung Carcinoma Performed By Clinical Laboratory Improvement Act Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions addressing EGFR Exon 20 insertion mutation, the presence of non-small cell lung carcinoma and testing performed by CLIA certification of the lab testing/providing analyses of samples collected in clinical care or research as outlined in the protocol.","longName":"EGFR_EXON_ NSCLC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C0CD0F7-6BB6-1DA3-E053-F662850A7164","latestVersionIndicator":"Yes","beginDate":"2017-03-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-03-31","modifiedBy":"SOKKERL","dateModified":"2017-04-06","changeNote":"3/31/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5731474","version":"1","preferredName":"Therapeutic Procedure Platinum Compound Progressive Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address EGFR Exon 20 insertion dose escalation and expansion cohort (Cohort E), progressive disease of on platinum based chemotherapy as outlined in the protocol.","longName":"THER_PROD_DIS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C0C8539-3AC3-3499-E053-F662850AD520","latestVersionIndicator":"Yes","beginDate":"2017-03-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-03-31","modifiedBy":"SOKKERL","dateModified":"2017-04-06","changeNote":"03/31/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5731744","version":"1","preferredName":"Agent Intervention or Procedure Disease or Disorder Dose Expansion Cohort B Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the use of agents that produce an effect, or that are intended to alter the course of a disease in a patient, as outlined in the study protocol, for patients registered in Dose Expansion Cohort B study.","longName":"AGNT_INT_DZ_DEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C4626AF-91AF-3A91-E053-F662850AC0DF","latestVersionIndicator":"Yes","beginDate":"2017-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-03","modifiedBy":"SOKKERL","dateModified":"2022-07-18","changeNote":"04/3/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5731748","version":"1","preferredName":"Agent Disease or Disorder Dose Expansion Cohort C Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the use of agents that produce an effect, or that are intended to alter the course of a disease in a patient, as outlined in the study protocol, for patients registered in Dose Expansion Cohort C study.","longName":"AGT_DIZ_DEC_COHC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C4626AF-920B-3A91-E053-F662850AC0DF","latestVersionIndicator":"Yes","beginDate":"2017-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-03","modifiedBy":"SOKKERL","dateModified":"2023-10-03","changeNote":"04/03/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5731756","version":"1","preferredName":"Protocol Agent Disease or Disorder Dose Expansion Cohort D Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the use of agents that produce an effect, or that are intended to alter the course of a disease in a patient, as outlined in the study protocol, for patients registered in Dose Expansion Cohort D study.","longName":"PRO_AGNT_ DIS_ COH_D","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C46F85C-8EC0-3A8F-E053-F662850AFDA6","latestVersionIndicator":"Yes","beginDate":"2017-04-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-03","modifiedBy":"SOKKERL","dateModified":"2018-10-01","changeNote":"04/03/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5734714","version":"1","preferredName":"Disease or Disorder Status Curative Therapeutic Procedure Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol that address the assessments of disease status and curative therapy.","longName":"DIZ_STAT_CUR_THPY_PRD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C6E4022-9CD5-66C9-E053-F662850A8B89","latestVersionIndicator":"Yes","beginDate":"2017-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-05","modifiedBy":"ZHWENDY","dateModified":"2022-08-04","changeNote":"04/05/2017 TT/LS","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5734748","version":"1","preferredName":"Disease Status Or Newly Diagnosed Disease or Disorder Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol that address the assessments of disease status or newly diagnosed disease.","longName":"DZ_STS_NEW_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C6E803E-1FB5-66BB-E053-F662850ABB4C","latestVersionIndicator":"Yes","beginDate":"2017-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-05","modifiedBy":"SOKKERL","dateModified":"2022-12-20","changeNote":"04/05/2017 LS/TT","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5734762","version":"1","preferredName":"Radiation Therapy Prior Enrollment Disease or Disorder Status Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol that address radiation therapy prior to enrollment and disease status.","longName":"RAD_THP_ PR_ENR_DZ_STS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C6E63AF-C86B-66A7-E053-F662850ADD05","latestVersionIndicator":"Yes","beginDate":"2017-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-05","modifiedBy":"STARGELM","dateModified":"2020-08-31","changeNote":"04/05/2017 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5734765","version":"1","preferredName":"Personal Medical History Exclusion Criteria Code Indicator","preferredDefinition":"The coded response to questions that address the patient's background regarding health and the occurrence of disease events and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"PER_MED_HX_EXN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C6ECCE9-93B9-4F64-E053-F662850AF7D3","latestVersionIndicator":"Yes","beginDate":"2017-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-05","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeNote":"04/05/2017 ls/tt 10012.","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5741173","version":"1","preferredName":"Treatment Cohort Study 10007 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10007 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10007_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C822BFB-8B88-25F3-E053-F662850AD460","latestVersionIndicator":"Yes","beginDate":"2017-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-04-06","modifiedBy":"TAYLORT","dateModified":"2017-04-06","changeNote":"4/6/17 tt/10007.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5771685","version":"1","preferredName":"Treatment Cohort Study 10026 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10026 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10026_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1029F9-CAC8-648E-E053-F662850A5E20","latestVersionIndicator":"Yes","beginDate":"2017-04-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-13","modifiedBy":"SOKKERL","dateModified":"2017-09-12","changeNote":"4/13/2017 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5776350","version":"1","preferredName":"Concomitant Medication Receive Investigational New Drug Administration Known Hazard Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation as outlined in the study protocol for questions related to the use of concomitant medications with known hazards regarding the administration of the investigational study drug.","longName":"PT_CON_MED_INTER","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D5ECD24-248B-7147-E053-F662850AEEFB","latestVersionIndicator":"Yes","beginDate":"2017-04-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-17","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 4/17/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5778182","version":"1","preferredName":"Anticoagulant Agent Requirement Drug Interaction Avoidance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the requirements of anticoagulation agents in order to avoid drug interactions as outlined in  the protocol.","longName":"ANTCOG_AGT_RQM_DR_INTER_ AVD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D9CAEC0-AEFB-26B8-E053-F662850A9621","latestVersionIndicator":"Yes","beginDate":"2017-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-20","modifiedBy":"SOKKERL","dateModified":"2024-01-08","changeNote":"11/8/18 TT released/PClark. 10058 - 4/20/2017 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5778196","version":"1","preferredName":"Prior Therapeutic Procedure Or Radiation Therapy Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior administration of agents intended to alter or stop a pathologic process or radiation therapy as outlined in the protocol.","longName":"PR_THRPY_RAD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D9D2A0A-E3EB-61E7-E053-F662850AE0C8","latestVersionIndicator":"Yes","beginDate":"2017-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-20","modifiedBy":"SOKKERL","dateModified":"2022-11-15","changeNote":"11/8/18 TT released/PClark. 10058-4/20/2017 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5778264","version":"1","preferredName":"Patient Reproduction Pregnancy Breast Feeding Criteria Code Indicator","preferredDefinition":"A coded response to questions that prevent a person from being allowed to participate in a clinical study that address reproduction, pregnancy, and breast feeding as outlined in the protocol.","longName":"PT_RPD_ PRGY_BRFD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D9E2655-2B7C-08C6-E053-F662850A8DD3","latestVersionIndicator":"Yes","beginDate":"2017-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-20","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"10058 4/20/2017 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5778760","version":"1","preferredName":"Patient And Partner Refuse Contraceptive Device Usage Investigational Agent Viral Transmission Avoidance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that address the refusal of the patient and partner to employ adequate contraception in order to avoid viral transmission of the investigational agent as outlined in the protocol.","longName":"PTPR_RFUS_CONTR_ TNSM_AVD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DACF2D0-199F-4D44-E053-F662850ACA14","latestVersionIndicator":"Yes","beginDate":"2017-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-21","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 10058 4/21/2017 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5778785","version":"1","preferredName":"Patient Prior Therapy Performed Imaging Requirement And No Imaging Evidence Progressive Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to prior treatments, requirements for imaging procedures that were performed, and no imaging evidence of disease progression.","longName":"PRTX_NO_IMG_DZEV","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DB35298-0413-1839-E053-F662850AC3D0","latestVersionIndicator":"Yes","beginDate":"2017-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-21","modifiedBy":"SOKKERL","dateModified":"2023-12-27","changeNote":"11/8/18 TT released/PClark. 10021 4/21/2017 LS/TT","administrativeNotes":"10.22.2023_Added AQT per ticket request CADSR0002989_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5781512","version":"1","preferredName":"Patient Immunodeficiency Diagnosis Or Receive Therapeutic Procedure Prior Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the diagnosis of immunodeficiency or the receipt of therapy prior to the administration of the protocol agent as outlined in  the protocol.","longName":"PT_IMN_REC_THRPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E00239B-4CC7-5C34-E053-F662850A2D4C","latestVersionIndicator":"Yes","beginDate":"2017-04-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-25","modifiedBy":"SOKKERL","dateModified":"2022-02-25","changeNote":"11/8/18 TT released/PClark. 10061 4/25/2017 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5791447","version":"1","preferredName":"Person Prior Chimeric Antigen Receptor T-Cell Therapy Persistent Disease CD19 Positive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to prior treatment of Chimeric Antigen Receptor T cells and persistent CD19 expression as outlined in the protocol.","longName":"PRR_CAR_PRST_DZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E2B215E-82E0-3A4A-E053-F662850A3EC2","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-04-27","modifiedBy":"GDEEN","dateModified":"2022-10-26","changeNote":"10030 4/27/2019 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5810644","version":"1","preferredName":"Treatment Cohort Study 10013 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10013 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10013_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F0BD9E7-4AFD-4D04-E053-F662850A4ECE","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-08","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeNote":"5/8/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5810660","version":"1","preferredName":"Person Abnormal Echocardiogram Result Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to abnormal echocardiogram results as outlined in the protocol.","longName":"ABN_ECHO_RES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F184F76-5E3A-5B1E-E053-F662850AC25F","latestVersionIndicator":"Yes","beginDate":"2017-05-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-09","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 5/9/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5823145","version":"1","preferredName":"Patient Human Immunodeficiency Virus Positive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study related to Human Immunodeficiency Virus Positive as outlined in the protocol.","longName":"HIV_POS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F568F3E-6CEF-1C23-E053-F662850AC2D0","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-12","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"2/12/18 semantic correction to definition. 2/8/18 tt released/forms usage. 5/12/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5823194","version":"1.1","preferredName":"Treatment Cohort Study 10042 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10042 in which subsets of a defined population are identified.","longName":"TX_COH_10042_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A23D81-62D0-59FF-E053-F662850AF221","latestVersionIndicator":"Yes","beginDate":"2017-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-03","modifiedBy":"SOKKERL","dateModified":"2019-04-03","changeNote":"5/12/2017 LS    versioned VD 4/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5828003","version":"1","preferredName":"Mutation Abnormality T790M Status","preferredDefinition":"A response for T790M status.","longName":"T790M_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FA97770-AA7A-6359-E053-F662850A0855","latestVersionIndicator":"Yes","beginDate":"2017-05-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-05-16","modifiedBy":"SOKKERL","dateModified":"2017-06-22","changeNote":"5/16/17 tt, 10042.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5828079","version":"1","preferredName":"Malignant Neoplasm New Negation Therapeutic Procedure Receive Or Progressive Disease Metastatic Tumor Count","preferredDefinition":"A response for the number of untreated new malignant neoplasms or progressive metastatic tumors.","longName":"NEW_UNTX_OR_PRG_TUM_CNT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FAAB2F2-1CEE-5B47-E053-F662850A9E0C","latestVersionIndicator":"Yes","beginDate":"2017-05-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-05-16","modifiedBy":"TAYLORT","dateModified":"2017-05-17","changeNote":"5/16/17 tt, 10042.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5834248","version":"1","preferredName":"Personal Medical History Cardiovascular Disease Or Interventional Procedures Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to medical history of cardiovascular disease/disorder or prior interventions and procedures as outlined in the protocol.","longName":"PMH_CV_DZ_INTV_PROC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FE36B6C-99D1-1A27-E053-F662850AAD78","latestVersionIndicator":"Yes","beginDate":"2017-05-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-19","modifiedBy":"SOKKERL","dateModified":"2022-11-17","changeNote":"5/19/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5839223","version":"1","preferredName":"Opportunistic Infection Symptom Or Personal Medical History Code","preferredDefinition":"A numeric coded response to questions related to patient symptoms or medical history of opportunistic infection.","longName":"OP_INF_PER_HX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"50737A8F-FD09-30CF-E053-F662850A3BFD","latestVersionIndicator":"No","beginDate":"2017-05-26","endDate":"2020-02-25","createdBy":"SOKKERL","dateCreated":"2017-05-26","modifiedBy":"SOKKERL","dateModified":"2020-02-25","changeNote":"5/26/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5839598","version":"1","preferredName":"Acquired Immunodeficiency Syndrome Immune Status Code","preferredDefinition":"A numeric coded response for questions related to AIDS immune status.","longName":"AIDS_IMM_ST_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"50C13D14-6D08-6A5C-E053-F662850A623C","latestVersionIndicator":"Yes","beginDate":"2017-05-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-30","modifiedBy":"SOKKERL","dateModified":"2017-05-30","changeNote":"5/30/2017 LS/TT  CITN-12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5859546","version":"1","preferredName":"Recurrent/Refractory Disease Or Refuse Therapeutic Procedure To Extend Life Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related a recurrent, refractory disease and therapy refusal to  prolong life as outlined in the protocol.","longName":"PER_REF_DIS_REF_THRPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51753A26-8E0D-0F84-E053-F662850A0A44","latestVersionIndicator":"Yes","beginDate":"2017-06-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-08","modifiedBy":"SOKKERL","dateModified":"2021-09-28","changeNote":"5/4/20 Added comma to question text; tmt. 6/8/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5859565","version":"1","preferredName":"Advanced Skin Carcinoma Or Refractory Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related skin cancer and refractory disease as outlined in the protocol.","longName":"ADV_SK_CAN_REF_NEO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"517645D6-C8C7-7ED6-E053-F662850A6419","latestVersionIndicator":"Yes","beginDate":"2017-06-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-08","modifiedBy":"SOKKERL","dateModified":"2019-11-20","changeNote":"6/8/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5859573","version":"1","preferredName":"Skin Nodule Intralesional Route of Administration Clinical Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related skin lesions that are suitable to administer intralesional injection as outlined in the protocol.","longName":"SK_NOD_INTRA_ADM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51766F3A-CE6D-1BA4-E053-F662850A8B3F","latestVersionIndicator":"Yes","beginDate":"2017-06-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-08","modifiedBy":"SOKKERL","dateModified":"2017-06-13","changeNote":"6/8/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5861787","version":"1","preferredName":"Progressive Disease Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to disease that is increasing in scope or severity after the administration of therapeutic agents.","longName":"PRG_DIS_THPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"518BB60E-1A9C-669D-E053-F662850ABB88","latestVersionIndicator":"Yes","beginDate":"2017-06-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-09","modifiedBy":"CLOHNES","dateModified":"2022-12-21","changeNote":"6/9/2017 LS","administrativeNotes":"12/21/22 added AQT and alt OID, CCTG for ticket number CADSR0001818 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5863886","version":"1","preferredName":"Disease or Disorder Recurrent Refractory Progressive Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that address recurrent, refractory, progressive disease assessments as outlined in the study protocol.","longName":"REC_REF_PRG_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C5E1E0-8EF3-2DA8-E053-F662850A9163","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-12","modifiedBy":"SOKKERL","dateModified":"2023-05-24","changeNote":"6/26/17 tt, approved and released.  6/12/17 tt, 10076.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5863935","version":"1","preferredName":"Disease or Disorder M Protein Urine Free Immunoglobulin Light Chain Measurable Indicator Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether the patient has disease measurable by monoclonal immunoglobulin (M protein) and/or urine free immunoglobulin light chain, and the final outcome, as outlined in the protocol to allow clinical trial participation.","longName":"MDZ_MPRO_UFILC_INC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C669AC-6C32-3FBA-E053-F662850AD6FF","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-12","modifiedBy":"SOKKERL","dateModified":"2021-04-28","changeNote":"6/26/17 tt, approved and released. 6/12/17 tt, 10076.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5863936","version":"1","preferredName":"Substance Abuse Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that has known substance dependencies as outlined in the protocol.","longName":"SUB_ABU_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C61B10-471A-7CEB-E053-F662850A8F15","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-12","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6/12/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5864197","version":"1","preferredName":"Corticosteroid Discontinue Prior To Protocol Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the discontinuation of corticosteroids prior to the administration of a medical product that is tested in a clinical trial as outlined in the protocol.","longName":"CORT_DISC_PRR_PRAG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C6E265-F6B4-1CCB-E053-F662850A885F","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-12","modifiedBy":"SOKKERL","dateModified":"2020-02-20","changeNote":"6/26/17 tt, approved and released.  6/12/17 tt, 10076.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5864228","version":"1","preferredName":"Person Autologous Hematopoietic Stem Cell Transplantation And Graft Versus Host Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation that are related to stem cell transfer or transplantation in which the patient is his own donor and graft versus host disease, as outlined in the protocol.","longName":"AHSCT_GVHD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C62444-B0F9-1D7E-E053-F662850A4264","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-12","modifiedBy":"SOKKERL","dateModified":"2020-10-06","changeNote":"6/26/17 tt, approved and released.  6/12/17 t, 10076.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5864358","version":"1","preferredName":"Laboratory Finding Corrected QT Interval Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to QTc results as outlined in the protocol.","longName":"QTC_OCM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C77C81-BB17-2601-E053-F662850A8863","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-12","modifiedBy":"KUMMEROA","dateModified":"2023-05-03","changeNote":"2020-7-27 AQT added for protocol 10389. AK 6/12/17 tt, 10076; approved/released.","administrativeNotes":"2023.5.3 AQT added per ticket request CADSR0002390. ak 8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5864420","version":"1","preferredName":"Patient Consent Disease or Disorder Genotyping Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation that address the patient's willingness to undergo disease genotyping as outlined in the protocol.","longName":"CONS_DZ_GNTYP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51CA49BE-2A78-6669-E053-F662850AC57D","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-12","modifiedBy":"SOKKERL","dateModified":"2022-05-18","changeNote":"6/26/17 tt, approved and released.  6/12/17 tt, 10076.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5864470","version":"1","preferredName":"Current Therapeutic Procedure Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the current administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process as outlined in  the protocol.","longName":"CUR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51CBAE0A-2CD9-38EC-E053-F662850AAD00","latestVersionIndicator":"Yes","beginDate":"2017-06-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-13","modifiedBy":"SOKKERL","dateModified":"2020-12-29","changeNote":"6/26/17 tt, approved and released.  6/13/17 tt, 10076","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5864482","version":"1","preferredName":"Bleeding Diathesis Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the medical history of bleeding diathesis as outlined in the protocol.","longName":"BLEED_DIATH_HX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51D8901C-A9AE-3257-E053-F662850A64DC","latestVersionIndicator":"Yes","beginDate":"2017-06-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-13","modifiedBy":"SOKKERL","dateModified":"2023-05-16","changeNote":"6/26/17 tt, approved and released.  6/13/17 tt, 10076.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5865072","version":"1","preferredName":"Radiation Therapy Last Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the requirements of last dose of radiation therapy as outlined in the protocol.","longName":"RAD_THPY_DOS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51ECB159-B863-3919-E053-F662850AEF39","latestVersionIndicator":"Yes","beginDate":"2017-06-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-14","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6/14/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5865143","version":"1","preferredName":"Topical Corticosteroid Therapy Stable Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to stable dose of topical agents as outlined in the protocol.","longName":"TRP_CORST_STAB_DOS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51ECB159-B88B-3919-E053-F662850AEF39","latestVersionIndicator":"Yes","beginDate":"2017-06-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-14","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6.14.2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5865147","version":"1","preferredName":"Phototherapy Last Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study of phototherapy treatment as outlined in the protocol.","longName":"PHO_LAS_DOS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51ED209F-E409-58C3-E053-F662850ABE05","latestVersionIndicator":"Yes","beginDate":"2017-06-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-14","modifiedBy":"SOKKERL","dateModified":"2020-10-06","changeNote":"11/8/18 TT released/PClark. 6/14/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5865152","version":"1","preferredName":"Prior Radiation Therapy Neoplasm Measurable Due To Disease Progression Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to disease progression prior to treatment as outlined in  the protocol.","longName":"PR_RAD_THYP_NEO_DIS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51ED9CA2-5DB4-3E70-E053-F662850AE2EF","latestVersionIndicator":"Yes","beginDate":"2017-06-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-14","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6/14/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5865166","version":"1","preferredName":"Patient Hypersensitivity Escherichia coli Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding hypersensitivity to Escherichia coli as outlined in the protocol.","longName":"PT_HYPER_ECOLI_","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51EE7934-896D-216C-E053-F662850A4EF8","latestVersionIndicator":"Yes","beginDate":"2017-06-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-14","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6/14/2014 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5879998","version":"1","preferredName":"T2 and Fluid Attenuated Inversion Recovery MRI Response Assessment in Neuro-Oncology Criteria Status","preferredDefinition":"The status of lesions by response assessment in neuro-oncology criteria measured using T2 and fluid attenuated inversion recovery MRI.","longName":"T2_FLAIR_RANO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"527D4959-3EFE-59AE-E053-F662850A57E7","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-21","modifiedBy":"SOKKERL","dateModified":"2017-06-22","changeNote":"6/21/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5880642","version":"1","preferredName":"Systemic Corticosteroid Administered Response Assessment in Neuro-Oncology Criteria Status","preferredDefinition":"The  status of disease when administrator systemic corticosteroids.","longName":"SYS_CORT_RANO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"528D1C73-95C4-40C2-E053-F662850AA753","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-22","modifiedBy":"SOKKERL","dateModified":"2017-06-22","changeNote":"6/22/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5880643","version":"1","preferredName":"Response Assessment in Neuro-Oncology Criteria Clinical Status","preferredDefinition":"The status related to the RANO response assessment (an update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","longName":"RANO_CLINC_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"528D6A08-C1B7-1DAD-E053-F662850A7E51","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-22","modifiedBy":"SOKKERL","dateModified":"2017-06-22","changeNote":"6/22/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5880690","version":"1","preferredName":"Target Lesion Gadolinium-Enhancing Response Assessment in Neuro-Oncology Criteria Status","preferredDefinition":"The status related to the RANO response assessment (an update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM) of T1 gadolinium enhancing target lesion sites.","longName":"GAD_ ENHAN_ RANO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"528E67A5-D3F0-4885-E053-F662850ADC1D","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-22","modifiedBy":"SOKKERL","dateModified":"2017-06-22","changeNote":"6/22/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5880873","version":"1","preferredName":"New Lesion Appearance Criteria Status","preferredDefinition":"The status of appearance and size of new lesions as outlined in protocol.","longName":"NEW_ LESI_APP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52908B5E-08AD-2D61-E053-F662850A98ED","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-22","modifiedBy":"SOKKERL","dateModified":"2017-06-22","changeNote":"6/22/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5887340","version":"1","preferredName":"Treatment Cohort Study 10021 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10021 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10021_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52A4F8A1-114F-2568-E053-F662850A4846","latestVersionIndicator":"Yes","beginDate":"2017-06-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-06-23","modifiedBy":"SOKKERL","dateModified":"2019-03-20","changeNote":"11/8/18 TT released/PClark. 6/23/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5889188","version":"1","preferredName":"Navitoclax Prior Administration And Stop Reason Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior administration of navitoclax and stop reasons as outlined in the protocol.","longName":"NAV_PRTX_STOP_RSN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52DFC919-13EB-5E35-E053-F662850AEFB2","latestVersionIndicator":"Yes","beginDate":"2017-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-26","modifiedBy":"TAYLORT","dateModified":"2017-06-26","changeNote":"6/25/17 tt, 9466; approved and released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5889491","version":"1","preferredName":"Intervention Required Negation Discontinue Prior To Therapeutic Procedure Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to patient required interventions considered essential and mandatory in order to prevent permanent impairment or damage that cannot be stopped prior to the administration of a therapeutic procedure as outlined in the study protocol.","longName":"INTVN_REQ_NEG_DXD_PRR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52E010C3-402C-5668-E053-F662850A9FC6","latestVersionIndicator":"Yes","beginDate":"2017-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-26","modifiedBy":"KUMMEROA","dateModified":"2020-08-03","changeNote":"6/28/17 tt, approved/released.  6/26/17 tt, 10013.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5889649","version":"1","preferredName":"AML Recurrent Refractory Disease Or Newly Diagnosed Or Negation Treatment Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to recurrent/refractory AML, or newly diagnosed AML, or the patients non-agreement to treatment as outlined in the study protocol.","longName":"AML_REC_REF_NEWDX_NEG_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52F4F08B-4BE8-616E-E053-F662850A9BF8","latestVersionIndicator":"Yes","beginDate":"2017-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-27","modifiedBy":"SOKKERL","dateModified":"2023-07-05","changeNote":"11/8/18 TT released/PClark. 6/27/17 tt, 10075.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5889858","version":"1","preferredName":"Disease Measurable Indicator Bone Marrow Blast Cell Percentage Value Or Extramedullary Leukemia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to disease that is measurable by the percentage value of bone marrow blast cells or extramedullary leukemia as defined by the study protocol.","longName":"DZ_MSRBL_BMBC_PTG_EXLEUK_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52F5BF32-5280-668D-E053-F662850AFB51","latestVersionIndicator":"Yes","beginDate":"2017-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-27","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6/27/17 tt, 10075.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5889872","version":"1","preferredName":"Disease TP53 wt Allele Evidence DNA Sequencing Facility Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that address disease with evidence of wild-type p53 assessed by a shared facility which provides services for DNA sequencing as defined by the study protocol.","longName":"DZ_EVD_WTP53_DNA_SEQ_FCTY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52F6719E-0DDA-3CB4-E053-F662850AA681","latestVersionIndicator":"Yes","beginDate":"2017-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-27","modifiedBy":"KUMMEROA","dateModified":"2023-06-23","changeNote":"6/27/17 tt, 10075.","administrativeNotes":"2023.6.23 Corrected symbol in AQT. per ticket request CADSR0002546. ak 8/4/2022: fixed the box symbol in AQT_wz 7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5890003","version":"1","preferredName":"Antibiotic Current Therapy Patient Medical Status Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that address the current administration of antibiotics and the medical condition or state of the patient as defined by the study protocol.","longName":"ABXTX_MED_STAT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52F6F88D-FDFC-6695-E053-F662850ADCA3","latestVersionIndicator":"Yes","beginDate":"2017-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-27","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6/27/17 tt, 10075.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5890021","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia No Prior Therapy Clinical Trial Eligibility Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that confirm the patient has previously untreated AML characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) as defined by the protocol.","longName":"CBF_AML_NO_PRTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"52F7E7DE-918D-4EE4-E053-F662850A7000","latestVersionIndicator":"Yes","beginDate":"2017-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-06-27","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 6/27/17 tt, 10075.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5894739","version":"1","preferredName":"Newly Diagnosed Neoplasm Biopsy Confirmation Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to biopsy proven and  newly diagnosed  gynecological disease, and has established to activities that produce an effect, or intended to alter the course of disease as outlined in the protocol.","longName":"NEW_DIAG_BX_INTV_PROC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"536B6252-2267-1CA1-E053-F662850A3387","latestVersionIndicator":"Yes","beginDate":"2017-07-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-03","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 7/3/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5894743","version":"1","preferredName":"Patient Receive Weekly Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to receive weekly therapeutic agents as outlined in the protocol.","longName":"PT_WEK_THPY_PROC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"536C0B9B-1744-17CB-E053-F662850A3295","latestVersionIndicator":"Yes","beginDate":"2017-07-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-03","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 7/3/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5894763","version":"1","preferredName":"Person Receive Pelvic Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to treatment of disease by means of radiation therapy as outlined in the protocol.","longName":"PER_PEL_RAD_THPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"536C6BD4-E030-17C3-E053-F662850A7520","latestVersionIndicator":"Yes","beginDate":"2017-07-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-03","modifiedBy":"SOKKERL","dateModified":"2020-08-05","changeNote":"11/8/18 TT released/PClark. 7/3/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5894767","version":"1","preferredName":"Neoplasm CurativeTherapeutic Procedure No Evidence of Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to previous malignancy treated with administration of therapeutic agents to produce an effect that is intended to alter, stop or cure disease as outlined in the protocol.","longName":"NEOP_CUR_THRPY_NO_DX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"536CBAE2-A1A6-3A52-E053-F662850AB3EC","latestVersionIndicator":"Yes","beginDate":"2017-07-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-03","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 7/3/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5894814","version":"1","preferredName":"Patient Paraaortic Region Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the administration of radiation therapy to regions near the aorta as outlined in the protocol.","longName":"PT_PARA_RAD_THPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"538272A2-4678-7A19-E053-F662850AD3C2","latestVersionIndicator":"Yes","beginDate":"2017-07-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-04","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 7/3/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5899759","version":"1","preferredName":"Disease or Disorder Histologic Confirmation Recurrent Refractory Disease To Standard Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that histologically confirms B-cell non-Hodgkin lymphoma that is recurrent or refractory to widely used therapy as outlined in protocol.","longName":"DX_HIST _CON_RECUR_REFR_THPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"53FD7F7B-B068-139D-E053-F662850A5929","latestVersionIndicator":"Yes","beginDate":"2017-07-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-10","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 7/10/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5899856","version":"1","preferredName":"Hepatitis B Virus Antiviral Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that has evidence Hepatitis B Virus and on suppressive therapy as outlined in protocol.","longName":"MIN_HBV__ANTI_THPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"53FE52D5-F17F-1BA5-E053-F662850ADA4F","latestVersionIndicator":"Yes","beginDate":"2017-07-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-10","modifiedBy":"KENNISHM","dateModified":"2021-08-25","changeNote":"7/10/2017 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5900076","version":"1","preferredName":"Prior Therapy And No Evidence of Hepatitis C Virus Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that has had prior therapy and no presence of Hepatitis C Virus as outlined in protocol.","longName":"PR_THPY_NO_EVD_HCV","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"53FCEE09-7FEA-4CA8-E053-F662850A7973","latestVersionIndicator":"Yes","beginDate":"2017-07-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-11","modifiedBy":"SOKKERL","dateModified":"2020-12-03","changeNote":"7/11/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5900081","version":"1","preferredName":"Composite Lymphoma B-Cell Non-Hodgkin Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that has Coexistence of Hodgkin and non-Hodgkin lymphoma in the same anatomic site with a non B-Cell as outlined in protocol.","longName":"COM_LYPH_BCEL_NON_HODG_","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"53FF33C7-50D0-0F6E-E053-F662850AE9B6","latestVersionIndicator":"Yes","beginDate":"2017-07-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-11","modifiedBy":"SOKKERL","dateModified":"2023-06-08","changeNote":"11/8/18 TT released/PClark. 7/11/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5914105","version":"1","preferredName":"Treatment Cohort Study 10056 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10056 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10056_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"549EB2C6-3970-0356-E053-F662850A2D77","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-18","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 7/18/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5914203","version":"1","preferredName":"Biospecimen Submission Original Number Available Count","preferredDefinition":"The original number of specimens available for submission.","longName":"ORIG_NUM_SPEC_AVL_SUBM_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54ADB955-6EDE-6C44-E053-F662850A86B1","latestVersionIndicator":"Yes","beginDate":"2017-07-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-19","modifiedBy":"TAYLORT","dateModified":"2017-07-19","changeNote":"7/19/17 tt, per Peter Clark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5914868","version":"1","preferredName":"Patient Intolerance Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions that prevent a person from being allowed to participate in a clinical study whose inability to absorb or metabolize certain substances in the normal way as outlined in the protocol.","longName":"PT_INTOL_THPY_PRD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D6C379-827D-5E84-E053-F662850A8383","latestVersionIndicator":"Yes","beginDate":"2017-07-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-21","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"11/8/18 TT released/PClark. 7/21/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5915915","version":"1","preferredName":"Treatment Cohort Study 10056 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10056 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10056","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"553B53F7-1C4D-50CC-E053-F662850AC014","latestVersionIndicator":"Yes","beginDate":"2017-07-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-07-26","modifiedBy":"SOKKERL","dateModified":"2017-07-26","changeNote":"protocol 10056 LS 7/26/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5916593","version":"1","preferredName":"Treatment Cohort Study 10056 Cohort Step 1 Code","preferredDefinition":"The code that represents the information pertaining to step 1 protocol10056 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10056_STEP_1_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"55A336B3-CF2A-2EA0-E053-F662850A25C2","latestVersionIndicator":"Yes","beginDate":"2017-07-31","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-07-31","modifiedBy":"SOKKERL","dateModified":"2018-11-21","changeNote":"Curated for Protocol 10056. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5916594","version":"1","preferredName":"Therapeutic Procedure Daily Requirement Prior And During Protocol Agent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation, as outlined in the study protocol, that are related to daily treatment requirements before and during a substance that is tested in a clinical trial","longName":"DAILTX_REQ_PRR_DUR_PA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"55A33DFC-3DBD-0427-E053-F662850A24D1","latestVersionIndicator":"Yes","beginDate":"2017-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-31","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 7/31/17 tt, 9922.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5916911","version":"1","preferredName":"Treatment Cohort Study 10056 Cohort Step 2 Code","preferredDefinition":"The code that represents the information pertaining to step 2 protocol10056 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10056_STEP_2_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B62667-0378-609D-E053-F662850AC7EB","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-08-01","modifiedBy":"SOKKERL","dateModified":"2018-11-21","changeNote":"Curated for Protocol 10056. bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5919210","version":"1","preferredName":"Whole-Brain Radiotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to Radiation treatment modality used as major component in treatment of primary and metastatic brain tumors as outlined in the protocol.","longName":"WBRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5644FEA2-AE3D-1A9E-E053-F662850A92CB","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-08","modifiedBy":"SOKKERL","dateModified":"2020-12-04","changeNote":"8/8/17 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5920613","version":"1","preferredName":"Patient Pathologic Diagnosis Confirmation Dose Escalation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient has a confirmed pathologic diagnosis that meets the criteria for participating in the dose escalation portion of a clinical trial.","longName":"PATHDX_DS_ESC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"565639B5-078C-5198-E053-F662850A651E","latestVersionIndicator":"Yes","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"SOKKERL","dateModified":"2023-01-09","changeNote":"Curated to support EC9930","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5920614","version":"1","preferredName":"Patient Pathologic Diagnosis Confirmation Dose Expansion Cohort Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient has a confirmed pathologic diagnosis that meets the criteria for participating in the dose expansion or dose confirmation phase of a clinical trial.","longName":"PATHDX_DOSEXP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56555E02-F78A-6565-E053-F662850AC095","latestVersionIndicator":"Yes","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"SOKKERL","dateModified":"2020-09-17","changeNote":"Curated to support EC9930","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5920615","version":"1","preferredName":"Patient Exclusion Criteria Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient has a diagnosis that meets the exclusion criteria for participating in a clinical trial.","longName":"EXCL_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"565639B5-07B2-5198-E053-F662850A651E","latestVersionIndicator":"Yes","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"SOKKERL","dateModified":"2021-09-28","changeNote":"10/12/17 tt semantic edit to def. Curated to support EC9930","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5920709","version":"1","preferredName":"Patient Moderate And Severe Cohort Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating if a patient meets the criteria regarding patient enrollment to the moderate and severe cohorts that meets the criteria for enrollment in a clinical trial.","longName":"MODSEV_COH_ENR_C_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"565BE5E8-ABB7-5F2F-E053-F662850A7E67","latestVersionIndicator":"Yes","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; Curated to support EC9591","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5920713","version":"1","preferredName":"Patient Known Gene Mutation Or Deletion Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates whether the patient has a known gene mutation or deletion mutation that meets the criteria for participation in a clinical trial.","longName":"GENMUT_DELMUT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"565BE5E8-ABDE-5F2F-E053-F662850A7E67","latestVersionIndicator":"Yes","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. Curated to support EC10075","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5935497","version":"1","preferredName":"Modified Body Weight Assessment Site","preferredDefinition":"The modification and evaluation of patient body weight.","longName":"CHNG_BOD_WGHT_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"56D35E05-C85E-67EC-E053-F662850A8E88","latestVersionIndicator":"Yes","beginDate":"2017-08-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-15","modifiedBy":"SOKKERL","dateModified":"2017-08-17","changeNote":"8/15/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5935510","version":"1","preferredName":"Person Skin Involvement EvaluationType","preferredDefinition":"Person skin significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"PER_SKN_EVAL_TY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"56D3DF3A-1894-49FC-E053-F662850A2586","latestVersionIndicator":"Yes","beginDate":"2017-08-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-15","modifiedBy":"SOKKERL","dateModified":"2023-06-15","changeNote":"8/15/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5938888","version":"2","preferredName":"Disease or Disorder Cytogenetic Analysis Method Text","preferredDefinition":"The free-text field used to describe the techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","longName":"DZ_CYTO_ANALY_METH_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A3B31F4-4A80-5600-E053-F662850A2A0D","latestVersionIndicator":"Yes","beginDate":"2017-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-11-09","modifiedBy":"MAESKEB","dateModified":"2018-11-09","changeNote":"Curated for Protocol 10026 11/9/18 versioned CDE in order to use VD that was not retired.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5938889","version":"2","preferredName":"Disease Present Text","preferredDefinition":"The free-text field used to describe the type of disease present.","longName":"DZ_PRES_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A39FB3F-C8EC-55E8-E053-F662850A3DBC","latestVersionIndicator":"Yes","beginDate":"2017-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-11-09","modifiedBy":"MAESKEB","dateModified":"2018-11-09","changeNote":"Curated for Protocol 10026. 11/9/18 versioned CDE in order to use VD that was not retired.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5946761","version":"1","preferredName":"Person Plasma Cell Myeloma Diagnosis Code Indicator","preferredDefinition":"A code Y (Yes) or N (No) response used to determine whether a person has a diagnosis of multiple myeloma.","longName":"PRSN_PLSMA_MYL_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5821BFC5-B1DB-353F-E053-F662850A1E4D","latestVersionIndicator":"Yes","beginDate":"2017-09-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-09-01","modifiedBy":"SOKKERL","dateModified":"2021-04-28","changeNote":"Curated for EC10076 bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5947598","version":"1","preferredName":"Cytogenetic Analysis Performed Indicator","preferredDefinition":"The indicator that describes if cytogenetics were tested.","longName":"CYTOGEN_ANALYS_PERF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5825538F-5936-05EE-E053-F662850AB6EE","latestVersionIndicator":"Yes","beginDate":"2017-09-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-09-01","modifiedBy":"SOKKERL","dateModified":"2017-09-05","changeNote":"Curated for Protocol 10075.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5961681","version":"1","preferredName":"Patient Hematopoietic and Lymphoid Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to hematologic malignancies and Lymphomas as outlined in the protocol.","longName":"HEM_LYPM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"58863BEC-C357-5DBD-E053-F662850A041E","latestVersionIndicator":"Yes","beginDate":"2017-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-06","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"11/8/18 TT released/PClark. 9/6/17 LS","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5961695","version":"1","preferredName":"Growth Factor Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the administration of substances made by the body that function to regulate cell division and cell survival as outlined in the protocol.","longName":"GF_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5886EE23-D6E9-3ABE-E053-F662850AC077","latestVersionIndicator":"Yes","beginDate":"2017-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"11/8/18 TT released/PClark. 9/6/17 LS","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5961700","version":"1","preferredName":"Patient Intolerance Oral Medication Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions that prevent a person from being allowed to participate in a clinical study that address the inability to absorb or metabolize pharmacological medication through the mouth as outlined in the protocol.","longName":"PT_INTOL_MEDS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5886A365-A196-1CAD-E053-F662850AEAEE","latestVersionIndicator":"Yes","beginDate":"2017-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeNote":"11/8/18 TT released/PClark. 9/6/17 LS","administrativeNotes":"2023.4.4 AQT added per ticket request CADSR0002268. ak 2022.11.3 AQT added for ticket request CADSR0001656. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5975361","version":"1","preferredName":"Progressive Disease Refuse Or Intolerance Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related progression of disease despite of therapy or refusal or tolerance as outlined in the protocol.","longName":"PR_DIS_REF_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"58AEAF01-E8B9-1D13-E053-F662850ACF8A","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-08","modifiedBy":"SOKKERL","dateModified":"2022-05-17","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.; 9/8/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5975426","version":"1","preferredName":"Pulmonary Function Test Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that assesses the diffusion capacity of the lungs for carbon monoxide adjusted for hemoglobin concentration as outlined in the protocol.","longName":"PF_DCL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"58AE0916-399A-77DA-E053-F662850AFE73","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-08","modifiedBy":"TAYLORT","dateModified":"2018-02-12","changeNote":"2/12/18 tt released/form usage.  9/8/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5976626","version":"1","preferredName":"Laboratory Procedure Cytogenetic Analysis Chimerism Outcome Percentage Value","preferredDefinition":"The value in percentage estimating the portion of chimeric cells present in a donor sample.","longName":"CHM_PTG_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"58EB2782-4296-378D-E053-F662850AA747","latestVersionIndicator":"Yes","beginDate":"2017-09-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-11","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark. 9/11/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5977098","version":"1","preferredName":"Disease or Disorder Myelodysplastic Syndrome IPPS Category","preferredDefinition":"A response for the score or categorization of myelodysplasia syndrome progression risk.","longName":"DZ_MDS_IPPS_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"58EEA2A3-B4B8-7D45-E053-F662850AEA9C","latestVersionIndicator":"Yes","beginDate":"2017-09-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-11","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 9/11/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5977904","version":"1","preferredName":"Treatment Cohort Study 10089 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10089 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10089_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"590511D1-4053-3265-E053-F662850A01CF","latestVersionIndicator":"Yes","beginDate":"2017-09-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-09-12","modifiedBy":"SOKKERL","dateModified":"2017-09-13","changeNote":"9/12/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5978091","version":"1","preferredName":"Randomized Clinical Trial Diagnosis Category","preferredDefinition":"The diagnosis in which the participants are assigned to separate groups that compare different treatments in a randomized trial.","longName":"RCT_DX_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59127196-8B4D-1BDE-E053-F662850A86CB","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-13","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 9/13/17 tt EC10089.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985282","version":"1","preferredName":"Treatment Cohort Study 10139 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10139 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10139_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A9672E6-5293-3A61-E053-F662850AE0AD","latestVersionIndicator":"Yes","beginDate":"2017-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-02","modifiedBy":"TAYLORT","dateModified":"2017-10-03","changeNote":"10/2/17 Curated for Protocol 10139 tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985293","version":"1","preferredName":"Intervention or Procedure Receive Prior To Randomization Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior receipt of any activity that produces an effect, or that is intended to alter the course of a disease in a patient prior to randomization, as outlined in the protocol.","longName":"INT_PROC_PRR_RNDM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AA53A38-8116-6133-E053-F662850AF61F","latestVersionIndicator":"Yes","beginDate":"2017-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-03","modifiedBy":"SOKKERL","dateModified":"2019-01-04","changeNote":"10/3/17 tt 10139.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985304","version":"1","preferredName":"Immunotherapy Receive Prior To Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to the receipt of therapy designed to induce changes in a patient's immune status in order to treat disease, preceding study entry, as outlined in the protocol.","longName":"ITX_PRR_ENR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AA5B8E4-C93B-79FA-E053-F662850A4A3D","latestVersionIndicator":"Yes","beginDate":"2017-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-03","modifiedBy":"KUMMEROA","dateModified":"2022-12-22","changeNote":"10/3/17 tt 10139.","administrativeNotes":"2022.12.22 AQT added per ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985308","version":"1","preferredName":"Palliative Radiation Therapy Receive Prior To Randomization Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to the receipt of any radiation treatment done with the intent to relieve symptoms and reduce the suffering caused by the cancer, preceding randomization, as outlined in the study protocol.","longName":"PAL_RT_PRR_RNDM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AA5B8E4-C965-79FA-E053-F662850A4A3D","latestVersionIndicator":"Yes","beginDate":"2017-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-03","modifiedBy":"SOKKERL","dateModified":"2017-10-05","changeNote":"10/3/17 tt 10139.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985320","version":"1","preferredName":"Personal Medical History Congenital Long QT Syndrome Or Corrected QT Interval Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical study for questions related to personal history of congenital long QT syndrome or corrected QT interval as outlined in the study protocol.","longName":"HX_CGL_LQTS_CQTI_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AA5B8E4-C993-79FA-E053-F662850A4A3D","latestVersionIndicator":"Yes","beginDate":"2017-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-03","modifiedBy":"SOKKERL","dateModified":"2021-09-22","changeNote":"10/3/17 tt 10139.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985332","version":"1","preferredName":"Disease or Disorder Personal Medical History Or Risk Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical study for questions related to personal history or risk factors for diseases/disorders, as outlined in the study protocol.","longName":"HX_DZ_RSKFTR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AA7DE6C-5775-15DA-E053-F662850AB76F","latestVersionIndicator":"Yes","beginDate":"2017-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-03","modifiedBy":"ZHWENDY","dateModified":"2022-08-04","changeNote":"10/3/17 tt 10139.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz 7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985529","version":"1","preferredName":"Medical History Malabsorption Syndrome Or Absorption Interference Other Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response as to whether a patient meets the eligibility criteria regarding personal history of malabsorption syndrome or other conditions that interfere with absorption, as outlined in the protocol.","longName":"HX_MALSYN_ABINF_OTH_DSR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AA891DE-10DE-2886-E053-F662850A11EA","latestVersionIndicator":"Yes","beginDate":"2017-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-03","modifiedBy":"SOKKERL","dateModified":"2022-02-24","changeNote":"10/3/17 tt 10139.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985545","version":"1","preferredName":"Treatment Cohort Study 9898 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9898 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9898_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AAC1010-5D6A-3D3E-E053-F662850A217A","latestVersionIndicator":"Yes","beginDate":"2017-10-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-03","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":"10/3/17 LS 9898 cohort study","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5987525","version":"1","preferredName":"Patient Whole Blood Transfusion Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for question addressing the intravenous administration of whole blood (blood that contains plasma and red blood cells) as outlined in the protocol.","longName":"PT_BLD_TRAN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ACFE4E9-A14E-020F-E053-F662850AC502","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-05","modifiedBy":"SOKKERL","dateModified":"2021-01-27","changeNote":"10/5/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5987541","version":"1","preferredName":"Patient Involvement Or Conduct Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person in the planning and/or conduct of the study as outlined in the protocol.","longName":"PT_INVLT_CON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ACDA829-7E86-10AF-E053-F662850A4F86","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-05","modifiedBy":"SOKKERL","dateModified":"2019-02-18","changeNote":"10/5/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989290","version":"1","preferredName":"Patient Previous Enrollment Same Trial Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which allow a person information related to a patient repeated to register on a research study to allow an individual to participate in a specific clinical trial as outlined in the protocol.","longName":"PT_ENRL_CLN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD1E1AE-938A-707E-E053-F662850A8127","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-05","modifiedBy":"TAYLORT","dateModified":"2017-10-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989303","version":"1","preferredName":"Spinal Cord Compression Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to acute and chronic conditions characterized by external mechanical compression of the spinal cord as outlined in the protocol.","longName":"SPN_CD_COMP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD1EF49-5140-7A1A-E053-F662850A745F","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-05","modifiedBy":"SOKKERL","dateModified":"2022-03-21","changeNote":"11/8/18 TT released/PClark.; 10/5/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6001038","version":"1","preferredName":"Clinical Study Protocol Disease or Disorder Assessment Timepoint Identifier","preferredDefinition":"One or more characters used to identify, name, or characterize the protocol point in time for the assessment of disease.","longName":"PROT_DZ_TPT_ID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B379B02-63A2-054A-E053-F662850A3496","latestVersionIndicator":"Yes","beginDate":"2017-10-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-10","modifiedBy":"TAYLORT","dateModified":"2017-10-17","changeNote":"10/17/17 tt approved and released/PC. 10/10/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6001809","version":"1","preferredName":"Laboratory Procedure Serum Immunofixation Electrophoresis Assessment Text","preferredDefinition":"Text field for assessments of the immunofixation-based laboratory test performed to detect and type monoclonal immunoglobulins present in a serum sample.","longName":"SIFE_ASSESS_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4BAF55-9B4B-6085-E053-F662850A400C","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-11","modifiedBy":"TAYLORT","dateModified":"2017-10-17","changeNote":"10/17/17 tt approved and released/PC. 10/11/17 tt created for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6001815","version":"1","preferredName":"Laboratory Procedure Urine Immunofixation Electrophoresis Assessment Text","preferredDefinition":"Text field for assessments of the immunofixation-based laboratory test performed to detect and type monoclonal immunoglobulins present in a urine sample.","longName":"UIFE_ASSESS_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4BAF55-9B6D-6085-E053-F662850A400C","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-11","modifiedBy":"TAYLORT","dateModified":"2017-10-17","changeNote":"10/17/17 tt approved and released/PC. 10/11/17 tt created for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6002247","version":"1","preferredName":"Diagnosis HIV Hepatitis B Or C Infection Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to the investigation, analysis, recognition and presence of HIV, hepatitis B or hepatitis C as outlined in the study protocol.","longName":"DX_HIV_HEPB_HEPC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B592C74-6936-50C7-E053-F662850AB016","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"GALITG","dateModified":"2021-08-11","changeNote":"10/12/17 tt 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6002251","version":"1","preferredName":"Pulmonary Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to any abnormal condition of the lungs, as outlined in the protocol.","longName":"PULM_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B59D2E9-57A0-5728-E053-F662850AA082","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"SOKKERL","dateModified":"2021-03-15","changeNote":"10/12/17 t 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6002255","version":"1","preferredName":"Personal Medical History Digestive System Perforation Or Abdominal Abscess Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the patient's history of gastrointestinal perforation or intra-abdominal abscesses, as outlined in the protocol.","longName":"MEDHX_GI_PERF_ABSCES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B592C74-695E-50C7-E053-F662850AB016","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"SOKKERL","dateModified":"2022-11-16","changeNote":"10/12/17 tt 9984.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6002713","version":"1","preferredName":"Performed Specimen Collection Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to assessments of samples for subsequent analysis, as outlined in the study protocol.","longName":"SPEC_ASSESS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5C0788-121A-6E69-E053-F662850A3416","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"SOKKERL","dateModified":"2024-01-24","changeNote":"2020-7-27 AQT added for protocol 10389. AK 10/12/17 tt 10130.","administrativeNotes":"2023.8.9 AQT added per ticket request CADSR0002718. ak 2023.4.5 AQT added per ticket request CADSR0002271. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6002899","version":"1","preferredName":"Palliative Radiation Therapy Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to the receipt of radiation therapy with the intent to relieve symptoms and reduce the suffering caused by the cancer, as outlined in the study protocol.","longName":"PALRT_RCV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5BF10C-8B7F-5DE3-E053-F662850A837D","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-12","modifiedBy":"ZHWENDY","dateModified":"2023-02-20","changeNote":"10/12/17 tt 10130.","administrativeNotes":"1/20/2023: Added AQT per cadsr0002069.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6005234","version":"1","preferredName":"Laboratory Procedure Serum Total Cholesterol Measurement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response indicating whether a patient meets the eligibility requirements regarding serum cholesterol levels as outlined in the protocol.","longName":"LAB_SER_TCHOL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD31FE6-EAEA-07E1-E053-F662850AE71C","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-18","modifiedBy":"TYRRELLM","dateModified":"2023-09-29","changeNote":"10/18/17 LS","administrativeNotes":"9.29.2023 Added AQT per request CADSR0002901_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6010393","version":"1","preferredName":"Patient Negation Crossover Study Reason Text","preferredDefinition":"Text field to explain why the patient did not crossover.","longName":"NEGN_CROVR_RSN_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C5F2350-6F07-2455-E053-F662850A5C0A","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-25","modifiedBy":"TAYLORT","dateModified":"2017-10-25","changeNote":"10/25/17 tt 9706.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6010404","version":"1","preferredName":"Laboratory Procedure Bone Marrow Outcome Text","preferredDefinition":"Text field for the results of a bone marrow lab procedure.","longName":"LAB_BMW_OUTCM_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C60EF73-D6CB-35CA-E053-F662850AE11A","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-25","modifiedBy":"TAYLORT","dateModified":"2017-10-25","changeNote":"10/25/17 tt 9706.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6010461","version":"1","preferredName":"Crossover Study Recurrent Disease Reason","preferredDefinition":"The explanation of crossover/relapse.","longName":"CROVR_RECDZ_RSN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C60ED4F-6486-352A-E053-F662850A82E8","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-25","modifiedBy":"TAYLORT","dateModified":"2017-10-25","changeNote":"10/25/17 tt 9706.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6010502","version":"1","preferredName":"Agent Administration Start Date To Bone Marrow Recurrent Disease Date Day Interval","preferredDefinition":"The number of days elapsed between the start date of agent administration to the return date of bone marrow disease.","longName":"AGT_BGN_DT_BMW_RECDZ_DT_INR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C5D7715-DB2D-19F6-E053-F662850A0A90","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-25","modifiedBy":"TAYLORT","dateModified":"2017-10-25","changeNote":"10/25/17 tt 9706.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6013128","version":"1","preferredName":"Disease or Disorder HER2 Positive Breast Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to biologic subset of breast carcinoma defined by high expression of HER2 by lack of expression of estrogen receptor (ER) therapy as outlined in the protocol.","longName":"DX_BC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5CC51A5A-BEFB-75E9-E053-F662850ABCD2","latestVersionIndicator":"Yes","beginDate":"2017-10-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-30","modifiedBy":"SOKKERL","dateModified":"2021-01-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6013132","version":"1","preferredName":"Gene Mutation Concurrent Known Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related a known gene mutation as outlined in the protocol.","longName":"GEN_MUT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5CC5FEC1-4E08-0BDB-E053-F662850A977F","latestVersionIndicator":"Yes","beginDate":"2017-10-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-30","modifiedBy":"GALITG","dateModified":"2022-01-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6025227","version":"1","preferredName":"Malignant Tissue Mesothelin Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to malignant tissue involving the encoded MSLN gene as outlined in the protocol.","longName":"MAL_TIS_MES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D69152C-0D0A-497C-E053-F662850ACAB9","latestVersionIndicator":"Yes","beginDate":"2017-11-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-07","modifiedBy":"SOKKERL","dateModified":"2020-03-18","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6028519","version":"1","preferredName":"Disease or Disorder Newly Diagnosed Central Pathology Review Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a person to participate in a clinical study, as outlined in the protocol, that are related to the histopathological confirmation of newly diagnosed disease by central pathology review.","longName":"DZDR_NEW_DX_CONF_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E0BC8E9-FB8E-5C52-E053-F662850AD412","latestVersionIndicator":"Yes","beginDate":"2017-11-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-15","modifiedBy":"TAYLORT","dateModified":"2018-02-06","changeNote":"11/15/17 tt 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6028524","version":"1","preferredName":"Mandatory Biospecimen Protocol Timepoint Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that address the patients consent to mandatory biospecimens at a protocol specific timepoint.","longName":"MAND_BIOS_PROT_TMPT_CONS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E09C4D4-949C-735D-E053-F662850A8CE0","latestVersionIndicator":"Yes","beginDate":"2017-11-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-15","modifiedBy":"SOKKERL","dateModified":"2021-12-21","changeNote":"11/15/17 tt 10056.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6029620","version":"1","preferredName":"Treatment Cohort Study 10107 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10107 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10107_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E327178-636A-460A-E053-F662850A18D7","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-17","modifiedBy":"SOKKERL","dateModified":"2017-11-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6032322","version":"1","preferredName":"Patient Proteinuria Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study related to abnormal amounts of protein in the urine as outlined in the study protocol.","longName":"PT_PRO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E9631A0-EA42-2DD6-E053-F662850A4E34","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-22","modifiedBy":"SOKKERL","dateModified":"2020-12-21","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033070","version":"1","preferredName":"Patient Endometrial Neoplasm Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to malignant endometrial as outlined in the protocol.","longName":"PT_ENDO_NEO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F1106AF-23E4-3D45-E053-F662850AF2D1","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-28","modifiedBy":"SOKKERL","dateModified":"2017-12-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033071","version":"1","preferredName":"Biospecimen Or Biopsy Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation, as outlined in the study protocol, that address biospecimen or biopsy requirements.","longName":"BIOSPN_BX_REQ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F1106AF-240B-3D45-E053-F662850AF2D1","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SOKKERL","dateModified":"2017-12-13","changeNote":"12/5/17 tt approved and release/MD. 11/28/17 tt/10100.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033121","version":"1","preferredName":"Clinical Study Protocol Patient Compliance Assessment Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow clinical trial participation for assessments related to the patient compliance of research activities as outlined in the study protocol.","longName":"PROT_PT_COMP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F10EC54-F5C0-4643-E053-F662850A4A6D","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"12/5/17 tt approved and release/MD. 11/28/17 tt/10100.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033170","version":"1","preferredName":"Laboratory Procedure Microsatellite Stability Assessment Mismatch Repair Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator related to the outcome of Microsatellite Stability Assessment Mismatch Repair as outlined in the protocol.","longName":"LP_MS_MMR_OC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F206AB1-5DF1-5FB2-E053-F662850A1178","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-29","modifiedBy":"SOKKERL","dateModified":"2017-12-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033174","version":"1","preferredName":"Medical History Heart Disease Risk Factor Concomitant Agent Use Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, that address the patients medical history regarding heart abnormalities, risk factors that increase the chance of developing heart disease/disorders, and the use of  concomitant medications.","longName":"HX_HRTDZ_RSKFAC_CONMED_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F20C8DC-C693-0CCE-E053-F662850A8500","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"ZHWENDY","dateModified":"2022-08-04","changeNote":"12/5/17 tt approved and release/MD. 11/29/17 tt/10100. 2020-7-21 AK  Added AQT for 10100 update.","administrativeNotes":"8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033178","version":"1","preferredName":"Disease or Disorder Clinical Significance Intervention Required Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, that address the clinical significance of any abnormal condition(s) of the body requiring intervention(s) to improve health or alter the course of disease, in order to prevent permanent impairment or damage.","longName":"DZDR_CLNSIG_INRVTN_REQ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F206A19-C648-5CCF-E053-F662850A377A","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"TAYLORT","dateModified":"2017-12-05","changeNote":"12/5/17 tt approved and release/MD. 11/29/17 tt/10100.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033184","version":"1","preferredName":"Personal Medical History Organ Allograft Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, that address the patient's medical background regarding the receipt of an organ graft transfer from a donor.","longName":"HX_ORGN_ALGFT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F206A19-C670-5CCF-E053-F662850A377A","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"TAYLORT","dateModified":"2017-12-05","changeNote":"12/5/17 tt approved and release/MD. 11/29/17 tt/10100.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033194","version":"1","preferredName":"Autoimmune Disease Intervention Required Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, that address the mandatory intervention(s) to improve health or to alter the course of autoimmune disease.","longName":"AUT_IMMUN_DZ_INRVTN_REQ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F22042F-3A9C-5F55-E053-F662850A7442","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"KUMMEROA","dateModified":"2023-11-03","changeNote":"2020-8-4 AQT added for P10398. AK 12/5/17 tt approved and release/MD. 11/29/17 tt/10100.","administrativeNotes":"2023.11.3 AQT added per ticket request CADSR0003032. ak 8/4/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6033229","version":"1","preferredName":"Disease or Disorder Malignant Neoplasm Histology Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation as outlined in the study protocol that address cancer histology and prior treatment(s) for disease.","longName":"MAL_NEOP_HIST_PRR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F2320B9-AD02-6AB5-E053-F662850A7FDF","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"SOKKERL","dateModified":"2019-01-02","changeNote":"12/5/17 tt approved and release/MD. 11/29/17 tt/10170.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6034118","version":"1","preferredName":"Next Generation Sequencing Report Molecular Tumor Board Review Verification Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation as outlined in the study protocol that address the review and verification of the NGS sequencing report by a molecular tumor board.","longName":"NGS_REP_MOL_TBR_VERFN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F246768-2B2F-60FE-E053-F662850A9F1E","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"SOKKERL","dateModified":"2019-01-02","changeNote":"12/5/17 tt approved and release/MD. 11/29/17 tt/10170.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6034134","version":"1","preferredName":"Radiation Therapy Adverse Event Recovery Prior Study Agent Initiation Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, that address the receipt of radiation therapy and the recovery from adverse events prior to the start of investigational therapy.","longName":"RTX_AE_RECVY_PRR_PROT_AGT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F23EF63-E5FC-0332-E053-F662850A0838","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"SOKKERL","dateModified":"2023-01-27","changeNote":"12/5/17 tt approved and release/MD. 11/29/17 tt/10107","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6034295","version":"1","preferredName":"Patient Minor Surgical Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to minor surgical interventions.","longName":"MIN_SUR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F25D778-9B20-7DB0-E053-F662850A1255","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-29","modifiedBy":"SOKKERL","dateModified":"2021-08-02","changeNote":"12/5/17 tt approved and release/MD. 11/29/17 tt/10170.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6034959","version":"1","preferredName":"Disease Abscopal Response Text","preferredDefinition":"The free text field that describes the abscopal effect on disease after radiotherapy.","longName":"DZ_ABSCL_RSPN_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F341FCF-F255-758B-E053-F662850A9B0E","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-30","modifiedBy":"TAYLORT","dateModified":"2017-11-30","changeNote":"11/30/17 tt/10021; approved/released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035030","version":"1","preferredName":"Patient Percutaneous Endoscopic Gastrostomy Or Total Parenteral Nutrition Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions which are necessary to allow clinical trial participation, as outlined in the study protocol, to address a feeding tube placed through the abdominal wall into the stomach or total parenteral nutrition formulated for intravenous administration in patients who cannot eat or cannot get enough nutrients from the foods they eat.","longName":"PEG_TPN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F3333AE-B6CB-79BB-E053-F662850A7CD2","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-30","modifiedBy":"SOKKERL","dateModified":"2018-08-14","changeNote":"12/5/17 tt approved and release/MD. 11/30/17 tt/10170.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035046","version":"1","preferredName":"Intervention or Procedure Negation Discontinue Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation as outlined in the study protocol to address any activity that produces an effect or intended to alter the course of disease that cannot be stopped.","longName":"INTVN_PROC_NEG_DXD_OCRR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F35D590-D0BE-6627-E053-F662850A7ECE","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-30","modifiedBy":"SOKKERL","dateModified":"2023-05-15","changeNote":"12/5/17 tt approved and release/MD. 11/30/17 tt/10170.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035051","version":"1","preferredName":"Negation Surgical Procedure Decision Date Time","preferredDefinition":"Date and time decision was made not to attempt surgery.","longName":"NO_SURG_DEC_DT_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F344D29-2191-7542-E053-F662850A5472","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-30","modifiedBy":"CLOHNES","dateModified":"2023-11-07","changeNote":null,"administrativeNotes":"11/7/23 Added AQT and alt OID for CCTG for ticket number CADSR0003018 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035061","version":"1","preferredName":"Agent Administration Receive During Study Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, to address the receipt of medical products or other agents during the study.","longName":"AGT_ADM_RCV_DUR_STDY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F34F484-17CF-77A2-E053-F662850AC643","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-30","modifiedBy":"TAYLORT","dateModified":"2017-12-05","changeNote":"12/5/17 tt approved and release/MD. 11/30/17 tt/10170.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035064","version":"1","preferredName":"Operative Report Date Time","preferredDefinition":"Date and time of operative report.","longName":"OR_REP_DT_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F344D29-21B2-7542-E053-F662850A5472","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-30","modifiedBy":"SOKKERL","dateModified":"2017-11-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035070","version":"1","preferredName":"Agent Administration Substrate Sensitivity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, to address the administration of agent(s) sensitive to any chemical that can be modified or consumed during a chemical reaction or biological process.","longName":"AGT_ADM_SUBTRT_SNTVTY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F34F484-17FD-77A2-E053-F662850AC643","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-30","modifiedBy":"TAYLORT","dateModified":"2017-12-05","changeNote":"12/5/17 tt approved and release/MD. 11/30/17 tt/10170","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035073","version":"1","preferredName":"Pathology Specimen Report Date Time","preferredDefinition":"Date and time of pathology report.","longName":"PATH_SPEC REP_DT_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F344D29-21F5-7542-E053-F662850A5472","latestVersionIndicator":"Yes","beginDate":"2017-11-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-30","modifiedBy":"SOKKERL","dateModified":"2017-11-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035173","version":"1","preferredName":"Laboratory Procedure EGFR Gene Mutation Abnormality Performed Indicator","preferredDefinition":"Indicator to signify whether or not a lab test for an EGFR gene mutation was performed.","longName":"LAB_EGFR_MUTAB_PERF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F481F35-5C69-0795-E053-F662850A723E","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"TAYLORT","dateModified":"2017-12-04","changeNote":"12/4/17 tt approved/released/PC; restored Short Name. 12/1/17 tt/9898.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035955","version":"1","preferredName":"Treatment Cohort Study 10080 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10080 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10080_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F8598C8-8B81-63F3-E053-F662850A48C6","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-04","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6041944","version":"1","preferredName":"Treatment Cohort Study 10100 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10100 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10100_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"60177EC0-2165-6278-E053-F662850ADD6F","latestVersionIndicator":"Yes","beginDate":"2017-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-11","modifiedBy":"SOKKERL","dateModified":"2017-12-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6042296","version":"1","preferredName":"Histologic Advanced Solid Tumor CCNE1 Amplification Refractory Disease Or No Standard Therapy Study Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study pertaining to histologic advanced solid tumor, CCNE1 gene amplification, refractory disease, or no standard of care therapy, as outlined in the protocol.","longName":"HIST_ADTMR_CCAMP_REFDZ_NO_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"603F8D1F-4EF6-6612-E053-F662850A5401","latestVersionIndicator":"Yes","beginDate":"2017-12-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-13","modifiedBy":"SOKKERL","dateModified":"2018-04-03","changeNote":"12/18/17 tt/approved and released. 12/13/17 tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6042302","version":"1","preferredName":"Molecular Genetic Variation Confirmation Method Prior To Treatment Begin Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial pertaining to method(s) that confirm genetic abnormalities prior to the start of treatment, as outlined in the study protocol.","longName":"MGV_CONF_PRR_TX_BEG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"603F8D1F-4F1D-6612-E053-F662850A5401","latestVersionIndicator":"Yes","beginDate":"2017-12-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-13","modifiedBy":"TAYLORT","dateModified":"2017-12-18","changeNote":"12/18/17 tt/approved and released. 12/13/17 tt/10136.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6042415","version":"1","preferredName":"Patient Specimen Availability Or Disease Biopsy Ability And Pretreatment Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the availability of specimens or the ability to biopsy disease and the patients consent to pre-treatment biopsies.","longName":"SPE_AV_BXABL_DZ_CONS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"604DA8A7-3B9E-03F5-E053-F662850A6994","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-14","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeNote":"12/18/17 tt/approved and released. 12/14/17 tt/10136.","administrativeNotes":"2022.12.21 AQT added per ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6042525","version":"1","preferredName":"Investigational New Drug Known Hypersensitivity Or Medical Contraindication Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to known hypersensitivities or contraindications to the new drug or biological drug that is used in a clinical investigation.","longName":"IND_KNO_HYPR_CONTRA_CODE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"604FF1C5-CF21-5AD9-E053-F662850AA985","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-14","modifiedBy":"TAYLORT","dateModified":"2017-12-18","changeNote":"12/18/17 tt/approved and released. 12/14/17 tt/10136.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6042541","version":"1","preferredName":"Serious Disease or Disorder Investigational New Drug Receive Impairment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to any serious abnormal conditions of the body or mind that would impair the receipt of study drug(s).","longName":"DZDR_IMP_IND_RECV_CODE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6050FBE0-2D1A-5180-E053-F662850AED18","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-14","modifiedBy":"SOKKERL","dateModified":"2018-07-17","changeNote":"12/18/17 tt/approved and released. 12/14/17 tt/10136.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6042878","version":"1","preferredName":"Anatomic Site Symptomatic And Uncontrolled Metastasis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to symptomatic and uncontrolled metastasis of named locations within the body.","longName":"SITE_SYM_UNC_MET_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"60517D73-D7D5-346B-E053-F662850AD2F9","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-14","modifiedBy":"SOKKERL","dateModified":"2022-05-23","changeNote":"12/18/17 tt/approved and released. 12/14/17 tt/10136.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6042890","version":"1","preferredName":"Invasive Carcinoma Negation Molecular Genetic Variation Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the presence of invasive cancer that does not harbor genetic abnormalities.","longName":"INV_CA_NEG_MGV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6051BDCA-F2E4-109B-E053-F662850A96A8","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-14","modifiedBy":"TAYLORT","dateModified":"2017-12-18","changeNote":"12/18/17 tt/approved and released. 12/14/17 tt/10136.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6043065","version":"1","preferredName":"Patient Mismatch Repair Status","preferredDefinition":"The text that describes the condition or state of MMR.","longName":"PT_MMR_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6061FFA3-46EE-62FF-E053-F662850A39E8","latestVersionIndicator":"Yes","beginDate":"2017-12-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-15","modifiedBy":"SOKKERL","dateModified":"2018-01-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6043072","version":"1","preferredName":"Treatment Cohort Study 10104 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10104 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10104_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6063F38B-33E4-103E-E053-F662850AFB4F","latestVersionIndicator":"Yes","beginDate":"2017-12-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-15","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6045204","version":"1","preferredName":"Therapeutic Procedure Disease or Disorder Status","preferredDefinition":"The condition or state of disease with regards to treatment.","longName":"TX_PROC_DZ_DIS_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"616B0D81-9F58-611C-E053-F662850ABF58","latestVersionIndicator":"Yes","beginDate":"2017-12-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-28","modifiedBy":"SOKKERL","dateModified":"2017-12-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6046558","version":"1","preferredName":"Treatment Cohort Study 10126 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10126 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10126_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"61E2D1D7-12F2-5593-E053-F662850AFB31","latestVersionIndicator":"Yes","beginDate":"2018-01-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-03","modifiedBy":"TAYLORT","dateModified":"2018-01-03","changeNote":"1/3/18 tt/10126; approved & released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6047488","version":"1","preferredName":"Newly Diagnosed Or Recurrent Refractory Disease Receive Prior Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol that address a new diagnosed or relapsed/refractory disease who have received prior therapeutic treatments.","longName":"NEW_DZ_PR_THRPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6208E0E7-AE99-11DA-E053-F662850A52F9","latestVersionIndicator":"Yes","beginDate":"2018-01-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-01-05","modifiedBy":"SOKKERL","dateModified":"2022-11-21","changeNote":"11/8/18 TT released/PClark.; 1/5/18 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6047738","version":"1.1","preferredName":"Treatment Cohort Study 10166 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10166 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10166_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"700ADB33-33BE-0310-E053-F662850AEEF2","latestVersionIndicator":"Yes","beginDate":"2018-01-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-02","modifiedBy":"SOKKERL","dateModified":"2018-07-02","changeNote":"version CDE due to version VD. 7/1/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6049956","version":"1","preferredName":"KRAS Mutation Analysis Absent Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine eligibility for clinical trial participation regarding the absence of KRAS gene mutation(s).","longName":"KRAS_MUTN_ABSENT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6247595B-08C0-1785-E053-F662850ABFE1","latestVersionIndicator":"Yes","beginDate":"2018-01-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-08","modifiedBy":"TAYLORT","dateModified":"2018-01-10","changeNote":"1/10/18 approval received and released. 1/8/18 tt/10166.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6050019","version":"1","preferredName":"Biomarker Genetic Alteration Sensitivity Diagnosis Disease Progression Or Approved Treatment Intolerance Occurrence Code Indicator","preferredDefinition":"The coded response to questions regarding the diagnosis of sensitizing genetic alterations and whether the patient has experienced the worsening of disease over time or an intolerance to approved therapeutic procedures.","longName":"GENTC_ALTN_SNVY_DZPRO_TX_INTLC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6247545E-AC3B-5205-E053-F662850ADE02","latestVersionIndicator":"Yes","beginDate":"2018-01-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-08","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 1/10/18 approval received and released. 1/8/18 tt/10166.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6050028","version":"1","preferredName":"Therapeutic Procedure Disease Response Duration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions which are necessary to allow clinical trial participation that address the period of time during which pathologic and/or clinical changes resulting from treatment continued, as outlined in the study protocol.","longName":"TX_DZ_RESP_DUR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"624A64B7-9F01-3AD4-E053-F662850A06D9","latestVersionIndicator":"Yes","beginDate":"2018-01-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-08","modifiedBy":"SOKKERL","dateModified":"2019-04-08","changeNote":"1/10/18 approval received and released. 1/8/18 tt/10166.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6050105","version":"1","preferredName":"Patient Uncontrolled Effusion Or Ascites Present Drainage Procedure Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions which are necessary to allow clinical trial participation that address the presence of uncontrolled abnormal fluids in body cavities (e.g. pleural, pericardial, or peritoneal) and drainage procedure requirements.","longName":"6050104v1.0:3298541v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"624A497E-D85A-3943-E053-F662850A9CBE","latestVersionIndicator":"Yes","beginDate":"2018-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-09","modifiedBy":"KUMMEROA","dateModified":"2022-07-25","changeNote":"1/10/18 approval received and released. 1/9/18 tt/10166.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6051215","version":"1","preferredName":"Mesothelin Positive Outcome Central Laboratory Determination Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow clinical trial participation, as outlined in the study protocol, to address the establishment of mesothelin expression by a laboratory delivering the data for a particular study.","longName":"MSLN_POS_LAB_DTRMN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"629A687D-DB62-5307-E053-F662850A39A1","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-12","modifiedBy":"SOKKERL","dateModified":"2019-10-28","changeNote":"2/1/18 approved/released.  1/12/18 tt/10150.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6051364","version":"1","preferredName":"Palliative Radiation Treatment Timepoint Asymptomatic Duration Without Steroid Maintenance Therapy Trial Eligibility Criteria Code Ind","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the timepoint of palliative radiation therapy and the period of time during which the patient is asymptomatic without maintenance steroid therapy.","longName":"PAL_RT_ASYM_WO_MAIN_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"629B0128-FA74-7171-E053-F662850AE986","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-12","modifiedBy":"TAYLORT","dateModified":"2018-02-01","changeNote":"2/1/18 approved/released. 1/12/18 tt/10150.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6051375","version":"1","preferredName":"Personal Medical History Thrombosis Or Vascular Hemorrhagic Disorder Prior To Treatment Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow clinical trial participation that address the patient's medical background of thrombosis or vascular hemorrhagic disorders prior to the administration of therapeutic agents.","longName":"HX_THRMB_VHMRG_PRR_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"629B0128-FAAD-7171-E053-F662850AE986","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-12","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"2/1/18 approved/released. 1/16/18 tt/10150. remove special character 03-24-2020 DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6051443","version":"1","preferredName":"Platinum Compound Resistance Process Prior Weekly Therapeutic Procedure Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the prior weekly receipt of therapeutic agents in the platinum resistance process.","longName":"PLAT_RES_PRR_WKLY_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"62E7CC3C-96FD-3E37-E053-F662850A1DED","latestVersionIndicator":"Yes","beginDate":"2018-01-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-16","modifiedBy":"TAYLORT","dateModified":"2018-02-01","changeNote":"2/1/18 approved/released. 1/16/18 tt/10150.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6053521","version":"1","preferredName":"Treatment Cohort Study 10147 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10147 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10147_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6324A481-8319-774A-E053-F662850A8BA4","latestVersionIndicator":"Yes","beginDate":"2018-01-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-01-19","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 1/19/18 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6059620","version":"1","preferredName":"Cancer Diagnosis Progressive Disease Post Standard Treatment Or No Standard Treatment Exists Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the patient's diagnosis of cancer that is increasing in scope or severity after standard of care treatment for the disease, or for which no standard of care treatment for the disease exists.","longName":"CA_DX_PROG_DZ_STD_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"642BA3D2-18C0-66F5-E053-F662850A598C","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-01","modifiedBy":"SOKKERL","dateModified":"2023-01-19","changeNote":"2/1/18 LS/TT remove special character 03-24-2020 DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6059630","version":"1","preferredName":"Biopsy Confirmation Mutation Abnormality Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the patient's biopsy confirmation of genetic mutations.","longName":"BX_CONF_MUT_ABN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"642C4633-B398-5AF6-E053-F662850A32AE","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-01","modifiedBy":"DWARZEL","dateModified":"2020-03-24","changeNote":"2/1/18 LS/TT remove special character 3-24-2020 dw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6059636","version":"1","preferredName":"Mutation Abnormality Prior Central Laboratory Identification Certification Verification Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator for questions to determine eligibility for clinical trial participation related to the previous identification of genetic mutations by certified, verified, central labs.","longName":"MUT_ABN_CEN_LAB_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"642C6FCF-6CA2-6530-E053-F662850A26A6","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-01","modifiedBy":"SOKKERL","dateModified":"2018-02-06","changeNote":"2/1/18 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6059838","version":"1","preferredName":"Disease or Disorder Definitive Treatment Receive Stable Disease Clinical Evidence Duration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the receipt of a treatment for a disorder that has been chosen as the best one for the patient after all other choices have been considered, with evidence of clinically stable disease for the period of time outlined in the study protocol.","longName":"DZ_DEFIN_TX_STBL_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"642DC86C-0CBF-61B1-E053-F662850A6DF6","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-01","modifiedBy":"SOKKERL","dateModified":"2018-02-06","changeNote":"2/1/18 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6059864","version":"1","preferredName":"Patient Diagnosis Recurrent Glioma Or Transformation Glioma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the patient's diagnosis of recurrent glioma or transformation.","longName":"PT_DX_REC_GIL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"642BDBB1-BE70-5061-E053-F662850A5184","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-01","modifiedBy":"SOKKERL","dateModified":"2023-07-28","changeNote":"2/1/18 LS/TT remove special character 03-24-2020 DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6059869","version":"1","preferredName":"Malignant Neoplasm Pretreatment Imaging Procedure Disease Enhance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the enhancement of disease for the malignant neoplasm on pre-treatment imaging procedure(s) as outlined in the study protocol.","longName":"MALG_NEO_PRETX_IMG_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"642DC86C-0CF7-61B1-E053-F662850A6DF6","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-01","modifiedBy":"SOKKERL","dateModified":"2018-02-06","changeNote":"2/1/18 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6059875","version":"1","preferredName":"Patient Diagnosis Malignant Neoplasm And Progressive Disease Post Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the diagnosis of cancer and progressive disease after treatment as outlined in the study protocol.","longName":"PT_MALG_NEO_PROG_DZ_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"642C40F3-1BA7-5E19-E053-F662850A3739","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-01","modifiedBy":"SOKKERL","dateModified":"2023-05-30","changeNote":"2/1/18 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6060060","version":"1","preferredName":"Patient Uncontrolled Seizure Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to uncontrolled seizure as outlined in the protocol.","longName":"PT_UNCON_SZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6478AAF6-E1E4-1502-E053-F662850A38B1","latestVersionIndicator":"Yes","beginDate":"2018-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-05","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6060082","version":"1","preferredName":"AML Diagnosis Post DNMT Inhibitor Therapy Initiation Disease Phase Study Chair Agreement Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the diagnosis of AML after DNMTi therapy and study chair agreement to the phase of disease when DNMTi therapy was initiated, as outlined in the study protocol.","longName":"AML_DNMTI_TX_INATN_STCHR_AGR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"647BB9FD-62DD-0A7A-E053-F662850A91F4","latestVersionIndicator":"Yes","beginDate":"2018-02-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-05","modifiedBy":"TAYLORT","dateModified":"2018-02-05","changeNote":"2/5/18 TT/10009","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6060298","version":"1","preferredName":"Disease or Disorder IDH Gene Family Mutation Category","preferredDefinition":"A response for the disease group of change in the nucleotide sequence of the IDH1/IDH2 gene.","longName":"IDH_DZ_GRP_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"647D7FFF-398E-5751-E053-F662850A189F","latestVersionIndicator":"Yes","beginDate":"2018-02-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-05","modifiedBy":"TAYLORT","dateModified":"2018-02-08","changeNote":"2/5/18 tt/10129.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6060387","version":"1","preferredName":"Prior Therapeutic Procedure Isocitrate Dehydrogenase Inhibitor Status","preferredDefinition":"A response for the state of the prior administration of any agent that inhibits isocitrate dehydrogenase (IDH).","longName":"PRR_IDH_IBTR_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"647EA833-A9E0-4028-E053-F662850AB06C","latestVersionIndicator":"Yes","beginDate":"2018-02-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-05","modifiedBy":"TAYLORT","dateModified":"2018-02-08","changeNote":"2/5/18 tt/10129.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6064157","version":"1","preferredName":"Ascites Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that ascites is present as outlined in the protocol.","longName":"ASCT_PRES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"64C8641F-CED9-538E-E053-F662850A419B","latestVersionIndicator":"Yes","beginDate":"2018-02-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-09","modifiedBy":"SOKKERL","dateModified":"2021-07-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6064169","version":"1","preferredName":"Schirmer Test Outcome Value","preferredDefinition":"A test used to determine the amount of tears collected on a filter paper strip in 5 minutes, measured in millimeters.","longName":"SCHM_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"64C95D9D-6A63-0D3D-E053-F662850A99FE","latestVersionIndicator":"Yes","beginDate":"2018-02-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-09","modifiedBy":"TAYLORT","dateModified":"2018-02-09","changeNote":"2/9/18 tt/10107.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6065885","version":"1","preferredName":"Dose Expansion Cohort Histologic Diagnosis Confirm Relapse Or Refractory Disease Treatment Clinical Evaluation Result Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine phase I clinical trial participation for questions related to the histologic confirmation of relapsed disease or disease that resists treatment, and the outcome of clinical evaluations for treatment methods as outlined in the study protocol.","longName":"DEC_HIST_CONF_DZ_TX_EVAL_RSLT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"64CAD3B6-AABB-2731-E053-F662850AC4AA","latestVersionIndicator":"Yes","beginDate":"2018-02-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-09","modifiedBy":"SOKKERL","dateModified":"2022-03-24","changeNote":"2/9/18 tt/10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6066758","version":"1","preferredName":"Disease Transformation Histologic Confirmation Clinical Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the histologic confirmation of transforming disease, as outlined in the study protocol.","longName":"DZ_TFMN_HIST_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"64CD4FD9-A507-77D1-E053-F662850A4336","latestVersionIndicator":"Yes","beginDate":"2018-02-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-09","modifiedBy":"SOKKERL","dateModified":"2022-03-24","changeNote":"2/9/18 tt/10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6066764","version":"1","preferredName":"Patient Measurable Disease Lugano Classification Oncology Response Criteria Clinical Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to measurable disease according to the 2014 Lugano Classification Criteria.","longName":"MEADZ_LUGANO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"64CABE9A-D007-4501-E053-F662850A6F4B","latestVersionIndicator":"Yes","beginDate":"2018-02-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-09","modifiedBy":"TAYLORT","dateModified":"2018-02-22","changeNote":"2/9/18 tt/10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6066774","version":"1","preferredName":"Patient Receive Therapeutic Procedure And Autologous Stem Cell Transplantation Assessment Clinical Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the administration of therapeutic agents and the assessment of autologous stem cell transplantation, as outlined in the study protocol.","longName":"TX_AND_ALOG_STEM_CELL_TRANS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"64CC59FA-DEFF-6D3C-E053-F662850A7E69","latestVersionIndicator":"Yes","beginDate":"2018-02-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-09","modifiedBy":"TAYLORT","dateModified":"2018-02-22","changeNote":"2/9/18 tt/10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6066795","version":"1","preferredName":"Adequate Specimen Submitted Procedure Timepoint Or Patient Biopsy Immunohistochemical Genetic Testing Agreement Consent Trial Eligibility Criteria Code","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address the submission of adequate specimens, procedure timepoints, or the patients consent to the removal of tissue samples for immunohistochemical assessment and genetic testing.","longName":"SPEC_SUB_TMPT_PT_BX_CON","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6502CE86-1822-3B82-E053-F662850AE193","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-12","modifiedBy":"TAYLORT","dateModified":"2019-03-18","changeNote":"2/12/18 tt/10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6067862","version":"1","preferredName":"Disease Measurable And Biopsy Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to disease that is measurable and patients consent to a biopsy procedure as outlined in the protocol.","longName":"DZ_MEAS_BX_CON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65073354-0200-7BCE-E053-F662850A3C77","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-12","modifiedBy":"TSESU","dateModified":"2023-02-06","changeNote":"11/8/18 TT released/PClark.; 2/12/18 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6072648","version":"1","preferredName":"Lesion Site Injection Status","preferredDefinition":"The lesion status of the site injection.","longName":"LES_SIT_INJ_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6546AF6E-A134-1FF0-E053-F662850A6B02","latestVersionIndicator":"Yes","beginDate":"2018-02-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-15","modifiedBy":"SOKKERL","dateModified":"2018-02-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6072762","version":"1","preferredName":"Treatment Cohort Study 10131 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10131 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10131_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6557602D-7256-45E8-E053-F662850AD349","latestVersionIndicator":"Yes","beginDate":"2018-02-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-16","modifiedBy":"SOKKERL","dateModified":"2018-02-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077822","version":"1","preferredName":"Specimen Submission Correlative Study Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to submission of specimens for a correlative study as outlined in the protocol.","longName":"SPEC_SUB_CORR_STDY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65AA96B2-C882-30A5-E053-F662850A42C1","latestVersionIndicator":"Yes","beginDate":"2018-02-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-20","modifiedBy":"SOKKERL","dateModified":"2020-09-16","changeNote":"11/8/18 TT released/PClark.; 2/20/2018 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077825","version":"1","preferredName":"Treatment Cohort Study 10106 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10106 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10106_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65AB1A55-0D24-5706-E053-F662850AC7A3","latestVersionIndicator":"Yes","beginDate":"2018-02-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-20","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077832","version":"1","preferredName":"Treatment Cohort Study 10130 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10130 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10130_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65AC687D-31EC-7B00-E053-F662850AE107","latestVersionIndicator":"Yes","beginDate":"2018-02-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-20","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077839","version":"1","preferredName":"Treatment Cohort Study EC10130 Code","preferredDefinition":"The code that represents the information pertaining to protocol EC10130 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_EC10130_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65AC9197-145E-7552-E053-F662850A7E6B","latestVersionIndicator":"Yes","beginDate":"2018-02-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-20","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077856","version":"1","preferredName":"Palliative Radiation Therapy Complete Prior To Therapeutic Procedure Initiation Clinical Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address the completion of palliative radiation therapy before the administration of therapeutic agents, as outlined in the study protocol.","longName":"PALRT_COMPL_PRR_TX_INATN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65BA2CBF-D6EC-5B7E-E053-F662850A5160","latestVersionIndicator":"Yes","beginDate":"2018-02-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-21","modifiedBy":"SOKKERL","dateModified":"2021-07-26","changeNote":"11/8/18 TT released/PClark.; 2/21/18 tt/9673.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077864","version":"1","preferredName":"Patient Childbearing Potential Pregnancy Avoidance And Unintended Pregnancy Risk Factor Advising Discussion Documentation Signed Informed Consent Code Ind","preferredDefinition":"A coded response that indicates whether the female patient with the potential to become pregnant signed the informed consent documenting the discussion and advisement of pregnancy avoidance, and risk factors for unintended pregnancies.","longName":"CHILDPOT_RFAC_DSCN_SIG_CON","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65BB7A39-5FEF-6AB7-E053-F662850A3A10","latestVersionIndicator":"Yes","beginDate":"2018-02-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-21","modifiedBy":"TAYLORT","dateModified":"2018-11-09","changeNote":"11/9/18 TT released/PClark. 2/21/18 tt/9673.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077876","version":"1","preferredName":"Patient Childbearing Potential Contraception Requirement Agreement And Negation Breast Feeding Clinical Trial Eligibility Criteria Code Ind","preferredDefinition":"A coded indicator as to whether a female patient with the potential to become pregnant agrees to the contraception requirements outlined in the study protocol, and the negation of breast feeding in order to determine clinical trial participation.","longName":"CHILDPOT_CTCPT_AGRE_NOT_BRFD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65BCE18B-929C-0F85-E053-F662850AAD65","latestVersionIndicator":"Yes","beginDate":"2018-02-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-21","modifiedBy":"KUMMEROA","dateModified":"2021-04-02","changeNote":"11/9/18 TT released/PClark. 2/21/18 tt/9673.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077898","version":"1","preferredName":"Medical History CHF Cardiovascular Disease Cardiac Toxicity Drug Exposure Risk Factor Procedure Agreement Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the personal medical history of congestive heart failure, risk factors due to cardiovascular disease, exposure to cardiotoxic drugs, and the patients agreement to interventions or procedures outlined in the protocol.","longName":"CHF_CVD_CTOX_RISK_PROC_AGRMT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65BDEA4A-E103-0B16-E053-F662850A66D9","latestVersionIndicator":"Yes","beginDate":"2018-02-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-21","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 2/21/18 tt/9673.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6077946","version":"1","preferredName":"Patient Prior Taxane Compound Administration Sensitivity Maintain And Further Benefit Investigator Decision Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the previous administration of a type of drug that blocks cell growth, with maintained taxane sensitivity by patient, and further benefit from the administration of a taxane compound in the opinion of the investigator.","longName":"PR_TAXCOMP_STVY_MAIN_FRTH_BEN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65C11227-9029-1FD1-E053-F662850AD81B","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-22","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.; 2/22/18 tt/10131.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6085072","version":"1","preferredName":"Patient Major Surgical Procedure Prior To Treatment And Negation Complete Recovery Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the administration of therapeutic agents prior to major surgery and the negation of a complete healing process from major surgery.","longName":"MAJ_SUR_PRR_TO_TX_NEG_RECOV","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66239F67-92B4-09E2-E053-F662850A901E","latestVersionIndicator":"Yes","beginDate":"2018-02-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-26","modifiedBy":"SOKKERL","dateModified":"2023-02-09","changeNote":"2/26/18 tt/10066.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6091428","version":"1","preferredName":"Biospecimen Relevance Processing Type","preferredDefinition":"The type of relevant process for preparing a sample or portion of a sample for storage, preservation, or further analysis.","longName":"SPCMN_RLVN_PRSC_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6635D05F-DAC2-3212-E053-F662850A2FC2","latestVersionIndicator":"Yes","beginDate":"2018-02-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-27","modifiedBy":"TAYLORT","dateModified":"2018-02-27","changeNote":"2/27/18 tt/specimen tracking.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6091664","version":"1","preferredName":"Treatment Cohort Study 10150 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10150 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10150_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6636E93E-462A-4793-E053-F662850AAD33","latestVersionIndicator":"Yes","beginDate":"2018-02-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-27","modifiedBy":"SOKKERL","dateModified":"2018-09-13","changeNote":"2/27/28 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6098727","version":"1","preferredName":"Radiation Therapy Treatment Regimen Clinical Trial Eligibility Indicator","preferredDefinition":"The yes or no response indicating whether or not a patient will receive radiation therapy as the treatment regimen that meet the criteria for participation in a clinical trial.","longName":"RT_TX_REG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66606632-70E1-1B53-E053-F662850A811D","latestVersionIndicator":"Yes","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"SOKKERL","dateModified":"2019-08-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6101658","version":"1","preferredName":"Malignant Neoplasm Visceral Metastatic Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to metastatic malignant neoplasm affecting the internal organs as outlined in the protocol.","longName":"MAL_NEO_VIS_MET_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66ABD252-A4FC-4356-E053-F662850A287C","latestVersionIndicator":"Yes","beginDate":"2018-03-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-05","modifiedBy":"SOKKERL","dateModified":"2021-05-17","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6101670","version":"1","preferredName":"Patient Prior External Beam Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that meets the criteria to participate in a clinical trial with regards to  prior administration of external beam radiation therapy.","longName":"PAT_PR_EXTRN_RT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66ACA5C2-D39B-32DA-E053-F662850A4B65","latestVersionIndicator":"Yes","beginDate":"2018-03-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-05","modifiedBy":"SOKKERL","dateModified":"2021-04-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6101703","version":"1","preferredName":"Laboratory Procedure Testosterone Level Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/exception indicator whether a laboratory procedure has been performed that involves testing a sample of castrate levels of serum testosterone.","longName":"LP_TEST_LEV_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66AE6839-F688-3D5E-E053-F662850AEA0E","latestVersionIndicator":"Yes","beginDate":"2018-03-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-05","modifiedBy":"SOKKERL","dateModified":"2020-10-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6101732","version":"1","preferredName":"Patient Luteinizing Hormone-Releasing Hormone Agonist Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to luteinizing hormone releasing hormone agonist/antagonist as outlined in the protocol.","longName":"PAT_LUT_HORM_REL_AGNT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66ADA5FF-9811-2747-E053-F662850AE936","latestVersionIndicator":"Yes","beginDate":"2018-03-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-05","modifiedBy":"SOKKERL","dateModified":"2019-08-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6101760","version":"1","preferredName":"Prostate Small Cell Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to small cell carcinoma of the prostate as outlined in the protocol.","longName":"PROST_SMAL_CEL_CAR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66AE5487-6738-6CD8-E053-F662850A662C","latestVersionIndicator":"Yes","beginDate":"2018-03-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-05","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6102866","version":"1","preferredName":"Treatment Cohort Study 10096 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10096 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10096_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66C03FE2-24D2-0E28-E053-F662850A682E","latestVersionIndicator":"Yes","beginDate":"2018-03-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-06","modifiedBy":"SOKKERL","dateModified":"2018-03-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6133441","version":"1","preferredName":"Patient Nonprescription Or Complementary And Alternative Medical Therapy Administration Without Consulting Physician Code Indicator","preferredDefinition":"A coded response to determine clinical trial eligibility for questions that address the administration of over the counter medication or CAM therapy by the patient without consulting a physician.","longName":"PT_NONSCPT_COM_ALT_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6761BB67-87C3-32E7-E053-F662850A2A24","latestVersionIndicator":"Yes","beginDate":"2018-03-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-14","modifiedBy":"SOKKERL","dateModified":"2020-04-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6133466","version":"1","preferredName":"Malignant Neoplasm Progressive Disease Post Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related malignant cancer and progressive disease after treatment as outlined in the study protocol.","longName":"MAL_NEO_PG_DZ_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"67605C64-EE82-2BC6-E053-F662850A55EC","latestVersionIndicator":"Yes","beginDate":"2018-03-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-14","modifiedBy":"SOKKERL","dateModified":"2022-07-19","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6133714","version":"1","preferredName":"Patient Agreement No Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation related to the patient's agreement to have no other therapeutic agents as outlined in the protocol.","longName":"PT_NO_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6767E98C-4F09-624B-E053-F662850A6F94","latestVersionIndicator":"Yes","beginDate":"2018-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-15","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6134037","version":"1","preferredName":"Genetic Variation Gene Function Alteration Description Text","preferredDefinition":"The free text field to describe the genetic variant which alters gene function.","longName":"GEN_VAR_FUNC_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"676723E0-DC78-2A64-E053-F662850AEC4B","latestVersionIndicator":"Yes","beginDate":"2018-03-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-15","modifiedBy":"TAYLORT","dateModified":"2018-03-15","changeNote":"3/15/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6139474","version":"1","preferredName":"Docetaxel Chemotherapy Agent Administration Indicator","preferredDefinition":"The yes/no indicator related to the administration of docetaxel, a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata, as treatment to arrest or kill the growth and spread of cancer cells.","longName":"DOC_CT_AGT_ADM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"678AF7B4-FCD9-5288-E053-F662850A3C53","latestVersionIndicator":"Yes","beginDate":"2018-03-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-16","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6140432","version":"1","preferredName":"Bone Lesion Count","preferredDefinition":"The number of bone lesions.","longName":"BON_LES_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"678B0556-3A8D-5281-E053-F662850A30B8","latestVersionIndicator":"Yes","beginDate":"2018-03-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-16","modifiedBy":"KENNISHM","dateModified":"2021-05-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6148373","version":"1","preferredName":"Bone Marrow Or Organ Function Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to bone marrow or organ function as outlined in the protocol.","longName":"BON_MAR_ORG_FUNC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"681B9DDA-4F96-15A3-E053-F662850ABE10","latestVersionIndicator":"Yes","beginDate":"2018-03-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-23","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":null,"administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6155897","version":"1","preferredName":"Treatment Cohort Study 10030 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10030 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10030_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6890CFA9-6CF2-1B07-E053-F662850A7065","latestVersionIndicator":"Yes","beginDate":"2018-03-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-03-29","modifiedBy":"SOKKERL","dateModified":"2019-02-07","changeNote":"11/9/18 TT released/PClark. Curated to support protocol 10030_ghd_03.296.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6161748","version":"1","preferredName":"Acute Myeloid Leukemia Myelodysplastic Syndrome Cytogenetic Response Status","preferredDefinition":"Text term to describe the status of acute myeloid leukemia and myelodysplastic syndrome based on cytogenetic evaluation.","longName":"AML_MDS_CYT_RESP_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6921214A-EA4F-4250-E053-F662850ACE3F","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"SOKKERL","dateModified":"2019-10-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6162796","version":"1","preferredName":"Treatment Cohort Study 10145 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10145 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10145_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"693304AE-F971-11C3-E053-F662850AC5C8","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6180808","version":"1","preferredName":"Person Prior Combination Drug Therapy Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior drug combination therapy as outlined in the protocol.","longName":"PER_COMB_ DRG_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"696C67E4-9612-5BE8-E053-F662850A1B20","latestVersionIndicator":"Yes","beginDate":"2018-04-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-09","modifiedBy":"SOKKERL","dateModified":"2022-03-25","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199757","version":"1","preferredName":"Disease Computed Tomography Response Assessment Status","preferredDefinition":"Text that describe the response status of diseases or disorder based on the evaluation of computed tomography (CT).","longName":"DZ_CT_RES_ASSES_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FB8DF6-6EB9-7839-E053-F662850AF76F","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"SOKKERL","dateModified":"2018-04-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199761","version":"1","preferredName":"Disease Positron Emission Tomography Metabolic Response Type","preferredDefinition":"Text that describe the evaluation of the metabolic response of disease or disorder by positron emission tomography (PET).","longName":"DZ_PET_MET_RESP_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FC2277-BA1B-2DAE-E053-F662850AC025","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2020-12-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199763","version":"1","preferredName":"Bone Marrow Biopsy Outcome","preferredDefinition":"A positive or negative outcome of a bone marrow biopsy.","longName":"BON_MAR_BX_OC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FB499C-FE09-308A-E053-F662850A21B1","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"SOKKERL","dateModified":"2018-04-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199766","version":"1","preferredName":"Extranodal Disease Site Indicator","preferredDefinition":"Indicator for whether or not there are more than 1 extranodal sites.","longName":"EXTR_DZ_ST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FC5CDC-373B-773D-E053-F662850AB724","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-16","modifiedBy":"SOKKERL","dateModified":"2018-04-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6212056","version":"1.2","preferredName":"Treatment Cohort Study 10144 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol 10144 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10144_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E7AC890-1ED0-682A-E053-F662850A9CA2","latestVersionIndicator":"Yes","beginDate":"2020-02-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-02-13","modifiedBy":"SOKKERL","dateModified":"2020-05-07","changeNote":"2/13/20 Version CDE and VD. Ls 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6220243","version":"1","preferredName":"Patient Benign Or Variant of Unknown Significance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to benign or variants of unknown significance as outlined in  the protocol.","longName":"PT_BEGN_VAR_UNK_SIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A346720-61A9-57CD-E053-F662850AD478","latestVersionIndicator":"Yes","beginDate":"2018-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-19","modifiedBy":"SOKKERL","dateModified":"2020-05-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6230565","version":"1","preferredName":"Person Pheochromocytoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that has been diagnosed with pheochromocytoma as outlined in the protocol..","longName":"PER_PHM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6AB4E7D0-A2B1-30B2-E053-F662850AF628","latestVersionIndicator":"Yes","beginDate":"2018-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-26","modifiedBy":"SOKKERL","dateModified":"2020-05-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6230716","version":"1","preferredName":"Patient Kaposi Sarcoma Cohort Study Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response regarding patient enrollment in the cohort study and meets the clinical trial eligibility criteria, as outlined in the protocol, for study participation.","longName":"PT_KP_COH_STDY_ENRL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6AC42FC9-EEBD-64DE-E053-F662850A2FB9","latestVersionIndicator":"Yes","beginDate":"2018-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-26","modifiedBy":"SOKKERL","dateModified":"2021-06-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6270947","version":"1.1","preferredName":"Treatment Cohort Study EC10026 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10026 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_EC10026_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8608AEB6-617B-4A11-E053-F662850AA938","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-08","modifiedBy":"SOKKERL","dateModified":"2019-04-08","changeNote":"Version VD. 4/8/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6273332","version":"1","preferredName":"Pathology Tissue Specimen Source Type","preferredDefinition":"The type of tissue that was submitted for assessment of disease.","longName":"PATH_TISS_SPEC_TYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BF1F6EB-82DA-603A-E053-F662850A398B","latestVersionIndicator":"Yes","beginDate":"2018-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-11","modifiedBy":"PROSVIROVAB","dateModified":"2019-01-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6285038","version":"1","preferredName":"Disease Response Imaging Procedure Assessment Method Type","preferredDefinition":"The type of imaging procedure used to assess the disease response.","longName":"DZ_RESP_IMG_PROC_METH_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C3DE693-4BC6-2147-E053-F662850A89D8","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-15","modifiedBy":"SOKKERL","dateModified":"2018-05-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6290510","version":"1","preferredName":"Intervention or Procedure Receive Text","preferredDefinition":"The text that provides a description for the receipt of any activity that produces an effect, or that is intended to alter the course of disease in a patient.","longName":"INTER_PROC_REC_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C593109-F3A7-6BDB-E053-F662850AB178","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-16","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6290657","version":"1","preferredName":"Treatment Cohort Study 10191 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10191 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10191_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C5A07D0-DD9A-6CBC-E053-F662850A607E","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-16","modifiedBy":"SOKKERL","dateModified":"2019-09-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6290663","version":"1","preferredName":"Intervention or Procedure Receive Indicator","preferredDefinition":"The indicator for questions related to the receipt of any activity that produces an effect, or that is intended to alter the course of disease in a patient.","longName":"INTER_PROC_REC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C664F25-5386-7EA0-E053-F662850A9232","latestVersionIndicator":"Yes","beginDate":"2018-05-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-17","modifiedBy":"SOKKERL","dateModified":"2023-07-11","changeNote":"11/8/18 TT released/PClark.; 5/17/18 TT/LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6293819","version":"1","preferredName":"Latent Indolent Non-Hodgkin Lymphoma Diagnosis Name","preferredDefinition":"The name to describe the diagnosed underlying non-Hodgkin's lymphoma with an indolent clinical course.","longName":"LAT_INHL_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C67C739-CD24-0C40-E053-F662850A946C","latestVersionIndicator":"Yes","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"5/17/18 tt/10106 & 10126.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295959","version":"1","preferredName":"Patient Progressive Disease Or Intolerance Occurrence Post Therapeutic Procedure Clinical Trial Eligibility Criteria Ind","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to progressive disease or the inability to absorb/metabolize certain substances after treatment.","longName":"PDZ_INTOL_POST_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C771650-E348-3914-E053-F662850A36C0","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"KUMMEROA","dateModified":"2023-05-03","changeNote":"11/8/18 TT released/PClark.; 5/18/18 tt/10006.","administrativeNotes":"2023.5.3 AQT added per ticket request CADSR0002390. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295963","version":"1","preferredName":"Gene Expression Immunohistochemistry Staining Method Finding Ind","preferredDefinition":"The indicator for questions related to the evidence of gene expression by IHC.","longName":"GEXP_IHC_FIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C78491A-F077-3918-E053-F662850A315C","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"TAYLORT","dateModified":"2018-05-21","changeNote":"5/18/18 tt/10126 & 10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295967","version":"1","preferredName":"Gene Expression Finding Type","preferredDefinition":"The type of gene expression by clinical, laboratory, or molecular evidence.","longName":"GEXP_FIND_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C78E7BB-3B01-6590-E053-F662850AF411","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"5/18/18 tt/10126 & 10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295970","version":"1","preferredName":"Gene Expression Finding Ind","preferredDefinition":"The indicator for questions related to clinical, laboratory, or molecular evidence of gene expression.","longName":"GEXP_FIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C774647-9213-3928-E053-F662850A9741","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"5/18/18 tt/10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295974","version":"1","preferredName":"BCL2 Positive Gene Expression Finding Ind","preferredDefinition":"The indicator for questions related to clinical, laboratory, or molecular evidence of BCL2 expression detected in a sample.","longName":"BCL2_GEXP_FIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C774647-9235-3928-E053-F662850A9741","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"TAYLORT","dateModified":"2018-05-21","changeNote":"5/18/18 tt/10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295980","version":"1","preferredName":"Patient Castration Levels of Testosterone Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the results of low concentrations of testosterone in a subject's serum that results from the use of surgical or chemical castration procedures.","longName":"PT_CASTR_TEST_LEVL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C781BE1-21A2-392C-E053-F662850A9405","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":"5/18/18 LS/TT","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295984","version":"1","preferredName":"Evaluable Patient Disease Response Or Measurable Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to evaluable and measurable disease response.","longName":"EVL_PT_DZ_RESP_MEAS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C7BBA00-776F-10B6-E053-F662850A70EF","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-05-24","changeNote":"2020-12-15 minor edit to definition/TL. 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6295992","version":"1","preferredName":"Patient Hypersensitivity Or Intolerance Disease Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to allergic reactions, hypersensitivities, abnormal conditions of the body or mind, and treatments.","longName":"PT_HYPER_INTOL_DZ_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C790A23-EEAD-3930-E053-F662850AC87E","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2021-01-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6296026","version":"1","preferredName":"Patient Therapeutic Procedure Negation Ability Discontinue Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the patients inability to discontinue therapy as outlined in the protocol.","longName":"PT_THPY_PROC_NO_DISC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C781BE1-221D-392C-E053-F662850A9405","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-18","modifiedBy":"KUMMEROA","dateModified":"2023-07-21","changeNote":null,"administrativeNotes":"2023.7.21 AQT added per ticket request CADSR0002642. ak 2023.5.3 AQT added per ticket request CADSR0002390. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6296064","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Ann Arbor Stage","preferredDefinition":"The anatomic stage for diffuse large B-cell lymphoma using the Ann Arbor classification criteria.","longName":"DLBCL_AA_STAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C7DB211-6890-4D2A-E053-F662850A65EA","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"6/29/18 approved/released tt. 5/18/18 tt/10126 & 10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6296255","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Combined Ann Arbor Stage","preferredDefinition":"The combined anatomic stages for diffuse large B-cell lymphoma using Ann Arbor classification criteria.","longName":"DLBCL_AA_COM_STAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C800E86-4179-4A1D-E053-F662850A15E9","latestVersionIndicator":"Yes","beginDate":"2018-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeNote":"6/29/18 approved/released tt. 5/18/18 tt/10126 &10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6316773","version":"1","preferredName":"Treatment Cohort Study 10194 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10194 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10194_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D81DD1C-9A2E-44D1-E053-F662850A33CA","latestVersionIndicator":"Yes","beginDate":"2018-05-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-31","modifiedBy":"SOKKERL","dateModified":"2018-06-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6323371","version":"1","preferredName":"Additional Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the addition of therapeutic agents as outlined in the protocol.","longName":"ADD_TX_PROC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D9835DC-317F-3956-E053-F662850A4D5A","latestVersionIndicator":"Yes","beginDate":"2018-06-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-01","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6324267","version":"1","preferredName":"Treatment Cohort Study CITN-14 Code","preferredDefinition":"The code that represents the information pertaining to protocol CITN-14 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_CITN14_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6DD1C199-762F-64DB-E053-F662850AD266","latestVersionIndicator":"No","beginDate":"2018-06-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-04","modifiedBy":"SOKKERL","dateModified":"2018-08-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6324267","version":"1.1","preferredName":"Treatment Cohort Study CITN-14 Code","preferredDefinition":"The code that represents the information pertaining to protocol CITN-14 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_CITN14_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73F40202-36D1-1B4F-E053-F662850AB477","latestVersionIndicator":"Yes","beginDate":"2018-06-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-21","modifiedBy":"SOKKERL","dateModified":"2018-11-08","changeNote":"Version VD for to change existing PV","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6324282","version":"1","preferredName":"Patient Small Cell Or Neuroendocrine Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to small cell or neuroendocrine carcinoma  as outlined in  the protocol.","longName":"PT_SMAL_NEUR_CARCIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6DD260B7-2CB0-4246-E053-F662850A890E","latestVersionIndicator":"Yes","beginDate":"2018-06-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-04","modifiedBy":"SOKKERL","dateModified":"2022-08-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6324422","version":"1","preferredName":"Leptomeningeal Neoplasm Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response used to determine whether a malignant neoplasm that has spread from its original site to the innermost layers of tissue that cover the brain and spinal cord exists.","longName":"LEP_NEO_PRES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6DD4CC67-97C8-5FFC-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-06-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-04","modifiedBy":"SOKKERL","dateModified":"2022-02-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333727","version":"1","preferredName":"Cigarettes Smoking Indicator","preferredDefinition":"A yes/no indicator related to cigarette smoking.","longName":"CIG_SMOK_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E5EF557-8C4A-193D-E053-F662850A45AD","latestVersionIndicator":"Yes","beginDate":"2018-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-11","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333742","version":"1","preferredName":"Blunt Daily Use Count","preferredDefinition":"Number of blunts used daily.","longName":"BLNT_DAILY_USE_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E5FD698-D182-6B0E-E053-F662850A9EAC","latestVersionIndicator":"Yes","beginDate":"2018-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-11","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333761","version":"1","preferredName":"Marijuana Use Year Number","preferredDefinition":"A number of years indicating the use of marijuana.","longName":"MARIJ_USE_YR_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E6055D0-D31B-0E56-E053-F662850A6739","latestVersionIndicator":"Yes","beginDate":"2018-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-11","modifiedBy":"TSESU","dateModified":"2022-12-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333781","version":"1","preferredName":"Marijuana Current Use Indicator","preferredDefinition":"A yes/no indicator related to current use of marijuana.","longName":"MARIJ_CUR_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E5F1C5F-834A-0E4B-E053-F662850A241C","latestVersionIndicator":"Yes","beginDate":"2018-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-11","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333887","version":"1","preferredName":"Cigar Smoking Use Year Number","preferredDefinition":"A number of years indicating the use of cigars.","longName":"CIG_SMOK_USE_YR_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7271C2-B1AE-72D1-E053-F662850A569E","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333888","version":"1","preferredName":"Pipe Current Use Indicator","preferredDefinition":"A yes/no indicator related to current use of pipe tobacco.","longName":"PIPE_CUR_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E681C49-3C66-0728-E053-F662850A04A3","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333926","version":"1","preferredName":"Pipe Marijuana Use Indicator","preferredDefinition":"A yes/no indicator related to the use of pipe marijuana.","longName":"PIPE_MARIJ_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E747FE3-686B-137E-E053-F662850A204B","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333927","version":"1","preferredName":"Pipe Marijuana Use Year Number","preferredDefinition":"A number of years indicating the use of pipe marijuana.","longName":"PIPE_MARIJ_USE_YR_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E73CA9F-DEAE-1F84-E053-F662850A8014","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333934","version":"1","preferredName":"Pipe Marijuana Current Use Indicator","preferredDefinition":"A yes/no indicator related to current use of pipe marijuana.","longName":"PIPE_MARIJ_CUR_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E734551-D6F5-7231-E053-F662850AC516","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333935","version":"1","preferredName":"Smokeless Tobacco Use Indicator","preferredDefinition":"A yes/no indicator related to the use of smokeless tobacco.","longName":"SMKLESS_TOB_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E73CA9F-DED2-1F84-E053-F662850A8014","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333938","version":"1","preferredName":"Smokeless Tobacco Use Year Number","preferredDefinition":"A number of years indicating the use of smokeless tobacco.","longName":"SMKLESS_TOB_USE_YR_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7551D4-6BC7-04D6-E053-F662850A54A8","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333948","version":"1","preferredName":"Smokeless Tobacco Current Use Indicator","preferredDefinition":"A yes/no indicator related to current use of smokeless tobacco.","longName":"SMKLESS_TOB_CUR_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E747FE3-688C-137E-E053-F662850A204B","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333979","version":"1","preferredName":"Pipe Use Indicator","preferredDefinition":"A yes/no indicator related the use of pipe tobacco.","longName":"PIPE_USE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E764FD9-1C63-3659-E053-F662850A75C1","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-12","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6334929","version":"1","preferredName":"Smokeless Tobacco Daily Use Count","preferredDefinition":"Number of pouches or cans of smokeless tobacco used daily.","longName":"SMKLESS_TOB_DAILY_USE_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E85B0D3-94FE-6CBF-E053-F662850A3AB5","latestVersionIndicator":"Yes","beginDate":"2018-06-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-13","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6334983","version":"1","preferredName":"Marijuana Bowl Daily Use Count","preferredDefinition":"Number of marijuana bowls used daily.","longName":"MARIJ_BOWL_DAILY_USE_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E87F604-3D71-0E68-E053-F662850AA484","latestVersionIndicator":"Yes","beginDate":"2018-06-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-13","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6335125","version":"1","preferredName":"Tobacco Bowl Daily Use Count","preferredDefinition":"Number of  tobacco bowls used daily.","longName":"TOB_BOWL_USE_DAILY_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E88EDA7-0793-7BDF-E053-F662850A5C42","latestVersionIndicator":"Yes","beginDate":"2018-06-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-13","modifiedBy":"SOKKERL","dateModified":"2018-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6335888","version":"1","preferredName":"Patient Gene Mutation Abnormality Detection Genetic Testing Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to address patient gene mutation(s) detected by the study protocol requirements for genetic testing and analysis in order to allow clinical trial participation.","longName":"GEN_MUT_DET_TEST_REQMT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6EFDF45C-8711-63D1-E053-F662850ABA38","latestVersionIndicator":"Yes","beginDate":"2018-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-19","modifiedBy":"SOKKERL","dateModified":"2019-10-08","changeNote":"11/9/18 TT released/PClark. 6/19/18 tt/EC10129.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6343962","version":"1","preferredName":"Outcome Unknown Reason","preferredDefinition":"Text field to explain why the results are not known, not observed, not recorded, or refused.","longName":"UNK_RSN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FC7A8B4-5D1A-52EB-E053-F662850A0F31","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 6/29/18 tt/10106 & 10126.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6344328","version":"1","preferredName":"Disease Histopathologic Or Molecular Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that address histopathological or molecular confirmation of the disease.","longName":"DZDSR_HISTP_MOL_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCBBD5A-1A03-6FAC-E053-F662850AAF96","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-29","modifiedBy":"SPRINGERL","dateModified":"2021-11-23","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6344567","version":"1","preferredName":"Patient Stable Or Reduced Dose Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study that address if patient has been on a stable or reduced dose of therapeutic agents as outlined in the clinical trial protocol.","longName":"PT_STAB_REDUC_DOS_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCDFC83-33B0-2318-E053-F662850AD774","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-06-29","modifiedBy":"SOKKERL","dateModified":"2020-07-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6344592","version":"1","preferredName":"Disease Response LYRIC Criteria Outcome","preferredDefinition":"The result of the patient's disease to treatment using a tumor response criteria for immunomodulatory therapies designed to account for tumor flares.","longName":"LYRIC_OUTCM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCF1AB1-4D38-6D28-E053-F662850A2629","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 6/29/18 tt/ 10106 & 10126.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6344777","version":"1","preferredName":"Patient Infratentorial Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to evidence of either infratentorial or spinal involvement as outlined in the protocol.","longName":"PT_INFRA_NEOP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70059355-B9D1-7247-E053-F662850A472F","latestVersionIndicator":"Yes","beginDate":"2018-07-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-02","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6344982","version":"1","preferredName":"Patient Measurable Disease Response Assessment in Neuro-Oncology Criteria Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a patient who has measurable disease defined by RANO as outlined in the protocol.","longName":"MEA_DZ_RANO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70059355-BA30-7247-E053-F662850A472F","latestVersionIndicator":"Yes","beginDate":"2018-07-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-02","modifiedBy":"SOKKERL","dateModified":"2023-07-28","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345228","version":"1","preferredName":"Prior Carmustine Wafer Dosage Form Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to prior administration of an antineoplastic nitrosourea (carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis) given in a thin slice as outlined in the protocol.","longName":"PR_CARM_WFER_DOS_FORM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"700A36FE-B0D2-4315-E053-F662850A912A","latestVersionIndicator":"Yes","beginDate":"2018-07-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-02","modifiedBy":"WISEM","dateModified":"2019-06-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6354295","version":"1","preferredName":"Patient Sedation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the process of allaying nervous excitement or the state of being calmed as outlined in the protocol.","longName":"PT_SED_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70D21DD2-60A7-6C7F-E053-F662850ABC22","latestVersionIndicator":"Yes","beginDate":"2018-07-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-12","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6355690","version":"1","preferredName":"Patient Disease Refractory Or Therapeutic Procedure Intolerance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has a disease that does not respond to treatment, or that is intolerant to the therapeutic agent(s) outlined in the study protocol.","longName":"REF_DZ_OR_TX_INT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70D41DD7-BFA7-4856-E053-F662850A16DF","latestVersionIndicator":"Yes","beginDate":"2018-07-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-12","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"11/9/18 TT released/PClark. 7/12/18 tt/10219.","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6355827","version":"1","preferredName":"Therapeutic Procedure Patient Fit Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation related to the patient's condition to receive therapeutic agent as outlined in the protocol.","longName":"THPY_PROC_PT_FIT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70D53754-79A1-345B-E053-F662850A9398","latestVersionIndicator":"Yes","beginDate":"2018-07-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-12","modifiedBy":"CLOHNES","dateModified":"2023-11-16","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":"9/26/23 Added alt OID, CCTG and AQT per CCTG ticket request CADSR0002884 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6355934","version":"1","preferredName":"Patient Receive Prior High Dose Corticosteroid And Immunotherapeutic Agent Prior Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has received prior high doses of corticosteroids and immunomodulatory drugs, as outlined in the protocol, prior to registration.","longName":"PR_CORT_IMMTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70DFEEAA-9F39-4824-E053-F662850AB9EF","latestVersionIndicator":"Yes","beginDate":"2018-07-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-13","modifiedBy":"BMAESKE","dateModified":"2022-09-23","changeNote":"11/9/18 TT released/PClark. 7/13/18 tt/10219.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6355949","version":"1","preferredName":"Patient Additional Malignancy Diagnosis Or Receive Therapeutic Procedure Prior Enrollment And Residual Disease Evidence Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has been diagnosed with another cancer or treated for another cancer prior to registration and has evidence of residual disease.","longName":"ADD_MAL_TX_RESDZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70E18366-566C-0FB8-E053-F662850A5088","latestVersionIndicator":"Yes","beginDate":"2018-07-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-13","modifiedBy":"SOKKERL","dateModified":"2022-08-10","changeNote":"11/9/18 TT released/PClark. 7/13/18 tt/10219.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6355956","version":"1","preferredName":"Patient Receive HIV Protease Inhibitor Concurrent Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient is receiving concurrent treatment with an HIV protease inhibitor.","longName":"HIV_PI_CONC_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70E2077E-D18E-0FBC-E053-F662850A6940","latestVersionIndicator":"Yes","beginDate":"2018-07-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-13","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 7/13/18 tt/10219.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356012","version":"1","preferredName":"Patient Concurrent Primary Amyloidosis Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has concurrent light-chain amyloidosis.","longName":"CONC_AL_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70E4B43D-313B-2E51-E053-F662850A9FB4","latestVersionIndicator":"Yes","beginDate":"2018-07-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-13","modifiedBy":"SOKKERL","dateModified":"2021-04-28","changeNote":"11/9/18 TT released/PClark. 7/13/18 tt/10219.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356048","version":"1","preferredName":"Patient Measurable Disease International Myeloma Working Group Criterion Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has measurable disease defined by the International Myeloma Working Group (IMWG) criteria as outlined in the protocol.","longName":"MEAS_DZ_IMWG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70E582A0-E58E-2E7B-E053-F662850AC46D","latestVersionIndicator":"Yes","beginDate":"2018-07-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-13","modifiedBy":"HARTLEYG","dateModified":"2021-01-25","changeNote":"7/13/18 tt/10219.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356285","version":"1","preferredName":"Treatment Cohort Study 10219 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10219 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10219_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7121DEC9-4783-2B58-E053-F662850A69D9","latestVersionIndicator":"Yes","beginDate":"2018-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-16","modifiedBy":"SOKKERL","dateModified":"2018-07-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356387","version":"1","preferredName":"Biospecimen MET Amplification Screening Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that is related to the biospecimen assessment of a molecular genetic abnormality indicating the presence of multiple copies of the MET gene as outlined in the protocol.","longName":"BIOSPN_METAMP_SRCEN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"71208599-0AB4-4040-E053-F662850AB745","latestVersionIndicator":"Yes","beginDate":"2018-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-16","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356585","version":"1","preferredName":"Primary Or Metastatic Neoplasm KRAS NRAS wt Allele BRAF Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that is related to wild-type in KRAS and NRAS BRAF taken from primary or metastatic site as outlined in  the protocol.","longName":"MEST_NEO_KRA_NRA_BRAF_WT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7133B41D-2627-4C3B-E053-F662850AB37E","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-17","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356740","version":"1","preferredName":"MET Amplification Detection Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to identifying the abnormality indicating the presence of multiple copies of the MET gene as outlined in the protocol.","longName":"MET AMP_DET_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"71340552-461F-62A6-E053-F662850ADB58","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-17","modifiedBy":"RICHARDS","dateModified":"2022-03-24","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356749","version":"1","preferredName":"Therapeutic Procedure Progressive Disease Or Intolerance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to treatments, progressive disease, and the inability to absorb or metabolize certain substances in a normal way as outlined in the protocol.","longName":"THEPY_PROC_PROG_DZ_INTOL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"71343C8F-C0D9-1E6C-E053-F662850A5485","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-17","modifiedBy":"SOKKERL","dateModified":"2021-11-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356752","version":"1","preferredName":"Progressive Disease Prior Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to disease progression prior to administration of therapeutic agents.","longName":"PROG_DZ_PR_THEPY_PROC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"71343C8F-C102-1E6C-E053-F662850A5485","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-17","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6356779","version":"1","preferredName":"Laboratory Procedure Alanine Aminotransferase (ALT) Aspartate Aminotransferase (AST) Total Bilirubin (TBL) Upper Limit of Normal Result Code Indicator","preferredDefinition":"A coded response to questions that are related to the top value range for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and total bilirubin (TBL) outcome as outlined in the protocol.","longName":"LAB_PROC_ALT_AST_TBL_RES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7134AED1-261A-2E78-E053-F662850AB951","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-17","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6361549","version":"1","preferredName":"Patient Receive Non Platinum-Based Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has received any non-platinum regimen as outlined in the protocol.","longName":"REC_NON_PLAT_REG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7158E46B-A468-6A06-E053-F662850AFBC2","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-19","modifiedBy":"TAYLORT","dateModified":"2018-11-09","changeNote":"11/9/18 TT released/PClark. 7/19/18 tt/9948.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6361557","version":"1","preferredName":"Patient Neoplasm Fulfill Protocol Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions whether the patient can satisfy protocol criteria for treatment of the tumors as outlined in the protocol.","longName":"PT_NEO_FUL_PROT_THEPY_PROC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"715110DF-A25A-086F-E053-F662850A0BA8","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-19","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6361561","version":"1","preferredName":"Advanced Malignant Neoplasm Pharmacologic Substance Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to administration of agents intended to alter or stop for advanced malignancy as outlined in the protocol.","longName":"MALG_NEO_PHARM_SUB_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"714B7C73-1298-1300-E053-F662850AA458","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-19","modifiedBy":"SOKKERL","dateModified":"2019-10-10","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6361565","version":"1","preferredName":"Patient Intervention or Procedure Medical Requirement Neoplasm Collection Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient will have a procedure due to medical necessity with tumor collection as outlined in the protocol","longName":"PT_INT_PROC_MED_REQ_NEO_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"714DB6BA-9A2B-690E-E053-F662850A754A","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-19","modifiedBy":"SOKKERL","dateModified":"2021-12-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6361570","version":"1","preferredName":"Patient Current Malignant Neoplasm Interventional Study Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient is currently enrolled on an interventional clinical trial for the current malignancy as outlined in the protocol.","longName":"PT_CUR_NEO_INTRV_STDY_ENR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"715E1F35-11DF-2AE3-E053-F662850A96C4","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-07-19","modifiedBy":"SOKKERL","dateModified":"2020-08-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6361735","version":"1","preferredName":"Patient Therapy Related AML MDS Diagnosis Or Features Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has treatment-related acute myeloid leukemia/myelodysplastic syndrome, or features of acute myeloid leukemia/myelodysplastic syndrome as outlined in the protocol.","longName":"TAML_MDS_OR_FEAT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"715CFE2F-C05E-6834-E053-F662850A1429","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-19","modifiedBy":"SOKKERL","dateModified":"2018-12-13","changeNote":"11/9/18 TT released/PClark. 7/19/18 tt/9914.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6381763","version":"1","preferredName":"Patient Receive Alkylating Agent And Anthracyclines Prior Registration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has received alkylators and anthracyclines before registration as outlined in the protocol.","longName":"ALK_ANTH_PR_REG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72692A91-5622-5121-E053-F662850ABAB6","latestVersionIndicator":"Yes","beginDate":"2018-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-02","modifiedBy":"SOKKERL","dateModified":"2020-04-21","changeNote":"11/8/18 TT released/PClark.; 8/2/18 tt/10219.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6384072","version":"1","preferredName":"Acute Leukemia Or Chronic Myelogenous Leukemia Morphologic Response Status","preferredDefinition":"Text term to describe the acute leukemia or chronic myelogenous leukemia disease status based on morphologic evaluation.","longName":"AML_CML_MORP_RESP_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-62B3-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6384123","version":"1","preferredName":"Bone Marrow Molecular Genetics Result Status","preferredDefinition":"Text term to describe the outcome of the bone marrow status based on molecular genetic therapy.","longName":"BONMW_MOL_GEN_RST_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF1A-28F9-344B-E053-F662850A067A","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6384241","version":"1","preferredName":"Myeloproliferative Neoplasm Blast Count Greater Than Twenty Assessment Code","preferredDefinition":"A code that  represents the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages the number of blast cells blasts as a percentage of greater than 20  present in a blood sample.","longName":"MNP_BLT_GRT_THN_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CA8836-D475-4CA3-E053-F662850A170E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"SOKKERL","dateModified":"2019-04-30","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6384255","version":"1","preferredName":"Myeloproliferative Neoplasm Blast Count Less Than Or Equal To Twenty Assessment Code","preferredDefinition":"A code that represents the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages the number of blast cells blasts as a percentage of less than or equal to than 20 present in a blood sample.","longName":"MNP_BLT_LES_THN_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C9D925-F51A-3753-E053-F662850A82E6","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"SOKKERL","dateModified":"2019-04-30","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6384263","version":"1","preferredName":"Disease Present Person Biopsy Ability Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine clinical trial eligibility that address the present of dieases and the ability of a person to have a biopsy as outlined in the study protocol.","longName":"DZ_PRST_PER_BX_ABLY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CAC024-BFB5-383D-E053-F662850A793F","latestVersionIndicator":"Yes","beginDate":"2018-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-07","modifiedBy":"SOKKERL","dateModified":"2021-01-27","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6400782","version":"1","preferredName":"Treatment Cohort Study 10186 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10186 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10186_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"737A4035-063F-668F-E053-F662850A7AC1","latestVersionIndicator":"Yes","beginDate":"2018-08-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-15","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6403773","version":"1","preferredName":"Prostate-Specific Antigen Prior To Therapy Value","preferredDefinition":"The numerical value for Prostate-specific antigen prior to administration of therapy.","longName":"PSA_PRO_THPY_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73DEF205-47A8-63B7-E053-F662850A02E8","latestVersionIndicator":"Yes","beginDate":"2018-08-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-20","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6404049","version":"1","preferredName":"Prostate-Specific Antigen Post To Therapy Value","preferredDefinition":"The numerical value for Prostate-specific antigen post to administration of therapy.","longName":"PSA_ PST_THPY_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73E01AEA-9C66-0896-E053-F662850A63A3","latestVersionIndicator":"Yes","beginDate":"2018-08-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-20","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6404315","version":"1","preferredName":"Pathology Diagnosis Text","preferredDefinition":"Text that describes the identification or classification of a patient's cancer using data reported by a pathologist.","longName":"PATH_DX_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73E165EC-FECA-6C06-E053-F662850A413D","latestVersionIndicator":"Yes","beginDate":"2018-08-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-20","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6405748","version":"1","preferredName":"Pathology Review Diagnosis Text","preferredDefinition":"Text that describes a pathology evaluation of the presence and the scientific determination of the disease.","longName":"PATH_REV_DX_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73E27851-213E-62E2-E053-F662850A61BA","latestVersionIndicator":"Yes","beginDate":"2018-08-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-20","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6405772","version":"1","preferredName":"Patient Dose Expansion Cohort Disease or Disorder Receive Best Practice Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial eligibility as to whether the patient has received standard of care treatment if participating in the dose expansion cohort for disease as outlined in the study protocol.","longName":"DOSEXP_DIS_SOC_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73E39032-4EDD-7C30-E053-F662850AFA71","latestVersionIndicator":"Yes","beginDate":"2018-08-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-20","modifiedBy":"TAYLORT","dateModified":"2018-08-20","changeNote":"8-20-18 9676/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6407343","version":"1","preferredName":"Malignant Neoplasm Anatomic Type","preferredDefinition":"The type of malignant neoplasms related to the anatomy.","longName":"MALG_NEO_ANTM_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73F364F1-6E0A-025B-E053-F662850AF0BE","latestVersionIndicator":"Yes","beginDate":"2018-08-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-21","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6408733","version":"1","preferredName":"Malignant Neoplasm Targeted Receive Therapy Second Targeted Anatomic Site Indicator","preferredDefinition":"Indicator for whether or not if patient has more than one target, will they receive therapy for the second target.","longName":"MALG_NEO_TARG_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74062C07-B677-3B5D-E053-F662850AB088","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-22","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6409017","version":"1","preferredName":"Patient Recurrent Disease Refractory Or Newly Diagnosed Disease Status","preferredDefinition":"The status of the patient disease.","longName":"PT_REL_REF_NEWDX_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7408911F-EE69-1FD1-E053-F662850A0DA2","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-22","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6411707","version":"1","preferredName":"Treatment Cohort Study 9676 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9676 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9676_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"742DE9DA-C5B7-080E-E053-F662850A0D67","latestVersionIndicator":"Yes","beginDate":"2018-08-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-24","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6411842","version":"1","preferredName":"Medication Osteoporosis Current Administered Indicator","preferredDefinition":"A yes/no indicator relating to the current administration of a biologically active substance to reverse or slow the condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","longName":"MED_OSTEO_CUR_ADMIN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"742FEA2E-78A3-5399-E053-F662850A97E3","latestVersionIndicator":"Yes","beginDate":"2018-08-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-24","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6412696","version":"1","preferredName":"Person Primary Refractory Disease Indicator","preferredDefinition":"A yes/no indicator related to a person having a primary disease that resists treatment.","longName":"PER_PRIM_REFT_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74317749-ED4D-0E84-E053-F662850A2C06","latestVersionIndicator":"Yes","beginDate":"2018-08-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-24","modifiedBy":"LEEW","dateModified":"2021-12-01","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6421708","version":"1","preferredName":"Patient Measurable Disease Immune-related Response Evaluation Criteria In Solid Tumors Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has measurable disease as defined by irRECIST.","longName":"MEA_DS_IRRECIST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"748252AB-2EC2-694D-E053-F662850A9B07","latestVersionIndicator":"Yes","beginDate":"2018-08-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-28","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6422611","version":"1","preferredName":"New Enhancement Lesion Status","preferredDefinition":"The new improvement status of lesions.","longName":"NEW_ENHM_LES_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7495B4D8-1FE8-5557-E053-F662850AE06C","latestVersionIndicator":"Yes","beginDate":"2018-08-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-29","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6423006","version":"1","preferredName":"Chemotherapy Regimen First-Line Therapy Metastatic Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow person to participate in a preferred standard treatment that is used for the treatment of metastatic neoplasm as outlined in the protocol.","longName":"CHMTHPY_REG_FLN_THPY_MEST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74B13854-66FC-3976-E053-F662850AD51D","latestVersionIndicator":"Yes","beginDate":"2018-08-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-30","modifiedBy":"SOKKERL","dateModified":"2022-06-02","changeNote":"11/8/18 TT released/PClark.; 11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6423715","version":"1","preferredName":"Patient Receive Cure Intent Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the administration of therapy with the intention of remedying or restoring health as outlined in the protocol.","longName":"PT_CUR_THPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75207101-80D4-6A32-E053-F662850A8D97","latestVersionIndicator":"Yes","beginDate":"2018-09-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-05","modifiedBy":"SOKKERL","dateModified":"2019-04-01","changeNote":"11/8/18 TT released/PClark.; LS 9/5/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6423764","version":"1","preferredName":"Pharmacologic Substance Exposure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the exposre of specific agents and some combination agents as outlined in the protocol.","longName":"PHARM_SUB_EXP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75219A43-3E5B-42C3-E053-F662850A55EA","latestVersionIndicator":"Yes","beginDate":"2018-09-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-05","modifiedBy":"SOKKERL","dateModified":"2021-06-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6424049","version":"1","preferredName":"Patient Curative Surgery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related curative surgery as outline in the protocol.","longName":"PT_CUR_SURG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7524AAD2-70DB-7D7B-E053-F662850A95E4","latestVersionIndicator":"Yes","beginDate":"2018-09-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-05","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6424614","version":"1","preferredName":"Person Disease or Disorder High Risk Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial with regards to any abnormal condition of the body or mind at risk for potential future harm that may arise from some present action or attribute or condition as outlined in the protocol.","longName":"PT_DZ_HIRSK_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7535830E-2F91-5368-E053-F662850AF6C0","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-06","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":"LS 9/6/18","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6425186","version":"1","preferredName":"Diagnostic Imaging Consent Ability Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded response indicating a patient's willingness and ability to undergo a diagnostic evaluation as outlined in the protocol.","longName":"DX_IMG_CNST_ABLT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7536FB64-4B8C-69A6-E053-F662850A15BD","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-06","modifiedBy":"SOKKERL","dateModified":"2022-07-13","changeNote":"11/8/18 TT released/PClark.; 9/6/18 LS for theradex","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6425326","version":"1","preferredName":"Diagnostic Imaging Medical Contraindication Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions that prevent a person from being allowed to participate in a clinical study related to a diagnostic imaging procedure or treatment inadvisable, usually because of the risk as outlined in the protocol.","longName":"DX_IMG_MD_CONTRA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7535D806-6CCE-0351-E053-F662850A2101","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-06","modifiedBy":"FINCHAMB","dateModified":"2023-10-25","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6425436","version":"1","preferredName":"Patient Contraception Or Spermatozoon Donor Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trail related to the patient's agreement of contraceptives or donation of sperm as outlined in the protocol.","longName":"PT_CONTR_SPRM_AGRM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7539D150-BFF8-6E9B-E053-F662850AFC6B","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-06","modifiedBy":"SOKKERL","dateModified":"2020-12-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6426954","version":"1","preferredName":"Patient B-Cell Lymphoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to B-Cell Non-Hodgkin Lymphoma as outlined in the protocol.","longName":"PT_BCEL_LYPH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"754ABC47-B7AD-0C5F-E053-F662850A2436","latestVersionIndicator":"Yes","beginDate":"2018-09-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-07","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeNote":"6/7/18 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6428100","version":"1","preferredName":"Surgical Excision Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the removal of a diseased organ or tissue as outlined in  the protocol.","longName":"SUR_EXCN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7578FA10-06CB-60E9-E053-F662850AF6F3","latestVersionIndicator":"Yes","beginDate":"2018-09-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-09","modifiedBy":"TYRRELLM","dateModified":"2024-01-12","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":"01.12.2024 Edited AQT per request ticket CADSR0003281_mmt\r\n01.10.2024 Added AQT for request ticket CADSR0003248_mmt\r\n9/27/23 Added alt OID, CCTG and AQT for ticket number CADSR0002884 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6428104","version":"1","preferredName":"Targeted Imaging Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to imaging that uses tagged molecules that are specific for a target molecule or biomarker as outlined in the protocol.","longName":"TARGT_IMG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75793C04-D79B-60D8-E053-F662850A9C15","latestVersionIndicator":"Yes","beginDate":"2018-09-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-09","modifiedBy":"SOKKERL","dateModified":"2021-04-15","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6428327","version":"1","preferredName":"Failed First-Line Therapy Negation Autologous Stem Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trail regarding failed therapy and are not candidates for autologous stem cell transplant as outlined in the protocol.","longName":"FAIL_THPY_NO_ASCT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7585F1DA-0BEB-0297-E053-F662850AD9C7","latestVersionIndicator":"Yes","beginDate":"2018-09-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-10","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6428488","version":"1","preferredName":"Lesion Site Injection Anatomic Location Name","preferredDefinition":"Text name of the anatomical location site for injection of a lesion.","longName":"LES_ST_INJ_LOC_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7588D5EF-B0D2-1EA0-E053-F662850A7A67","latestVersionIndicator":"Yes","beginDate":"2018-09-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-10","modifiedBy":"SOKKERL","dateModified":"2018-09-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6429868","version":"1","preferredName":"Treatment Cohort Study EC10184 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10184 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10184_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C2C3F9-E90E-75FE-E053-F662850AB5D1","latestVersionIndicator":"Yes","beginDate":"2018-09-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-13","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6438220","version":"1","preferredName":"Planned Hysterectomy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to which are necessary to allow a person to participate in a clinical study that address a planned  hysterectomy procedure as outlined in the protocol.","longName":"PLND_HYSTMY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"76B31CAD-2A47-3C9A-E053-F662850A20B7","latestVersionIndicator":"Yes","beginDate":"2018-09-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-25","modifiedBy":"SOKKERL","dateModified":"2020-08-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6438235","version":"1","preferredName":"Adjuvant Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to adjuvant chemotherapy treatment as outlined in the protocol.","longName":"ADJVNT_CT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"76B3180E-1A51-7134-E053-F662850A88A9","latestVersionIndicator":"Yes","beginDate":"2018-09-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-25","modifiedBy":"SOKKERL","dateModified":"2020-12-03","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6447530","version":"1","preferredName":"Patient Subsequent Trial Activity Indicator","preferredDefinition":"Indicator for whether or not a patient can be started on the next trial activity.","longName":"PT_SUB_TRL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"76DD3B65-15D6-59D7-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-27","modifiedBy":"SOKKERL","dateModified":"2018-09-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6450452","version":"1","preferredName":"Nab-paclitaxel Therapy Subsequent Trial Activity Indicator","preferredDefinition":"Indicator for whether or not a patient next treatment will be changed to nab-paclitaxel.","longName":"NAB_PCTL_THPY_SUB_TRL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"76E04A84-9989-4BEB-E053-F662850A0B26","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-27","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":null,"administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454108","version":"1","preferredName":"Progressive Disease Therapeutic Procedure Dose Expansion Cohort Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to disease that is increasing in scope or severity after the administration of therapeutic agents for patients registered in Dose Expansion Cohort E study as outline in the study protocol..","longName":"PRG_DZ_THPY_PRC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"772F3B79-DDE0-5A0F-E053-F662850A3442","latestVersionIndicator":"Yes","beginDate":"2018-10-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-01","modifiedBy":"SOKKERL","dateModified":"2021-05-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454320","version":"1","preferredName":"Treatment Cohort Study 10200 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10200 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10200_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7742AB4C-75A9-1DDE-E053-F662850A29F8","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-02","modifiedBy":"SOKKERL","dateModified":"2019-09-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454324","version":"1","preferredName":"Patient Histologic Or Cytopathology Confirmation Acute Myeloid Leukemia Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to histological or cytological confirmation of AML as outlined in the study protocol.","longName":"HISTO_CYTO_CONF_AML_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7742EA02-327B-29A9-E053-F662850A9ECE","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"SOKKERL","dateModified":"2021-03-17","changeNote":"11/1/18 TMT released. 10-2-18 TMT/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454486","version":"1","preferredName":"Patient Measurable Disease or Disorder Diagnosis Definition Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the diagnosis of measurable disease as defined by the study protocol.","longName":"MEAS_DZ_DEF_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"774431CD-0119-447E-E053-F662850A259D","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"SOKKERL","dateModified":"2018-12-05","changeNote":"11/1/18 TMT released. 10-2-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454521","version":"1","preferredName":"Patient HIV Infectious Disorder Current Effective Antiretroviral Therapy With Undetectable Viral Load Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to HIV infection, current effective treatment with medication(s) that target the virus directly with undetectable viral load, as outlined in the study protocol.","longName":"HIV_EFF_ANTVRL_TX_UNDET_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77450A99-FD79-3165-E053-F662850A691D","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"KUMMEROA","dateModified":"2023-11-02","changeNote":"11/1/18 TMT released. 10-2-18 tmt/10200.","administrativeNotes":"2023.11.2 AQT added per ticket request CADSR0003032. ak 2023.1.17 AQT added per ticket request CADSR0001913. ak 8/2/2022: fixed the box symbol in AQT_wz 6.21.2022: added AQT for Alliance per req#CADSR0001212.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454558","version":"1","preferredName":"Patient History Hepatitis C Virus Infection Therapeutic Procedure Occurrence And Undetectable HCV Viral Load Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the patient's medical background regarding an infection that is caused by hepatitis C virus, the administration of therapeutic agents, and undetectable HCV viral load as outlined in the study protocol.","longName":"PMH_HCV_TX_UNDET_VL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"774431CD-0158-447E-E053-F662850A259D","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"11/1/18 TMT released. 10-2-18 tmt/10200. Deleted duplicated AQT per LK. AK 2020-4-28","administrativeNotes":"9/21/22 added AQT for Theradex cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454575","version":"1","preferredName":"Patient Receive Drug Substance CYP3A4 Or CYP450 Inhibition Or Induction Local Institution Drug Interaction Review And Adjustment Best Practice Eligibility Criteria Ind","preferredDefinition":"The coded indicator as to whether medications been reviewed and adjusted for interactions according to local institutional practice if the patient is receiving any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity that are inhibitors or inducers of the CYP3A4 or CYP450 system as outlined in the clinical trial protocol in order to determine study eligibility.","longName":"CYP_LOC_INST_BP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77463BA9-BBFA-420C-E053-F662850A4D41","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"SOKKERL","dateModified":"2018-12-05","changeNote":"11/1/18 TMT released. 10-2-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454630","version":"1","preferredName":"Patient Receive Drug Substance MATE1 MATE2-K Inhibition Or Induction Local Institution Drug Interaction Review And Adjustment Best Practice Eligibility Criteria Ind","preferredDefinition":"The coded indicator as to whether medications been reviewed and adjusted for interactions as appropriate for local institutional practice if the patient is receiving any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity that are inhibitors or inducers of MATE1 and MATE2-K transporters as outlined in the clinical trial protocol in order to determine study eligibility.","longName":"MATE_LOC_INST_BP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7753E4EB-96F9-4A7E-E053-F662850AC03B","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeNote":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6456311","version":"1","preferredName":"Person Human Immunodeficiency Virus Receive Combination Antiretroviral Therapy Treatment Regimen Drug Interaction Review Eligibility Criteria Ind","preferredDefinition":"The coded indicator to determine study eligibility as to whether the treatment plan has been reviewed for drug interactions if the patient has HIV and is receiving combination antiretroviral therapy as outlined in the clinical trial protocol.","longName":"HIV_TX_REGMN_RVW_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7754902E-CECA-4299-E053-F662850ABCCA","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeNote":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6459359","version":"1","preferredName":"Patient Current Upfront Treatment Setting Refuse Best Practice Therapeutic Procedure Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient declined standard of care therapy if being treated in the up-front setting as outlined in the clinical trial protocol.","longName":"UPFRTX_RFUS_BP_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77590520-F374-2AC7-E053-F662850A967C","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeNote":"11/1/18 TMT released.  10-3-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6459381","version":"1","preferredName":"Patient Chronic Hepatitis B Virus Infectious Disorder Receiving Suppressive Antiviral Therapy Undetectable Viral Load Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine trial eligibility for questions related to chronic HBV infection and undetectable viral loads when taking suppressive therapy as outlined in the study protocol.","longName":"HBV_SUPRSV_TX_UNDET_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775690E5-5ECA-4D14-E053-F662850A1A63","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeNote":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":"2023.5.3 AQT added per ticket request CADSR0002390. ak 8/2/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6459391","version":"1","preferredName":"Patient 11q23 Chromosomal Translocation Or MLL Partial Tandem Duplication Diagnosis Cytogenetics FISH Or Myeloid Panel Confirmation Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has 11q23 translocation or partial tandem duplication that is confirmed by cytogenetics, FISH, or myeloid panel as outlined in the study protocol.","longName":"DX_MLLPTD_CYT_FISH_MMP_CONF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775909C7-4F8B-29F4-E053-F662850AB629","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeNote":"11/1/18 TMT released.10-3-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6459395","version":"1","preferredName":"Patient Other Targeted Mutation Myeloid Panel Identification Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether patient has other targetable mutations identified by myeloid mutational panel as outlined in the clinical trial protocol.","longName":"OTH_TGT_MUT_MMP_ID_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7759EE29-E3BA-4994-E053-F662850AD2FE","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"SOKKERL","dateModified":"2020-08-05","changeNote":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6464905","version":"1","preferredName":"Common Terminology Criteria for Adverse Events Version 5.0 Low Level Term MeDRA Text","preferredDefinition":"A text field that represents any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure (adverse event),using terminology from the Medical Dictionary for Regulatory Affairs (MedDRA) version 5.0.","longName":"CTCAE5_LLTMEDDRA_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"777CCCC8-89F5-06A9-E053-F662850A6AFA","latestVersionIndicator":"Yes","beginDate":"2018-10-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-05","modifiedBy":"RODELAA","dateModified":"2019-11-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6471113","version":"1","preferredName":"Related Adverse Event Blood Product Collection Text","preferredDefinition":"Text field which reports adverse event that may be related to any process that harvests blood or blood products for clinical or manufacturing purposes.","longName":"RELT_AE_BLD_PRDT_COL_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77B80F90-CA82-5C95-E053-F662850A4805","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-08","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6483046","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Subtype Basis Indicator","preferredDefinition":"Indicator for whether or not DLBCL is present defined by molecular subtypes.","longName":"DLBCL_SUBTYP_BAS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78598358-3602-1D37-E053-F662850AE93D","latestVersionIndicator":"Yes","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.; 10/16/18 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6483072","version":"1","preferredName":"Malignant Lymphoma Extranodal Anatomic Site Involvement Count","preferredDefinition":"Numeric value to represent the number of extranodal sites involved with malignant lymphoma.","longName":"MALG_LYPM_EXTN_SIT_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"785B1672-E332-0E82-E053-F662850A9032","latestVersionIndicator":"Yes","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"MORENOC","dateModified":"2019-06-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6483078","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Subtype Basis MYC Arrangement Type","preferredDefinition":"The arrangement type of Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.","longName":"DLBCL_SUB_MYC_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"785BAAC9-2789-2B4D-E053-F662850AEC5A","latestVersionIndicator":"Yes","beginDate":"2018-10-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-16","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6483322","version":"1","preferredName":"Disease Most Recent Therapy Lymphoma Response Status","preferredDefinition":"The most recent response status to therapy for Lymphoma.","longName":"DZ_RECT_THPY_LYP_RESP_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"786C460B-8FA3-1A4F-E053-F662850A7638","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-17","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6486826","version":"1","preferredName":"Patient Gene Sequence Consent Indicator","preferredDefinition":"Indicator for whether or not a patient gives permission for WES/RNA sequencing assay for exploratory and research purposes.","longName":"PT_GEN_SEQ_CON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"786DBEE8-2922-1A43-E053-F662850AA396","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-17","modifiedBy":"SOKKERL","dateModified":"2018-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6488199","version":"1","preferredName":"Patient Germline Sequence Consent Indicator","preferredDefinition":"Indicator for whether or not a patient gives permission for germline sequencing assay for exploratory and research purposes.","longName":"PT_GER_SEQ_CON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"786E6C54-5214-1A3B-E053-F662850A771F","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-17","modifiedBy":"SOKKERL","dateModified":"2018-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6488287","version":"1","preferredName":"Cardiac Condition Antiarrhythmic Therapy Code Indicator","preferredDefinition":"The yes/no/not applicable indicator whether a patient is using anti-arrhythmic therapy.","longName":"CARD_COND_ANTMIC_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"787235A7-BD68-13FD-E053-F662850A0072","latestVersionIndicator":"Yes","beginDate":"2018-10-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-17","modifiedBy":"SOKKERL","dateModified":"2019-08-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6492426","version":"1.1","preferredName":"Specimen Good Condition Receive Count","preferredDefinition":"Number that represent the specimen received in good condition.","longName":"SPEC_GOOD_COND_REC_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"845F1CF0-B265-2BB9-E053-F662850AEB9B","latestVersionIndicator":"Yes","beginDate":"2018-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-18","modifiedBy":"SOKKERL","dateModified":"2019-03-18","changeNote":"Created a new DEC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6501182","version":"1","preferredName":"Shipping Receive Person Comment Text","preferredDefinition":"The free text field for general comments from the receiver.","longName":"SHIP_REC_PER_COM_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78832DAB-A5F9-50D2-E053-F662850AC69E","latestVersionIndicator":"Yes","beginDate":"2018-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-18","modifiedBy":"SOKKERL","dateModified":"2018-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6501190","version":"1","preferredName":"Shipping Sender Comment Text","preferredDefinition":"The free text field for general comments from the sender.","longName":"SHIP_SENDR_PER_COM_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"788348EB-5622-50BA-E053-F662850A998D","latestVersionIndicator":"Yes","beginDate":"2018-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-18","modifiedBy":"SOKKERL","dateModified":"2018-11-01","changeNote":"LS 10/18/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517177","version":"1","preferredName":"Patient Histologic Or Cytopathology Confirmation Progressive Metastatic Or Unresectable Disease Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine study eligibility as to whether the patient has histologically or cytologically confirmed progressive metastatic or unresectable disease as outlined in the clinical trial protocol.","longName":"HIST_CYT_PRO_MET_UNRES_DZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7893A7A1-3716-602B-E053-F662850AC82C","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-19","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"11/1/18 TMT released. 10-19-2018 10211/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517178","version":"1","preferredName":"Patient NGS Report Availability TP53 Gene Mutation Confirmation CLIA Certification Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine study eligibility that addresses the availability of the Next Generation Sequencing report confirming TP53 mutation by a CLIA-certified lab as outlined in the protocol.","longName":"NGS_REP_TP53_CONF_CLIA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7893F249-3447-5FD7-E053-F662850AFE8D","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-19","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeNote":"11/1/18 TMT released. 10-19-2018 10211/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517206","version":"1","preferredName":"Patient HER2 Measurement Positive Disease First Line Therapy Progression Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine study eligibility that addresses HER2 positive disease with progression in the first line treatment setting as outlined in the clinical trial protocol.","longName":"HER2_POS_DZ_FLT_PROG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"789462AD-A6AC-5730-E053-F662850A2DD9","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-19","modifiedBy":"SOKKERL","dateModified":"2021-02-22","changeNote":"11/1/18 TMT released. 10-19-2018 10211/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517219","version":"1","preferredName":"Patient Microsatellite Instability High Diagnosis Prior Immunotherapy Occurrence Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation that addresses the occurrence of prior immunotherapy if the patient has microsatellite instability-high tumor cells as outlined in the study protocol.","longName":"MSIH_PR_ITX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"789544E4-56E6-1697-E053-F662850AC8D4","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-19","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeNote":"11/1/18 TMT released. 10-19-2018 10211/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517244","version":"1","preferredName":"Patient TP53 Gene Mutation Diagnosis Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient is diagnosed with a change in the nucleotide sequence of the TP53 gene as outlined in the study protocol.","longName":"TP53_MUT_DX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7895B49A-1BF3-2204-E053-F662850A6297","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-19","modifiedBy":"SOKKERL","dateModified":"2020-01-10","changeNote":"11/1/18 TMT released. 10-19-2018 10211/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517263","version":"1","preferredName":"Patient Early Phase Negation Treated Or Resectable Disease Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator as to whether the patient has early stage untreated or resectable disease as outlined in the study protocol in order to determine clinical trial participation.","longName":"ERLY_STG_UNTX_RES_DZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78964979-B96C-1DCE-E053-F662850ACB81","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-19","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeNote":"11/1/18 TMT released. 10-19-2018 10211/tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517408","version":"1","preferredName":"Clinics and Hospitals Healthcare Facility Name","preferredDefinition":"The name of the organizations where healthcare services are provided.","longName":"CLN_HOSP_FACT_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78979BBF-BBDA-1539-E053-F662850AF897","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-19","modifiedBy":"SOKKERL","dateModified":"2018-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6535646","version":"1","preferredName":"Specimen Condition Received Shipment Status","preferredDefinition":"The condition status the specimen was received.","longName":"SPEC_COND_RCV_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78D3F9E5-67CD-5CF9-E053-F662850A43C6","latestVersionIndicator":"Yes","beginDate":"2018-10-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-22","modifiedBy":"SOKKERL","dateModified":"2018-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6542643","version":"1","preferredName":"Biopsy Imaging Procedure Lesion Detection Indicator","preferredDefinition":"Indicator of whether any lesion were detected during the biopsy on PET/CT Scan.","longName":"BX_IMG_PROC_LES_DET_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"790ED465-D516-5A61-E053-F662850A9A84","latestVersionIndicator":"Yes","beginDate":"2018-10-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-25","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6542705","version":"1","preferredName":"Biopsy Imaging Procedure Lesion Detection Text","preferredDefinition":"A free-text field used to describe if any lesion were detected during the  biopsy on PET/CT Scan.","longName":"BX_IMG_PROC_LES_DET_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"790F48B7-CD5F-5CA2-E053-F662850A565F","latestVersionIndicator":"Yes","beginDate":"2018-10-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-25","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6542876","version":"1","preferredName":"Prostate Neoplasm Diagnosis Histologic Type Text","preferredDefinition":"A text field that describes the histologic type of prostate neoplasm at time of diagnosis.","longName":"PRS_NEO_DX_HIST_TP_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"79102CDF-631D-631F-E053-F662850AB0F3","latestVersionIndicator":"Yes","beginDate":"2018-10-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-25","modifiedBy":"SOKKERL","dateModified":"2018-12-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6544048","version":"1","preferredName":"Biopsy Timepoint Type","preferredDefinition":"The specific point in time continuum which a  biopsy was performed.","longName":"BX_TMPT_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"79148947-298A-6960-E053-F662850AE50D","latestVersionIndicator":"Yes","beginDate":"2018-10-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-25","modifiedBy":"TITARENI","dateModified":"2021-09-02","changeNote":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6546141","version":"1","preferredName":"Fresh Or Frozen Tissue Medium Text","preferredDefinition":"Text term that describes the type of suspension or solution the frozen or fresh tissue specimen was collected in.","longName":"FRSH_FRZN_TISS_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"798BED0C-6E91-24E4-E053-F662850A95A1","latestVersionIndicator":"Yes","beginDate":"2018-10-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-10-31","modifiedBy":"SOKKERL","dateModified":"2018-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6556032","version":"1","preferredName":"Treatment Cohort Study 10218 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10218 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10218_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A292864-4864-57B1-E053-F662850ABB17","latestVersionIndicator":"Yes","beginDate":"2018-11-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-08","modifiedBy":"SOKKERL","dateModified":"2019-09-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563293","version":"1","preferredName":"Treatment Cohort Study 10247 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol 10247 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10247_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1B3C26-CC7D-732B-E053-F662850A098C","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-20","modifiedBy":"TAYLORT","dateModified":"2018-11-20","changeNote":"11-20-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563331","version":"1","preferredName":"Person Registration Age Category","preferredDefinition":"The categorization of a person's age at registration.","longName":"REG_AGE_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1BDFD4-7A34-68E2-E053-F662850ADF09","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-20","modifiedBy":"TAYLORT","dateModified":"2018-11-20","changeNote":"11-20-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564057","version":"1","preferredName":"Patient Acute Myeloid Leukemia Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the diagnosis of AML as outlined in the study protocol.","longName":"AML_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1C9E3E-6836-166C-E053-F662850ADB08","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-20","modifiedBy":"SOKKERL","dateModified":"2022-12-12","changeNote":"12/17/18 TT released/POC. 11-20-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564077","version":"1","preferredName":"Patient Disease Negation Response Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address no disease response as outlined in the study protocol.","longName":"DZ_NEG_RESP_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1C96E1-79C4-1680-E053-F662850AC2B0","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-20","modifiedBy":"SOKKERL","dateModified":"2019-02-19","changeNote":"12/17/18 TT released/POC. 11-20-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564105","version":"1.1","preferredName":"Treatment Cohort Study 10204 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10204 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10204_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"862D5668-F331-707A-E053-F662850A2FFA","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-10","modifiedBy":"SOKKERL","dateModified":"2022-08-22","changeNote":"10.16.20 TL changed WFS from RETIRED DELETED to RETIRED ARCHIVED in preparation of OneData.; LS Curated for 10204","administrativeNotes":"2022.8.10 Took out of retirement due to reusing VD 1.1 for Ticket Request CADSR0001350. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564296","version":"1","preferredName":"Patient Allogeneic Hematopoietic Cell Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to allogeneic HCT as outlined in the study protocol.","longName":"ALLO_HCT_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1EA961-E91F-5BF1-E053-F662850A2300","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-20","modifiedBy":"GALITG","dateModified":"2021-08-11","changeNote":"12/17/18 TT released/POC. 11-20-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564305","version":"1","preferredName":"Solid Neoplasm Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to any abnormal conditions to benign or malignant neoplasm as as outlined in the protocol.","longName":"SOL_NEOP_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1E4905-FF10-5E1B-E053-F662850AAE91","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-20","modifiedBy":"SOKKERL","dateModified":"2022-09-07","changeNote":"LS curated for 10204 -theradex 11/20/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564321","version":"1","preferredName":"Patient Other Investigational Or Commercial Agent Or Therapeutic Procedure Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to the patient receiving other investigational or commercial agents, or therapies as outlined in the study protocol.","longName":"OTH_INV_AGT_TX_REC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1DD564-2A37-0190-E053-F662850AC72E","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-20","modifiedBy":"BMAESKE","dateModified":"2022-09-23","changeNote":"12/17/18 TT released/POC. 11-20-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564338","version":"1","preferredName":"Patient Metabolic Enzyme Inducer Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to the patient receiving metabolic enzyme inducers as outlined in the study protocol.","longName":"MET_ENZ_IND_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1E5A47-C84D-02F9-E053-F662850A4E01","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-20","modifiedBy":"TAYLORT","dateModified":"2018-12-17","changeNote":"12/17/18 TT released/POC. 11-20-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564369","version":"1","preferredName":"Patient Complete Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to a person having completed the therapy regimen as outlined in the protocol.","longName":"PT_COMPL_TRT_REGM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B1DA905-CDBD-4261-E053-F662850ACF24","latestVersionIndicator":"Yes","beginDate":"2018-11-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-20","modifiedBy":"SOKKERL","dateModified":"2019-10-02","changeNote":"11/20/18 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564383","version":"1","preferredName":"Patient Known Hepatic Cirrhosis Or Severe Pre-existing Impairment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to known hepatic cirrhosis or severe pre-existing hepatic impairment as outlined in the study protocol.","longName":"HEP_CIR_PREX_IMPT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2D83D8-1D5B-0EDC-E053-F662850AC53F","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-21","modifiedBy":"ZHWENDY","dateModified":"2022-07-22","changeNote":"12/19/18 TT released. 11-21-18 TT curated / 10247.","administrativeNotes":"7/22/2022: fixed the box symbol in AQTs.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564387","version":"1","preferredName":"Other Autoimmune Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related other non-specified (NS) autoimmune diseases as outlined in  the protocol.","longName":"OTHR_AUTO_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2E30F1-ACF9-783E-E053-F662850AF1C8","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"11/21/18 EC10204 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564391","version":"1","preferredName":"Patient Life Threatening Disease or Disorder Unrelated To Malignant Neoplasm Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to the patient having any life-threatening illness that is unrelated to cancer as outlined in the study protocol.","longName":"LIFTH_DZ_UNRL_CA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2E4615-9400-18DA-E053-F662850A9AC6","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-21","modifiedBy":"TAYLORT","dateModified":"2018-12-19","changeNote":"12/19/18 TT released. 11-21-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564401","version":"1","preferredName":"Female Patient Oocyte Donor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to female patients donating their eggs as outlined in the study protocol.","longName":"F_EGG_DON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2F1A77-824E-27D4-E053-F662850AD234","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-21","modifiedBy":"SOKKERL","dateModified":"2022-03-21","changeNote":"12/19/18 TT released.  11-21-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564402","version":"1","preferredName":"Patient New Or Progressive Metastatic Brain Disease Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to new or progressive metastatic brain disease as outlined in the protocol.","longName":"PT_NW_PRG_MEST_BRN_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2F2BD5-FB0C-1875-E053-F662850A96B6","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"SOKKERL","dateModified":"2023-12-27","changeNote":"2020-7-27 AQT added for protocol 10389. AK 11/21/18 for EC10204 LS","administrativeNotes":"2022.12.20 AQT added for ticket request CADSR0001812.ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564408","version":"1","preferredName":"Male Patient Spermatozoon Donor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to male patients donating their sperm as outlined in the study protocol.","longName":"M_SPERM_DON_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2E4615-943A-18DA-E053-F662850A9AC6","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-11-21","modifiedBy":"SOKKERL","dateModified":"2019-03-12","changeNote":"12/19/18 TT released. 11-21-18 TT curated / 10247.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564525","version":"1","preferredName":"Autoimmune Disease Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a diagnosis of  Systemic Lupus Erythematosus as outlined in the protocol.","longName":"AUTO_DZ_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2F6547-6A22-7031-E053-F662850AE851","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-08-10","changeNote":"11/21/18 LS","administrativeNotes":"2022.7.28 Added AQT. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564754","version":"1","preferredName":"Inflammatory Bowel Disease Diagnosis Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to inflammatory bowel disease diagnosed by interventional  procedure as outlined in  the protocol.","longName":"INFL_BWL_DZ_INTER_PRD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B30F72D-4D94-4A4A-E053-F662850A58A6","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"LS 11/21/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6564922","version":"1","preferredName":"Gastrointestinal System Disorder Diagnosis Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to gastrointestinal system disorder diagnosed by interventional procedure as outlined in the protocol.","longName":"GI_DIS_DX_INTER_PRD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B318EAA-7936-41C7-E053-F662850ACB62","latestVersionIndicator":"Yes","beginDate":"2018-11-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-21","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"11/21/18 LS","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6565021","version":"1","preferredName":"Patient  Rheumatoid Arthritis Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a diagnosis of rheumatoid arthritis as outlined in the protocol.","longName":"PT_RA_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B56B92F-AA24-46C3-E053-F662850ADB67","latestVersionIndicator":"Yes","beginDate":"2018-11-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-23","modifiedBy":"KUMMEROA","dateModified":"2022-07-28","changeNote":"11/23/18 LS Ec10204","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6570972","version":"1","preferredName":"Fluorescence in Situ Hybridization Molecular Abnormality Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the present of cytogenetic or molecular by using physical mapping approach of fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin as outlined in the protocol.","longName":"FISH_MOLCLR_ABN_PRSNT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BBD578F-1C9E-7C79-E053-F662850AFDC7","latestVersionIndicator":"Yes","beginDate":"2018-11-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-28","modifiedBy":"SOKKERL","dateModified":"2023-12-19","changeNote":"11/28/18 LS EC10212","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6570977","version":"1","preferredName":"Acute Myeloid Leukemia No Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that confirm the patient has previously untreated Acute Myeloid Leukemia as outlined in the protocol.","longName":"AML_NO_PRTX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BBD77FC-03DD-123E-E053-F662850A7D4F","latestVersionIndicator":"Yes","beginDate":"2018-11-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-28","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"11/28/18 LS Ec10212","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6571197","version":"1","preferredName":"Patient Consent Study Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient complies with the study procedure as outlined in the protocol.","longName":"PT_CNST_STDY_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCF7E65-D43E-7918-E053-F662850A1239","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-29","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"11/29/18 LS EC10212","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6572597","version":"1","preferredName":"Patient Symptomatic Leukemia Central Nervous System Leptomeninges Involvement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has symptomatic leukemia of the central nervous system including leptomeningeal leukemic involvement as outlined in the protocol.","longName":"PT_SYM_LEUK_CNS_LEP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD4225D-2C24-2C22-E053-F662850A592F","latestVersionIndicator":"Yes","beginDate":"2018-11-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-11-29","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"11/29/18 LS EC 10212","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6577316","version":"1","preferredName":"Patient Consent Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient's willingness to undergo intensive induction therapy as outlined in the protocol.","longName":"PT_CONS_THP_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C47E2CE-4BD0-2047-E053-F662850A974A","latestVersionIndicator":"Yes","beginDate":"2018-12-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-05","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"10200 for theradex -ls 12/5/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6577874","version":"1","preferredName":"Laboratory Procedure Blood Cell Count with Differential Specimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to a hematologic procedure to determine the number of red blood cells, white blood cells, and platelets, including the white cell differential count and red cell morphology, in a blood sample as outline in the protocol.","longName":"LABP_CBC_DIF_SPEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C4CC749-D886-4408-E053-F662850AA6D1","latestVersionIndicator":"Yes","beginDate":"2018-12-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-05","modifiedBy":"SOKKERL","dateModified":"2019-05-02","changeNote":"12/5/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6580620","version":"1","preferredName":"Hematologic Disease Or Prior Malignancies Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to blood disease and malignancies as outlined in the protocol.","longName":"HEM_DZ_MALG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5C5680-669C-60A0-E053-F662850AFD99","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-06","modifiedBy":"SOKKERL","dateModified":"2022-07-20","changeNote":"12/6/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6580629","version":"1","preferredName":"Patient Abnormality Associated Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to abnormalities known to be associated with disease or disorders as outlined in the protocol.","longName":"PT_ABN_ASCT_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5CAC40-B15C-4866-E053-F662850A65EA","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-06","modifiedBy":"SOKKERL","dateModified":"2020-12-02","changeNote":"12/6/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6584949","version":"1","preferredName":"Fine-Needle Aspiration Specimen Sufficient Biopsy Count","preferredDefinition":"The numerical count of adequate fine needle aspiration biopsy.","longName":"FNA_SPEC_SUF_BX_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB05F13-A140-4C90-E053-F662850AF00E","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-10","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586241","version":"1","preferredName":"Fine-Needle Aspiration Specimen Sufficient Biopsy Number Unknown Indicator","preferredDefinition":"A yes/no indicator for unknown number sufficient fine needle biopsy.","longName":"FNA_SPEC_BX_UNKN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB14677-C6E4-0968-E053-F662850A4A2E","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-10","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/10/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586428","version":"1","preferredName":"Diagnostic Cytology Performed Indicator","preferredDefinition":"A yes/no/unknown indicator if a cytology assessment was performed.","longName":"DX_CYTLGY_PERM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB20D49-1040-76A1-E053-F662850A2FCD","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-10","modifiedBy":"SOKKERL","dateModified":"2019-05-06","changeNote":"12/10/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586485","version":"1","preferredName":"Needle Biopsy Procedure Timepoint Type","preferredDefinition":"Timing of the needle core biopsy procedure.","longName":"NEDL_BX_PROC_TIMPT_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CB26C25-95F1-71C6-E053-F662850AA5E4","latestVersionIndicator":"Yes","beginDate":"2018-12-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-10","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/10/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586649","version":"1","preferredName":"Needle Biopsy Gauge Unknown Indicator","preferredDefinition":"A yes/no indicator for unknown needle gauge.","longName":"NEDBX_GAUG_UNKN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CC0F5EE-FB1C-08B2-E053-F662850A6AEE","latestVersionIndicator":"Yes","beginDate":"2018-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-11","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/11/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586701","version":"1","preferredName":"Tumor Site Laterality Segment Biopsy Anatomic Site Name","preferredDefinition":"Text term that represents the name and side of the body where the tumor is located.","longName":"TUM_ST_LAT_SEG_BX_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CC3E0EA-810B-038F-E053-F662850AC7FB","latestVersionIndicator":"Yes","beginDate":"2018-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-11","modifiedBy":"SOKKERL","dateModified":"2019-02-26","changeNote":"created for Theradex 12/11/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586713","version":"1","preferredName":"Lesion Size Centimeter Measurement","preferredDefinition":"Lesion size measured in centimeters.","longName":"LES_SIZ_CM_MSMT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CC437E4-0298-7CB3-E053-F662850A85F5","latestVersionIndicator":"Yes","beginDate":"2018-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-11","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586717","version":"1","preferredName":"Lesion Size Unknown Indicator","preferredDefinition":"A yes/no indicator for unknown size of lesion.","longName":"LES_SIZ_UNKN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CC47258-4020-66AF-E053-F662850A79C3","latestVersionIndicator":"Yes","beginDate":"2018-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-11","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/11/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6586789","version":"1","preferredName":"Lesion Measurement Source Diagnostic Imaging Modality Name","preferredDefinition":"The text describes the imaging modality source used for lesion measurement.","longName":"LES_MSRMT_DX_IMG_MOD_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CC4E772-37C8-7EA3-E053-F662850AFA78","latestVersionIndicator":"Yes","beginDate":"2018-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-11","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6587599","version":"1","preferredName":"Lesion Axis Coordinate Identifier","preferredDefinition":"One or more characters used to identify the axis position of the lesion.","longName":"LES_AX_CORD_ID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD525A6-693A-49DD-E053-F662850A8950","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-12","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"12/12/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6587731","version":"1","preferredName":"Lesion Low Score Prior Biopsy Indicator","preferredDefinition":"An indicator of yes/no of low values of the lesions score prior to biopsy.","longName":"LES_LW_SCR_PR_BX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD7AE63-F744-55BD-E053-F662850AEACF","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-12","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeNote":"12/12/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6587733","version":"1","preferredName":"Lesion Score Scale Prior Biopsy Other Specify","preferredDefinition":"A text field that specifies other reasons for lesion score prior to biopsy.","longName":"LES_SCR_PR_BX_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD64555-8FDC-379F-E053-F662850A06D1","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-12","modifiedBy":"SOKKERL","dateModified":"2019-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6588936","version":"1","preferredName":"Nodal Disease or Disorder Assessment Indicator","preferredDefinition":"A yes/no/unknown indicator related to assessment of nodal disease or disorder.","longName":"NOD_DZ_DISRD_ASSES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE9ED31-A507-685F-E053-F662850A3669","latestVersionIndicator":"Yes","beginDate":"2018-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6589112","version":"1","preferredName":"Prostate Multiparametric Magnetic Resonance Imaging Performed Date","preferredDefinition":"The date on which the mpMRI of the prostate was performed.","longName":"PROST_MPMRI_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CECED17-49B5-22F2-E053-F662850A4381","latestVersionIndicator":"Yes","beginDate":"2018-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6593637","version":"1","preferredName":"Estimated Glomerular Filtration Rate Result Value","preferredDefinition":"The estimated numerical quantity of a kidney function test that measures fluid volume by the specified value for glomerular filtration rate.","longName":"ESTM_GFR_RAT_RST_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D3F1F51-87C8-66DF-E053-F662850AE5DF","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-17","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeNote":"12/18/18 ls","administrativeNotes":"2023.3.21 AQTs added per ticket request CADSR0002191. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6594085","version":"1","preferredName":"Radiation Therapy Anatomic Site Text","preferredDefinition":"A text describes the area of the body that received radiation therapy.","longName":"RT_ANAT_SITE_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D3D72BC-1D48-66D3-E053-F662850A9619","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-17","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/18/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6596197","version":"1","preferredName":"Collected Duration","preferredDefinition":"The duration of the treatment as collected.","longName":"ECCDUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7D5068E3-ED69-72F6-E053-F662850A597B","latestVersionIndicator":"Yes","beginDate":"2018-12-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-18","modifiedBy":"TAYLORT","dateModified":"2020-04-09","changeNote":"4/9/20 tmt transferred ownership from NCI Standards to Theradex. 12/18/18 TT created for Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6596232","version":"4","preferredName":"Anatomical Region","preferredDefinition":"A description of the anatomical location relevant for the laboratory data.","longName":"LBANTREG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B25585-79E6-7493-E053-731AD00A414B","latestVersionIndicator":"Yes","beginDate":"2018-12-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-02","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeNote":"2022-4-14 ak Versioned due to needing newer VD to reflect CT Pkg 49 updates. 2/18/20 tmt transferred ownership from NCI Standards to Theradex and versioned to 2.0 per VD v1.1.  12/18/18 TT created for Theradex. Released. AK 2020-6-2","administrativeNotes":"2022.9.2 Versioned due to needing newer VD to reflect CT Pkg 50 updates. ak  2022.11.28 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6600717","version":"1","preferredName":"Target Lesion Sum Diameter Measurement","preferredDefinition":"The sum of diameter of the target lesions measured in millimeters.","longName":"TARG_LES_SM_DIAMT_MESURMNT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E068176-F4D7-088C-E053-F662850A50B0","latestVersionIndicator":"Yes","beginDate":"2018-12-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-12-27","modifiedBy":"SOKKERL","dateModified":"2019-02-26","changeNote":"12/27/18 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6601612","version":"1","preferredName":"Therapeutic Procedure Frequency Code","preferredDefinition":"A code that represent the frequency treatment is given.","longName":"THPY_PROC_FRQ_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E90D187-7B6D-41F9-E053-F662850A2363","latestVersionIndicator":"Yes","beginDate":"2019-01-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-03","modifiedBy":"SOKKERL","dateModified":"2019-01-03","changeNote":"1/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6601785","version":"1","preferredName":"Specimen Adequate Assessment Indicator","preferredDefinition":"A yes/no indicator whether the specimen is adequate.","longName":"SPEC_ADQ_ASSMT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E92D235-F3C2-725B-E053-F662850A1229","latestVersionIndicator":"Yes","beginDate":"2019-01-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-03","modifiedBy":"SOKKERL","dateModified":"2019-09-17","changeNote":"1/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6606295","version":"1","preferredName":"Induction Therapeutic Procedure Next Cycle Indicator","preferredDefinition":"A yes/no indicator related to undergoing  re-induction therapy in next cycle.","longName":"IND_THRPY_PROC_NXT_CYC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EDFC3DA-A813-46C1-E053-F662850A7200","latestVersionIndicator":"Yes","beginDate":"2019-01-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-07","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"1/7/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6608039","version":"1","preferredName":"Patient Receive Radiation Therapy And Lifetime Risk Chemotherapy Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a patient receiving radiation therapy and a cumulative lifetime exposure of chemotherapy as outlined in the protocol.","longName":"PT_RAD_THPY_LT_CHEMO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F21B82B-F3C4-243A-E053-F662850A44D3","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-10","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"1/10/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6608297","version":"1","preferredName":"Patient Relapse Refractory Myeloma Measurable Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to relapsed and refractory myeloma with measure disease as outlined in  the protocol.","longName":"PT_RELP_REFRA_MEAS_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F328370-B4B7-0BB0-E053-F662850A83F6","latestVersionIndicator":"Yes","beginDate":"2019-01-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-11","modifiedBy":"TAYLORT","dateModified":"2019-03-18","changeNote":"1/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6608757","version":"1","preferredName":"Proteasome Sensitive Recurrent/Refractory Disease Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related proteasome sensitivity and recurrent, refractory disease and one line of therapy as outlined in the protocol.","longName":"PRT_SENS_REC_REL_THPY_PROC_CD_","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6BF6BA-654B-209B-E053-F662850A22DB","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"1/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6608799","version":"1","preferredName":"Patient Hepatitis B Antibody Positive HBV Undetectable Viral Load Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to Hepatitis B Virus Core Antibody Positive and HBV undetectable viral load as outlined in the study protocol.","longName":"PT_HBV_POST_UNDET_VL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6CD95A-4437-643B-E053-F662850AB3F3","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"1/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609348","version":"1","preferredName":"Treatment Cohort Study 10249 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10249 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10249_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F701E61-A036-0BE9-E053-F662850A63D9","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-02-26","changeNote":"1/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609366","version":"1","preferredName":"Patient Kidney Graft Recipient Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation as to whether or not the patient is a kidney transplant recipient as outlined in the study protocol.","longName":"KDNY_GRFT_RCPNT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F702255-CB65-16C7-E053-F662850A40E0","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1-14-19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609370","version":"1","preferredName":"Proteasome Inhibitor Assessment Status","preferredDefinition":"The condition or state related to proteasome inhibitor.","longName":"PROTM_INHBT_ASSM_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F700863-4CCB-06B3-E053-F662850A468B","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-03-25","changeNote":"1/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609376","version":"1","preferredName":"Patient Measurable Or Evaluable Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient has measurable or evaluable disease as out lined in the study protocol to determine clinical trial participation.","longName":"MSRBL_EVABL_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F705EC7-2CC0-05D7-E053-F662850A5FE7","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2023-07-11","changeNote":"1-14-19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609398","version":"1","preferredName":"Azacitidine Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to administration of azacitidine as outline in the protocol.","longName":"AZ_ADMIN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F701EED-D04C-1621-E053-F662850A9A07","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2020-02-20","changeNote":"1/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609409","version":"1","preferredName":"Treatment Cohort Study 10212 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10212 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10212_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F7051A5-0C36-4254-E053-F662850ACB37","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-09-03","changeNote":"1/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609902","version":"1","preferredName":"Patient Medical History BRAF Mutation Melanoma Receive Refuse Or Ineligible For Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation with regards to the patients health record addressing the receipt, refusal, or ineligibility of treatment if the patient has BRAF-mutant melanoma as outlined in the study protocol.","longName":"BRAF_MLOMA_RECV_RFUS_INLG_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F72C02B-A0E2-4FDE-E053-F662850AA4D6","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1-14-19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6609907","version":"1","preferredName":"Patient Medical History Merkel Cell Carcinoma Receive Refuse Or Ineligibility For Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation with regards to the patients health record addressing the receipt, refusal, or ineligibility of treatment if the patient has merkel cell carcinoma as outlined in the study protocol.","longName":"MCC_RECV_RFUS_INLG_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F728C70-9753-69F5-E053-F662850A68C6","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1-14-19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6610047","version":"1","preferredName":"Patient Medical History Basal Cell Carcinoma Receive Refuse Or Ineligibility For Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation with regards to the patients health record addressing the receipt, refusal, or ineligibility of treatment if the patient has basal cell carcinoma as outlined in the study protocol.","longName":"BCC_RECV_RFUS_INLG_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F728C70-977A-69F5-E053-F662850A68C6","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1-14-19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6610048","version":"1","preferredName":"Patient Medical History Cutaneous Squamous Cell Carcinoma Receive Refuse Or Ineligibility For Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation with regards to the patients health record addressing the receipt, refusal, or ineligibility of treatment if the patient has cutaneous squamous cell carcinoma as outlined in the study protocol.","longName":"CSCC_RECV_RFUS_INLG_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F72DAA2-CA50-5B2E-E053-F662850A09A7","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1-14-19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6610049","version":"1","preferredName":"Patient History Microsatellite Instability Colorectal Carcinoma Receive Refuse Or Ineligibility For Therapeutic Procedure Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation with regards to the patients health record addressing the receipt, refusal, or ineligibility of treatment if the patient has MSI colorectal carcinoma as outlined in the study protocol.","longName":"MSICRC_RECV_RFUS_INLG_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F72C631-5588-4FF8-E053-F662850A5487","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1-14-19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6610535","version":"1","preferredName":"Autoimmune Disease or Disorder Present Code","preferredDefinition":"Text code to represent the presence of disease related to autoimmune disorders.","longName":"AUTO_DZ_DIS_PRST_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F81F502-8A42-04D3-E053-F662850A8BB4","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-15","modifiedBy":"SOKKERL","dateModified":"2019-02-26","changeNote":"1/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6610563","version":"1","preferredName":"Patient Dialysis Refuse Or Ineligibility Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient declines or is ineligible for a procedure to remove toxic substances from the blood as out lined in the study protocol to determine clinical trial participation.","longName":"DIALYS_RFUS_INLG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F830F1D-0812-55D0-E053-F662850A68D4","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-15","modifiedBy":"KUMMEROA","dateModified":"2023-06-27","changeNote":"1/15/19 TMT created for 10124.","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6610722","version":"1","preferredName":"Patient Donor Specific Antibodies Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator for questions to address donor-specific antibodies as outlined in the study protocol to determine clinical trial participation.","longName":"DSA_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F830F1D-0839-55D0-E053-F662850A68D4","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-15","modifiedBy":"SOKKERL","dateModified":"2019-09-25","changeNote":"1/15/19 TMT created for 10124.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6610758","version":"1","preferredName":"Personal Medical History Allograft Graft Rejection Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation with regards to the patients health record addressing allograft rejection as out lined in the study protocol.","longName":"HX_ALGRFT_REJN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F835C99-DDCC-5885-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-15","modifiedBy":"TAYLORT","dateModified":"2019-01-16","changeNote":"1/15/19 TMT created for 10214.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6612625","version":"1","preferredName":"Disease or Disorder Flow Cytometry Response Status","preferredDefinition":"The status of the disease response using the flow cytometry technique. .","longName":"DZ_DIS_FLW_CYMTY_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F85F63B-2E36-2819-E053-F662850AD2A9","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-15","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"1/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6617456","version":"1","preferredName":"Disease or Disorder Molecular Analysis Response Status","preferredDefinition":"Text term that describes the disease response through a laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","longName":"DZ_DIS_MOLCR_ANYLS_RESP_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAE77E7-24DD-0D31-E053-F662850A32F3","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-17","modifiedBy":"SOKKERL","dateModified":"2019-10-07","changeNote":"1/17/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6617595","version":"1","preferredName":"Prior Anthracycline Therapy Regimen Code Indicator","preferredDefinition":"The coded response that indicates whether there was a prior anthracycline therapy regimen.","longName":"PR_ANTH_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FC1EB51-4B84-69E3-E053-F662850A8A93","latestVersionIndicator":"Yes","beginDate":"2019-01-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-01-18","modifiedBy":"SOKKERL","dateModified":"2023-01-30","changeNote":"Curated for Theradex EC10212_ghd_01.18.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6617600","version":"1","preferredName":"Laboratory Procedure Pediatric Creatinine Outcome Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to a pediatric creatinine laboratory procedure.","longName":"LAB_PED_CREAT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FC2B06A-B82C-64F5-E053-F662850A081F","latestVersionIndicator":"Yes","beginDate":"2019-01-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-01-18","modifiedBy":"SOKKERL","dateModified":"2021-12-08","changeNote":"Curated to support EC10212","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6617855","version":"1","preferredName":"Leukemia Diagnosis Morphologic Finding Response Status","preferredDefinition":"Text term to describe the disease status based on morphologic evaluation.","longName":"LEUK_DX_MFR_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"800DEA32-E177-5B5A-E053-F662850AA5D1","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-22","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1/22/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6617865","version":"1","preferredName":"Erythrocyte Blood Transfusion Administered Last Date","preferredDefinition":"The date on which the last red blood transfusion was administrated.","longName":"RBC_BLDTRNSF_ADM_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"800E1FE1-7D83-59ED-E053-F662850A3492","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-22","modifiedBy":"SORENSENS","dateModified":"2020-05-13","changeNote":"1/22/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6617866","version":"1","preferredName":"Platelet Transfusion Received Last Date","preferredDefinition":"The last date of received transfer of blood platelets.","longName":"PLT_TRNSF_RECVD_LAS_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"800EE182-293B-5847-E053-F662850AC644","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-22","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1/22/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6617874","version":"1","preferredName":"Patient Hepatitis C Virus Positive Undetectable HCV Viral Load Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to positive hepatitis C virus and undetectable HCV viral load as outlined in the study protocol.","longName":"PT_HCV_POS_UNDET VL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8010617A-708E-1A72-E053-F662850AD2B2","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-22","modifiedBy":"GALITG","dateModified":"2020-12-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6618094","version":"1","preferredName":"Prostate Carcinoma Risk Factor Assessment Stage Grouping NCCN Category","preferredDefinition":"Text term used to describe the gathering of information regarding the variables associated with an individual's increased risk of getting prostate cancer as outlined by the NCCN guidelines.","longName":"PRS_CA_RSK_FAC_ASSES_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"80221FCC-AE36-6E69-E053-F662850A1ADA","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"CLOHNES","dateModified":"2023-11-16","changeNote":"CDE to capture NCCN guidelines Version 3.2018 Prostate Cancer Risk Groups. 1/23/19 ls","administrativeNotes":"11/16/23 Added alt OID for CCTG ticket number CADSR0003085 cjl","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6618520","version":"1","preferredName":"Acute Myeloid Leukemia Or Myelodysplastic Syndrome Cytogenetic Response Status","preferredDefinition":"Text term to describe the acute myeloid leukemia or myelodysplastic syndrome disease status based on cytogenetic evaluation.","longName":"AML_MDS_CYTO_RESP_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"802BA466-1BB0-6268-E053-F662850AD948","latestVersionIndicator":"Yes","beginDate":"2019-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-24","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeNote":"1/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6619682","version":"1","preferredName":"Other Therapy Receive And Recovery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to other therapies received and has recovered as outlined in the protocol.","longName":"OTH_THPY_RECVY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8097458D-02EC-6F8E-E053-F662850A2413","latestVersionIndicator":"Yes","beginDate":"2019-01-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-29","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"1/29/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6629804","version":"1","preferredName":"Patient Disease Progression Combination Drug Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to disease progression while patient is on combination drug therapy as outlined in the protocol.","longName":"PT_DZ_PRG_COMB_DRG_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"80D97F89-19E8-1053-E053-F662850A93D0","latestVersionIndicator":"Yes","beginDate":"2019-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-01","modifiedBy":"TSESU","dateModified":"2023-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6630233","version":"1","preferredName":"Therapy Discontinue Or Reduced Prior Imaging Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to discontinuing or reducing therapy prior to an imaging procedure as outlined in the protocol.","longName":"THPY_DISC_RED_IMG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"80D9E813-C045-308B-E053-F662850A7DE7","latestVersionIndicator":"Yes","beginDate":"2019-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-01","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/1/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6630527","version":"1","preferredName":"Systemic Corticosteroid Therapy Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related receiving treatment with corticosteroids via a delivery method that will affect the entire body as outlined in the protocol.","longName":"SYS_CORT_THPY_ADMN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81152161-AEE6-54EB-E053-F662850A2BDD","latestVersionIndicator":"Yes","beginDate":"2019-02-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-04","modifiedBy":"SOKKERL","dateModified":"2024-02-13","changeNote":null,"administrativeNotes":"2023.11.3 QT added per ticket request CADSR0003032. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6630653","version":"1","preferredName":"Patient Seizure Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to an abnormal condition of the body or mind that causes sudden, involuntary skeletal muscular contractions of cerebral or brain stem as outlined in the protocol.","longName":"PT_SEIZ_DIS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"811712D8-C02C-311E-E053-F662850AF57B","latestVersionIndicator":"Yes","beginDate":"2019-02-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-04","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/4/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6631206","version":"1","preferredName":"Gene Expression Mesothelin Positive Immunohistochemistry Staining Clinical Trial Eligibility Criteria Applicable Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to evidence of gene expression by IHC as outlined in the protocol.","longName":"GEXP_MEST_POS_IHC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81268D9F-40D4-083E-E053-F662850AF2B3","latestVersionIndicator":"Yes","beginDate":"2019-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-05","modifiedBy":"SOKKERL","dateModified":"2019-08-30","changeNote":"2/5/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6631636","version":"1","preferredName":"Patient Belinostat Or Pevonedistat Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates a patient has received prior therapy with belinostat or pevonedistat as outlined in the protocol.","longName":"BELI_MLN_PRTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"812C77EA-62FF-5D45-E053-F662850A742F","latestVersionIndicator":"Yes","beginDate":"2019-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-05","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/5/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6631654","version":"1","preferredName":"Patient BCRP Inhibition Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation related to taking drug products or substances that bring about something, interfere with, or prevent an action or response as outlined in the protocol .","longName":"PT_BCRP_INH_PRTX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"812C557C-9840-1B56-E053-F662850AA712","latestVersionIndicator":"Yes","beginDate":"2019-02-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeNote":"2/5/19 ls","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6631760","version":"1","preferredName":"Patient Correlative Study Tissue Specimen Availability Or Pretreatment Biopsy Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study regarding patients consent  to provide tissue or pre-treatment tissues availability  samples for correlative study as outlined in the protocol.","longName":"COR_TIS_SPEC_PRTNT_BX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"813BBC68-B05C-6297-E053-F662850AD389","latestVersionIndicator":"Yes","beginDate":"2019-02-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-06","modifiedBy":"SOKKERL","dateModified":"2019-08-07","changeNote":"2/6/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6635861","version":"1","preferredName":"Treatment Cohort Study EC10208 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10208 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_EC10208_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"814F6319-AF22-0882-E053-F662850A4632","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"2/7/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6635878","version":"1","preferredName":"Treatment Cohort Study 10208 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10208 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10208_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8141EE99-86D2-15E1-E053-F662850A3D67","latestVersionIndicator":"Yes","beginDate":"2019-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-07","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6639171","version":"1","preferredName":"Treatment Cohort Study 10195 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10195 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10195_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81634200-6BFB-4121-E053-F662850AE635","latestVersionIndicator":"Yes","beginDate":"2019-02-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-08","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"2/8/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6640576","version":"1","preferredName":"Short Somatic Variant Likely Gene Mutation Text","preferredDefinition":"The free text field to describe the likely gene alternation by Single nucleotide polymorphisms (SNPs) or short nucleotide insertions, deletions or indels that originate in cells that are not destined to become gametes and are not passed on to progeny.","longName":"SHORT_SOM_VAR_LIK_GEN_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81A2823F-A8BC-48B3-E053-F662850A9005","latestVersionIndicator":"Yes","beginDate":"2019-02-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-11","modifiedBy":"SOKKERL","dateModified":"2020-02-19","changeNote":"2/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6640580","version":"1","preferredName":"Short Somatic Variant Known Gene Mutation Text","preferredDefinition":"The free text field to describe the known gene alternation by Single nucleotide polymorphisms (SNPs) or short nucleotide insertions, deletions or or indels that originate in cells that are not destined to become gametes and are not passed on to progeny.","longName":"SHORT_SOM_VAR_GEN_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81A2E4B0-D133-48A7-E053-F662850A2E3E","latestVersionIndicator":"Yes","beginDate":"2019-02-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-11","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6640594","version":"1","preferredName":"Gene Amplification High Level Carcinoma Text","preferredDefinition":"The free text field to describe a high level DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene amplified in cancer.","longName":"GEN_AMP_HIG_LEV_CARC_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81A2DE84-8859-5EBF-E053-F662850A0F2D","latestVersionIndicator":"Yes","beginDate":"2019-02-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-11","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6640599","version":"1","preferredName":"Gene Amplification Low Level Carcinoma Text","preferredDefinition":"The free text field to describe a lower level DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene amplified in cancer.","longName":"GEN_AMP_LOW_LEV_CARC_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81A435C7-7F05-63BA-E053-F662850AB277","latestVersionIndicator":"Yes","beginDate":"2019-02-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-11","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641022","version":"1","preferredName":"Foundation Medicine Inc Specimen Qualifying Status","preferredDefinition":"A condition or state of the specimen that satisfying a test or requirement criteria of Foundation Medicine Incorporated.","longName":"FMI_SPEC_QUA_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B391D1-7487-0DB1-E053-F662850AF311","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641072","version":"1","preferredName":"Exon Median Coverage Estimated Value","preferredDefinition":"The estimated value of the median coverage in a exon.","longName":"EXON_MED_COV_EST_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B3EE3D-C37D-7C21-E053-F662850ACCE4","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641124","version":"1","preferredName":"Homozygous Gene Deletion Text","preferredDefinition":"The free text field to describe the deletion of the homologous gene.","longName":"HOM_GEN_DEL_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81A83130-F81E-7C09-E053-F662850AC2AB","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641158","version":"1","preferredName":"Gene Function Rearrangement Result Text","preferredDefinition":"A free text that describes the DNA sequence and gene rearrangement as well as class switching of immunoglobulins.","longName":"GEN_FUN_REAGMNT_RES_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B391D1-74DF-0DB1-E053-F662850AF311","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641166","version":"1","preferredName":"Short Somatic Variant Unknown Significant Text","preferredDefinition":"A free text that describes the unknown significant of a Single nucleotide polymorphisms (SNPs) or short nucleotide insertions, deletions that originate in cells that are not destined to become gametes and are not passed on to progeny.","longName":"SHORT_SOM_VAR_UNK_SIGN_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B3780A-C966-7C19-E053-F662850AE77A","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641331","version":"1","preferredName":"Other Gene Variant Copy Number Polymorphism Result Text","preferredDefinition":"A free text that describes the other gene variation and copies of a particular sequence within the genetic material of an individual.","longName":"OTHR_GEN_VAR_CNV_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B372BE-67E4-7C15-E053-F662850ABE88","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641349","version":"1","preferredName":"Other Homozygous Gene Deletion Text","preferredDefinition":"The free text field to describe the deletion of other homologous gene.","longName":"OTH_HOM_GEN_DEL_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B69A3D-29FE-6036-E053-F662850A6667","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641353","version":"1","preferredName":"New Gene Rearrangement Unknown SignificantText","preferredDefinition":"A free text that describes a new unknown DNA sequence and gene rearrangement as well as class switching of immunoglobulins.","longName":"NW_GEN_REAGMN_UNK_SIGN_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B3E967-2C9A-6EBD-E053-F662850A421A","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6642092","version":"1","preferredName":"Foundation Medicine Inc Specimen Identifier Number","preferredDefinition":"A unique identification number used to identify a FMI specimen/sample.","longName":"FMI_SPEC_ID_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81CA3EC1-16B8-18A4-E053-F662850A390D","latestVersionIndicator":"Yes","beginDate":"2019-02-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-13","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/13/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6643225","version":"1","preferredName":"Confirmation Gilbert Syndrome Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to confirmation of the Gilbert Syndrome disorder as outlined in the protocol.","longName":"CONF_GSD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81DDA460-D6D1-582D-E053-F662850AA902","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-14","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6643627","version":"1","preferredName":"Patient Blood Specimen Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to patent agree not to donate blood as outlined in  the protocol.","longName":"PT_BLD_SPEC_CONS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E0BDA5-C769-5D9A-E053-F662850AB8DB","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-14","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6643727","version":"1","preferredName":"Inflammatory Disorder And Autoimmune Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to autoimmune or inflammatory disorders as outlined in the protocol.","longName":"INFM_DIS_AUTO_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E1446C-BB2F-04BA-E053-F662850A3CB0","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-14","modifiedBy":"TYRRELLM","dateModified":"2023-07-20","changeNote":"2/14/19 ls","administrativeNotes":"7/20/23 removed special character from AQT_mmt\r\n7/22/2022: fixed the box symbol in AQT.wz 2022.8.10 Added AQT for Ticket CADSR0001350. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6643968","version":"1","preferredName":"EGFR 790M Mutation Biopsy Progression Post First-Line Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to biopsy existence of genetic alterations of EGFR T790M progression after first line therapy as outlined in the protocol.","longName":"EGFR_MUT_BX_POS_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81EFA84E-57EB-14A4-E053-F662850A84A0","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-15","modifiedBy":"SOKKERL","dateModified":"2019-11-08","changeNote":"2/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6644365","version":"1","preferredName":"Prior Therapeutic Procedure Adverse Event Recovery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation for questions related to prior therapeutic agents and outcomes of adverse events as outlined in the study protocol.","longName":"PRTX_AE_RCVRY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F136AD-A7DF-2D20-E053-F662850A40B3","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-15","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"2/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6644375","version":"1","preferredName":"Study Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to enrollment of study as outlined in the study protocol.","longName":"STDY_ENROL_CLN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F081EF-0A70-655C-E053-F662850A603A","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-15","modifiedBy":"SOKKERL","dateModified":"2019-11-08","changeNote":"2/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6644387","version":"1","preferredName":"Spinal Cord Compression Or Central Nervous System Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to mechanical compression of the spinal cord or central nervous system disease as outlined in the protocol.","longName":"SPN_CRD_COMP_CNS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F243B0-311C-2D18-E053-F662850ADE69","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-15","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6648433","version":"1","preferredName":"Treatment Cohort Study 10246 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10246 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10246_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F4BB48-F0C9-6CB8-E053-F662850A826E","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-02-15","modifiedBy":"HARTLEYG","dateModified":"2019-02-15","changeNote":"Curated to suport EC10246_02.15.19_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6648953","version":"1","preferredName":"Treatment Cohort Study 10216 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10216 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10216_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"822D3C1B-19D5-7FD3-E053-F662850A9891","latestVersionIndicator":"Yes","beginDate":"2019-02-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-18","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/18/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6651558","version":"1","preferredName":"Specimen Analysis Text","preferredDefinition":"Text description of the sample examination.","longName":"SPEC_ANALYSIS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82557F7A-2BE2-3CE1-E053-F662850A846D","latestVersionIndicator":"Yes","beginDate":"2019-02-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-02-20","modifiedBy":"TAYLORT","dateModified":"2019-02-20","changeNote":"2/20/19 tmt curated/Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6651563","version":"1","preferredName":"Specimen Analysis Date","preferredDefinition":"The date when a sample for a lab test was analyzed.","longName":"SPEC_ANALYSIS_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82557F7A-2C03-3CE1-E053-F662850A846D","latestVersionIndicator":"Yes","beginDate":"2019-02-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-02-20","modifiedBy":"TITARENKOI","dateModified":"2021-02-23","changeNote":"2/20/19 tmt curated/Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6651570","version":"1","preferredName":"Specimen Analysis Time","preferredDefinition":"The time when a sample for a lab test was analyzed.","longName":"SPEC_ANALYSIS_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8257FD0A-6C6C-1FEB-E053-F662850A9F74","latestVersionIndicator":"Yes","beginDate":"2019-02-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-02-20","modifiedBy":"TAYLORT","dateModified":"2019-02-20","changeNote":"2/20/19 tmt curated/Theradex.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6659826","version":"1","preferredName":"Molecular Analysis Report Upload Text","preferredDefinition":"The free-text field related to transfer of a molecular analysis report that contains information to a central computer from a smaller computer or a computer at a remote location.","longName":"MOL_AN_REP_UPL_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82E1D6BF-563E-01C2-E053-F662850A0A99","latestVersionIndicator":"Yes","beginDate":"2019-02-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-27","modifiedBy":"SOKKERL","dateModified":"2019-02-28","changeNote":"2/27/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6659846","version":"1","preferredName":"Postmortem Biospecimen Collected Indicator","preferredDefinition":"A yes/no indicator to a question that asks whether a postmortem tissue sample was submitted.","longName":"POSTM_BIOSP_COL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82E2E996-D9E7-01E1-E053-F662850A7415","latestVersionIndicator":"Yes","beginDate":"2019-02-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-27","modifiedBy":"SOKKERL","dateModified":"2019-02-28","changeNote":"2/27/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6659852","version":"1","preferredName":"Biospecimen Source Site Name","preferredDefinition":"The names of hospitals and/or research facilities contracted to collect, process, store, and ship clinically-annotated biospecimens and associated data.","longName":"BIOSP_SRC_ST_NAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82E29073-730D-01D1-E053-F662850AF724","latestVersionIndicator":"Yes","beginDate":"2019-02-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-27","modifiedBy":"SOKKERL","dateModified":"2019-08-20","changeNote":"2/27/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660289","version":"1","preferredName":"Biospecimen Blood Collection Related Adverse Event Indicator","preferredDefinition":"A yes/no/not applicable indicator to signify an adverse event related to collection of blood samples.","longName":"BIOSP_BLD_COL_REL_AE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82E52671-83C9-01D9-E053-F662850A9BE8","latestVersionIndicator":"Yes","beginDate":"2019-02-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-27","modifiedBy":"SOKKERL","dateModified":"2019-02-28","changeNote":"2/27/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660822","version":"1","preferredName":"Specimen Alcohol Processing Start Date","preferredDefinition":"The date indicator related to the start of alcohol processing of a specimen.","longName":"SPEC_ALCH_PROCES_ST_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F64033-A28A-3F88-E053-F662850ADFC6","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-28","modifiedBy":"SOKKERL","dateModified":"2019-03-01","changeNote":"2/28/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660823","version":"1","preferredName":"Specimen Alcohol Processing Start Time","preferredDefinition":"Time indicator related to the start of alcohol processing of a specimen.","longName":"SPEC_ALCH_PROCES_ST_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F6C70D-B505-1E84-E053-F662850A2733","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-28","modifiedBy":"SOKKERL","dateModified":"2019-03-01","changeNote":"2/28/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660827","version":"1","preferredName":"Specimen Alcohol Processing End Date","preferredDefinition":"The date indicator related to the end of alcohol processing of a specimen.","longName":"SPEC_ALCH_PROCES_END_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F6F8A6-370B-4AB6-E053-F662850ABB74","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-28","modifiedBy":"SOKKERL","dateModified":"2019-03-01","changeNote":"2/28/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660828","version":"1","preferredName":"Specimen Alcohol Processing End Time","preferredDefinition":"The end time indicator related to the alcohol processing of a specimen.","longName":"SPEC_ALCH_PROCES_END_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F7070B-ED29-48C6-E053-F662850AADC8","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-28","modifiedBy":"SOKKERL","dateModified":"2019-03-01","changeNote":"2/28/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660834","version":"1","preferredName":"Specimen Processing Formaldehyde Solution Fixation End Time","preferredDefinition":"The end time indicator of processing the specimen with formaldehyde solution.","longName":"SPEC__PROCES_FFX_END_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F73230-563C-6C98-E053-F662850A039B","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-28","modifiedBy":"SOKKERL","dateModified":"2019-03-01","changeNote":"2/28/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660835","version":"1","preferredName":"Specimen Processing Formaldehyde Solution Fixation End Date","preferredDefinition":"The end date indicator of processing the specimen with formaldehyde solution.","longName":"SPEC__PROCES_FFX_END_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F742BF-5DAD-6C8E-E053-F662850ADA0B","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-28","modifiedBy":"SOKKERL","dateModified":"2019-03-01","changeNote":"2/28/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6660842","version":"1","preferredName":"Treatment Cohort Study 9910 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9910 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9910_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82F7D381-B324-7C58-E053-F662850A09DE","latestVersionIndicator":"Yes","beginDate":"2019-02-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-28","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeNote":"2/28/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6663269","version":"1","preferredName":"Treatment Cohort Study 10216 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10216 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10216_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8394B857-7080-39AD-E053-F662850A44A2","latestVersionIndicator":"Yes","beginDate":"2019-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-08","modifiedBy":"SOKKERL","dateModified":"2019-09-03","changeNote":"3/8/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6663693","version":"1","preferredName":"Treatment Cohort Study 10183 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10183 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10183_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83991D8A-D9CD-6E39-E053-F662850AD95E","latestVersionIndicator":"Yes","beginDate":"2019-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-08","modifiedBy":"SOKKERL","dateModified":"2019-08-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6670485","version":"1","preferredName":"Patient Cardiac Function Documented Diagnostic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the assessment of cardiac function documented by a diagnostic procedure as outlined in the protocol.","longName":"PT_CARD_FUNC_DX_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83DA7EAE-5B33-78BF-E053-F662850A79AA","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-12","modifiedBy":"SOKKERL","dateModified":"2022-11-01","changeNote":"4/11/19 tmt corrected typo in question text.  3/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6670500","version":"1","preferredName":"Patient Comprehension And Consent Ability Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the patient comprehends and complies with the study procedure as outlined in the protocol.","longName":"PT_COMP_CONS_ABIL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83DA7EAE-5B69-78BF-E053-F662850A79AA","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-12","modifiedBy":"TAYLORT","dateModified":"2019-04-18","changeNote":"4/11/19 tmt changed question text (Draft New CDE). 3/12/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6670509","version":"1","preferredName":"Patient Refractory Progressive Disease Therapeutic Procedure Intolerance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to disease progression which is resistant and intolerant to therapy as outlined in the protocol.","longName":"REF_PROG_DZ_THYP_INTOL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E7CDC0-9246-649E-E053-F662850AD7BD","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-12","modifiedBy":"TAYLORT","dateModified":"2019-04-11","changeNote":"3/12/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6674529","version":"1","preferredName":"Person Psychiatric Disorder Family Sociological Or Geographical Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study related to psychiatric and familial, sociological or geographical condition as outlined in the protocol.","longName":"PER_PSY__FMSOC_GEO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E9ED02-6DB2-2AE4-E053-F662850A73E8","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-12","modifiedBy":"SOKKERL","dateModified":"2020-03-30","changeNote":"3/12/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6675079","version":"1","preferredName":"Disease Cohort Histologic Category","preferredDefinition":"Text that describes the disease or disorders defined by common characteristic by microscopic physical features of cells in tissues.","longName":"DZ_COHT_HIST_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"84106BB2-0416-4F5B-E053-F662850A81F0","latestVersionIndicator":"Yes","beginDate":"2019-03-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-14","modifiedBy":"SOKKERL","dateModified":"2019-03-26","changeNote":"3/14/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6676372","version":"1","preferredName":"Treatment Cohort Study 10248 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10248 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10248_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"845FA585-9FF7-2643-E053-F662850A9771","latestVersionIndicator":"Yes","beginDate":"2019-03-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-18","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"3/18/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6679317","version":"1","preferredName":"Other Exam And Finding Symptom Review Text","preferredDefinition":"A descriptive text of other medical exams and finding on the evaluation of symptoms.","longName":"OTHR_EX_FIND_SYMPT_TX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"849BB921-A214-1DF9-E053-F662850A1214","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-21","modifiedBy":"SOKKERL","dateModified":"2019-03-21","changeNote":"3/21/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6679320","version":"1","preferredName":"Ophthalmology Final Report Text","preferredDefinition":"A descriptive text of the final ophthalmology report.","longName":"OPHM_FNL_REP_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"849BB03B-DB67-1E0D-E053-F662850AD980","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-21","modifiedBy":"SOKKERL","dateModified":"2019-03-21","changeNote":"3/21/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6680247","version":"1","preferredName":"Patient Dose Expansion Cohort Genetic Abnormality Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial eligibility as to whether the patient has a molecular or cytogenic abnormality which occurs in either human disease states or disease models if participating in the dose expansion cohort as outlined in the study protocol.","longName":"DOSEXP_GENT_ABN_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"84A0415B-7ED1-32E4-E053-F662850AA365","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-21","modifiedBy":"SOKKERL","dateModified":"2019-06-07","changeNote":"3/21/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6680659","version":"1","preferredName":"Blood Transfusion Administered Clinical Trial Eligibility Criteria Applicable Code Indicator","preferredDefinition":"A coded response for questions addressing administration of components of blood into the blood stream as outlined in the protocol.","longName":"BLD_TRANSF_ADMIN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AC21F8-4BC2-2CA8-E053-F662850ACCA4","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-22","modifiedBy":"SOKKERL","dateModified":"2023-12-13","changeNote":"3/22/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6680701","version":"1","preferredName":"Laboratory Procedure Hemoglobin A1c Measurement Clinical Trial Eligibility Criteria Applicable Code Indicator","preferredDefinition":"A coded response for questions related to the value of the amount of glycosylated hemoglobin present in a sample of blood as outlined in the protocol.","longName":"LAB_PROC_HBA1C_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"84ADFBD2-C8B1-2C7D-E053-F662850A4FBC","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-22","modifiedBy":"SOKKERL","dateModified":"2019-10-25","changeNote":"3/22/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681227","version":"1","preferredName":"Treatment Cohort Study 10217 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10217 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10217_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"84EC334A-E0AC-7373-E053-F662850ACE2F","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2023-04-26","changeNote":"3/25/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681233","version":"1","preferredName":"Patient Immunotherapeutic Agent Or Inhibitor Therapeutic Procedure Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the occurrence of immunotherapy or treatment with substances that binds to and inhibits the function or activity of a target as outlined in the study protocol.","longName":"IMUTX_OR_INHTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84EDA7B5-7178-66CC-E053-F662850A5252","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2020-12-01","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681459","version":"1","preferredName":"Patient Disease Type And Therapeutic Procedure Ineligibility Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to disease type and treatment ineligibility as outlined in the study protocol.","longName":"DZ_TP_AND_TX_INELG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84EF1C61-6AA3-5092-E053-F662850A854A","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2022-03-15","changeNote":"3-29-18 released/MD. 3-25-19 protocol10138; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681484","version":"1","preferredName":"Patient Therapeutic Procedure Ineligibility Assessment Laboratory Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to treatment ineligibility assessed by lab tests as outlined in the study protocol.","longName":"TX_INELG_LAB_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84EFA27C-4C0A-4272-E053-F662850AF17D","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2019-05-02","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681510","version":"1","preferredName":"Patient Therapeutic Procedure Ineligibility Assessment ECOG Performance Status Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to treatment ineligibility assessed by ECOG performance status as outlined in the study protocol.","longName":"TX_INELG_ECOG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84F0552B-8231-46C9-E053-F662850A9F06","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2019-04-26","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681511","version":"1","preferredName":"Patient Therapeutic Procedure Ineligibility Assessment Audiometric Test Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to treatment ineligibility assessed by audiometric tests as outlined in the study protocol.","longName":"TX_INELG_AUDTST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84F0683F-76E5-4213-E053-F662850A63A3","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2019-04-26","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681513","version":"1","preferredName":"Patient Therapeutic Procedure Ineligibility Assessment Heart Failure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to treatment ineligibility assessed by heart failure as outlined in the study protocol.","longName":"TX_INELG_HRTFLR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84EE7E41-8139-4F53-E053-F662850A045F","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2019-04-26","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681514","version":"1","preferredName":"Patient Therapeutic Procedure Ineligibility Assessment Peripheral Neuropathy Clinical Trial Eligibility Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to treatment ineligibility assessed by peripheral neuropathy as outlined in the study protocol.","longName":"TX_INELG_PERNPY_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84EF6BA7-F1AB-40C3-E053-F662850A2AD8","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"VUJANOVA","dateModified":"2019-09-03","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681518","version":"1","preferredName":"Patient Immunohistochemical Test Outcome Method Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the method for results of immunohistochemical tests as outlined in the study protocol.","longName":"IHC_RES_MTHD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84EFCAF4-C95C-38DB-E053-F662850A5118","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2019-04-26","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681521","version":"1","preferredName":"Patient Immunohistochemical Test Outcome Central Laboratory Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the confirmation of immunohistochemical test results by a laboratory delivering the data for a particular study as outlined in the study protocol.","longName":"IHC_RES_CLAB_CONF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84F0A634-3723-3801-E053-F662850A9F67","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2019-04-26","changeNote":"3-29-18 released/MD. 3-25-19 protocol 10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681527","version":"1","preferredName":"Patient Consent Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the patient's consent to interventions or procedures as outlined in the study protocol.","longName":"CONS_INT_PROC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84ECF936-46C6-6ED2-E053-F662850AD921","latestVersionIndicator":"Yes","beginDate":"2019-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-25","modifiedBy":"SOKKERL","dateModified":"2019-04-26","changeNote":"3-29-18 released/MD. 3-25-19 protocol10183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6681633","version":"1","preferredName":"Disease or Disorder Cohort Histologic Category","preferredDefinition":"Text that describes the disease or disorders defined by common characteristic by microscopic physical features of cells in tissues.","longName":"DZ_DIS_COH_HIST_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85018E3A-51E7-6ADD-E053-F662850AEE9C","latestVersionIndicator":"Yes","beginDate":"2019-03-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-03-26","modifiedBy":"SOKKERL","dateModified":"2019-03-26","changeNote":"3/26/19 ls Jacob wanted the same DEC and VD from CDE 6675079, for the Prerequisite.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685558","version":"1","preferredName":"Patient Medical History Intervention or Procedure Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation with regards to the patients medical history and the results of activities that produces an effect, or intended to alter the course of a disease.","longName":"PMH_INVPR_RSLT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"858EBBD2-9DBF-75D8-E053-F662850AF186","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-02","modifiedBy":"SOKKERL","dateModified":"2019-05-30","changeNote":"5-2-19 released/form usage; tmt. 4-16-19 edit to Draft New CDE for 10250 (unused on 9930).  4-2-19 Protocol 9930; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6686878","version":"1","preferredName":"Treatment Cohort Study 10292 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10292 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10292_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CC2ABB-A994-1D82-E053-F662850AEDB9","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-05","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"4/5/19 ls cohort study","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6687945","version":"1","preferredName":"Patient Hepatitis A Virus Antibody IgM Clinical Trial Eligibility Criteria  Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the amount of Hepatitis A virus antibody IgM present in a sample as outlined in a protocol.","longName":"PT_HEP_ IGM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8605A0D9-50C5-4697-E053-F662850A752C","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-08","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"4/8/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6689424","version":"1","preferredName":"Hypotension Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has blood pressure that is abnormally low as outlined in the study protocol.","longName":"HPYO_DZ_DIS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"862DA1EC-5A61-4C04-E053-F662850A925E","latestVersionIndicator":"Yes","beginDate":"2019-04-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-10","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"4/10/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6689669","version":"1","preferredName":"Disease or Disorder Neoplasm Cohort Category","preferredDefinition":"The category for disease in which subsets of a defined population are identified.","longName":"DZ_NEO_COH_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86341917-584D-40E4-E053-F662850AFFD7","latestVersionIndicator":"Yes","beginDate":"2019-04-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-10","modifiedBy":"TAYLORT","dateModified":"2019-05-03","changeNote":"5/3/19 tmt released/MD. 4-10-19 EC1022; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6689878","version":"1","preferredName":"Patient Negation Induction Candidate Therapeutic Procedure Occurrence Disease Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to post treatment disease assessments when the patient is not a candidate for induction as outlined in the study protocol.","longName":"NEG_CANDT_TX_OCUR_DZ_ASSESS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8633F08E-84A0-3921-E053-F662850AAF2D","latestVersionIndicator":"Yes","beginDate":"2019-04-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-11","modifiedBy":"TAYLORT","dateModified":"2019-04-18","changeNote":"4/11/19 10237; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6692739","version":"1","preferredName":"Patient Histologic Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regards to disease that is based on the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","longName":"HIST_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8698F07D-532D-07E9-E053-F662850A851D","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-15","modifiedBy":"SOKKERL","dateModified":"2020-12-21","changeNote":"5-2-19 released/form usage; tmt.  4-15-19 tmt/10250.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6692906","version":"1","preferredName":"Clinical Trial Eligibility Criteria Intervention or Procedure Prior To Protocol Agent Occurrence Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regards to interventions or procedures prior to study treatment.","longName":"INVPR_PRR_TO_PROT_AGT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86A8405F-9081-7783-E053-F662850AFE8B","latestVersionIndicator":"Yes","beginDate":"2019-04-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-16","modifiedBy":"SOKKERL","dateModified":"2023-01-24","changeNote":"5-2-19 released/form usage; tmt.  4-16-19 tmt/10250.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6703580","version":"1","preferredName":"EGFR Gene Mutation Abnormality Identified Type","preferredDefinition":"Text term that represents the kind of EGFR gene mutation abnormality identified.","longName":"EGFR_MUT_ABN_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D5A60B-D239-4CD5-E053-F662850AA23B","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"SOKKERL","dateModified":"2019-05-01","changeNote":"4-18-19 10042; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6712214","version":"1","preferredName":"Cisplatin Prior Exposure Type","preferredDefinition":"The text response that indicates the prior exposure type a patient has had with regards to cisplatin.","longName":"CISPL_PR_EXP_TYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87384F0A-F7C1-24B1-E053-F662850AEAAC","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"HARTLEYG","dateModified":"2019-04-23","changeNote":"Curated to support EC10183","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6712259","version":"1","preferredName":"Programmed Cell Death 1 Ligand 1 Immunohistochemistry Staining Method Outcome Combined Positive Score","preferredDefinition":"The text response that indicates a combined positivity score in cells for the presence of the programmed cell death 1 ligand 1 protein that is encoded by the human CD274 gene observed immunohistochemical staining method techniques.","longName":"PD-L1_COMB_POS_SCR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87362511-B2CB-24FC-E053-F662850A59E3","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"SOKKERL","dateModified":"2019-05-15","changeNote":"Curated to support EC10183","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6730249","version":"1","preferredName":"Treatment Cohort Study 10220 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10220 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10220_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8747E9C6-D187-4FF9-E053-F662850A0798","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-24","modifiedBy":"TAYLORT","dateModified":"2019-07-11","changeNote":"Curated for Protocol 10220_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6730284","version":"1","preferredName":"Patient Glioma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The response that indicates whether or not a patient has a diagnosis of glioma that is eligible for participation in a clinical trial.","longName":"GLIOMA_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"874F36C2-DD7E-6C8F-E053-F662850A2496","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-24","modifiedBy":"HARTLEYG","dateModified":"2019-05-03","changeNote":"Curated to support 10220","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6730741","version":"1","preferredName":"Clinical Data Entry Complete Indicator","preferredDefinition":"The response that indicates whether clinical data entry was completed.","longName":"CLIN_DAT_COMPL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"875CFD26-116C-27E3-E053-F662850A3E8B","latestVersionIndicator":"Yes","beginDate":"2019-04-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-25","modifiedBy":"SOKKERL","dateModified":"2019-04-25","changeNote":"4/25/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6733087","version":"1","preferredName":"Response Assessment Disease Type","preferredDefinition":"A response assessment based on common qualities of any abnormal condition of the body or mind that causes discomfort, dysfunction or distress to the person.","longName":"RESP_ASSESS_DZ_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8770BD3C-EDE5-3B5D-E053-F662850A8D1F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeNote":"4/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6738989","version":"1","preferredName":"Treatment Cohort Study 10268 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10268 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10268_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C5C975-875B-1759-E053-F662850AE472","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-30","modifiedBy":"TAYLORT","dateModified":"2019-05-31","changeNote":"4/30/19 curated for 10268; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6739146","version":"1","preferredName":"Exploratory Research Cohort Enrollment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions to determine eligibility for clinical trial participation in an exploratory cohort study as outlined in the protocol.","longName":"EXPL_RSCH_COH_ENR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87D45C76-5C85-09A0-E053-F662850A9A0B","latestVersionIndicator":"Yes","beginDate":"2019-05-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-01","modifiedBy":"SOKKERL","dateModified":"2023-04-26","changeNote":"5/1/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6740264","version":"1","preferredName":"Image Guided Biopsy Method Use Modality Type","preferredDefinition":"A response for questions related to type of imaging procedure used in the biopsy of tissue or fluid.","longName":"IMG_GUIDE_BX_METH_MOD_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87FD1E0B-91EE-29CE-E053-F662850A5B98","latestVersionIndicator":"Yes","beginDate":"2019-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-03","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"5/3/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6740285","version":"1","preferredName":"Coaxial Biopsy Technique Performed Indicator","preferredDefinition":"A  yes/ no indicator if a coaxial technique was used to perform a biopsy.","longName":"COAX_BX_TECHQ_PERF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87FD1E0B-923A-29CE-E053-F662850A5B98","latestVersionIndicator":"Yes","beginDate":"2019-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-03","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"5/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6741908","version":"1","preferredName":"Bone Marrow Aspiration Blood Specimen Submission Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to submission of bone marrow aspirated and blood specimen as outlined in the study protocol.","longName":"BM_ASPT_BLD_SPEC_SUBM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883D1951-69AC-3E2E-E053-F662850A5EBD","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-06","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"5/6/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6751800","version":"1","preferredName":"Newly Diagnosed Disease or Disorder No Treatment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a newly diagnosed disease or disorder and has had no treatment as outlined in the protocol.","longName":"NEWDX_DZ_NO_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8861CBD1-B714-4330-E053-F662850A3134","latestVersionIndicator":"Yes","beginDate":"2019-05-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-08","modifiedBy":"SOKKERL","dateModified":"2023-12-01","changeNote":"5/8/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6759373","version":"1","preferredName":"Person Histologically Or Cytological Confirmation Thyroid Gland Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a person to participate in a clinical study addressing the histological or cytological verification of thyroid gland carcinoma as outlined in the clinical trial protocol.","longName":"HIST_CYTO_THYD_CARC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8905DB89-770C-3DC5-E053-F662850A5166","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-16","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"5/16/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6759443","version":"1","preferredName":"Refractory Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to diseases that are resistant to treatment as outlined in the study protocol.","longName":"REFRAC_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8905967D-E01A-4189-E053-F662850A0B9A","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-16","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"5/16/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6759608","version":"1","preferredName":"Patient Thyroid Gland Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to thyroid cancer as outlined in the protocol.","longName":"PT_THYD_CARC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8907A357-E528-2E7B-E053-F662850A980E","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-16","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"5/16/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6759620","version":"1","preferredName":"Therapeutic Procedure Prior VEGFR Tyrosine Kinase Inhibitor Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related therapeutic agents have been administered prior to VEGFR-TKI as outlined in  the protocol.","longName":"THPY_PROC_PR_VEGFR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8907A357-E554-2E7B-E053-F662850A980E","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-16","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"5/16/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6760898","version":"1","preferredName":"Therapeutic Procedure Complication Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to complications due to a therapeutic agents as outlined in the protocol.","longName":"THPY_PROC_COMP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8915E1AC-BA99-3B8C-E053-F662850A3A79","latestVersionIndicator":"Yes","beginDate":"2019-05-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-17","modifiedBy":"SOKKERL","dateModified":"2020-09-15","changeNote":"5/17/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6762812","version":"1","preferredName":"Urinary Creatinine Protein Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to an assessment of urine, creatinine and protein as outlined in the protocol.","longName":"UA_CREAT_PRT_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"891A0E31-19A1-113E-E053-F662850A1A2D","latestVersionIndicator":"Yes","beginDate":"2019-05-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-17","modifiedBy":"SOKKERL","dateModified":"2020-09-14","changeNote":"5/17/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6763180","version":"1","preferredName":"Patient Immune System and Related Disorders Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility requirements for participation in a clinical trial regarding immunodeficiency and Immunosuppression disorders as outlined in the study protocol.","longName":"IMUN_DISOR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8952A64D-B6EB-47EA-E053-F662850A428B","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-05-20","modifiedBy":"TAYLORT","dateModified":"2019-05-31","changeNote":"5-20-19 created for 10250; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6763184","version":"1","preferredName":"Patient Standard Of Care Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility requirements for participation in a clinical trial regarding treatment(s) that experts agree is appropriate, accepted, and widely used.","longName":"SOC_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8951E83D-5980-47CF-E053-F662850A860D","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-05-20","modifiedBy":"SOKKERL","dateModified":"2022-09-07","changeNote":"5-20-19 created for 10250; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6771086","version":"1","preferredName":"Patient Bone Marrow Involvement Laboratory Procedure Performed Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator whether a laboratory procedure has been performed that involves testing of bone marrow as outlined in the study protocol.","longName":"PT_BN_MAR_LAB_PER_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A1C8499-0AAF-0A8F-E053-F662850AE1E7","latestVersionIndicator":"Yes","beginDate":"2019-05-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-05-30","modifiedBy":"SOKKERL","dateModified":"2020-03-18","changeNote":"5/30/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6775347","version":"1","preferredName":"Patient Human Immunodeficiency Virus Infection No Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to HIV infection and is not receiving therapeutic agents as outlined in the protocol.","longName":"PT_HIV_NO_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA455C6-236F-38C8-E053-F662850A1216","latestVersionIndicator":"Yes","beginDate":"2019-06-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-06","modifiedBy":"SOKKERL","dateModified":"2019-06-07","changeNote":"6/6/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6776321","version":"1","preferredName":"Longest Tumor Diameter Measurement","preferredDefinition":"Numeric measurement value in millimeters to represent the size of a tumor.","longName":"LON_NEO_DIAM_MSRMT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AC08627-B7B8-0B54-E053-F662850A0889","latestVersionIndicator":"Yes","beginDate":"2019-06-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-07","modifiedBy":"SOKKERL","dateModified":"2019-11-29","changeNote":"6/7/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6779614","version":"1","preferredName":"Personal Medical History Autoimmune Disease Indicator","preferredDefinition":"An indicator response as to whether the patient has a medical history in which the body recognizes its own tissue as foreign and directs an immune response against them.","longName":"PER_MED_HX_AUTOIM_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B100B2A-802D-70F2-E053-F662850A88EE","latestVersionIndicator":"Yes","beginDate":"2019-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-11","modifiedBy":"GDEEN","dateModified":"2022-09-09","changeNote":"6/11/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6779621","version":"1","preferredName":"Patient Brain Metastases History Indicator","preferredDefinition":"An indicator if the patient has a history of brain metastases.","longName":"PT_BRN_METS_HX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B0F4A7D-C7A2-6A47-E053-F662850A374C","latestVersionIndicator":"Yes","beginDate":"2019-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-11","modifiedBy":"SOKKERL","dateModified":"2022-03-01","changeNote":"6/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6779705","version":"1","preferredName":"Person Histologically Or Cytopathology Thyroid Gland Carcinoma Confirmation Type","preferredDefinition":"The use of histological or cytopathology to identify the type of carcinoma arising from thyroid gland carcinoma.","longName":"PER_HIST_CYTO_THYD_GLD_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B11BE5C-A6A1-65E2-E053-F662850A3807","latestVersionIndicator":"Yes","beginDate":"2019-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-11","modifiedBy":"SOKKERL","dateModified":"2019-06-14","changeNote":"6/11/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780273","version":"1","preferredName":"Thyroid Gland Carcinoma Other Name Specify Text","preferredDefinition":"A text that describes the name of thyroid gland cancer not otherwise specified.","longName":"THYD_CA_OTH_SPEC_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B1F28E8-F1EB-48DA-E053-F662850AB58A","latestVersionIndicator":"Yes","beginDate":"2019-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-12","modifiedBy":"SOKKERL","dateModified":"2019-06-14","changeNote":"6/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780334","version":"1","preferredName":"Progressive Disease Therapeutic Procedure Receive Timepoint Type","preferredDefinition":"A specific point in the time when therapeutic agents was administrated to alter or stop progressive disease.","longName":"PRG_DZ_THPY_REC_TMPT_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B2249A4-4E77-0A45-E053-F662850A8352","latestVersionIndicator":"Yes","beginDate":"2019-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-12","modifiedBy":"SOKKERL","dateModified":"2019-06-19","changeNote":"6/12/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780782","version":"1","preferredName":"Prior Non-VEGFR Tyrosine Kinase Inhibitor Target Small Molecule Present Indicator","preferredDefinition":"An indicator if there is prior Non-VEGF target small molecule kinase inhibitor present.","longName":"NON_VEGFRTKI_SM_MOL_PRES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B27603C-0F5D-3A7D-E053-F662850AA1E3","latestVersionIndicator":"Yes","beginDate":"2019-06-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-13","modifiedBy":"SOKKERL","dateModified":"2019-06-14","changeNote":"6/13/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780804","version":"1","preferredName":"Patient Psychiatric Disorder Consent Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that address the assessment of patient's disease or illness to give permission as outlined in the study protocol.","longName":"PT_PSYDIS_CONS_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B36A593-5BBA-3F7F-E053-F662850A8368","latestVersionIndicator":"Yes","beginDate":"2019-06-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-13","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"6/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780822","version":"1","preferredName":"Patient Malignant Neoplasm Therapeutic Procedure Interference Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the use of therapeutic agents to produce an effect that is intended to alter or stop malignant neoplasm that interferes as outlined in the study protocol.","longName":"PT_MAL_NEO_THPY_INT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B361070-1B27-02AA-E053-F662850A59A4","latestVersionIndicator":"Yes","beginDate":"2019-06-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-13","modifiedBy":"SOKKERL","dateModified":"2023-03-07","changeNote":"6/13/19 ls","administrativeNotes":"9/23/22 added AQT for Theradex cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6782219","version":"1","preferredName":"Malignant Neoplasm Bone Metastatic Medication Receive Indicator","preferredDefinition":"A yes/no indicator if medication is being received for metastatic bone neoplasm.","longName":"MALG_NEOP_BN_METS_MEDS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B4AEFB1-0DC1-3E3B-E053-F662850A5DD6","latestVersionIndicator":"Yes","beginDate":"2019-06-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-14","modifiedBy":"CLOHNES","dateModified":"2023-02-16","changeNote":"6/14/19 ls","administrativeNotes":"2/16/23 added AQT for URMC ticket number CADSR0002058 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6782262","version":"1","preferredName":"Person Histologically Or Cytological Procedure Breast Carcinoma Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a person to participate in a clinical study addressing the histological or cytological verification of breast carcinoma as outlined in the clinical trial protocol.","longName":"HIST_CYTO_BRST_CARC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B4E1764-7DA2-68F8-E053-F662850A3CF9","latestVersionIndicator":"Yes","beginDate":"2019-06-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-14","modifiedBy":"SOKKERL","dateModified":"2020-04-06","changeNote":"6/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6783926","version":"1","preferredName":"Tumor Tissue Block Radiation Therapy Assessment Timepoint Type","preferredDefinition":"A tumor sample, or entire tumor that is removed for microscopic examination._Refers to preserved specimens embedded in support material.  These are typically cut into thin slices for microscopic examination, with or without an enhancement such as staining._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._The final result of a determination of the value, significance, or extent of._A specific point in the time continuum, including those established relative to an event._Something distinguishable as an identifiable class based on common qualities.","longName":"TUM_TIS_BLK_RAD_THPY_TMPT_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B9BBBD6-5148-278B-E053-F662850A7793","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-18","modifiedBy":"SOKKERL","dateModified":"2019-06-19","changeNote":"6/18/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6788482","version":"1","preferredName":"Treatment Cohort Study 10268 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10268 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10268_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BD70505-AE5F-4991-E053-F662850AA32B","latestVersionIndicator":"Yes","beginDate":"2019-06-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-21","modifiedBy":"SOKKERL","dateModified":"2019-06-21","changeNote":"6/21/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6792277","version":"1","preferredName":"Treatment Cohort Study 10264 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10264 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10264_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C3D680C-AC2E-540B-E053-F662850AC63E","latestVersionIndicator":"Yes","beginDate":"2019-06-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-26","modifiedBy":"SOKKERL","dateModified":"2019-11-07","changeNote":"6/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6796488","version":"1","preferredName":"Pharmacologic Agent Administered Or Chemically Analogue Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to administration of pharmacologic agents or synthetic chemical which structurally or functionally resembles a naturally occurring compound as outlined in the study protocol.","longName":"PHRM_AGT_ADMN_CHEM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C3F7B84-176B-6533-E053-F662850AC338","latestVersionIndicator":"Yes","beginDate":"2019-06-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-06-26","modifiedBy":"SOKKERL","dateModified":"2023-07-20","changeNote":"6/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6818958","version":"1","preferredName":"Treatment Cohort Study 10220 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10220 in which subsets of a defined population are identified.","longName":"COH_SDY_10220","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DBD87CD-AE4F-5623-E053-F662850A48B2","latestVersionIndicator":"Yes","beginDate":"2019-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-15","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/15/19 Theradex required an additional cohort CDE for this trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6821367","version":"1","preferredName":"Laboratory Procedure Within Clinical Study Protocol Upper Limit of Normal Total Bilirubin Measurement Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to the top value of the range for total bilirubin falling within parameters set forth by the guidelines for a clinical trial.","longName":"LAB_PROC_TMB_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E4A3450-8122-3694-E053-F662850AE1C8","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-23","modifiedBy":"TYRRELLM","dateModified":"2023-07-20","changeNote":"7/23/19 ls","administrativeNotes":"7/20/23 removed special characters from AQT_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6824989","version":"1","preferredName":"Tumor Lysis Syndrome Initiation Therapy Present  Status","preferredDefinition":"A condition or state at a particular time related to the presence of Tumor Lysis Syndrome at the initiation of treatment.","longName":"TLS_INT_THPY_PRES_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6ED1D0-C4DE-7ACA-E053-F662850AEC02","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"SOKKERL","dateModified":"2019-07-24","changeNote":"7/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6825037","version":"1","preferredName":"Tumor Lysis Syndrome Present Anatomic Site Name","preferredDefinition":"The anatomic site name related to the presence of Tumor Lysis Syndrome.","longName":"TLS_PRES_ANAT_ST_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E708FF6-0C65-1D0D-E053-F662850AABD0","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-24","modifiedBy":"SOKKERL","dateModified":"2019-07-24","changeNote":"7/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6835247","version":"1","preferredName":"Patient Receive Oral Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a patient receiving oral therapeutic agents as outlined in the protocol.","longName":"PT_REC_ORL_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED593C3-8E6F-1E97-E053-F662850AA13F","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-29","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"7/29/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6841638","version":"1","preferredName":"Patient PD-L1 Negative Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient is PD-L1 Negative as outlined in the study protocol.","longName":"PT_PDL_NEG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFDCA5F-EFFF-0FE4-E053-F662850AB442","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-07-31","modifiedBy":"SOKKERL","dateModified":"2021-03-18","changeNote":"7/31/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845577","version":"1","preferredName":"Treatment Cohort Study 10273 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10273 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10273_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F27FC29-2AD4-7837-E053-F662850A1CB4","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-02","modifiedBy":"SOKKERL","dateModified":"2019-08-15","changeNote":"8/2/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845798","version":"1","preferredName":"Disease or Disorder Detection Molecular Analysis DNA Probes Name","preferredDefinition":"The text response that indicates the name of the DNA probe used in determining disease status using FISH and/or karyoptyping methods of assessment.","longName":"DZDET_DNA_PROBE_NAME","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2CC8F4-4450-771D-E053-F662850A28D3","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845821","version":"1","preferredName":"Laboratory Procedure Bone Marrow Fibrosis Reticulum Staining Method Finding Status","preferredDefinition":"The response that indicates the status of the bone marrow fibrosis assessment.","longName":"BM_FIBR_RET_STAIN_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2D2197-F999-366A-E053-F662850A4B83","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845822","version":"1","preferredName":"DNA Probes Positive Finding Cell Count","preferredDefinition":"The numeric response that indicates the number of positive cells identified by DNA probes.","longName":"DNAPROB_POS_CELL_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2D295B-35B5-4610-E053-F662850A9349","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845823","version":"1","preferredName":"DNA Probes Total Cell Count","preferredDefinition":"The numeric response that indicates the total number of cells evaluated using DNA probes.","longName":"DNAPROB_TOT_CELL_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2D2197-F9BB-366A-E053-F662850A4B83","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845824","version":"1","preferredName":"DNA Probes Positive Finding Cell Percentage Value","preferredDefinition":"The numerical response that indicates the percentage of positive finding cells tested using DNA probes.","longName":"POS_CELL_PRCT_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2D2197-F9DD-366A-E053-F662850A4B83","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845825","version":"1","preferredName":"Cytogenetic Abnormality Recurrent Chromosomal Translocation Process Present Status","preferredDefinition":"The text response that indicates the presence or absence of recurrent chromosomal translocation for the evaluated individual.","longName":"REC_CHROM_TRANS_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2D4947-30F7-56A9-E053-F662850AF0AA","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845826","version":"1","preferredName":"Cytogenetic Abnormality Recurrent Chromosomal Translocation Process Type","preferredDefinition":"The response indicating the type of recurrent chromosomal translocation identified.","longName":"REC_CHROM_TRANS_TYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2D4FE9-DDDD-7193-E053-F662850AE225","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845827","version":"1","preferredName":"Cytogenetic Abnormality Diagnosis Present Status","preferredDefinition":"The text response indicating the presence, absence or unknown status of cytogenetic abnormalities.","longName":"CYTOGEN_ABN_DX_ST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2D2197-F9FF-366A-E053-F662850A4B83","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6845828","version":"1","preferredName":"Cytogenetic Abnormality Diagnosis Type","preferredDefinition":"The response indicating the type of cytogenetic abnormality present.","longName":"CYTOGEN_ABN_DX_TYPE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F2835E2-5383-7833-E053-F662850AFF60","latestVersionIndicator":"Yes","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"HARTLEYG","dateModified":"2019-08-05","changeNote":"Curated to support protocol 10264","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848360","version":"1","preferredName":"Treatment Cohort Study 10273 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10273 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_PTR_10273_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F894FCF-DB4D-4E74-E053-F662850A352B","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-07","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"8/7/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6848515","version":"1","preferredName":"Treatment Cohort Study 9924 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9924 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9924_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F9BF14D-3825-5E5E-E053-F662850A5FA9","latestVersionIndicator":"Yes","beginDate":"2019-08-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-08","modifiedBy":"SOKKERL","dateModified":"2019-08-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6849059","version":"1","preferredName":"Treatment Cohort Study 10287 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10287 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10287_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FF17346-FB46-305E-E053-F662850A60BB","latestVersionIndicator":"Yes","beginDate":"2019-08-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-12","modifiedBy":"SOKKERL","dateModified":"2019-08-13","changeNote":"8/12/19 Cohort study 10287 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6856337","version":"1","preferredName":"Patient Gene Mutation Abnormality Receive Targeted Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that addresses genomic aberration and is receiving targeted therapy as outlined in  the protocol.","longName":"GEN_MUT_ABN_TRGT_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"903E18FC-235E-4576-E053-F662850A9464","latestVersionIndicator":"Yes","beginDate":"2019-08-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-16","modifiedBy":"KUMMEROA","dateModified":"2023-07-21","changeNote":"8/16/19 ls","administrativeNotes":"2023.7.21 AQT added per ticket request CADSR0002642. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6857210","version":"1","preferredName":"Specimen Adequate Assessment Other Specify Text","preferredDefinition":"The free text field that describes other requirement for specimen assessment which are different from the ones previously specified.","longName":"SPEC_ADQ_ASSMT_OTHR_SPEC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"907A83CC-3702-7A54-E053-F662850A167D","latestVersionIndicator":"Yes","beginDate":"2019-08-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-19","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeNote":"8/19/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6857214","version":"1","preferredName":"Specimen Destination Institution Name","preferredDefinition":"The name of the site that receives or is intended to receive a specimen","longName":"SPEC_REC_INST_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"907AE8F8-B8CA-3AF3-E053-F662850AFBF4","latestVersionIndicator":"Yes","beginDate":"2019-08-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-19","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"10/29/19 jk upd revised DEC.  8/19/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6857362","version":"1.1","preferredName":"Total Mastectomy Or Wide Local Excision Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has had a total mastectomy or wide local excision as outlined in the study protocol.","longName":"TTL_MAST_WLEX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3B0847E-193C-2D0E-E053-4EBD850ACEF4","latestVersionIndicator":"Yes","beginDate":"2019-08-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-11-09","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"8/19/19 ls 11/9/20 version DEC to meet semantical change.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6857381","version":"1","preferredName":"Patient Breast Surgical Procedure And Chemotherapy Complete Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has completed breast surgery and chemotherapy as outlined in the study protocol.","longName":"BRST_SX_CHEM_COMP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"907D8399-1733-3F14-E053-F662850A98D0","latestVersionIndicator":"Yes","beginDate":"2019-08-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-19","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"8/19/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6857577","version":"1","preferredName":"Patient Receive Adjuvant Systemic Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation as outlined in the protocol for questions related to administration of adjuvant systemic therapy  as outlined in the study protocol..","longName":"PT_ADJ_SYTM_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"908B87D8-F916-3349-E053-F662850A205C","latestVersionIndicator":"Yes","beginDate":"2019-08-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-20","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"8/20/19  ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6857592","version":"1","preferredName":"Patient Breast Chest Wall Regional Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to radiation therapy to breast/chest wall and regional area as outlined in the study protocol.","longName":"PT_BRST_CXR_REG_RT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"907F670D-5241-16EC-E053-F662850AA6CC","latestVersionIndicator":"Yes","beginDate":"2019-08-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-20","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"8/20/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6857598","version":"1","preferredName":"Bilateral Breast Carcinoma Radiation Therapy Administered Unilateral Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to a patient with bilateral breast cancer and administration of radiation therapy only to one side as outlined in the study protocol.","longName":"BIL_BC_RT_ADMIN_UNIL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"907F670D-5268-16EC-E053-F662850AA6CC","latestVersionIndicator":"Yes","beginDate":"2019-08-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-08-20","modifiedBy":"SOKKERL","dateModified":"2020-02-19","changeNote":"8/20/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6871990","version":"1","preferredName":"Treatment Cohort Study 10291 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10291 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10291_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"91A7ADE9-33B5-7F5F-E053-F662850A81C5","latestVersionIndicator":"Yes","beginDate":"2019-09-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-03","modifiedBy":"SOKKERL","dateModified":"2019-09-03","changeNote":"9/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6888422","version":"1","preferredName":"Patient Histological Confirmation Metastatic Solid Neoplasm Progressive Disease Standard Therapy Or No Standard Therapy Exist Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine eligibility for clinical trial participation for questions related to confirmation of metastatic solid neoplasm that is increasing in scope or severity after standard of care treatment for the disease, or for which no standard of care treatment for the disease exists as outlined in the study protocol.","longName":"HIS_CNFM_PROG_STD_TX_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"91ABAFF2-C243-0B01-E053-F662850AFBC7","latestVersionIndicator":"Yes","beginDate":"2019-09-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-03","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":"9/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6897912","version":"1","preferredName":"Radiation Therapy Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation for questions related to radiation therapy to neoplasm as outlined in the study protocol.","longName":"RT_NEOP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"91BAB792-BFF7-17FC-E053-F662850A4552","latestVersionIndicator":"Yes","beginDate":"2019-09-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-04","modifiedBy":"SOKKERL","dateModified":"2019-11-21","changeNote":"9/4/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6898002","version":"1","preferredName":"Patient Negation Ability Discontinue Intervention or Procedure Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related weather the patient is able to discontinue a procedure to treat disease as outlined in the study protocol.","longName":"PT_NO_ABLE_DISC_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"91BD5B2F-B7A5-1CF8-E053-F662850AB2F3","latestVersionIndicator":"Yes","beginDate":"2019-09-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-04","modifiedBy":"SOKKERL","dateModified":"2023-07-18","changeNote":"9/4/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6909066","version":"1","preferredName":"Brain Metastatic Disease No Imaging Evidence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to metastatic brain disease with no imaging evidence of disease as outlined in the study protocol.","longName":"BR_METS_NO_IMG_EVID_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91D1DD2F-CC3E-495C-E053-F662850A0EEE","latestVersionIndicator":"Yes","beginDate":"2019-09-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-05","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"9/5/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6922030","version":"1","preferredName":"Treatment Cohort Study 10276 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10276 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10276_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"92380E2F-2ABA-4CD6-E053-F662850A5FE6","latestVersionIndicator":"Yes","beginDate":"2019-09-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-10","modifiedBy":"SOKKERL","dateModified":"2019-09-10","changeNote":"9/10/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6922466","version":"1","preferredName":"Treatment Cohort Study 9948 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9948 in which subsets of a defined population are identified.","longName":"TX_COH_STDY_9948_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"924670B3-F581-1939-E053-F662850AF557","latestVersionIndicator":"Yes","beginDate":"2019-09-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-11","modifiedBy":"SOKKERL","dateModified":"2019-09-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6941853","version":"1","preferredName":"Tumor Tissue Specimen Adequate Assessment Indicator","preferredDefinition":"A yes/no indicator whether the specimen is adequate for examination.","longName":"TM_TISS_SPEC_ADQ_ASSES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"92C32A5C-58C3-4DD2-E053-F662850AE1D8","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-17","modifiedBy":"SOKKERL","dateModified":"2019-09-18","changeNote":"9/17/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944733","version":"1","preferredName":"Allele (Chromosome) Identifier","preferredDefinition":"One or more characters used to differentiate between the subjects two alleles when comparing records.","longName":"PFALLELC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93684E7F-D273-6E09-E053-F662850ABFA3","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM.; 9-26-19 tmt released/MM.; 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944734","version":"1","preferredName":"Genetic Location of Interest","preferredDefinition":"A location within the sequence of a genetic read.","longName":"PFGENLI","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93688CFB-AC55-323A-E053-F662850A0B37","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944735","version":"1","preferredName":"Alternative Allele Identifier","preferredDefinition":"A secondary sequence of characters used to identify the allele.","longName":"PFALLELA","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9368C16A-26D3-308C-E053-F662850A7B9A","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM.; 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944736","version":"1","preferredName":"Transcript","preferredDefinition":"The outcome of the test or finding as originally received or collected.","longName":"PFORRES_TRANSCRIPT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93671531-E441-3965-E053-F662850AB923","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944737","version":"1","preferredName":"Coding Sequence","preferredDefinition":"The outcome of the test or finding as originally received or collected.","longName":"PFORRES_CODSEQ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9367D353-EF32-056C-E053-F662850AD318","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944738","version":"1","preferredName":"Amino Acids","preferredDefinition":"The outcome of the test or finding as originally received or collected.","longName":"PFORRES_AMACID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93690A69-8B67-33C2-E053-F662850A1286","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944739","version":"1","preferredName":"Variant ID","preferredDefinition":"One or more characters used to identify the variant.","longName":"PFVARID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9362E7BE-AE49-5B24-E053-F662850A505D","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944742","version":"1","preferredName":"Variant Allele Frequency","preferredDefinition":"The outcome of the test or finding as originally received or collected.","longName":"PFORRES_VAF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9367D353-EF53-056C-E053-F662850AD318","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944747","version":"1","preferredName":"Function","preferredDefinition":"The outcome of the test or finding as originally received or collected.","longName":"PFORRES_FUNCTION","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93690A69-8B88-33C2-E053-F662850A1286","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"TAYLORT","dateModified":"2019-09-26","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6944764","version":"1","preferredName":"Report Upload","preferredDefinition":"The report identifier for an external file.","longName":"RPTXFN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93673772-DBF0-044B-E053-F662850A373C","latestVersionIndicator":"Yes","beginDate":"2019-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-25","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeNote":"9-26-19 tmt released/MM. 9-25-19 Created for Oncomine Form; tmt.","administrativeNotes":"2022.9.13 AQT added for ticket request CADSR0001486. ak 2022.9.16 AQT added for ticket request CADSR0001520. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6945860","version":"1","preferredName":"Medical History Cardiac Disease Cardiac Toxicity Agent Assessment Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the patient medical history of cardiac disease and history to cardiotoxic drug assessment as outlined in the protocol.","longName":"MEDHX_CARD_DZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"936B6754-F904-419D-E053-F662850A43AB","latestVersionIndicator":"Yes","beginDate":"2019-09-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-26","modifiedBy":"KUMMEROA","dateModified":"2023-06-27","changeNote":"9/26/19 ls","administrativeNotes":"2023.6.27 AQT added per ticket request CADSR0002556. ak 9/23/22 added AQT for Theradex cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950260","version":"1","preferredName":"Genetic Region of Interest","preferredDefinition":"The region or sub-location of the genetic or genomic sequence that is described by the test.","longName":"PFGENRI","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93891F84-5EDD-6C9A-E053-F662850A28D4","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"TAYLORT","dateModified":"2019-09-30","changeNote":"9-30-19 tmt released/mm. 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950266","version":"1","preferredName":"Coverage","preferredDefinition":"The total number of sequencing reads at this position.","longName":"PFORRES_COV","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93894B52-72AD-2E45-E053-F662850A42E1","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"TAYLORT","dateModified":"2019-09-30","changeNote":"9-30-19 tmt released/mm. 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950267","version":"1","preferredName":"Reference Coverage","preferredDefinition":"The total number of reference reads.","longName":"PFORRES_COVR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93894B52-72CE-2E45-E053-F662850A42E1","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"TAYLORT","dateModified":"2019-09-30","changeNote":"9-30-19 tmt released/mm. 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950268","version":"1","preferredName":"Alternative Coverage","preferredDefinition":"The total number of alternative reads.","longName":"PFORRES_COVA","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"938682E0-BCCA-18C3-E053-F662850A3EA1","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"TAYLORT","dateModified":"2019-09-30","changeNote":"9-30-19 tmt released/mm.; 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950269","version":"1","preferredName":"Copy Number","preferredDefinition":"The number of times that a pharmacogenomics region of interest is present in the genome.","longName":"PFORRES_COPYNUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93895E86-AE3B-2FA3-E053-F662850A2ACD","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"TAYLORT","dateModified":"2019-09-30","changeNote":"9-30-19 tmt released/mm. 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950271","version":"1","preferredName":"Read Count","preferredDefinition":"The number of sequencing reaction results that were pooled to obtain the pharmacogenomics coverage.","longName":"PFORRES_COUNT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9389643C-B8F1-1881-E053-F662850A505D","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"TAYLORT","dateModified":"2019-09-30","changeNote":"9-30-19 tmt released/mm. 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950487","version":"1","preferredName":"Mutation Type","preferredDefinition":"The type of transmissible change in the genetic material.","longName":"PFMUTYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93894B52-7433-2E45-E053-F662850A42E1","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"NIKITAP","dateModified":"2022-02-24","changeNote":"9-30-19 tmt released/mm. 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950488","version":"1","preferredName":"Reference Allele Identifier","preferredDefinition":"Terminology associated with the pharmacogenomics findings test code codelist.","longName":"PFALLELR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"938A6196-9521-71AC-E053-F662850A2A50","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-09-27","modifiedBy":"TAYLORT","dateModified":"2019-09-30","changeNote":"9-30-19 tmt released/mm. 9-27-19 Created for Oncomine Form; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6950927","version":"1","preferredName":"Medical History Osteonecrosis of Jaw Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the patient's medical history of osteonecrosis of the  jaw as outlined in the study protocol.","longName":"MED_HX_OSTSN_JAW_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"938A012D-676E-3867-E053-F662850AAFD0","latestVersionIndicator":"Yes","beginDate":"2019-09-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-09-27","modifiedBy":"SOKKERL","dateModified":"2019-10-02","changeNote":"9/27/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6953221","version":"1","preferredName":"Molecular Analysis Gene Name Text","preferredDefinition":"The text term used to describe a gene name by a laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","longName":"MOL_MUT_GEN_NM_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"93DA025F-A370-06C7-E053-F662850AF334","latestVersionIndicator":"Yes","beginDate":"2019-10-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-01","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeNote":"10/1/19 ls","administrativeNotes":"2023.3.13 AQT added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6962626","version":"1","preferredName":"Enrollment Treatment Study Assignment Code","preferredDefinition":"Code delivered at the time of patient enrollment onto a clinical trial to denote the treatment assignment.","longName":"ENROLL_TX_ASSIGNT_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"940511F9-2226-590E-E053-F662850A035F","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-03","modifiedBy":"SOKKERL","dateModified":"2019-10-03","changeNote":"10/3/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6962951","version":"1","preferredName":"Any Tumors Reported","preferredDefinition":"An indication whether or not any tumors were reported.","longName":"TUYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94057A26-0ED3-16F7-E053-F662850AF404","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-03","modifiedBy":"KUMMEROA","dateModified":"2023-07-24","changeNote":"10-7-19 released/mm.  10-3-19 Created for Theradex/custom CDISC request; tmt.","administrativeNotes":"2023.7.24 AQT/Alt SN added per ticket request CADSR0002649. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6964544","version":"1","preferredName":"Protocol Criteria Versions","preferredDefinition":"An identifier for the version of the Inclusion/Exclusion criteria.","longName":"TIVERS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"940511F9-2281-590E-E053-F662850A035F","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-03","modifiedBy":"TAYLORT","dateModified":"2019-10-07","changeNote":"10-7-19 released/mm. 10-3-19 Created for Theradex/custom CDISC request; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6964545","version":"1","preferredName":"Lab End Date","preferredDefinition":"The end date related to laboratory data represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"LBENDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F6BA9E-BA98-6C6A-E053-F662850A7805","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-03","modifiedBy":"TAYLORT","dateModified":"2019-10-07","changeNote":"10-7-19 released/mm. 10-3-19 Created for Theradex/custom CDISC request; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6964546","version":"1","preferredName":"Lab End Time","preferredDefinition":"The end time related to laboratory data represented in an unambiguous time format (e.g., hh:mm:ss).","longName":"LBENTIM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94054C78-C2FB-1599-E053-F662850ACD84","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-03","modifiedBy":"TAYLORT","dateModified":"2019-10-07","changeNote":"10-7-19 released/mm.  10-3-19 Created for Theradex/custom CDISC request; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6964580","version":"1","preferredName":"Informed Consent Version","preferredDefinition":"An identifier for the version of the Consent Form.","longName":"DSICVERS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94049CC9-DF55-6118-E053-F662850A8E4F","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-03","modifiedBy":"ZHANGWE","dateModified":"2020-05-28","changeNote":"10-7-19 released/mm. 10-3-19 Created for Theradex/custom CDISC request; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6964626","version":"1","preferredName":"Source Form","preferredDefinition":"A text description for the source form.","longName":"SRCFRM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F78A94-0443-159D-E053-F662850A6FBE","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-03","modifiedBy":"TAYLORT","dateModified":"2019-10-07","changeNote":"10-7-19 released/mm. 10-3-19 Created for Theradex/custom CDISC request; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6964658","version":"2","preferredName":"Analysis Method","preferredDefinition":"Method of the test or examination.","longName":"LBANMETH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD451EF4-D07A-385D-E053-4EBD850AF1DE","latestVersionIndicator":"Yes","beginDate":"2019-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-03-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-16","changeNote":"3/11/21 TL versioned / v2 VD.","administrativeNotes":"2022.8.16 Reviewed and changed RS from 'Incomplete' to 'Application'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6968096","version":"1","preferredName":"Inflammatory Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to inflammatory disease or disorders as outlined in the protocol.","longName":"INFM_DZ_DISOR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9413CEDB-C753-68C7-E053-F662850ABDDF","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-04","modifiedBy":"SOKKERL","dateModified":"2020-07-16","changeNote":"10/4/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6978626","version":"1","preferredName":"Patient Treatment Failure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the lack of expected or desired effect to therapy as outlined in the study protocol.","longName":"TX_FAIL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94942209-8F8B-1204-E053-F662850A6CB4","latestVersionIndicator":"Yes","beginDate":"2019-10-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-10","modifiedBy":"SOKKERL","dateModified":"2023-01-10","changeNote":"10-10-19 tmt/10315.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6978645","version":"1","preferredName":"Patient Lesion Biopsy Safely And Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether or not lesions can be safely biopsied and that patient permission was received for the removal of tissue specimens or fluids for microscopic examination in order to determine eligibility for clinical trial participation","longName":"LES_BX_SAFE_CONS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9495C98D-6674-6078-E053-F662850A673E","latestVersionIndicator":"Yes","beginDate":"2019-10-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-10","modifiedBy":"TAYLORT","dateModified":"2019-10-14","changeNote":"10-14-19 tt Released/VM.; 9/26/16 tt, approved/released. 9/22/16 tt, created for 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6978844","version":"1","preferredName":"Patient Personal Medical History Radiation Therapy Complications Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the patient's medical history of any disease or disorder caused by radiation therapy.","longName":"PMH_RT_COMPL_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94A29C9F-0667-0750-E053-F662850A67F2","latestVersionIndicator":"Yes","beginDate":"2019-10-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-11","modifiedBy":"TAYLORT","dateModified":"2019-10-14","changeNote":"10-11-19 tmt/10315.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6978965","version":"1","preferredName":"Patient Personal Medical History Physical And Concomitant Therapy Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the patient's medical history of requirements for physical and pharmaceutical agents other than agent(s) tested in a given protocol.","longName":"PMH_PHYS_CONTRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94A32FB0-996B-0746-E053-F662850A4BEC","latestVersionIndicator":"Yes","beginDate":"2019-10-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-11","modifiedBy":"SOKKERL","dateModified":"2022-07-18","changeNote":"10-11-19 tmt/10315.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6979049","version":"1","preferredName":"Personal Medical History Disease or Disorder Patient Compliance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine trial eligibility for questions related to the patient's medical background of any abnormal condition(s) of the body or mind that would hinder his/her ability to follow study protocol requirements.","longName":"PMH_DZDIS_COMPLI_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94A29C9F-06BC-0750-E053-F662850A67F2","latestVersionIndicator":"Yes","beginDate":"2019-10-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-11","modifiedBy":"TAYLORT","dateModified":"2019-10-14","changeNote":"10-11-19 tt/10315.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6982509","version":"1","preferredName":"Patient Human Immunodeficiency Virus Positive Undetectable Viral Load Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to HIV infection with undetectable viral load as outlined in the study protocol.","longName":"HIV_UNDET_VL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94DFEE96-B1AD-1671-E053-F662850A450E","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-14","modifiedBy":"SOKKERL","dateModified":"2019-10-21","changeNote":"10/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6983215","version":"1","preferredName":"Start Date of Biospecimen Event","preferredDefinition":"The start date of the biospecimen event represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"BESTDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E40AE0-A0FD-2CB1-E053-F662850A9B79","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-14","modifiedBy":"TAYLORT","dateModified":"2020-05-05","changeNote":"5-5-20 tmt released per MM. 10-14-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6986568","version":"1","preferredName":"End Date of Biospecimen Event","preferredDefinition":"The end date of the biospecimen event represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"BEENDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E504C5-9F65-0353-E053-F662850AE8B2","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-14","modifiedBy":"TAYLORT","dateModified":"2020-05-05","changeNote":"5-5-20 tmt released per MM. 10-14-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6986611","version":"1","preferredName":"Date of Specimen Collection","preferredDefinition":"The date of specimen collection represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"BEDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E3FB57-320B-2CBB-E053-F662850AFC6A","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-14","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-14-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6986713","version":"1","preferredName":"Reference ID","preferredDefinition":"A sequence of characters used to identify, name, or characterize the biospecimen event reference.","longName":"BEREFID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E58C63-F0DA-6C35-E053-F662850A35C0","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-14","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-14-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6986728","version":"1","preferredName":"Accountable Party","preferredDefinition":"The person, organization, or location responsible for the transferable object (e.g. specimen).","longName":"BEPARTY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E55742-0E2E-0381-E053-F662850A6AEC","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-14","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-14-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6995456","version":"3","preferredName":"Anatomical Location of Event","preferredDefinition":"The anatomic site relative to the specimen event.","longName":"BELOC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B26624-953F-7699-E053-731AD00ABACB","latestVersionIndicator":"Yes","beginDate":"2019-10-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-02","modifiedBy":"RAGUNATHANU","dateModified":"2023-07-28","changeNote":"2022-4-14 ak Versioned due to needing newer VD to reflect CT Pkg 49 updates. 10-15-19 created for Seed Study, Specimen tracking; tt.","administrativeNotes":"2022.9.2 Versioned due to needing newer VD to reflect CT Pkg 50 updates. ak  2022.11.28 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6995465","version":"1","preferredName":"Treatment Cohort Study 9930 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9930 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9930_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E65BD6-A9C3-7F50-E053-F662850A76DE","latestVersionIndicator":"Yes","beginDate":"2019-10-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-15","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"10/15/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6995490","version":"1","preferredName":"Sponsor-Defined Identifier","preferredDefinition":"One or more sponsor defined characters used to identify, name, or characterize the biospecimen collection and storage information.","longName":"BESPID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E84D06-8EAF-329F-E053-F662850ACA58","latestVersionIndicator":"Yes","beginDate":"2019-10-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-15","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-09","changeNote":"6-2-20 released/MM. 10-15-19 created for Seed Study, Specimen tracking; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6998893","version":"1","preferredName":"Specimen Type","preferredDefinition":"The type of biospecimen collected and stored.","longName":"BESPEC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9506F27A-56F5-242B-E053-F662850A82CD","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-16","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"10-16-19 created for Seed Study, Specimen tracking; tt.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6999331","version":"1","preferredName":"Trial Title","preferredDefinition":"Short name for an individual characteristic of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial.","longName":"TITLE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95094308-519F-0939-E053-F662850AD584","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-16","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"10-16-19 created for Seed Study; tmt.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6999521","version":"1","preferredName":"Check box","preferredDefinition":"Tickbox indicator as to whether a table requires corrections, revisions, or refreshing.","longName":"CKBOX_REFRESH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950A4F65-098B-1871-E053-F662850AF719","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-16","modifiedBy":"TAYLORT","dateModified":"2021-04-28","changeNote":"10-16-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001218","version":"1","preferredName":"Copy Shipping Status","preferredDefinition":"Tickbox indicator to address the status of copy shipping for specimen tracking.","longName":"CPYSHP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95107C06-69CD-2D12-E053-F662850ABB1C","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001243","version":"1","preferredName":"Tracking Number","preferredDefinition":"The free-text field for the sample tracking number.","longName":"TRKNUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951C5436-D865-4271-E053-F662850A5D80","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001271","version":"1","preferredName":"Check box to add form","preferredDefinition":"Tickbox indicator to add a form.","longName":"CKBOX_ADD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951CFD60-FBC7-069E-E053-F662850A43E9","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"KUMMEROA","dateModified":"2020-06-26","changeNote":"10-16-19 created for Seed Study; tmt. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001583","version":"1","preferredName":"Courier Name","preferredDefinition":"The name of the group that facilitates the exchange of specimens.","longName":"COURIER","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951D0158-CD05-0698-E053-F662850A9CEE","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-05-05","changeNote":"5-5-20 tmt released per MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001597","version":"1","preferredName":"Shipping Tracking Number","preferredDefinition":"The free-text field for the shipping tracking number of a specimen.","longName":"SHTRKNUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951D2EA4-6BD1-0694-E053-F662850A9500","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-05-05","changeNote":"5-5-20 tmt released per MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001610","version":"1","preferredName":"Shipping Source","preferredDefinition":"A free-text field to provide the shipping source of a specimen.","longName":"SRC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951D2EA4-6BF2-0694-E053-F662850A9500","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001629","version":"1","preferredName":"Contact Person Name","preferredDefinition":"The name of the contact person associated with the shipping source of a specimen.","longName":"SRCNAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951DE889-0FD9-63E1-E053-F662850AFDBE","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001647","version":"1","preferredName":"Telephone Number:","preferredDefinition":"The telephone number for the shipping source of a specimen.","longName":"SRCTELE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951D2EA4-6C13-0694-E053-F662850A9500","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM.10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001669","version":"1","preferredName":"Notice sent to","preferredDefinition":"A free-text field to provide the email address of the contact person for specimen tracking.","longName":"EMAIL_REC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951D15E0-5C84-0690-E053-F662850A46EA","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001679","version":"1","preferredName":"Shipping Conditions","preferredDefinition":"The surrounding conditions of a shipped specimen.","longName":"SHPCOND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951D2EA4-6C34-0694-E053-F662850A9500","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001789","version":"1","preferredName":"Send E-mail Alert","preferredDefinition":"A tickbox indicator as to whether or not an email alert is to be sent.","longName":"CKBOX_ALERT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951CFD60-FCBD-069E-E053-F662850A43E9","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7001796","version":"1","preferredName":"Number of Samples Sent","preferredDefinition":"The number of specimens sent.","longName":"SENTNUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"951EC667-2EA6-5FAC-E053-F662850AC657","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-05-05","changeNote":"5-5-20 tmt released per MM.  3/0/17 tt, EA1151.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7002949","version":"1","preferredName":"If Other, specify","preferredDefinition":"A free-text field to provide the other condition of a sample upon receipt.","longName":"RCVCOND_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9520E3E6-249A-5FD4-E053-F662850A3721","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":"2021-09-24","createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"10-17-19 created for Seed Study; tmt. 9/24/21 ls  retired per theradex","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7002999","version":"1","preferredName":"Specimen is Adequate","preferredDefinition":"The indicator as to whether or not a sample is sufficient.","longName":"SPCADQYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951F5889-35FC-105E-E053-F662850A481A","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"SPRINGERL","dateModified":"2020-06-28","changeNote":"2/7/20 tmt released/MM. 11/17/18 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7003001","version":"1","preferredName":"Explanatory Reason","preferredDefinition":"A set of statements describing a group of facts that clarifies the cause, context and/or consequence for the packaging and shipping submission condition(s) of a specimen.","longName":"ADREAS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951DE889-1028-63E1-E053-F662850AFDBE","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-03-31","changeNote":"3-31-20 tmt released/MM. 3-25-20 edits to Draft New content; tmt. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7003002","version":"1","preferredName":"Primary Diagnosis Disease Group","preferredDefinition":"The sample disease group at initial diagnosis.","longName":"DXGRP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951F5889-361D-105E-E053-F662850A481A","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"GALITG","dateModified":"2022-01-28","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7003008","version":"1","preferredName":"SnoMed Disease Term/Code","preferredDefinition":"SNOMED disease term/code for specimen tracking.","longName":"SNOMED","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951027E9-F4BD-547F-E053-F662850A18F6","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"AK 2020-6-2; 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7003892","version":"1","preferredName":"Tissue Type","preferredDefinition":"A grouping of items based on user defined characteristics for the kind of tissue submitted.","longName":"TISTYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"952307A0-9356-762C-E053-F662850AEDF0","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"FINCHAMB","dateModified":"2023-08-07","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":"8/7/23 Added CSI and Alt Names with source of “CMB” in the CTDC data model. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7004266","version":"1","preferredName":"Number of Labels","preferredDefinition":"The number of labels necessary for sample tracking.","longName":"LBLNUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9522F1ED-0FFB-7628-E053-F662850A9C86","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7005726","version":"1","preferredName":"Upload pathology report","preferredDefinition":"A free-text field to address the upload of a pathology report for specimen tracking.","longName":"PATHXFN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95233020-C7C8-7632-E053-F662850A1DA6","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"SOKKERL","dateModified":"2020-06-22","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7006025","version":"1","preferredName":"Upload molecular report","preferredDefinition":"A free-text field to address the upload of a molecular analysis report for specimen tracking.","longName":"MOLXFN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"952398C6-EB18-7642-E053-F662850A36ED","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-17","modifiedBy":"TAYLORT","dateModified":"2020-06-02","changeNote":"6-2-20 released/MM. 10-17-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7008317","version":"1","preferredName":"Shipper's email address","preferredDefinition":"A free-text field to provide the shipper's email address for specimen tracking.","longName":"EMAIL_SHP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"953057C5-ABFB-3630-E053-F662850ABFF7","latestVersionIndicator":"Yes","beginDate":"2019-10-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-18","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 10-18-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7008434","version":"1","preferredName":"Recurrent Persistent Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to recurrent or persistent  disease as outlined in the protocol.","longName":"RECUR_PERST_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9530ACAB-9131-3B12-E053-F662850A84A6","latestVersionIndicator":"Yes","beginDate":"2019-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-18","modifiedBy":"SOKKERL","dateModified":"2019-10-25","changeNote":"10/18/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7008452","version":"1","preferredName":"Specimen Availability Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address specimen availability as outlined in the study protocol.","longName":"SPEC_AVAIL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9530ADF9-406F-199D-E053-F662850A80D4","latestVersionIndicator":"Yes","beginDate":"2019-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-18","modifiedBy":"SOKKERL","dateModified":"2023-12-27","changeNote":"10/18/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7008457","version":"1","preferredName":"Person Platinum Compound Chemotherapy Sensitivity Therapy Option Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions that allow a person to participate in a clinical study that address platinum-sensitive chemotherapy as an alternative choice or action as outlined in the study protocol.","longName":"CT_PLT_SNTVTY_TX_OPT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95339BE9-6219-19A1-E053-F662850A9D0D","latestVersionIndicator":"Yes","beginDate":"2019-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-18","modifiedBy":"SOKKERL","dateModified":"2020-10-19","changeNote":"10/18/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7008463","version":"1","preferredName":"High Grade Ovarian Serous Adenocarcinoma Recurrent Persistent Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to recurrent or persistent high grade serous ovarian cancer as outlined in the study protocol?","longName":"HGSOC__REC_PERS_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"952E55B8-5C33-0FDB-E053-F662850A0FC2","latestVersionIndicator":"Yes","beginDate":"2019-10-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-18","modifiedBy":"SOKKERL","dateModified":"2019-10-25","changeNote":"10/18/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7010119","version":"2","preferredName":"Laboratory Selection Indicator","preferredDefinition":"An indication whether or not a laboratory procedure was selected.","longName":"LBSLCTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FEB180-BC21-3FC9-E053-4EBD850A2DD2","latestVersionIndicator":"Yes","beginDate":"2019-10-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-26","modifiedBy":"TAYLORT","dateModified":"2020-06-26","changeNote":"6-26-20 Versioned to 2.0 for correction to Long Name; tmt. Released. AK 2020-6-2. 10-22-19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7010147","version":"1","preferredName":"Investigator's Email","preferredDefinition":"A free-text field to provide the email address of the investigator who is responsible for all aspects of the conduct of a study.","longName":"EMAIL_TRTINV","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"957FB6ED-E4B9-3BD4-E053-F662850ABB4A","latestVersionIndicator":"Yes","beginDate":"2019-10-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-22","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"Released. AK 2020-6-2; 10-22-19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7010805","version":"1","preferredName":"Related to Study Disease","preferredDefinition":"A free-text field to address the relationship of the adverse event to the study disease.","longName":"RELDZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9580B8CD-9AD6-3BDC-E053-F662850A6645","latestVersionIndicator":"Yes","beginDate":"2019-10-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-22","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"Released. AK 2020-6-2; 10-22-19 Created for Seed Study;tmt. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7011803","version":"1","preferredName":"Protocol Date","preferredDefinition":"The version date of the clinical trial protocol.","longName":"PROTDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9582CEE5-1984-7202-E053-F662850A54DB","latestVersionIndicator":"Yes","beginDate":"2019-10-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-22","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"Released. AK 2020-6-2; 10-22-19 Created for Seed Study;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7022184","version":"1","preferredName":"Specimen Consent","preferredDefinition":"An indication whether or not the patient consented to specimen collection and use.","longName":"SPECCNSTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95952F3E-8C86-7E2D-E053-F662850A7A0F","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-23","modifiedBy":"SOKKERL","dateModified":"2023-08-01","changeNote":"2/7/20 tmt released/MM. Created for Seed Study; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7024460","version":"1","preferredName":"Storage and Future Use Consent","preferredDefinition":"An indication whether or not the patient consented to specimen storage and future use.","longName":"STORCNSTNY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9598D867-7D59-084E-E053-F662850AC1C1","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-23","modifiedBy":"SOKKERL","dateModified":"2023-08-01","changeNote":"6-3-20 released/MM. Created for Seed Study; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7024557","version":"1","preferredName":"Reason for withdrawal of consent","preferredDefinition":"An explanation why the consent was withdrawn.","longName":"CNSTREAS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"959AA135-FEDC-7977-E053-F662850A743E","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-23","modifiedBy":"LUY","dateModified":"2020-04-01","changeNote":"Created for Seed Study;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7024581","version":"1","preferredName":"Future Contact Consent","preferredDefinition":"An indication whether or not the patient consented to be contacted in the future for participating in a research study.","longName":"FTCCNSTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"959AC286-075E-4E1B-E053-F662850A220A","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-23","modifiedBy":"SOKKERL","dateModified":"2023-08-01","changeNote":"6-3-20 released/MM. Created for Seed Study; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7024613","version":"1","preferredName":"CLIA Consent","preferredDefinition":"An indication whether or not the patient consented to CLIA sequencing assay for tumor profiling.","longName":"CLIACNSTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95986141-1840-7B7F-E053-F662850A8743","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-23","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. Created for Seed Study; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7024627","version":"1","preferredName":"Comments from Sender","preferredDefinition":"A free-text to provide comments from the sender.","longName":"COVAL_SNDR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"959A904E-9052-5C31-E053-F662850AA2B8","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-23","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. Created for Seed Study;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7024628","version":"1","preferredName":"Comments from Receiver","preferredDefinition":"A free-text to provide comments from the receiver.","longName":"COVAL_RCVR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"959B3032-FEA5-27CA-E053-F662850A7652","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-23","modifiedBy":"TAYLORT","dateModified":"2020-06-04","changeNote":"5-5-20 tmt released per MM. Created for Seed Study;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7027223","version":"1","preferredName":"Patient Medical History Other Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the patient's medical records related to other neoplasm as outlined in the protocol.","longName":"PT_MEDHX_OTH_NEOP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AC3360-B6B9-6EBA-E053-F662850ADF88","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-24","modifiedBy":"CLOHNES","dateModified":"2023-10-31","changeNote":"10/24/19 ls","administrativeNotes":"10/31/23 Added AQT for CCTG ticket number CADSR0003018 cjl; 9/27/23 Added alt OID, CCTG and alt OID, CCTG cjl. 5/13/22 CJL AQT added for Theradex for protocol 10405","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7027272","version":"1","preferredName":"Chemotherapy Or Immunotherapy Therapeutic Procedure Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to chemotherapy or immunotherapy as outlined in the protocol.","longName":"CT_IIMTX_TX_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"959AE0BD-778D-7766-E053-F662850AD186","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-24","modifiedBy":"KUMMEROA","dateModified":"2022-04-01","changeNote":"10/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7027278","version":"1","preferredName":"Laboratory Procedure Troponin T Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether the patient's lab test for troponin T meets the eligibility criteria outlined in the study protocol.","longName":"LAB_TNNT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AE7213-B0CF-228E-E053-F662850A0CD6","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-24","modifiedBy":"SOKKERL","dateModified":"2021-12-06","changeNote":"11-4-19 Released/VM; tmt. 10295;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7027438","version":"1","preferredName":"Prior Investigational Therapeutic Procedure Administration Elapsed Time Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the criteria for enrolling onto a clinical trial for questions related to the interval between the prior administration of investigational therapeutic agents that produce an effect intended to alter or stop a pathological process as outlined in the study protocol.","longName":"PR_INVES_TX_PROC_EL_TM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AED059-1860-75FC-E053-F662850A1745","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-24","modifiedBy":"SOKKERL","dateModified":"2023-01-24","changeNote":"10/24/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7027489","version":"1","preferredName":"Patient Personal Medical History Investigational Treatment Regimen Interference Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether or not the patient's medical background may interfere with the assessments of the investigational treatment plan as outlined in the eligibility criteria of the study protocol.","longName":"PMH_INVGL_TX_INTRF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AF60BC-1BFF-7610-E053-F662850A7319","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-24","modifiedBy":"SOKKERL","dateModified":"2024-02-13","changeNote":"2020-8-3 AQT added for P10398.  AK 2020-7-27 AQT added for protocol 10389. AK 11-4-19 Released/VM; tmt. 10295;tmt.","administrativeNotes":"2023.3.17 AQT added per ticket request CADSR0002164. ak 7/26/2022: fixed the symbol in AQT per ticket #CADSR0001349.wz 7/21/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7027729","version":"1","preferredName":"Patient Protocol Agent Administration Treating Investigator Determine Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to provide the treating investigator's determination for the administration of study agents to the patient as outlined in the eligibility criteria of the study protocol.","longName":"PAGT_ADMIN_TRINV_DET_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95B96D66-0A1C-0A7D-E053-F662850ACE93","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-25","modifiedBy":"BOWSERC","dateModified":"2021-10-19","changeNote":"10295;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7027802","version":"1","preferredName":"Patient Protocol Agent Administration Treating Investigator Judgment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to provide the treating investigator's judgement for the administration of study agents to the patient as outlined in the eligibility criteria of the study protocol.","longName":"PAGT_ADMIN_TRINV_JDG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95BC168C-9208-0A89-E053-F662850AA6D3","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-25","modifiedBy":"SOKKERL","dateModified":"2020-01-03","changeNote":"11-4-19 Released/VM; tmt. 10295;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7028138","version":"1","preferredName":"Patient Heart Medical Device Exclusion Criteria Code Indicator","preferredDefinition":"The coded response for questions related to cardiac physical objects that prevent a subject from being allowed to participate in a clinical study as outlined in the protocol.","longName":"HEART_DVIC_EXC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95BD1E5F-5FE8-1B8D-E053-F662850A01D7","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-25","modifiedBy":"TAYLORT","dateModified":"2019-11-04","changeNote":"11-4-19 Released/VM; tmt. 10295;tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7028157","version":"1","preferredName":"Treatment Cohort Study 10301 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10301 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10301_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95BD7B25-E0E2-3D4C-E053-F662850AB342","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-25","modifiedBy":"SOKKERL","dateModified":"2019-10-25","changeNote":"10/25/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7028199","version":"1","preferredName":"Treatment Cohort Study 10324 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol 10324 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10324_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95BF5C57-53DB-1B7B-E053-F662850AB580","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-25","modifiedBy":"SOKKERL","dateModified":"2019-10-25","changeNote":"10/25/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7028329","version":"1","preferredName":"Patient Clinical Significance Heart Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient has a finding that has treatment or management implications for cardiac disease as outlined in the eligibility criteria of the study protocol.","longName":"CLSIG_HEART_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95F6C4BB-1821-16B1-E053-F662850AD7F5","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-28","modifiedBy":"TAYLORT","dateModified":"2019-11-04","changeNote":"10295/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7028333","version":"1","preferredName":"Patient Cancer Therapeutic Procedure Related Toxicity Dose Reduced Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient's treatment was modified by subtraction due to the poisonous effects associated with the action or administration of therapeutic agents as outlined in the eligibility criteria of the study protocol.","longName":"TX_TOX_DOSRED_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95F68C76-23F1-16CE-E053-F662850A5A01","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-28","modifiedBy":"TAYLORT","dateModified":"2019-11-04","changeNote":"11-4-19 Released/VM; tmt. 10295/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7028339","version":"1","preferredName":"Patient Primary Site of Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to address the patient's first site of disease of interest as outlined in the eligibility criteria of the study protocol.","longName":"PSODZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95F6C4BB-189A-16B1-E053-F662850AD7F5","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-28","modifiedBy":"SOKKERL","dateModified":"2021-08-27","changeNote":"11-4-19 Released/VM; tmt. 10295/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7029833","version":"1","preferredName":"Patient Childbearing Potential Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator as to whether or not the female patient who has the potential to become pregnant meets the eligibility criteria as outlined in the study protocol.","longName":"CHBR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95FE4E7C-215B-4C90-E053-F662850A96BB","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-28","modifiedBy":"SOKKERL","dateModified":"2023-01-11","changeNote":"10221; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7029840","version":"1","preferredName":"Patient Hepatitis B Infection Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether or not the patient's background regarding a viral infection caused by the hepatitis B virus meets the eligibility criteria outlined in the study protocol.","longName":"HEPB_PMH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95FEE76A-D120-359A-E053-F662850A3EF4","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-11-03","changeNote":"2020-8-40 AQT added for P10398. AK  10221; tmt.","administrativeNotes":"2023.11.3 AQT added per ticket request CADSR0003032. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7029848","version":"1","preferredName":"Patient Hepatitis C Infection Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether or not the patient's background regarding a viral infection caused by the hepatitis C virus meets the eligibility criteria outlined in the study protocol.","longName":"HEPC_PMH_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95FCB0F2-CE6F-6A94-E053-F662850A95EB","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-11-03","changeNote":"10221; tmt.","administrativeNotes":"2023.11.3 AQT added per ticket request CADSR0003032. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7031978","version":"1","preferredName":"Accrual Cohort Study 10221 Code","preferredDefinition":"The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study 10221.","longName":"ACC_COH_SDY_10221_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9600BA80-F252-320D-E053-F662850AD582","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-29","modifiedBy":"SOKKERL","dateModified":"2019-12-16","changeNote":"10/29/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7032121","version":"1","preferredName":"Treatment Cohort Study EC10221 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10221 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_EC10221_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"960D1076-9038-25B2-E053-F662850A1C10","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-29","modifiedBy":"SOKKERL","dateModified":"2019-11-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7032267","version":"1","preferredName":"Treatment Cohort Study 10221 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10221 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10221_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"960D1D50-FD63-2D4D-E053-F662850A9C71","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-29","modifiedBy":"SOKKERL","dateModified":"2019-11-04","changeNote":"10/31/19 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7032757","version":"1","preferredName":"Patient Central Nervous System Metastases And Or Meningeal Carcinomatosis Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine patient eligibility for questions related to the diagnosis of central nervous system (CNS) metastases and/or carcinomatous meningitis as outlined in the protocol.","longName":"CNSMETS_CM_DX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"960DA713-F7F2-4A9A-E053-F662850AC0CA","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-29","modifiedBy":"SOKKERL","dateModified":"2024-02-13","changeNote":"10221; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7032851","version":"1","preferredName":"Patient Receive Complementary and Alternative Medicine Or Antiarrhythmic Agent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether the patient meets the eligibility criteria outlined in the study protocol for receiving complementary and alternative medicine or antiarrhythmic agents.","longName":"RECV_CAM_AAD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"961000C1-BB72-0A73-E053-F662850A6004","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-29","modifiedBy":"SOKKERL","dateModified":"2019-10-31","changeNote":"10221; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7032855","version":"1","preferredName":"Patient Molecular Genetic Variation Laboratory Test Result Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response at to whether or not the results of the patient's lab test for alterations in the inherited nucleic acid sequence of the genotype of an organism meet the eligibility criteria outlined in the study protocol.","longName":"MGV_LAB_RES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"961010FC-D234-23B7-E053-F662850AF493","latestVersionIndicator":"Yes","beginDate":"2019-10-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-29","modifiedBy":"SOKKERL","dateModified":"2022-11-07","changeNote":"10221; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7033544","version":"1","preferredName":"Gender","preferredDefinition":"The assemblage of properties that distinguish people on the basis of the societal roles expected for the two sexes.","longName":"GENDER","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9620567F-DD7E-458E-E053-F662850A37BD","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-30","modifiedBy":"MALUMK","dateModified":"2021-03-17","changeNote":"3/27/20 tmt released/Peter Clark. 10-30-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7034315","version":"1","preferredName":"Evaluation Interval Text","preferredDefinition":"A free-text description of the evaluation interval.","longName":"LBEVINTX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96219BD4-B72C-3142-E053-F662850A17B7","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-30","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"10-30-19 created for Seed Study; tmt. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7034360","version":"1","preferredName":"Radiation Extent","preferredDefinition":"A free-text field to provide the extent of radiation therapy.","longName":"RDTNEXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96219F07-9C5A-3123-E053-F662850AE0BD","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-30","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"10-30-19 created for Seed Study; tmt. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7034364","version":"1","preferredName":"Best Overall Response","preferredDefinition":"A free-text field to provide the most clinically favorable response recorded from the start of the study treatment until the end of treatment.","longName":"BESTRESP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96219BD4-B759-3142-E053-F662850A17B7","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-10-30","modifiedBy":"TAYLORT","dateModified":"2020-02-07","changeNote":"2/7/20 tmt released/MM. 10-30-19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7034867","version":"1","preferredName":"Treatment Cohort Study 10302 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10302 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10302_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96260197-416B-7FD3-E053-F662850A84C7","latestVersionIndicator":"Yes","beginDate":"2019-10-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-31","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7039005","version":"1","preferredName":"Treatment Cohort Study 10295 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10295 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10295_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96857106-834A-5174-E053-F662850A6610","latestVersionIndicator":"Yes","beginDate":"2019-11-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-04","modifiedBy":"SOKKERL","dateModified":"2019-11-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7041711","version":"1","preferredName":"Patient Myelodysplastic Syndrome Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to assessments related to Myelodysplastic Syndrome as outlined in the study protocol.","longName":"PT_MDS_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"969B5E2B-072B-4606-E053-F662850A736D","latestVersionIndicator":"Yes","beginDate":"2019-11-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-05","modifiedBy":"SOKKERL","dateModified":"2019-11-07","changeNote":"11/5/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044582","version":"1","preferredName":"Vendor Name","preferredDefinition":"The literal identifier of the vendor or laboratory that performs a biospecimen assessment.","longName":"BSNAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96B3F413-1410-2F7C-E053-F662850A2998","latestVersionIndicator":"Yes","beginDate":"2019-11-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-06","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"6-3-20 released/MM. 11/6/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044678","version":"1","preferredName":"Treatment Cohort Study 10296 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10296 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10296_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96C3C1F3-4024-06B1-E053-F662850AE5D4","latestVersionIndicator":"Yes","beginDate":"2019-11-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-07","modifiedBy":"SOKKERL","dateModified":"2019-11-07","changeNote":"11/8/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044691","version":"1","preferredName":"Biospecimen Test or Examination Name","preferredDefinition":"Descriptive name of the biospecimen test or examination used to obtain the measurement or finding.","longName":"BSTEST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96C33FF8-A104-7E08-E053-F662850ADB16","latestVersionIndicator":"Yes","beginDate":"2019-11-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-07","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/7/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044695","version":"1","preferredName":"Start Date of Specimen Process","preferredDefinition":"The start date of the biospecimen event represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"BSSTDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96C59EE1-9D00-3FD2-E053-F662850AF253","latestVersionIndicator":"Yes","beginDate":"2019-11-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-07","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"6-3-20 released/MM. 11/7/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044698","version":"1","preferredName":"Start Time of Specimen Process","preferredDefinition":"The start time of the biospecimen event in an unambiguous time format (e.g., hh:mm:ss).","longName":"BSSTTIM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96C59EE1-9D21-3FD2-E053-F662850AF253","latestVersionIndicator":"Yes","beginDate":"2019-11-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-07","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/7/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044728","version":"1","preferredName":"Eastern Cooperative Oncology Group And Karnofsky And Lansky Play-Performance Assessment Status Score","preferredDefinition":"The number or value that determines the value, significance, or extent of how well a patient is able to perform ordinary tasks and to carry out daily activities based on the Eastern Cooperative Oncology Group (ECOG), the Karnofsky or the Lansky Play-Performance Status assessments.","longName":"ECOG_K_L_PRF_STAT_SC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96C5FBDB-C784-3F45-E053-F662850A6443","latestVersionIndicator":"Yes","beginDate":"2019-11-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-07","modifiedBy":"KUMMEROA","dateModified":"2020-06-02","changeNote":"Released. AK 2020-6-2; Curated to support Theradex combination performance status score question_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7044928","version":"1","preferredName":"Biospecimen Slide Prep","preferredDefinition":"A textual description for the slide preparation of the biospecimen event.","longName":"BESLPR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96C33E66-79D6-05EA-E053-F662850A4C52","latestVersionIndicator":"Yes","beginDate":"2019-11-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-07","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/7/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7049766","version":"1","preferredName":"Specimen ID","preferredDefinition":"A free-text field to identify the specimen.","longName":"SPECID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D5AA59-B4D8-788A-E053-F662850A156F","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2021-06-29","changeNote":"6-3-20 released/MM. 11-8 -19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7049993","version":"1","preferredName":"Collection Method Indicator","preferredDefinition":"An indication as to whether or not the specimen was collected by a means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"CLMTHIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D6D222-4655-6946-E053-F662850A654C","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM.11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7049997","version":"1","preferredName":"Time of Specimen Collection","preferredDefinition":"The time of specimen collection represented in an unambiguous time format (e.g., hh:mm:ss).","longName":"BETIM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D7A15D-E491-6893-E053-F662850A21F0","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"ZHWENDY","dateModified":"2023-10-09","changeNote":"6-3-20 released/MM. 11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7049998","version":"1","preferredName":"Tube Type","preferredDefinition":"The kind of tube used to collect the sample(s) taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes.","longName":"TUBETYPE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D5490B-9190-0F89-E053-F662850A3845","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/8/19 tmt reused 5573292 to create new for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050000","version":"1","preferredName":"Number of Specimens collected","preferredDefinition":"The number of samples collected.","longName":"NUMSPEC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D8494B-1A67-2A29-E053-F662850ACE1B","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-11-19","changeNote":"11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050005","version":"1","preferredName":"Media Type","preferredDefinition":"A free-text field for the type of specimen culture medium.","longName":"MEDTYPE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D62BD8-BADF-787A-E053-F662850AF134","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11-8 -19 created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050016","version":"1","preferredName":"Number of aliquots","preferredDefinition":"The number of aliquots.","longName":"NUMALIQ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D99E6E-B223-6B94-E053-F662850A010F","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"MMADDINENI","dateModified":"2023-03-02","changeNote":"6-3-20 released/MM. 11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050017","version":"1","preferredName":"Original number of specimens available for submission","preferredDefinition":"The original number of specimens available for submission.","longName":"ORNUMSPC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D99A87-1630-6B73-E053-F662850AD640","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-09-22","changeNote":"6-3-20 released/MM. 11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050041","version":"1","preferredName":"Number of charged slides","preferredDefinition":"The number of slides submitted that have a positive surface charge.","longName":"NUMCHSD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DA7999-E9C2-14AB-E053-F662850AEEB5","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050042","version":"1","preferredName":"Number of uncharged slides","preferredDefinition":"The number of slides submitted that lack a positive surface charge.","longName":"NUMUCHSD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DA9396-0239-149B-E053-F662850A52D0","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050052","version":"1","preferredName":"Start Time of Biospecimen Event","preferredDefinition":"The start time of the biospecimen event represented in an unambiguous time format (e.g., hh:mm:ss).","longName":"BESTTIM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DA9396-025A-149B-E053-F662850A52D0","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050053","version":"1","preferredName":"End Time of Biospecimen Event","preferredDefinition":"The end time of the biospecimen event represented in an unambiguous time format (e.g., hh:mm:ss).","longName":"BEENTIM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DAC294-804F-14A7-E053-F662850A9BD5","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050057","version":"1","preferredName":"Receiver's name","preferredDefinition":"The person's name who received the specimen.","longName":"RECNAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DA7E16-8DB5-1495-E053-F662850AEFBA","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-08","modifiedBy":"TAYLORT","dateModified":"2019-12-27","changeNote":"12/27/19 tmt released.  11/8/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050058","version":"1","preferredName":"Patient Treatment Completed Without Disease Progression Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response related to a person having completed the therapy without disease progression as outlined in the protocol.","longName":"TX_COMP_WO_DZ_PROG_CD_ID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DAC294-8070-14A7-E053-F662850A9BD5","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-08","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"11/8/19ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050392","version":"1","preferredName":"Previously Irradiated Indicator Result","preferredDefinition":"An indication whether or not the tumor was previously irradiated.","longName":"TUORRES_PREVIR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97283D82-1874-50FC-E053-F662850A9980","latestVersionIndicator":"Yes","beginDate":"2019-11-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-12","modifiedBy":"TAYLORT","dateModified":"2020-02-25","changeNote":"2/25/20 added alternate question text and released; tmt.11-12-19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050396","version":"1","preferredName":"Measurable Tumor Indicator Result","preferredDefinition":"An indication as to whether a measurable tumor is present.","longName":"TUORRES_MEASIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"971E6E51-5AEE-4349-E053-F662850A1C00","latestVersionIndicator":"Yes","beginDate":"2019-11-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-12","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"11-12-19 tmt created for Seed Study.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050433","version":"1","preferredName":"Lesion Response","preferredDefinition":"The reaction of a lesion to some foregoing stimulus or agent.","longName":"LSRESP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"972CA07F-FEA5-75FC-E053-F662850A27CB","latestVersionIndicator":"Yes","beginDate":"2019-11-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-12","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"11-12-19 tmt created for Seed Study. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7050457","version":"1","preferredName":"Medical History Toxicity Grade","preferredDefinition":"The toxicity grade using a standard toxicity scale (such as the NCI CTCAE).","longName":"MHTOXGR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"972D72C8-534B-67F8-E053-F662850A97E0","latestVersionIndicator":"Yes","beginDate":"2019-11-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-12","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"11-12-19 tmt created for Seed Study. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7051630","version":"1","preferredName":"Patient Biopsy Timepoint Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that addresses  patient is wiliness to go though a biopsy at specific time point as outlined in the protocol.","longName":"BX_TMPT_CONST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"973BCFAF-0522-2BE9-E053-F662850A4083","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-13","modifiedBy":"SOKKERL","dateModified":"2023-04-18","changeNote":"11/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7051647","version":"1","preferredName":"Patient Thromboembolism Anticoagulant Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to thrombosis and is on anticoagulant therapy as outlined in the protocol.","longName":"THRMB_ANTG_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"973C7665-1E07-1169-E053-F662850AA555","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-13","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"11/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058589","version":"1","preferredName":"Treatment Cohort Study 10208 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10208 in which subsets of a defined population are identified.","longName":"TX_COH_STDY_10208_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"974FAE72-27F3-5CB4-E053-F662850AFFE8","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-14","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"11/14/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058615","version":"1","preferredName":"Report Type","preferredDefinition":"The type of a clinical trial report.","longName":"RPTTYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97451AE9-FA3D-17B4-E053-F662850AB615","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-14","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"Released. AK 2020-6-2; 11-14-19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058616","version":"1","preferredName":"Laboratory Procedure Creatinine Clearance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to a creatinine laboratory procedure.","longName":"LAB_CREAT_CLR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"975045B7-7AE4-117E-E053-F662850A06CC","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-14","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":"2020-8-3 AQT added for P10398. AK  11/14/19 ls","administrativeNotes":"7/21/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058661","version":"1","preferredName":"Evaluator Initials","preferredDefinition":"The initials of a person who determines the significance, worth, or condition of something by careful appraisal and study.","longName":"EVAL_INIT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97508BD8-4FA6-49E5-E053-F662850AD62F","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-14","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11-14-19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058665","version":"1","preferredName":"Evaluator Name","preferredDefinition":"The name of a person who determines the significance, worth, or condition of something by careful appraisal and study.","longName":"EVAL_NAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"975045B7-7BD1-117E-E053-F662850A06CC","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-14","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11-14-19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058666","version":"1","preferredName":"Date of signature","preferredDefinition":"The date of the responsible individual's name or personal mark.","longName":"SIGNDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97451AE9-FAC0-17B4-E053-F662850AB615","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-14","modifiedBy":"ZHWENDY","dateModified":"2022-07-21","changeNote":"6-3-20 released/MM. 11-14-19 Created for Seed Study; tmt.","administrativeNotes":"7/21/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058670","version":"1","preferredName":"Diagnosis","preferredDefinition":"The reported or pre-specified name of the medical condition or diagnosis.","longName":"MHTERM_DIAGNOSIS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97514FC6-E2D1-117A-E053-F662850AC2B9","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-14","modifiedBy":"GDEEN","dateModified":"2023-08-01","changeNote":"6-3-20 released/MM. 11-14-19 Created for Seed Study; tmt.","administrativeNotes":"2023.8.1 AQT added per ticket request CADSR0002655. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058685","version":"1","preferredName":"Diagnosis Verification","preferredDefinition":"The outcome of the investigation, analysis, and recognition of disease as verified by the pathologist.","longName":"DXVERIF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9751B989-E011-34B2-E053-F662850AC4AD","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-14","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 12-6-19 edit to Short Name/MM; tmt. 11-14-19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7058730","version":"1","preferredName":"Sample Adequacy Flag","preferredDefinition":"An indicator flag as to whether a sample is adequate.","longName":"SPLADQFL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9750D334-C39A-118B-E053-F662850A14C8","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-14","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 11-14-19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060220","version":"1","preferredName":"Pharmacotherapy Testing","preferredDefinition":"A coding system for the classification of the pharmacotherapy evaluation.","longName":"PHARMACO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97666771-A68D-6350-E053-F662850ACD9C","latestVersionIndicator":"Yes","beginDate":"2019-11-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-15","modifiedBy":"LEEW","dateModified":"2021-12-09","changeNote":"Released. AK 2020-6-2; 11/15/19 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7060637","version":"1","preferredName":"Breast Hormone Receptor Tumor Marker Diagnosis Result Type","preferredDefinition":"The outcome from pathological tests to determine presence of the hormone receptor in the nature of cancer by evaluating a sample of breast tissue.","longName":"BRST_HR_RECP_TM_DX_RST_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97B60688-952E-3965-E053-F662850AB196","latestVersionIndicator":"Yes","beginDate":"2019-11-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-19","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"11/19/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063007","version":"1","preferredName":"Findings from procedure","preferredDefinition":"A free-text field for the clinical, laboratory or molecular evidence, or absence of evidence of disease.","longName":"PRFIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97C7D9A7-FA4B-6711-E053-F662850A421B","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-20","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"11-20-19 tmt curated for Seed Study. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063008","version":"1","preferredName":"Residual Disease Extent","preferredDefinition":"A free- text field for the extent of tumor cells that remain in the body following cancer treatment.","longName":"RSDZEXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97C7D9A7-FA6C-6711-E053-F662850A421B","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-20","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"11-20-19 tmt curated for Seed Study. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063016","version":"1","preferredName":"Therapeutic Indicator","preferredDefinition":"The coded indicator as to whether or not a beneficial response or outcome is the purpose of the treatment intervention.","longName":"THERIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97C7D9A7-FA8D-6711-E053-F662850A421B","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-20","modifiedBy":"KUMMEROA","dateModified":"2020-06-04","changeNote":"11-20-19 tmt curated for Seed Study. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063020","version":"1","preferredName":"Patient Refractory Progressive Disease Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to refractory and disease progression which is resistant to therapy as outlined in the protocol.","longName":"REF_PROG_DZ_THYP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97C6021C-AF9F-3781-E053-F662850A2C91","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-20","modifiedBy":"SOKKERL","dateModified":"2022-04-27","changeNote":"11/20/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063084","version":"1","preferredName":"Patient Treated Stable Metastatic Malignant Neoplasm in the Brain Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to treated and stable metastatic brain cancer as outlined in the study protocol.","longName":"TX__STBLE_BRN_MET_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CB9A2D-6EE1-0B9C-E053-F662850A1F93","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-20","modifiedBy":"SOKKERL","dateModified":"2022-03-01","changeNote":"11/20/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7063710","version":"1","preferredName":"Molecular Abnormality Result Mutation Status","preferredDefinition":"The outcome status of a molecular or cytogenic abnormality which occurs in either human disease states or disease models.","longName":"MOL_ABN_RSLT_MUT_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97F3D528-062C-52BF-E053-F662850A5688","latestVersionIndicator":"Yes","beginDate":"2019-11-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-22","modifiedBy":"SOKKERL","dateModified":"2020-02-14","changeNote":"11/22/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7065962","version":"1","preferredName":"Longest Measurement","preferredDefinition":"A tickbox indicator for the longest measurement.","longName":"CKBOX_LONG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"982C7C51-8753-2B2F-E053-F662850AB4FF","latestVersionIndicator":"Yes","beginDate":"2019-11-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-25","modifiedBy":"KUMMEROA","dateModified":"2020-06-02","changeNote":"11-25-19 created for Seed Study; tmt. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7065963","version":"1","preferredName":"Assessment Timepoint","preferredDefinition":"A free-text field for the point in time of the study assessment.","longName":"ASMTTPT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"982CC735-16A0-6A46-E053-F662850A7B3B","latestVersionIndicator":"Yes","beginDate":"2019-11-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-11-25","modifiedBy":"FINCHAMB","dateModified":"2023-08-07","changeNote":"11-25-19 tmt/Seed Study. Released. AK 2020-6-2","administrativeNotes":"8/7/23 Added CSI and Alt Names with source of “CMB” in the CTDC data model. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7065973","version":"1","preferredName":"Patient Attempt Remission Induction Therapy Administration Cycle Count","preferredDefinition":"The number of induction therapy the patient received.","longName":"PT_RMN_IND_THPY_ADMIN_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"982D30A7-6044-3466-E053-F662850AA177","latestVersionIndicator":"Yes","beginDate":"2019-11-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-25","modifiedBy":"TSESU","dateModified":"2023-03-27","changeNote":"11/25/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7069877","version":"1","preferredName":"Specimen Category","preferredDefinition":"The kind of material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes.","longName":"SPECCAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98E1658A-DED9-595E-E053-F662850A0B1C","latestVersionIndicator":"Yes","beginDate":"2019-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-12-04","modifiedBy":"FINCHAMB","dateModified":"2023-08-07","changeNote":"6-3-20 released/MM. 12/4/19 tmt created for Seed Study.","administrativeNotes":"8/7/23 Added CSI and Alt Names with source of “CMB” in the CTDC data model. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7071718","version":"1","preferredName":"Patient Standard Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response indicating whether a patient meets the eligibility criteria with regards to standard therapy.","longName":"PT_STND_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F7EF46-8E75-3A4E-E053-F662850A8497","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-05","modifiedBy":"SOKKERL","dateModified":"2020-08-04","changeNote":"12/5/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7071752","version":"1","preferredName":"Enrichment Instructions","preferredDefinition":"The instruction(s) for the technique designed to select or increase a target item in a mixed sample.","longName":"ENRICH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98FBBFD5-166D-3662-E053-F662850A3061","latestVersionIndicator":"Yes","beginDate":"2019-12-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-12-05","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM.12-5-19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7072096","version":"1","preferredName":"Other Inadequate Reason","preferredDefinition":"Free-text field to provide another reason for the inadequate condition of a specimen.","longName":"INADREAS_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"990B17E9-79A7-0428-E053-F662850AAF80","latestVersionIndicator":"Yes","beginDate":"2019-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-12-06","modifiedBy":"TAYLORT","dateModified":"2020-05-05","changeNote":"5-5-20 tmt released per MM. 12-6-19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7072101","version":"1","preferredName":"Estimated Tumor Content","preferredDefinition":"Result of the estimated tumor content as originally received or collected.","longName":"MIORRES_TUCONT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9909C965-BDA1-6DD1-E053-F662850AAC34","latestVersionIndicator":"Yes","beginDate":"2019-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-12-06","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 12-6-19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7072130","version":"1","preferredName":"Sub-Specimen ID","preferredDefinition":"A unique alphanumeric identifier assigned to a discrete part of a specimen, such as an individual tube from a multi-tube blood draw.","longName":"SUBSPCM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"990E57E4-D507-07F2-E053-F662850AACD2","latestVersionIndicator":"Yes","beginDate":"2019-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-12-06","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"5-5-20 tmt released per MM. 12-6-19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074609","version":"1","preferredName":"Laboratory Procedure Osteocalcin Measurement Assessment Value","preferredDefinition":"A lab procedure that involves testing or manipulating a sample of blood to determine the numerical quantity of osteocalcin present in a sample.","longName":"LAB_PROC_OSTEO_MSRMT_ASSES_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"994A3951-02CC-18FE-E053-F662850A24E2","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-09","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"12/9/19. ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074614","version":"1","preferredName":"Laboratory Procedure Alkaline Phosphatase Assessment Value","preferredDefinition":"A lab procedure that involves testing or manipulating a sample of blood to determine the numerical quantity of alkaline phosphatase present in a sample.","longName":"LAB_PROC_AP_ASSES_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"994A2548-1E93-18F9-E053-F662850A110A","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-09","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/9/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7074636","version":"1","preferredName":"Laboratory Procedure Bone Specific Alkaline Phosphatase Measurement Assessment Value","preferredDefinition":"A lab procedure that involves testing or manipulating a sample of blood to determine the numerical quantity of bone specific alkaline phosphatase present in a sample.","longName":"LAB_PROC_BN_SPFC_AP_ASSES_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"994B1C09-0645-3D71-E053-F662850AB977","latestVersionIndicator":"Yes","beginDate":"2019-12-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-09","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"12/9/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092429","version":"1","preferredName":"Radiation Therapy Beam Equipment Name Type","preferredDefinition":"A name identifying  the type of diagnostic radiation therapy beam.","longName":"RT_EQUP_NM_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99978626-47A0-4B58-E053-F662850A9C61","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092483","version":"1","preferredName":"Anatomic Site Number","preferredDefinition":"A numeral or string of numerals identifying the anatomic site.","longName":"ANAT_SIT_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9999ACF2-2FE3-4E1C-E053-F662850A7425","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092484","version":"1","preferredName":"Radiation Therapy Total Administered Count","preferredDefinition":"Total number of treatment administrated.","longName":"RT_TOT_ADMIN_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9999DE84-940A-4CD3-E053-F662850A8B64","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092488","version":"1","preferredName":"Stereotactic Body Radiation Therapy Right Kidney Mean Dose Administered Value","preferredDefinition":"Number value of the stereotactic body radiation mean dose given to the right kidney.","longName":"SBRT_RT_KIDN_MDS_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99988AA1-674B-4AD3-E053-F662850A57C3","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092492","version":"1","preferredName":"Stereotactic Body Radiation Therapy Left Kidney Mean Dose Administered Value","preferredDefinition":"Number value of the stereotactic body radiation mean dose given to the left kidney.","longName":"SBRT_LT_KIDN_MDS_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"999A5421-9202-49E2-E053-F662850AE455","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092517","version":"1","preferredName":"Radiation Therapy Liver Volume 5Gy Irradiation Percentage Value","preferredDefinition":"Number value in percent of the liver tissue volume exposed to 5Gy radiation.","longName":"RT_LIV_VOL_IRDAT_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"999B5561-3583-6A44-E053-F662850A9C44","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092521","version":"1","preferredName":"Radiation Therapy Liver Volume 10Gy Irradiation Percentage Value","preferredDefinition":"Number value in percent of the liver tissue volume exposed to 10 Gy radiation.","longName":"RT_LIV_PERC_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"999B2906-1E9A-6A36-E053-F662850A2489","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092541","version":"1","preferredName":"Radiation Therapy Lung Volume 10Gy Irradiation Percentage Value","preferredDefinition":"Number value in percent of the lung tissue volume exposed to 10Gy radiation.","longName":"RT_LUNG_PERC_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"999B99F1-A229-4B21-E053-F662850A5370","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-13","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/13/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092543","version":"1","preferredName":"Device Type","preferredDefinition":"A character or string that represents the short code name of the device type.","longName":"DEVTYPE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"999BBAD5-CB6C-4EC7-E053-F662850AA1B2","latestVersionIndicator":"Yes","beginDate":"2019-12-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-12-13","modifiedBy":"TAYLORT","dateModified":"2020-07-07","changeNote":"12/27/19 tmt released. 12/13/19 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092758","version":"1","preferredName":"Radiation Therapy Administered 5cc Esophagus Dose Value","preferredDefinition":"Numeric dose value of radiation therapy that was administrated to the esophagus.","longName":"RT_ADMIN_ESPG_DOS_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D7421B-AF91-2719-E053-F662850A2820","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-16","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/16/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092853","version":"1","preferredName":"Radiation Therapy Administered 5cc Duodenum Dose Value","preferredDefinition":"Numeric dose value of radiation therapy that was administrated to the duodenum.","longName":"RT_ADMIN_DUDNM_DOS_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D8B00C-2C1A-44CA-E053-F662850AFAF7","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-16","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/16/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092867","version":"1","preferredName":"Radiation Therapy Administered 5cc Stomach Dose Value","preferredDefinition":"Numeric dose value of radiation therapy that was administrated to the stomach.","longName":"RT_ADMIN_STOM_DOS_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D89B57-CE38-41EF-E053-F662850AAC7C","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-16","modifiedBy":"SOKKERL","dateModified":"2021-09-24","changeNote":"12/16/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7092896","version":"1","preferredName":"Radiation Therapy Administered 15cc Heart Dose Value","preferredDefinition":"Numeric dose value of radiation therapy that was administrated to the heart.","longName":"RT_ADMN_HRT_DOS_VL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D8E0CC-9975-2E5B-E053-F662850A802D","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-16","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"12/16/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7110086","version":"1","preferredName":"Check box end date","preferredDefinition":"Tickbox indicator as to whether the calendar date on which something is to terminate or did terminate is the same as the the calendar date on which something is to start or did start.","longName":"CKBOX_ENDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A623E46-79BA-31A5-E053-F662850ACED0","latestVersionIndicator":"Yes","beginDate":"2019-12-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-12-23","modifiedBy":"KUMMEROA","dateModified":"2020-06-02","changeNote":"12-23-19 created for Seed Study; tmt. Released. AK 2020-6-2","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7110626","version":"3","preferredName":"Specimen Source","preferredDefinition":"A description of the anatomical location of the specimen source.","longName":"SPECSRC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B284FE-B704-79AA-E053-731AD00ABFEF","latestVersionIndicator":"Yes","beginDate":"2019-12-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-02","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeNote":"2022-4-14 ak Versioned due to needing newer VD to reflect CT Pkg 49 updates. 6-3-20 released/MM. 12-23-19 tmt created for Seed Study.","administrativeNotes":"2022.9.2 Versioned due to needing newer VD to reflect CT Pkg 50 updates. ak 2022.11.28 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7113590","version":"1","preferredName":"Patient Receive Other Systemic Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to receiving other treatment that travel through the bloodstream, reaching and affecting cells all over the body as outlined in the protocol.","longName":"PT_RECV_OTH_SYSMC_THPY_IND_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A9F206D-A931-15FC-E053-F662850A0001","latestVersionIndicator":"Yes","beginDate":"2019-12-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-12-26","modifiedBy":"SOKKERL","dateModified":"2020-10-06","changeNote":"12/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7118727","version":"1","preferredName":"Study Protocol Accrual 10221 Cohort Code","preferredDefinition":"The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study 10221.","longName":"SDY_PRT_ACC_COH_10221_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B2AE117-9FCC-201F-E053-F662850A5859","latestVersionIndicator":"Yes","beginDate":"2020-01-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-02","modifiedBy":"SOKKERL","dateModified":"2020-01-02","changeNote":"1/2/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7135868","version":"1","preferredName":"Infectious Disease Controlled Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study related to disorders resulting from the presence and activities of microbial, viral, fungal, or parasitic agents that is being managed successfully as outlined in the study protocol.","longName":"INFEC_DZ_CONTR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BCBDCA5-3B05-588B-E053-F662850AE371","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-10","modifiedBy":"SOKKERL","dateModified":"2020-01-14","changeNote":"1/10/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7135874","version":"1","preferredName":"Electrocardiogram Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a patient to participate in a clinical study relating to the final result and interpretation of electrical manifestations of heart activity as outlined in the study protocol.","longName":"ECG_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BCBB1D5-6738-4857-E053-F662850ABFFF","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-10","modifiedBy":"KUMMEROA","dateModified":"2020-07-27","changeNote":"2020-7-27 AQT added for protocol 10389. AK 1/10/20ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7135879","version":"1","preferredName":"Regimen End Date","preferredDefinition":"The date when the treatment regimen ended represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"RGMENDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BCB734C-CC9E-4AEF-E053-F662850A97B5","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-10","modifiedBy":"SOKKERL","dateModified":"2020-02-13","changeNote":"2/12/20 ls CPTAC/Linda approved CDE; AI released, RS chg to Qualified.1/10/20 tmt created for seed study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7136092","version":"1","preferredName":"Tracking Number Refresh","preferredDefinition":"The kind of database update for the tracking of patient specimen numbers.","longName":"TRKNUM_REFRESH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BCE7E9E-947F-7740-E053-F662850AD94D","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-10","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 1/10/20 tmt created for seed study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7136594","version":"1","preferredName":"Patient Leukostasis Cytoreductive Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address hyperleukocytosis requiring immediate cytoreductive chemotherapy as outlined in the study protocol.","longName":"LEUK_CYO_CHEMO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C068506-5038-08AD-E053-F662850AF667","latestVersionIndicator":"Yes","beginDate":"2020-01-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-13","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":"1/13/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7136601","version":"1","preferredName":"Extramedullary Leukemia Central Nervous System Involvement Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions relating to extramedullary leukemia involvement of CNS disease as outlined in the study protocol.","longName":"EXM_LEUK_CNS_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C06EEC2-62A9-08C1-E053-F662850AC166","latestVersionIndicator":"Yes","beginDate":"2020-01-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-13","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeNote":"1/13/20 ls","administrativeNotes":"2023.8.9 AQT added per ticket request CADSR0002722. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7138203","version":"1","preferredName":"Patient Medical Contraindication Immunotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions that prevent a person from being allowed to participate in a clinical study related to a therapy designed to induce changes in a patient's immune status in order to treat disease due to risk as outlined in the study protocol.","longName":"PT_MED_CONTR_IMMTHPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C1EB8EB-7225-3DAC-E053-F662850AF1CC","latestVersionIndicator":"Yes","beginDate":"2020-01-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-14","modifiedBy":"SOKKERL","dateModified":"2020-11-16","changeNote":"1/14/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7138442","version":"1","preferredName":"Treatment Cohort Study 10313 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10313 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10313_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C2F9549-A213-5B43-E053-F662850A0F4B","latestVersionIndicator":"Yes","beginDate":"2020-01-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-15","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"1/15/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7138917","version":"1","preferredName":"Patient Attenuated Live Vaccine Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine patient eligibility for questions related to the receipt of any live vaccine(s) as outlined in the protocol.","longName":"ALV_ELIG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C329C63-0E19-50D2-E053-F662850A56FA","latestVersionIndicator":"Yes","beginDate":"2020-01-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-15","modifiedBy":"SOKKERL","dateModified":"2023-12-13","changeNote":"1/15/20 tmt created for 10221.","administrativeNotes":"3/28/2023: Added AQT per CADSR0002213.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7140413","version":"1","preferredName":"Treatment Cohort Study EC10295 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10295 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_EC10295_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C43CF77-5D28-119D-E053-F662850AD772","latestVersionIndicator":"Yes","beginDate":"2020-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-16","modifiedBy":"SOKKERL","dateModified":"2020-01-16","changeNote":"1/16/20 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7140419","version":"1","preferredName":"Bone Marrow Suppression Or Bleeding Diathesis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to bone marrow suppression or bleeding disorders as outlined in the study protocol.","longName":"BM_SUP_BLD_DIATH_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C44EA9E-A4F5-5476-E053-F662850A619B","latestVersionIndicator":"Yes","beginDate":"2020-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-16","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"1/16/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7153774","version":"1","preferredName":"Marked Cytogenetic Abnormality Present Number","preferredDefinition":"The number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","longName":"CYTN_ABN_PRNT_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-04A7-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-27","modifiedBy":"SOKKERL","dateModified":"2020-01-31","changeNote":"1/27/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7155954","version":"1","preferredName":"Circulating Blasts Cell Bone Marrow Assessment Cell Count","preferredDefinition":"The number of immature blood cells in the circulation in the bone marrow.","longName":"CIRCL_BLST_BM_CEL_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D7019CC-C5D1-6841-E053-F662850A7A30","latestVersionIndicator":"Yes","beginDate":"2020-01-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-31","modifiedBy":"SOKKERL","dateModified":"2020-01-31","changeNote":"1/31/20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7155958","version":"1","preferredName":"Blast Cells Bone Marrow Flow Cytometry Biomarker Count","preferredDefinition":"The number of biomarkers of immature blood cells in the circulation in the bone marrow by the technique of examining and sorting microscopic particles suspended in a stream of fluid.","longName":"BLST_CELL_BM_ MRK_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D70C4FD-88D7-681F-E053-F662850ACB8E","latestVersionIndicator":"Yes","beginDate":"2020-01-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-31","modifiedBy":"SOKKERL","dateModified":"2020-01-31","changeNote":"1/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7158733","version":"1","preferredName":"Patient Non BRD4 Gene Mutation Present Indicator","preferredDefinition":"A yes or no indicator indicating whether a non- BRD4 gene mutation is present.","longName":"PT_NON_BRD4_MUT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DC2FB07-0377-6196-E053-F662850AE051","latestVersionIndicator":"Yes","beginDate":"2020-02-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-02-04","modifiedBy":"SOKKERL","dateModified":"2020-02-04","changeNote":"2/4/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7159115","version":"1","preferredName":"Comment","preferredDefinition":"A free text comment.","longName":"COVAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DD64FCA-2150-12E0-E053-F662850ACDE0","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-05","modifiedBy":"TAYLORT","dateModified":"2020-02-05","changeNote":"2/5/20 tmt reused CDE 6355806 to create new/Theradex request for a VD with max length of 1024.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7161783","version":"1","preferredName":"Followed for Response","preferredDefinition":"An indication as to whether or not the tumor was followed for response.","longName":"TUORRES_FFRIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DDA0525-0BAB-61F1-E053-F662850A486A","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-05","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"2/5/20 tmt curated for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164494","version":"1","preferredName":"NUTM1 Gene Fusion Known Indicator","preferredDefinition":"A yes or no indication that a known NUTM1 fusion gene has been detected in a sample.","longName":"NUTM1_INF_KNW_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFEA51E-E3D0-2EB8-E053-F662850AE376","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-02-07","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/7/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164502","version":"1","preferredName":"Autopsy Results Available","preferredDefinition":"An indication as to whether or not the autopsy results are available.","longName":"DDORRES_AUTOPSY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFE86A0-9279-2EC4-E053-F662850AB12F","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-07","modifiedBy":"TAYLORT","dateModified":"2021-04-28","changeNote":"8.28.20 TL released/MM. 2/7/20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164503","version":"1","preferredName":"NUTM1 Gene Fusion Known Gene Type","preferredDefinition":"A response used to determine the type of gene detected in the NUTM1 fusion gene sample.","longName":"NUTM1_INF_KNW_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFEA51E-E3F2-2EB8-E053-F662850AE376","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-02-07","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/7/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165816","version":"1","preferredName":"Patient Immunohistochemical Test Positive Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the method for positive results of immunohistochemical tests as outlined in the study protocol.","longName":"IHC_POST_OUTC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E3C3163-78AD-63E5-E053-F662850A9D7E","latestVersionIndicator":"Yes","beginDate":"2020-02-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-02-10","modifiedBy":"SOKKERL","dateModified":"2020-02-18","changeNote":"2/20ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165836","version":"1","preferredName":"Other Reason for Tumor Score","preferredDefinition":"A free text field that describes the other reason for a low pre-biopsy score.","longName":"TRREAS_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E405350-5AA8-3BD8-E053-F662850A2500","latestVersionIndicator":"Yes","beginDate":"2020-02-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-10","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"2/10/20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165837","version":"1","preferredName":"Check box to select response","preferredDefinition":"Tickbox indicator to address the reason for a low pre-biopsy score.","longName":"CKBOX_SELECT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E40978C-367B-5B30-E053-F662850A0B04","latestVersionIndicator":"Yes","beginDate":"2020-02-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-10","modifiedBy":"SOKKERL","dateModified":"2021-08-03","changeNote":"2/10/20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165847","version":"1","preferredName":"Device Usage","preferredDefinition":"An indication whether or not devices were employed.","longName":"DOYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E4EDB34-A431-0EC1-E053-F662850A1E09","latestVersionIndicator":"Yes","beginDate":"2020-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-11","modifiedBy":"SOKKERL","dateModified":"2021-08-03","changeNote":"2/11/20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165850","version":"1","preferredName":"Result or Finding in Original Units","preferredDefinition":"Result of the Device Property as originally observed or collected.","longName":"DOORRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E4E0FD3-669E-500D-E053-F662850AA154","latestVersionIndicator":"Yes","beginDate":"2020-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-11","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"2/11/20 tmt created for Theradex Seed Study.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7181423","version":"1","preferredName":"Reason for Tumor Score","preferredDefinition":"A reason for the the low pre-biopsy score.","longName":"TRREAS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F164356-8DA8-2F35-E053-F662850A40E0","latestVersionIndicator":"Yes","beginDate":"2020-02-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-21","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"2/21/20 tmt created for Seed Study.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7182243","version":"1","preferredName":"Treatment Cohort Study 10076 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10076 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10076_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F53AE79-D9BA-6942-E053-F662850A71A1","latestVersionIndicator":"Yes","beginDate":"2020-02-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-02-24","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"2/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7182268","version":"1","preferredName":"Folder Name","preferredDefinition":"The name of the directory for a collection of computer files.","longName":"FOLDER","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F53A3A4-351B-77CB-E053-F662850A9D1F","latestVersionIndicator":"Yes","beginDate":"2020-02-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-24","modifiedBy":"TAYLORT","dateModified":"2020-02-24","changeNote":"2/24/2020 created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7182286","version":"1","preferredName":"Patient Prior Exposure Antineoplastic Enzyme Inhibitor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for question addressing prior exposure to antineoplastic enzyme inhibitors specifically target tumor cells by targeting enzymes that are not normally expressed or are minimally expressed in normal, healthy tissues as outline in the study protocol.","longName":"PR_EXP_ANTIPLST_ENYZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F53A3A4-358B-77CB-E053-F662850A9D1F","latestVersionIndicator":"Yes","beginDate":"2020-02-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-02-24","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"2/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7187820","version":"1","preferredName":"Dose-Limiting Toxicity ","preferredDefinition":"An indication whether or not the adverse event was considered a dose limiting toxicity.","longName":"AEDLTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A009DF5B-0161-0509-E053-F662850A97D1","latestVersionIndicator":"Yes","beginDate":"2020-03-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-04","modifiedBy":"PONCEO","dateModified":"2021-05-13","changeNote":"3-4-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7187824","version":"1","preferredName":"AER Filed","preferredDefinition":"An indication whether or not the adverse event was reported.","longName":"AERFYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A00E51E6-5ECE-309E-E053-F662850A8532","latestVersionIndicator":"Yes","beginDate":"2020-03-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-04","modifiedBy":"CARPIOJ","dateModified":"2021-08-17","changeNote":"3-4-2020 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7190127","version":"1","preferredName":"AE Treatment Relationship","preferredDefinition":"A textual field to specify which treatment in a multi-drug regimen the adverse event is related to.","longName":"AERELTRT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A01EB8A3-79E2-58F9-E053-F662850A9527","latestVersionIndicator":"Yes","beginDate":"2020-03-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-05","modifiedBy":"SHEIKHM","dateModified":"2021-08-05","changeNote":"3-5-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7190199","version":"1","preferredName":"Treatment Cohort Study 9952 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9952 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9952_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0241E0B-AC01-4F9F-E053-F662850A5F9D","latestVersionIndicator":"Yes","beginDate":"2020-03-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-05","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"3/5/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7190290","version":"1","preferredName":"Adverse Event Therapy","preferredDefinition":"The type of therapeutic intervention for the adverse event.","longName":"AETHPY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A030FAC7-801A-7F2D-E053-F662850ACA0E","latestVersionIndicator":"Yes","beginDate":"2020-03-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-06","modifiedBy":"TAYLORT","dateModified":"2020-03-06","changeNote":"3/6/20 tmt created for seed study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7197091","version":"1","preferredName":"Treatment Cohort Study EC 10329 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol 10329 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10329_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A07128EA-657E-4A66-E053-F662850A1713","latestVersionIndicator":"Yes","beginDate":"2020-03-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-09","modifiedBy":"SOKKERL","dateModified":"2020-03-09","changeNote":"3/9/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7197387","version":"1","preferredName":"Treatment Complete Stable Metastatic Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to completing treatment and stable metastatic disease as outlined in the study protocol.","longName":"TX_COMP_STBL_METC_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A070A382-634F-4B4A-E053-F662850AC446","latestVersionIndicator":"Yes","beginDate":"2020-03-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-10","modifiedBy":"SOKKERL","dateModified":"2021-01-19","changeNote":"3/10/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7198637","version":"1","preferredName":"Biopsy Imaging Technique Consent Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded response indicating whether the patient complies to a biopsy under an imaging screening as outlined in the study protocol.","longName":"BX_IMG_CONS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A089FAB2-6248-2866-E053-F662850A619D","latestVersionIndicator":"Yes","beginDate":"2020-03-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-10","modifiedBy":"SOKKERL","dateModified":"2020-03-11","changeNote":"3/10/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7211783","version":"1","preferredName":"Bone Marrow Aspirate Involvement And/Or Biopsy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical study participation that are related to bone marrow involvement on aspirate or biopsy as outlined in the study protocol.","longName":"BM_APR_INVLM_BX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1248B67-48BD-54B8-E053-F662850A64CA","latestVersionIndicator":"Yes","beginDate":"2020-03-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-18","modifiedBy":"SOKKERL","dateModified":"2020-04-06","changeNote":"3/18/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7213126","version":"1","preferredName":"Personal Medical History Hepatitis B Virus Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to a personal history of Hepatitis B Virus and on therapy as outlined in the study protocol.","longName":"PMH_HEPB_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A125F8B7-A4AA-6DC8-E053-F662850A9D4E","latestVersionIndicator":"Yes","beginDate":"2020-03-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-18","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"3/18/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7213130","version":"1","preferredName":"Malignant Hematologic Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to malignant hematologic disease or disorder as outlined in the study protocol.","longName":"MLG_HEM_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A125FE7E-85D2-722E-E053-F662850A6E95","latestVersionIndicator":"Yes","beginDate":"2020-03-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-18","modifiedBy":"SOKKERL","dateModified":"2023-09-20","changeNote":"3/18/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7213262","version":"1","preferredName":"FLT3 Mutation Acute Myeloid Leukemia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility criteria regarding FTL3 mutation of acute myeloid leukemia as outlined in the study protocol.  .","longName":"FLT3_MUT_AML_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1364F4D-2742-25F2-E053-F662850A2CC2","latestVersionIndicator":"Yes","beginDate":"2020-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-19","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"3/19/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7213268","version":"1","preferredName":"Patient Active Hemolytic Anemia Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation relating to anemia resulting from the premature destruction of the peripheral blood red cells that require therapeutic agent as outlined in the study protocol.","longName":"PT_ACT_HEM_ANM_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A136EEE2-E640-7FC6-E053-F662850A9868","latestVersionIndicator":"Yes","beginDate":"2020-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-19","modifiedBy":"KUMMEROA","dateModified":"2021-04-02","changeNote":"3/19/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7213279","version":"1","preferredName":"Environmental Occurrence","preferredDefinition":"An indication the exposure occurrence was environmental or occupational.","longName":"EROCCUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1391265-3CC7-551D-E053-F662850ABF78","latestVersionIndicator":"Yes","beginDate":"2020-03-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-19","modifiedBy":"TAYLORT","dateModified":"2020-03-25","changeNote":"3-25-20 tmt released. 3-19-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7215669","version":"1","preferredName":"Environmental Term","preferredDefinition":"Name of the environmental or occupational exposure.","longName":"ERTERM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A13B5EA1-614C-2D48-E053-F662850A4000","latestVersionIndicator":"Yes","beginDate":"2020-03-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-19","modifiedBy":"SOKKERL","dateModified":"2020-06-25","changeNote":"3-25-20 tmt released. 3-19-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7215677","version":"1","preferredName":"Collected Duration of the Substance Use","preferredDefinition":"The duration of substance use.","longName":"SUDUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A13A9BB3-72F9-46C8-E053-F662850AC920","latestVersionIndicator":"Yes","beginDate":"2020-03-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-19","modifiedBy":"TAYLORT","dateModified":"2020-04-14","changeNote":"3-19-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7215679","version":"1","preferredName":"Smoking Age Started","preferredDefinition":"The age when an individual began smoking tobacco.","longName":"SMOKE_SUSTAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A13BAA72-27D1-209B-E053-F662850AE2B4","latestVersionIndicator":"Yes","beginDate":"2020-03-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-19","modifiedBy":"TAYLORT","dateModified":"2020-03-25","changeNote":"3-25-20 tmt released. 3-19-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7215680","version":"1","preferredName":"Smoking Age Ended","preferredDefinition":"The age when an individual stopped smoking tobacco.","longName":"SMOKE_SUENAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A13B6E15-7272-71AC-E053-F662850A052E","latestVersionIndicator":"Yes","beginDate":"2020-03-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-19","modifiedBy":"TAYLORT","dateModified":"2020-03-25","changeNote":"3-25-20 tmt released.  3-19-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217166","version":"1.1","preferredName":"Treatment Cohort Study EC10300 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol EC10300 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_EC10300_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2169D26-2123-1031-E053-F662850A975F","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-30","modifiedBy":"SOKKERL","dateModified":"2020-03-31","changeNote":"3/23/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7217224","version":"1","preferredName":"Treatment Cohort Study 10300 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10300 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10300_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1892AD6-0973-3F54-E053-F662850A070C","latestVersionIndicator":"Yes","beginDate":"2020-03-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-23","modifiedBy":"SOKKERL","dateModified":"2020-03-24","changeNote":"3/23/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218640","version":"1","preferredName":"Agent Intervention Other Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the use of agents that produce an effect, or that are intended to alter the course of a disease other than the one previously specified as outlined in the study protocol.","longName":"AGNT_INT_OTHR_DZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A19A4459-D489-6958-E053-F662850AEF70","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-24","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"3/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218749","version":"1","preferredName":"Drug Class","preferredDefinition":"The name of the group or classification of an active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"ECDRGCLS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A19E7F67-3414-378C-E053-F662850AFAA1","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-24","modifiedBy":"ZHANGWE","dateModified":"2020-03-25","changeNote":"03/24/2020 wz created for Seed Study. 03/25/2020 wz released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218811","version":"1","preferredName":"Therapy Target","preferredDefinition":"A description of the malignant neoplasm of an anatomic site targeted for a particular therapeutic intervention.","longName":"ECTARGET","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A19AC014-18B8-3933-E053-F662850A817E","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-24","modifiedBy":"ZHANGWE","dateModified":"2020-03-25","changeNote":"03/24/2020 wz created for Seed Study. 03/25/2020 wz released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218819","version":"1","preferredName":"Treatment Cohort Study 9938 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9938 in which subsets of a defined population are identified.","longName":"TX_COHRT_STDY_9938_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A19E8DF7-91C4-2D9E-E053-F662850AE3B4","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-24","modifiedBy":"SOKKERL","dateModified":"2020-03-25","changeNote":"3/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218826","version":"1","preferredName":"Employee Job","preferredDefinition":"The name of the principal activity that a person does to earn money.","longName":"EMPJOB_SCORRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A19E7F67-345D-378C-E053-F662850AFAA1","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-24","modifiedBy":"ZHANGWE","dateModified":"2020-03-25","changeNote":"03/24/2020 wz created for Seed Study. 03/25/2020 wz released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218837","version":"1","preferredName":"Income Level","preferredDefinition":"A description of the position on a scale measuring compensation or monetary support.","longName":"INCMLVL_SCORRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A19BB6A6-4C45-351B-E053-F662850A58E4","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-24","modifiedBy":"SOKKERL","dateModified":"2020-06-23","changeNote":"03/24/2020 wz created for Seed Study. 03/25/2020 wz released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7218848","version":"1","preferredName":"PDMR Eligible","preferredDefinition":"An indication as to whether or not the patient is eligible for Patient-Derived Models Repository.","longName":"PDMRELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1A1529A-36CE-544C-E053-F662850A8746","latestVersionIndicator":"Yes","beginDate":"2020-03-24","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-24","modifiedBy":"ZHANGWE","dateModified":"2020-03-25","changeNote":"03/24/2020 wz created for Seed Study. 03/25/2020 wz released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222761","version":"1","preferredName":"Abnormalities Detected","preferredDefinition":"An indication whether or not abnormalities were detected.","longName":"ABNDETYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1C72DB5-EDA2-4E84-E053-F662850A2D8B","latestVersionIndicator":"Yes","beginDate":"2020-03-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-26","modifiedBy":"TAYLORT","dateModified":"2020-06-04","changeNote":"6/4/20 tmt released/MM. 03/26/2020 wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222773","version":"1","preferredName":"Pregnancy Test Consent Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded response indicating whether the patient complies with a pregnancy test as as outlined in the protocol.","longName":"PREG_CNST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1C6E979-9F96-4ADB-E053-F662850A2A9E","latestVersionIndicator":"Yes","beginDate":"2020-03-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-26","modifiedBy":"SOKKERL","dateModified":"2021-03-17","changeNote":"3/26/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222792","version":"1","preferredName":"Patient Pregnancy Precaution Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address pregnancy precautions as outlined in the study protocol.","longName":"PREG_PRCT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1C6EDBC-4F58-4EE3-E053-F662850A9E71","latestVersionIndicator":"Yes","beginDate":"2020-03-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-26","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"3/26/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222796","version":"1","preferredName":"Patient Contact Physician Medical Problem Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The  indicator for information related to a patient's consent to contact the physician if a medical problem arises as outlined in the study protocol.","longName":"PT_CNT_PHYS_MED_PRLM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1C72DB5-EE2D-4E84-E053-F662850A2D8B","latestVersionIndicator":"Yes","beginDate":"2020-03-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-26","modifiedBy":"SOKKERL","dateModified":"2020-04-30","changeNote":"3/26/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222864","version":"1","preferredName":"Patient Uterine obstruction Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a disorder characterized by blockage of the uterine outlet as outlined in the study protocol.","longName":"PT_UTRN_OBST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1D642F8-580D-7A8E-E053-F662850A0758","latestVersionIndicator":"Yes","beginDate":"2020-03-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-27","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/27/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222869","version":"1","preferredName":"Patient Demyelinating Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a broad group of disorders that affect the myelin sheaths that cover the neurons as outlined in the study protocol.","longName":"PT_DEMYTN_DIS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1D68D6A-1951-6156-E053-F662850AB439","latestVersionIndicator":"Yes","beginDate":"2020-03-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-27","modifiedBy":"WISEM","dateModified":"2020-08-20","changeNote":"3/27/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222874","version":"1","preferredName":"Treatment Cohort Study EC10335 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10335 in which subsets of a defined population are identified.","longName":"TX_COHRT_STDY_10335_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1D8105B-CE0C-7692-E053-F662850AFF67","latestVersionIndicator":"Yes","beginDate":"2020-03-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-27","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"3/27/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7223022","version":"1","preferredName":"Tumor/Lesion Identification Performed","preferredDefinition":"An indication whether or not a tumor/lesion identification was performed.","longName":"TUPERF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2126847-9455-1585-E053-F662850AAA21","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-30","modifiedBy":"TAYLORT","dateModified":"2020-06-04","changeNote":"6/4/20 tmt released/MM.  03/30/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7223071","version":"2","preferredName":"Result or Finding in Original Units","preferredDefinition":"Result of the measurement or finding as originally received or collected.","longName":"MBORRES_CHAR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F40D66F6-6BAB-6EDC-E053-731AD00A4EB5","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-06-05","changeNote":"6-3-20 released/MM. 3-30-20 tmt created for Seed Study.","administrativeNotes":"2023.6.5 Released per wz review. ak 2023.2.6 Versioned due to VD CT Pkg 52 updates. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7223088","version":"1","preferredName":"Assay Date","preferredDefinition":"Date of the assay procedure.","longName":"ASYDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A21990E4-2DF7-0E1D-E053-F662850A4E0D","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-30","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 3-30-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7229588","version":"1","preferredName":"Assay Name","preferredDefinition":"Free text field for the name of the assay procedure.","longName":"ASYNAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A219D6A4-056D-3CD9-E053-F662850A2655","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-30","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 3-30-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7231919","version":"1","preferredName":"Protocol Deviation Reported Term","preferredDefinition":"The reported or pre-specified protocol deviation as defined by the sponsor.","longName":"DVTERM_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A226963E-08E5-33CB-E053-F662850AA7E6","latestVersionIndicator":"Yes","beginDate":"2020-03-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-03-31","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 3-31-20 tmt created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7231943","version":"1","preferredName":"Treatment Cohort Study EC10334 Code","preferredDefinition":"The code that represents the information pertaining to protocol EC10334 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_EC10334_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A226963E-0906-33CB-E053-F662850AA7E6","latestVersionIndicator":"Yes","beginDate":"2020-03-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-03-31","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"3/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7232073","version":"1","preferredName":"Microbiology Test Performed","preferredDefinition":"An indication whether or not a microbiology test was performed.","longName":"MBPERF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A22A0BBD-E818-69CE-E053-F662850AF2B0","latestVersionIndicator":"Yes","beginDate":"2020-03-31","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-05-08","changeNote":"6-3-20 released/MM. 3/31/2020 wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7232089","version":"1","preferredName":"Protocol Deviation Description","preferredDefinition":"A description of the protocol deviation.","longName":"DVDESC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A22AD2AB-40FF-0D79-E053-F662850A0007","latestVersionIndicator":"Yes","beginDate":"2020-03-31","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-31","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. 3/31/2020 wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7233223","version":"1","preferredName":"Disposition Event Occurrence","preferredDefinition":"An indication whether or not any disposition events occurred.","longName":"DSYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A22D0593-8235-69C4-E053-F662850A79CE","latestVersionIndicator":"Yes","beginDate":"2020-03-31","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-03-31","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeNote":"6-3-20 released/MM. 3/31/2020 wz created for Seed Study.","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002164. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7235713","version":"1","preferredName":"Other reason for withdrawal of consent","preferredDefinition":"A free text field to describe the other reason for consent withdrawal.","longName":"CNSTREAS_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A23C68DE-B129-26DF-E053-F662850AC4EE","latestVersionIndicator":"Yes","beginDate":"2020-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-01","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 released/MM. Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7235768","version":"1","preferredName":"Other Tumor/Lesion ID Result","preferredDefinition":"A free text field to describe the other outcome of the tumor identification assessment.","longName":"TUORRES_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A23D9328-C8E1-1F93-E053-F662850AC258","latestVersionIndicator":"Yes","beginDate":"2020-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-01","modifiedBy":"LUY","dateModified":"2020-04-08","changeNote":"4-1-20 Created for 10300; tmt. 04/08/20202 Released for 10300; ylu","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7235772","version":"1","preferredName":"Other Result or Finding in Original Units","preferredDefinition":"A free text field to describe the other outcome of the disease response assessment.","longName":"RSORRES_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A23DB850-9814-24D8-E053-F662850A6C6B","latestVersionIndicator":"Yes","beginDate":"2020-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-01","modifiedBy":"LUY","dateModified":"2020-04-08","changeNote":"4-1-20 Created for 10300; tmt. 04/08/2020 Released, ylu","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7236025","version":"1","preferredName":"Protocol Deviation IRB CIRB Informed Indicator","preferredDefinition":"An indication whether the Institutional Review Board/Central Institutional Review Board was informed of the deviation.","longName":"DVIRBYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A240499B-439B-3CB8-E053-F662850A6EE9","latestVersionIndicator":"Yes","beginDate":"2020-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-01","modifiedBy":"ZHANGWE","dateModified":"2021-04-09","changeNote":"6-3-20 released/ MM. 4-1-20 Created for Seed Study; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7238950","version":"1","preferredName":"Patient Ineligibility Or Refuse Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator that addressing the patient's refusal, or ineligibility of treatment as outlined in the study protocol.","longName":"PT_INEGBT_REF_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A255DB75-FF7D-3486-E053-F662850A574C","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-02","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeNote":"4/2/20 ls","administrativeNotes":"2023.4.12 Replaced special character in 'patient's'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7239747","version":"1","preferredName":"Patient Major Surgical Procedure Recovery Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has recovered from major surgical procedure as outlined in the study protocol.","longName":"MAJ_SUR_PR_RECOV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2A0DBC2-2D6C-4103-E053-F662850A4C19","latestVersionIndicator":"Yes","beginDate":"2020-04-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-06","modifiedBy":"SOKKERL","dateModified":"2022-01-09","changeNote":"4/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7239753","version":"1","preferredName":"Patient Core Binding Factor Acute Myeloid Leukemia Or Acute Promyelocytic Leukemia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions that address if patient has Core Binding Factor Acute Myeloid  or Acute Promyelocytic Leukemia as outlined in the study protocol.","longName":"CBLAML_APL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2A062D7-3EBE-7F7F-E053-F662850A9F02","latestVersionIndicator":"Yes","beginDate":"2020-04-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-06","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"4/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7239764","version":"1","preferredName":"Patient Disease or Disorder Risk Factor History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for participation in a clinical trial with regards to the record of an individual's risk factors for disease as outlined in the protocol.","longName":"DZDIS_RSK_FT_HX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2A37032-29B4-4532-E053-F662850A78EF","latestVersionIndicator":"Yes","beginDate":"2020-04-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-06","modifiedBy":"CLOHNES","dateModified":"2023-11-17","changeNote":"4/6/20 ls","administrativeNotes":"11/17/23 Added  alt OID and AQT for CCTG ticket number CADSR0003085 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7239829","version":"2","preferredName":"Treatment Cohort Study 10327 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10327 in which subsets of a defined population are identified.","longName":"TX_COHRT_STDY_10327_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"102CF356-21B8-5243-E063-731AD00ACF9A","latestVersionIndicator":"Yes","beginDate":"2020-04-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-30","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeNote":"4/6/20 ls","administrativeNotes":"1/30/24- Versioned CDE to reflect a version in VD","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7241679","version":"1","preferredName":"Person Spermatozoon Oocyte Donor Consent Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation related to the patient's agreement/consent for any questions related to sperm or egg donation as outlined in the protocol.","longName":"SPRM_OCYT_DNR_CNST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2C83146-8727-15C1-E053-F662850A14A4","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-08","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"4/8/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244393","version":"1","preferredName":"Patient Administration Granulocyte Colony-Stimulating Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to administration of (G-CSF) as outlined in the study protocol.","longName":"PT_ADMN_GCSF_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CCAA20-C813-1A17-E053-F662850AB33F","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-08","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"4/8/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244523","version":"1","preferredName":"Genetic Test Type","preferredDefinition":"The type of genetic testing performed.","longName":"GENTSTYP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CC8CA5-78DE-7A54-E053-F662850A080C","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-08","modifiedBy":"TAYLORT","dateModified":"2020-04-09","changeNote":"4-8-20 NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244524","version":"1","preferredName":"Prior Immunotherapy And/Or Monoclonal Antibody Therapy Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior administration of immunotherapy, including monoclonal antibody therapy as outlined in the study protocol.","longName":"ITX_MONTX_ADMIN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CCAA20-C83B-1A17-E053-F662850AB33F","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-08","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"4/8/20 ls","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244823","version":"1","preferredName":"Osteoclast Targeted Therapy Negation Use Reason","preferredDefinition":"An explanation for why osteoclast targeted therapy was not used.","longName":"NO_OSTEO_TARGTX_REAS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2E0C0E0-79B0-4828-E053-F662850ABDBA","latestVersionIndicator":"Yes","beginDate":"2020-04-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-09","modifiedBy":"TAYLORT","dateModified":"2020-06-04","changeNote":"6/4/20 tmt released/MM. 4/9/20 tmt/10096.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7248837","version":"1","preferredName":"Measurable Residual Disease Assessment Flow Cytometry Method CDISC Ind","preferredDefinition":"The indicator as to whether or not measurable residual disease was assessed by flow cytometry.","longName":"MRDFCYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A37BC0AF-8A22-16B8-E053-F662850AD3D2","latestVersionIndicator":"Yes","beginDate":"2020-04-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-17","modifiedBy":"TAYLORT","dateModified":"2020-04-17","changeNote":"4-17-20 NSV/10300; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252485","version":"1","preferredName":"Patient Malignant Neoplasm Diagnosis Or Complete Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response related to a person having a cancer diagnosis or has  completed therapy regimen as outlined in  the protocol.","longName":"CA_DX_CMP_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3B9AEC6-51CE-5A54-E053-F662850A4D92","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-05-14","changeNote":"4/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252491","version":"1","preferredName":"Patient Hospitalization COVID-19 Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to hospitalization due to confirmed COVID -19 infection as outlined in the study protocol.","longName":"PT_HOSP_CONF_COVID_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3B9D3D4-F82C-4801-E053-F662850AAE5B","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2022-09-06","changeNote":"4/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252506","version":"1","preferredName":"Group Residence Indicator","preferredDefinition":"An indication as to whether or not a transfer occurred from a group facility.","longName":"GRPRESYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BA6714-0AC4-4831-E053-F662850ACD87","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"TAYLORT","dateModified":"2020-04-20","changeNote":"4-20-20 NSV created for TRC-10446; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252511","version":"1","preferredName":"Disease Status","preferredDefinition":"The condition or state of disease at a particular time.","longName":"MHDZSTAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3B9CBC3-1E6E-481F-E053-F662850AB808","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"TAYLORT","dateModified":"2020-04-20","changeNote":"4-20-20 NSV created for TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252669","version":"1","preferredName":"Patient Receive Therapeutic Procedure COVID-19 Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address a patient receiving of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process relating to COVID-19 as outlined in the study protocol.","longName":"PT_REC_TX_COVID_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BB8938-91CD-62CF-E053-F662850AF42F","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-05-14","changeNote":"4/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252753","version":"1","preferredName":"Clinical Status Ordinal Scale Result","preferredDefinition":"The outcome of the scale designed to assess a patient's clinical status at enrollment.","longName":"CSO0101_RSORRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BC19A1-3CCC-51CC-E053-F662850A1091","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"TAYLORT","dateModified":"2020-05-04","changeNote":"5-4-20 minor edit to definition.  4-20-20 Created for TRC-10446; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252758","version":"1","preferredName":"Death Certain Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address the certainty of death as outlined in the study protocol.","longName":"DEATH_CERT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BC3BFB-66EC-53A5-E053-F662850ACE34","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-05-14","changeNote":"4/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252798","version":"1","preferredName":"Patient COVID-19 Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 as outlined in the study protocol.","longName":"PT_COVID_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BC35C2-BC90-50DD-E053-F662850A4986","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-12-04","changeNote":"4/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252807","version":"1","preferredName":"Concomitant Medication Name","preferredDefinition":"Verbatim medication name or treatments (include only treatments with data collection characteristics similar to medications), as defined by the sponsor.","longName":"CMTRT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD29FA-CB47-7E8E-E053-F662850A01C5","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeNote":"4-20-20 Created for TRC-10446; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252814","version":"1","preferredName":"Treatment Cohort Study TRC- 10446 Code","preferredDefinition":"The code that represents the information pertaining to protocol TRC-10446 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10446_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD9803-4FC5-019E-E053-F662850AB3B3","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"4/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252820","version":"1","preferredName":"Treatment Cohort Study TRC- 10446 Code","preferredDefinition":"The code that represents the information pertaining to protocol TRC-10446 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_TRC-10446_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BDA578-68FD-6AD3-E053-F662850A94A4","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-20","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"4/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7252824","version":"1","preferredName":"Lesion Talimogene Laherparepvec Injection Occurrence Ind","preferredDefinition":"An indication as to whether or not the lesion was injected with talimogene laherparepvec.","longName":"TVEC_INJ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD26D2-3EA9-7A6E-E053-F662850A3F7E","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-20","modifiedBy":"TAYLORT","dateModified":"2020-04-22","changeNote":"4-20-20 Created for 10057; tmt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7255252","version":"2","preferredName":"Disease or Disorder Clinical Significance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation that address the clinical significance of any abnormal condition(s) of the body as outlined in the study protocol.","longName":"DZDR_CLNSIG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A48E40-9189-6B1A-E063-731AD00AF336","latestVersionIndicator":"Yes","beginDate":"2020-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-09-18","modifiedBy":"SOKKERL","dateModified":"2023-09-18","changeNote":null,"administrativeNotes":"9/18/23 versioned to 2.0 to cleanup rules. Long Name is misspelled. LS versioning DEC as well.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7260765","version":"1","preferredName":"Tocilizumab Administered CDISC Ind","preferredDefinition":"An indication whether or not tocilizumab was given.","longName":"TOCADMYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F75BB3-54CB-4EF4-E053-F662850A18D7","latestVersionIndicator":"Yes","beginDate":"2020-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-23","modifiedBy":"GDEEN","dateModified":"2022-10-26","changeNote":"4-23-20 Created for COVID-19 TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7260795","version":"1","preferredName":"Mechanical Ventilation Intervention or Procedure Occurrence CDISC Ind","preferredDefinition":"An indication whether or not mechanical ventilation occurred.","longName":"VENTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F8F782-6DF9-1A59-E053-F662850A0196","latestVersionIndicator":"Yes","beginDate":"2020-04-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-23","modifiedBy":"TAYLORT","dateModified":"2020-06-29","changeNote":"4-23-20 Created for COVID-19 TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7261169","version":"1","preferredName":"Patient Receive Investigational Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to receiving investigational therapies as outlined in the study protocol.","longName":"PT_REC_INV_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A40A97F9-8703-2BBD-E053-F662850ACD88","latestVersionIndicator":"Yes","beginDate":"2020-04-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-24","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeNote":"4/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7261187","version":"1","preferredName":"Patient Enrollment Other Investigational Study COVID-19 Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study addressing the enrollment in other investigational study for COVID-19 as outlined in the protocol.","longName":"ENRL_OTH_INVES_COVID_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A40A8C83-120F-2BC1-E053-F662850A8A12","latestVersionIndicator":"Yes","beginDate":"2020-04-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-24","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"4/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7261254","version":"1","preferredName":"Chronic Hepatitis B Infection Suppressive Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related  to a chronic an infection caused by the hepatitis B virus and on suppressive therapy as outlined in protocol.","longName":"HBV_SUPRS_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A40D8D68-0A64-3AC3-E053-F662850AF0CA","latestVersionIndicator":"Yes","beginDate":"2020-04-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-24","modifiedBy":"SOKKERL","dateModified":"2021-03-26","changeNote":"4/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7261258","version":"1","preferredName":"Patient Medical History Hepatitis C Infection Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the patient's medical background regarding an infection that is caused by hepatitis C virus, the administration of therapeutic agents as outlined in the study protocol.","longName":"PMH_HCV_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A40E3193-4996-716B-E053-F662850AF50B","latestVersionIndicator":"Yes","beginDate":"2020-04-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-24","modifiedBy":"SOKKERL","dateModified":"2020-07-16","changeNote":"4/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7263048","version":"1","preferredName":"Non Invasive Procedure Oxygen Therapy Requirement CDISC Ind","preferredDefinition":"An indication whether or not non-invasive oxygen supplementation is/was required.","longName":"O2SUPPYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41E1FC0-16E8-7DDC-E053-F662850AD0D8","latestVersionIndicator":"Yes","beginDate":"2020-04-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-25","modifiedBy":"COOPERJ","dateModified":"2022-02-11","changeNote":"4-25-20 Created for TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7263053","version":"1","preferredName":"Fever Resolution Occurrence CDISC Ind","preferredDefinition":"An indication whether or not fever resolution occurred.","longName":"FVRSVYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41E60A2-A54F-7E70-E053-F662850ADE05","latestVersionIndicator":"Yes","beginDate":"2020-04-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-25","modifiedBy":"TAYLORT","dateModified":"2020-04-28","changeNote":"4-25-20 Created for TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7263057","version":"1","preferredName":"Respiratory System Intervention or Procedure Support Reduced CDISC Ind","preferredDefinition":"An indication whether or not the intervention(s) or procedure(s) to support the respiratory system were decreased.","longName":"RESPTDYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41E1FC0-1733-7DDC-E053-F662850AD0D8","latestVersionIndicator":"Yes","beginDate":"2020-04-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-25","modifiedBy":"TAYLORT","dateModified":"2020-04-28","changeNote":"4-25-20 Created for TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7263135","version":"1","preferredName":"Previous Finding Result","preferredDefinition":"The finding relative to a prior test result.","longName":"PREVFIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41F7B12-0EC7-7E74-E053-F662850AA937","latestVersionIndicator":"Yes","beginDate":"2020-04-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-04-25","modifiedBy":"TAYLORT","dateModified":"2020-04-28","changeNote":"4-25-20 Created for TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7264750","version":"1","preferredName":"Patient Receive Induction Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the first choice of treatment of synthetic or naturally-occurring chemicals to treat disease as outlined in the study protocol.","longName":"PT_REC_IND_CHEMO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A45CF6E6-D504-75F2-E053-F662850A0416","latestVersionIndicator":"Yes","beginDate":"2020-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-28","modifiedBy":"TSESU","dateModified":"2023-01-09","changeNote":"4/28/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7264784","version":"1","preferredName":"Patient Medical History Hypersensitivity Contrast Agent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response indicating whether a patient meets the criteria to participate in a clinical trial regarding an immune response that occurs following exposure to contrast agent as outlined in the study protocol.","longName":"PMH_HYPER_CNT_AGNT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4604E1C-A71D-1906-E053-F662850A7911","latestVersionIndicator":"Yes","beginDate":"2020-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-28","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"4/28/20 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7264860","version":"1","preferredName":"Treatment Cohort Study EC10366 Code","preferredDefinition":"The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study EC10366.","longName":"TX_COH_SDY_EC10366_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A46E77C8-8DAF-3B5C-E053-F662850AA3DF","latestVersionIndicator":"Yes","beginDate":"2020-04-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-29","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"4/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7264864","version":"1","preferredName":"Neoplasm Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to a diagnosis of cancer as outlined in the protocol.","longName":"NEO_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A46F5FF3-13FE-7213-E053-F662850A8162","latestVersionIndicator":"Yes","beginDate":"2020-04-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-29","modifiedBy":"SOKKERL","dateModified":"2021-03-12","changeNote":"4/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7267171","version":"1","preferredName":"Patient Lab Procedure SARS Coronavirus 2 Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to testing for COVID- 19 as outlined in the study protocol.","longName":"PT_LAB_PRCD_COVID_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4709252-8DA0-5B94-E053-F662850A4844","latestVersionIndicator":"Yes","beginDate":"2020-04-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-29","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"4/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7267399","version":"1","preferredName":"Patient SARS Coronavirus 2 Positive Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions addressing positive finding for COVID- 19 as outlined in the study protocol.","longName":"PT_COVID_POS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A473D8A2-4E6E-346B-E053-F662850A4F89","latestVersionIndicator":"Yes","beginDate":"2020-04-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-29","modifiedBy":"ZHWENDY","dateModified":"2022-07-21","changeNote":"4/29/20 ls AQT added. 2020-9-21 AK","administrativeNotes":"7/21/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7275591","version":"1","preferredName":"Patient Histological Confirmation Metastatic Neoplasm Progressive Disease Standard Therapy Extend Life Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address disease progression on standard therapy to prolong life as outlined in the study protocol.","longName":"MET__STD_TX_PRGDZ_EXT_LF_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A489F34B-72EA-08E6-E053-F662850A207D","latestVersionIndicator":"Yes","beginDate":"2020-04-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-30","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"4/30/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7275593","version":"1","preferredName":"Treatment Cohort Study 10349 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10349 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10349_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A48C79C6-D428-7DF8-E053-F662850AAF6C","latestVersionIndicator":"Yes","beginDate":"2020-04-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-04-30","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":"4/30/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7278932","version":"1","preferredName":"Consent Acquired Remotely","preferredDefinition":"An indication as to whether or not remote informed consent was acquired.","longName":"CNSTRMYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4D616D8-28C6-21C5-E053-F662850ACD5A","latestVersionIndicator":"Yes","beginDate":"2020-05-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-04","modifiedBy":"TAYLORT","dateModified":"2020-05-04","changeNote":"5-4-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283674","version":"1","preferredName":"Primary Disease Site Histologic Type Name","preferredDefinition":"Descriptive name of the primary disease site which may include histotype.","longName":"DZSITE_TYPE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4FCDFD9-37E4-7A29-E053-F662850A950F","latestVersionIndicator":"Yes","beginDate":"2020-05-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-06","modifiedBy":"TAYLORT","dateModified":"2020-05-07","changeNote":"5-7-20 tmt released/MM. 5-6-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283677","version":"1","preferredName":"Primary Disease Recurrence CDISC Ind","preferredDefinition":"An indication whether or not there was a return of the primary disease.","longName":"DZRECUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4FCDFD9-3833-7A29-E053-F662850A950F","latestVersionIndicator":"Yes","beginDate":"2020-05-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-06","modifiedBy":"SPRINGERL","dateModified":"2020-06-28","changeNote":"5-7-20 tmt released/MM. 5-6-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283699","version":"1","preferredName":"Specimen Collected Indicator","preferredDefinition":"An indication whether or not a specimen was collected.","longName":"SPECYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5009C39-F3B8-2F95-E053-F662850A4E31","latestVersionIndicator":"Yes","beginDate":"2020-05-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-06","modifiedBy":"TAYLORT","dateModified":"2020-05-07","changeNote":"5-7-20 tmt released/MM. 5-6-30 TRC-10446 NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283726","version":"1","preferredName":"Visit Method","preferredDefinition":"A response to determine if the method of follow-up was by a call or visit.","longName":"VISITMTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A501C420-3D99-6B09-E053-F662850A6344","latestVersionIndicator":"Yes","beginDate":"2020-05-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-06","modifiedBy":"TAYLORT","dateModified":"2020-05-07","changeNote":"5-7-20 tmt released/MM. 5-6-20 TRC-10446 NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283812","version":"1","preferredName":"Metastatic Disease Indicator","preferredDefinition":"An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.","longName":"METADZYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A50F4E7A-66CB-0BF8-E053-F662850ACA27","latestVersionIndicator":"Yes","beginDate":"2020-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-07","modifiedBy":"TAYLORT","dateModified":"2020-05-07","changeNote":"5-7-20 NCICOVID NSV, released/MM; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283817","version":"1","preferredName":"Ann Arbor Staging Indicator","preferredDefinition":"An indication as to whether an evaluation by the Ann Arbor Staging System has relevance.","longName":"ANNARBYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A50F7781-FB6B-782D-E053-F662850AF4AA","latestVersionIndicator":"Yes","beginDate":"2020-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-07","modifiedBy":"TAYLORT","dateModified":"2020-05-07","changeNote":"5-7-20 NCICOVID NSV, released/MM; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283862","version":"1","preferredName":"Treatment Cohort Study EC10057 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10057 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10057_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5143618-7C64-13C2-E053-F662850A36C6","latestVersionIndicator":"Yes","beginDate":"2020-05-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-07","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"5/7/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7283947","version":"1","preferredName":"Treatment Cohort Study EC10334 Code","preferredDefinition":"The code that represents the information pertaining to protocol EC10334 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_EC10334_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A52566B3-B7AB-46C0-E053-F662850A7934","latestVersionIndicator":"Yes","beginDate":"2020-05-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-08","modifiedBy":"SOKKERL","dateModified":"2020-09-15","changeNote":"5/8/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7290133","version":"1","preferredName":"Patient Consideration Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient can be considered for administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process as outlined in the study protocol.","longName":"PT_CONSD_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5623DEC-92B8-09EA-E053-F662850A3F77","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-11","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"5/11/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7290137","version":"1","preferredName":"Leukemia Central Nervous System Involvement Induction Chemotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions relating to leukemia involvement of the CNS that is eligible for induction therapy as outlined in the study protocol.","longName":"LEUK_CNS_IND_CHEMO_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A56250F5-9E6E-25AD-E053-F662850ADFF0","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-11","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"5/11/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7290141","version":"1","preferredName":"Therapy Complementary and Alternative Medicine Discontinue Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to whether nontraditional therapeutic agents/procedures were discontinued as outlined in the study protocol.","longName":"TX_ALT_MD_DISCN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A56388E7-1536-2B8A-E053-F662850A5276","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-11","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"5/11/20 ls","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7290183","version":"1","preferredName":"Treatment Cohort Study EC10367 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10367 in which subsets of a defined population are identified.","longName":"TX_COH_STDY_10367_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5640722-6DF5-40A9-E053-F662850AEBBC","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-11","modifiedBy":"SOKKERL","dateModified":"2020-09-01","changeNote":"5/11/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7290918","version":"1","preferredName":"Patient Employed Indicator","preferredDefinition":"An indication whether or not the patient is currently employed.","longName":"EMPJOBYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A57494AF-1ACD-0D99-E053-F662850A1534","latestVersionIndicator":"Yes","beginDate":"2020-05-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-12","modifiedBy":"TAYLORT","dateModified":"2020-05-26","changeNote":"5-26-20 tmt released/MM. 5-12-20 NCICOVID NSV/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7290921","version":"1","preferredName":"Employed in Health Care","preferredDefinition":"An indication whether or not a person is employed in healthcare or as a first responder.","longName":"EMPHLTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A563DE2F-821D-37C4-E053-F662850A8BC5","latestVersionIndicator":"Yes","beginDate":"2020-05-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-12","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 Released/MM; tmt. 5-12-20 NCICOVID NSV/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7290929","version":"1","preferredName":"Study Name","preferredDefinition":"A free text field for the name of the study.","longName":"STUDYNM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A574030D-19F7-130E-E053-F662850A0146","latestVersionIndicator":"Yes","beginDate":"2020-05-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-12","modifiedBy":"ARCHERJ","dateModified":"2021-02-26","changeNote":"5-26-20 tmt released/MM. 5-12-20 NCICOVID NSV/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7292046","version":"1","preferredName":"Testing Location","preferredDefinition":"The location where a lab test was performed.","longName":"TSTLOC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5897FF6-E6DE-5D3F-E053-F662850A75F7","latestVersionIndicator":"Yes","beginDate":"2020-05-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-13","modifiedBy":"NIKITAP","dateModified":"2022-02-22","changeNote":"6-3-20 Released/MM; tmt. 5-13-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7292047","version":"1","preferredName":"Reason Test Performed","preferredDefinition":"Descriptive reason for the lab test as defined by the sponsor.","longName":"MBREAS_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A58784F9-E779-6815-E053-F662850AAFE1","latestVersionIndicator":"Yes","beginDate":"2020-05-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-13","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 Released/MM; tmt. 5-13-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7292051","version":"1","preferredName":"Treatment Cohort Study 10330 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10330 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10330_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A589D5B9-91FA-411F-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2020-05-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-13","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"5/13/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297133","version":"1","preferredName":"Prior Different Cancer Diagnosis","preferredDefinition":"An indication whether or not a person was previously diagnosed with a different type of cancer.","longName":"PCANDXYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69019BD-5E33-2828-E053-4EBD850AC2FA","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-26","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 Released/MM; tmt. 5-26-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297159","version":"1","preferredName":"Current Clinical Trial Or Study Registry Enrollment","preferredDefinition":"An indication whether or not a person is currently enrolled in a clinical trial or study registry.","longName":"CTRSUBYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A68F264D-7A2A-7CAC-E053-4EBD850A82C2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-26","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 Released/MM; tmt. 5-26-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297167","version":"1","preferredName":"Tumor Mutation Burden Known","preferredDefinition":"An indication whether or not tumor mutational burden is known.","longName":"TUMUTBYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6906105-E459-5148-E053-4EBD850AC67D","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-26","modifiedBy":"TAYLORT","dateModified":"2020-06-03","changeNote":"6-3-20 Released/MM; tmt. 5-26-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297201","version":"1","preferredName":"Neoplasm Gene Mutation Tissue Specimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address neoplasm from a mutated gene collected from a non-liquid tissue as outlined in the study protocol.","longName":"NEO_GNMUT_TIS_SPEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A690C3AE-206C-1669-E053-4EBD850A3708","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-26","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"5/26/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297243","version":"1","preferredName":"Personal Medical History Pneumocystis Pneumonia Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patients medical background with Pneumocystis pneumonia as outlined in the study protocol.","longName":"PER_MED_HX_PCP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69147CA-C573-62CE-E053-4EBD850AA7DC","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-26","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"5/26/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7298051","version":"1","preferredName":"Treatment Cohort Study 10382 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10382 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10382_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A694583C-607D-30E0-E053-4EBD850AEA19","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-26","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"5/26/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7307639","version":"1","preferredName":"Patient Receive Prophylactic Antiemetic Agent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to patient receiving a pharmacological agent that prevents nausea and/or vomiting as outlined in the study protocol.","longName":"PT_REC_PROPL_ANTM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69F4AAD-F2E9-31CB-E053-4EBD850A7E36","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-27","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"5/27/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7307659","version":"1","preferredName":"Myeloid Growth Factor Administered Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related administration of certain types of hematopoietic (blood-forming) cells found in the bone marrow and substances made by the body that function to regulate cell division and cell survival as outlined in the study protocol.","longName":"MYEL_GF_ADM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A00509-8075-6050-E053-4EBD850A8745","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-05-27","modifiedBy":"SOKKERL","dateModified":"2022-12-28","changeNote":"5/27/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7308914","version":"1","preferredName":"Patient Conventional Chondrosarcoma Biopsy Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to biopsy results for conventional chondrosarcoma.","longName":"CCS_BX_RES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B568B8-7111-22DA-E053-4EBD850A2764","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-28","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"5-28-20 Protocol 10330; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7308918","version":"1","preferredName":"Patient Disease Unresectable Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to disease that is not capable of being removed by surgery.","longName":"DZ_UNRES_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A53F76-D128-1EE7-E053-4EBD850A657D","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-28","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"5-28-20 Protocol 10330; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7308925","version":"1","preferredName":"Patient Personal Medical History Disease-Free Survival Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the medical history of disease-free survival.","longName":"PMH_DZFRE_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B490B5-6469-253B-E053-4EBD850A21C6","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-28","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"5-28-20 10330; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7309037","version":"1","preferredName":"Patient Pregnancy Physician Notification Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the eligibility requirement was met with regards to the patient's agreement to notify a physician of pregnancy.","longName":"PREG_DR_NOTIF_AGR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B868D3-E1E5-489F-E053-4EBD850AAEDE","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-28","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"5-28-20 Protocol 10330; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7309069","version":"1","preferredName":"Patient Medication Or Substance Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the protocol eligibility criteria was met with regards to the patient's requirements for substances, or drug products intended to treat, prevent or alleviate the symptoms of disease.","longName":"MEDS_SUBS_REQ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B8CE19-57D9-535C-E053-4EBD850A4EA4","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-28","modifiedBy":"SOKKERL","dateModified":"2022-11-16","changeNote":"7-31-20 released; TL. 5-28-20 Protocol 10330; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7309083","version":"1","preferredName":"Patient Personal Medical History Psychiatric Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the medical history of a mental disorder characterized by behavioral and/or psychological abnormalities, impairment in social or other areas of functioning, and may be accompanied by physical symptoms.","longName":"PMH_PSYDZ_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B87012-665C-7530-E053-4EBD850A9B3B","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-28","modifiedBy":"SOKKERL","dateModified":"2020-10-06","changeNote":"5-28-20 Protocol 10330; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312599","version":"1","preferredName":"Essential Employee Occupation","preferredDefinition":"An indication whether or not a person is an essential worker.","longName":"EMPESNYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA4691-CC7A-6883-E053-4EBD850A9E85","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312601","version":"1","preferredName":"Acute Renal Failure Comorbid Condition","preferredDefinition":"An indication whether or not acute kidney injury is concomitant or concurrent with the primary condition or disease under study.","longName":"AKIDINYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6C92EF4-DEE3-6880-E053-4EBD850A7681","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312613","version":"1","preferredName":"Acute Respiratory Distress Syndrome Comorbid Condition","preferredDefinition":"An indication whether or not acute respiratory distress syndrome is concomitant or concurrent with the primary condition or disease under study.","longName":"ARDSYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6C98E52-47C7-5D9C-E053-4EBD850A2449","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312615","version":"1","preferredName":"Hemorrhage Comorbid Condition","preferredDefinition":"An indication whether or not bleeding is concomitant or concurrent with the primary condition or disease under study.","longName":"BLEEDYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA1FC4-7474-5D97-E053-4EBD850A476A","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312697","version":"1","preferredName":"Cardiovascular Disorder Comorbid Condition","preferredDefinition":"An indication whether or not a cardiovascular disorder is concomitant or concurrent with the primary condition or disease under study.","longName":"CARDIOYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CD344F-489B-7336-E053-4EBD850A0B5C","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"SOKKERL","dateModified":"2021-08-03","changeNote":"5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312740","version":"1","preferredName":"Infectious Disorder Comorbid Condition","preferredDefinition":"An indication whether or not an infectious disorder is concomitant or concurrent with the primary condition or disease under study.","longName":"INFECTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CF686B-E294-3EE4-E053-4EBD850A8A62","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"SOKKERL","dateModified":"2020-09-03","changeNote":"5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312811","version":"1","preferredName":"Nervous System Disorder Comorbid Condition","preferredDefinition":"An indication whether or not a neurological disorder is concomitant or concurrent with the primary condition or disease under study.","longName":"NEUROYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CFCE91-B6B1-4ED5-E053-4EBD850A311E","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312818","version":"1","preferredName":"Pancreatitis Comorbid Condition","preferredDefinition":"An indication whether or not pancreatitis is concomitant or concurrent with the primary condition or disease under study.","longName":"PANCYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D060E0-E272-6F31-E053-4EBD850AD266","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7312822","version":"1","preferredName":"Pulmonary Disorder Comorbid Condition","preferredDefinition":"An indication whether or not a pulmonary disorder is concomitant or concurrent with the primary condition or disease under study.","longName":"PULMYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D00257-C6BB-6EE9-E053-4EBD850A3E89","latestVersionIndicator":"Yes","beginDate":"2020-05-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-29","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-29-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313065","version":"1","preferredName":"Gangrene Comorbid Condition","preferredDefinition":"An indication whether or not gangrene is concomitant or concurrent with the primary condition or disease under study.","longName":"GANGYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E2FBA7-D2A8-631F-E053-4EBD850ADE67","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313066","version":"1","preferredName":"Gastrointestinal Disorder Comorbid Condition","preferredDefinition":"An indication whether or not a digestive system disorder is concomitant or concurrent with the primary condition or disease under study.","longName":"GASTROYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E30FA4-3688-66BB-E053-4EBD850A685D","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313067","version":"1","preferredName":"Respiratory System Disorder Comorbid Condition","preferredDefinition":"An indication whether or not a respiratory system disorder is concomitant or concurrent with the primary condition or disease under study.","longName":"RESPYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D00257-C840-6EE9-E053-4EBD850A3E89","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313068","version":"1","preferredName":"Rhabdomyolysis Myositis Comorbid Condition","preferredDefinition":"An indication whether or not rhabdomyolysis/myositis is concomitant or concurrent with the primary condition or disease under study.","longName":"RHABDYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CFEAFC-16AB-5D13-E053-4EBD850ACD62","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313069","version":"1","preferredName":"Thromboembolism Comorbid Condition","preferredDefinition":"An indication whether or not thromboembolism is concomitant or concurrent with the primary condition or disease under study.","longName":"THROMYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E30FA4-36A9-66BB-E053-4EBD850A685D","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313070","version":"1","preferredName":"Concomitant Medication Change Since Last Report","preferredDefinition":"An indication whether or not there was a change in concomitant medications since the last report.","longName":"CMUPDYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E26D20-F2E4-5CDA-E053-4EBD850A0CF1","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313071","version":"1","preferredName":"Comorbid Condition Occurrence Since Last Report","preferredDefinition":"An indication whether or not the patient developed co-morbidities since the last report.","longName":"COMORBYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E26D20-F305-5CDA-E053-4EBD850A0CF1","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313073","version":"1","preferredName":"Hospice Care Current Enrollment","preferredDefinition":"An indication whether or not the patient is currently enrolled in hospice.","longName":"HOSPICYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E30FA4-36CA-66BB-E053-4EBD850A685D","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313074","version":"1","preferredName":"Disruption Related To COVID-19","preferredDefinition":"An indication whether or not the disruption to an intervention or procedure is/was related to COVID-19.","longName":"DISRPTTP_C19","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E26D20-F326-5CDA-E053-4EBD850A0CF1","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"TAYLORT","dateModified":"2020-06-22","changeNote":"6-22-20 tmt released/MM. 5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313075","version":"1","preferredName":"Hospital Discharge Location Disposition","preferredDefinition":"Terminology to describe patient disposition when discharged from the hospital.","longName":"DISPLOC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E26D20-F347-5CDA-E053-4EBD850A0CF1","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313077","version":"1","preferredName":"COVID-19 Disruption Type","preferredDefinition":"Terminology to describe the type of disruption to the intervention or procedure by COVID-19.","longName":"DISRPTTP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E39B0F-79B3-6C20-E053-4EBD850A67C3","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"TAYLORT","dateModified":"2021-02-26","changeNote":"8.28.20 TL released/MM.. 5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313078","version":"1","preferredName":"COVID-19 Disruption Reason","preferredDefinition":"Terminology to describe the reason for the disruption of systemic therapy due to COVID-19.","longName":"DISRPTTP_REAS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E26D20-F386-5CDA-E053-4EBD850A0CF1","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"TAYLORT","dateModified":"2020-06-22","changeNote":"6-22-20 tmt released/MM. 5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313079","version":"1","preferredName":"Treatment Intervention or Procedure Or Assessment COVID-19 Disruption Type","preferredDefinition":"Terminology to describe the type of treatment, intervention or procedure, or assessment that was disrupted by COVID-19.","longName":"DISRPTTP_TYPE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D00257-C861-6EE9-E053-4EBD850A3E89","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313080","version":"1","preferredName":"COVID-19 Disease Response Current Medical Status","preferredDefinition":"Terminology to describe the status of the patient's current disease response due to COVID-19.","longName":"DZRESP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E43836-6E87-6ADA-E053-4EBD850AF33E","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"5-30-20 NCICOVID NSV; tmt.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313081","version":"1","preferredName":"Employment Status","preferredDefinition":"Terminology to address the status of being engaged in an activity or service for wages or salary.","longName":"EMPJOB_STATUS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E26D20-F3A7-5CDA-E053-4EBD850A0CF1","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7313082","version":"1","preferredName":"Occupation Physical Function Difficulty","preferredDefinition":"Terminology to describe how physically taxing the patient's job is.","longName":"EMPPHYS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6E26D20-F3C8-5CDA-E053-4EBD850A0CF1","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 5-30-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7315091","version":"1","preferredName":"Person Prior Exposure Peptide Receptor Radionuclide Therapy Clinical Trial Eligibility Criteria Applicable Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial regarding prior exposure to PRRT.","longName":"PER_PR_EXP_PRRT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A70673A4-DBE4-315C-E053-4EBD850A3A87","latestVersionIndicator":"Yes","beginDate":"2020-06-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-01","modifiedBy":"CLOHNES","dateModified":"2023-01-20","changeNote":"6/1/20 ls","administrativeNotes":"1/20/23 added AQT for ticket number CADSR0001948 for CCTG cjl; 12/21/22 added AQT and alt OID, CCTG for ticket number CADSR0001818 cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7315246","version":"1","preferredName":"Pregnancy Avoidance Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patient's agreement to avoid pregnancy as outlined in the study protocol.","longName":"PRGN_AVD_AGRM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7067F45-2FF3-3158-E053-4EBD850A1BC3","latestVersionIndicator":"Yes","beginDate":"2020-06-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-01","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"6/1/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7315399","version":"1","preferredName":"Radiation Therapy Complete Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation related to completeing radiation therapy as outlined in the study protocol.","longName":"RT_COMPL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A709AFEB-54BB-785D-E053-4EBD850A66EC","latestVersionIndicator":"Yes","beginDate":"2020-06-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-02","modifiedBy":"SOKKERL","dateModified":"2021-11-15","changeNote":"6/2/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7317705","version":"1","preferredName":"Treatment Cohort Study 10388 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10388 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10388_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A71C5D3E-BCAE-6A55-E053-4EBD850A4AFF","latestVersionIndicator":"Yes","beginDate":"2020-06-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-02","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"6/2/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318193","version":"1","preferredName":"Assessment Date","preferredDefinition":"The date on which the assessment of the patient/participant was performed.","longName":"ASMTDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A733916B-3ACD-203D-E053-4EBD850A2BE9","latestVersionIndicator":"Yes","beginDate":"2020-06-03","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-03","modifiedBy":"SPRINGERL","dateModified":"2021-11-23","changeNote":"03/30/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318220","version":"1","preferredName":"Maximum Diastolic Blood Pressure Measurement","preferredDefinition":"The maximum value of the diastolic blood pressure measurement.","longName":"DIABP_VSORRES_MAX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A733854F-C70E-144E-E053-4EBD850AF29C","latestVersionIndicator":"Yes","beginDate":"2020-06-03","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-03","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/03/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318263","version":"1","preferredName":"Minimum Diastolic Blood Pressure Measurement","preferredDefinition":"The minimum value of the diastolic blood pressure measurement.","longName":"DIABP_VSORRES_MIN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7339308-02E0-1483-E053-4EBD850A4929","latestVersionIndicator":"Yes","beginDate":"2020-06-03","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-03","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/03/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318476","version":"1","preferredName":"Maximum Systolic Blood Pressure Measurement","preferredDefinition":"The maximum value of the systolic blood pressure measurement.","longName":"SYSBP_VSORRES_MAX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A74433DD-06EA-7CB0-E053-4EBD850AE76A","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318480","version":"1","preferredName":"Maximum Oxygen Saturation Measurement","preferredDefinition":"The maximum value of the oxygen saturation measurement.","longName":"OXYSAT_VSORRES_MAX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A744C291-76D1-2FDA-E053-4EBD850A5CA3","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318485","version":"1","preferredName":"Maximum Pulse Rate Measurement","preferredDefinition":"The maximum value of the pulse rate measurement.","longName":"PULSE_VSORRES_MAX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A744EACA-18AD-3EA7-E053-4EBD850A5C7B","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318489","version":"1","preferredName":"Maximum Respiratory Rate Measurement","preferredDefinition":"The maximum value of the respiratory rate measurement.","longName":"RESP_VSORRES_MAX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A744F739-4A39-44A7-E053-4EBD850AF949","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318493","version":"1","preferredName":"Minimum Oxygen Saturation Measurement","preferredDefinition":"The minimum value of the oxygen saturation measurement.","longName":"OXYSAT_VSORRES_MIN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A744FFC9-2F31-538E-E053-4EBD850A3170","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318497","version":"1","preferredName":"Maximum Temperature Measurement","preferredDefinition":"The maximum value of the temperature measurement.","longName":"TEMP_VSORRES_MAX","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A745640C-8764-7B3D-E053-4EBD850A02AE","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318590","version":"1","preferredName":"Ventilator Treatment Duration","preferredDefinition":"The numeric value for the number of days the patient was on a ventilator.","longName":"VENTDYS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A744EACA-1974-3EA7-E053-4EBD850A5C7B","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"LUY","dateCreated":"2020-06-04","modifiedBy":"TAYLORT","dateModified":"2020-06-29","changeNote":"ylu 06/04/2020 created for 10300","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318622","version":"1","preferredName":"Treatment Disruption Description","preferredDefinition":"The free-text field to provide descriptive information on the disruption of the therapeutic procedure.","longName":"DISRPTTP_DESC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7480EF3-5293-61DB-E053-4EBD850A7186","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318631","version":"1","preferredName":"Treatment Disruption Duration","preferredDefinition":"The free-text field to provide the duration that therapeutic procedure has been disrupted.","longName":"DISRPTTP_DYSPEC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A747EB02-15EA-6DC2-E053-4EBD850A2736","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318647","version":"1","preferredName":"Intensive Care Unit Stay Duration","preferredDefinition":"The number of days that the patient stays in an Intensive Care Unit.","longName":"ICUDYS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7495714-3569-7B49-E053-4EBD850AB9EC","latestVersionIndicator":"Yes","beginDate":"2020-06-04","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-04","modifiedBy":"CLOHNES","dateModified":"2023-11-06","changeNote":"06/04/2020,wz created for Seed Study.","administrativeNotes":"11/06/23 Added alt OID, CCTG for ticket number CADSR0003018 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318691","version":"1","preferredName":"Reason for Assessment or Test","preferredDefinition":"The free-text field to provide the reason for a medical assessment/testing.","longName":"LBREAS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A757468E-347D-26D5-E053-4EBD850A3EF0","latestVersionIndicator":"Yes","beginDate":"2020-06-05","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-05","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/05/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318695","version":"1","preferredName":"Estimated Gestational Age","preferredDefinition":"The estimated value for the period of fetal development in the uterus from the start of conception until its birth.","longName":"SCORRES_GESTAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A757394F-4754-26DB-E053-4EBD850ABC6C","latestVersionIndicator":"Yes","beginDate":"2020-06-05","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-05","modifiedBy":"ZHANGWE","dateModified":"2020-06-22","changeNote":"06/05/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318699","version":"2","preferredName":"Substance Use Method","preferredDefinition":"The free-text field to provide the method of substance use.","longName":"SUMETHOD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8AEA745-DE77-1194-E053-4EBD850A1A40","latestVersionIndicator":"Yes","beginDate":"2020-06-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-22","modifiedBy":"TAYLORT","dateModified":"2020-06-22","changeNote":"6/22/20 tmt versioned to 2.0 for changes to Long Name, question text and definition; released per MM. 06/05/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7318704","version":"1","preferredName":"Comorbidity Code","preferredDefinition":"The description of the concomitant condition that the person has.","longName":"COMORBID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A757FBD2-4F93-26CE-E053-4EBD850A3A84","latestVersionIndicator":"Yes","beginDate":"2020-06-05","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-06-05","modifiedBy":"TAYLORT","dateModified":"2020-07-07","changeNote":"06/05/2020,wz created for Seed Study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7329878","version":"1","preferredName":"Symptom Occurrence","preferredDefinition":"A tickbox indicator for symptom events.","longName":"SYMPCUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7B9D93B-282D-165E-E053-4EBD850ACEA5","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7329972","version":"1","preferredName":"Patient Prior Combination Therapeutic Procedure Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior administration of combination agents intended to alter or stop a pathologic process as outlined in the study protocol.","longName":"PT_PR_COMB_THYP_REC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BD8B50-DCED-3061-E053-4EBD850AB8AD","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-10","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeNote":"6/10/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7331381","version":"1","preferredName":"Patient Therapy Complete Randomization Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions addressing if a patient completed therapy and randomization as outlined in the study protocol.","longName":"PT_THPY_COMP_RND_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4C635-F8BB-01CE-E053-4EBD850A01CC","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-11","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"6/11/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7335592","version":"1","preferredName":"Clinical Status Ordinal Scale Result","preferredDefinition":"Numeric code for the patient's clinical status at enrollment, prior to any on-study therapy, as originally received or collected.","longName":"CSO0201_RSORRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A84BABFF-C978-0BDB-E053-4EBD850AFB0C","latestVersionIndicator":"Yes","beginDate":"2020-06-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-17","modifiedBy":"TAYLORT","dateModified":"2020-09-14","changeNote":"6-17-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7335647","version":"1","preferredName":"Patient Consent Bone Marrow Biopsy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient's willingness to undergo a bone marrow biopsy as outlined in the study protocol.","longName":"PT_CNST_BM_BX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A84C3E9F-BD08-3552-E053-4EBD850A8A10","latestVersionIndicator":"Yes","beginDate":"2020-06-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-17","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"6/17/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339333","version":"1","preferredName":"Medical History Pulmonary Category","preferredDefinition":"An indication whether or not there is a medical history pertaining to the lungs.","longName":"MHCAT_PULM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8605A0E-0617-6681-E053-4EBD850A5AC0","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-18","modifiedBy":"TAYLORT","dateModified":"2020-06-18","changeNote":"6-18-20 tmt released/MM.; 6-18-20 NCICOVID: tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339334","version":"1","preferredName":"Medical History Cardiac Category","preferredDefinition":"An indication whether or not there is a medical history pertaining to the heart.","longName":"MHCAT_CARD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A85FB713-E5F8-6677-E053-4EBD850A01D5","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-18","modifiedBy":"TAYLORT","dateModified":"2020-06-18","changeNote":"6-18-20 tmt released/MM.; 6-18-20 NCICOVID: tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339338","version":"1","preferredName":"Medical History Renal Category","preferredDefinition":"An indication whether or not there is a medical history pertaining to the kidney(s).","longName":"MHCAT_REN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A860789B-6216-667F-E053-4EBD850AC589","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-18","modifiedBy":"TAYLORT","dateModified":"2020-06-18","changeNote":"6-18-20 tmt released/MM.; 6-18-20 NCICOVID: tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339339","version":"1","preferredName":"Medical History Hepatic Category","preferredDefinition":"An indication whether or not there is a medical history pertaining to the liver.","longName":"MHCAT_HEP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A85FB713-E61C-6677-E053-4EBD850A01D5","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-18","modifiedBy":"TAYLORT","dateModified":"2020-06-18","changeNote":"6-18-20 tmt released/MM.; 6-18-20 NCICOVID: tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339343","version":"1","preferredName":"Medical History Neurologic Category","preferredDefinition":"An indication whether or not there is a medical history pertaining to the nerves or the nervous system.","longName":"MHCAT_NEUR","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A85FB713-E671-6677-E053-4EBD850A01D5","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-18","modifiedBy":"TAYLORT","dateModified":"2020-06-18","changeNote":"6-18-20 tmt released/MM.; 6-18-20 NCICOVID: tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339347","version":"1","preferredName":"Medical History Pregnancy Category","preferredDefinition":"An indication whether or not there is a medical history pertaining to pregnancy.","longName":"MHCAT_PREG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A860789B-6237-667F-E053-4EBD850AC589","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-18","modifiedBy":"TAYLORT","dateModified":"2020-06-18","changeNote":"6-18-20 tmt released/MM.; 6-18-20 NCICOVID: tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339359","version":"1","preferredName":"Medical History Prior Malignancy Category","preferredDefinition":"An indication whether or not there is a medical history pertaining to previously diagnosed malignant neoplastic disease.","longName":"MHCAT_PRMAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A860B6C1-719B-72F1-E053-4EBD850AF6A7","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-18","modifiedBy":"TAYLORT","dateModified":"2020-06-18","changeNote":"6-18-20 tmt released/MM.; 6-18-20 NCICOVID: tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339681","version":"1","preferredName":"Treatment Cohort Study 10346 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10346 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10346_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A87139AC-88B1-4B57-E053-4EBD850ACFBE","latestVersionIndicator":"Yes","beginDate":"2020-06-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-06-19","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"6/19/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7340611","version":"1","preferredName":"Minimum Systolic Blood Pressure Measurement","preferredDefinition":"The minimum value of the systolic blood pressure measurement.","longName":"SYSBP_VSORRES_MIN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8AF856A-4022-3841-E053-4EBD850A44ED","latestVersionIndicator":"Yes","beginDate":"2020-06-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-22","modifiedBy":"TAYLORT","dateModified":"2020-06-22","changeNote":"6-22-20 NCICOVID; tmt; released/MM.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342413","version":"1","preferredName":"Subject Income Level","preferredDefinition":"Terminology to describe the grouping of compensation or monetary support.","longName":"SCINCMLVL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8D64A79-A0C4-45B8-E053-4EBD850AE30D","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-24","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"6-24-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7342518","version":"1","preferredName":"Exposure Source","preferredDefinition":"Terminology to describe the source of environmental and social factors that might influence a subject's disease or medical condition.","longName":"EXPSOURCE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8D9A105-D4DF-58A1-E053-4EBD850A6916","latestVersionIndicator":"Yes","beginDate":"2020-06-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-24","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 6-24-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7343490","version":"1","preferredName":"Substance Use Name","preferredDefinition":"Terminology to describe the type of substance use as defined by the sponsor.","longName":"SUTRT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EC4320-D4D6-157A-E053-4EBD850AF7C5","latestVersionIndicator":"Yes","beginDate":"2020-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-25","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"6-25-20 NCICOVID; TMT.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7343793","version":"1","preferredName":"Concomitant Medication Intent","preferredDefinition":"Terminology for the anticipated outcome that is the purpose for the administration of concomitant medication(s).","longName":"CMINTENT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FEF4FC-4CAD-4594-E053-4EBD850AF4F9","latestVersionIndicator":"Yes","beginDate":"2020-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-26","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"6-26-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7344577","version":"1","preferredName":"DRSN Eligible","preferredDefinition":"An indication whether or not the patient is eligible for the NCI Drug Resistance and Sensitivity Network.","longName":"DRSNELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A93DC8F0-2D41-0CAA-E053-4EBD850AE8D1","latestVersionIndicator":"Yes","beginDate":"2020-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-29","modifiedBy":"TAYLORT","dateModified":"2020-07-08","changeNote":"7-8-30 tmt released; MM.6-29-20 10323; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7344580","version":"1","preferredName":"Histologic Subtype","preferredDefinition":"A free-text field to provide the classification of tumors based on their histology.","longName":"HISTSUBT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A93DC8F0-2D92-0CAA-E053-4EBD850AE8D1","latestVersionIndicator":"Yes","beginDate":"2020-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-29","modifiedBy":"TAYLORT","dateModified":"2020-07-08","changeNote":"7-8-20 tmt released/MM. 10323; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346574","version":"1","preferredName":"Off Study","preferredDefinition":"An indication whether or not the patient is off study.","longName":"OSTUDYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A951091B-EB2B-7716-E053-4EBD850ABC8E","latestVersionIndicator":"Yes","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"TAYLORT","dateModified":"2020-06-30","changeNote":"6-30-20 Created for 10005 custom CDASH request; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346613","version":"1","preferredName":"Other Concomitant Medication","preferredDefinition":"A free-text field to capture a concomitant medication not listed.","longName":"CMTRT_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A952774E-1A9D-6D91-E053-4EBD850A2A00","latestVersionIndicator":"Yes","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"SOKKERL","dateModified":"2021-09-24","changeNote":"6-30-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7346802","version":"1","preferredName":"Intended Dose Regimen","preferredDefinition":"Terminology for the (intended) schedule or regimen for concomitant medication as defined by the sponsor.","longName":"CMDOSRGM_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A960E0B2-BD90-551C-E053-4EBD850AC175","latestVersionIndicator":"Yes","beginDate":"2020-07-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-01","modifiedBy":"TAYLORT","dateModified":"2020-07-08","changeNote":"7-1-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7347867","version":"1","preferredName":"Medical History Reported Term","preferredDefinition":"The reported or pre-specified name of the medical condition or event as defined by the sponsor.","longName":"MHTERM_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A979A2D6-22E9-30E1-E053-4EBD850AF6E7","latestVersionIndicator":"Yes","beginDate":"2020-07-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-02","modifiedBy":"SOKKERL","dateModified":"2020-09-03","changeNote":"7-2-20 NCICOVID; TMT.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7349373","version":"1","preferredName":"Patient Primary Language English Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether English is the primary language as outlined in the study protocol.","longName":"PT_PRM_LNG_ENG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9D1246A-ED1A-5331-E053-4EBD850AD94E","latestVersionIndicator":"Yes","beginDate":"2020-07-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-07","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"7/7/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7349894","version":"1","preferredName":"Berlin Criteria","preferredDefinition":"A grouping of topic-variable values based on the Berlin criteria for acute respiratory distress syndrome.","longName":"RS_BERLIN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9EE5339-7DDC-0E19-E053-4EBD850A9923","latestVersionIndicator":"Yes","beginDate":"2020-07-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-08","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"7-8-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7350387","version":"1","preferredName":"Subcategory for Concomitant Medication","preferredDefinition":"A sub-division of the CMCAT values based on sponsor defined characteristics.","longName":"CMSCAT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA03A918-6A33-4C4F-E053-4EBD850A7F4B","latestVersionIndicator":"Yes","beginDate":"2020-07-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-09","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeNote":"7-9-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7350640","version":"1","preferredName":"Intensive Care Unit Or High-Dependency Unit Admission Occurrence","preferredDefinition":"An indication whether or not ICU or high dependency unit admission happened.","longName":"HOOCCUR_ICUHDU","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA16ECD2-2188-2198-E053-4EBD850AD8A5","latestVersionIndicator":"Yes","beginDate":"2020-07-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-10","modifiedBy":"CLOHNES","dateModified":"2023-11-06","changeNote":"7-10-20 NCICOVID; tmt","administrativeNotes":"11/06/23 Added alt OID, CCTG and AQT for ticket number CADSR0003018 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351298","version":"1","preferredName":"Assessment Timepoint","preferredDefinition":"An identifier for a specific point in time, including those relative to an event, as defined by the sponsor.","longName":"ASMTTPT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA553D7E-1DAE-0D7F-E053-4EBD850ACD8E","latestVersionIndicator":"Yes","beginDate":"2020-07-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-13","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeNote":"8.28.20 TL released/MM. 7-13-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351405","version":"1","preferredName":"Procedure Name","preferredDefinition":"The name of the surgical, therapeutic, or diagnostic procedure as defined by the sponsor.","longName":"PRTRT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA56E9E1-7E22-16AE-E053-4EBD850AB99E","latestVersionIndicator":"Yes","beginDate":"2020-07-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-13","modifiedBy":"TAYLORT","dateModified":"2020-11-19","changeNote":"11-19-20 TL released. 7-13-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351703","version":"1","preferredName":"Date/Time of Reference Time Point","preferredDefinition":"The date and time of a specific reference point for the laboratory assessment.","longName":"LBRFTDTC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA67F955-7494-3129-E053-4EBD850A0934","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":"2020-07-14","createdBy":"TAYLORT","dateCreated":"2020-07-14","modifiedBy":"TAYLORT","dateModified":"2020-07-14","changeNote":"7-14-20 Released/POC. 7-14-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353109","version":"1","preferredName":"Category for Concomitant Medication","preferredDefinition":"A grouping of topic-variable values based on sponsor defined characteristics.","longName":"CMCAT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA83AA5F-0232-44F3-E053-4EBD850A893B","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"7-16-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353114","version":"1","preferredName":"Colorectal Disease Intact Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that addresses a portion of the undamaged tumor relating to the colon and rectum, or to the entire large bowel as outlined in the study protocol.","longName":"COLR_DZ_INT_NEPM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA83A524-BB48-44F5-E053-4EBD850A00A6","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-16","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"7/16/20 ls","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353118","version":"1","preferredName":"Patient Rectal Carcinoma Advanced Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to a patient who has advanced rectal cancer as outlined in the study protocol.","longName":"PT_RECT_CA_ADV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA84235C-4EDC-44EC-E053-4EBD850A9516","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-03-15","changeNote":"7/16/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353122","version":"1","preferredName":"Person Neoadjuvant Therapy Receive And Complete Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation that address the administration and completion of therapeutic agents as outlined in the study protocol.","longName":"NEO_TX_COMP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA83A524-BBA4-44F5-E053-4EBD850A00A6","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"7/16/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353132","version":"1","preferredName":"Findings About Sign or Symptom","preferredDefinition":"The status of sign or symptom events or interventions as defined by the sponsor.","longName":"FASYM_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA859F67-F448-384E-E053-4EBD850A6129","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"7-16-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353145","version":"1","preferredName":"Patient Dihydropyrimidine Dehydrogenase Deficiency Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions whether the patient has DPD (dihydro pyrimidine dehydrogenase) deficiency as outlined in the study protocol.","longName":"PT_DPD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA9018E2-BC1C-293B-E053-4EBD850A3BD9","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-16","modifiedBy":"CLOHNES","dateModified":"2023-09-29","changeNote":"7/16/20 ls","administrativeNotes":"9/27/23 Added AQT and alt OID, CCTG for ticket number CADSR0002884 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353167","version":"1","preferredName":"Specimen Collection Method","preferredDefinition":"The method or procedure by which biological material is obtained, as defined by the sponsor.","longName":"BECLMETH_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA92DB64-E93F-7070-E053-4EBD850AEFD0","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"TAYLORT","dateModified":"2020-07-16","changeNote":"7-16-20 tmt released/MM. 7-16-20 tmt/10323.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353271","version":"1","preferredName":"Infectious Disorder Intervention Required Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow clinical trial participation that address the mandatory intervention(s) to improve health or to alter the course of infectious disease as outlined in the study protocol.","longName":"INFECT_DZ_INRVTN_REQ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA9395C6-F6AC-6B9C-E053-4EBD850A30C0","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/16/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353305","version":"1","preferredName":"Immunodeficiency Disease Or Receive Immunosuppressive Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to immunodeficiency disease or receiving immunosuppressive therapy as outlined in the protocol.","longName":"IMMU_DZ_REC_ITX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA93EC8B-578A-6B9E-E053-4EBD850A8735","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2023-12-13","changeNote":"7/16/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353320","version":"1","preferredName":"Patient Invasive Malignant Neoplasm Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to invasive malignancy and is receiving therapeutic agents to produce an effect that is intended to alter or stop a pathologic process as outlined in the protocol.","longName":"PT_INV_MAL_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D68E-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"7/16/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7356971","version":"1","preferredName":"Lab Result","preferredDefinition":"Result of the measurement or finding as originally received or collected, as defined by the sponsor.","longName":"LBORRES_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAA3DA05-C19C-0FA9-E053-4EBD850A2316","latestVersionIndicator":"Yes","beginDate":"2020-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-17","modifiedBy":"TAYLORT","dateModified":"2020-09-02","changeNote":"9-2-20 Released. 7-17-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7358119","version":"1","preferredName":"Treatment Cohort Study 10070 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10070 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10070_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAA4B900-DC3C-2438-E053-4EBD850A1934","latestVersionIndicator":"Yes","beginDate":"2020-07-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-17","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/17/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7358128","version":"1","preferredName":"Treatment Cohort Study 10410 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10410 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10410_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAA3E385-19C8-0FA1-E053-4EBD850A337C","latestVersionIndicator":"Yes","beginDate":"2020-07-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-17","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/17/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359328","version":"1","preferredName":"Medical History Event Reported Term Code","preferredDefinition":"A numeric coded representation of the reported or pre-specified medical condition or event, as defined by the sponsor.","longName":"MHTERM_CD_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAA5B36E-9D80-3D44-E053-4EBD850A02BA","latestVersionIndicator":"Yes","beginDate":"2020-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-17","modifiedBy":"FINCHAMB","dateModified":"2022-08-15","changeNote":"7-17-20 NCICOVID; tmt.","administrativeNotes":"8/15/22 Changed RS to Application to match WF status of Released","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359807","version":"1","preferredName":"Inhaled Nitric Oxide Occurrence","preferredDefinition":"An indication whether or not inhaled nitric oxide happened.","longName":"PROCCUR_INO","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE04062-F952-6EF7-E053-4EBD850A28AB","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"SOKKERL","dateModified":"2020-09-03","changeNote":"7-20-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359808","version":"1","preferredName":"Tracheostomy Occurrence","preferredDefinition":"An indication whether or not tracheostomy happened.","longName":"PROCCUR_TRACH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE0C247-B30C-6EF3-E053-4EBD850A7FB2","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"SOKKERL","dateModified":"2020-09-03","changeNote":"7-20-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359809","version":"1","preferredName":"Renal Replacement Therapy Occurrence","preferredDefinition":"An indication whether or not renal replacement therapy happened.","longName":"PROCCUR_RRT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE0DB97-1D77-18B2-E053-4EBD850ABF12","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"SOKKERL","dateModified":"2020-09-03","changeNote":"7-20-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359810","version":"1","preferredName":"Prone Position Occurrence","preferredDefinition":"An indication whether or not prone positioning happened.","longName":"PROCCUR_PP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE0DB97-1D98-18B2-E053-4EBD850ABF12","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"SOKKERL","dateModified":"2020-09-03","changeNote":"7-20-20 NCICOVID NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359824","version":"1","preferredName":"Lab Method","preferredDefinition":"Method of test or examination as defined by the sponsor.","longName":"LBMETHOD_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE133D5-7DD2-15C9-E053-4EBD850ADB8D","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeNote":"7-20-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359826","version":"1","preferredName":"Lab Test or Examination Name","preferredDefinition":"Descriptive name of the lab test or examination used to obtain the measurement or finding. Any test normally performed by a clinical laboratory is considered a lab test.","longName":"LBTEST_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE1CC47-4878-17F4-E053-4EBD850A8C30","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeNote":"7-20-20 NCICOVID; TMT.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7359934","version":"1","preferredName":"Biospecimen Type","preferredDefinition":"The type of a material sample taken from a biological entity for testing, as defined by the sponsor.","longName":"BESPEC_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE44C60-C1CB-09DE-E053-4EBD850A52C6","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"SOKKERL","dateModified":"2020-09-08","changeNote":"7-20-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7363082","version":"1","preferredName":"Patient Progressive Disease Or Recurrent Disease Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patients cancer that is increasing in scope or severity, or the return of disease after a period of remission as outlined in the study protocol.","longName":"PT_PD_RC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE447F6-BDB5-0961-E053-4EBD850A7E9C","latestVersionIndicator":"Yes","beginDate":"2020-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-07-21","modifiedBy":"SOKKERL","dateModified":"2023-01-10","changeNote":"Created for 10100. AK 2020-7-21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7363101","version":"1","preferredName":"Patient Immunohistochemical Status of PD-L1 Availability For Stratification Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patients PD-L1 status availability for stratification as outlined in the study protocol.","longName":"PDL1_STRAT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE685AD-EE70-4C46-E053-4EBD850A5505","latestVersionIndicator":"Yes","beginDate":"2020-07-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-07-21","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"Created for 10100. AK 2020-7-21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7366668","version":"1","preferredName":"Reference ID","preferredDefinition":"A character or string used to name, or characterize a biospecimen reference.","longName":"BSREFID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB30E033-4362-5E02-E053-4EBD850A80A3","latestVersionIndicator":"Yes","beginDate":"2020-07-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-24","modifiedBy":"SOKKERL","dateModified":"2022-02-08","changeNote":"7-24-20 10323; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7366678","version":"1","preferredName":"Result or Finding in Original Units","preferredDefinition":"Result of the measurement or finding as originally received or collected.","longName":"BSORRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB310261-A3A5-703B-E053-4EBD850A7C42","latestVersionIndicator":"Yes","beginDate":"2020-07-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-24","modifiedBy":"MMADDINENI","dateModified":"2023-06-21","changeNote":"7-24-20 10323; tmt per POC.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7366793","version":"1","preferredName":"Treatment Cohort Study 10389 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol10389 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10389_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB31C62D-24D6-7036-E053-4EBD850AE96A","latestVersionIndicator":"Yes","beginDate":"2020-07-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-24","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7-24-20 tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7369802","version":"1","preferredName":"PDMR Specimen Submission Indicator","preferredDefinition":"An indication whether or not the specimen was submitted to the Patient-Derived Models Repository (PDMR).","longName":"BSPDMRYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB6CBC8B-FA34-0FFB-E053-4EBD850AFBFE","latestVersionIndicator":"Yes","beginDate":"2020-07-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-27","modifiedBy":"SOKKERL","dateModified":"2021-09-16","changeNote":"7-27-20 10323 NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7369803","version":"1","preferredName":"Result or Finding in Original Units","preferredDefinition":"The outcome of the test or finding as originally received or collected, as defined by the sponsor.","longName":"PFORRES_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB6D4043-BE0D-65A6-E053-4EBD850AACC1","latestVersionIndicator":"Yes","beginDate":"2020-07-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-27","modifiedBy":"TAYLORT","dateModified":"2020-07-28","changeNote":"7-27-20 10323; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7369805","version":"1","preferredName":"Result Reason","preferredDefinition":"An explanation for the outcome of the finding for gene expression and genetic variation assessment.","longName":"PFRESRS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB6D4043-BE2E-65A6-E053-4EBD850AACC1","latestVersionIndicator":"Yes","beginDate":"2020-07-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-27","modifiedBy":"TAYLORT","dateModified":"2020-07-28","changeNote":"7-27-20 10323 NSV; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7369811","version":"1","preferredName":"BRCA1 Gene Mutation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether the participant has met the eligibility criteria regarding the BRCA mutation as outlined in the study protocol.","longName":"BRCA_GEN_MUT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB6D9D75-50C4-1004-E053-4EBD850A3F8B","latestVersionIndicator":"Yes","beginDate":"2020-07-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-27","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/27/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7369908","version":"1","preferredName":"Disease Cure Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions indicating if a disease is curable with intervention or procedure as outlined in the study protocol.","longName":"DZ_CURE_ITVN_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB6EABE7-1361-5E5A-E053-4EBD850A2520","latestVersionIndicator":"Yes","beginDate":"2020-07-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-27","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"7/27/20 ls","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7369920","version":"1","preferredName":"Person Torsades De Pointes Personal Medical History Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the patients medical history with Torsades de pointes as outlined in the study protocol.","longName":"TDP_MH_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB717049-27E2-7B15-E053-4EBD850AAB9C","latestVersionIndicator":"Yes","beginDate":"2020-07-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-07-27","modifiedBy":"KUMMEROA","dateModified":"2020-07-28","changeNote":"Created for protocol 10389. AK","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7372000","version":"1","preferredName":"Treatment Cohort Study 10398 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10398 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10398_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB8091D5-8E87-4114-E053-4EBD850A2CBE","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"SOKKERL","dateModified":"2020-09-29","changeNote":"7/28/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7372117","version":"1","preferredName":"Treatment Cohort Study 10100 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10100 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_EC10100_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB8224B8-89FA-5363-E053-4EBD850A543F","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/28/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374397","version":"1","preferredName":"Tumor Mutation Burden Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address the total number of genomic alterations found in the cells of a cancer as outlined in the study protocol.","longName":"TUM_MUT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABAC7DB9-02B2-3410-E053-4EBD850A54CC","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-30","modifiedBy":"SOKKERL","dateModified":"2021-06-17","changeNote":"7/30/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374430","version":"1","preferredName":"Patient Microsatellite Stability Assessment Hypermutation Carcinoma Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"A coded response to determine patient eligibility for clinical trial participation related to microsatellite stability assessment and other types of hypermutation carcinomas as outlined in the study protocol.","longName":"MICSASSES_HYPER_CARC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABAA8214-819B-5169-E053-4EBD850AB62B","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-30","modifiedBy":"TAYLORT","dateModified":"2020-09-23","changeNote":"7/30/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374470","version":"1","preferredName":"DNA Use And Extraction Certified Laboratory Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"he coded indicator to determine clinical trial participation related to extraction of DNA in certified clinical laboratory as outlined in the study protocol.","longName":"DNA_EXT_CERT_LAB_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABADE1DE-FDA9-73AD-E053-4EBD850A3E00","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-30","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/30/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374777","version":"1","preferredName":"Carcinoma Tumor Mutation Burden Confirmation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to confirmation of cancer by tumor mutation burden as outlined in the study protocol.","longName":"CAR_TMB_CONF_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABAF2C9F-992B-5979-E053-4EBD850A8CBF","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-30","modifiedBy":"NIKITAP","dateModified":"2022-02-23","changeNote":"7/30/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374824","version":"1","preferredName":"Therapeutic Procedure Elapse Time Last Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to interval between the last dose administration of therapeutic agent as outlined in the protocol.","longName":"THPY_PROC_ELAP_TM_LST_DS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBC1465-7210-75BF-E053-4EBD850AEA7D","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-31","modifiedBy":"SOKKERL","dateModified":"2022-04-18","changeNote":"7/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374837","version":"1","preferredName":"Immunostimulant Therapy Elapse Time Last Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to interval between the last dose administration of immune therapy as outlined in the protocol.","longName":"IMTX_ELS_LTDS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBCB5BA-32E3-75CE-E053-4EBD850AA9A7","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-31","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"7/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374856","version":"1","preferredName":"Radiopharmaceutical Therapy Elapse Time Last Dose Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to interval between the last dose administration of radioactive isotope used for diagnostic or therapeutic purposes as outlined in the protocol.","longName":"RT_ELP_TM_LTDS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBCB5BA-330B-75CE-E053-4EBD850AA9A7","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-31","modifiedBy":"SOKKERL","dateModified":"2023-05-24","changeNote":"7/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374879","version":"1","preferredName":"Patient Bone Marrow Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has disease or disorders relating to the bone marrow as outlined the study protocol.","longName":"PT_BM_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBBCF9C-73BA-75C3-E053-4EBD850AAD15","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-31","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"7/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374894","version":"1","preferredName":"Patient Pulmonary Function Test Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions that prevent a person from being allowed to participate in a clinical study that address the assessment of a pulmonary function exam as outlined in the study protocol.","longName":"PT_PFT_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBD35DE-668B-75C7-E053-4EBD850AE71C","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-31","modifiedBy":"SOKKERL","dateModified":"2022-03-01","changeNote":"7/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7374998","version":"1","preferredName":"Therapy Discontinue Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation as to whether if therapy was discontinued as outlined in the study protocol.","longName":"TX_DISCN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBFEC96-E63D-636E-E053-4EBD850A94EC","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-31","modifiedBy":"TSESU","dateModified":"2023-06-06","changeNote":"7/31/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375417","version":"1","preferredName":"Chest Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the chest segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR2","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABC02597-5636-635D-E053-4EBD850A9598","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375418","version":"1","preferredName":"Head Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the head segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR1","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBCECAA-86CF-75C1-E053-4EBD850A144A","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375419","version":"1","preferredName":"Thoracic Spine Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the thoracic spine segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR3","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABC0392C-4003-635B-E053-4EBD850A9FC9","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375420","version":"1","preferredName":"Lumbar Spine Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the lumbar spine segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR4","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBCB5BA-33C4-75CE-E053-4EBD850AA9A7","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375421","version":"1","preferredName":"Pelvis Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the pelvis segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR5","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABC0392C-4024-635B-E053-4EBD850A9FC9","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375422","version":"1","preferredName":"Upper Arm Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the upper arms segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR6","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBCB5BA-33E5-75CE-E053-4EBD850AA9A7","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375423","version":"1","preferredName":"Forearm Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the lower arms segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR7","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABC02597-5657-635D-E053-4EBD850A9598","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375424","version":"1","preferredName":"Femur Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the femurs segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR8","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABC1F137-78F3-634B-E053-4EBD850A514C","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375425","version":"1","preferredName":"Lower Leg Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the lower legs segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR9","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBFEC96-E698-636E-E053-4EBD850A94EC","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375426","version":"1","preferredName":"Soft Tissue Disease Curie mIBG Score","preferredDefinition":"The Curie mIBG score assigned to the soft tissue disease segment to indicate the quantity of metastases, as defined by the sponsor.","longName":"TRORRES_SPD_CSR10","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABC02AE8-8710-65FE-E053-4EBD850AFB73","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"MMADDINENI","dateModified":"2024-01-24","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7375427","version":"1","preferredName":"Total Curie mIBG Score","preferredDefinition":"The sum of a set of numeric values for the Curie mIBG score.","longName":"TRORRES_SPD_CSRTOTAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABC029F4-5780-6600-E053-4EBD850AF52C","latestVersionIndicator":"Yes","beginDate":"2020-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-31","modifiedBy":"MMADDINENI","dateModified":"2024-02-12","changeNote":"PED-CITN-01 NSV;TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7378378","version":"1","preferredName":"Patient Medical History Hyperthyroidism Hormone Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether or not the patient's medical history regarding hyperthyroidism received thyroid replacement hormone meets the eligibility criteria outlined in the study protocol.","longName":"PMH_HT_HMRT_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC0DEFEA-BC68-322B-E053-4EBD850AA99F","latestVersionIndicator":"Yes","beginDate":"2020-08-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-08-04","modifiedBy":"KUMMEROA","dateModified":"2020-08-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7378939","version":"1","preferredName":"Informed Consent Provide Cinical Trial Eligibility Code Indicator","preferredDefinition":"The response indicating whether informed consent was provided.","longName":"INFM_CONS_PRVD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC12146A-84D0-674A-E053-4EBD850AE59F","latestVersionIndicator":"Yes","beginDate":"2020-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-04","modifiedBy":"SOKKERL","dateModified":"2021-12-17","changeNote":"8/4/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7378963","version":"1","preferredName":"Patient ECOG Performance Status Health Care Provider Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The indicator to address the patient's ECOG performance status addressed by persons licensed to supply health care as outlined in the study protocol.","longName":"ECOG_PERF_STAT_HCP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC13517F-FA84-5BF7-E053-4EBD850A1566","latestVersionIndicator":"Yes","beginDate":"2020-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-04","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"8/4/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7378973","version":"1","preferredName":"Specimen Collected Prior Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the collection of specimens prior to therapy as outlined in the study protocol.","longName":"SPEC_COL_PR_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC12C26C-9DD6-513A-E053-4EBD850A01D8","latestVersionIndicator":"Yes","beginDate":"2020-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-04","modifiedBy":"SOKKERL","dateModified":"2022-12-20","changeNote":"8/4/20 ls","administrativeNotes":"7/21/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7379004","version":"1","preferredName":"Patient Meet Patient-Derived Models Repository Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient fulfill the PDMR criteria as outlined in the study protocol.","longName":"PT_MEET_PDMR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC1253AE-A5F3-51FA-E053-4EBD850A2458","latestVersionIndicator":"Yes","beginDate":"2020-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-04","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"8/4/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7379079","version":"1","preferredName":"Patient Other Clinical Trial Participant Eligibility Criteria Code Indicator","preferredDefinition":"A coded Indicator to specify whether the patient is participating in any other clinical protocol trial as outlined in the study.","longName":"PT_CLIN_TRL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC13517F-FAAC-5BF7-E053-4EBD850A1566","latestVersionIndicator":"Yes","beginDate":"2020-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-04","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"8/4/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7379123","version":"1","preferredName":"Patient RECIST Measurable Lesion Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to measurable lesion evaluated by RECIST as outlined in the study protocol.","longName":"RECIST_MLES_OR_DZ_CDIND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC21F143-C31B-1A25-E053-4EBD850A8B12","latestVersionIndicator":"Yes","beginDate":"2020-08-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-05","modifiedBy":"TSESU","dateModified":"2023-01-04","changeNote":"8/5/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7380757","version":"1","preferredName":"Treatment Cohort Study PED-CITN-01 Code","preferredDefinition":"The code that represents the information pertaining to protocol PED-CITN-01 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_PED-CITN_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC2631C0-E209-4FC5-E053-4EBD850AE7D2","latestVersionIndicator":"Yes","beginDate":"2020-08-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-05","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"8/5/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7380830","version":"1","preferredName":"Informed Consent Paper Form Complete Indicator","preferredDefinition":"An indication whether or not paper informed consent was completed.","longName":"ICPAPYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC369C25-E351-4B62-E053-4EBD850AFC76","latestVersionIndicator":"Yes","beginDate":"2020-08-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-06","modifiedBy":"TAYLORT","dateModified":"2020-08-06","changeNote":"10323 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7381169","version":"1","preferredName":"Patient Molecular Genetic Variation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address irregularity in either the expression or sequence of a gene in diseased versus normal tissue sources as outlined in the study protocol.","longName":"PT_MGV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC3C5969-DF14-4A7B-E053-4EBD850A40ED","latestVersionIndicator":"Yes","beginDate":"2020-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-06","modifiedBy":"SOKKERL","dateModified":"2021-06-07","changeNote":"8/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7385080","version":"1","preferredName":"Death Certificate COVID-19 Contributing Factor Registration","preferredDefinition":"An indication whether or not COIVD-19 was listed or recorded officially as a contributing factor to a person's death on the death certificate.","longName":"DDC19FCT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC5F6612-F577-42E8-E053-4EBD850A9B72","latestVersionIndicator":"Yes","beginDate":"2020-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-08","modifiedBy":"TAYLORT","dateModified":"2020-08-10","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7391764","version":"1","preferredName":"Specimen Requirement","preferredDefinition":"A sub-division of the biospecimen collection and storage information for requirements.","longName":"SPECREQ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC2F066-189F-7350-E053-4EBD850A0911","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-13","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeNote":"CDASH NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7391771","version":"2","preferredName":"Clinical Trial Phase Code","preferredDefinition":"A character or string that represents the stage in the lifecycle of a clinical trial.","longName":"PHASECD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEDFAC77-8EBE-5CE8-E053-731AD00A9477","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-12-02","modifiedBy":"MMADDINENI","dateModified":"2023-01-31","changeNote":"8.28.20 TL released/MM. CDASH NSV; TL.","administrativeNotes":"01/31/2023-VD upversioned as change in max length, CDE version changed-MM","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7391778","version":"1","preferredName":"Treatment Cohort Study EC9930 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9930 in which subsets of a defined population are identified","longName":"TX_COH_SDY_EC9930_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC4D89A-A133-5B55-E053-4EBD850A356A","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-13","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"8/13/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7391785","version":"1","preferredName":"Cohort","preferredDefinition":"One or more characters used to identify, name, or define the cohort.","longName":"COHORT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC512F0-DDE2-2563-E053-4EBD850A2A94","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-13","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"CDASH NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392785","version":"1","preferredName":"Subject Relationship","preferredDefinition":"A qualifier to describe the relationships of the associated person(s) to the related subject or pool of subjects.","longName":"SREL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD00D805-90AC-2082-E053-4EBD850A4550","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID_SDTMIG 3.4 (Public Review); TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392789","version":"1","preferredName":"Whole Blood Submission","preferredDefinition":"An indication of whether whole blood was submitted.","longName":"BLOODYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD01472B-EADE-21A7-E053-4EBD850A9603","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392790","version":"1","preferredName":"Plasma Submission","preferredDefinition":"An indication of whether plasma was submitted.","longName":"PLASMAYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD01544D-22A4-28CC-E053-4EBD850A54A0","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392791","version":"1","preferredName":"Serum Submission","preferredDefinition":"An indication of whether serum was submitted.","longName":"SERUMYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD010C5B-52BA-2A62-E053-4EBD850A5027","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392792","version":"1","preferredName":"Questionnaire Participation Consent","preferredDefinition":"An indication of whether the patient consented to participate in a questionnaire.","longName":"QSICYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD017BAA-0678-221E-E053-4EBD850A34A9","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392793","version":"1","preferredName":"Number of Household Residents","preferredDefinition":"The number of individuals living together in the same dwelling.","longName":"HHLDRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD0191FD-EAF8-26A5-E053-4EBD850A4032","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392794","version":"1","preferredName":"Secondhand Smoke Exposure","preferredDefinition":"An indication of whether secondhand smoke exposure is present in the current household.","longName":"EROCCUR_SECHD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD01B316-BF04-2213-E053-4EBD850A38AC","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7392795","version":"1","preferredName":"Influenza Vaccine Exposure","preferredDefinition":"An indication whether the subject was exposed to an influenza vaccine that might influence a disease or medical condition.","longName":"EROCCUR_INFVAC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD02A94D-262C-2642-E053-4EBD850AFA79","latestVersionIndicator":"Yes","beginDate":"2020-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-16","modifiedBy":"TAYLORT","dateModified":"2020-08-24","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7406430","version":"1","preferredName":"Treatment Cohort Study 10404 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10404 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10404_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADA3AF62-9287-5838-E053-4EBD850A1451","latestVersionIndicator":"Yes","beginDate":"2020-08-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-24","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"8/24/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7408861","version":"1","preferredName":"Patient Histologically Confirmation Advanced Solid Neoplasm Chemotherapy Recommendation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study with regards to histological confirmation of advanced solid tumor that chemotherapy is recommended as outlined in the study protocol.","longName":"PT_HIST_NEO_CTX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADA81303-66F8-7817-E053-4EBD850A4029","latestVersionIndicator":"Yes","beginDate":"2020-08-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-08-25","modifiedBy":"SOKKERL","dateModified":"2020-08-25","changeNote":"8/25/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413204","version":"1","preferredName":"Analyte Code","preferredDefinition":"The assigned dictionary code for the information affixed to the sample container that contains all additional required information to properly and completely identify the specimen.","longName":"ANALYTCD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED17DD9-B488-4EF0-E053-4EBD850A2643","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-08","modifiedBy":"TAYLORT","dateModified":"2020-09-14","changeNote":"9.14.20 TL released/MM. PED-CITN-01 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7413274","version":"1","preferredName":"Patient Peripheral Sensory Neuropathy Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient is experiencing peripheral sensory neuropathy, a nerve disorder that affects the patient's sensory nerves as outlined the study protocol.","longName":"PER_SEN_NEU_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED2806C-8D25-2ACA-E053-4EBD850A0428","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-09-08","modifiedBy":"SOKKERL","dateModified":"2023-10-31","changeNote":"9/8/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7415477","version":"1","preferredName":"Sub-Specimen Identifier List","preferredDefinition":"A free text field for the list of unique alphanumeric identifiers assigned to the discrete parts of specimens.","longName":"SUBSPCML","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C35FE-0043-17A7-E053-4EBD850AA14B","latestVersionIndicator":"Yes","beginDate":"2020-09-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-11","modifiedBy":"TAYLORT","dateModified":"2020-09-11","changeNote":"10323 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7418090","version":"1","preferredName":"Diagnosis Confirmation Kaposi Sarcoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions regarding  the diagnosis confirmation of kaposi sarcoma as outlined in the study protocol.","longName":"DX_CONF_KS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF475DC9-1A23-1CDA-E053-4EBD850AF9EE","latestVersionIndicator":"Yes","beginDate":"2020-09-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-09-14","modifiedBy":"SOKKERL","dateModified":"2021-03-25","changeNote":"9/14/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7420041","version":"1","preferredName":"Patient Therapeutic Procedure Or Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regards to treatments or treatment plans as outlined in the protocol.","longName":"PT_TX_OR_TXRG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF4B88CC-9DED-02A2-E053-4EBD850A9C51","latestVersionIndicator":"Yes","beginDate":"2020-09-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-09-14","modifiedBy":"SOKKERL","dateModified":"2022-11-21","changeNote":"9/14/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7421327","version":"1","preferredName":"Treatment Cohort Study EC10387 Code","preferredDefinition":"The code that represents the information pertaining to protocol EC10387 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_EC10387_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF5C4C19-E97C-1723-E053-4EBD850A6DB0","latestVersionIndicator":"Yes","beginDate":"2020-09-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-09-15","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"9/15/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7421345","version":"1","preferredName":"Treatment Cohort Study EC10401 Code","preferredDefinition":"The code that represents the information pertaining to protocol EC10401 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_EC10401_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF5D8BD4-9FDB-1953-E053-4EBD850AAE02","latestVersionIndicator":"Yes","beginDate":"2020-09-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-09-15","modifiedBy":"SOKKERL","dateModified":"2020-09-15","changeNote":"9/15/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7426184","version":"1","preferredName":"Minor Person SARS Coronavirus 2 Positive Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions addressing positive finding for COVID- 19 for a patient less than or equal to 18 years old as outlined in the study protocol.","longName":"MIN_PRS_COVID_POS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFD18F56-3FDC-5F42-E053-4EBD850A03F9","latestVersionIndicator":"Yes","beginDate":"2020-09-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-09-21","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeNote":"Created for Theradex. AK 2020-9-21","administrativeNotes":"7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429178","version":"1","preferredName":"Tumor Marker Result","preferredDefinition":"Results of the tumor marker disease response assessment using the terminology associated with the normal abnormal response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","longName":"RSORRES_TM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFD6D54E-7D57-3A91-E053-4EBD850A4906","latestVersionIndicator":"Yes","beginDate":"2020-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-21","modifiedBy":"TAYLORT","dateModified":"2020-09-23","changeNote":"PED-CITN-01 NSV; TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429183","version":"1","preferredName":"Disease Response","preferredDefinition":"Results of the disease response assessment based on sponsor defined terminology.","longName":"RSORRES_RESP_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFD7B5B1-8030-47A5-E053-4EBD850A1FEE","latestVersionIndicator":"Yes","beginDate":"2020-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-21","modifiedBy":"SOKKERL","dateModified":"2023-09-21","changeNote":"PED-CITN-01 NSV; TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429193","version":"1","preferredName":"Timepoint Response","preferredDefinition":"Results of the disease response timepoint assessment based on sponsor defined coded terminology.","longName":"RSORRES_TPTRESP_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFD9A413-5B72-731F-E053-4EBD850ABD3E","latestVersionIndicator":"Yes","beginDate":"2020-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-21","modifiedBy":"GDEEN","dateModified":"2023-04-20","changeNote":"PED-CITN-01 NSV; TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429296","version":"1","preferredName":"Deauville Assessment Occurrence","preferredDefinition":"An indication whether or not the target lesions were assessed by the London Deauville Criteria 5 Point Scale disease response assessment.","longName":"RSPERF_DEUVL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFDA3836-ABE3-7260-E053-4EBD850A66C3","latestVersionIndicator":"Yes","beginDate":"2020-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-22","modifiedBy":"TAYLORT","dateModified":"2020-09-23","changeNote":"PED-CITN-01 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429302","version":"1","preferredName":"Deauville Result","preferredDefinition":"Numeric score for the outcome of the London Deauville Criteria 5 Point Scale disease response assessment.","longName":"RSORRES_DEUVL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFD9DB6C-865E-7AF2-E053-4EBD850A88B8","latestVersionIndicator":"Yes","beginDate":"2020-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-22","modifiedBy":"TSESU","dateModified":"2023-08-28","changeNote":"PED-CITN-01 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429306","version":"1","preferredName":"FDG-Pet Avid Tumor","preferredDefinition":"An indication of whether or not there is a result of increased FDG uptake by a solid tumor on PET imaging.","longName":"RSORRES_FDG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFD9E056-D149-4475-E053-4EBD850AF22C","latestVersionIndicator":"Yes","beginDate":"2020-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-22","modifiedBy":"TAYLORT","dateModified":"2020-09-23","changeNote":"PED-CITN-01 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429485","version":"1","preferredName":"Relative Score by Curie Scale","preferredDefinition":"The sponsor defined numeric representation of the Curie score as originally received or collected.","longName":"TRORRES_SPD_CSRREL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFDA2E1D-3029-46A6-E053-4EBD850AD21B","latestVersionIndicator":"Yes","beginDate":"2020-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-22","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeNote":"PED-CITN-01 NSV; TL.","administrativeNotes":"2023.6.12 Alt SN added per ticket request CADSR0002508. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7429602","version":"1","preferredName":"Disease Staging System","preferredDefinition":"The name of the staging system used in the evaluation of the disease.","longName":"DZSTAGE_SYS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFED5C50-33F2-29DF-E053-4EBD850AE728","latestVersionIndicator":"Yes","beginDate":"2020-09-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-09-22","modifiedBy":"GDEEN","dateModified":"2023-11-29","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452279","version":"1","preferredName":"Treatment Cohort Study 10402 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10402 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10402_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0B058B5-7889-1095-E053-4EBD850AC254","latestVersionIndicator":"Yes","beginDate":"2020-10-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-02","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7452985","version":"1","preferredName":"Treatment Cohort Study 10406 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10406 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10406_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0F1DE44-74CF-37A8-E053-4EBD850ABF70","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-05","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"10/05/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7460958","version":"1","preferredName":"Patient Active Herpes Simplex Virus Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to questions which are necessary to allow a subject to participate in a clinical study that are related to active herpes simplex as outlined in the study protocol.","longName":"PT_ACT_HSV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B10361C3-73B6-3A92-E053-4EBD850A7654","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-06","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"10/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7460980","version":"1","preferredName":"Patient Systemic Therapy Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to administration of systemic therapy as outlined in the study protocol.","longName":"PT_RECIV_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B104864D-017C-676F-E053-4EBD850A9291","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-06","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"10/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7461033","version":"1","preferredName":"Patient Systemic Therapy Off Treatment Duration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the protocol eligibility criteria was met with regards to the period of time during which the patient was off systemic treatment.","longName":"PT_OFF_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B107435C-BDFE-33BA-E053-4EBD850AD046","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-06","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"10/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7461053","version":"1","preferredName":"Patient Off Treatment Week Duration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the protocol eligibility criteria was met with regards to the period of time, in weeks, during which the patient was off treatment.","longName":"PT_OFF_TX_WK_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047687-BB42-3334-E053-4EBD850AC907","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-06","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"10/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7461059","version":"1","preferredName":"Patient Off Treatment Duration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the protocol eligibility criteria was met with regards to the period of time during which the patient was off treatment.","longName":"PT_OFF_TX_DURT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B10779D7-1850-67A2-E053-4EBD850A4FE0","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-06","modifiedBy":"SOKKERL","dateModified":"2021-08-05","changeNote":"10/6/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7461101","version":"1","preferredName":"Treatment Cohort Study 10384 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10384 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10384_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1143A60-F268-6FC8-E053-4EBD850A3980","latestVersionIndicator":"Yes","beginDate":"2020-10-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-07","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"10/7/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7464332","version":"2","preferredName":"Protocol Treatment Arm Criterion Fulfill Protocol Treatment Arm Category","preferredDefinition":"A text response for the treatment arm criteria that the patient meets.","longName":"PTX_ARM_CRT_FULF_CAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA2FBB2B-4815-1577-E053-4EBD850ABDC9","latestVersionIndicator":"Yes","beginDate":"2020-10-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-14","modifiedBy":"SOKKERL","dateModified":"2022-06-13","changeNote":"10/14/20 LS TT   versioned VD and CDE 3/14/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7469859","version":"1","preferredName":"Patient Cytogenetic Abnormality Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study address n irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material as outlined in the study protocol.","longName":"PT_CYTOGEN_ABN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B206FFD0-F2B4-649E-E053-4EBD850A3E68","latestVersionIndicator":"Yes","beginDate":"2020-10-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-19","modifiedBy":"SOKKERL","dateModified":"2023-06-15","changeNote":"10/19/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7470315","version":"1","preferredName":"Patient Progressive Disease Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to disease that is increasing in scope or severity after the administration of therapeutic agents as outlined in the study protocol.","longName":"PD_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2096A9D-E233-6541-E053-4EBD850AAAAE","latestVersionIndicator":"Yes","beginDate":"2020-10-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-19","modifiedBy":"SOKKERL","dateModified":"2023-07-11","changeNote":"10/19/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7473920","version":"1","preferredName":"Advanced Disease Prior Line of Therapy Stratification Factors Count","preferredDefinition":"The prior number of lines of therapy administered for advanced disease that is used during the randomization process to ensure there is balance of these factors across all subjects within each arm of a study.","longName":"PR_LOTX_STRATFCT_CT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B21D3A9C-8C3E-0DAB-E053-4EBD850A8AC7","latestVersionIndicator":"Yes","beginDate":"2020-10-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-20","modifiedBy":"TAYLORT","dateModified":"2020-10-20","changeNote":"10100; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7474040","version":"1","preferredName":"Treatment Cohort Study 10371 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10371 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10371_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B21FD59A-51E5-3D37-E053-4EBD850A661A","latestVersionIndicator":"Yes","beginDate":"2020-10-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-20","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7480133","version":"1","preferredName":"Specimen Type","preferredDefinition":"The type of specimen used for a measurement as defined by the sponsor.","longName":"MISPECTYP_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2974879-9973-706B-E053-4EBD850A1F0D","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-26","modifiedBy":"TAYLORT","dateModified":"2020-10-26","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7480142","version":"1","preferredName":"Collected Planned Elapsed Time from Time Point Reference","preferredDefinition":"The collected time interval between a planned time point and a reference time point related to microscopic findings.","longName":"MIELTIM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B29712D7-FBBD-5993-E053-4EBD850A8A55","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-26","modifiedBy":"TAYLORT","dateModified":"2020-10-26","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7480145","version":"1","preferredName":"Run Name","preferredDefinition":"Descriptive name of the sequencing process used to obtain the measurement or microscopic finding.","longName":"RUNNAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2974C0A-96B8-58E8-E053-4EBD850ABE53","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-26","modifiedBy":"TITARENI","dateModified":"2021-12-27","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7480147","version":"1","preferredName":"Kit Lot Number","preferredDefinition":"Lot Number of the test kit product used to obtain the measurement or microscopic finding.","longName":"KITLOTNM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2974E0B-02BC-2E95-E053-4EBD850AE77A","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-26","modifiedBy":"TAYLORT","dateModified":"2020-10-26","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7480160","version":"1","preferredName":"Operator Name","preferredDefinition":"The name or identifier of the operator that provided the test results related to microscopic findings.","longName":"OPNAM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2974C0A-9718-58E8-E053-4EBD850ABE53","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-26","modifiedBy":"TAYLORT","dateModified":"2020-10-26","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7480166","version":"1","preferredName":"Certificate Number","preferredDefinition":"Certificate Number related to the submission of information encompassing and representing data, or records related to microscopic findings.","longName":"CERTNUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2974B87-1070-5B00-E053-4EBD850AF75B","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-26","modifiedBy":"TAYLORT","dateModified":"2020-10-26","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7480176","version":"1","preferredName":"Run Date","preferredDefinition":"The date of the sequencing process used to obtain the measurement or microscopic finding.","longName":"RUNDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B29712D7-FCAB-5993-E053-4EBD850A8A55","latestVersionIndicator":"Yes","beginDate":"2020-10-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-26","modifiedBy":"TAYLORT","dateModified":"2020-10-26","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7485294","version":"1","preferredName":"Method of Test","preferredDefinition":"The sponsor-defined technique used for the completion of the questionnaire.","longName":"QSMETHOD_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CF8693-9623-1AF6-E053-4EBD850ADCE8","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-29","modifiedBy":"TAYLORT","dateModified":"2020-10-29","changeNote":"10.29.2020 NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7485444","version":"1","preferredName":"Questionnaire Language","preferredDefinition":"The language of the subject utilized for the submission of information encompassing and representing data, vocabulary or records related to questionnaire.","longName":"QSLANG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D239DE-C2F3-0922-E053-4EBD850AD992","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-29","modifiedBy":"TAYLORT","dateModified":"2020-10-29","changeNote":"10.29.2020 NCICOVID; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7485449","version":"1","preferredName":"Cancer Treatment Interruption Indicator","preferredDefinition":"An indication whether or not the cancer treatment was interrupted.","longName":"DISRPTYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D2CD69-FD0B-012D-E053-4EBD850A2452","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-29","modifiedBy":"TAYLORT","dateModified":"2020-10-29","changeNote":"10.29.2020 NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7485721","version":"1","preferredName":"Cell Fraction Type","preferredDefinition":"Descriptive name of the cell lysate fraction used to obtain the measurement or finding.","longName":"MIFRACT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D5DC06-7863-14FD-E053-4EBD850A4A59","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-10-29","modifiedBy":"TAYLORT","dateModified":"2020-10-30","changeNote":"NSV for NCLN PD CRF Development; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7487199","version":"1","preferredName":"Prior Hormone Therapy Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial related to the prior administration of various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level as outlined in the study protocol.","longName":"PR_HRMTX_RCD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3150639-B256-6F00-E053-4EBD850ABA4E","latestVersionIndicator":"Yes","beginDate":"2020-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-11-02","modifiedBy":"SOKKERL","dateModified":"2022-07-14","changeNote":"11/2/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7489662","version":"1","preferredName":"Study Protocol Accrual Cohort Study 10166 Code","preferredDefinition":"The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study 10166.","longName":"SDY_PRT_ACC_COH_10166_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B329A2E9-8BBA-39C0-E053-4EBD850AFB0C","latestVersionIndicator":"Yes","beginDate":"2020-11-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-11-03","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"11/3/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7497818","version":"1","preferredName":"Reason Biospecimen Collection Not Complete","preferredDefinition":"An explanation as to why the expected specimen collection was not completed.","longName":"BSNCREAS","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3B0847E-19AD-2D0E-E053-4EBD850ACEF4","latestVersionIndicator":"Yes","beginDate":"2020-11-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-11-09","modifiedBy":"TAYLORT","dateModified":"2020-11-09","changeNote":"Seed Study NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7502246","version":"1","preferredName":"Patient Head and Neck Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to benign or malignant neoplasm that affects the anatomic structures of the head and neck region as outlined in the study protocol.","longName":"HD_NEC_MAL_NEO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3ED04A6-C1CE-4A01-E053-4EBD850A666B","latestVersionIndicator":"Yes","beginDate":"2020-11-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-11-12","modifiedBy":"SOKKERL","dateModified":"2023-05-08","changeNote":"11/12/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7502573","version":"1","preferredName":"Clinical Study Subgroup Assignment Code","preferredDefinition":"The coded response for the study subgroup a participant is assigned to.","longName":"SGCODE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3FE3EC6-E6A1-1300-E053-4EBD850A6611","latestVersionIndicator":"Yes","beginDate":"2020-11-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-11-13","modifiedBy":"TAYLORT","dateModified":"2020-11-16","changeNote":"TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7505132","version":"1","preferredName":"Patient Neoplasm Involvement Mandible Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has a benign or malignant tissue growth involving the mandible as outlined in the study protocol.","longName":"PT_NEO_INVLT_MND_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43DD61D-9054-7E21-E053-4EBD850A4CF4","latestVersionIndicator":"Yes","beginDate":"2020-11-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-11-16","modifiedBy":"SOKKERL","dateModified":"2020-11-17","changeNote":"11/16/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7505137","version":"1","preferredName":"Negation Infectious Disorder Pneumonitis Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether an non- infectious inflammatory  process affecting the lung parenchyma that requires an therapeutic agents to produce an effect that is intended to alter or stop a pathologic process as outlined in the study protocol.","longName":"NOINFECT_PNM_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43DC98D-428D-6928-E053-4EBD850A6C27","latestVersionIndicator":"Yes","beginDate":"2020-11-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-11-16","modifiedBy":"KUMMEROA","dateModified":"2023-11-03","changeNote":"11/16/20 ls","administrativeNotes":"2023.11.3 AQT added per ticket request CADSR0003032. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7506839","version":"1","preferredName":"Male Patient Spermatozoon Donor Contraception Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to male patients donating their sperm and using contraceptive as outlined in the study protocol.","longName":"M_SPRM_DON_CONTR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B44F613F-1A8D-1333-E053-4EBD850A71B6","latestVersionIndicator":"Yes","beginDate":"2020-11-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-11-17","modifiedBy":"SOKKERL","dateModified":"2020-12-18","changeNote":"11/17/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7513401","version":"1","preferredName":"Reason Not Performed","preferredDefinition":"The rationale why questionnaire data was not obtained based on sponsor defined terminology.","longName":"QSREASND_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B48BC756-637D-1E58-E053-4EBD850AE880","latestVersionIndicator":"Yes","beginDate":"2020-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-11-20","modifiedBy":"TAYLORT","dateModified":"2020-11-20","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7514954","version":"1","preferredName":"Questionnaire Completion Status","preferredDefinition":"Terminology used to describe the state or condition of the completeness of the questionnaire data.","longName":"QSCPSTAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B491E7F1-58ED-4C5C-E053-4EBD850AFBF4","latestVersionIndicator":"Yes","beginDate":"2020-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-11-20","modifiedBy":"TAYLORT","dateModified":"2020-11-20","changeNote":"NCICOVID NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7516273","version":"1","preferredName":"Medical Record Consent","preferredDefinition":"An indication whether or not consent was obtained for the research use of the patient's medical records.","longName":"MRCNSTNY","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4E26AF2-8297-13D0-E053-4EBD850A50F4","latestVersionIndicator":"Yes","beginDate":"2020-11-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-11-24","modifiedBy":"TAYLORT","dateModified":"2020-11-24","changeNote":"10323 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7518852","version":"1","preferredName":"Patient Therapeutic Procedure Performed Imaging Requirement Imaging Evidence Progressive Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to treatments, requirements for imaging procedures that were performed, and imaging evidence of disease progression.","longName":"TX_IMG_PROG_DZ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B567C36D-A1F7-0C6E-E053-4EBD850A91E4","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-01","modifiedBy":"SOKKERL","dateModified":"2022-03-24","changeNote":"12/1/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7518897","version":"1","preferredName":"Patient Prior Therapy Stable Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person having received prior treatment and having stable disease as outlined in the study protocol.","longName":"PR_TX_STBL_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56858F7-F186-0C6C-E053-4EBD850ADEA0","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-01","modifiedBy":"SOKKERL","dateModified":"2022-04-22","changeNote":"12/1/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7521841","version":"1","preferredName":"Patient Histologically Confirmation Solid Neoplasm No Cure Best Practice Clinical Trial Eligibility Criteria Applicable Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has histologic confirmation of solid neoplasm with no cure with standard care as outlined in the study protocol.","longName":"SOL_TUM_NOCUR_ TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B59093D4-5C5F-70AF-E053-4EBD850A5796","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-03","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/3/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7524425","version":"1","preferredName":"Treatment Cohort Study 10285 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10285 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10285_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5939FD7-777C-709F-E053-4EBD850A429E","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-03","modifiedBy":"SOKKERL","dateModified":"2020-12-03","changeNote":"12/3/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7524434","version":"1","preferredName":"Patient Safety Biopsy Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the safety of biopsy  assessment as outlined in the study protocol.","longName":"SAFE_BX_ASSMNT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593B495-9E34-0892-E053-4EBD850A76A8","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-03","modifiedBy":"TYRRELLM","dateModified":"2023-10-22","changeNote":"12/3/20 ls","administrativeNotes":"10.22.23_Added AQT per request CADSR0002989_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7525214","version":"1","preferredName":"Elapsed Time Indicator","preferredDefinition":"An indicator to address the interval between the activities of a biospecimen.","longName":"ELTIMYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5DAAF32-44B7-2E0B-E053-4EBD850A658A","latestVersionIndicator":"Yes","beginDate":"2020-12-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-07","modifiedBy":"TAYLORT","dateModified":"2020-12-08","changeNote":"10402 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7525216","version":"1","preferredName":"Elapsed Time","preferredDefinition":"The interval between the activities of a biospecimen represented in an unambiguous time format (e.g., hh:mm:ss).","longName":"BEELTIM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5E25D80-5838-2E07-E053-4EBD850A0F49","latestVersionIndicator":"Yes","beginDate":"2020-12-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-07","modifiedBy":"TAYLORT","dateModified":"2020-12-08","changeNote":"10402 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7525218","version":"1","preferredName":"Sufficient For Analysis","preferredDefinition":"An indication as to whether the biospecimen is adequate for analysis.","longName":"ANLYZYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5E25D80-5859-2E07-E053-4EBD850A0F49","latestVersionIndicator":"Yes","beginDate":"2020-12-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-07","modifiedBy":"TAYLORT","dateModified":"2020-12-08","changeNote":"10402 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7525254","version":"1","preferredName":"Treatment Cohort Study 9892 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9892 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9892_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5E26465-24B3-6F9E-E053-4EBD850A0E89","latestVersionIndicator":"Yes","beginDate":"2020-12-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-07","modifiedBy":"SOKKERL","dateModified":"2020-12-07","changeNote":"12/7/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7532180","version":"1","preferredName":"Treatment Cohort Study 10411 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10411 in which subsets of a defined population are identified.","longName":"10411_COHORT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66E6881-86CE-2159-E053-4EBD850A7416","latestVersionIndicator":"Yes","beginDate":"2020-12-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-14","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"TL/10411.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7533501","version":"1","preferredName":"Patient Osteosarcoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to osteosarcoma.","longName":"OS_DX_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B68529C7-3967-124D-E053-4EBD850A01FF","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-15","modifiedBy":"KUMMEROA","dateModified":"2021-04-02","changeNote":"PED-CITN-02/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7533512","version":"1","preferredName":"Patient Neuroblastoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to neuroblastoma.","longName":"NB_DX_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B68530BD-B114-06D3-E053-4EBD850AC5D1","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-15","modifiedBy":"SOKKERL","dateModified":"2023-06-07","changeNote":"PED-CITN-02/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7533540","version":"1","preferredName":"Patient Measurable Or Evaluable Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to measurable or evaluable disease.","longName":"MEAS_OR_EVAL_DZ_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B686C8D7-4F2B-5315-E053-4EBD850A86DF","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-15","modifiedBy":"SOKKERL","dateModified":"2022-05-31","changeNote":"PED-CITN-02/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7533633","version":"1","preferredName":"Patient Ganglioside GD2 Immunohistochemistry Staining Method Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to GD2 results by immunohistochemistry.","longName":"GD2_IHC_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6984600-4BDA-3735-E053-4EBD850A0991","latestVersionIndicator":"Yes","beginDate":"2020-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-16","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"PED-CITN-02/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7535639","version":"1","preferredName":"Patient Enrollment Age Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions related to patient age the time of enrollment as outlined in the study.","longName":"PT_ENRLMNT_AGE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6C3C684-2EBC-233D-E053-4EBD850AE067","latestVersionIndicator":"Yes","beginDate":"2020-12-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-18","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/18/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7535793","version":"1","preferredName":"Patient Age Range Screened Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator related to the age of a patient is screened between the lowest and highest numerical values to allow a subject to participate in a clinical study.","longName":"PT_AGE_RANG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FCEEBA-5E8A-0308-E053-4EBD850A6914","latestVersionIndicator":"Yes","beginDate":"2020-12-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-21","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/21/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537013","version":"1","preferredName":"Patient Iobenguane I-131 Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to 131I-MIBG.","longName":"1311MIBG_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FCEA57-E813-0D23-E053-4EBD850AC865","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-22","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"PED-CITN-02; TL.","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537016","version":"1","preferredName":"Patient Monoclonal Antibody Or Immune Checkpoint Inhibitor Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to monoclonal antibodies or immune checkpoint inhibitors.","longName":"MAB_ICI_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FD6F09-EC01-437A-E053-4EBD850A93EA","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-22","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"PED-CITN-02; TL.","administrativeNotes":"2023.85.2 AQT added per ticket request CADSR0002685. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537017","version":"1","preferredName":"Patient Cellular Therapy Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to cell therapy.","longName":"CELLTX_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FE8DE3-97FF-43E6-E053-4EBD850A9018","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-22","modifiedBy":"TAYLORT","dateModified":"2021-03-31","changeNote":"PED-CITN-02; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537019","version":"1","preferredName":"Patient Neurotoxicity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to neurotoxicity.","longName":"NEURTOX_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FD6F09-EC28-437A-E053-4EBD850A93EA","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-22","modifiedBy":"SOKKERL","dateModified":"2023-05-24","changeNote":"PED-CITN-02; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537020","version":"1","preferredName":"Patient Personal Medical History Central Nervous System Neoplasm Involvement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient's medical background meets the eligibility requirements for participation in a clinical trial with regards to tumor involvement of the central nervous system.","longName":"CNS_TUMR_INV_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FD25F9-3A7B-22CA-E053-4EBD850A7BA7","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-22","modifiedBy":"KUMMEROA","dateModified":"2022-04-01","changeNote":"PED-CITN-02; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537021","version":"1","preferredName":"Patient Asymptomatic Central Nervous System Lesion Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to asymptomatic CNS lesions.","longName":"ASYM_CNS_LES_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FCD959-2D63-0310-E053-4EBD850AFC91","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-22","modifiedBy":"SOKKERL","dateModified":"2022-02-24","changeNote":"PED-CITN-02; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537022","version":"1","preferredName":"Patient Performance Status Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the assessment(s) of performance status.","longName":"PS_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FCD959-2D8A-0310-E053-4EBD850AFC91","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-12-22","modifiedBy":"KUMMEROA","dateModified":"2023-11-02","changeNote":"PED-CITN-02; TL.","administrativeNotes":"2023.11.2 AQT added per ticket request CADSR0003032. ak 2023.4.4 AQT added per ticket request CADSR0002268. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7537052","version":"1","preferredName":"Chloroquine Or Hydroxychloroquine Therapy Within Timepoint Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine if chloroquine or hydroxychloquine was administered as outlined in the study protocol.","longName":"CHLQUIN_HYDRCHLQUIN_ADMN_CD_IN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B711B0FC-F674-58C2-E053-4EBD850A86C5","latestVersionIndicator":"Yes","beginDate":"2020-12-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-22","modifiedBy":"SOKKERL","dateModified":"2021-01-20","changeNote":"12/20/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7539970","version":"1","preferredName":"Patient Metabolic Process Ability Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient abilityof all chemical changes that take place in a cell, including the synthesis of new molecules and the breakdown and removal of others as outlined in the study protocol.","longName":"PT_METBPRC_ABLTY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7886633-6310-3258-E053-4EBD850A12D8","latestVersionIndicator":"Yes","beginDate":"2020-12-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-29","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7539996","version":"1","preferredName":"Patient Morphologic Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample as outlined in the study protocol.","longName":"MORH_FNDG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B79CFABB-44A6-4947-E053-4EBD850A1B63","latestVersionIndicator":"Yes","beginDate":"2020-12-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-29","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7540004","version":"1","preferredName":"Patient Pain Level Analysis Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient identifying the level of  the sensation of discomfort, distress, or agony as outlined in the study protocol.","longName":"PT_PN_LEV_ANYL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B79F1992-A4AD-3227-E053-4EBD850A13DA","latestVersionIndicator":"Yes","beginDate":"2020-12-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-29","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7540012","version":"1","preferredName":"Laboratory Procedure PSA Level Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response indicating whether a patient meets the eligibility requirements regarding  PSA levels in a sample as outlined in the study protocol.","longName":"LAB_PSA_LEV_OT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B79F3481-4852-32B2-E053-4EBD850A499E","latestVersionIndicator":"Yes","beginDate":"2020-12-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-29","modifiedBy":"SOKKERL","dateModified":"2022-01-19","changeNote":"12/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7540015","version":"1","preferredName":"Urinary System Adverse Event Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response indicating whether a patient meets the eligibility requirements regarding signs or unfavorable symptoms of excretion of urine as outlined in the study protocol.","longName":"URNYSYS_AE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B79F1992-A4E2-3227-E053-4EBD850A13DA","latestVersionIndicator":"Yes","beginDate":"2020-12-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-29","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7540021","version":"1","preferredName":"Patient Malignant Lymphadenopathy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to questions which are necessary to allow a patient to participate in a clinical study that address malignant lymphadenopathy as outlined in the study protocol.","longName":"MALGN_LYPHTY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B79F6F41-B50F-5F5D-E053-4EBD850ABF35","latestVersionIndicator":"Yes","beginDate":"2020-12-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-29","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7540026","version":"1","preferredName":"Patient Bone Fracture Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regards to bone fracture assessment as outlined in the study protocol.","longName":"BN_FX_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B79E37D1-4F8D-2E92-E053-4EBD850A2952","latestVersionIndicator":"Yes","beginDate":"2020-12-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-29","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"12/29/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7541193","version":"1","preferredName":"Treatment Cohort Study 10437 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10437 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10437_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B79F04C8-BEA9-26B8-E053-4EBD850A9A05","latestVersionIndicator":"Yes","beginDate":"2020-12-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-12-30","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"12/30/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7544340","version":"1","preferredName":"Biospecimen Group ID","preferredDefinition":"A character or string that represents a biospecimen group.","longName":"BEGRPID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B81537F2-B335-5B40-E053-4EBD850ACE47","latestVersionIndicator":"Yes","beginDate":"2021-01-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-01-04","modifiedBy":"SPRINGERL","dateModified":"2021-05-11","changeNote":"10335; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7550029","version":"1","preferredName":"Pharmacologic Substance Administration Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to an assessment of administration pharmacologic substance as outlined in the study protocol.","longName":"PHRM_SUB_ADMN_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8F4A17D-016C-678A-E053-4EBD850AD33C","latestVersionIndicator":"Yes","beginDate":"2021-01-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-01-15","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"1/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7550037","version":"1","preferredName":"Patient Biopsy Ability Clinical Trial Eligibility Criteria Yes No Not Applicable Code Indicator","preferredDefinition":"The coded response for questions to determine clinical trial eligibility that address the ability of a person to have a biopsy as outlined in the study protocol.","longName":"PT_BX_ABLTY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8F46EFF-9668-6786-E053-4EBD850A973E","latestVersionIndicator":"Yes","beginDate":"2021-01-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-01-15","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"1/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7550054","version":"1","preferredName":"Patient Nausea Vomiting Limited Pharmacologic Substance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related limit administration to a drug due to expelling the contents of the stomach and the sensations associated with it as outlined in the study protocol.","longName":"NAUS_VMT_LMT_PHM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8F4C135-A8D1-6780-E053-4EBD850ACDEF","latestVersionIndicator":"Yes","beginDate":"2021-01-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-01-15","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"1/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7551766","version":"1","preferredName":"Prior Systemic Therapy Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the prior administration of systemic therapy as outlined in the study protocol.","longName":"PR_SYSMC_TX_ADMN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B957CDBA-863E-5D20-E053-4EBD850A0CBA","latestVersionIndicator":"Yes","beginDate":"2021-01-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-01-20","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":"1/21/21 ls","administrativeNotes":"2023.5.3 Updated AQT per ticket CADSR0002390. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7551863","version":"1","preferredName":"Disease Measurable And Biopsy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to disease that is measurable and to a biopsy procedure as outlined in the protocol.","longName":"DZ_MEAS_BX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B95989AC-73DC-3A42-E053-4EBD850ADA3B","latestVersionIndicator":"Yes","beginDate":"2021-01-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-01-20","modifiedBy":"SOKKERL","dateModified":"2022-07-01","changeNote":"1/21/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7554838","version":"1","preferredName":"COVID-19 Vaccine Initial Immunization Administered Date","preferredDefinition":"The response indicating the date the initial COVID-19 vaccine immunization was administered.","longName":"7554833v1.0:2018550v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BF8845-6E56-1E89-E053-4EBD850AF2EC","latestVersionIndicator":"Yes","beginDate":"2021-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-01-25","modifiedBy":"SOKKERL","dateModified":"2021-09-24","changeNote":"2021-1-25 ak Created for COVID-19 vaccinations.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7554843","version":"1","preferredName":"COVID-19 Vaccine Booster Immunization Administered Date","preferredDefinition":"The response indicating the date the booster COVID-19 vaccine immunization was administered.","longName":"7554842v1.0:2018550v1.0","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BFA180-FFFA-15E8-E053-4EBD850AB1AA","latestVersionIndicator":"Yes","beginDate":"2021-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-01-25","modifiedBy":"TITARENI","dateModified":"2022-02-11","changeNote":"2021-1-25 ak Created for COVID-19 vaccinations.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7554859","version":"1","preferredName":"COVID-19 Vaccine Pharmaceutical Manufacturer Name","preferredDefinition":"A textual description of the pharmaceutical manufacturer of COVID-19 vaccine.","longName":"COVID19_VAC_PHARM_MFG_NM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BF8CF2-0FE7-5533-E053-4EBD850A8EC7","latestVersionIndicator":"Yes","beginDate":"2021-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-01-25","modifiedBy":"RAGUNATHANU","dateModified":"2022-06-17","changeNote":"2021-1-25 ak Created for COVID-19 vaccinations.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7554939","version":"1","preferredName":"COVID-19 Vaccine Pharmaceutical Manufacturer Other Specify Text","preferredDefinition":"The free text field that describes other pharmaceutical manufacturers of COVID-19 vaccine which are different from the ones previously specified.","longName":"COVID19_VAC_PHARM_MFG_SP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9CE2A5E-A611-08A5-E053-4EBD850A6141","latestVersionIndicator":"Yes","beginDate":"2021-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-01-26","modifiedBy":"KUMMEROA","dateModified":"2022-06-07","changeNote":"2021-1-26 ak Created for COVID-19 vaccinations.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7557022","version":"1","preferredName":"Patient Primary Peritoneal High Grade Serous Adenocarcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a serous adenocarcinoma that arises from the lining of the peritoneum as outlined in the study protocol.","longName":"PHGSA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9D3BB85-A3B8-441E-E053-4EBD850AB1E6","latestVersionIndicator":"Yes","beginDate":"2021-01-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-01-26","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"1/26/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7559664","version":"1","preferredName":"Planned Time Point Name","preferredDefinition":"One or more sponsor defined characters used to identify a point in time that questionnaire data is obtained.","longName":"QSTPT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9E2D1D6-9802-7D00-E053-4EBD850A61FC","latestVersionIndicator":"Yes","beginDate":"2021-01-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-01-27","modifiedBy":"TAYLORT","dateModified":"2021-01-27","changeNote":"10405; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7559692","version":"1","preferredName":"Patient Locally Advanced Malignant Neoplasm Unresectable Metastatic Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"An indicator related to whether the patient has locally advanced, unresectable or metastatic disease as outlined in the study protocol.","longName":"PT_ADVD_DZ_MAL_NEO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9E25738-8993-4CAC-E053-4EBD850A98FA","latestVersionIndicator":"Yes","beginDate":"2021-01-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-01-27","modifiedBy":"SOKKERL","dateModified":"2022-07-18","changeNote":"1/27/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7562535","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Lacks Energy Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they have a lack of energy, using a five-point Likert scale.","longName":"FAC04001","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9FB39ED-E5D5-53A3-E053-4EBD850AABBF","latestVersionIndicator":"Yes","beginDate":"2021-01-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-28","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/28/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7562544","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Trouble Meeting Family Needs Because of Physical Condition Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they have trouble meeting the needs of the family because of their physical condition, using a five-point Likert scale.","longName":"FAC04003","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9FAEC9B-8BBE-53C2-E053-4EBD850A5E4F","latestVersionIndicator":"Yes","beginDate":"2021-01-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-28","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/28/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7564878","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Have Pain Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they have pain, using a five-point Likert scale.","longName":"FAC04004","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9FCF9A4-282F-0F63-E053-4EBD850A5CBE","latestVersionIndicator":"Yes","beginDate":"2021-01-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-28","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/28/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7564883","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Bothered By Side Effects of Treatment Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are bothered by side effects of treatment, using a five-point Likert scale.","longName":"FAC04005","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9FEABF7-3A97-1871-E053-4EBD850A9695","latestVersionIndicator":"Yes","beginDate":"2021-01-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-28","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/28/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7564887","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Feel Ill Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they feel ill, using a five-point Likert scale.","longName":"FAC04006","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9FDFF08-D5A7-09DF-E053-4EBD850AE732","latestVersionIndicator":"Yes","beginDate":"2021-01-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-28","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/28/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7569305","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Forced to be in Bed Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are forced to spend time in bed, using a five-point Likert scale.","longName":"FAC04007","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA0E5A40-26C2-4743-E053-4EBD850A7F91","latestVersionIndicator":"Yes","beginDate":"2021-01-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-29","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/29/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7569334","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Feel Close to Friends Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they feel close to their friends, using a five-point Likert scale.","longName":"FAC04008","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA0E6DC9-1442-454D-E053-4EBD850A8FE3","latestVersionIndicator":"Yes","beginDate":"2021-01-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-29","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/29/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7569368","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Emotional Support from Family Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they get emotional support from their family, using a five-point Likert scale.","longName":"FAC04009","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA0E5A40-270F-4743-E053-4EBD850A7F91","latestVersionIndicator":"Yes","beginDate":"2021-01-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-29","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/29/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7569415","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Receive Support from Friends Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they get support from their friends, using a five-point Likert scale.","longName":"FAC04010","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA0EA5C1-FD11-4384-E053-4EBD850A4C50","latestVersionIndicator":"Yes","beginDate":"2021-01-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-29","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/29/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7569427","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Family Accepts Illness Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days their family has accepted their illness, using a five-point Likert scale.","longName":"FAC04011","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA0EBBD5-719E-34C4-E053-4EBD850A51BD","latestVersionIndicator":"Yes","beginDate":"2021-01-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-01-29","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 1/29/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574298","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Satisfied with Family Communication Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are satisfied with family communication about their illness, using a five-point Likert scale.","longName":"FAC04012","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA5D8686-1A31-6EFC-E053-4EBD850A50B7","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574348","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Feel Close to Partner Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they feel close to their partner (or the person who is their main support), using a five-point Likert scale.","longName":"FAC04013","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA6235DD-4981-731A-E053-4EBD850AEBF5","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574360","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Satisfied with Sex Life Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are satisfied with their sex life, using a five-point Likert scale.","longName":"FAC04014","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA629A4C-CFD6-7F74-E053-4EBD850A700E","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574370","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Feel Sad Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they feel sad, using a five-point Likert scale.","longName":"FAC04015","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA62A836-12C9-559B-E053-4EBD850A2C62","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574374","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Satisfied with Coping with Illness Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are satisfied with how they are coping with their illness, using a five-point Likert scale.","longName":"FAC04016","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA6306FC-85A6-577E-E053-4EBD850A3037","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574378","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Losing Hope Against Illness Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are losing hope in the fight against their illness, using a five-point Likert scale.","longName":"FAC04017","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA631A30-5DD8-7E47-E053-4EBD850AA727","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574382","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Feel Nervous Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they feel nervous, using a five-point Likert scale.","longName":"FAC04018","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA62720C-8C06-56F0-E053-4EBD850AE8D9","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574418","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Worry About Dying Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they worry about dying, using a five-point Likert scale.","longName":"FAC04019","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA6356F4-C4A8-09C7-E053-4EBD850A65F2","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574422","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Worry About Worsening Condition Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they worry that their condition will get worse, using a five-point Likert scale.","longName":"FAC04020","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA627828-8B74-0916-E053-4EBD850A5A53","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. wz 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574426","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Able to Enjoy Life Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are Able to Enjoy Life, using a five-point Likert scale.","longName":"FAC04023","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA629E93-3C0C-589A-E053-4EBD850A0021","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"LISU","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. SL 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574430","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Accepted Illness Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they have Accepted their Illness, using a five-point Likert scale.","longName":"FAC04024","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA627828-8B95-0916-E053-4EBD850A5A53","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"LISU","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. SL 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574434","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Sleeping Well Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they have been Sleeping Well, using a five-point Likert scale.","longName":"FAC04025","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA663B75-C69E-034F-E053-4EBD850A81DD","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"LISU","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. SL 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574438","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Enjoy Things for Fun Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they have been Enjoy Things for Fun, using a five-point Likert scale.","longName":"FAC04026","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA627828-8BB6-0916-E053-4EBD850A5A53","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"LISU","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. SL 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574442","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Content with Quality of Life Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they have been Content with Quality of Life, using a five-point Likert scale.","longName":"FAC04027","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA663B75-C6C2-034F-E053-4EBD850A81DD","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"LISU","dateCreated":"2021-02-02","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. SL 2/2/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7575406","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Able to Work Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days they are Able to Work, using a five-point Likert scale.","longName":"FAC04021","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA761E4D-2C17-4923-E053-4EBD850AACCB","latestVersionIndicator":"Yes","beginDate":"2021-02-03","endDate":null,"createdBy":"LISU","dateCreated":"2021-02-03","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. SL 2/3/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7575411","version":"1","preferredName":"FACT-H&N Questionnaire Past Week How True Work is Fulfilling Score 5 Point Likert Scale","preferredDefinition":"Persons' stated observation of how true in the past 7 days their Work is Fulfilling, using a five-point Likert scale.","longName":"FAC04022","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA7469A7-3132-3D5A-E053-4EBD850A600B","latestVersionIndicator":"Yes","beginDate":"2021-02-03","endDate":null,"createdBy":"LISU","dateCreated":"2021-02-03","modifiedBy":"ZHANGWE","dateModified":"2021-02-04","changeNote":"Created for FACT H&N v4 questionnaire in Rave. SL 2/3/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7575450","version":"1","preferredName":"Patient Metastatic Malignant Neoplasm Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a malignant tumor that has spread from its original (primary) site of growth to another site close to or distant from the primary site as outlined in the study protocol.","longName":"METC_MALG_NEO_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA83FF86-A462-562B-E053-4EBD850A655C","latestVersionIndicator":"Yes","beginDate":"2021-02-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-02-04","modifiedBy":"TSESU","dateModified":"2023-09-07","changeNote":"2/4/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7584383","version":"1","preferredName":"Patient Topical Steroid Therapy Requirement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to the application of steroid medications to the skin for the treatment of various conditions as outlined in the study protocol.","longName":"TP_TX_REQMNTS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC07389F-72C9-5162-E053-4EBD850AD8AC","latestVersionIndicator":"Yes","beginDate":"2021-02-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-02-23","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"2/23/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7584478","version":"1","preferredName":"Patient Active Epstein-Barr Virus Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient has an active Epstein-Barr virus (EBV) as outlined in the study protocol.","longName":"ACT_EBV_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC18BF43-A62E-3F02-E053-4EBD850ACCF4","latestVersionIndicator":"Yes","beginDate":"2021-02-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-02-24","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":"2/24/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7589564","version":"1","preferredName":"Assessment Required Indicator","preferredDefinition":"An indication whether or not a disease response assessment was required.","longName":"RSREQ","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCA87815-6DEB-21EC-E053-4EBD850A6936","latestVersionIndicator":"Yes","beginDate":"2021-03-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-03-03","modifiedBy":"TAYLORT","dateModified":"2021-03-04","changeNote":"10347 NSV_TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7591789","version":"1","preferredName":"Treatment Cohort Study 10444 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10444 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10444_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD1F43C4-A5F6-5DC6-E053-4EBD850AA61E","latestVersionIndicator":"Yes","beginDate":"2021-03-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-09","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"3/9/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7591957","version":"1","preferredName":"Enrollment NCI COVID-19 in Cancer Patients Cohort Study Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions to determine eligibility for clinical trial participation, as outlined in the study protocol.","longName":"NCCAPS_COHRT_STDY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD32F476-26FE-243A-E053-4EBD850AAC96","latestVersionIndicator":"Yes","beginDate":"2021-03-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-10","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"3/10/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7591984","version":"1","preferredName":"Pediatric COVNET Large Genome-wide Association Study Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility questions related to a pediatric study regarding COVNET as outlined in the study protocol.","longName":"PEDS_COVNET_COHRT_STDY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD3341D6-3B46-34D2-E053-4EBD850A9380","latestVersionIndicator":"Yes","beginDate":"2021-03-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-10","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/10/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595591","version":"1","preferredName":"Patient Epstein-Barr Virus Positive Hodgkin Lymphoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to Epstein-Barr virus positive Hodgkin lymphoma as outlined in the study protocol.","longName":"EBV_HDG_LYMP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5B4D27-6FF3-16C6-E053-4EBD850ABDD0","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-12","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"3/12/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595606","version":"1","preferredName":"Patient Epstein-Barr Virus Positive Non-Hodgkin Lymphoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to Epstein-Barr virus positive Non-Hodgkin lymphoma as outlined in the study protocol.","longName":"EBV_NONHDG_LYMP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5AD7FE-A4C5-07E6-E053-4EBD850A69B1","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-12","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"03/12/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595766","version":"1","preferredName":"Patient Nasopharyngeal Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to a benign or malignant neoplasm affecting the nasopharynx as outlined in the study protocol.","longName":"NASOPHX_NEOPl_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD941EBC-9D4A-2F25-E053-4EBD850AE924","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595771","version":"1","preferredName":"Patient Leiomyosarcoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to an uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women as outlined in the study protocol.","longName":"LEMSTCMA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD9497F6-A873-5AAA-E053-4EBD850ABD5A","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2023-01-30","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595789","version":"1","preferredName":"Patient Primary Effusion Lymphoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to primary effusion lymphomas as outlined in the study protocol.","longName":"PT_PEL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD94DD4C-9EA0-4FCD-E053-4EBD850A50EC","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595790","version":"1","preferredName":"Patient Cervical Carcinoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator related to allow an individual to participate in a specific clinical trial regarding if a person receiving medical care, or treatment has the investigation, analysis and recognition of the presence of cervical carcinoma as outlined in the study protocol.","longName":"PT_CRX_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD951B97-3814-7CF9-E053-4EBD850AB789","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595798","version":"1","preferredName":"Patient Vaginal Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to a benign or malignant neoplasm affecting the vagina as outlined in the study protocol.","longName":"PT_VAG_NEOP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD9555A3-80EE-3501-E053-4EBD850AAFE7","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595808","version":"1","preferredName":"Patient Penile Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to the majority of penile carcinomas as outlined in the study protocol.","longName":"PT_PNL_CA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD9572CB-234C-2D2C-E053-4EBD850AADFC","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595813","version":"1","preferredName":"Patient Vulvar Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related a benign or malignant neoplasm that affects the vulva as outlined in the study protocol.","longName":"PT_VLR_NEOPL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD958E1C-8DEA-1D57-E053-4EBD850A8161","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595818","version":"1","preferredName":"Patient Merkel Cell Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related a benign or malignant neoplasm that affects the epidermal cell, primarily located in the basal layer, that is thought to function in tactile sensory perception as outlined in the study protocol.","longName":"PT_MC_NEOP_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD95B0D3-DC1A-7CF6-E053-4EBD850A0684","latestVersionIndicator":"Yes","beginDate":"2021-03-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-15","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"3/15/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7601815","version":"1","preferredName":"Specimen Shipping Instructions Text","preferredDefinition":"Text field to capture the shipping instructions for a specimen.","longName":"SHPINST","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDA6FA4D-0AF9-45A2-E053-4EBD850AE7EC","latestVersionIndicator":"Yes","beginDate":"2021-03-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-03-16","modifiedBy":"TAYLORT","dateModified":"2021-03-16","changeNote":"TL/Seed Study NSV.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7601832","version":"1","preferredName":"Person COVNET Human Study Subject Indicator","preferredDefinition":"An indication whether or not the individual is a participant in the \"COVNET: Large-scale Genome-wide Association Study and Whole Genome Sequencing of COVID-19 Severity\" study that is designed to identify common and rare germline genetic variants associated with susceptibility to severe or fatal COVID-19 disease.","longName":"COVNETYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDAA2D49-89A2-225B-E053-4EBD850A1BED","latestVersionIndicator":"Yes","beginDate":"2021-03-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-03-16","modifiedBy":"TAYLORT","dateModified":"2021-03-17","changeNote":"TL/NCICOVID NSV.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7604479","version":"1","preferredName":"Patient Metabolic Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to a congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process as outlined in the protocol.","longName":"METLIC_DIS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDBCD0BC-BF02-7D0A-E053-4EBD850A3021","latestVersionIndicator":"Yes","beginDate":"2021-03-17","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-17","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"3/17/21 ls","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7604770","version":"1","preferredName":"Treatment Cohort Study 10363 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10363 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10363_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDCF7448-BC93-300C-E053-4EBD850AD216","latestVersionIndicator":"Yes","beginDate":"2021-03-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-18","modifiedBy":"SOKKERL","dateModified":"2021-03-18","changeNote":"3/18/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7607232","version":"1.1","preferredName":"Treatment Cohort Study 10434 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10434 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10434_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16CE3FC-2B9C-704E-E053-4EBD850A8311","latestVersionIndicator":"Yes","beginDate":"2021-03-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"SOKKERL","dateModified":"2021-05-04","changeNote":"3/18/21ls . 5/3/21 reversion CDE  and VD deleted PVs .ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7614918","version":"1","preferredName":"Patient Neoplasm Visceral Involvement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to neoplasm affecting the internal organs as outlined in the study protocol.","longName":"NEO_VIS_INVLMT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE61C30E-8195-5F3F-E053-4EBD850A0858","latestVersionIndicator":"Yes","beginDate":"2021-03-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-25","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/25/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7615439","version":"1","preferredName":"Patient Kaposi Sarcoma Antiretroviral Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regards to treatment of retro-viral infections with medications that target the virus directly related to Kaposi sarcoma as outlined in the study protocol.","longName":"KS_ART_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE72EB22-201D-4A91-E053-4EBD850A4180","latestVersionIndicator":"Yes","beginDate":"2021-03-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-26","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"3/26/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7615815","version":"1","preferredName":"Treatment Cohort Study CITN-17 Code","preferredDefinition":"The code that represents the information pertaining to protocol CITN-17 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_CITN 17_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE735B9A-FE3E-3305-E053-4EBD850ABF22","latestVersionIndicator":"Yes","beginDate":"2021-03-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-03-26","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"3/26/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7621071","version":"1","preferredName":"Treatment Cohort Study PED-CITN-03 Code","preferredDefinition":"The code that represents the information pertaining to protocol PED-CITN-03 in which subsets of a defined population are identified.","longName":"PED_CITN_03_COHORT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEEFD45C-019C-1119-E053-4EBD850A940B","latestVersionIndicator":"Yes","beginDate":"2021-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-01","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":"PED_CITN_03; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7648193","version":"1","preferredName":"Patient Organ Involvement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to organ involvement as outlined in the study protocol.","longName":"ORGN_INVLMNT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C10913BF-46D9-047F-E053-4EBD850A570E","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-28","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":"4/28/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7648208","version":"1","preferredName":"Patient Measurable AL Amyloidosis Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial associated with measurable AL Amyloidosis Assessment as outlined in the study protocol.","longName":"MSRBL_ALAMYD_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C108AB81-CC49-117C-E053-4EBD850A2541","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-28","modifiedBy":"SOKKERL","dateModified":"2022-11-01","changeNote":"4/28/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7648212","version":"1","preferredName":"Patient Negation Disease or Disorder Consistent With Multiple Myeloma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patients meets the eligibility requirements for participation in a clinical trial for having no abnormal condition(s) consistent with multiple myeloma.","longName":"NO_DZ_CNST_MYL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1081B06-D96E-2430-E053-4EBD850AE35B","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-28","modifiedBy":"SOKKERL","dateModified":"2021-08-18","changeNote":"4/28/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7648228","version":"1","preferredName":"Patient Diarrhea Symptom Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether patient has diarrhea symptoms as outlined in the study protocol.","longName":"DIARR_SYMT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C10BE773-72E8-231B-E053-4EBD850A9895","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-28","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7648234","version":"2","preferredName":"Best Overall Response Sponsor Defined Code","preferredDefinition":"A character or string that represents the short code for the best overall disease response as defined by the sponsor.","longName":"BESTRESP_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05CC2CFD-1613-06EE-E063-731AD00AA31B","latestVersionIndicator":"Yes","beginDate":"2021-04-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-09-20","modifiedBy":"SOKKERL","dateModified":"2023-09-20","changeNote":"10329 CDISC NSV; TL.","administrativeNotes":"9/20/23 versioned to 2.0 to increase max VD length. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7648985","version":"1","preferredName":"Treatment Cohort Study 10075 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10075 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10075_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16DC77B-13B6-5C46-E053-4EBD850A0F3D","latestVersionIndicator":"Yes","beginDate":"2021-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-03","modifiedBy":"SOKKERL","dateModified":"2021-05-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7649417","version":"1","preferredName":"Treatment Cohort Study 10411 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10437 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10411_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1803ACA-4BAC-3369-E053-4EBD850A7FD4","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-04","modifiedBy":"SOKKERL","dateModified":"2021-08-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7651570","version":"1","preferredName":"Person Plasma Cell Myeloma Diagnosis Clinical Trial Eligibility Criteria  Code Indicator","preferredDefinition":"A code indcitor whether a person has a diagnosis of multiple myeloma as outlined in the study protocol.","longName":"PLSMA_MYL_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C182BBFA-22E8-6B88-E053-4EBD850A025E","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-04","modifiedBy":"SOKKERL","dateModified":"2021-08-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652513","version":"1","preferredName":"Label ID","preferredDefinition":"The numeric identifier of a descriptive marker that is attached to an object.","longName":"LBLID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1AEF7F6-8392-7B94-E053-4EBD850A0B48","latestVersionIndicator":"Yes","beginDate":"2021-05-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-05-06","modifiedBy":"TAYLORT","dateModified":"2021-05-06","changeNote":"10268 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652683","version":"1","preferredName":"Patient Diagnosis Malignant Neoplasm Therapeutic Procedure Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the diagnosis of malignant neoplasm and treatment as outlined in the study protocol.","longName":"DX_MAL_NEO_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1C18D5A-C0D9-50D5-E053-4EBD850A6BC2","latestVersionIndicator":"Yes","beginDate":"2021-05-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-07","modifiedBy":"SOKKERL","dateModified":"2024-02-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7652803","version":"1","preferredName":"Treatment Cohort Study 10005 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10005 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10005_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1FE47CD-0598-031B-E053-4EBD850ADC2E","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-10","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7668397","version":"1","preferredName":"Disease Response Result Indicator","preferredDefinition":"An indication whether or not disease response was achieved.","longName":"RSRESPYN","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2A24E72-98C6-72FD-E053-4EBD850ABD60","latestVersionIndicator":"Yes","beginDate":"2021-05-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-05-18","modifiedBy":"MMADDINENI","dateModified":"2023-06-07","changeNote":"10434 NSV; TL.","administrativeNotes":"05/07/2023-Added AQT for CADSR0002497-MM","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7671224","version":"1","preferredName":"Patient Grapefruit Avoidance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to abstaining from grapefruit as outlined in the study protocol.","longName":"PT_GRPFT_AVD_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3BA7BDE-3A3F-0C98-E053-4EBD850A7E78","latestVersionIndicator":"Yes","beginDate":"2021-06-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-01","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7678340","version":"1","preferredName":"Patient Acute Myeloid Leukemia Risk Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address the potential future harm that may arise from acute myeloid leukemia as outlined in the study protocol.","longName":"AML_RSK_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C42E0AC1-0439-7A0E-E053-4EBD850ABA50","latestVersionIndicator":"Yes","beginDate":"2021-06-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-07","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7678352","version":"1","preferredName":"Treatment Cohort Study 10417 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10417 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10417_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C42E231D-F994-6086-E053-4EBD850A7904","latestVersionIndicator":"Yes","beginDate":"2021-06-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-07","modifiedBy":"SOKKERL","dateModified":"2021-08-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7678359","version":"1","preferredName":"Treatment Assignment Code","preferredDefinition":"A coded response to indicate whether a specific treatment is assigned to the participant.","longName":"TX_ASSGNT_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C42F2CD3-98E2-63A5-E053-4EBD850A7EBB","latestVersionIndicator":"Yes","beginDate":"2021-06-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-07","modifiedBy":"SOKKERL","dateModified":"2021-08-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7678364","version":"1","preferredName":"Morphology Examination Date","preferredDefinition":"The date of the morphology examination represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"MODAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C43005D2-2853-3336-E053-4EBD850ACFD5","latestVersionIndicator":"Yes","beginDate":"2021-06-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-06-07","modifiedBy":"TAYLORT","dateModified":"2021-06-08","changeNote":"6/8/21 TL released.; 10363; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7678367","version":"1","preferredName":"Morphology Examination Performed Indicator","preferredDefinition":"An indication whether or not a morphology examination was performed.","longName":"MOPERF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C430CA08-B8FE-5A0B-E053-4EBD850A088E","latestVersionIndicator":"Yes","beginDate":"2021-06-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-06-07","modifiedBy":"TAYLORT","dateModified":"2021-06-08","changeNote":"6/8/21 TL released. 10363; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7715453","version":"1","preferredName":"Amyloidosis Organ Involvement Type","preferredDefinition":"A description of the organ involved in amyloidosis for disease response evaluations.","longName":"RSORGINV","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59750C7-2A89-5E6B-E053-4EBD850A40A3","latestVersionIndicator":"Yes","beginDate":"2021-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-06-25","modifiedBy":"TAYLORT","dateModified":"2021-06-25","changeNote":"10440 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7717899","version":"1","preferredName":"Patient Mixed Histology Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the presence and nature of mixed histologies.","longName":"MIX_HIST_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C68DF14B-D46F-7C08-E053-4EBD850AAABC","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-07","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":"10483; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7717924","version":"1","preferredName":"Patient Activating FGFR Gene Mutation Detection Method Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the means of identifying changes in the nucleotide sequence of an FGFR family gene.","longName":"FGFR_DET_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C68E3E91-45D9-0506-E053-4EBD850ACCA0","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-07","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":"10483; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7717956","version":"1","preferredName":"Patient Personal Medical History Prostate Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient's medical background of prostate cancer meets the eligibility requirements for participation in a clinical trial.","longName":"PMH_PC_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C68E86DC-66D5-3554-E053-4EBD850A4E31","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-07","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":"10483; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7725059","version":"1","preferredName":"Patient Therapeutic Procedure Or Disease Response Status Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the administration of therapeutic agents or the pathologic and/or clinical changes that result from treatment.","longName":"TX_OR_DRSTAT_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6A143D3-C71F-55EB-E053-4EBD850A1FED","latestVersionIndicator":"Yes","beginDate":"2021-07-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-08","modifiedBy":"SOKKERL","dateModified":"2022-04-27","changeNote":"10483;TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7735265","version":"1","preferredName":"Patient Biological Agent Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the administration of biotechnology-derived pharmaceutical agents made from living organisms or their products that includes recombinant proteins, monoclonal antibodies, and nucleic acids.","longName":"BIOAG_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6A1A3F5-3262-0EB2-E053-4EBD850A3CD8","latestVersionIndicator":"Yes","beginDate":"2021-07-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-08","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":"10483; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7735270","version":"1","preferredName":"Patient FGFR Inhibitor Therapeutic Procedure Occurrence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to treatments that inhibit the fibroblast growth factor receptor (FGFR).","longName":"FGFR_TX_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6A2D0BF-5DCE-565B-E053-4EBD850A8E0A","latestVersionIndicator":"Yes","beginDate":"2021-07-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-08","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":"10483; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7736579","version":"1","preferredName":"Tumor Clinical T Stage","preferredDefinition":"Extent of the primary tumor determined prior to treatment based on evidence obtained from clinical assessment parameters (physical examination, imaging, endoscopy, etc.). The AJCC staging version to use is protocol specific.","longName":"RSORRES_TSTAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6F12D6A-EB99-7CAB-E053-4EBD850A87AB","latestVersionIndicator":"Yes","beginDate":"2021-07-12","endDate":null,"createdBy":"TITARENI","dateCreated":"2021-07-12","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeNote":"07/12/2021 created for Theradex_TI","administrativeNotes":"9/26/23 Added alt OID, CCTG and AQT for CCTG ticket number CADSR0002884 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7736594","version":"1","preferredName":"Tumor Clinical N Stage","preferredDefinition":"The extent of nodal involvement of cancer as determined prior to treatment based on evidence obtained from clinical assessment parameters (physical examination, imaging, endoscopy, biopsy, surgical exploration, etc.).","longName":"RSORRES_NSTAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6F18FFF-2B27-31FD-E053-4EBD850A835D","latestVersionIndicator":"Yes","beginDate":"2021-07-12","endDate":null,"createdBy":"TITARENI","dateCreated":"2021-07-12","modifiedBy":"ZHWENDY","dateModified":"2022-08-11","changeNote":"07/12/2021 created for Theradex_TI","administrativeNotes":"8/11/2022: removed the AQT accidently added.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7736598","version":"1","preferredName":"Treatment Cohort Study 10476 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10476 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10476_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6F17C18-D797-5CE5-E053-4EBD850AB5E8","latestVersionIndicator":"Yes","beginDate":"2021-07-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-12","modifiedBy":"SOKKERL","dateModified":"2021-08-27","changeNote":"7/12/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7736603","version":"1","preferredName":"Tumor Clinical M Stage","preferredDefinition":"The absence or presence of distant metastases from cancer as determined prior to treatment based on evidence obtained from clinical assessment parameters (physical examination, imaging, endoscopy, biopsy, surgical exploration, etc.).","longName":"RSORRES_MSTAGE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6F17C18-D811-5CE5-E053-4EBD850AB5E8","latestVersionIndicator":"Yes","beginDate":"2021-07-12","endDate":null,"createdBy":"TITARENI","dateCreated":"2021-07-12","modifiedBy":"ZHANGWE","dateModified":"2021-07-13","changeNote":"07/12/2021 created for Theradex_TI","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7748761","version":"1","preferredName":"Patient Receive Other Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to receiving other treatment as outlined in the study protocol.","longName":"PT_RECV_OTH_THPY_IND_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C807B996-6C60-03E0-E053-4EBD850A8057","latestVersionIndicator":"Yes","beginDate":"2021-07-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-26","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7748836","version":"1","preferredName":"Patient Disease or Disorder Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress as outlined in the study protocol.","longName":"PT_DZ_DISDR_ASSESNT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C806AD18-6F2F-42F6-E053-4EBD850A65E7","latestVersionIndicator":"Yes","beginDate":"2021-07-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeNote":null,"administrativeNotes":"2023.4.5 AQT added per ticket request CADSR0002271. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7748851","version":"1","preferredName":"Patient Tobacco Nicotine Use Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to any tobacco, nicotine use as outlined in the study protocol.","longName":"PT_TOBCO_NICT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C809F58D-DF56-3A9F-E053-4EBD850AFCAB","latestVersionIndicator":"Yes","beginDate":"2021-07-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-26","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7748937","version":"1","preferredName":"Treatment Cohort Study 10466 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10466 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10466_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C81B87E4-461B-455A-E053-4EBD850AA1A0","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-27","modifiedBy":"SOKKERL","dateModified":"2021-08-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7755535","version":"1","preferredName":"Patient Anticoagulation Therapy Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating a patient meets the eligibility criteria for participation in a clinical trial with relating  to receiving anti-coagulation therapy as outlined in the study protocol.","longName":"PT_ANTIGL_THPY_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C893A1AF-3D2D-0DCE-E053-4EBD850AD177","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-02","modifiedBy":"CLOHNES","dateModified":"2023-11-16","changeNote":null,"administrativeNotes":"11/16/23 Added alt OID and AQT for CCTG ticket number CADSR0003085 cjl","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7755539","version":"1","preferredName":"Patient Neoplasm Relate Pain Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to tumor pain as outlined in the study protocol.","longName":"PT_NPLSM_RLT_PN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C89438AB-65AD-3D45-E053-4EBD850A861E","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-02","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":"8/2/21 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7755562","version":"1","preferredName":"Laboratory Procedure Symptomatic Hypercalcemia Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation as to whether the patient has abnormally high concentration of calcium in the peripheral blood that involves testing or manipulating a sample of blood as outlined in the study protocol.","longName":"SYMT_HYPCALC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C894E9FE-9BB3-7594-E053-4EBD850A6966","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-02","modifiedBy":"SOKKERL","dateModified":"2022-02-28","changeNote":"8/2/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7755568","version":"1","preferredName":"Patient Metastatic Disease Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical trial that are related to metastatic disease and administration of therapeutic agents as outlined in the study protocol.","longName":"MET_DZ_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C896949B-1EA0-0B3A-E053-4EBD850A18E7","latestVersionIndicator":"Yes","beginDate":"2021-08-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-02","modifiedBy":"SOKKERL","dateModified":"2022-02-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7759583","version":"1","preferredName":"Patient Off Treatment Disease Progression Occurrence Indicator","preferredDefinition":"An indicator if patient is off treatment due to disease progression.","longName":"PT_OFFTX_DIZ_PROG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8D56679-95CD-7903-E053-4EBD850A6199","latestVersionIndicator":"Yes","beginDate":"2021-08-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-05","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7762285","version":"1","preferredName":"Patient Combination Drug Therapy Administration Indicator","preferredDefinition":"An indicator weather the patient will be treated with combination drug therapy.","longName":"PT_COMBIN_DRG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C920DA5F-CEC5-0F17-E053-4EBD850A3F52","latestVersionIndicator":"Yes","beginDate":"2021-08-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-09","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7762289","version":"1","preferredName":"Patient Monoclonal Antibody Combination Inclusion Criteria Indicator","preferredDefinition":"An indicator weather the patient meets the criteria to participate in combination antibody therapy as outlined in the study protocol.","longName":"MONTX_COMBTN_INC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9212917-FE93-0FEB-E053-4EBD850A9FC8","latestVersionIndicator":"Yes","beginDate":"2021-08-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-09","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7763818","version":"1","preferredName":"Patient Ethinyl Estradiol Oral Contraceptive Use Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that is related to the use of Ethinyl estradiol containing  oral contraceptives as outlined in the study protocol.","longName":"ETHEST_ORLCONSPER_USE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C934EF67-5BB5-3EEB-E053-4EBD850AD4E6","latestVersionIndicator":"Yes","beginDate":"2021-08-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-10","modifiedBy":"SOKKERL","dateModified":"2021-09-14","changeNote":"ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7768100","version":"1","preferredName":"Concomitant Medication Use Status","preferredDefinition":"A description regarding the use of a concomitant medication at a particular time.","longName":"CMDSUSE","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9F077A1-F637-61D8-E053-4EBD850A7BB4","latestVersionIndicator":"Yes","beginDate":"2021-08-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-08-19","modifiedBy":"TAYLORT","dateModified":"2021-08-20","changeNote":"10437 NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7771559","version":"1","preferredName":"Exploratory Cohort Study Enrollment Prior Medical History Malignancy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions to determine eligibility for clinical trial participation in an exploratory cohort study with previous history of malignancy as outlined in the protocol.","longName":"EXPL_COH_HX MAL_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA77284D-3CC2-2FD4-E053-4EBD850A086B","latestVersionIndicator":"Yes","beginDate":"2021-08-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-26","modifiedBy":"SOKKERL","dateModified":"2022-01-05","changeNote":"8/26/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7771584","version":"1","preferredName":"Treatment Cohort Study 10507 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10507 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10507_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA89E28D-9A4B-1C1B-E053-4EBD850A7F3D","latestVersionIndicator":"Yes","beginDate":"2021-08-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-27","modifiedBy":"SOKKERL","dateModified":"2023-07-26","changeNote":"curated for prot10507 ls 8/27/21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7774000","version":"1","preferredName":"Brief Pain Inventory Short Form Questionnaire 1 Have Pain Other Than Everyday Kind of Pain Indicator","preferredDefinition":"A person's indication whether pain, other than everyday kinds of pain such as minor headaches, sprains, and toothaches, is being experienced today.","longName":"QSORRES_BPI201","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA9154CF-3F3C-71B4-E053-4EBD850A8247","latestVersionIndicator":"Yes","beginDate":"2021-08-27","endDate":null,"createdBy":"TITARENI","dateCreated":"2021-08-27","modifiedBy":"SOKKERL","dateModified":"2022-01-05","changeNote":"Created on 08/27/2021 for CDISC CDE_10437_24AUG2021_Measures_ti","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7774056","version":"1","preferredName":"Brief Pain Inventory Short Form Questionnaire 7 Treatment or Medication Receiving for Pain Name","preferredDefinition":"A person's stated observation that describes treatment or medication name currently being received for pain.","longName":"QSORRES_BPI207","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA905B3F-6C11-6B4A-E053-4EBD850A2B1D","latestVersionIndicator":"Yes","beginDate":"2021-08-27","endDate":null,"createdBy":"TITARENI","dateCreated":"2021-08-27","modifiedBy":"SOKKERL","dateModified":"2022-01-05","changeNote":"Created on 08/27/2021 CDISC CDE_10437_24AUG2021_Measures_ti","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7775199","version":"1","preferredName":"Patient Medical Record Documentation Cancer Treatment Specimen Consent Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related patients consent to medical documentation of cancer treatment and specimen result as outlined in the study protocol.","longName":"MX_ CA_TX_SPEC_CONST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAC7375F-E8B1-2A0F-E053-4EBD850A7F6F","latestVersionIndicator":"Yes","beginDate":"2021-08-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-08-30","modifiedBy":"SOKKERL","dateModified":"2022-01-05","changeNote":"8/30/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7775228","version":"3","preferredName":"Brief Pain Inventory Short Form Questionnaire 2A Feel Pain Diagram Area Shading Anatomic Site","preferredDefinition":"A description of the anatomical location of where pain is felt, using a diagram.","longName":"QSORRES_BPI202A","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B32107-AB2D-1459-E053-731AD00A667B","latestVersionIndicator":"Yes","beginDate":"2022-04-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-02","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeNote":"8/30/2021 created for spreadsheet 'CDISC  CDE_10437_24AUG2021_Measures.xlsx', wz","administrativeNotes":"2022.9.2 Versioned to reflect CT Pkg release. ak  2022.11.28 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7775229","version":"3","preferredName":"Brief Pain Inventory Short Form Questionnaire 2B Area that Hurts Most Diagram Anatomic Site","preferredDefinition":"A description of the anatomical location of where pain is felt the most, using a diagram.","longName":"QSORRES_BPI202B","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B31159-1B44-0A2C-E053-731AD00AFF94","latestVersionIndicator":"Yes","beginDate":"2021-08-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-02","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeNote":"8/30/2021 created for spreadsheet 'CDISC  CDE_10437_24AUG2021_Measures.xlsx', wz","administrativeNotes":"2022.9.2 Versioned to reflect CT Pkg 50 release. ak  2022.11.28 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7788949","version":"1","preferredName":"Treatment Cohort Study 10499 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10499 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10499_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD00B9AF-6CDA-4772-E053-4EBD850A62F4","latestVersionIndicator":"Yes","beginDate":"2021-09-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-09-27","modifiedBy":"SOKKERL","dateModified":"2022-01-05","changeNote":"9/27/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7792984","version":"1","preferredName":"Patient Treated Stable Central Nervous System Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to providing treatment to the central nervous system and patient is stable as outlined in the study protocol.","longName":"TX_STBL_CNS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD37DF6A-05B3-36FE-E053-4EBD850AD0FC","latestVersionIndicator":"Yes","beginDate":"2021-09-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-09-30","modifiedBy":"SOKKERL","dateModified":"2022-01-05","changeNote":"9/30/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7799236","version":"1","preferredName":"Treatment Cohort Study 10402 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10402 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10402_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEDBBCBA-19B3-3335-E053-4EBD850ADD4C","latestVersionIndicator":"Yes","beginDate":"2021-10-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-21","modifiedBy":"SOKKERL","dateModified":"2021-10-21","changeNote":"10/21/21 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7799611","version":"1","preferredName":"Vaccination Status","preferredDefinition":"The response indicating the status of an individual's vaccinations.","longName":"CMVXSTAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEE4F4EE-52C1-3C45-E053-4EBD850A8E65","latestVersionIndicator":"Yes","beginDate":"2021-10-21","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-10-21","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeNote":"10/21/2021 created for NCICOVID study, wz","administrativeNotes":"7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801245","version":"1","preferredName":"Biospecimen Original Result or Finding Sponsor Defined Outcome","preferredDefinition":"The outcome of the biospecimen test or examination as originally received or collected, as defined by the sponsor.","longName":"BSORRES_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF7EEB94-B993-3368-E053-4EBD850A069C","latestVersionIndicator":"Yes","beginDate":"2021-10-29","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-10-29","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"10/29/2021, created for Specimen Tracking, wz.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801771","version":"1","preferredName":"Medical History Event Date Unknown Checkbox Indicator","preferredDefinition":"A checkbox indicator used when the date of the subject's medical history event is unknown.","longName":"MHDATUNK","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFD02C27-FBA8-7183-E053-4EBD850A0020","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-11-02","changeNote":"NSV curated for Seed Study; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7802115","version":"1","preferredName":"Biospecimen Assay Sponsor Defined Name","preferredDefinition":"The name of the assay procedure as defined by the sponsor.","longName":"ASYNAM_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE50788-6339-1FAE-E053-4EBD850A837F","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-11-03","modifiedBy":"ZHANGWE","dateModified":"2021-11-05","changeNote":"11/3/2021 created for Biospecimen Tracking, wz.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7802173","version":"2","preferredName":"Biospecimen Test or Examination Sponsor Defined Name","preferredDefinition":"The name of the biospecimen test or examination used to obtain the measurement or finding, as defined by the sponsor.","longName":"BSTEST_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7998EAE-FCAE-5D8F-E053-4EBD850A1E63","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-02-09","modifiedBy":"SOKKERL","dateModified":"2022-02-18","changeNote":"11/3/2021 created for Biospecimen Tracking, wz. Versioned CDE and VD Ls 2/9/2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7826395","version":"1","preferredName":"Biospecimen Test Failure Reason","preferredDefinition":"The reason that the biospecimen test or examination failed.","longName":"BSREASF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D072F262-698D-55ED-E053-4EBD850AE33F","latestVersionIndicator":"Yes","beginDate":"2021-11-10","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-11-10","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"11/10/2021 created for Specimen Tracking, wz.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7843540","version":"1","preferredName":"Patient DNA Damage Response Deficiency Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator related to DNA repair deficiency caused by mutations in the genes involved in the DNA damage response and/or DNA repair as outlined in the study protocol.","longName":"PT_DDR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D18979CA-0EC6-4B7A-E053-4EBD850AEF47","latestVersionIndicator":"Yes","beginDate":"2021-11-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-24","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":"11/24/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7843548","version":"1","preferredName":"Laboratory Measurement Test or Examination Detail Sponsor Defined Type","preferredDefinition":"The detail of the laboratory examination used to obtain the measurement or finding.","longName":"LBTSTDTL_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D18DDD64-0914-6739-E053-4EBD850AFAD6","latestVersionIndicator":"Yes","beginDate":"2022-06-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-11-24","modifiedBy":"SOKKERL","dateModified":"2022-06-13","changeNote":"11/24/2021 created for IFA form, wz.","administrativeNotes":"released QRTLY metrics. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7847925","version":"1","preferredName":"Experimental Result Finding Location Text","preferredDefinition":"The text description for the location where the laboratory result was observed","longName":"LBRESLOC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D233621C-55DF-4305-E053-4EBD850A42A0","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-12-02","modifiedBy":"TITARENI","dateModified":"2021-12-27","changeNote":"12/02/2021 created for IFA forms, wz.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7848453","version":"1","preferredName":"Patient Measurable Disease Response Evaluation Criteria In Lymphoma Lugano Classification Oncology Response Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to measurable disease according to the RECIL, Lugano Classification Oncology criteria as outlined in the study protocol.","longName":"RECIL_LCOR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D27C0047-1AC0-69A3-E053-4EBD850AA8CA","latestVersionIndicator":"Yes","beginDate":"2021-12-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-06","modifiedBy":"SOKKERL","dateModified":"2023-06-08","changeNote":"12/6/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7849210","version":"1","preferredName":"Intervention or Procedure Complete Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation for questions related to an intervention or procedure was completed as outlined in the study protocol.","longName":"INVPR_PRR_CMPLT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2A4241B-CF5C-2EE8-E053-4EBD850A11DF","latestVersionIndicator":"Yes","beginDate":"2021-12-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-08","modifiedBy":"SOKKERL","dateModified":"2022-02-25","changeNote":"12/8/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7849664","version":"1","preferredName":"Treatment Cohort Study 10490 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10490 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10490_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2A6CA67-0159-17E5-E053-4EBD850A08F2","latestVersionIndicator":"Yes","beginDate":"2021-12-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-08","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":"12/8/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7978126","version":"1","preferredName":"Fresh Tissue Specimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to obtaining fresh tissue specimen as as outlined in the study protocol.","longName":"FRSH_TIS_SPEC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D347CDBF-BCAF-4160-E053-4EBD850A192B","latestVersionIndicator":"Yes","beginDate":"2021-12-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-16","modifiedBy":"SOKKERL","dateModified":"2022-12-20","changeNote":"12/16/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7982579","version":"1","preferredName":"Patient Programmed Cell Death 1 Ligand 1 Immunohistochemistry Staining Method Combined Positive Score Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address the combined positivity score in cells for the presence of the programmed cell death 1 ligand 1 protein that is encoded by the human CD274 gene observed immunohistochemical staining method technique outcome as outlined in the study protocol.","longName":"PDL-IHC_CPS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3950AAF-F114-1DF5-E053-4EBD850A6F32","latestVersionIndicator":"Yes","beginDate":"2021-12-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-20","modifiedBy":"SOKKERL","dateModified":"2021-12-21","changeNote":"12/20/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7982584","version":"1","preferredName":"Patient Positive Pregnancy Test Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address a positive pregnancy test as outlined in the study protocol.","longName":"PT_POS_TST _PREG_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D396DCAB-C277-4FD4-E053-4EBD850AB4DD","latestVersionIndicator":"Yes","beginDate":"2021-12-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-20","modifiedBy":"SOKKERL","dateModified":"2023-06-12","changeNote":"12/20/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7982588","version":"1","preferredName":"Patient Serum Total Cholesterol And Triglyceride Measurement Outcome Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the eligibility requirements regarding cholesterol and  triglyceride serum levels as outlined in the study protocol.","longName":"PT_CHO_TRI_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3958632-DE7D-20EB-E053-4EBD850A01C9","latestVersionIndicator":"Yes","beginDate":"2021-12-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-20","modifiedBy":"SOKKERL","dateModified":"2022-01-18","changeNote":"12/20/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7982640","version":"1","preferredName":"Patient Oropharyngeal Carcinoma Known HPV Status p16 Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions to participate in a clinical study related to oropharyngeal cancer, and neoplastic sample that is positive or negative for expression of CDKN2A-p16 known related to HPV as outlined in the study protocol.","longName":"PT_ORL_CA_HPV_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D39A6883-AB49-6FBF-E053-4EBD850A6FD6","latestVersionIndicator":"Yes","beginDate":"2021-12-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-20","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeNote":"12/20/21 ls","administrativeNotes":"7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7984683","version":"1","preferredName":"Treatment Cohort Study 10496 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10496 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10496_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3A96A10-CC1B-1D42-E053-4EBD850A5A45","latestVersionIndicator":"Yes","beginDate":"2021-12-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-21","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7990980","version":"1","preferredName":"Patient Diabetes Mellitus Require Therapeutic Insulin Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that is related a metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization that requires therapeutic insulin as outlined in the study protocol.","longName":"DM_REQ_INSULIN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3AA01A9-A807-1D3F-E053-4EBD850AA4E3","latestVersionIndicator":"Yes","beginDate":"2021-12-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-12-21","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8002731","version":"1","preferredName":"Microscopic Findings Planned Time Point Clinical Study Sponsor Defined Name","preferredDefinition":"The planned point in time related to microscopic evaluations as defined by the sponsor.","longName":"MITPT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D56426DC-412E-6D62-E053-4EBD850A3E76","latestVersionIndicator":"Yes","beginDate":"2022-01-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-12","modifiedBy":"TAYLORT","dateModified":"2022-01-13","changeNote":"IHC/TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8003941","version":"1","preferredName":"Patient Invasive Breast Carcinoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation for questions related to the diagnosis of invasive breast cancer as as outlined in the study protocol.","longName":"IBC_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5DC05CD-4DBE-5B3D-E053-4EBD850ABE26","latestVersionIndicator":"Yes","beginDate":"2022-01-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-01-18","modifiedBy":"SOKKERL","dateModified":"2022-01-24","changeNote":"1/18/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8003945","version":"1","preferredName":"Patient Diabetes Mellitus Oral Medication Use Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related the use of oral medication for the management of a metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization as outlined in the study protocol.","longName":"DM_ORL_MEDS_USE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5DCA4B7-8FC2-7777-E053-4EBD850A539F","latestVersionIndicator":"Yes","beginDate":"2022-01-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-01-18","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":"1/18/22","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8003950","version":"1","preferredName":"Patient Cardiopulmonary Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to an evaluation of cardiopulmonary functioning, as outlined in the study protocol.","longName":"CRPLMY_ASSESS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5DD52C4-B8B9-492E-E053-4EBD850AF345","latestVersionIndicator":"Yes","beginDate":"2022-01-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-01-18","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":"1/18/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8004146","version":"1","preferredName":"Treatment Cohort Study 10480 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10480 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10480_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5DD6A38-78A1-0F14-E053-4EBD850AF8F8","latestVersionIndicator":"Yes","beginDate":"2022-01-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-01-18","modifiedBy":"SOKKERL","dateModified":"2022-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8004147","version":"1","preferredName":"Biospecimen Other Failure Reason Text","preferredDefinition":"A free text field to provide the other reason for why the biospecimen test or examination failed.","longName":"BSREASF_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5DFD517-9F69-3143-E053-4EBD850AD5F3","latestVersionIndicator":"Yes","beginDate":"2022-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-18","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"Specimen tracking; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8004152","version":"1","preferredName":"Biospecimen Sponsor Defined Identifier","preferredDefinition":"The sponsor-defined numeric identifier of a specimen.","longName":"BSSPID","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5DD52C4-B8EF-492E-E053-4EBD850AF345","latestVersionIndicator":"Yes","beginDate":"2022-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-18","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"Specimen tracking; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8004179","version":"1","preferredName":"Biospecimen Test Sponsor Defined Category","preferredDefinition":"The collection of values for biospecimen test as defined by the sponsor.","longName":"BSCAT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5E15AA4-DB91-335B-E053-4EBD850A320A","latestVersionIndicator":"Yes","beginDate":"2022-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-18","modifiedBy":"TAYLORT","dateModified":"2022-02-15","changeNote":"Specimen tracking; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8004201","version":"1","preferredName":"Patient Progressive Castration-Resistant Prostate Carcinoma Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation related to the assessments of activities that produce an effect, or that is intended to alter the course of progressive CRPR as outlined in the protocol.","longName":"PRG_CRPR_INVN_PRDR_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5EFFBBF-6F0E-78A5-E053-4EBD850A0CAD","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-01-19","modifiedBy":"SOKKERL","dateModified":"2023-03-30","changeNote":"1/19/22 ls","administrativeNotes":"LS released part of Quarterly metric review","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8004237","version":"1","preferredName":"Patient New York Heart Association Class Assessment Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A code indicator whether the patient has cardiac disease classified by the NYHA as outlined in the study protocol.","longName":"NYHA_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5F12E73-32D8-6365-E053-4EBD850AFEF6","latestVersionIndicator":"Yes","beginDate":"2022-01-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-01-19","modifiedBy":"SOKKERL","dateModified":"2022-08-10","changeNote":"1/19/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8014404","version":"1","preferredName":"Patient Biopsy Assessment Intervention or Procedure Clinical Trial Eligibility Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the determination of biopsies to establish a diagnosis to interventional strategies as outlined in the study protocol.","longName":"BX_ASMT_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68394E5-96D1-28CE-E053-4EBD850A2665","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-01-26","modifiedBy":"SOKKERL","dateModified":"2022-12-20","changeNote":"1/26/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8038914","version":"1","preferredName":"Patient Histologic Confirmation Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regards to a histologically confirmed disease.","longName":"CONF_HSTL_DIS_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7FFBBE6-65C2-6637-E053-4EBD850A489C","latestVersionIndicator":"Yes","beginDate":"2022-02-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-02-14","modifiedBy":"SOKKERL","dateModified":"2023-05-30","changeNote":"2022-2-14 ak Created for protocol 10144.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8038920","version":"1","preferredName":"Patient Therapeutic Procedure Platinum Compound Ineligibility Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to platinum therapy ineligibility as outlined in the study protocol.","longName":"THRP_PLTM_INELG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D800DE17-FCF1-3D5A-E053-4EBD850A8BCC","latestVersionIndicator":"Yes","beginDate":"2022-02-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-02-14","modifiedBy":"KUMMEROA","dateModified":"2022-02-14","changeNote":"2022-2-14 ak Created for protocol 10183. Released per Theradex review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8038924","version":"1","preferredName":"Patient Therapeutic Procedure Ineligibility Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to therapy ineligibility as outlined in the study protocol.","longName":"THRP_INELG_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D801209E-FF05-4B3F-E053-4EBD850AB9BF","latestVersionIndicator":"Yes","beginDate":"2022-02-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-02-14","modifiedBy":"SOKKERL","dateModified":"2022-08-09","changeNote":"2022-2-14 ak Created for protocol 10183. Released per Theradex review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8053719","version":"1","preferredName":"Patient Advanced Soft Tissue Sarcoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address a sarcoma of soft tissue that has spread extensively to other anatomic sites or is no longer responding to treatment as outlined in the study protocol.","longName":"ADV_ST_SARC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8B6B517-6479-2CE8-E053-4EBD850AC4E5","latestVersionIndicator":"Yes","beginDate":"2022-02-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-02-23","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":"2/23/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8057630","version":"1","preferredName":"Patient Other Medical Contraindicated Finding Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response regarding whether there were additional or unlisted medical contraindications of patient as outlined in the study protocol.","longName":"PT_OMD_CIND_FND_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8C3C855-DEAE-51EB-E053-4EBD850A0AD1","latestVersionIndicator":"Yes","beginDate":"2022-02-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-02-24","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8058285","version":"1","preferredName":"Treatment Cohort Study 10504 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10504 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10504_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8D87B22-0CDC-11F1-E053-4EBD850AF837","latestVersionIndicator":"Yes","beginDate":"2022-02-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-02-25","modifiedBy":"SOKKERL","dateModified":"2022-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8067932","version":"1","preferredName":"Patient Receive Somatic Mutation Analysis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study related to a procedure used to detect and identify mutations in the genome of a somatic cell sample as outlined in the study protocol..","longName":"SOM_ANYLS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9511AE1-14F6-53C1-E053-4EBD850ABB62","latestVersionIndicator":"Yes","beginDate":"2022-03-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-03","modifiedBy":"TYRRELLM","dateModified":"2023-12-07","changeNote":null,"administrativeNotes":"12.07.2023 Add AQT per ticket request CADSR0003164_mmt\r\n2023.11.22 AQT added per ticket request CADSR0003113. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8072501","version":"1","preferredName":"Patient Medical History Autoimmune Cytopenia Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study regarding a medical history of an autoimmune blood disease or disorders as outlined in the study protocol.","longName":"MHX_AUTCYP_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9B93932-680B-4F5F-E053-4EBD850AC11B","latestVersionIndicator":"Yes","beginDate":"2022-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-08","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":"3/8/22 ls","administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002682. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8077967","version":"1","preferredName":"Biospecimen Events Domain Other Failure Reason Text","preferredDefinition":"A free text field to provide the other reason for biospecimen collection and/or storage failure.","longName":"BEREASF_OTH","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9D155F8-AB96-381E-E053-4EBD850AF2D1","latestVersionIndicator":"Yes","beginDate":"2022-03-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-09","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"Leidos Biospecimen Roadmap; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8078618","version":"1","preferredName":"Biospecimen Events Domain Event Sponsor Defined Outcome","preferredDefinition":"Terminology assigned by the sponsor to the codelist associated with the outcome of biospecimen collection and/or storage.","longName":"BEOUT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E41524-B5D8-49BD-E053-4EBD850AE30A","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-10","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"Leidos Biospecimen Roadmap;TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8081470","version":"1","preferredName":"Biospecimen Events Domain Vendor Sponsor Defined Name","preferredDefinition":"Terminology assigned by the sponsor to the codelist associated with the vendor that performs a biospecimen assessment or examination.","longName":"BENAM_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9F1C569-D822-6B39-E053-4EBD850A88B6","latestVersionIndicator":"Yes","beginDate":"2022-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-11","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"Leidos Biospecimen Roadmap; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8081471","version":"1","preferredName":"Biospecimen Events Domain Reported Event Term Sponsor Defined Type","preferredDefinition":"Terminology assigned by the sponsor to the codelist associated with the biospecimen event observation.","longName":"BETERM_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9F1C569-D861-6B39-E053-4EBD850A88B6","latestVersionIndicator":"Yes","beginDate":"2022-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-11","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"Leidos Biospecimen Roadmap; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8081472","version":"1","preferredName":"Biospecimen Events Domain Other Action Taken Sponsor Defined Type","preferredDefinition":"Terminology assigned by the sponsor to the codelist associated with the other activity for biospecimen collection and/or storage.","longName":"BEACNOTH_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9F1C569-D888-6B39-E053-4EBD850A88B6","latestVersionIndicator":"Yes","beginDate":"2022-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-11","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"Leidos Biospecimen Roadmap; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8081473","version":"1","preferredName":"Biospecimen Events Domain Failure Sponsor Defined Reason","preferredDefinition":"Terminology assigned by the sponsor to the codelist associated with the reason biospecimen collection and/or storage failed.","longName":"BEREASF_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9F1C569-D8AF-6B39-E053-4EBD850A88B6","latestVersionIndicator":"Yes","beginDate":"2022-03-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-11","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"Leidos Biospecimen Roadmap; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8081490","version":"1","preferredName":"Person Prior Platinum Compound Chemotherapy Exposure Eligibility Status","preferredDefinition":"The status of whether a subject is suitable for enrollment in a study based on prior exposure to platinum compound chemotherapy.","longName":"PLT_CHEM_EXPO_ELIG_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9F194E8-6E2E-1AE0-E053-4EBD850AFEB9","latestVersionIndicator":"Yes","beginDate":"2022-03-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-11","modifiedBy":"SOKKERL","dateModified":"2022-03-11","changeNote":"3/11/22","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8092562","version":"1","preferredName":"Biospecimen Events Domain Details Sponsor Defined Outcome","preferredDefinition":"Terminology assigned by the sponsor to the codelist associated with the outcome of biospecimen collection and/or storage.","longName":"BEOUTDTL_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA58D102-D73A-4C33-E053-4EBD850A14F6","latestVersionIndicator":"Yes","beginDate":"2022-03-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-16","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"Leidos Biospecimen Roadmap; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8112873","version":"1","preferredName":"Female Patient Hormone Replacement Therapy Contraception Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine eligibility for clinical trial participation with regards to female patients on hormonal therapy agrees to contraception to prevent pregnancy as outlined in the study protocol.","longName":"HRT_CTCPT_AGRE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DABC550E-054F-1846-E053-4EBD850A6B1C","latestVersionIndicator":"Yes","beginDate":"2022-03-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-21","modifiedBy":"SOKKERL","dateModified":"2022-03-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8115349","version":"1","preferredName":"Treatment Cohort Study 10495 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10495 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10495_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACDE99F-2B9A-77C6-E053-4EBD850A7844","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-22","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8119786","version":"1","preferredName":"Patient Skin Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to determine eligibility for clinical trial participation for questions related to any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs as outlined in the study protocol.","longName":"SKN_DIS_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAFA86B2-BF5C-0CC7-E053-4EBD850A3DB7","latestVersionIndicator":"Yes","beginDate":"2022-06-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-24","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":"3/24/22 ls","administrativeNotes":"6/21/22 Q- metric released. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8119791","version":"1","preferredName":"Patient Complete Therapeutic Procedure Remission Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether a patient meets the eligibility criteria for enrollment onto a clinical trial regarding completing treatment and the disease is in remission as outlined in the study protocol.","longName":"COM_TX_REMISN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAFAEA6C-5AAE-1F0F-E053-4EBD850ABD80","latestVersionIndicator":"Yes","beginDate":"2022-03-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-24","modifiedBy":"SOKKERL","dateModified":"2022-08-22","changeNote":"3/24/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8119871","version":"1","preferredName":"Female Patient Contraception Oocyte Donor Agreement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation with regards to female patients donating their eggs and agreement to use contraception as outlined in the study protocol.","longName":"CONTR_OCYT_DON_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB09D357-1871-4F73-E053-4EBD850A199B","latestVersionIndicator":"Yes","beginDate":"2022-03-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-25","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8119910","version":"1","preferredName":"Treatment Cohort Study 10508 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10508 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10508_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0A58B4-1DBB-4C16-E053-4EBD850A3737","latestVersionIndicator":"Yes","beginDate":"2022-03-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-25","modifiedBy":"SOKKERL","dateModified":"2022-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8127572","version":"1","preferredName":"Date of Specimen Collection","preferredDefinition":"The date on which the biospecimen sample or data was collected.","longName":"BSDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB5DD617-3631-54CE-E053-4EBD850ABA03","latestVersionIndicator":"Yes","beginDate":"2022-03-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-29","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"TL created for Leidos project.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131155","version":"1","preferredName":"Auditory Test Performed Indicator","preferredDefinition":"An indication whether or not a planned audiologic test was performed.","longName":"AUPERF","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB9B4554-2FC5-0765-E053-4EBD850ADFC5","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-01","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"1057; CDISC consultant came up with this custom domain. AU will house Auditory data.  TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131156","version":"1","preferredName":"Auditory Test Date","preferredDefinition":"The date the audiologic test was performed represented in an unambiguous date format (e.g., DD-MON-YYYY).","longName":"AUDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB9B1A7A-4E10-5D55-E053-4EBD850A53BF","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-01","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"1057; CDISC consultant came up with this custom domain. AU will house Auditory data.  TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131173","version":"2","preferredName":"Auditory Test Location","preferredDefinition":"A description of the anatomical location for the audiologic procedure.","longName":"AULOC","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B301D3-B9B8-088F-E053-731AD00AE48E","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-09-02","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeNote":"2022-4-14 ak Updated to reflect CT Pkg 49 updates. 1057; CDISC consultant came up with this custom domain. AU will house Auditory data.  TL.","administrativeNotes":"2022.9.2 Versioned to reflect CT Pkg 50 updates.  ak  2022.11.28 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131183","version":"1","preferredName":"Auditory Test Result","preferredDefinition":"Result of the finding as originally received or collected.","longName":"AUORRES","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB9B4554-2FEC-0765-E053-4EBD850ADFC5","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-01","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"1057; CDISC consultant came up with this custom domain. AU will house Auditory data.  TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131184","version":"1","preferredName":"Auditory Test or Examination Detail","preferredDefinition":"Further description of the auditory test.","longName":"AUTSTDTL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB9C07CB-22FD-7132-E053-4EBD850AF1DB","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-01","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"1057; CDISC consultant came up with this custom domain. AU will house Auditory data.  TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131186","version":"1","preferredName":"Auditory Test Laterality","preferredDefinition":"A qualifier for the side of the body related to auditory tests.","longName":"AULAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB9B4554-3013-0765-E053-4EBD850ADFC5","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-01","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"1057; CDISC consultant came up with this custom domain. AU will house Auditory data.  TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131255","version":"1","preferredName":"Auditory Test Method Type","preferredDefinition":"The technique used to administer the audiologic assessment.","longName":"AUMETHOD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB9B1A7A-4E62-5D55-E053-4EBD850A53BF","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-01","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"1057; CDISC consultant came up with this custom domain. AU will house Auditory data.  TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8131256","version":"1","preferredName":"Patient Malignant Neoplasm And Positive Finding Lesion Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to malignancies or positive lesions.","longName":"MLG_POS_LES_DZ_ELIG","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB9C958B-B592-44C3-E053-4EBD850A9BBC","latestVersionIndicator":"Yes","beginDate":"2022-04-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-01","modifiedBy":"KUMMEROA","dateModified":"2022-04-01","changeNote":"2022-4-1 ak Created for protocol PED-CITN-03.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8158328","version":"1.1","preferredName":"Study Protocol Accrual Cohort Study EC 10403 Code","preferredDefinition":"The code that represents the information pertaining to intervention regimen(s), proposed methods for protocol obtaining subjects for a study 10403.","longName":"SDY_PRT_ACC_COH_10403_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD07E859-5D02-741B-E053-4EBD850AFF53","latestVersionIndicator":"Yes","beginDate":"2022-04-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-04-19","modifiedBy":"SOKKERL","dateModified":"2022-06-13","changeNote":"4/13/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8176570","version":"1","preferredName":"Patient Immunohistochemical Status of PD-L1 Outcome Receive Therapy Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regarding the immunohistochemical test result that refers to the overexpression or lack of expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm and will receive therapy as outline in the study protocol.","longName":"IMCHM_ST_PDL_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD4384F2-480B-2A11-E053-4EBD850A2596","latestVersionIndicator":"Yes","beginDate":"2022-04-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-04-22","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8176776","version":"1","preferredName":"Patient Pathologic Confirmation Disease Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation to address pathological confirmation of disease or disorder as outlined in the study protocol.","longName":"PATH_CONF_DZ_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD91FCA9-4A89-56C3-E053-4EBD850AA2A8","latestVersionIndicator":"Yes","beginDate":"2022-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-04-26","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":"4/26/22 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10348348","version":"1","preferredName":"Patient KRAS Gene Mutation Advanced Solid Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the change in the nucleotide sequence of the KRAS gene and malignant solid neoplasm as outlined in the study protocol.","longName":"PT_KRAS_SOL_TUM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFA627E9-B840-49F8-E053-731AD00A5194","latestVersionIndicator":"Yes","beginDate":"2022-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-23","modifiedBy":"SOKKERL","dateModified":"2022-06-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10350142","version":"1","preferredName":"Treatment Cohort Study 10486 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10486 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10486_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-1817-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-07-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10389023","version":"1","preferredName":"Treatment Cohort 10464 Study","preferredDefinition":"The code that represents the information pertaining to protocol EC10464 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10464_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-99EF-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-05-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-31","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10429358","version":"1","preferredName":"Treatment Genetic Finding 10144 Cohort Study","preferredDefinition":"The code that represents the information pertaining to protocol EC10144 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10144_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-675B-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-06-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-06-08","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10503829","version":"1","preferredName":"Treatment Cohort Study 10486 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10486 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10486_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7F07-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-06-23","modifiedBy":"SOKKERL","dateModified":"2022-06-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10547534","version":"1","preferredName":"Treatment Cohort Study 10505 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10505 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10505_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-35B2-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-07-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-07-01","modifiedBy":"SOKKERL","dateModified":"2022-07-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10571399","version":"1","preferredName":"Treatment Cohort Study 10487 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10487 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10487_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3AF9B56-6BD3-5894-E053-731AD00AC697","latestVersionIndicator":"Yes","beginDate":"2022-07-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-07-13","modifiedBy":"SOKKERL","dateModified":"2022-07-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10624796","version":"1","preferredName":"Patient Prior Chemotherapy Taxane Compound Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to prior  administration of Taxane therapy as outlined in the study protocol.","longName":"PR_CHEMO_TAX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4159384-AEE0-35BF-E053-731AD00ABAF1","latestVersionIndicator":"Yes","beginDate":"2022-07-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-07-18","modifiedBy":"SOKKERL","dateModified":"2022-08-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11028322","version":"1","preferredName":"Genetic Predisposition to Neoplasm Testing Clinical Trial Eligibility Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to genetic predisposition to neoplasm based on testing as outlined in the study protocol.","longName":"GENE_PRDSP_NEO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D593B3-D140-27FA-E053-731AD00A7B8E","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-08-09","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11028362","version":"1","preferredName":"Patient Fit Surgical Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator for whether a patient is fit to undergo surgical procedure as outline in the study protocol.","longName":"PT_FT_SURG_PROC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D5EABE-869A-3AAA-E053-731AD00A03F3","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-08-09","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11060759","version":"1","preferredName":"Patient Significant Endocrine Alteration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to significant endocrine alternations as outlined in the study protocol.","longName":"PT_SIGNF_ENDRN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5E92306-7490-2CEB-E053-731AD00A814C","latestVersionIndicator":"Yes","beginDate":"2022-08-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-08-10","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11066560","version":"1","preferredName":"Treatment Cohort Study 10517 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10517 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10517_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5F91574-6060-1FB1-E053-731AD00A98D1","latestVersionIndicator":"Yes","beginDate":"2022-08-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-08-11","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11066565","version":"1","preferredName":"Muscle Invasive Bladder Carcinoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to muscle Invasive Bladder Carcinoma as outlined in the study protocol.","longName":"MUS_INVS_BLAD_CA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5F98D9A-DCFF-2CE8-E053-731AD00AAA8B","latestVersionIndicator":"Yes","beginDate":"2022-08-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-08-11","modifiedBy":"SOKKERL","dateModified":"2022-08-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11159303","version":"1","preferredName":"Patient Surgical Procedure Planned Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response that indicates the patient meets the eligibility for clinical trial participation related to a planned surgical interventions as outlined in the study protocol.","longName":"PT_SUR_PROD_PLN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7685BBF-F54A-7BBB-E053-731AD00A5B8B","latestVersionIndicator":"Yes","beginDate":"2022-08-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-08-29","modifiedBy":"SOKKERL","dateModified":"2023-06-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11192538","version":"1","preferredName":"Treatment Cohort Study10528 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10007 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10528_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8299B52-D6D7-5738-E053-731AD00A5F49","latestVersionIndicator":"Yes","beginDate":"2022-09-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-08","modifiedBy":"SOKKERL","dateModified":"2023-06-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11555881","version":"1","preferredName":"Patient Stable Dose Administered Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation as to whether the patient on a stable dose as outlined in the study protocol.","longName":"PT_STBL_ADMIN_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECE8D323-7C14-2F8E-E053-731AD00AAB8B","latestVersionIndicator":"Yes","beginDate":"2022-11-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-07","modifiedBy":"SOKKERL","dateModified":"2023-02-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12054211","version":"1","preferredName":"Emerging Disease-directed Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the therapies newly developed to treat conditions that were previously treated with more established therapies as outlined in the study protocol.","longName":"EMG_DZ_TX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED832F50-3559-71E2-E053-731AD00A6BF1","latestVersionIndicator":"Yes","beginDate":"2022-11-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-15","modifiedBy":"SOKKERL","dateModified":"2023-06-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12054408","version":"1","preferredName":"Patient Preexisting Condition Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address a health condition or medical problem that was diagnosed or treated before a specific date as outlined in the study protocol.","longName":"PT_PREXTNG_COND_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED87730A-10A6-0861-E053-731AD00A3FB7","latestVersionIndicator":"Yes","beginDate":"2022-11-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-15","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12197694","version":"1","preferredName":"Patient Receive Hematopoietic Growth Factor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to the administration of endogenous growth factors which promote the development of blood cells as outlined in the study protocol.","longName":"PT_HEMO_GF_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F0578E33-DAA4-1880-E053-731AD00A4CEE","latestVersionIndicator":"Yes","beginDate":"2022-12-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-12-21","modifiedBy":"SOKKERL","dateModified":"2023-10-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12197717","version":"1","preferredName":"Treatment Cohort Study 10527 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10527 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10527_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F0583273-3F16-38E8-E053-731AD00AE172","latestVersionIndicator":"Yes","beginDate":"2022-12-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-12-21","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12290821","version":"1","preferredName":"Treatment Cohort Study 105046 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10546 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10546_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F175EA5D-0CC8-79CF-E053-731AD00A2406","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-04","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12309171","version":"1","preferredName":"Treatment Cohort Study 10538 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10538 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10538_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D626B2-B434-4DCD-E053-731AD00A6419","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-09","modifiedBy":"SOKKERL","dateModified":"2023-02-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12326589","version":"1","preferredName":"Personal Medical History Inherited Genetic Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine eligibility for clinical trial participation for questions related to medical history of inherited genetic disorders associated with cancer as outlined in the study protocol.","longName":"HX_INH_GENT_DX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1DCC91D-5055-764F-E053-731AD00A9AE5","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-09","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12332606","version":"1","preferredName":"Treatment Cohort Study 10558 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10558 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10558_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1E96850-5296-562F-E053-731AD00A9A81","latestVersionIndicator":"Yes","beginDate":"2023-01-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-10","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12353343","version":"1","preferredName":"Brain Metastatic Stable Disease Imaging Evidence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address imaging evidence of stable disease as outlined in the study protocol.","longName":"BR_MET_SBDX_IMG_EVD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1FE7867-147E-4050-E053-731AD00A575F","latestVersionIndicator":"Yes","beginDate":"2023-01-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-11","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12367188","version":"1","preferredName":"Prior Targeted Therapy Androgen Receptor Administered Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to Androgen receptor target therapy as outlined in the study protocol.","longName":"PR_AR_TX_ADM_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F22635DB-AA16-0C87-E053-731AD00A9C3C","latestVersionIndicator":"Yes","beginDate":"2023-01-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-13","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12426619","version":"1","preferredName":"Personal Medical History Rhabdomyolysis Or Elevated Creatine Kinase Clinical Trial Eligibility Criteria  Applicable Code Indicator","preferredDefinition":"A coded Indicator of whether the patient has a medical history related to Rhabdomyolysis or elevated Creatine Kinase as outlined in the study protocol.","longName":"MD_HX_RHM_CPK_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2EEEC59-5D92-29C9-E053-731AD00A783C","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-23","modifiedBy":"SOKKERL","dateModified":"2023-10-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12434218","version":"1","preferredName":"Indolent Lymphoma Effective Therapy Option Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that addresses indolent Lymphoma where effective therapy is an option as outlined in the study protocol.","longName":"IND_LYPH_TX _OPT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F304C53B-6048-736E-E053-731AD00A6353","latestVersionIndicator":"Yes","beginDate":"2023-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-24","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12456104","version":"1","preferredName":"Cancer Diagnosis No Standard Treatment Exist Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine eligibility for clinical trial participation for questions related to the diagnosis of cancer that no standard of care treatment for the disease exist as outlined in the study protocol.","longName":"CA_DX_DZ_STD_TX_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F32C3715-813C-3687-E053-731AD00A755C","latestVersionIndicator":"Yes","beginDate":"2023-01-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-26","modifiedBy":"SOKKERL","dateModified":"2023-01-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12461354","version":"1","preferredName":"Prior Bcl-2 Family Protein Inhibitor Exposure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to exposure to any agent of the Bcl-2 family inhibitors as outlined in the study protocol.","longName":"PR_BCL_INHBT_EX_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33FEA8A-C632-1A2C-E053-731AD00A9624","latestVersionIndicator":"Yes","beginDate":"2023-01-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-27","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12539400","version":"1","preferredName":"Treatment Cohort Study 10553 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10553 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10553_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F40FB1EF-F8FE-5A89-E053-731AD00A4373","latestVersionIndicator":"Yes","beginDate":"2023-02-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-02-06","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12545237","version":"1","preferredName":"Treatment Cohort Study 10577 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10577 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10577_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F41D1463-C751-2550-E053-731AD00A08C8","latestVersionIndicator":"Yes","beginDate":"2023-02-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-02-07","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12554297","version":"1","preferredName":"Treatment Cohort Study 10561 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10561 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10561_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F431F2D4-2BBA-3976-E053-731AD00A00C3","latestVersionIndicator":"Yes","beginDate":"2023-02-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-02-08","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12982696","version":"1","preferredName":"Tumor Response Domain Planned Timepoint CDISC Variable Name","preferredDefinition":"The planned timepoint of the tumor response findings recorded.","longName":"TRTPT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6053B89-6E22-7B6D-E053-731AD00A08D5","latestVersionIndicator":"Yes","beginDate":"2023-03-03","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-03","modifiedBy":"MMADDINENI","dateModified":"2023-06-02","changeNote":null,"administrativeNotes":"03/03/2023-Created CDE-CADSR0002109-MM","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12982712","version":"1","preferredName":"Tumor Identifier Domain Planned Timepoint CDISC Variable Name","preferredDefinition":"The planned timepoint of the tumor identification findings recorded.","longName":"TUTPT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6055BA1-EB2D-7EE5-E053-731AD00A114A","latestVersionIndicator":"Yes","beginDate":"2023-03-03","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-03","modifiedBy":"MMADDINENI","dateModified":"2023-06-02","changeNote":null,"administrativeNotes":"03/03/2023-Created CDE-CADSR0002109-MM","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13223090","version":"1","preferredName":"Ophthalmic Examinations Domain Planned Timepoint Clinical Study Sponsor Defined Name","preferredDefinition":"The planned timepoint related to ophthalmic examinations as defined by the sponsor.","longName":"OETPT_SPD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F76EAA57-6D50-3ABE-E053-731AD00AD41F","latestVersionIndicator":"Yes","beginDate":"2023-03-21","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-21","modifiedBy":"MMADDINENI","dateModified":"2023-06-02","changeNote":null,"administrativeNotes":"03/21/2023-Created CDE-CADSR0002161-MM","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13316460","version":"1","preferredName":"Squamous Cell Carcinoma American Joint Committee on Cancer Stage Clinical Trial Eligibility Criteria Code Ind","preferredDefinition":"The coded response that indicates that a patient's squamous cell carcinoma staging used the AJCC and meets the criteria for enrollment into a clinical trial.","longName":"SQCEL_AJCC_STG_CTEC_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F89C2253-11B2-4BCE-E053-731AD00AE530","latestVersionIndicator":"Yes","beginDate":"2023-04-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-05","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeNote":null,"administrativeNotes":"2023.4.5 Created per ticket request CADSR0002271. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328607","version":"1","preferredName":"PASI Head Erythema Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of erythema of the head, using a 5-point rating scale.","longName":"PASI_HD_ERYTH_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B1AD2E-475C-2B53-E053-731AD00A2AA1","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328633","version":"1","preferredName":"PASI Head Induration/Thickness Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of induration/thickness of the head, using a 5-point rating scale.","longName":"PASI_HD_INDUR_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B213F0-64B9-3B2F-E053-731AD00ACF95","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328637","version":"1","preferredName":"PASI Head Scaling Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of scaling of the head, using a 5-point rating scale.","longName":"PASI_HD_SCLNG_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B224F3-9097-3E3F-E053-731AD00AC049","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328643","version":"1","preferredName":"PASI Upper Limbs Erythema Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of erythema of the upper limbs, using a 5-point rating scale.","longName":"PASI_UPEX_ERYTH_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B22B6B-8C94-3F30-E053-731AD00ADE33","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328644","version":"1","preferredName":"PASI Upper Limbs Induration/Thickness Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of induration/thickness of the upper limbs, using a 5-point rating scale.","longName":"PASI_UPEX_INDUR_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B24436-A358-42B3-E053-731AD00A336A","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328645","version":"1","preferredName":"PASI Upper Limbs Scaling Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of scaling of the upper limbs, using a 5-point rating scale.","longName":"PASI_UPPEREX_SCLNG_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B2487B-5E02-433B-E053-731AD00A2BD8","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328647","version":"1","preferredName":"PASI Trunk Erythema Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of erythema of the trunk, using a 5-point rating scale.","longName":"PASI_TRNK_ERYTH_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B24DBB-FD96-43DC-E053-731AD00AC504","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328648","version":"1","preferredName":"PASI Trunk Induration/Thickness Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of induration/thickness of the trunk, using a 5-point rating scale.","longName":"PASI_TRNK_INDUR_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B2526B-B86C-479B-E053-731AD00A0A13","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328660","version":"1","preferredName":"PASI Trunk Scaling Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of scaling of the trunk, using a 5-point rating scale.","longName":"PASI_TRNK_SCLNG_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B25A0E-3304-48BB-E053-731AD00AA234","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328672","version":"1","preferredName":"PASI Lower Limbs Erythema Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of erythema of the lower limbs, using a 5-point rating scale.","longName":"PASI_LOWEX_ERYTH_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B2611B-8AA4-49B6-E053-731AD00A4A21","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328681","version":"1","preferredName":"PASI Lower Limbs Induration/Thickness Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of induration/thickness of the lower limbs, using a 5-point rating scale.","longName":"PASI_LOWEX_INDUR_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B264D9-B8D2-4A32-E053-731AD00A72D9","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13328682","version":"1","preferredName":"PASI Lower Limbs Scaling Score 5 Point Scale","preferredDefinition":"Response indicating the chronic plaque type psoriasis intensity of scaling of the lower limbs, using a 5-point rating scale.","longName":"PASI_LOWEX_SCLNG_SCL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8B2696E-F22B-4AB9-E053-731AD00AA8F8","latestVersionIndicator":"Yes","beginDate":"2023-04-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-06","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13336621","version":"1","preferredName":"PASI Percent Area of Head and Neck Affected Number","preferredDefinition":"Number representing the percent area of head and neck affected.","longName":"PASI_HD_AFF_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8FF31AB-8ACC-03F7-E053-731AD00A057F","latestVersionIndicator":"Yes","beginDate":"2023-04-10","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-10","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13336622","version":"1","preferredName":"PASI Percent Area of Upper Limbs Affected Number","preferredDefinition":"Number representing the percent area of upper limbs affected.","longName":"PASI_UPEX_AFF_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8FF5ACD-3DB9-0D67-E053-731AD00AC9F8","latestVersionIndicator":"Yes","beginDate":"2023-04-10","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-10","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13336623","version":"1","preferredName":"PASI Percent Area of Trunk Affected Number","preferredDefinition":"Number representing the percent area of trunk affected.","longName":"PASI_TRNK_AFF_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8FF604E-F52F-0DFD-E053-731AD00A825F","latestVersionIndicator":"Yes","beginDate":"2023-04-10","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-10","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13336624","version":"1","preferredName":"PASI Percent Area of Lower Limbs Affected Number","preferredDefinition":"Number representing the percent area of lower limbs affected.","longName":"PASI_LOWEX_AFF_NUM","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"PASI: Psoriasis Area and Severity Index - Fredriksson T et al., Dermatologica, 1978","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8FF6754-87C3-0F1C-E053-731AD00A9C5F","latestVersionIndicator":"Yes","beginDate":"2023-04-10","endDate":null,"createdBy":"TSESU","dateCreated":"2023-04-10","modifiedBy":"TSESU","dateModified":"2023-11-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13369308","version":"1","preferredName":"Patient Disease Therapeutic Procedure Interference Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the patient's disease which may interfere with the treatment plan as outlined in the eligibility criteria of the study protocol.","longName":"PT_DZ_TX_INTF_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F99D7E37-386C-26EB-E053-731AD00AA653","latestVersionIndicator":"Yes","beginDate":"2023-04-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-18","modifiedBy":"SOKKERL","dateModified":"2023-10-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13370638","version":"1","preferredName":"Tumor Burden Assessment Clinical Trial Eligibility  Code Indicator","preferredDefinition":"A coded response for questions related to the the number of cancer cells, the size of a tumor, or the amount of cancer in the body as outlined in the study protocol.","longName":"TUM_BRD_ASSES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9A0ED06-FE2C-4150-E053-731AD00A5B0F","latestVersionIndicator":"Yes","beginDate":"2023-04-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-18","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13443888","version":"1","preferredName":"Disease or Disorder Immunotherapy-Related Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that addresses disease or disorder related to immunotherapy as outlined to the study protocol.","longName":"DZ_ITX_RELT_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA40583F-8EBF-5B37-E053-731AD00AED40","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13451934","version":"1","preferredName":"Treatment Cohort Study 10217 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10217 in which subsets of a defined population are identified.","longName":"TX_COH_10217_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA427185-1CF1-3EE6-E053-731AD00A8118","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeNote":null,"administrativeNotes":"4/26/2023 curated for cohort study 10217 ls.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13471157","version":"1","preferredName":"Body Surface Area Head and Neck Assessment Percentage Value","preferredDefinition":"The numerical percentage value of the BSA assessment for the head and neck.","longName":"BSA_ ASSES_HD_NCK _VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAA206A4-B09D-32E6-E053-731AD00AC1D1","latestVersionIndicator":"Yes","beginDate":"2023-05-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-01","modifiedBy":"SOKKERL","dateModified":"2023-08-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13471163","version":"1","preferredName":"Body Surface Area Upper Extremity Assessment Percentage Value","preferredDefinition":"The numerical percentage value of the BSA assessment for the upper extremity.","longName":"BSA_ ASSES_UPP_EXT _VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAA340BB-0DE9-5EB0-E053-731AD00A67CE","latestVersionIndicator":"Yes","beginDate":"2023-05-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-01","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13471166","version":"1","preferredName":"Body Surface Area Lower Extremity Assessment Percentage Value","preferredDefinition":"The numerical percentage value of the BSA assessment for the lower extremity.","longName":"BSA_ ASSES_L_EXT _VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAA38A13-C58C-7406-E053-731AD00A056C","latestVersionIndicator":"Yes","beginDate":"2023-05-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-01","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13471169","version":"1","preferredName":"Body Surface Area Trunk Assessment Percentage Value","preferredDefinition":"The numerical percentage value of the BSA assessment for the trunk.","longName":"BSA_ ASSES_TRNK _VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAA3A3BA-549C-76EA-E053-731AD00A0050","latestVersionIndicator":"Yes","beginDate":"2023-05-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-01","modifiedBy":"SOKKERL","dateModified":"2023-08-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13523499","version":"1","preferredName":"Surgical Procedure Disease Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions that address disease present while undergoing a surgical procedure as outline in the study protocol.","longName":"SURG_PROC_PRES_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAF6FEB1-6323-6CBC-E053-731AD00A17B6","latestVersionIndicator":"Yes","beginDate":"2023-05-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-05","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13526862","version":"1","preferredName":"Treatment Cohort Study 10603 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10603 in which subsets of a defined population are identified.","longName":"TX_COH_STDY_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB2E1AAD-D513-6CE2-E053-731AD00A94A2","latestVersionIndicator":"Yes","beginDate":"2023-05-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-08","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13571195","version":"1","preferredName":"Malignant Neoplasm Histology Stratification Type","preferredDefinition":"The histological category of malignant neoplasm as it pertains to Information the process of classifying participants into strata for purposes of data analysis.","longName":"MAL_NEO_HX_STRAT_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBBF519F-BD59-2398-E053-731AD00AA6D6","latestVersionIndicator":"Yes","beginDate":"2023-05-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-15","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":"5/15/23 curated for ec10556.LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13574488","version":"1","preferredName":"Hypertension Treatment Received Code Indicator","preferredDefinition":"A coded indicator related to therapy received alter the course of a pathologic process of increase in blood pressure as outlined in the study protocol.","longName":"HTN_TX_REC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBC0518B-1CD9-533D-E053-731AD00A66E5","latestVersionIndicator":"Yes","beginDate":"2023-05-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-15","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":"5/15/23 curated for EC 10556.LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13574509","version":"1","preferredName":"Treatment Cohort Study 10556 Study","preferredDefinition":"The code that represents the information pertaining to protocol 10556 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10556_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBC1F152-2798-1F76-E053-731AD00A1746","latestVersionIndicator":"Yes","beginDate":"2023-05-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-15","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13752644","version":"1","preferredName":"FGFR/TACC Family Fusion Gene Present Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions addressing a fusion gene that results from chromosomal rearrangements involving a fibroblast growth factor receptor (FGFR) family gene and a transforming acidic coiled-coil-containing protein (TACC) family gene is present as outlined in the study protocol.","longName":"FGFR_GN_PRST_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCFCCD31-3445-506D-E053-731AD00A2167","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-31","modifiedBy":"SOKKERL","dateModified":"2023-09-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13752646","version":"1","preferredName":"Treatment Cohort Study 10559 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10559 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10559_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCFD6D3C-8701-7213-E053-731AD00A755C","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-31","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13816892","version":"1","preferredName":"Killed Vaccine Toxoid Vaccine Medication Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the administration of Killed or Toxoid Vaccine as outlined in the study protocol.","longName":"KIL_TX_VAC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDA07370-D924-7D08-E053-731AD00ACD8E","latestVersionIndicator":"Yes","beginDate":"2023-06-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-08","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13818608","version":"1","preferredName":"Known Disease or Disorder Hemophagocytic Lymphohistiocytosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to known hemophagocytic lymphohistiocytosis as outlined in the study protocol.","longName":"13818607v1.00:3298541v1.00","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDA34891-6A6D-0536-E053-731AD00A67FD","latestVersionIndicator":"Yes","beginDate":"2023-06-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-08","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13903867","version":"1","preferredName":"Therapeutic Procedure Administered Timepoint Type","preferredDefinition":"A timepoint when the therapy was administered.","longName":"TX_PROC_TM_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDEDDEB2-47CE-78FF-E053-731AD00AD048","latestVersionIndicator":"Yes","beginDate":"2023-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-12","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13908219","version":"1","preferredName":"Prior Radiation Therapy Administered Indicator","preferredDefinition":"An indicator whether the patient had prior radiation therapy.","longName":"PT_PR_RAD_ADM_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDF0272F-005D-5E1A-E053-731AD00A2732","latestVersionIndicator":"Yes","beginDate":"2023-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-12","modifiedBy":"SOKKERL","dateModified":"2023-07-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13908220","version":"1","preferredName":"Patient Crossover Study Code Indicator","preferredDefinition":"A coded indicator related to a patient being in a type of clinical study in which each study subject receives the same series of treatments but in a random order that differs across arms of the study as outlined in the study protocol.","longName":"PT_CROVR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDF094CB-9A1D-7823-E053-731AD00AD923","latestVersionIndicator":"Yes","beginDate":"2023-06-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-12","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13928864","version":"1","preferredName":"Treatment Cohort Study 10590 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10590 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10590_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE079308-D706-135A-E053-731AD00AAA46","latestVersionIndicator":"Yes","beginDate":"2023-06-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-13","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13958150","version":"1","preferredName":"Patient Diagnosis Age Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response to questions which are necessary to allow a person to participate in a clinical study that are related to the age of diagnosis as outlined in the study protocol.","longName":"PT_DX_AGE_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE43BE40-087B-38FE-E053-731AD00A9616","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-16","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13965383","version":"1","preferredName":"Patient Isolated Myeloid Sarcoma Exclusion Criteria Code Indicator","preferredDefinition":"A coded response to questions relating to the separating of tumor mass composed of myeloblasts or immature myeloid cells occurs in extramedullary sites, or the bone as outlined in the study protocol.","longName":"PT_ISLT_MYL_SARC_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE93884F-333C-0B7C-E053-731AD00AF8D7","latestVersionIndicator":"Yes","beginDate":"2023-06-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-20","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13965384","version":"1","preferredName":"Patient Diagnosis Down Syndrome Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation as to whether the patient has Down Syndrome as outlined in the study protocol.","longName":"DX_DN_SYNDR_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE93BADF-DF1F-15D9-E053-731AD00A2711","latestVersionIndicator":"Yes","beginDate":"2023-06-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-20","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13966067","version":"1","preferredName":"Biospecimen Events Domain Biospecimen Event Planned Time Point","preferredDefinition":"The planned time point when the biospecimen events to be done as defined in protocol.","longName":"BETPT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEA932CB-55AF-673F-E053-731AD00A51D1","latestVersionIndicator":"Yes","beginDate":"2023-06-21","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-06-21","modifiedBy":"ZHWENDY","dateModified":"2023-10-10","changeNote":null,"administrativeNotes":"09/07/2023-Reviewed and released-MM\r\n06/21/2023- Created CDE(CADSR0002536)-MM","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13998514","version":"1","preferredName":"Treatment Cohort Study 10614 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10614 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10614_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF213B75-2753-18F6-E053-731AD00A142F","latestVersionIndicator":"Yes","beginDate":"2023-06-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-06-27","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeNote":null,"administrativeNotes":"2023.6.27 Created per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14000152","version":"1","preferredName":"Prior Non Immunotherapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to prior non-immunotherapy.","longName":"PR_NON_IMMUNO_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF219665-F50C-2CF1-E053-731AD00ACC03","latestVersionIndicator":"Yes","beginDate":"2023-06-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-06-27","modifiedBy":"KUMMEROA","dateModified":"2023-07-05","changeNote":null,"administrativeNotes":"2023.7.5 Released per review. ak 2023.6.27 Created per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14000155","version":"1","preferredName":"Laboratory Procedure DNA Clinical Study Protocol Code Indicator","preferredDefinition":"The coded response to determine eligibility for clinical trial participation for questions related to a DNA laboratory procedure.","longName":"LAB_DNA_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF21E5C4-6104-37CC-E053-731AD00A1B55","latestVersionIndicator":"Yes","beginDate":"2023-06-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-06-27","modifiedBy":"KUMMEROA","dateModified":"2023-07-05","changeNote":null,"administrativeNotes":"2023.7.5 Released per review. ak 2023.6.27 Created per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14056375","version":"1","preferredName":"Treatment Cohort Study 10592 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10592 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10592_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005E7BD0-26C9-0C93-E063-731AD00A377D","latestVersionIndicator":"Yes","beginDate":"2023-07-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-07-13","modifiedBy":"SOKKERL","dateModified":"2023-07-17","changeNote":null,"administrativeNotes":"7/17/23 CDE released per Kathryn M from Theradex- LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14057937","version":"1","preferredName":"Immune Checkpoint Inhibitor Disease or Disorder Assessment Stratification Status","preferredDefinition":"The condition or state at particular time related to the use of Immune Checkpoint Inhibitor to assess the disease or disorder stratification.","longName":"ICI_DX_ASSES_SRT_STAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005FA870-FF40-40AD-E063-731AD00A1318","latestVersionIndicator":"Yes","beginDate":"2023-07-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-07-13","modifiedBy":"SOKKERL","dateModified":"2023-07-17","changeNote":null,"administrativeNotes":"7/17/23 cde release per Kathryn M from Theradex. ls","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14175982","version":"1","preferredName":"Treatment Cohort Study Subgroup 10507 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10507 in which a subdivision of a larger group with members often exhibiting similar characteristics in a population are identified,","longName":"TX_COH_SDY_SUB_10507_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"016668FB-1504-6580-E063-731AD00AC253","latestVersionIndicator":"Yes","beginDate":"2023-07-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-07-26","modifiedBy":"SOKKERL","dateModified":"2023-08-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14437346","version":"1","preferredName":"End Relative to Reference Time Point","preferredDefinition":"An indicator of the conclusion of the disease response in relation to a specific point in time.","longName":"RSENRTPT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"041686DB-4829-7517-E063-731AD00AA5F4","latestVersionIndicator":"Yes","beginDate":"2023-08-29","endDate":null,"createdBy":"LISU","dateCreated":"2023-08-29","modifiedBy":"MMADDINENI","dateModified":"2024-01-10","changeNote":null,"administrativeNotes":"01/10/2024: CDISC concept created and updated DEC-MM  08/29/2023: created for Theradex CADSR0002597. CDICS concept is pending.  -SL","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14461973","version":"1","preferredName":"Treatment Cohort Study 10601 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10601 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10601_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B51716-B567-3ACB-E063-731AD00A9464","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-09-06","modifiedBy":"SOKKERL","dateModified":"2023-10-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14475549","version":"1","preferredName":"Concomitant Medication Administered Action Taken with Study Treatment Type","preferredDefinition":"A textual description of the action that was taken with the concomitant medication.","longName":"CON_MEDS_ADM_ACTN_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"053D9529-7C59-1C2A-E063-731AD00ACDFE","latestVersionIndicator":"Yes","beginDate":"2023-09-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-09-13","modifiedBy":"SOKKERL","dateModified":"2023-09-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14476343","version":"1","preferredName":"Protocol Treatment Arm First Randomization Assignment Text","preferredDefinition":"The assignment to a specific treatment regimen or arm at first randomization when more than one protocol treatment is described.","longName":"PROT_TX_RAND_ARM_TXT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0555C33C-2B8C-15DD-E063-731AD00A88D0","latestVersionIndicator":"Yes","beginDate":"2023-09-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-09-14","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14522630","version":"1","preferredName":"Laboratory Procedure Fasting Plasma Glucose And Glycosylated Hemoglobin Measurement Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response for questions related to the value of the amount of fasting glucose and glycosylated hemoglobin present in a sample of blood as outlined in the protocol.","longName":"LP_FGL_HGBA1C_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06E5AE94-814F-1CAC-E063-731AD00AE647","latestVersionIndicator":"Yes","beginDate":"2023-10-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-10-04","modifiedBy":"SOKKERL","dateModified":"2023-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14590168","version":"1","preferredName":"Treatment Cohort Study 10608 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10608 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10608_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0904A7D1-7349-310A-E063-731AD00AD38D","latestVersionIndicator":"Yes","beginDate":"2023-10-31","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-10-31","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14596137","version":"1","preferredName":"Consent Form Version Date","preferredDefinition":"A date for the version of the Consent Form.","longName":"DSICDAT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"092DDB8F-6C73-26E6-E063-731AD00A0C0D","latestVersionIndicator":"Yes","beginDate":"2023-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-11-02","modifiedBy":"SOKKERL","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14619882","version":"1","preferredName":"Treatment Cohort Study 10433 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10433 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10433_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0AE7134A-1241-2308-E063-731AD00A925F","latestVersionIndicator":"Yes","beginDate":"2023-11-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-11-24","modifiedBy":"SOKKERL","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14637598","version":"1","preferredName":"CD79B Positive Detection Indicator","preferredDefinition":"A coded indicator of whether or not CD79B is detected in a sample.","longName":"CD79B_DET_CD_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B65D3AD-EA51-1E7F-E063-731AD00A43E3","latestVersionIndicator":"Yes","beginDate":"2023-11-30","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-11-30","modifiedBy":"SOKKERL","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14640647","version":"1","preferredName":"Bone Marrow Aspirate And/Or Biopsy Performed Date","preferredDefinition":"The date of which the bone marrow aspirate and/or biopsy was performed.","longName":"BM_ASP_BX_PFRM_DT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B746D60-8D32-2856-E063-731AD00AEF4D","latestVersionIndicator":"Yes","beginDate":"2023-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-01","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":"2023.12.1 Created per ticket request CADSR0003111. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14640660","version":"1","preferredName":"Laboratory Procedure Bone Marrow Cellularity Outcome Percentage Value","preferredDefinition":"Numeric percentage of cellularity in a bone marrow sample.","longName":"BM_CELL_PRCNT_VAL","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B751549-8D54-48CB-E063-731AD00A92FC","latestVersionIndicator":"Yes","beginDate":"2023-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-01","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":"2023.12.1 Created per ticket request CADSR0003111. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14640771","version":"1","preferredName":"Treatment Cohort Study 10612 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10612 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10612_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B788D9D-834E-06BF-E063-731AD00A12BB","latestVersionIndicator":"Yes","beginDate":"2023-12-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-12-01","modifiedBy":"SOKKERL","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14643207","version":"1","preferredName":"Cytogenetic Analysis Assessment Performed Bone Marrow Test Outcome","preferredDefinition":"The outcome of the bone marrow cytogenetic analysis test.","longName":"BM_CYTO_TEST_RSLT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB66C78-8644-1863-E063-731AD00ABE73","latestVersionIndicator":"Yes","beginDate":"2023-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-04","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":"2023.12.4 Created per ticket request CADSR0003111. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14643208","version":"1","preferredName":"Flow Cytometry Performed Bone Marrow Test Outcome","preferredDefinition":"The outcome of the bone marrow flow cytometry test.","longName":"BM_FLOW_TEST_RSLT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB684D4-E6FC-1F4D-E063-731AD00AC0AB","latestVersionIndicator":"Yes","beginDate":"2023-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-04","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":"2023.12.4 Created per ticket request CADSR0003111. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14643209","version":"1","preferredName":"Molecular Analysis Laboratory Procedure Performed Bone Marrow Test Outcome","preferredDefinition":"The outcome of the bone marrow molecular analysis test.","longName":"BM_MOLE_TEST_RSLT","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BB69731-1F05-2292-E063-731AD00A0D94","latestVersionIndicator":"Yes","beginDate":"2023-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-04","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":"2023.12.4 Created per ticket request CADSR0003111. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14667048","version":"1","preferredName":"Treatment Cohort Study 10605 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10605 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_10605_CD","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D928643-7BD8-6628-E063-731AD00A3362","latestVersionIndicator":"Yes","beginDate":"2023-12-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-12-28","modifiedBy":"SOKKERL","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14723031","version":"1","preferredName":"Clinical Study Chemotherapy Stratification Type","preferredDefinition":"Information related to the process of classifying patients based on chemotherapy as part of the randomization process or for purposes of data analysis in a clinical trial.","longName":"CLN_STDY_CHEMO_STRT_TP","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FB1E9F2-1BD7-23F2-E063-731AD00A90A0","latestVersionIndicator":"Yes","beginDate":"2024-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-24","modifiedBy":"SOKKERL","dateModified":"2024-01-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14741290","version":"1","preferredName":"Therapeutic Procedure Interruption And Restart Administered Indicator","preferredDefinition":"An indicator that describes whether therapy was interrupted and restarted as outlined in the protocol.","longName":"TX_INTERP_RST_IND","contextName":"Theradex","contextVersion":"1","dataElementConceptPublicId":"2010663","dataElementConceptVersion":"2.31","valueDomainPublicId":"3506034","valueDomainVersion":"1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"10532F99-EE1B-4ECF-E063-731AD00A960F","latestVersionIndicator":"Yes","beginDate":"2024-02-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-02-01","modifiedBy":"SOKKERL","dateModified":"2024-02-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}]}